<SEC-DOCUMENT>0001610618-22-000085.txt : 20221103
<SEC-HEADER>0001610618-22-000085.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103172710
ACCESSION NUMBER:		0001610618-22-000085
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cidara Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001610618
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461537286
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36912
		FILM NUMBER:		221359261

	BUSINESS ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-752-6170

	MAIL ADDRESS:	
		STREET 1:		6310 NANCY RIDGE DRIVE
		STREET 2:		SUITE 101
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	K2 THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20140611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cdtx-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:a568bcbd-732c-4e03-9327-71091167a8dd,g:435374c1-7d67-4ed0-913a-245b913da5ec,d:103e7621649e479aa89c7d0167cfd96f--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:cdtx="http://cidara.com/20220930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cdtx-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY18zLTEtMS0xLTQyMzY3_3a4b0bc1-0e3c-4f83-a97c-4f0ec06484d4">false</ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY180LTEtMS0xLTQyMzY3_0893f1c2-493a-4f28-ba96-de411f67e669">2022</ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY181LTEtMS0xLTQyMzY3_08b10f97-dc3b-41f6-ae0c-6f6540276527">Q3</ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY182LTEtMS0xLTQyMzY3_7bd02998-a920-4fbc-be16-c8272fbf3258">0001610618</ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY183LTEtMS0xLTQyMzY3_c2c01c33-f539-430f-a6a7-ad46a9395723">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_011b2109-21a8-464f-bb1e-33d79328bc43">http://cidara.com/20220930#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_278b3e2b-3ca4-47d9-97c2-0c16a9fc93d4">http://cidara.com/20220930#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_be7bbebb-4238-4090-b165-d91c10c23ad7">http://cidara.com/20220930#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" name="us-gaap:TypeOfRevenueExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_f777ca9d-6e93-4f97-b8fd-af359bd8aa31">http://cidara.com/20220930#CollaborationRevenueMember</ix:nonNumeric><ix:nonNumeric contextRef="i55632fa7f7f64ff2a296fb450fc05947_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTIzOA_4025d4e0-b32b-4383-8a9a-aee6ae64d94d">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i7005c05e48314e688d999cdea4698c80_D20150301-20150331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTQ2NQ_548f15b5-a1d8-4cd3-872c-e2f333fda6b9">P3Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ie6a10d1d7b8341e48e7157fc9809cb9e_D20190903-20190903" decimals="INF" name="cdtx:CollaborativeArrangementCostSharingPercentage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81Mi9mcmFnOjQwMWMxNTdjMWU0YTQwZjRiY2VkYzljMzI0OGI3MTdkL3RleHRyZWdpb246NDAxYzE1N2MxZTRhNDBmNGJjZWRjOWMzMjQ4YjcxN2RfNTM_64166873-704d-4fa8-8988-1cbbe7e1c510">0.50</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cdtx-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea934756b6a4b36acc5dce537f5d6cd_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia4364c8090e34068aa4c7347a141f4a0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ib5225fdc3f334ed69fa883c887f70abe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i08d686bd4def4018a3689e8e8c4201a4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1541d551c68f4ed2b3a7797a2421af03_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a6f6259262c4efcb61b27512dc283e6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a96ee88a724103bd21dea2ce351a6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bdf276fab234f5793b92dd0eab61737_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cb92875f7444accb8df71f69d1e6823_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i098de05c0a73424893e619674f8ede0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i439485f4e8e2471190cf787925ce765f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id549c6dc162445b0a8b51e25ba53845f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8bf3279b1814f298a5a4e543dffe461_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ddfea5cb5ac4dbba5969c5c32dc405f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcfbfe674ada4806903f264b16edff10_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3fd27b6890e4826a59b299ceb905038_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i160c27cee64e434eabaaa10605b89946_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb81e64d8f846e1b7b1aedc4305a63b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc647f0b1f5d4ee99cd69cc22038ac7b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70591917e30b4422865fea663b0f796f_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a186807702543a3b16705ccfa44e627_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5122efa490e14a07b68b1661470c2d68_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26800230236f4cc9bc3aac4ee89d9783_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a3f0c9c39f4de6bf503a1bbe64da16_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib82d7061381343cf8fd9d02f13182140_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i956248bf259a4879bbb53a8a82a26ec7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a529f48c1e14479a8bac0af6684dfed_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba7ab5417525497fb3acb2513449bdd2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb414282b9dc4b85bc63049a4f25a84f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31de05b5ec874e73a1ec0902444ca46e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109b1669ef4d446f8220b8cba5c0ae2e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dea2fc105bf4d31866b9f83d65b2932_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf881d2c650347459458b36b03ca94d0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i864469b8adce4fbb956b05333e046b7e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693eb172a4d347d0b0a8944c52cb7b00_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5738d3cb61f1420b9d7309c2a207e112_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94201b3baa82482bbac00a56f5e155fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd091b6d62174e4d8d75ae1cf5dc7c1a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0d525f23739440fbefcb160732067b9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc56da2da39740feb3ec19fc507a66e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07c2a73a148b485f89fc5f997009213f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if133fdbf28ba4b219f3f376b31de78bf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6911289ff2c4b749f20e55b06a07c49_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87017a31f5664b1b9432ba825c9cffd3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c805b66507a4ce5a2a3ea7b4ce88a7c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id436a614bbc4407580ad8a47424abedc_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4453b17a58014dc49d268e838656cf76_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40678b795d7a4f77b2887ee7e28b9d6b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica9486a33c544927bc063333539cd357_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5f7c9d49964f0c9dd7ecb39b9e7a9a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89f47ece2c56488f873e04e2b611b0a9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib177b93cb8ec46ba81e03a7d526bc97b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d7d33deac174ca1acff18720307d200_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5347a69850cb4e3a9c600e3f046564c5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id376015bef2f4799bc27e985203d46bd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d1ea8a7959445a95096c4b864be06d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i818d0f7b825449cda1e49ae8b91e0960_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ee68c9bbb94758b8465a6d2c6abd10_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d162d88a05494b9a13cdb4bb8b29d6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cdtx:segment</xbrli:measure></xbrli:unit><xbrli:context id="i55632fa7f7f64ff2a296fb450fc05947_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6abcad7d8034ab09ccfc1455cc8aca2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d3b55bd5de40eab1cd422f39bee135_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="obligation"><xbrli:measure>cdtx:obligation</xbrli:measure></xbrli:unit><xbrli:context id="i39f7d4a95df44e80aad5a7828af660e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3728c48f4fff45e48fd89bdb795841d3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdtx:JanssenCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie84641f18b5b49039831316c6a1bf0a1_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ib67565edcae74a3cb712ae982e16c451_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4bdc30657f14452b62cb74aaa0c1c02_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9489bd66399422eba3c70350fb1aec6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eba19ec547f41fe9cb7fcf6f8323c4e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53017c7a53ac41bba664c2e94189573a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5bb1e9a932d46abbb6c2af18fe748bf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8290788acae94198a642171a08cb981e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67bd62ef1d93442c8672b744fb64dba0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea096aaf8a964de0a3100d448444ba50_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6c2025ff77482496d4861d17864fb7_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89983bfbaa774a6089ebf1552008beed_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib71ae47f80d7456fa74d8430a1187edd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90bb450d4b14645876a8c40853f0f80_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c9e1bc6d28645a0a88c59ae7c3b268d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id64416d06cee4e5ca72c5b5ca3dd7cdf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9923c3f04494ea08d78070db565dec5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d1ba8de76cf4d50a911304fc4244f77_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2787b199372343b4b03ee56c6d782676_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052c13aef942486698daafbe3f173f65_I20161003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i959c564f9e4f4f058243fb9d370aa5de_D20161003-20161003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-03</xbrli:startDate><xbrli:endDate>2016-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb67d01a4acc4c67a09bea73d61871ed_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf66717d514a49d7b24e502df0f65ed9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae88c6865e4e458ba163ba5e2108e78e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id488125f97f9422c86fe3f9a0f62e61e_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicStockOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b0440e80904930ac842fa7429f8b17_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2873a315ee3b49fb92caf5729891639a_I20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd41362b50874d8d8249094d91ca90f6_I20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df29006f187417e816e2158bd2f9209_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7f37a17eb6a463698c6b8c41d120df5_D20211013-20211013"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-13</xbrli:startDate><xbrli:endDate>2021-10-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94af5aa812844c758cdfa1475671e9a6_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc162d67bbe4dca8bd989529e6ae2b3_D20200812-20200812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-12</xbrli:startDate><xbrli:endDate>2020-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43db71acffc7473da141de0be728b1f4_D20200812-20200812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-12</xbrli:startDate><xbrli:endDate>2020-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ec61aa3e0b43378a90a84041d66908_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>cdtx:vote</xbrli:measure></xbrli:unit><xbrli:context id="i86b952768f264a7b874692f258aa5053_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62d149e810834aceba4d99488eae77db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf327b331dbc430d85c195531d36f8df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fe30b7973da4dffb8da105c119dfe8b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5324603762448499a4ae28f38d54d1b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d844b63d15b429cbac3aefd54d810e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic05c4f78a48f4a4dbf218b042d1d1f6e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541af1a514f347a69bd1214db5ee6761_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38ddb97add1a4265b3f354df1f33347f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i782d88c1c80c43aeb3ee3636280e0ec3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31cc8c5f67c647a8bb8f8d484fb20097_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i445ea361a0534f34b979c1b9c39c0ee4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i036bdcca976a44cf9a1566845a5fb841_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1395be4faaed4f909c2d9d668463d93d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib506537ee0944bfcbcb6c12ae798c59c_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7005c05e48314e688d999cdea4698c80_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b111eb9e1724eb4b52920f38d9f5ac1_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b01287deb64faf84f4daa9f17bb5e0_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71ef06f8cb854b7abf2c1ca8ca9f0400_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide919cb038934f0c97c7be8388a351c8_D20150301-20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-03-01</xbrli:startDate><xbrli:endDate>2015-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56e4c68ba76241baa53301e647eb569c_I20150331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i967a2fb933ca4d77a5793520831dca91_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad586f67e1e64183ba99bd648dfdad0f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc7909cccd3141d4980af143ffea9363_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9912047c193415f8d530486835fc858_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4c2b554012041d29eba537838cbb84c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0437175fbfa46dbba01f38007dbede7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfeff9f96ab8411fa8bca991c8031822_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dcbfc97d2f34fb9a0872c85a82593c5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfddad092a44527821fd2ac2ffc91ed_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96c9f00db2034a07ab38792b24541941_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i244171b35f434cc39f5129662239663e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c6df55d735d4a3584f2bf2d709732de_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19798a6430cc425eaf630f93c7d82742_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e07da4e20844708da921b1866aff4a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9746cabdad4f4ba5ad36b76a394afa49_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6bd1aaba9504281a7c3adc36f4d33c8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd9ae8d02994db09c6c17d85d05eb8e_D20190903-20190903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-03</xbrli:startDate><xbrli:endDate>2019-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9b69a06369d4a8e88c985f8b0d67518_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab15c514b9d45d58fb7d77080e63dbd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8e503d246dc400e926a1ee2b976a58e_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc0df86722f14e688642f553eeef0df3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083a9e97a9064a748f3e9e13753ecc2e_D20211201-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i050a34311f2f464091d42f5ee44e4c79_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie658ef0290234febab93dba91faae5e1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a4ea630ca944ade94e8636670a33f15_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i161035ba306c4c2cbad3a08836c61a30_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80867d87eba64530a2fb32636e6cfb8f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9170170c08441b781c4c6d06c63beeb_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294b1ca2af214dad80eaf69f5050931a_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:RDFundingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a391d92ba84000b49895803c8b0101_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ec5bff221b34504b1e0fbb18258fed7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae8af69b23b64ece8613fb9204fc9c4b_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34737c9c45ac487189c88b240a304577_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a85bab3728d4eada2f9bcaf61036888_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad6fb4866e44519aefef3041cf4c2cb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i577b14f0889b45eb8cb9da83fcc52acf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2539318f504eba964d023b1f0971c9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3992b0eb8484b4aaf5f1a209d2603dc_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib906710cf3274c668e80b30f6e1ec734_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3f48f173a7046749372f5bdca47960e_D20220726-20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-26</xbrli:startDate><xbrli:endDate>2022-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd947fb9100e419d90d6c2dfa4983059_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i693aca7e97aa4503a8037a869333ca1b_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7f54e53e964d7c9958ac2b8a920ce5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ce9bdb2fb7b4bf88fc587dee9f5a817_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b5450d72e34c33b4dec3e66a44b756_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd098fd38fd419896b25481459eb489_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5c7726e1d4f43d6ada81fc4d023fd3d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa27a7d5291744e8a8982d3d8fd39e8b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief418486b3fd4aeaa1b3a28dde7a1f60_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i810b267149e44965acbf595fbb6b9e33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac7381acc7e4e059c3e2321b8b15239_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c38f20f22ba485bb4c251fc607c0a9e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d550357dd0498aa73e25001de9cc1a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefc06d4abeb64a938a55a63bbfcfedc8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief933a73262047ada7ce3fa9a403b153_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e6e40b20bd48d29415c8c3c7305f97_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c1d8dcb1b3c4b8bacd38918de4039b1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib709c1ffb8854bb481421062c0b218f9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab1678b723954fb2a37229ed7298c334_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04cff27d9bb54d1fa6f4a32a4b7398df_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9f4882fb39748e396fbfb4e6f2141a1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2363ec926c83422882f201f395e6418e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia89c179f7606467791e1ccda6296e332_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied8bda146b1e42518db4ad5b9607da40_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a13d205acea4035b1472638de599302_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i608d2c0acd8a446f97ea23de80771ca2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86142a8002b4fb3bfa67f3114a2168c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdb93712507e4b0d9bcf6e602fc11d8f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b76d577a5a04ef2a426145c4efdec1f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i330a14431e6c447f850339e8183a87c2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib64ac500c81045e0900ce23c27023a2c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ee636604f0544608be83b816d561a04_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8993710e84743d28a95a4b2457fa9cb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43870715ac94163bfa487cc20cc7a5c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26a535ba45543e8a02c93c70be14f9c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i791e53caa07d4e4ea55fd15972c74a19_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ef6e2feb31a41178bada54e92855b1b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a540ce1f4734c1b8df74de8131b45d3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb8ca4cb3f04e0ebddd7c2383d433d7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8e5492e892a4011aeca081fc7b607fa_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05496cda0e33452896f54514996a1288_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad9574638cde472faee405847f9f3e1a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i586689ef6a80408b93ad64b72f84c672_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04ff76c144cd4408a9a52fbbc69b19cf_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a54ee7566ce41918832cd3479ef935e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i805c213b2c0743b087c75996e2d88021_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62d5577ed469475da80b700a69f04f2c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c636231d35f4bf0971afbbb890c922e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c2b515fd83f4999933be813beb65c48_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcd3b7ed4d6b4262a23a7634c2c7aff2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9fb95774ab143ebafe375c57e2fac61_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefed914e0ec24b92964d9459ffc3d327_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id406989deae044f4acf764c75f7ad87b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic04da1d4150b40a8abe55e454e756c44_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c71d7b0754c47a8818fc47cb60bf5b8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605912304b144c4bba382814666efe0a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib370fe55235440b19f13161583777fca_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3e4af26d3548a0905d4625e4c6960f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8777634ed6ab43ceb831077cb1ba1505_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf075aa78dbb48cb952fb65ae88fc07a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c01b6b14c1a485fb20538cac3587498_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida8b4e5a23a9418d8c44be5a1e0e74a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i515a17efa892472b86a77214dfa7ef7b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41b2c7dcf954060af28af4c157705cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib77a7ee0b23046cc9cb75730e07ea8c6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica341a5f24ad4bcab2e21eea5d444a9d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76dc324051474558a170627d6a003711_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d4f5d1f93e04d73aa48631d7518db9c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d0c3d06b8544eda7efed1647c21a9c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3011064556b748619173464bff0d68e3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9776e033e33d450695fa795370df723c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940b58f0b39b440d929568bd00af95e5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if417d192e5eb43008abe45d33168ea61_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id433e60fe208470fa98c4a38610c659c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a3ec63d2d654bbe9108ebb110c10485_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i661d0dfb1ecb4a8e85c58f301a66b3bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef1c49cdd9a44d09573c601607368e6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6a10d1d7b8341e48e7157fc9809cb9e_D20190903-20190903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-03</xbrli:startDate><xbrli:endDate>2019-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib12d63d710f14cf2a688757cc358ebca_I20210714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001610618</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>cdtx:option</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i103e7621649e479aa89c7d0167cfd96f_1"></div><div style="min-height:30.6pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODc4_0a614a74-3ede-413b-a760-3445350e4c24">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NWY2MTU1YjI2NjhlNDg0NmI2MmU4YTk5YjdlOTc3MjYvdGFibGVyYW5nZTo1ZjYxNTViMjY2OGU0ODQ2YjYyZThhOTliN2U5NzcyNl8wLTAtMS0xLTQyMzY3_924ce57b-b042-4b40-b5cc-65ee14337c56">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xMzU_535fa9e6-f04a-459d-a05a-419aef07ce23">SEPTEMBER&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6YTUxMzNmNmEyNGI2NDhhODhmYmE0NzY1MDE4MTlhZWIvdGFibGVyYW5nZTphNTEzM2Y2YTI0YjY0OGE4OGZiYTQ3NjUwMTgxOWFlYl8wLTAtMS0xLTQyMzY3_a5898101-8d60-4889-90ab-b63a5d05622b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgz_4f38336c-4a2c-4101-92e5-07748a6e3c07">001-36912</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODc5_92df4576-a419-4b20-80e7-4c986dad503e">CIDARA THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:23.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.469%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.405%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8wLTAtMS0xLTQyMzY3_1b97eadc-5fcb-492b-95bb-af1642eef5ff">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8wLTUtMS0xLTQyMzY3_a6b9be63-8996-4347-b559-c95665882d9c">46-1537286</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporation or Organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:14pt"><td colspan="12" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8zLTAtMS0xLTQyMzY3_5e66dfde-ef80-4f81-80a2-385bb3e1f76c">6310 Nancy Ridge Drive,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8zLTMtMS0xLTQyMzY3_62002cfe-55c9-485a-92d2-c670ed933cc4">Suite 101</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTAtMS0xLTQyMzY3_4db9bd7e-c7bf-4735-9595-8929aab2cca7">San Diego,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTEtMS0xLTQyMzY3_d0e422a5-4195-4f16-8968-29b451ce5f57">CA</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTItMS0xLTQyMzY3_8ad313ff-9ae3-4c39-9337-4aea32e600ab">92121</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTUtMS0xLTQyMzY3_3c8b78ca-89e5-4b95-829d-6c8b23c83e4f">(858)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTYtMS0xLTQyMzY3_2b381d2a-3444-47dc-a998-b0725823b341">752-6170</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of Principal Executive Offices, including Zip Code)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:34.649%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:38.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6MWU5ZjNjNDNiNDA5NDNkMmI2YjFlNjlmYjAyYzkwZmIvdGFibGVyYW5nZToxZTlmM2M0M2I0MDk0M2QyYjZiMWU2OWZiMDJjOTBmYl8xLTAtMS0xLTQyMzY3_52322cf2-de9f-4996-8707-39cd7ea02ee9">Common Stock, Par Value $0.0001 Per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6MWU5ZjNjNDNiNDA5NDNkMmI2YjFlNjlmYjAyYzkwZmIvdGFibGVyYW5nZToxZTlmM2M0M2I0MDk0M2QyYjZiMWU2OWZiMDJjOTBmYl8xLTItMS0xLTQyMzY3_6f11d7fc-a0a8-4a43-90fe-b8d98d68b901">CDTX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6MWU5ZjNjNDNiNDA5NDNkMmI2YjFlNjlmYjAyYzkwZmIvdGFibGVyYW5nZToxZTlmM2M0M2I0MDk0M2QyYjZiMWU2OWZiMDJjOTBmYl8xLTQtMS0xLTQyMzY3_43f5112f-7d82-4561-a8f6-01e59fee9a5c">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;<ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgw_2d873fa6-f055-4e44-a96a-9d08c7b12ecb">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;<ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgx_bba2f01b-4dc5-40f1-9659-eb491de74cf0">Yes</ix:nonNumeric>&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.573%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.863%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6ZGI1MDc5ZDIwMmVlNDI0ZTkwOTU0ODZjYjQzOTczOTcvdGFibGVyYW5nZTpkYjUwNzlkMjAyZWU0MjRlOTA5NTQ4NmNiNDM5NzM5N18yLTAtMS0xLTQyMzY3_9fc38916-7d11-4f46-a78b-7590b120e615">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6ZGI1MDc5ZDIwMmVlNDI0ZTkwOTU0ODZjYjQzOTczOTcvdGFibGVyYW5nZTpkYjUwNzlkMjAyZWU0MjRlOTA5NTQ4NmNiNDM5NzM5N18yLTQtMS0xLTQyMzY3_91dd4496-01ca-4a6f-bbb8-c274a4391449">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6ZGI1MDc5ZDIwMmVlNDI0ZTkwOTU0ODZjYjQzOTczOTcvdGFibGVyYW5nZTpkYjUwNzlkMjAyZWU0MjRlOTA5NTQ4NmNiNDM5NzM5N180LTQtMS0xLTQyMzY3_8de11e3c-d05f-4006-8653-7b0b2be444a3">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgy_524116e8-bb4c-4007-bf72-0f07101190cb">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;&#160;&#9746;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">As of October&#160;31, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="i3ea934756b6a4b36acc5dce537f5d6cd_I20221031" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODIy_8a2fdcec-75e8-4b39-b1ce-fd2150241ec9">71,618,091</ix:nonFraction> shares of Common Stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODUw_23e7add0-450d-48cd-88cb-4126784e4caa"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODUw_84ad136b-49cc-4eec-952d-5ddcadeb53b2">0.0001</ix:nonFraction></ix:nonFraction> par value) outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:30.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.009%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_10">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_13">Item&#160;1. Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_16">Condensed Consolidated Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_19">Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_22">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_25">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) for the three and nine months ended September 30, 2022 and 2021 (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-6.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_28">Notes to Condensed Consolidated Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_28">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_61">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_61">26</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_79">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_79">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_82">Item&#160;4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_82">37</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_85">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_82">37</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_88">Item&#160;1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_88">39</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_91">Item&#160;1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_91">39</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_127">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_127">76</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_130">Item&#160;3. Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_130">77</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_133">Item&#160;4. Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_133">77</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_136">Item&#160;5. Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_136">77</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_139">Item&#160;6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_139">78</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_142">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i103e7621649e479aa89c7d0167cfd96f_142">79</a></span></div></td></tr></table></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_13"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1. FINANCIAL STATEMENTS</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNC0xLTEtMS00MjM2Nw_a9d2478f-da0c-4a44-bcb9-4af811b2b81f">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNC0zLTEtMS00MjM2Nw_64268cb1-b76c-47ba-9bd3-deb2cf8e2ea2">59,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNS0xLTEtMS00MjM2Nw_6a5b943b-f620-404a-b85f-b9a268e98827">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNS0zLTEtMS00MjM2Nw_bc30d3b3-8dcf-4b49-9f29-7661163fae15">2,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNi0xLTEtMS00MjM2Nw_4961c698-6496-419c-bafa-633457de3dd3">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNi0zLTEtMS00MjM2Nw_85f81e96-7bdd-470e-a041-097accdf2f6c">5,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNy0xLTEtMS00MjM2Nw_257537f6-02da-4472-a43c-bc6e4d4752b6">5,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNy0zLTEtMS00MjM2Nw_2ce08f2e-1819-420c-bd4d-ebeffe65f813">4,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOC0xLTEtMS00MjM2Nw_e99b6d7f-dec3-44dd-98a8-d10c43081810">63,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOC0zLTEtMS00MjM2Nw_d6305344-77fa-4ce4-b6c2-e5044b314090">71,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOS0xLTEtMS00MjM2Nw_dc6d30b5-e3ed-49ea-91bb-3e3dee3de8b6">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOS0zLTEtMS00MjM2Nw_285fd04a-39b7-4d28-b4b7-40594d5eefb4">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTAtMS0xLTEtNDIzNjc_77ad1a5a-9e9d-40a0-b780-9ea082b3dbe1">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTAtMy0xLTEtNDIzNjc_10a6e9e2-fa69-4be8-98ca-09aaf76215f8">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTEtMS0xLTEtNDIzNjc_4ea5d6f2-63f0-4204-83c4-a50f940279cd">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTEtMy0xLTEtNDIzNjc_f4f39644-aeba-4b7c-ad5e-fbb1cec92f2d">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTItMS0xLTEtNDIzNjc_6d70413e-962f-4378-82dd-4fd54fbcde8b">66,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTItMy0xLTEtNDIzNjc_7d36c14d-0645-4d5a-be25-65e76d2a676d">75,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTYtMS0xLTEtNDIzNjc_ae8b9b80-8166-4552-8141-4098ff9c9c51">4,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTYtMy0xLTEtNDIzNjc_887c47c9-bb30-4de0-ac54-34a85aa7e1ed">1,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTctMS0xLTEtNDIzNjc_5f3d32d7-780f-4770-ad1a-3b571892265c">8,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTctMy0xLTEtNDIzNjc_dcabccc8-27c6-4f45-a17c-00173482fc9e">10,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTgtMS0xLTEtNDIzNjc_afdb1152-5e41-4986-96ed-d2e592332140">4,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTgtMy0xLTEtNDIzNjc_9331c799-63ba-409b-a808-6cc330169e35">4,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current deferred revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTktMS0xLTEtNDIzNjc_d191e78c-3580-4c37-b962-5a904aad528a">15,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTktMy0xLTEtNDIzNjc_a5cab5f8-65b0-43e5-93b3-f4abc9884a98">13,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMS0xLTEtNDMxNjE_2b87fe1f-00b4-434f-acb2-c9fbaba5f7fc">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMy0xLTEtNDMxNjE_ede654c5-bf70-4044-b6b2-674edee5f2f7">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of term loan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMS0xLTEtNDIzNjc_e56f6185-3f6d-4e5c-b357-5350cda5d23e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMy0xLTEtNDIzNjc_ffa9ac20-f0c4-4566-bdf2-b80ee6b4795d">2,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjItMS0xLTEtNDIzNjc_99f69754-ea09-4d22-9195-9406d88ac675">33,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjItMy0xLTEtNDIzNjc_a3b22c1b-754b-4b43-a77f-a1028e1b2b07">34,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjMtMS0xLTEtNDIzNjc_ad7400bf-9b1f-487b-b6a8-8bb69d1a3813">24,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjMtMy0xLTEtNDIzNjc_18f9a57c-dffa-411c-804b-e10f15616586">18,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjQtMS0xLTEtNDIzNjc_cc603157-7632-45d1-ae7d-ba9c831e3af7">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjQtMy0xLTEtNDIzNjc_d4e565c6-61e8-47a0-bfb7-df67fbe5eea3">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjUtMS0xLTEtNDIzNjc_7fd00986-d878-40f5-a96b-c3f8c59ce7d1">57,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjUtMy0xLTEtNDIzNjc_fbbc3527-4548-4180-990b-c7a7b9126fbe">53,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjYtMS0xLTEtNDIzNjc_e101f2db-60c7-4267-84e2-c56e17041699"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjYtMy0xLTEtNDIzNjc_91d2afff-7b84-4121-83cb-4bc4da4de3fb"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8yMg_389f3a30-a477-42b1-9230-6b61fda4de8e"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8yMg_b039281c-5322-448e-8b03-a432723991b4">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8zNg_7e8fdd94-1cd7-4876-81dc-c3e424d3d322"><ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8zNg_dd92e960-c30e-468e-bfd2-a6d6c0388de4">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2022 and December&#160;31, 2021:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" xsi:nil="true" name="us-gaap:PreferredStockValue" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMS0xLTEtNDIzNjc_a86833c2-0131-40ac-b53b-a6f8d30c51c4"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" xsi:nil="true" name="us-gaap:PreferredStockValue" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMy0xLTEtNDIzNjc_6d52b54e-b7ca-4524-a1a3-d222525c27de"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV80Mw_262757f3-5ecd-4486-ad1f-c7598a681631"><ix:nonFraction unitRef="usdPerShare" contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV80Mw_4fb31243-83e4-4c9b-bbc7-8cf8cb4813f2">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV81Nw_423f430d-4302-4b05-958d-f62125ddb26d"><ix:nonFraction unitRef="shares" contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV81Nw_e137cc0d-b41c-462d-b0a1-f25eaefd051e">4,947,759</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV85Mg_2501dd97-5d39-4f4c-abf6-bf9b4b7307a2"><ix:nonFraction unitRef="shares" contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV85Mg_4fd7ff97-3cf0-40f2-a8af-11ec68b87ea9">1,870,713</ix:nonFraction></ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV8xMTM_59487669-2bbc-4d6d-8213-7290175db536"><ix:nonFraction unitRef="shares" contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV8xMTM_7688b69a-ad36-435d-a644-57024c568bb8">1,818,472</ix:nonFraction></ix:nonFraction> shares outstanding at September&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMS0xLTEtNDIzNjc_41a90ef2-821f-4161-a0b8-1cb3e80f3bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMy0xLTEtNDIzNjc_fb7d53bf-0758-4279-8a23-30a2981d9826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xOQ_23e7add0-450d-48cd-88cb-4126784e4caa"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xOQ_84ad136b-49cc-4eec-952d-5ddcadeb53b2">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8zMw_73da8890-124f-4bb9-a205-bc9ab0c40c8b"><ix:nonFraction unitRef="shares" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8zMw_e56b4d62-2a31-4fb5-8893-11ecc4bf502b">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized at September&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl82OA_4e4db261-a89e-47d4-98af-3ccd4bda0a3e"><ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl82OA_546c15d0-6993-4177-b81f-8eb87b19843a">71,181,197</ix:nonFraction></ix:nonFraction> shares issued and outstanding at September&#160;30, 2022 and <ix:nonFraction unitRef="shares" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xMTE_a9b63c23-93b8-4836-ac2b-07c686465fc9"><ix:nonFraction unitRef="shares" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xMTE_c4096338-8e79-4528-a04a-63575c4fc81f">67,863,674</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMS0xLTEtNDIzNjc_21a6d905-bb15-44cd-959b-df677f5f6557">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMy0xLTEtNDIzNjc_93b26415-c766-4a19-9aaa-9c4130436235">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzEtMS0xLTEtNDIzNjc_47c0c3aa-20f7-4c9b-bc90-a32a3578707b">402,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzEtMy0xLTEtNDIzNjc_67ffb368-41df-4b2c-976c-48e0d8f74d2d">398,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accumulated deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzItMS0xLTEtNDIzNjc_19a6ed5d-5743-4d50-aad5-19c4ebb02bcc">393,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzItMy0xLTEtNDIzNjc_f0ee4572-7169-490e-97d7-2eb82a5d5f77">377,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total stockholders' equity</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzMtMS0xLTEtNDIzNjc_600efc73-7849-440a-afe7-ced8b0ab9d5c">9,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzMtMy0xLTEtNDIzNjc_aa116c1d-83a3-4ec3-8d06-4f378f9a10a0">21,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzQtMS0xLTEtNDIzNjc_0fccc072-7997-4d15-99ed-caa119c2e0e4">66,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzQtMy0xLTEtNDIzNjc_1f74a5e9-533d-45a3-862a-964ab553f1a4">75,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands, except share and per share data)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_011b2109-21a8-464f-bb1e-33d79328bc43"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_278b3e2b-3ca4-47d9-97c2-0c16a9fc93d4"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_be7bbebb-4238-4090-b165-d91c10c23ad7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_f777ca9d-6e93-4f97-b8fd-af359bd8aa31">Collaboration revenue</span></span></span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0xLTEtMS00MjM2Nw_2ac52b5f-1f66-4eb9-9061-bf6555734413">40,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0zLTEtMS00MjM2Nw_358256ed-e3bc-41a8-9750-06e7ad68e7bb">7,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy01LTEtMS00MjM2Nw_4acaffc1-06d7-448f-baad-5c3d4ae3076c">54,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy03LTEtMS00MjM2Nw_246f6779-974f-45fa-97b6-40e74a78c4ae">42,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC0xLTEtMS00MjM2Nw_77f832cb-0cab-4af9-8e6b-8a4df04208d0">40,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC0zLTEtMS00MjM2Nw_043f4d9c-ea1d-4d4d-b381-d3e18b70cec4">7,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC01LTEtMS00MjM2Nw_c5c11dd4-cf0f-4abc-8094-39d7e05f67d6">54,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC03LTEtMS00MjM2Nw_85628603-1e51-465c-81a3-7e5452645db3">42,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi0xLTEtMS00MjM2Nw_7026519a-df37-43fc-878e-b303b53e6c77">20,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi0zLTEtMS00MjM2Nw_8c72a3e1-f8be-4aca-af2e-0fad27f7c543">20,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi01LTEtMS00MjM2Nw_81f37e87-f780-4735-9e2c-71b20b9ef4b1">55,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi03LTEtMS00MjM2Nw_3cd790e1-ef39-45b2-b94b-f28a8ad79f1f">54,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy0xLTEtMS00MjM2Nw_cd18f71d-438c-4ef0-b7ab-4a2d253b18ce">5,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy0zLTEtMS00MjM2Nw_2b63b90a-78dd-4327-bd7d-c7a6650c9993">4,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy01LTEtMS00MjM2Nw_ec7dd365-77f0-45d0-9e87-0f16ee603102">15,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy03LTEtMS00MjM2Nw_616a5f76-75d0-484d-a026-cae733b69862">13,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC0xLTEtMS00MjM2Nw_220c3c49-b8fd-4ff5-81d6-37f956e0472b">25,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC0zLTEtMS00MjM2Nw_75bfc9a7-504c-4bd7-b362-bcd003595af7">25,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC01LTEtMS00MjM2Nw_7c95b08d-c690-4651-a2ff-0007a4868c7f">70,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC03LTEtMS00MjM2Nw_f0970184-33a0-4a99-957e-dd07de2504a8">67,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS0xLTEtMS00MjM2Nw_541e8531-2435-4104-a2a7-cc94c2224b3f">14,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS0zLTEtMS00MjM2Nw_c3310585-4d3b-4af0-aefb-a157dc68c931">18,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS01LTEtMS00MjM2Nw_3597e9b8-a0f2-4651-8256-2456a5c921d2">16,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS03LTEtMS00MjM2Nw_429f3c6b-0ec6-41c0-b38a-c1bfaaeae2b3">25,485</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtMS0xLTEtNDIzNjc_d89198ee-16dd-44a5-bd1a-5eff7ddac052">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtMy0xLTEtNDIzNjc_ae3a8805-f874-4b95-ae74-cc18d3d802e6">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtNS0xLTEtNDIzNjc_1f0b16db-b883-403e-abd1-f23a277ca8aa">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtNy0xLTEtNDIzNjc_2d5b42d3-1515-48b7-9295-900e3270c94f">179</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItMS0xLTEtNDIzNjc_fd163b56-d02f-4c6e-8921-2fd3791d6663">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItMy0xLTEtNDIzNjc_71826f99-8877-42b5-b0b5-e990c168ff84">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItNS0xLTEtNDIzNjc_e71a5dce-24d8-46d4-b630-e97c9b98cb8b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItNy0xLTEtNDIzNjc_7064ade1-1346-477e-8885-0b047a15ea3d">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss) and comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMS0xLTEtNDIzNjc_a03a8234-392f-4c3d-83dd-de06b394cc0a"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMS0xLTEtNDIzNjc_e98118b6-9db8-49da-a44f-672c020f71bc">14,978</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMy0xLTEtNDIzNjc_5d178df8-65f1-4c36-afb8-5f76d9da6bf5"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMy0xLTEtNDIzNjc_71204ca7-d86d-49b5-8843-c27b90838725">18,083</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNS0xLTEtNDIzNjc_210d593f-b54f-4c38-b4fb-5e1b814673ba"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNS0xLTEtNDIzNjc_8f54952b-483e-48cb-83d6-5cad3372d671">16,422</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNy0xLTEtNDIzNjc_e479cc2b-fc0d-4dfc-8fbe-4a039f437803"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNy0xLTEtNDIzNjc_ee776232-ced5-4db5-8fc5-3cbe431a51cf">25,664</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtMS0xLTEtNDIzNjc_6e261422-e566-4015-9594-cf70c8d33218">3,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtMy0xLTEtNDIzNjc_94cc0080-93e0-4a73-913b-6304a294480b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtNS0xLTEtNDIzNjc_29c20057-961e-4b11-9042-6061f7acc181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtNy0xLTEtNDIzNjc_983aa547-33d2-4a1d-a133-860504bfebb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtMS0xLTEtNDIzNjc_67c9c26f-7aad-49ac-a014-6047b27a61cb">11,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtMy0xLTEtNDIzNjc_9c81812a-9375-4d42-970c-eba4e377b8c8">18,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtNS0xLTEtNDIzNjc_2c6810eb-929b-4d3b-9a6b-edd8f4262e0a">16,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtNy0xLTEtNDIzNjc_37cd46e1-85b3-4dab-894a-46aa4f49f6e6">25,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctMS0xLTEtNDIzNjc_04cac45a-c07f-491f-9415-7f154be1ff87">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctMy0xLTEtNDIzNjc_fc89585b-a28b-4c61-acb6-b39ac3ff68b9">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctNS0xLTEtNDIzNjc_155c0897-d948-430b-858e-381f0cbf7736">0.24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctNy0xLTEtNDIzNjc_29fbbc98-6bac-47c6-bf92-7ca2f949b05b">0.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtMS0xLTEtNDIzNjc_c5b37227-2a9c-4b66-9064-f9b7cce3a2d2">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtMy0xLTEtNDIzNjc_7623328b-b2de-474b-a981-7fa9cad3387f">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtNS0xLTEtNDIzNjc_4f5ad4a6-f67a-4eaf-b123-80700bc6e28b">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtNy0xLTEtNDIzNjc_286e0eeb-c4d1-4747-9360-de2de739f950">0.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute basic net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtMS0xLTEtNDIzNjc_d3ba94be-ba4d-49c7-8e8f-a50e0e4dabc0">70,217,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtMy0xLTEtNDIzNjc_b196dffb-c6bc-439b-b0a3-818ce27ca9f8">49,533,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtNS0xLTEtNDIzNjc_005ecc98-b91b-48b7-91c6-540e9541c0a4">69,170,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtNy0xLTEtNDIzNjc_d8d17f0f-0691-402d-a03e-b8114d616389">48,402,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Shares used to compute diluted net earnings (loss) per common share</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtMS0xLTEtNDIzNjc_7b19a23c-87c8-4c45-9e84-0555268510d6">88,592,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtMy0xLTEtNDIzNjc_e4a20d25-0f28-455d-a411-26a96cb2e994">49,533,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtNS0xLTEtNDIzNjc_a554538e-82e1-450b-ac5a-584c8b10b5a5">69,170,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtNy0xLTEtNDIzNjc_f9775731-d8d8-4b97-8fe0-9642f0215a6e">48,402,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net loss</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMy0xLTEtMS00MjM2Nw_7ffa5daa-3c83-4118-bcd7-aac46156998c">16,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMy0zLTEtMS00MjM2Nw_699eb247-9aa7-417c-80cd-4bf69b4d779d">25,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNS0xLTEtMS00MjM2Nw_39c61ee3-c2dd-45a7-b20d-98b03c8a0498">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNS0zLTEtMS00MjM2Nw_d554c854-3d0d-42bf-8b99-b17638fdbe30">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of costs to obtain a contract with a customer</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0xLTEtMS00MzQ4Mg_856dc14a-0c93-48ad-ad91-34b00fcdc4a3">1,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0zLTEtMS00MzQ4Mg_23b07f18-be7e-4f76-8394-2da2dcf0c735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0xLTEtMS00MzQwMw_9501eb89-611d-4037-a889-09386f0b5f27">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="cdtx:OperatingLeaseRightOfUseAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0zLTEtMS00MzQwMw_76dd04f0-3720-48ef-a4b3-8775f7ed5497">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0xLTEtMS00MjM2Nw_65e7493e-87f2-4bdf-bdda-f59580e8c395">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0zLTEtMS00MjM2Nw_b7f582ff-e60e-47d9-900d-8216af046049">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-cash interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0xLTEtMS00MjM2Nw_f7933b85-2085-4e4d-86cc-d4a8f1f23c5d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:PaidInKindInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0zLTEtMS00MjM2Nw_527bcb6d-6920-4dfc-a63e-712d8e059364">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfOC0xLTEtMS00MjM2Nw_dc545046-d617-4dfb-859e-76b8db0513b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfOC0zLTEtMS00MjM2Nw_70723ba7-c019-4630-8d93-44db3c283b1d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTEtMS0xLTEtNDIzNjc_3e701712-0e5e-4d8e-abdd-c1c4d29c3bed">314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTEtMy0xLTEtNDIzNjc_9af47669-97ed-4ccc-aef0-ef742dc7c9ff">7,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses, other current assets, and other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTItMS0xLTEtNDIzNjc_d7a937e1-e662-409c-b52e-9b9761e377cd">1,662</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTItMy0xLTEtNDIzNjc_5c8ed821-c88f-471d-9458-5317e99e59f1">713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTMtMS0xLTEtNDIzNjc_ccf55b14-124e-496f-abc5-a6b45fd71c99">1,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTMtMy0xLTEtNDIzNjc_b4e44674-ec83-47ed-b5fd-3c1f158e8628">811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTQtMS0xLTEtNDIzNjc_d5892b7b-accb-415c-9588-7ea3b031a502">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTQtMy0xLTEtNDIzNjc_3474fd7f-6fda-473a-a5d3-d46ce5823793">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred revenue</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTUtMS0xLTEtNDIzNjc_fe1d7cef-f1b9-46c1-ac16-dbc7a61f6de0">7,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTUtMy0xLTEtNDIzNjc_690c86f6-4a95-46d6-b259-06e29b3a2a7b">5,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTYtMS0xLTEtNDIzNjc_4cdf9c6c-8fa1-4f29-91a3-2215d852aef9">850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTYtMy0xLTEtNDIzNjc_c1af558f-2e45-4e2f-8692-315adef6b687">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTctMS0xLTEtNDIzNjc_813007e6-21db-484e-aeee-a42ddabca981">7,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTctMy0xLTEtNDIzNjc_4ea2d4da-d7df-48a9-abc9-fc53c1ebd94b">10,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjAtMS0xLTEtNDIzNjc_a766d77b-c4f4-49e0-8aee-1822eeb28634">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjAtMy0xLTEtNDIzNjc_4b4f7dc2-5cf5-4dfe-837b-8bb83eeceb20">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjEtMS0xLTEtNDIzNjc_ce701b2d-4fb9-4820-a5e6-90247bfc0f51">109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjEtMy0xLTEtNDIzNjc_60d03f68-7b5d-4a66-a820-12d2e43cad68">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjUtMS0xLTEtNDIzNjc_b770e116-a7ec-46bb-b847-6576d9ca6bd4">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjUtMy0xLTEtNDIzNjc_d2677185-b2d0-4389-ac04-4b4b23f7a528">11,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjYtMS0xLTEtNDIzNjc_8db47348-0d1c-4cec-b4c2-0b3dbfe15fb7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjYtMy0xLTEtNDIzNjc_6ba0ed48-594f-48ac-ad28-4b74cbe4f4d1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjctMS0xLTEtNDIzNjc_e039df7a-25a9-47fc-83ec-2a68349586a6">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjctMy0xLTEtNDIzNjc_a38e8d36-eb31-4214-b7c9-a86e8b55963b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Principal repayments of Term Loan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjgtMS0xLTEtNDIzNjc_6f31b541-c556-4452-97ae-e0d88d712ec0">2,593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjgtMy0xLTEtNDIzNjc_ea7d9ce2-e272-4f72-9209-77dcdf476cc9">3,333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjktMS0xLTEtNDIzNjc_a8a01bc1-44ba-4e1f-b6fb-778acd67bfb5">1,615</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjktMy0xLTEtNDIzNjc_7f0926e6-4a59-4e78-a68b-910fbafb17c0">7,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzAtMS0xLTEtNDIzNjc_00ce9262-97cb-460e-8344-e27a9bfa9ebb">9,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzAtMy0xLTEtNDIzNjc_31110cca-3b50-4fbb-b1d3-b34d2e7bbd66">2,644</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzEtMS0xLTEtNDIzNjc_38345cac-cf88-422f-b7bf-8e83ecf4a22e">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1541d551c68f4ed2b3a7797a2421af03_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzEtMy0xLTEtNDIzNjc_e9cf67dd-60ba-4097-8bf5-8cdda3bbe17f">42,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzItMS0xLTEtNDIzNjc_e4caab9a-e465-43f3-9a0f-1caf894047db">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6f6259262c4efcb61b27512dc283e6_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzItMy0xLTEtNDIzNjc_908f0865-977c-4fc5-b908-30b2c67c9773">40,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flows:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzUtMS0xLTEtNDIzNjc_568d5d9b-ef1e-4ac9-98fc-adfaee18617f">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzUtMy0xLTEtNDIzNjc_d42c1f76-1eed-45e1-9c61-70ce73e5defd">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right-of-use asset obtained in exchange for lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzgtMS0xLTEtNDIzNjc_587830e3-1e91-4732-bb46-c070fd327509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzgtMy0xLTEtNDIzNjc_e4cb2ae8-9ece-43a3-b536-2822bc08c044">2,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Purchase of shares pursuant to Employee Stock Purchase Plan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDAtMS0xLTEtNDIzNjc_e7c84200-682f-4efd-904b-19ab4f34a667">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDAtMy0xLTEtNDIzNjc_b3e6517c-bf0c-4524-b160-9b8a1c0d1406">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses and other current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDEtMS0xLTEtNDIzNjc_0c61e215-7103-4127-a9a3-7a5301b3a5b6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDEtMy0xLTEtNDIzNjc_1a0e531a-593a-4562-b307-c6a8baeeb2b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred financing costs incurred but not yet paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDMtMS0xLTEtNDI1MzI_4fa81166-1da3-4ebd-b038-a2087ba914e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDMtMy0xLTEtNDI1MzI_401fa832-5dd0-48b0-bbe8-49df5ee9d934">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three and Nine Months Ended September 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42a96ee88a724103bd21dea2ce351a6b_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0yLTEtMS00MjM2Nw_d08c4859-adb6-4f16-8209-7c7f0e0ebbe4">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a96ee88a724103bd21dea2ce351a6b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy00LTEtMS00MjM2Nw_ee41e5c5-4a20-4d4a-a9f6-b7f855929e25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bdf276fab234f5793b92dd0eab61737_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy02LTEtMS00MjM2Nw_bac1fc5c-9893-4c52-b3ea-54f7aee0cff0">67,863,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bdf276fab234f5793b92dd0eab61737_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy04LTEtMS00MjM2Nw_56269de5-3526-4477-944d-cea5f80b9f16">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb92875f7444accb8df71f69d1e6823_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0xMC0xLTEtNDIzNjc_58303de9-f35d-4485-883f-a0198f40e99e">398,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i098de05c0a73424893e619674f8ede0d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0xMi0xLTEtNDIzNjc_ecae09f8-d4b6-46df-9d41-c54f440c0766">377,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0xNi0xLTEtNDIzNjc_40755ac3-767b-4e48-80cc-94d086df85fe">21,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i439485f4e8e2471190cf787925ce765f_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfNi02LTEtMS00MjM2Nw_3c3bad82-0c0d-47de-969f-1fec56e9ffe7">644,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id549c6dc162445b0a8b51e25ba53845f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfNi0xMC0xLTEtNDIzNjc_0ae5b416-54c2-4b32-a922-b197d2f148f3">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfNi0xNi0xLTEtNDIzNjc_4959a338-7a69-43be-bf68-83e45b75dd5b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i439485f4e8e2471190cf787925ce765f_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfOC02LTEtMS00MjM2Nw_1afa0593-bb81-4cab-b282-83d7622a8823">541,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id549c6dc162445b0a8b51e25ba53845f_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfOS0xMC0xLTEtNDIzNjc_7b0920ba-844e-4014-b496-e5aa7a5a65bd">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfOS0xNi0xLTEtNDIzNjc_b9b4459a-40ab-417c-be27-6eaf40b5cf8d">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8bf3279b1814f298a5a4e543dffe461_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTAtMTItMS0xLTQyMzY3_f90094a9-0c52-4315-81e1-b3a2c86da187">18,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTAtMTYtMS0xLTQyMzY3_3736b5cc-1ee4-4683-a525-cae716c1bc50">18,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ddfea5cb5ac4dbba5969c5c32dc405f_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMi0xLTEtNDIzNjc_5305ef2f-0222-45d5-8f44-57f06d4d1ba0">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ddfea5cb5ac4dbba5969c5c32dc405f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtNC0xLTEtNDIzNjc_b5d7e936-5c4d-4682-baa2-8b3c23d6b58f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcfbfe674ada4806903f264b16edff10_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtNi0xLTEtNDIzNjc_7eebcd3a-3760-4a9b-83e7-3c9f5b0a1ca7">69,049,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfbfe674ada4806903f264b16edff10_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtOC0xLTEtNDIzNjc_ac209f9c-5210-47dc-9423-d6996098aede">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3fd27b6890e4826a59b299ceb905038_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMTAtMS0xLTQyMzY3_33f2d029-e580-4c29-ae1d-d9e887cd84d6">400,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i160c27cee64e434eabaaa10605b89946_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMTItMS0xLTQyMzY3_52c218e6-bda7-4a16-bf04-a73005e79769">395,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cb81e64d8f846e1b7b1aedc4305a63b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMTYtMS0xLTQyMzY3_bf4ffbfc-68a8-4ff0-9dbc-a5a28b1ca498">4,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc647f0b1f5d4ee99cd69cc22038ac7b_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTYtNi0xLTEtNDIzNjc_d41fc9e6-1743-432d-8917-31878c31238a">5,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idc647f0b1f5d4ee99cd69cc22038ac7b_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTctNi0xLTEtNDIzNjc_258b7846-4394-4605-8590-86ea8bb933f9">184,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70591917e30b4422865fea663b0f796f_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTctMTAtMS0xLTQyMzY3_12b387e9-cf01-498a-b076-0ef5d847ce3c">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTctMTYtMS0xLTQyMzY3_3897fb80-2ccd-4083-8571-fa7f43aeb705">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70591917e30b4422865fea663b0f796f_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTgtMTAtMS0xLTQyMzY3_9c99c0b7-d11c-47a3-b0bc-cc47000db808">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTgtMTYtMS0xLTQyMzY3_2b0fac4f-a63f-4579-8148-ab4fa8625368">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance costs for underwritten public offering</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70591917e30b4422865fea663b0f796f_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTktMTAtMS0xLTQyMzY3_42a4f2e4-b21e-4eed-a5e8-b5fecbecb896">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTktMTYtMS0xLTQyMzY3_4e217383-d4f8-4d03-b05a-2982c9cc4042">720</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5122efa490e14a07b68b1661470c2d68_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjAtMTItMS0xLTQyMzY3_a4a78b1a-c98f-4588-8fc5-e150a9b51c1c">13,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjAtMTYtMS0xLTQyMzY3_694c7127-56d1-4aaf-bc68-ae6fb2014287">13,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i26800230236f4cc9bc3aac4ee89d9783_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMi0xLTEtNDIzNjc_3e9518dc-aa76-439d-8d6f-4774b99db1f9">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26800230236f4cc9bc3aac4ee89d9783_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtNC0xLTEtNDIzNjc_45e655d4-df67-4c8f-894a-3608af22717d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1a3f0c9c39f4de6bf503a1bbe64da16_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtNi0xLTEtNDIzNjc_5e4231f4-5e14-43d9-8edb-44fc1458650b">69,238,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a3f0c9c39f4de6bf503a1bbe64da16_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtOC0xLTEtNDIzNjc_47a5642b-f775-42be-9b23-4b9b313b82fd">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82d7061381343cf8fd9d02f13182140_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMTAtMS0xLTQyMzY3_e4c0fe1a-f8cf-44f2-ae80-09b284faeea9">400,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i956248bf259a4879bbb53a8a82a26ec7_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMTItMS0xLTQyMzY3_972dcf9a-afd4-45d0-b68f-2caf9c1bc98d">408,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a529f48c1e14479a8bac0af6684dfed_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMTYtMS0xLTQyMzY3_fb5b35ef-b3df-41bf-ab39-b0e26d53c28e">7,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba7ab5417525497fb3acb2513449bdd2_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjQtNi0xLTEtNDIzNjc_205d533e-416c-46b9-9ee4-d5ed1f0a3538">1,664,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb414282b9dc4b85bc63049a4f25a84f_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjQtMTAtMS0xLTQyMzY3_9fabd33d-11fb-4ba8-a3de-9e5447decd7f">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjQtMTYtMS0xLTQyMzY3_ee60e396-b373-445f-aa87-bc70936cbf6b">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iba7ab5417525497fb3acb2513449bdd2_D20220701-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjYtNi0xLTEtNDIzNjc_89b793eb-e598-4bee-ae57-3752d5280163">278,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb414282b9dc4b85bc63049a4f25a84f_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjctMTAtMS0xLTQyMzY3_7d9b928d-54de-4f3e-bb19-997dc8425a83">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjctMTYtMS0xLTQyMzY3_a8d24193-64e9-4b5a-8125-f0b5f3709bb3">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31de05b5ec874e73a1ec0902444ca46e_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjgtMTItMS0xLTQyMzY3_9ae52d06-598d-4891-a52e-5a81baad5459">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjgtMTYtMS0xLTQyMzY3_c58898f5-1fb6-448c-922f-e99e8ef30799">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i109b1669ef4d446f8220b8cba5c0ae2e_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMi0xLTEtNDIzNjc_b37af4f9-da53-4c36-90b8-7fd7eccd4867">1,818,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i109b1669ef4d446f8220b8cba5c0ae2e_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktNC0xLTEtNDIzNjc_5f3c0cb5-8be0-4e45-8128-e9d782b01d0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3dea2fc105bf4d31866b9f83d65b2932_I20220930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktNi0xLTEtNDIzNjc_3084870a-2c5a-4512-a0fe-3f058678f756">71,181,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dea2fc105bf4d31866b9f83d65b2932_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktOC0xLTEtNDIzNjc_d0af73eb-ad1a-48ee-b00c-af53b301a8d7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf881d2c650347459458b36b03ca94d0_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMTAtMS0xLTQyMzY3_f59110bb-945c-4ae5-8cf4-aea4c661a794">402,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i864469b8adce4fbb956b05333e046b7e_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMTItMS0xLTQyMzY3_305d5d3a-5f54-40b5-8f52-e94b6dc01167">393,589</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMTYtMS0xLTQyMzY3_2f379e03-ea8b-4362-80d8-41cd0be2599a">9,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:30.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three and Nine Months Ended September 30, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Stockholders' Equity (Deficit)</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In thousands, except share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i693eb172a4d347d0b0a8944c52cb7b00_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0yLTEtMS00MjM2Nw_81dd1989-ad7c-44cf-8de8-8b69e8ab747a">1,044,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693eb172a4d347d0b0a8944c52cb7b00_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy00LTEtMS00MjM2Nw_323a9ae1-e8e7-4fc1-9b90-64660752dbc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5738d3cb61f1420b9d7309c2a207e112_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy02LTEtMS00MjM2Nw_924a1a0d-39e2-4623-a7b0-23be92598888">44,876,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5738d3cb61f1420b9d7309c2a207e112_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy04LTEtMS00MjM2Nw_abafdea8-b0c4-4ef1-9dec-418f5bbe44cd">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94201b3baa82482bbac00a56f5e155fd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0xMC0xLTEtNDIzNjc_292992d4-39ed-4c39-a98c-1aeb71b89772">345,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd091b6d62174e4d8d75ae1cf5dc7c1a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0xMi0xLTEtNDIzNjc_293ee1a2-385a-4d25-98bb-d3562afd53a6">334,700</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1541d551c68f4ed2b3a7797a2421af03_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0xNi0xLTEtNDIzNjc_84cef082-006f-451d-91f5-48b676b68e9e">10,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi02LTEtMS00MjM2Nw_5dae4945-3d4b-41fb-a0eb-2233a0313b43">3,327,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi04LTEtMS00MjM2Nw_bdd4bece-529e-4659-bd24-20e0e178e8f9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d525f23739440fbefcb160732067b9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi0xMC0xLTEtNDIzNjc_7c3fe6aa-1ec2-4d50-bb14-d54a77b881f6">8,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi0xNi0xLTEtNDIzNjc_9355d67c-a448-4186-9fff-bd8955d46715">8,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNy02LTEtMS00MjM2Nw_a577f08c-e501-4a60-bf27-56a3aacf037e">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d525f23739440fbefcb160732067b9_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNy0xMC0xLTEtNDIzNjc_093d938f-3332-43a5-a95c-3d900c887ed4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNy0xNi0xLTEtNDIzNjc_28377a17-afb8-4e66-aecf-455850240bb9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfOC02LTEtMS00MjM2Nw_97019a3b-b911-4ff6-998d-21e6759cf705">84,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0d525f23739440fbefcb160732067b9_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfOS0xMC0xLTEtNDIzNjc_dd800bc4-689d-4243-87b2-92a47651a7cb">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfOS0xNi0xLTEtNDIzNjc_812356db-5602-4276-81c0-efb57aa8a16d">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc56da2da39740feb3ec19fc507a66e8_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTAtMTItMS0xLTQyMzY3_7aee7e9c-a078-4412-a590-7054fe210a1a">18,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTAtMTYtMS0xLTQyMzY3_259f7bef-1295-4659-9945-3d389dad72ed">18,292</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07c2a73a148b485f89fc5f997009213f_I20210331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMi0xLTEtNDIzNjc_08b2e9cc-f470-4af1-885f-c6fc7a72b45d">1,044,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07c2a73a148b485f89fc5f997009213f_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtNC0xLTEtNDIzNjc_2635b74a-d111-4a81-9306-6e3ef3fe17f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if133fdbf28ba4b219f3f376b31de78bf_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtNi0xLTEtNDIzNjc_349131cc-9284-4997-9d7a-1a586a35e44e">48,288,670</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if133fdbf28ba4b219f3f376b31de78bf_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtOC0xLTEtNDIzNjc_800576a8-fd2e-40fc-9e8c-ee2223730c1f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6911289ff2c4b749f20e55b06a07c49_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMTAtMS0xLTQyMzY3_f36fe1e3-e190-4bee-8ea9-e827f4473f90">354,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87017a31f5664b1b9432ba825c9cffd3_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMTItMS0xLTQyMzY3_cbf28bb4-5098-4a7e-8b57-b00f026bcd86">352,992</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c805b66507a4ce5a2a3ea7b4ce88a7c_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMTYtMS0xLTQyMzY3_061ddf80-cf83-431c-994a-1a7ba753f8be">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTItNi0xLTEtNDIzNjc_e0ad3655-f874-46c5-9964-6e05b0fbb041">1,050,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTItMTAtMS0xLTQyMzY3_c912a864-9e45-4fb7-ab22-4dcb51621270">2,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTItMTYtMS0xLTQyMzY3_f193bc90-5a2f-4735-9969-9ba87a0b4624">2,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for exercise of options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTMtNi0xLTEtNDIzNjc_c88d6927-3445-419a-95b9-bd181320e771">2,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTMtMTAtMS0xLTQyMzY3_d06aed50-1dca-4ee3-b254-bf478cf4494e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTMtMTYtMS0xLTQyMzY3_52c32994-162e-4ed5-ad0a-fbd3b1b32847">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTQtNi0xLTEtNDIzNjc_e7d7195a-d6ad-441d-a7b6-27dc19265a76">18,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock under Employee Stock Purchase Plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTUtNi0xLTEtNDIzNjc_f81775de-4f53-4d7b-ba61-d892326101f3">145,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTUtMTAtMS0xLTQyMzY3_1d8dc775-8a47-4cea-be76-895f00e7fdf8">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTUtMTYtMS0xLTQyMzY3_03574b80-4802-4c4b-bb63-16108eece205">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTYtMTAtMS0xLTQyMzY3_312bc336-7de3-4cdb-a7dd-daf8182b2f72">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTYtMTYtMS0xLTQyMzY3_620b2810-50ba-4c61-88ce-67c20ee8373b">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4453b17a58014dc49d268e838656cf76_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTctMTItMS0xLTQyMzY3_f4ef645f-1361-4007-b4c8-e88651548c10">10,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTctMTYtMS0xLTQyMzY3_bfe35f88-f7e8-4026-a215-ee28c44ccedc">10,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, June 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40678b795d7a4f77b2887ee7e28b9d6b_I20210630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMi0xLTEtNDIzNjc_4caf6bbd-6f3b-439f-9ae3-f1227e65708b">1,044,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40678b795d7a4f77b2887ee7e28b9d6b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtNC0xLTEtNDIzNjc_e09dde7b-22c9-45f0-b816-89b99e7a71ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica9486a33c544927bc063333539cd357_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtNi0xLTEtNDIzNjc_5aa3b9a0-9d42-47ec-841f-89827f85e047">49,506,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica9486a33c544927bc063333539cd357_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtOC0xLTEtNDIzNjc_a53245b3-060f-4e8f-9a21-93834e40f8db">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5f7c9d49964f0c9dd7ecb39b9e7a9a_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMTAtMS0xLTQyMzY3_b42a1ed0-1ae3-4a04-be1e-a97f21b990ad">358,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89f47ece2c56488f873e04e2b611b0a9_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMTItMS0xLTQyMzY3_538b7e77-3f3c-42b5-9e3a-9bc6958d17a4">342,281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib177b93cb8ec46ba81e03a7d526bc97b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMTYtMS0xLTQyMzY3_9f9eaae2-c0d2-4b67-a5fd-3b6690d88985">15,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Public offering of common stock, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d7d33deac174ca1acff18720307d200_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTktNi0xLTEtNDIzNjc_3bd2158e-778e-4fb4-b4ad-3067f178fc99">113,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5347a69850cb4e3a9c600e3f046564c5_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTktMTAtMS0xLTQyMzY3_095cb1a2-664d-40a7-b6c4-a77eb8728f8c">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTktMTYtMS0xLTQyMzY3_b1f2c3bd-914c-4206-811c-8fd0f20f8354">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Issuance of common stock for restricted share units vested</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d7d33deac174ca1acff18720307d200_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjItNi0xLTEtNDIzNjc_8fa475a3-1ae8-4e8f-bb97-c8866d47433c">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5347a69850cb4e3a9c600e3f046564c5_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjMtMTAtMS0xLTQyMzY3_d23db4c1-9ad5-4cb9-9e91-863067eef05d">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjMtMTYtMS0xLTQyMzY3_78ee9a12-a412-4994-aff5-f70e4cad9e3d">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id376015bef2f4799bc27e985203d46bd_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjQtMTItMS0xLTQyMzY3_1c1f33e8-b99c-47e4-ab30-a3526575f411">18,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjQtMTYtMS0xLTQyMzY3_003f9738-b95a-43ac-9504-74700c5dda48">18,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60d1ea8a7959445a95096c4b864be06d_I20210930" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMi0xLTEtNDIzNjc_62b25723-fbeb-4ad3-a227-c2d5877a83d4">1,044,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60d1ea8a7959445a95096c4b864be06d_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtNC0xLTEtNDIzNjc_265a4f97-7446-417c-9a9d-addf77125d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i818d0f7b825449cda1e49ae8b91e0960_I20210930" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtNi0xLTEtNDIzNjc_85482cde-8b03-4a14-9e43-9b8f96eac4a2">49,621,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i818d0f7b825449cda1e49ae8b91e0960_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtOC0xLTEtNDIzNjc_50fdd2d5-ba85-4f97-938d-857225bb0edd">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94ee68c9bbb94758b8465a6d2c6abd10_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMTAtMS0xLTQyMzY3_ba20f416-757c-423a-9fb7-6a473371ac94">359,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1d162d88a05494b9a13cdb4bb8b29d6_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMTItMS0xLTQyMzY3_9c55ff95-0616-4e10-b329-f7164f44df60">360,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6f6259262c4efcb61b27512dc283e6_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMTYtMS0xLTQyMzY3_25fb5ee5-5ffc-46d4-a205-231b83d041a7">1,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CIDARA THERAPEUTICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgxMg_5ca039d6-dc60-48f8-be71-061ad6cf5f55" continuedAt="i9efbdc35c79c45e98ea25b7d3d5a8265" escape="true">THE COMPANY AND BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="i9efbdc35c79c45e98ea25b7d3d5a8265" continuedAt="i2c4f024d2701449c857af62751ef0868"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. The Company is focused on infectious diseases and oncology. The Company&#8217;s lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections. In addition, the Company is using its Cloudbreak&#174; platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. This technology couples potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. The Company's most advanced DFC program is CD388, a highly potent, long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting the SARS-CoV-2 strains causing COVID-19 and multiple solid tumor oncology indications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgyMA_c0eccd48-9772-4567-86f7-3424b9eda3d0" continuedAt="i71ad0195cef9411fb50028b1c758ef75" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At September&#160;30, 2022, the Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfMTg0Mw_16ddd025-5188-43cb-b9d3-e8f01a3bcb22">393.6</ix:nonFraction> million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfMjE1Mg_d721119b-3196-4af9-8a8d-759f6716614c">53.1</ix:nonFraction> million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i2c4f024d2701449c857af62751ef0868"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="i71ad0195cef9411fb50028b1c758ef75">financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.</ix:continuation></span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="cdtx:UnauditedInterimFinancialDataPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgwOQ_2d536841-0239-4254-8ff7-4a21f62aa54f" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended September&#160;30, 2022 and 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgyOQ_0a96f892-b20f-44cf-821a-847eda6a1138" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgwNA_0d67af6e-f820-4ee1-bd71-af4c390c8a95" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options, estimated collaboration expenses and incurred expenses related to the Company's collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company's collaboration and license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgwNQ_7da9e192-351e-4615-9b72-cf693226af22" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzc4Mw_ef15ef32-e4b6-4342-8729-4fd250f46a2a">one</ix:nonFraction> operating segment.</span></div></ix:nonNumeric></ix:continuation><div id="i103e7621649e479aa89c7d0167cfd96f_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0OTg_b668e61c-b088-4088-9ebd-6c050e4821a2" continuedAt="ia04a2c01b22b4f8dabf3247b166368fa" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="ia04a2c01b22b4f8dabf3247b166368fa" continuedAt="id50ce4e7ed6e4c20b695e1e9a33d24bd"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODk_0e08f6dc-e788-43eb-b1df-52d07c874f1c" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash represented cash that the Company was required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 4 for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODM_76121518-abcc-41fa-adb7-05db3c017966" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at September&#160;30, 2022 or December&#160;31, 2021.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="id50ce4e7ed6e4c20b695e1e9a33d24bd" continuedAt="i02911ed2dac94cfe8c8ed4b6840a5c90"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MDE_b1adad8d-88f3-42d6-a279-18499371cfb5" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTIzOA_4025d4e0-b32b-4383-8a9a-aee6ae64d94d">three</span> to <ix:nonNumeric contextRef="ib6abcad7d8034ab09ccfc1455cc8aca2_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTI0NA_5f7f1c9c-5085-4e1e-bf6f-f6ed9becf779">seven years</ix:nonNumeric>).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0NzU_80231646-11cd-4af1-8077-de6333d1cc42" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the FASB ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0NzQ_8b0c51ca-e1e9-48b9-a4ac-121a873f3b3d" continuedAt="i47142b7e48844a6d9441dcca6fbf3af9" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i02911ed2dac94cfe8c8ed4b6840a5c90" continuedAt="i0849d1907d77492d82ce6c1c46b04ce7"><ix:continuation id="i47142b7e48844a6d9441dcca6fbf3af9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were <ix:nonFraction unitRef="obligation" contextRef="ie8d3b55bd5de40eab1cd422f39bee135_I20190930" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDM5NA_c2727a6e-9daf-46d4-90fd-085b2f83c824">three</ix:nonFraction> performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, <ix:nonFraction unitRef="obligation" contextRef="i39f7d4a95df44e80aad5a7828af660e0_I20210331" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDQxMg_6d5d355f-5975-4fa9-bebd-90cbf807f055">one</ix:nonFraction> of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were <ix:nonFraction unitRef="obligation" contextRef="i3728c48f4fff45e48fd89bdb795841d3_I20210331" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDQwNA_95338466-d888-4e25-ad33-e1a49d29e16f">three</ix:nonFraction> performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a License Agreement, or the Melinta License Agreement, with Melinta Therapeutics, LLC, or Melinta. The Company concluded that there were <ix:nonFraction unitRef="obligation" contextRef="ie84641f18b5b49039831316c6a1bf0a1_I20220731" decimals="INF" name="cdtx:CollaborationAgreementNumberOfPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDM4MQ_68dc9fff-dbe9-45f8-95a9-3d381ff94bf0">three</ix:nonFraction> performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in August 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 for additional information.</span></div></ix:continuation><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0Nzc_7dd6f8dc-6ce8-428a-aa23-3ccaf18a1daa" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i0849d1907d77492d82ce6c1c46b04ce7" continuedAt="ic1b92b0e3e26472aaad77ab03e28ef75"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MDk_e790aafc-8076-440f-bd20-c1fce4b2d0ed" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODU_3bd9cc6e-373a-4d42-9d1d-f29dc235e4bc" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of <ix:nonFraction unitRef="number" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTQxOTU_301e24d9-adb0-4030-a569-fc23f1d15a86">zero</ix:nonFraction> reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MTA_df2a334f-a24e-4a2a-8291-c5c526f5b003" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Earnings (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the guidance in FASB ASC 260, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series X Preferred Stock (see Note 5). Basic net earnings per share is then calculated by dividing income allocable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net earnings per share using the more dilutive of the (1) if-converted method or contingently issuable share method, as applicable, or (2) the two-class method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the if-converted method. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ic1b92b0e3e26472aaad77ab03e28ef75" continuedAt="i031ef275bbc447e8969c3514066b1b54"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODc_adae7156-8a4f-455f-ba47-760f1a191a46" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net earnings (loss) per common share (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy0xLTEtMS00MjM2Nw_6939b52a-2bf0-4d77-9f73-4cb2f5369ea6">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy0zLTEtMS00MjM2Nw_90f8034a-befb-48fe-b961-dcc3ebc0a54e">18,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy01LTEtMS00MjM2Nw_9cd06061-0654-4386-b6f2-772a201873cb">16,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy03LTEtMS00MjM2Nw_597dbc56-5a36-478c-a8fb-f680aa3a34d0">25,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC0xLTEtMS00MjM2Nw_e3196023-a2f8-4625-a46b-4b5dc8510a05">3,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC0zLTEtMS00MjM2Nw_ea8497dc-1dd3-4974-88f1-6045e6f84a81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC01LTEtMS00MjM2Nw_25108109-0ae4-4e95-8548-5a8d8a7d5205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC03LTEtMS00MjM2Nw_bdbf3a6b-0f9d-439c-bf40-baf73060e3a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator for basic net earnings (loss) per share - net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi0xLTEtMS00MjM2Nw_3c542116-f22d-46d4-87ff-69557e33cf3e">11,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi0zLTEtMS00MjM2Nw_26ff5761-973d-4375-ab59-7cd55501fd58">18,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi01LTEtMS00MjM2Nw_8ded41fd-4f52-46a6-a410-31d55e25306d">16,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi03LTEtMS00MjM2Nw_9fb42532-9c11-4dec-9aa4-2e3ff83d7ecd">25,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of participating securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Add back allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS0xLTEtMS00MjM2Nw_f5ff9e9f-8e5e-46bf-aabd-bff9340f5dde">3,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS0zLTEtMS00MjM2Nw_66d257fa-3108-4fe0-8999-ac8125e44ed4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS01LTEtMS00MjM2Nw_cb73d282-ab2f-4085-9b0a-27a224fca174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS03LTEtMS00MjM2Nw_931b93e5-9014-4695-919c-a9bbc369f966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtMS0xLTEtNDIzNjc_5e69638b-02a5-4a22-8033-d2e1f0cf8efa">14,978</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtMy0xLTEtNDIzNjc_e7625468-2ee7-4747-84bc-d4c3e2e9b2b9">18,083</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtNS0xLTEtNDIzNjc_050dc154-3eea-479e-98a4-4abf7f693f25">16,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtNy0xLTEtNDIzNjc_0fddf889-faab-4d86-af51-9178111b2697">25,664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator for basic net earnings (loss) per share - common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtMS0xLTEtNDIzNjc_36339af6-862a-4979-addf-8c36b40eb9a1">70,217,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtMy0xLTEtNDIzNjc_2af04f23-af66-4471-836d-57416ead6a76">49,533,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtNS0xLTEtNDIzNjc_af8312d4-cf18-4a1b-8491-08dd5031a6a4">69,170,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtNy0xLTEtNDIzNjc_2aaad562-cdc8-4d74-a706-9e83b34bdb0d">48,402,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock, as converted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtMS0xLTEtNDIzNjc_5d636103-b09b-43c7-ad19-0b390a895d2e">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtMy0xLTEtNDIzNjc_cc336232-ed67-4ba7-a756-f66a8b5d344c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtNS0xLTEtNDIzNjc_7503c4ea-92a2-46da-9d61-3f283c60fc93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtNy0xLTEtNDIzNjc_015209c4-c4ba-4e11-add0-dea2ac609e4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs, PRSUs, and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtMS0xLTEtNDIzNjc_0c66528e-3d75-4de9-8194-a6c2e024aee3">189,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtMy0xLTEtNDIzNjc_2d1654a0-8467-4ce7-8aa2-ee8e479e7ecc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtNS0xLTEtNDIzNjc_7cc92876-a8fc-430f-9a63-9f16df87277e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="0" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtNy0xLTEtNDIzNjc_581b637c-c81c-42a6-a513-6ce9b81f5dd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctMS0xLTEtNDIzNjc_94bd9f9d-8139-42d7-93a1-c10bb16f0a23">88,592,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctMy0xLTEtNDIzNjc_e361949f-439b-4f8e-867a-07f0123ef7ff">49,533,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctNS0xLTEtNDIzNjc_e0df65c8-8ee6-4ba2-9f87-01489206fe77">69,170,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctNy0xLTEtNDIzNjc_4b9d1963-360d-460d-b051-4d017fb9f05a">48,402,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktMS0xLTEtNDIzNjc_4ffb8023-3688-4bc5-af2f-d0d182938337">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktMy0xLTEtNDIzNjc_6ccddc71-39a5-46eb-af68-659f16d0f243">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktNS0xLTEtNDIzNjc_f878a014-671b-4399-b157-b7cf7b1f8c9b">0.24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktNy0xLTEtNDIzNjc_0ae76e87-80a4-4281-834e-2b705a2176eb">0.53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtMS0xLTEtNDIzNjc_e59a8483-b5e4-468b-967e-4695a30a8ee2">0.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtMy0xLTEtNDIzNjc_c052d192-c81c-43e5-809a-46678872096f">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtNS0xLTEtNDIzNjc_6d82f322-12bf-4c09-b0bf-53699b982bfc">0.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtNy0xLTEtNDIzNjc_ce1d78bb-0546-4037-b043-e1605993718b">0.53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MDA_4c5e4c6c-b86a-478a-960e-be93225f0b13" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib67565edcae74a3cb712ae982e16c451_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi0xLTEtMS00MjM2Nw_13f6efe7-f86d-480b-80a8-1bfa27ae49d5">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4bdc30657f14452b62cb74aaa0c1c02_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi0zLTEtMS00MjM2Nw_06bf9296-aa0a-41af-b3eb-d06ad85093b9">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia9489bd66399422eba3c70350fb1aec6_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi01LTEtMS00MjM2Nw_24078329-198f-465b-a08d-7a361c1a204b">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1eba19ec547f41fe9cb7fcf6f8323c4e_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi03LTEtMS00MjM2Nw_056d55c3-b663-4e41-b0c3-4afb22b4cf28">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53017c7a53ac41bba664c2e94189573a_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy0xLTEtMS00MjM2Nw_4bf788a4-63d0-4319-932a-b841d809cd2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5bb1e9a932d46abbb6c2af18fe748bf_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy0zLTEtMS00MjM2Nw_b5ec3546-78b6-4c5c-906d-1bafe6a7420f">10,442,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8290788acae94198a642171a08cb981e_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy01LTEtMS00MjM2Nw_eb9e806d-d8e7-439e-b48d-905f1b559e50">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67bd62ef1d93442c8672b744fb64dba0_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy03LTEtMS00MjM2Nw_4d2420d5-4e0c-4e65-aad2-c00c25d8e319">10,442,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea096aaf8a964de0a3100d448444ba50_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC0xLTEtMS00MjM2Nw_cbdb7af1-6f03-4e58-8af7-794a84c77ff8">10,041,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e6c2025ff77482496d4861d17864fb7_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC0zLTEtMS00MjM2Nw_b4cc1704-ae43-4b2f-8073-55ba390de92e">10,356,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89983bfbaa774a6089ebf1552008beed_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC01LTEtMS00MjM2Nw_fb9c2826-720e-4a6e-a28c-4dba1c72d8ba">10,086,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib71ae47f80d7456fa74d8430a1187edd_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC03LTEtMS00MjM2Nw_1188a598-a3d5-4ceb-85fd-04e84e11e52a">10,356,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS0xLTEtMS00MjM2Nw_3e134dac-445f-42cf-bf9f-cc17012f6848">22,558,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS0zLTEtMS00MjM2Nw_e3af9e45-f9df-4089-88a9-1a2e87434882">33,316,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS01LTEtMS00MjM2Nw_c78ed389-c43a-43fa-929a-c4fc9ea84b74">40,788,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS03LTEtMS00MjM2Nw_e9cfc881-8e14-4340-8387-c712abca0985">33,316,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MTE_b8899ce2-3eb2-481e-8059-3e4f79f1e0ad" continuedAt="i82802f96cfd146e78650aca6453a7cb5" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i031ef275bbc447e8969c3514066b1b54"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:continuation id="i82802f96cfd146e78650aca6453a7cb5">reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</ix:continuation></span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0OTE_1f53dbb8-d202-453a-b44b-6d75c8f013b4" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i103e7621649e479aa89c7d0167cfd96f_37"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RleHRyZWdpb246NzYwMzMwNjM4YTBkNGE4N2E2ZTVjOGY4NGNlZTZlZThfMTczNw_ef749914-4c2d-4903-8baa-d28af852277e" continuedAt="ic4f71c73167349fb8747a61f40532a67" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic4f71c73167349fb8747a61f40532a67"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RleHRyZWdpb246NzYwMzMwNjM4YTBkNGE4N2E2ZTVjOGY4NGNlZTZlZThfMTczMA_f681fb5a-cdfa-49e8-8716-8438d2744a75" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy0xLTEtMS00MjM2Nw_41e937a3-b945-4c0b-9c44-e2999321fd83">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90bb450d4b14645876a8c40853f0f80_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy0zLTEtMS00MjM2Nw_1fd8f597-51a3-46fa-8c22-1672ab789953">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9e1bc6d28645a0a88c59ae7c3b268d_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy01LTEtMS00MjM2Nw_153bae6c-9e2f-4e4a-9f98-a9b60aa24873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64416d06cee4e5ca72c5b5ca3dd7cdf_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy03LTEtMS00MjM2Nw_64da0b73-db36-4e92-b219-445d040182cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS0xLTEtMS00MjM2Nw_12b60ef0-d365-4206-8ce5-7406792cf1af">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90bb450d4b14645876a8c40853f0f80_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS0zLTEtMS00MjM2Nw_de957591-8fed-4046-90dc-c710c0bfac53">53,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9e1bc6d28645a0a88c59ae7c3b268d_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS01LTEtMS00MjM2Nw_d8c73fd0-6968-4b8b-85f7-0e8fe97e1aaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id64416d06cee4e5ca72c5b5ca3dd7cdf_I20220930" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS03LTEtMS00MjM2Nw_f5a0f589-1877-4873-b749-17607ca4be23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtMS0xLTEtNDIzNjc_eb98042a-d29e-4c63-aa75-45bc84a1bebd">59,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9923c3f04494ea08d78070db565dec5_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtMy0xLTEtNDIzNjc_5855e430-7952-4735-b465-8d6d28d9a30f">59,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1ba8de76cf4d50a911304fc4244f77_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtNS0xLTEtNDIzNjc_5b896caf-8b30-4563-9655-f4fe06077587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2787b199372343b4b03ee56c6d782676_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtNy0xLTEtNDIzNjc_8521844e-56d5-4ded-9c34-cca263e4a928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtMS0xLTEtNDIzNjc_905f1aa9-c3da-4264-80fc-42a92d23c124">2,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9923c3f04494ea08d78070db565dec5_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtMy0xLTEtNDIzNjc_2f9b7a95-b10d-4d42-aaed-c9097ddaf8f8">2,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1ba8de76cf4d50a911304fc4244f77_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtNS0xLTEtNDIzNjc_b57985fe-7951-4d68-b35c-576097284452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2787b199372343b4b03ee56c6d782676_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtNy0xLTEtNDIzNjc_fdd98738-e902-4f8f-ac65-605a550d7239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtMS0xLTEtNDIzNjc_352055fd-b754-4cdf-84a4-471fbdead07f">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9923c3f04494ea08d78070db565dec5_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtMy0xLTEtNDIzNjc_566bfff0-315b-4525-9b43-889d02772a8d">62,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1ba8de76cf4d50a911304fc4244f77_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtNS0xLTEtNDIzNjc_2a77f940-e28e-4c7f-9ccb-5944ebbda008">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2787b199372343b4b03ee56c6d782676_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtNy0xLTEtNDIzNjc_52e20a37-e78a-4024-9bfb-af3c4250cbe3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfMTI1NA_22e71a83-b485-4604-9a2e-4c9eeaf5b8f6" continuedAt="idedb19c3fe44474b9c00b439198d7ad4" escape="true">DEBT</ix:nonNumeric></span></div><ix:continuation id="idedb19c3fe44474b9c00b439198d7ad4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $<ix:nonFraction unitRef="usd" contextRef="i052c13aef942486698daafbe3f173f65_I20161003" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfMjQ1_cee4916d-01a5-4dcb-8f20-860097b48ce1">10.0</ix:nonFraction>&#160;million&#160;from the Lender, or the Term A Loan. The Term A Loan bore interest at a variable annual rate equal to the greater of (i) <ix:nonFraction unitRef="number" contextRef="i052c13aef942486698daafbe3f173f65_I20161003" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfMzI2_a17b00ec-40a5-4c0d-924a-3620bf7536d8">4.5</ix:nonFraction>% or (ii) the Lender's prime interest rate plus <ix:nonFraction unitRef="number" contextRef="i959c564f9e4f4f058243fb9d370aa5de_D20161003-20161003" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfNTQ5NzU1ODE3NjIw_98a6459c-89b7-4392-93a4-7b22f3207b81">0.75</ix:nonFraction>%, and matured on July 3, 2022. The Term A Loan had an interest-only period through April 3, 2020, which was followed by equal monthly principal payments and was paid in full on July 5, 2022.</span></div></ix:continuation><div id="i103e7621649e479aa89c7d0167cfd96f_43"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzNA_70383b46-de09-496b-8d4f-38eb1f216d27" continuedAt="ied04bded0381442aaea8da73a45d9421" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ied04bded0381442aaea8da73a45d9421" continuedAt="i3c23fb1236534422ad04c7d12d67943d"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp; Co, or the Sales Agreement. During the nine months ended September&#160;30, 2022 and 2021, the company sold <ix:nonFraction unitRef="shares" contextRef="ifb67d01a4acc4c67a09bea73d61871ed_D20220101-20220930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjgx_45c9c964-5eda-43e2-9e02-447ec7fe09c0">2,308,435</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="icf66717d514a49d7b24e502df0f65ed9_D20210101-20210930" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjg4_cfdedb3b-9f4b-4b20-af0b-fed6cb4037a3">4,492,034</ix:nonFraction> shares of common stock, respectively, for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ifb67d01a4acc4c67a09bea73d61871ed_D20220101-20220930" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMzYz_d10cd139-e0c8-40d6-b27d-bcf5b0384616">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icf66717d514a49d7b24e502df0f65ed9_D20210101-20210930" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMzcw_df444bcf-1938-4d89-afde-cf0c227ecb7e">10.9</ix:nonFraction>&#160;million, respectively, after deducting placement agent fees. As of September&#160;30, 2022, the aggregate offering price remaining under the Sales Agreement is $<ix:nonFraction unitRef="usd" contextRef="iae88c6865e4e458ba163ba5e2108e78e_I20220930" decimals="-5" name="cdtx:SaleOfStockConsiderationRemainingOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTA0_f6b7e2ba-8471-4485-a29d-eb76678270a6">46.8</ix:nonFraction> million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2021 Public Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 13, 2021, the Company completed concurrent but separate public offerings of <ix:nonFraction unitRef="shares" contextRef="id488125f97f9422c86fe3f9a0f62e61e_D20211013-20211013" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjE2_b3daee5e-9c9a-473d-9d5b-0a85a1459523">17,064,511</ix:nonFraction> shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i44b0440e80904930ac842fa7429f8b17_D20211013-20211013" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNzQw_cdc584b1-91b7-4c5d-a555-87ff4ae8ad31">2,225,805</ix:nonFraction> shares of common stock, at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2873a315ee3b49fb92caf5729891639a_I20211013" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNzk1_cf86481f-e4d7-44e5-bf69-2c6e5be02339">1.55</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="idd41362b50874d8d8249094d91ca90f6_I20211013" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfODEz_f1a8213b-d42c-465a-96bf-2783f21e691f">774,194</ix:nonFraction> shares of its Series X Convertible Preferred Stock at a price to the public of $<ix:nonFraction unitRef="usdPerShare" contextRef="idd41362b50874d8d8249094d91ca90f6_I20211013" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfODk1_88f35efc-c30b-4874-8e4e-c4d035adec4c">15.50</ix:nonFraction> per share, for aggregate gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5df29006f187417e816e2158bd2f9209_D20211013-20211013" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfOTQx_2620ed82-e8c6-4681-ba69-f0c82cf83c67">38.5</ix:nonFraction>&#160;million. The Company received total net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if7f37a17eb6a463698c6b8c41d120df5_D20211013-20211013" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfOTg4_32212c33-adb4-4027-b861-1daae9396ef6">35.8</ix:nonFraction>&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to <ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTI3Ng_6d478240-0ec0-4365-830e-c8e6cc210cc7">10,000,000</ix:nonFraction> shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had <ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTcyMA_5ddb78f5-a60c-48fb-9cab-6f162f10f87c">10,000,000</ix:nonFraction> shares of preferred stock authorized at September&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated <ix:nonFraction unitRef="shares" contextRef="i94af5aa812844c758cdfa1475671e9a6_I20180531" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTgwMw_2af8489e-a1e9-42cb-9a61-a9c34d0ed8a8">5,000,000</ix:nonFraction> shares of preferred stock as Series X Convertible Preferred Stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i94af5aa812844c758cdfa1475671e9a6_I20180531" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTg5Mg_c5bca2f5-7a70-4d8a-b1b8-ca529e7934f6">0.0001</ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On August 12, 2020, at the request of certain holders, <ix:nonFraction unitRef="shares" contextRef="i7dc162d67bbe4dca8bd989529e6ae2b3_D20200812-20200812" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTk2MQ_0ef16366-c3af-48ad-b487-8b03becfd21c">52,241</ix:nonFraction> shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i43db71acffc7473da141de0be728b1f4_D20200812-20200812" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjA1OQ_df39b83c-6c36-4ae8-bf20-9129a40c28bd">522,410</ix:nonFraction> shares of the Company&#8217;s common stock. As of September&#160;30, 2022 and December&#160;31, 2021, shares of preferred stock designated as Series X Convertible Preferred Stock totaled <ix:nonFraction unitRef="shares" contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjIwMg_423f430d-4302-4b05-958d-f62125ddb26d"><ix:nonFraction unitRef="shares" contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjIwMg_e137cc0d-b41c-462d-b0a1-f25eaefd051e">4,947,759</ix:nonFraction></ix:nonFraction>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into <ix:nonFraction unitRef="shares" contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjM5Ng_2929a1d6-3f56-4f92-a8a0-42d46752ece6">10</ix:nonFraction> shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than <ix:nonFraction unitRef="number" contextRef="i13ec61aa3e0b43378a90a84041d66908_D20220101-20220930" decimals="4" name="cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjc2NQ_0d9c5e5d-c903-4b48-ad68-d20d9bdaba5b">9.99</ix:nonFraction>% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company's common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i3c23fb1236534422ad04c7d12d67943d"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNDc3NQ_ca75a3c8-ef3f-4b4a-98fe-823f79b7ba14">200,000,000</ix:nonFraction> shares of common stock authorized as of September&#160;30, 2022. Holders of outstanding shares of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="INF" name="cdtx:NumberOfVotesEntitlementForEachShareHeld" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzNg_6d3ed90e-c65e-47ef-a91c-88bf0e128895">one</ix:nonFraction> vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i86b952768f264a7b874692f258aa5053_I20220930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTg2MQ_20742c0d-117f-49ff-81b8-03b42aa3fdd7"><ix:nonFraction unitRef="shares" contextRef="i62d149e810834aceba4d99488eae77db_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTg2MQ_e63e81e1-716d-4c56-a7a8-a045205a0825">12,517,328</ix:nonFraction></ix:nonFraction> shares of the Company's common stock were outstanding with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="idf327b331dbc430d85c195531d36f8df_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTk2MA_797eb87b-5ac8-497f-8145-d9682542a343"><ix:nonFraction unitRef="usdPerShare" contextRef="i3fe30b7973da4dffb8da105c119dfe8b_I20220930" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTk2MA_c9fe452d-2471-45e1-8b4e-5432d076b5b3">6.82</ix:nonFraction></ix:nonFraction> per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had <ix:nonFraction unitRef="usd" contextRef="i86b952768f264a7b874692f258aa5053_I20220930" decimals="INF" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzMQ_2f820548-d0d3-4644-b0ca-7e11a5ea292f"><ix:nonFraction unitRef="usd" contextRef="i62d149e810834aceba4d99488eae77db_I20211231" decimals="INF" name="cdtx:WarrantsAggregateIntrinsicValueOutstanding" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzMQ_7173aca2-3660-4db6-92ca-a1d36f233feb">no</ix:nonFraction></ix:nonFraction> intrinsic value at September&#160;30, 2022 and December&#160;31, 2021. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzMw_3d471d36-a96e-419b-96cf-e0d83aa5629b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia5324603762448499a4ae28f38d54d1b_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMS0xLTEtMS00MjM2Nw_b2e769f4-8312-4b8c-a358-b2858cc0172e">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d844b63d15b429cbac3aefd54d810e1_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMS0zLTEtMS00MjM2Nw_a707365c-8a9e-4a22-b82c-8fc9e089ae62">12,517,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic05c4f78a48f4a4dbf218b042d1d1f6e_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMi0xLTEtMS00MjM2Nw_8bedb6f4-5a01-43e9-90dc-c0ad7cd34713">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i541af1a514f347a69bd1214db5ee6761_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMi0zLTEtMS00MjM2Nw_e4e08ef7-dd3c-4a21-9a8c-2cc757e61a8c">18,184,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38ddb97add1a4265b3f354df1f33347f_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMy0xLTEtMS00MjM2Nw_e95f37a5-ea74-4c6f-8601-a017991b171e">10,086,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i782d88c1c80c43aeb3ee3636280e0ec3_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMy0zLTEtMS00MjM2Nw_47b5cb6b-69a7-4d71-9feb-d1a5a674a3be">9,470,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31cc8c5f67c647a8bb8f8d484fb20097_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNC0xLTEtMS00MjM2Nw_1dba26ad-f43f-4977-8faa-b3b7f62b242b">3,710,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i445ea361a0534f34b979c1b9c39c0ee4_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNC0zLTEtMS00MjM2Nw_88dc6cdc-5822-4ef7-b5cb-f9b06dd788c5">2,436,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i036bdcca976a44cf9a1566845a5fb841_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNS0xLTEtMS00MjM2Nw_cd6841a9-e84a-4a75-bdac-63b12d14082f">986,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1395be4faaed4f909c2d9d668463d93d_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNS0zLTEtMS00MjM2Nw_fb6414f4-0b78-4578-948e-8d0e3e921079">680,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNi0xLTEtMS00MjM2Nw_3f38c0f5-7acd-49f7-b88a-513b3445fc77">45,485,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNi0zLTEtMS00MjM2Nw_5d071744-cab0-49da-b362-3d9fe9c65819">43,289,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i103e7621649e479aa89c7d0167cfd96f_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU4Nw_beb3c26a-7cf6-4e8c-8904-06c0dae2a7d3" continuedAt="i540546577141479099b718eaf4831aea" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span></div><ix:continuation id="i540546577141479099b718eaf4831aea" continuedAt="iac078d4ceb7f4bb685c64473dc7be132"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company's board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by <ix:nonFraction unitRef="number" contextRef="ib506537ee0944bfcbcb6c12ae798c59c_D20150301-20150331" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTA2MA_c4d665df-1960-4a54-8b2f-5cd71fe5b279">4</ix:nonFraction>% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="iac078d4ceb7f4bb685c64473dc7be132" continuedAt="ie2bc132644774c669f075924d704dd0e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTQ2NQ_548f15b5-a1d8-4cd3-872c-e2f333fda6b9">three</span>- or <ix:nonNumeric contextRef="i5b111eb9e1724eb4b52920f38d9f5ac1_D20150301-20150331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU4Mw_5522586b-d137-40fa-8dad-411cf6aefec6">four-year</ix:nonNumeric> period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to <ix:nonNumeric contextRef="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTY1OA_6ddb87c1-4d45-400c-b509-112afa26d4a0">10</ix:nonNumeric> years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than <ix:nonFraction unitRef="number" contextRef="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTc5NA_d909eb50-1ce9-4e35-bd7e-f05127a0ac48">100</ix:nonFraction>% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than <ix:nonFraction unitRef="number" contextRef="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTk3Nw_47cf3486-8e7e-4d7c-849d-280107a1bb6a">10</ix:nonFraction>% of the voting power of all classes of stock of the Company, the exercise price shall be no less than <ix:nonFraction unitRef="number" contextRef="i12b01287deb64faf84f4daa9f17bb5e0_D20150301-20150331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjA4MQ_5134d5a5-eb4e-423a-b4bd-f7b1e4ce5279">110</ix:nonFraction>% of the value on the date of grant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;<ix:nonFraction unitRef="number" contextRef="i71ef06f8cb854b7abf2c1ca8ca9f0400_D20150301-20150331" decimals="INF" name="cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjQyNw_588b2c8b-c106-4aea-9254-4221acc2a35d">1</ix:nonFraction>%&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii)&#160;<ix:nonFraction unitRef="shares" contextRef="ide919cb038934f0c97c7be8388a351c8_D20150301-20150331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjU0Mw_736bda93-607e-4588-8ec9-194009427ba7">490,336</ix:nonFraction>&#160;shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to <ix:nonFraction unitRef="number" contextRef="i71ef06f8cb854b7abf2c1ca8ca9f0400_D20150301-20150331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjc2NA_97a91835-0879-4647-9d38-9a876e57a30a">85</ix:nonFraction>% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to <ix:nonFraction unitRef="number" contextRef="i56e4c68ba76241baa53301e647eb569c_I20150331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjkzNw_3da9ed12-c4d4-4453-8f2b-aa31780e56e2">15</ix:nonFraction>% of the employee&#8217;s eligible compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During the nine months ended&#160;September&#160;30, 2022 and 2021, <ix:nonFraction unitRef="shares" contextRef="i967a2fb933ca4d77a5793520831dca91_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzAxOQ_0f8b64e1-d897-472e-a748-0da213575c3e">184,219</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="iad586f67e1e64183ba99bd648dfdad0f_D20210101-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzAzMw_8d76c552-f168-4355-a928-684f0ed7047f">145,696</ix:nonFraction> shares, respectively, were issued pursuant to the ESPP. As of September&#160;30, 2022, total unrecognized compensation expense related to the ESPP was approximately $<ix:nonFraction unitRef="usd" contextRef="i036bdcca976a44cf9a1566845a5fb841_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzE4MA_861dcfd5-79e8-4c41-888b-0c59f71f78fd">0.3</ix:nonFraction>&#160;million. This unrecognized compensation cost is expected to be recognized over approximately <ix:nonNumeric contextRef="i967a2fb933ca4d77a5793520831dca91_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzI2OA_905f0cff-782b-4a35-897a-1200bc4a0ebb">0.6</ix:nonNumeric> years.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU5MQ_358ede85-b44b-4ecb-94da-928ed42a5015" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc7909cccd3141d4980af143ffea9363_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMS0xLTEtMS00MjM2Nw_8c092b43-dace-42da-a7c0-dd5f58a163d6">1,174,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icc7909cccd3141d4980af143ffea9363_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMS0zLTEtMS00MjM2Nw_d2cd3bec-4c1a-4b8c-9d17-f0f5a13057ac">2.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMi0xLTEtMS00MjM2Nw_23592bed-4c26-4e23-9b03-7cbfec5cdc05">1,471,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMi0zLTEtMS00MjM2Nw_5161b3f2-096d-4e08-95d6-9af4fcfe3a55">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMy0xLTEtMS00MjM2Nw_12155d64-bc92-46ac-a235-7f9c968512c2">1,032,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMy0zLTEtMS00MjM2Nw_308d755c-8a01-42b2-880d-1011d74d5fd3">1.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNC0xLTEtMS00MjM2Nw_8a847463-312c-4037-9c9a-e1495fb0ad57">320,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNC0zLTEtMS00MjM2Nw_c207924d-690e-4b62-94b6-ac703545c709">2.06</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4c2b554012041d29eba537838cbb84c_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNS0xLTEtMS00MjM2Nw_13569443-06ad-4001-97c3-adcd6c70fc77">1,292,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4c2b554012041d29eba537838cbb84c_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNS0zLTEtMS00MjM2Nw_518ed4ab-54f8-4e44-a550-262ca9456345">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs and PRSUs granted during the nine months ended September&#160;30, 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0437175fbfa46dbba01f38007dbede7_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzQ4NA_918fe7dc-d564-4123-858f-88d680f27736">2.28</ix:nonFraction> per share. The total fair value of RSUs and PRSUs vested during the nine months ended September&#160;30, 2022 and 2021 was approximately $<ix:nonFraction unitRef="usd" contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzU5OQ_2bce7b24-5e45-4201-8153-6dae13e0f6ca">1.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia0437175fbfa46dbba01f38007dbede7_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzYwNg_c10e42f8-d92b-4ed4-9149-b7d75254987b">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At September&#160;30, 2022, estimated unrecognized compensation expense related to RSUs and PRSUs grants was approximately $<ix:nonFraction unitRef="usd" contextRef="if4c2b554012041d29eba537838cbb84c_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzcyNg_98dc351f-c07c-4bdf-adc2-192f766196c4">1.7</ix:nonFraction> million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ie2bc132644774c669f075924d704dd0e"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU4OQ_59a1ad4b-d68d-4b23-924e-957b2862f936" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">in Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS0xLTEtMS00MjM2Nw_a34dd35f-6f32-4f67-a3ed-2ca89cbccf12">8,296,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS0zLTEtMS00MjM2Nw_dbd28340-6583-4397-b36a-ec064dff92ec">3.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idfeff9f96ab8411fa8bca991c8031822_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS01LTEtMS00MjM2Nw_51c06d59-5e02-4c0e-98ea-b69adaac0646">6.31</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS03LTEtMS00MjM2Nw_d19c0ebf-f971-4342-8166-2ebf04ab6172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMi0xLTEtMS00MjM2Nw_f574c807-a71d-4a7b-87dc-52d2091c99d9">2,014,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMi0zLTEtMS00MjM2Nw_4bcfae37-f797-43ae-a362-8a36faa7fe57">0.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMy0xLTEtMS00MjM2Nw_67c92403-7b61-4195-bb15-6d867ee86a45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMy0zLTEtMS00MjM2Nw_4021e420-6f69-4c40-ab98-664d0b739576">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNC0xLTEtMS00MjM2Nw_4bfbd8ff-867e-492e-8f02-c972145864c8">1,516,146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNC0zLTEtMS00MjM2Nw_b8aec5ae-6d73-4d6c-b8b9-c18c747b6def">2.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS0xLTEtMS00MjM2Nw_16fa153f-0240-45a5-9270-d8b31fda8d57">8,794,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS0zLTEtMS00MjM2Nw_18f6d3d2-e92a-437b-aacc-06b5a7b74b7c">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS01LTEtMS00MjM2Nw_554a9525-5773-4158-bf53-efd2d22f00db">6.46</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS03LTEtMS00MjM2Nw_562598bc-3efe-4bb8-ad2b-f559089d064b">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi0xLTEtMS00MjM2Nw_8eace611-8c8a-4690-9adc-3423a99d44fc">8,794,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi0zLTEtMS00MjM2Nw_d4138b93-1f79-4732-8ab7-cd386c22e1ac">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi01LTEtMS00MjM2Nw_7ffbf194-860d-4e96-807e-ecfb0d30aa4c">6.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi03LTEtMS00MjM2Nw_5c4cc29d-079c-4d53-a9d7-98513334ff24">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy0xLTEtMS00MjM2Nw_78643fe9-b8d5-489a-8565-a4a7c6b5be35">5,749,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy0zLTEtMS00MjM2Nw_c0b4845e-4132-4b25-8802-e4747fa22b92">3.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy01LTEtMS00MjM2Nw_64274f82-4ff1-46e2-827f-055152e57661">5.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy03LTEtMS00MjM2Nw_27f7bb53-8638-49a8-8379-08f05cdc5b49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the nine months ended September&#160;30, 2022 and 2021 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDExNw_718a17e6-560f-48a5-8735-39c1078a05c7">0.51</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDEyNA_d1c58d03-e7e5-4bf2-a169-f69f6b747232">1.43</ix:nonFraction> per share, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, total unrecognized share-based compensation expense related to unvested stock options was approximately $<ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNTQ5NzU1ODE4ODQy_07f556cb-acf7-4aa0-a9e8-c4244caf7695">2.8</ix:nonFraction> million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="i1dcbfc97d2f34fb9a0872c85a82593c5_D20220101-20220930" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNTQ5NzU1ODE4OTYw_7246ff31-70ba-4cf3-9741-5a9c47f43b81">2.0</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU3OA_465bd83e-3454-4e1c-b4c8-58f84a28d1c6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cfddad092a44527821fd2ac2ffc91ed_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi0xLTEtMS00MjM2Nw_a6b3b8fe-392d-4e40-8ba6-66a165077dfa">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c9f00db2034a07ab38792b24541941_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi0zLTEtMS00MjM2Nw_22b42a38-d7cc-41fb-abe5-baa36f7eb662">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i244171b35f434cc39f5129662239663e_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi01LTEtMS00MjM2Nw_0c661a8d-83bd-4428-95d3-8ba2c7e5b4b7">1,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6df55d735d4a3584f2bf2d709732de_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi03LTEtMS00MjM2Nw_1c7722ac-3ccb-4704-8388-f68b70e05642">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19798a6430cc425eaf630f93c7d82742_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy0xLTEtMS00MjM2Nw_3e7d37ad-e320-4402-8539-6a4a21d8c012">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e07da4e20844708da921b1866aff4a_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy0zLTEtMS00MjM2Nw_1f484507-e749-4ac4-8128-8bcc9a7aeeac">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9746cabdad4f4ba5ad36b76a394afa49_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy01LTEtMS00MjM2Nw_2c6b11a1-7e45-4b37-bb36-47990b30573d">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6bd1aaba9504281a7c3adc36f4d33c8_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy03LTEtMS00MjM2Nw_035daae3-2898-42d6-87b2-9d3dc3a86342">1,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC0xLTEtMS00MjM2Nw_375cacb0-b50e-494a-933b-83d8ab51afdd">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC0zLTEtMS00MjM2Nw_de423ab9-60e1-4ba7-833f-fa9c3f650ce7">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC01LTEtMS00MjM2Nw_1e7768dd-dec0-4a8f-8fb0-9d82963fc78e">3,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC03LTEtMS00MjM2Nw_a2bdc306-1977-449b-bd48-ebc2208c2695">2,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i103e7621649e479aa89c7d0167cfd96f_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjIwNTk_263fa3fc-691a-4967-8007-4e5ef3b73c29" continuedAt="i46d98615767344c8b448ea6fa0e76366" escape="true">SIGNIFICANT AGREEMENTS AND CONTRACTS</ix:nonNumeric></span></div><ix:continuation id="i46d98615767344c8b448ea6fa0e76366" continuedAt="i24655fc77d684d6481d3ece4d892e9d5"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Mundipharma Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product in the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#8209;bearing license to develop, register and commercialize the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, subject to the Company&#8217;s retained right as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i24655fc77d684d6481d3ece4d892e9d5" continuedAt="i35a33a177ad14d70b39e3c37a66bd506"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#8209;exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#8217;s territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company retained the exclusive right to develop, register and commercialize the Mundipharma Licensed Product, Subcutaneous Product and Other Products in Japan, or the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Mundipharma Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the execution of the Mundipharma Collaboration Agreement, the parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#8217;s Global Development Cost share of $<ix:nonFraction unitRef="usd" contextRef="iecd9ae8d02994db09c6c17d85d05eb8e_D20190903-20190903" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNDMzMg_c0381fe3-2e33-47b3-861b-d77cca19fd60">31.2</ix:nonFraction>&#160;million. The total potential transaction value is $<ix:nonFraction unitRef="usd" contextRef="iecd9ae8d02994db09c6c17d85d05eb8e_D20190903-20190903" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNDM3Nw_f280fe59-3304-42e5-a72d-7df29be6cab0">568.4</ix:nonFraction>&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible for double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSTORE Trial and the ReSPECT Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company's patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$<ix:nonFraction unitRef="usd" contextRef="ia9b69a06369d4a8e88c985f8b0d67518_D20220101-20220930" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTcwMg_68857dc1-d766-4dd6-81df-44ea20f8f91e">30.0</ix:nonFraction>&#160;million, research and development funding of $<ix:nonFraction unitRef="usd" contextRef="ia9b69a06369d4a8e88c985f8b0d67518_D20220101-20220930" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTc1MA_8bbb0934-3af7-4532-8e60-2c3b300d7fb4">32.2</ix:nonFraction>&#160;million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="i2ab15c514b9d45d58fb7d77080e63dbd_D20220101-20220930" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODM4MjU1_b835576e-e849-477c-afcb-2937013f0d2d">13.9</ix:nonFraction>&#160;million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="ib8e503d246dc400e926a1ee2b976a58e_D20190901-20190930" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNzIyMQ_c0472bbf-759e-4058-bb66-3656f10b204a">17.9</ix:nonFraction>&#160;million&#160;in September 2019 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company's initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company determined that as of&#160;September&#160;30, 2022, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i35a33a177ad14d70b39e3c37a66bd506" continuedAt="i95ef6473f2ec44f48674642a176b792d"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In November 2020, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="ifc0df86722f14e688642f553eeef0df3_I20220930" decimals="-5" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfOTAyMw_a9383f60-375a-417c-b71a-345eadffa2b7">11.1</ix:nonFraction>&#160;million milestone under the Mundipharma Collaboration Agreement, which is recorded as long-term deferred revenue as of September&#160;30, 2022 because the rights to consideration is not expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. In December 2021 and August 2022, the Company achieved milestones of $<ix:nonFraction unitRef="usd" contextRef="i083a9e97a9064a748f3e9e13753ecc2e_D20211201-20211231" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfOTkzMw_fc1c10a1-cbff-4f82-8619-ca640610890d">2.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i050a34311f2f464091d42f5ee44e4c79_D20220801-20220831" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODM3MDEw_a6d4ec90-4545-4614-a221-93d2fab9f981">11.1</ix:nonFraction>&#160;million, respectively, under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in January 2022 and September 2022, respectively.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;<ix:nonFraction unitRef="usd" contextRef="ie658ef0290234febab93dba91faae5e1_D20220701-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_308991fa-1ae8-47e0-a4c0-5fca39baf69e"><ix:nonFraction unitRef="usd" contextRef="i3a4ea630ca944ade94e8636670a33f15_D20210101-20210930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_4b5423f1-111d-4cd5-a840-b0a192a6bc17"><ix:nonFraction unitRef="usd" contextRef="i161035ba306c4c2cbad3a08836c61a30_D20210701-20210930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_ac1e554f-d18a-4558-9459-239651ed56ed"><ix:nonFraction unitRef="usd" contextRef="i80867d87eba64530a2fb32636e6cfb8f_D20220101-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_fa40b235-5c59-4a80-9bff-71bdf30a303d">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;royalty revenue was recognized during the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs (previously called Antiviral Drug Conjugates, or AVCs) based on the Company's Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 Challenge Study. Unless otherwise agreed by the parties, the Company will be responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company will be the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Within <ix:nonNumeric contextRef="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331" name="cdtx:CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTI5NjA_c6f05680-51bc-4b09-8392-4bb395fecb97">90</ix:nonNumeric> days after delivery by the Company to Janssen of results of the Phase 2 Challenge Study and all then-available data from other clinical trials of the Development Candidate conducted under the Research Plan, or the Election Period, Janssen will be obligated to notify the Company of Janssen&#8217;s election to proceed with further clinical development of Products, such notice, an Election to Proceed Notice. If Janssen fails to deliver an Election to Proceed Notice prior to expiration of the Election Period, the Company will have the right to terminate the Janssen Collaboration Agreement upon written notice to Janssen. If Janssen provides an Election to Proceed Notice prior to expiration of the Election Period, then the parties will continue any then-ongoing Research Plan activities to completion, and Janssen will otherwise be solely responsible for the development, manufacture and commercialization of Products, at Janssen&#8217;s sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#8217;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="i95ef6473f2ec44f48674642a176b792d" continuedAt="id3b32e56e7a6493793d7d739b61aca93"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#8217;s DFC technology more broadly. The Company&#8217;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib9170170c08441b781c4c6d06c63beeb_D20210331-20210331" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTU4MDY_8b02492f-16c4-4dc0-9adb-fd8e072ac9b0">27.0</ix:nonFraction>&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company is eligible for reimbursement by Janssen of up to $<ix:nonFraction unitRef="usd" contextRef="i294b1ca2af214dad80eaf69f5050931a_D20210331-20210331" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTU5MzE_1f104634-a8f8-4bea-aab1-2cc262dec971">58.2</ix:nonFraction>&#160;million in research and development costs incurred in conducting Research Plan activities. The Company will also be eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="i58a391d92ba84000b49895803c8b0101_D20210331-20210331" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTYwODI_c0da4563-268d-46ca-aad0-42fcd34afb00">695.0</ix:nonFraction>&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In addition to the Company&#8217;s right to terminate the Janssen Collaboration Agreement for Janssen&#8217;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, upon <ix:nonNumeric contextRef="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331" name="cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTY4Mjg_c6138a77-a187-42b7-a51a-527ad76a80c4">90</ix:nonNumeric> days&#8217; written notice to the Company, provided that if any clinical trial under the Research Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after completion of the Phase 2 Challenge Study and before expiration of the Election Period, immediately upon written notice to the Company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after delivery of the Election to Proceed Notice, upon <ix:nonNumeric contextRef="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331" name="cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTcyNjQ_c6138a77-a187-42b7-a51a-527ad76a80c4">90</ix:nonNumeric> days&#8217; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of $<ix:nonFraction unitRef="usd" contextRef="i5ec5bff221b34504b1e0fbb18258fed7_D20220101-20220930" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTc1NDI_b3a239c8-1614-40a4-8c79-ea34464000d9">27.0</ix:nonFraction>&#160;million, research and development funding of $<ix:nonFraction unitRef="usd" contextRef="i5ec5bff221b34504b1e0fbb18258fed7_D20220101-20220930" decimals="-5" name="cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTc1ODY_2c8107a5-e4ca-4c73-bac4-d29fcf208cc8">61.2</ix:nonFraction>&#160;million, plus milestones achieved of $<ix:nonFraction unitRef="usd" contextRef="iae8af69b23b64ece8613fb9204fc9c4b_D20220301-20220331" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTc2MTg_b4d33315-55b2-453f-8f32-1188363c3fe0">3.0</ix:nonFraction>&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $<ix:nonFraction unitRef="usd" contextRef="i34737c9c45ac487189c88b240a304577_D20210501-20210531" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTg3MjI_bc54e6ea-47b8-4242-83e5-f40da148215d">27.0</ix:nonFraction>&#160;million in May 2021 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The research and development services to be performed represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company's initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company determined that as of the latest financial statement date all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are not included in the transaction price. At the end of each </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="id3b32e56e7a6493793d7d739b61aca93" continuedAt="id88840f7511b4b099af8006838e6c8a5"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In March 2022, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="iae8af69b23b64ece8613fb9204fc9c4b_D20220301-20220331" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjAwMTI_b4d33315-55b2-453f-8f32-1188363c3fe0">3.0</ix:nonFraction>&#160;million milestone under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in May 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. <ix:nonFraction unitRef="usd" contextRef="i5a85bab3728d4eada2f9bcaf61036888_D20210701-20210930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_0c9cfa60-5b27-498c-987a-6573fe284ad2"><ix:nonFraction unitRef="usd" contextRef="i6ad6fb4866e44519aefef3041cf4c2cb_D20220101-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_a0068196-6eb2-486e-83fd-c9976e161abf"><ix:nonFraction unitRef="usd" contextRef="i577b14f0889b45eb8cb9da83fcc52acf_D20210101-20210930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_c6352be1-e906-478d-9989-bbab6c8c6e7f"><ix:nonFraction unitRef="usd" contextRef="i4b2539318f504eba964d023b1f0971c9_D20220701-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_e20c2493-2bf0-4acb-9aac-3d1a887f0fdc">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> royalty revenue was recognized during the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Pursuant to the Melinta License Agreement, the Company granted Melinta an exclusive, royalty&#8209;bearing license (including the right to sublicense through multiple tiers), to develop, register and commercialize the Melinta Licensed Product for all uses in humans and non-human animals in the Melinta Territory, subject to the Company&#8217;s retained right, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Until the fifth anniversary of the first commercial sale of the first Melinta Licensed Product in the Melinta Territory, neither the Company nor Melinta, nor any of their respective majority-owned subsidiaries may, directly or indirectly, itself or in collaboration with any Third Party, develop, manufacture for development or commercialization, or commercialize any product in the echinocandin class of drugs in the Melinta Territory without the other party&#8217;s prior written consent, subject to certain provisions in connection with a change of control of a party.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Commercialization.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Melinta will be solely responsible for the commercialization of rezafungin in the Melinta Territory, at its sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s Retained Rights.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company retains the non-exclusive right to practice the intellectual property rights licensed to Melinta in the Melinta Territory solely for the purpose of performing its obligations under the Melinta License Agreement and Mundipharma Collaboration Agreement. The Company also retains the right to grant licenses under the intellectual property rights licensed to Melinta to third parties to which the Company has granted licenses or rights to market, promote and sell Melinta Licensed Product outside the Melinta Territory, to make and have made Melinta Licensed Product anywhere in the world solely to develop, register, use, sell, have sold, offer for sale, commercialize and import Melinta Licensed Product outside the Melinta Territory, subject to the terms of the Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Continued Development and Regulatory Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company will be responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that includes, among other activities, (a) completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the U.S. Food and Drug Administration, or FDA, of a supplemental New Drug Application, or NDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the Company&#8217;s ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain chemistry, manufacturing and controls activities for the Melinta Licensed Product, and (f) all other development activities that are required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company will remain the holder of all FDA submissions, including the rezafungin IND and NDA. The FDA submissions will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated supplemental NDA for the Prophylaxis Indication, after which Melinta will be responsible for performing all activities that may be necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta&#8217;s sole expense, subject to Melinta&#8217;s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket expenses incurred by Melinta.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Supply and Transfer of CMC activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Until Melinta assumes responsibility for the manufacture and supply of the Melinta Licensed Product for development and commercialization in the Melinta Territory, which it may do by direct purchase from the Company&#8217;s contract manufacturing organizations for the Melinta Licensed Product or by having a manufacturing </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="id88840f7511b4b099af8006838e6c8a5" continuedAt="ib1210fe9b59f4431a153fa3b8ffc009c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">technology transfer to Melinta or its designee performed at Melinta&#8217;s sole expense, which, in either case, will be no later than December 31, 2026, the Company will be responsible for the manufacture and supply of the Melinta Licensed Product for development and commercialization by Melinta in the Melinta Territory, and during such period, shall supply Melinta Licensed Product to Melinta pursuant to the terms of a supply agreement to be negotiated by the parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Upon execution of the Melinta License Agreement the total potential transaction value is $<ix:nonFraction unitRef="usd" contextRef="id3992b0eb8484b4aaf5f1a209d2603dc_D20220726-20220726" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5ODQy_8e4df3f8-745e-459b-b2de-9bd58f798458">460.0</ix:nonFraction>&#160;million, including a $<ix:nonFraction unitRef="usd" contextRef="ib906710cf3274c668e80b30f6e1ec734_D20220726-20220726" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5ODU4_8ba59393-79e6-48a9-b993-bfee864db17c">30.0</ix:nonFraction>&#160;million upfront payment and up to $<ix:nonFraction unitRef="usd" contextRef="if3f48f173a7046749372f5bdca47960e_D20220726-20220726" decimals="-5" name="cdtx:CollaborativeArrangementTransactionPotentialValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5ODcz_7a07d1ac-153a-427c-8b99-cea8902649e8">430.0</ix:nonFraction>&#160;million in regulatory and commercial milestones. In addition, the Company is eligible for tiered royalties on U.S. sales in the low double digits to mid-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Either party may terminate the Melinta License Agreement for uncured material breach by the other party. After July 26, 2023, Melinta may terminate the Melinta License Agreement at will. The Company may terminate the Melinta License Agreement if Melinta or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the patent rights licensed to Melinta by the Company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$<ix:nonFraction unitRef="usd" contextRef="ifd947fb9100e419d90d6c2dfa4983059_D20220101-20220930" decimals="-5" name="cdtx:PaymentsRelatedToCollaborativeAgreements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5OTE5_b2b1ae55-9f8a-4986-b787-ec8a334ceea1">30.0</ix:nonFraction>&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$<ix:nonFraction unitRef="usd" contextRef="i693aca7e97aa4503a8037a869333ca1b_D20220801-20220831" decimals="-5" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODcwNTM5_50db25bf-c048-4c55-bf09-220927b5f108">25.9</ix:nonFraction>&#160;million&#160;in August 2022 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company is required to provide research and development services, at its sole expense, as described under the Melinta Development Plan, which represents a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company's obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services. Revenue related to the clinical supply services performance obligation recognized during the three and nine months ended September&#160;30, 2022 was immaterial.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company determined that as of&#160;September&#160;30, 2022, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. <ix:nonFraction unitRef="usd" contextRef="i1a7f54e53e964d7c9958ac2b8a920ce5_D20220101-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzcx_71432a90-f773-4407-97cc-d3e93f446f49"><ix:nonFraction unitRef="usd" contextRef="i2ce9bdb2fb7b4bf88fc587dee9f5a817_D20220701-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzcx_98b8f510-8636-4d1e-80e1-6a2676b6c63c">No</ix:nonFraction></ix:nonFraction> revenue related to milestones was recognized during the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;<ix:nonFraction unitRef="usd" contextRef="id1b5450d72e34c33b4dec3e66a44b756_D20220101-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzgy_35950f02-dccc-4cb9-be6f-8d8793a1fd14"><ix:nonFraction unitRef="usd" contextRef="iabd098fd38fd419896b25481459eb489_D20220701-20220930" decimals="INF" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzgy_978d5b5f-955c-4e27-99ef-209c01eb1499">No</ix:nonFraction></ix:nonFraction> royalty revenue was recognized during the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $<ix:nonFraction unitRef="usd" contextRef="ic5c7726e1d4f43d6ada81fc4d023fd3d_I20220930" decimals="-5" name="us-gaap:CapitalizedContractCostGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMzg0ODI5MDc1OTI3MQ_386574fd-e1f7-451e-8fed-5201c6b372a3">2.0</ix:nonFraction>&#160;million upon execution of the Melinta License Agreement in accordance with ASC 340. The Company incurred these costs in connection with all the performance obligations identified in the Melinta License Agreement and allocated the capitalized contract costs to performance obligations on a relative basis (i.e., in proportion to the transaction price allocated to each </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><ix:continuation id="ib1210fe9b59f4431a153fa3b8ffc009c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">performance obligation) to determine the period of amortization. Amortization during the three and nine months ended September&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="iaa27a7d5291744e8a8982d3d8fd39e8b_D20220701-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc3OTM0_dbc0f4b7-ecbc-4adb-be48-81b3d7ff899a"><ix:nonFraction unitRef="usd" contextRef="ief418486b3fd4aeaa1b3a28dde7a1f60_D20220101-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc3OTM0_dc36500e-b66c-4da9-9fe3-039a7ad88035">1.8</ix:nonFraction></ix:nonFraction>&#160;million and is included within general and administrative expenses in the Company's condensed consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022, the remaining balance of the asset recognized from costs to obtain the Melinta License Agreement was $<ix:nonFraction unitRef="usd" contextRef="ic5c7726e1d4f43d6ada81fc4d023fd3d_I20220930" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczOTY1_e81122e1-690a-4181-9428-980ed094ebf2">0.2</ix:nonFraction>&#160;million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjIwNTg_4509d9ea-71e6-4d89-b92c-fdfc7a49c59a" continuedAt="i208449cc38784ac288ff36b55cc6c299" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the nine months ended&#160;September&#160;30, 2022&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i810b267149e44965acbf595fbb6b9e33_I20211231" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfMC0xLTEtMS00MjM2Nw_ae5a60a5-07bd-426c-b54c-38470848f510">32,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac7381acc7e4e059c3e2321b8b15239_D20220101-20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfMS0xLTEtMS00MjM2Nw_9922597b-e8b5-49ec-8e3d-af05e59b7da6">11,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac7381acc7e4e059c3e2321b8b15239_D20220101-20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfMy0xLTEtMS00MjM2Nw_755e926a-24e0-4f0c-bfe2-38720a2ea9e9">4,005</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c38f20f22ba485bb4c251fc607c0a9e_I20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfNC0xLTEtMS00MjM2Nw_b4b8d217-e402-442f-9663-47e72385f5a3">39,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfNi0xLTEtMS00MjM2Nw_4603133e-8c30-4c1e-b378-c7668f61c1c6">15,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfNy0xLTEtMS00MjM2Nw_b13f26fc-4ba2-4805-89d3-b3cca92012d1">24,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred revenue, September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfOC0xLTEtMS00MjM2Nw_a79ac1e2-f835-4c78-b976-f5b14aa3cfff">39,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, aggregate transaction price allocated to performance obligations that are unsatisfied is $<ix:nonFraction unitRef="usd" contextRef="i18d550357dd0498aa73e25001de9cc1a_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE0NTI_ff167815-8a24-4748-be5e-5217c7a3575b">18.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="iefc06d4abeb64a938a55a63bbfcfedc8_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE0NTk_9660aa1f-3a64-449c-8e95-d2a8115a7653">39.5</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="ief933a73262047ada7ce3fa9a403b153_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc2MDMw_8b2dc4de-888a-45f3-afe1-3928ab9ddfbe">3.8</ix:nonFraction>&#160;million under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. These amounts are expected to be recognized over <ix:nonNumeric contextRef="i18d550357dd0498aa73e25001de9cc1a_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc2MTE0_63f35d2e-a3b5-42a9-8b35-e1a3b00d9463">2.3</ix:nonNumeric> years, <ix:nonNumeric contextRef="iefc06d4abeb64a938a55a63bbfcfedc8_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE2MDg_94749e54-2af0-4672-bf41-57e6e1be1c31">1.3</ix:nonNumeric> years, and <ix:nonNumeric contextRef="ief933a73262047ada7ce3fa9a403b153_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc2MTIy_0aa89908-f713-419f-8dc6-0d7d280cced4">2.3</ix:nonNumeric> years which represent the remaining research periods under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i74e6e40b20bd48d29415c8c3c7305f97_I20220930" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE3NzI_5a40c607-ad34-4c13-a98e-155d0856fd11">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9c1d8dcb1b3c4b8bacd38918de4039b1_I20220930" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE3Nzk_4d89fb46-110b-44cd-8f3f-5b8fbb7cf6de">4.5</ix:nonFraction>&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.</span></div><ix:continuation id="i208449cc38784ac288ff36b55cc6c299"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our contract revenues disaggregated by collaborator and timing of revenue recognition and excludes royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib709c1ffb8854bb481421062c0b218f9_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0xLTEtMS00NTUzNg_f6a23065-0026-4831-87c7-57cbab96c833">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab1678b723954fb2a37229ed7298c334_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0zLTEtMS00NTUzNg_967c4225-ce11-4922-bec7-425b59af6730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04cff27d9bb54d1fa6f4a32a4b7398df_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC01LTEtMS00NTI2Mg_46e28102-ff46-48d5-b517-f1f9670aac4e">25,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9f4882fb39748e396fbfb4e6f2141a1_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC03LTEtMS00NTUzNg_dc692ff0-42f9-48f8-9cfa-e35f33ecf52c">3,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2363ec926c83422882f201f395e6418e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC05LTEtMS00NTUzNg_5e3c0487-cb7b-4140-99c2-790cf748e947">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia89c179f7606467791e1ccda6296e332_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0xMS0xLTEtNDUyODY_d2c553b2-80c8-4b57-8245-121c16f41d5d">25,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied8bda146b1e42518db4ad5b9607da40_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0xLTEtMS00NTUzNg_b07b81da-212c-4a75-beec-c7bd610fdf58">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a13d205acea4035b1472638de599302_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0zLTEtMS00NTUzNg_e9a3243f-c273-48bf-a76f-4f649872aa53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i608d2c0acd8a446f97ea23de80771ca2_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS01LTEtMS00NTUzNg_d852f934-440f-4589-b78d-155e4b3b2e36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86142a8002b4fb3bfa67f3114a2168c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS03LTEtMS00NTUzNg_92996eaf-9b3b-485f-a509-1387b7622377">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdb93712507e4b0d9bcf6e602fc11d8f_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS05LTEtMS00NTUzNg_3506f375-aa6b-4e93-a109-0f2443cbc19c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b76d577a5a04ef2a426145c4efdec1f_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0xMS0xLTEtNDU1MzY_b3190583-c8d9-47d0-a31b-6a59309fc6bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i330a14431e6c447f850339e8183a87c2_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0xLTEtMS00MjM2Nw_2123704e-11b2-46ff-b268-2dc1f9e3d2c5">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib64ac500c81045e0900ce23c27023a2c_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNy0zLTEtMS00NTUzNg_7fd15465-6d92-40cf-9550-df7f92c23e81">6,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee636604f0544608be83b816d561a04_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0zLTEtMS00MjM2Nw_e4f09204-9c61-4f33-922b-475ec6c31320">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8993710e84743d28a95a4b2457fa9cb_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC01LTEtMS00MjM2Nw_7b2d79c5-2ed5-43ce-909d-88579ef60900">7,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43870715ac94163bfa487cc20cc7a5c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNy05LTEtMS00NTUzNg_c90c65d0-af5d-4371-ab4a-0e130c57ddc3">11,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia26a535ba45543e8a02c93c70be14f9c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC03LTEtMS00MjM2Nw_c9e9cc04-1784-4cb9-a209-708d2e866ae3">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791e53caa07d4e4ea55fd15972c74a19_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0xLTEtMS00MjM2Nw_144e4078-3b68-4fb3-ba5e-566cd99417f2">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef6e2feb31a41178bada54e92855b1b_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOC0zLTEtMS00NTUzNg_7e832faa-b8d2-48e3-8677-ca299e18730c">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a540ce1f4734c1b8df74de8131b45d3_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0zLTEtMS00MjM2Nw_11b2b132-a466-4225-9f67-798da3b36e24">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb8ca4cb3f04e0ebddd7c2383d433d7_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS01LTEtMS00MjM2Nw_75d1305a-6a56-4596-9945-1b16414beefc">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8e5492e892a4011aeca081fc7b607fa_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOC05LTEtMS00NTUzNg_4090914b-cd19-4702-baff-b67b05d851f0">3,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05496cda0e33452896f54514996a1288_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS03LTEtMS00MjM2Nw_9a897145-5381-4620-ab38-fab2fa50e37f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad9574638cde472faee405847f9f3e1a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi0xLTEtMS00MjM2Nw_e1dcb2c3-0ab9-4bbc-a75d-caa6b8421947">8,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i586689ef6a80408b93ad64b72f84c672_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOS0zLTEtMS00NTI3Mg_37792259-99ac-4412-b0b0-c8005c43e948">6,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04ff76c144cd4408a9a52fbbc69b19cf_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi0zLTEtMS00MjM2Nw_a1b76dcb-a0c0-45ea-939e-82e6464f8b5b">26,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a54ee7566ce41918832cd3479ef935e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi01LTEtMS00MjM2Nw_586f7f21-1ba7-4c90-879f-c8d2f52182e5">12,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805c213b2c0743b087c75996e2d88021_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOS05LTEtMS00NTI5NA_580c641f-74c1-49d4-aa21-b3207a1b879b">15,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62d5577ed469475da80b700a69f04f2c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi03LTEtMS00MjM2Nw_c8e3faed-bed7-4e9f-ae2a-d582b22c5f4e">26,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c636231d35f4bf0971afbbb890c922e_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC0xLTEtMS00MjM2Nw_3cabd0df-6d20-4f3d-8f14-34a714342278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2b515fd83f4999933be813beb65c48_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC0zLTEtMS00NTU1MQ_b89d67ad-4ae3-465a-9e41-da8193438f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd3b7ed4d6b4262a23a7634c2c7aff2_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC0zLTEtMS00MjM2Nw_53c07258-01bb-4494-9807-22d76363dfd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9fb95774ab143ebafe375c57e2fac61_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC01LTEtMS00MjM2Nw_cab04173-a11c-40ea-948f-595154468bb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefed914e0ec24b92964d9459ffc3d327_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC05LTEtMS00NTU1MQ_597078df-9630-47c4-922b-b362fb8a7391">27,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id406989deae044f4acf764c75f7ad87b_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC03LTEtMS00MjM2Nw_51bcd273-2639-443d-bc8a-b9dc843f11df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic04da1d4150b40a8abe55e454e756c44_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS0xLTEtMS00MjM2Nw_af7828cd-d610-49d7-b253-b1a8bbdb849e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c71d7b0754c47a8818fc47cb60bf5b8_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS0zLTEtMS00NTU1MQ_187844d4-5d1f-4790-acea-ed09a7282dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605912304b144c4bba382814666efe0a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS0zLTEtMS00MjM2Nw_51c82890-6b23-4f32-b309-1366d1c01c81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib370fe55235440b19f13161583777fca_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS01LTEtMS00MjM2Nw_d189edf0-3ee1-4ee8-9725-4f5998bb1b3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc3e4af26d3548a0905d4625e4c6960f_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS05LTEtMS00NTU1MQ_5ba7751d-2dbe-4ac4-ac55-fe24d66d2109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8777634ed6ab43ceb831077cb1ba1505_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS03LTEtMS00MjM2Nw_8be6b002-89e2-4b48-8e03-d54ebbd2c9ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf075aa78dbb48cb952fb65ae88fc07a_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy0xLTEtMS00NTU1MQ_e52a0492-31d9-4909-8ebe-57216ffe08dc">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c01b6b14c1a485fb20538cac3587498_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy0zLTEtMS00NTU1MQ_7f10042b-2dbb-411c-9f17-c199358deaed">2,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida8b4e5a23a9418d8c44be5a1e0e74a0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy01LTEtMS00NTU1MQ_83964d41-7314-4009-8640-a727727eca9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i515a17efa892472b86a77214dfa7ef7b_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy03LTEtMS00NTU1MQ_b2b76610-f35c-4a0e-b620-849093c3c503">7,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41b2c7dcf954060af28af4c157705cb_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy05LTEtMS00NTU1MQ_620d1bf8-96a4-4083-a88a-4e872358e1d4">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib77a7ee0b23046cc9cb75730e07ea8c6_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy0xMS0xLTEtNDU1NTE_5fc5f94a-e265-4fa9-92c2-666f8927f1ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica341a5f24ad4bcab2e21eea5d444a9d_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC0xLTEtMS00NTU1MQ_435fc8a0-9623-4ddf-b706-fbdcac69285b">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76dc324051474558a170627d6a003711_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC0zLTEtMS00NTU1MQ_c80876ab-2cef-4397-b9ae-3b75ce9eec62">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4f5d1f93e04d73aa48631d7518db9c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC01LTEtMS00NTU1MQ_0cc6e4b7-c3a1-4351-af6b-be22ea9525a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d0c3d06b8544eda7efed1647c21a9c_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC03LTEtMS00NTU1MQ_8c6e9b1b-c11d-4b29-96de-1ceaab6e1bf8">598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3011064556b748619173464bff0d68e3_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC05LTEtMS00NTU1MQ_d92d3fac-b40f-4d12-b0c9-5d404a264392">3,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9776e033e33d450695fa795370df723c_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC0xMS0xLTEtNDU1NTE_01decfa7-4172-46bb-824d-ba9e2766f8ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i940b58f0b39b440d929568bd00af95e5_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS0xLTEtMS00MjM2Nw_8cf470d7-011c-4d65-899a-f87618220ded">3,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if417d192e5eb43008abe45d33168ea61_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS0zLTEtMS00NTU1MQ_53a9cc0e-ab07-447d-be1d-e711e3a9bc8d">3,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id433e60fe208470fa98c4a38610c659c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS0zLTEtMS00MjM2Nw_76e54f82-0009-447f-9fde-fc41d2639534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3ec63d2d654bbe9108ebb110c10485_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS01LTEtMS00MjM2Nw_a9f6c517-3f04-432e-a597-c75bf36e7e5c">8,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661d0dfb1ecb4a8e85c58f301a66b3bb_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS05LTEtMS00NTU1MQ_15c88f2b-4621-48a7-b2da-292449b10723">33,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef1c49cdd9a44d09573c601607368e6_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS03LTEtMS00MjM2Nw_94214be8-0f2d-4bc7-b561-6be86af84f96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3Nw_bfa07b7f-c056-4046-b702-6433c6d87a5d" continuedAt="i1e0a7a8e68cd4349950ae7ad2ffa4208" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i1e0a7a8e68cd4349950ae7ad2ffa4208"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 14, 2021, the Company entered into a sixth amendment to its lease with Nancy Ridge Technology Center, L.P. which extended the term of the lease by an additional <ix:nonNumeric contextRef="ib12d63d710f14cf2a688757cc358ebca_I20210714" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMjI1_e6f44ce9-3edf-4d45-b259-b2ca0d2c92f6">24</ix:nonNumeric> months and increases the base rent to $<ix:nonFraction unitRef="usd" contextRef="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714" decimals="0" name="cdtx:LesseeOperatingLeaseMonthlyRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMjU5_3e168c72-a819-4bb4-a736-9f9163084745">103,733</ix:nonFraction> per month effective January 1, 2022, subject to <ix:nonFraction unitRef="number" contextRef="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714" decimals="2" name="cdtx:LesseeOperatingLeaseAnnualRateIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMzEw_14146d8f-97c4-4fb6-8cf3-bd4dbcd47ce3">3</ix:nonFraction>% increases every January. The lease expires on December 31, 2023 with options for <ix:nonFraction unitRef="option" contextRef="ib12d63d710f14cf2a688757cc358ebca_I20210714" decimals="INF" name="cdtx:NumberOfOperatingLeaseOptionsForExtension" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMzk0_b67e7805-c672-433a-a1cf-f29481d41832">two</ix:nonFraction> individual <ix:nonNumeric contextRef="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714" name="cdtx:LesseeOperatingLeaseOptionRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3MQ_47faa439-5207-4d7a-a3eb-c75f42f02af0">two-year</ix:nonNumeric> extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of September&#160;30, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. The incremental borrowing rate used in measuring the Company's lease liability was <ix:nonFraction unitRef="number" contextRef="ib12d63d710f14cf2a688757cc358ebca_I20210714" decimals="3" name="cdtx:LesseeOperatingLeaseIncrementalBorrowingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfODQ4_8657ea41-296f-4ba7-a6ec-135cb4bc8e46">10.8</ix:nonFraction>%.</span></div><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3Mg_d9b7e79b-f61e-4d51-8bc5-bbc8823757b5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of September&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMC0xLTEtMS00MjM2Nw_1bcdad18-a2b2-4fab-8243-2412e1433289">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMS0xLTEtMS00MjM2Nw_cd6379c4-a41d-40ff-9ec3-d545ccfd5c05">1,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMi0xLTEtMS00MjM2Nw_5ff5125a-7659-4c5e-9615-db0f0bdffb37">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMy0xLTEtMS00MjM2Nw_7cc94d4a-8f16-437b-8702-3e050b509e74">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfNC0xLTEtMS00MjM2Nw_52aab868-c5a1-45fa-960b-9b69974a43e1">1,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="cdtx:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3NQ_2ce520da-ce7a-4125-a9f1-4f2606c1522f" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company's operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfMS0xLTEtMS00MjM2Nw_ef4d20e5-1837-4a75-8cb0-ee57dc297e56">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfMy0xLTEtMS00MjM2Nw_f595a43e-0e52-489d-aa1e-daf082e92f30">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfNC0xLTEtMS00MjM2Nw_5b81eec3-56f3-4f1a-8f32-42b355c9ad3e">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfNS0xLTEtMS00MjM2Nw_2d6a7f41-9a5d-4f0a-a9d3-0cd2114234be">1,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the weighted average remaining lease term was <ix:nonNumeric contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTE3Mg_ae0445f1-f3dc-4c65-b441-f24ecd358ddc">1.3</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTI2Mw_47371e0f-d77d-4675-b84e-483a90ab8df6">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTI3MA_1679b9d3-207d-4931-872f-45dfd8d85a38">0.7</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTM0OQ_fe1bb856-c4b0-4293-bce2-8b2a2e975e66">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTM1Ng_62c32ce1-62c3-4209-9cdd-e55cac63aeb6">0.9</ix:nonFraction>&#160;million for the nine months ended September&#160;30, 2022 and 2021 respectively. These costs are primarily related to the Company's long-term operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than <ix:nonNumeric contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930" name="cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTU4Nw_0d3c057b-24ef-4b61-8946-b1d3fb4a03ec">30</ix:nonNumeric> days.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report, and our Annual Report on Form 10-K, or our Annual Report, for the year ended December&#160;31, 2021, filed with the Securities and Exchange Commission, or the SEC, on March 7, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The information in this discussion contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, clinical and nonclinical data, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management and the impact of the COVID-19 pandemic on the foregoing. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. We are focused on infectious diseases and oncology. Our lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we are using our Cloudbreak platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. This technology couples potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. Our most advanced DFC program is CD388, a highly potent, long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting the SARS-CoV-2 strains causing COVID-19 and multiple solid tumor oncology indications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our business is subject to various trends, events or uncertainties that are reasonably likely to cause our reported financial information not to be necessarily indicative of future operating results or of future financial condition. As discussed below, the COVID-19 pandemic has delayed our conduct of clinical trials and other key activities and there is uncertainty regarding the emergence of potential new COVID-19 strains. We may also be impacted by broader macroeconomic conditions, high inflation, and supply chain disruptions. The stock market, and in particular the market for pharmaceutical and biotechnology company stocks, has recently experienced significant decreases in value. This volatility and valuation decline have affected the market prices of securities issued by many companies, often for reasons unrelated to their operating performance. These and other uncertainties are discussed in greater detail below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Initiation of Phase 2a trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2022, we initiated a Phase 2a trial (NCT05523089) to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Phase 2a trial, which dosed its first healthy volunteer in September 2022, is a single-center, randomized, double-blind, placebo-controlled, proof-of-concept study to assess the prophylactic antiviral activity, safety, tolerability and pharmacokinetics of CD388 against influenza via a human viral challenge (influenza) model. Multiple dose levels of CD388 will be evaluated in volunteers who will receive a single administration of CD388 or placebo prior to influenza viral challenge. The trial is expected to enroll up to 168 healthy adults. Results are expected in the first half of 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">NDA accepted by the FDA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration, or FDA, accepted for filing and granted Priority Review to our New Drug Application, or NDA, for rezafungin for the treatment of candidemia and invasive candidiasis, in September 2022. The FDA has assigned a Prescription Drug User Fee Act target action date of March 22, 2023, enabled by rezafungin's designation as a Qualified Infectious Disease Product, and is planning to hold an advisory committee meeting to discuss the application.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Compliance with Nasdaq listing requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 6, 2022, we attended a hearing before the Nasdaq Hearings Panel, or the Panel, and presented our plan to regain compliance with The Nasdaq Capital Market&#8217;s, or Nasdaq, $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a), and requested that the Panel allow us additional time within which to regain compliance. On October 18, 2022, the Panel granted our request for continued listing on Nasdaq, pursuant to an extension, through February 27, 2023. The extension is subject to certain specified conditions and our submission of certain interim updates to the Panel. To evidence compliance with the minimum bid price requirement, we must report a closing bid price of at least $1.00 per share for a minimum of ten consecutive trading days on or before February 27, 2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cloudbreak Platform</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe our Cloudbreak platform has the potential to offer a fundamentally new approach to prevent and treat serious diseases, by developing product candidates designed to provide potent disease targeting activity and immune system engagement in a single long-acting molecule. Because serious disease often results when a pathogen or cancer cell evades or overcomes the host immune system, our Cloudbreak DFC candidates are designed to counter diseases in two ways: prevention of disease proliferation or immune evasion by directly targeting and, where applicable, by focusing the immune system on a pathogen or infected cell. We believe this is a potentially transformative approach, distinct from current therapies, monoclonal antibodies and vaccines. In addition, DFCs are designed to have several advantages, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Multivalent binding which has the potential to increase potency;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Ability to engage different targets on the same target cell to decrease resistance or, in the case of a cancerous cell, to serve as a &#8220;drug cocktail&#8221; in a single molecule, which may improve response to treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential to target multiple viral pathogens or oncological targets with a single DFC; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Potential for universal coverage against all viral variants and all people irrespective of immune status.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In contrast to monoclonal antibodies, our DFCs are smaller, have the potential for better tissue penetration and are designed to target multiple sites. Unlike small molecules, we believe DFC optimization can be focused primarily on potency.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lead Cloudbreak candidates are DFCs for the prevention and treatment of influenza, or influenza DFCs. In September 2020, we nominated CD388, our influenza DFC, as a development candidate. We submitted an IND for CD388 in December 2021 and initiated a Phase 1 trial (NCT05285137) in March 2022. The Phase 1 trial is a randomized, double-blind, dose-escalation study to determine the safety, tolerability and pharmacokinetics of intramuscular and subcutaneous administration of CD388 in healthy subjects. Dosing of all six planned cohorts has been initiated as planned. In addition, a separate Phase 1 Japanese bridging study has been initiated.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">All Phase 1 and Phase 2a trials are being conducted under the Janssen Collaboration Agreement (as defined below).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Cloudbreak platform has also enabled us to expand the development of DFCs to target other life-threatening viral diseases including Coronavirus strains causing COVID-19.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we have expanded the Cloudbreak platform beyond infectious diseases, to discover and develop highly potent DFCs that can target multiple immune checkpoint pathways with a single DFC for oncologic diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 7, 2022, we presented preliminary data on our Oncology and Coronavirus DFCs as part of our Research and Development Day and expect to announce a development candidate for our CD73 oncology program by the end of 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we entered into the exclusive, worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, to develop and commercialize one or more DFCs based on our Cloudbreak platform for the prevention and treatment of influenza.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the terms of the Janssen Collaboration Agreement, we are collaborating in the research, preclinical and early clinical development of CD388, under a mutually-agreed research plan with the objective of advancing development through Phase 1 clinical trials and the first Phase 2a clinical trial. We are responsible for performing all IND-enabling nonclinical studies and early-stage clinical trials under the research plan. Both parties are responsible for conducting certain specified chemistry, manufacturing and controls development activities under the research plan. Janssen is solely responsible, and reimburses us for internal personnel and out-of-pocket costs incurred in performing the research plan activities in accordance with an agreed budget. After completion of the research plan and upon its election to proceed with development, Janssen will be solely responsible for late-stage development, manufacturing, licensure and commercialization. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid us an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, we are eligible for reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting research plan activities. As of September&#160;30, 2022, we have received the $27.0&#160;million up-front payment, $20.6&#160;million in research and development reimbursements, and $3.0&#160;million in milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to an additional $237.0&#160;million in development and regulatory milestone payments from Janssen for successful completion of certain activities over the next several years, including but not limited to Janssen's decision to proceed with clinical development and initiation of a pivotal trial. In addition, we may be eligible to receive approximately $455.0&#160;million in commercial milestones as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Rezafungin</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Rezafungin is a novel molecule in the echinocandin class of antifungals. We are developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSTORE Phase 3 clinical trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2021, we reported positive topline results from ReSTORE, our Phase 3 pivotal clinical trial in patients with candidemia and/or invasive candidiasis (NCT03667690). ReSTORE was a global, randomized, double-blind, controlled trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. ReSTORE enrolled 187 patients and evaluated one 400 milligram, or mg, loading dose of rezafungin for the first week followed by 200 mg of rezafungin dosed once-weekly for up to four weeks in total. The treatment arm was compared to approved daily dosing of caspofungin in a 1:1 randomization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Results from the ReSTORE trial showed that rezafungin met the primary endpoint for the FDA NDA submission of all-cause mortality at Day 30, and also met the primary endpoint for the European Medicines Agency, or EMA, Marketing Authorization Application, submission of global cure at Day 14. Both results demonstrated statistical non-inferiority of rezafungin dosed once-weekly, versus caspofungin dosed once-daily, the current standard of care.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">ReSPECT Phase 3 clinical trial</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are currently conducting the ReSPECT, single, global, randomized, double-blind, controlled Phase 3 pivotal clinical trial (NCT04368559) in patients undergoing allogeneic blood and marrow transplant to assess rezafungin in a 90-day prophylaxis regimen to prevent infections due to Candida, Aspergillus and Pneumocystis. Rezafungin, dosed at 400 mg for the first week followed by 200 mg once weekly out to 90 days, is being compared to a regimen containing two drugs (an azole and Bactrim) dosed once daily for 90 days. The primary efficacy outcome for this trial for the FDA and EMA is fungal-free survival at day 90. We expect this trial to enroll approximately 462 patients. While the ReSPECT trial remains open for enrollment, we continue to monitor the near- and long-term impact of COVID-19 on the ability of our clinical investigators to recruit patients at each of our global clinical trial sites. Thus far, we have relied on sites in the European Union, or EU, for enrollment. Our first four U.S. sites have been recently activated and we are activating additional U.S. sites by year end.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, we entered into a License Agreement, or the Melinta License Agreement, with Melinta Therapeutics, LLC, or Melinta, under which we granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Melinta will be solely responsible for the commercialization of rezafungin in the U.S., at its sole expense. We will be responsible for conducting an agreed upon development plan that includes, among other activities, completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prevention of invasive fungal infections in adult allogeneic blood and marrow transplant recipients. We will initially remain the holder of all FDA submissions, including the rezafungin </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">investigational new drug application, or IND, and NDA. The FDA submissions will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated supplemental NDA for the prophylaxis indication. Following the transfer date, we will remain financially responsible for post-marketing commitments and other remaining development obligations and the costs for those will be deducted from royalties owed to us by Melinta.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The total potential transaction value is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestones. In addition, we are eligible for tiered royalties on U.S. sales in the low double digits to mid-teens. As of September&#160;30, 2022, we have received the $30.0&#160;million up-front payment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we announced a strategic partnership with Mundipharma to develop and commercialize rezafungin in an intravenous formulation for the treatment and prevention of invasive fungal infections. Under the terms of the Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma, we granted Mundipharma an exclusive, royalty-bearing license to develop, register and commercialize rezafungin outside the U.S. and Japan. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible for double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we have received $9.0&#160;million from the sale of our equity to Mundipharma, a $30.0&#160;million up-front payment, $31.4&#160;million in global development funding, $25.1&#160;million in milestone payments (including an $11.1&#160;million milestone payment creditable against future royalties payable to us).</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We continue to monitor the potential impact of the COVID-19 global pandemic on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are reliant on our information technology systems, infrastructure and data to conduct our business. Adopting a work-from-home policy during this pandemic has increased the complexity of our computer systems, making them inherently more vulnerable to service interruption or destruction, malicious intrusion and random attack.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While we have not experienced significant disruptions to our manufacturing supply chain or distribution to date, we are unable to fully assess the potential impact that an extended duration of this pandemic may have on our manufacturing or distribution processes in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As we continue to actively advance our rezafungin Phase 3 clinical development program, we remain in close contact with our principal investigators and clinical sites and continue to monitor the impact of COVID-19 on our trials, expected timelines and costs on an ongoing basis. While the ReSPECT Phase 3 clinical trial for prophylaxis remains open for enrollment, we continue to monitor the near- and long-term impact of COVID-19 on the ability of our clinical investigators to recruit patients at each of our global clinical trial sites.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our clinical trials, employees and vendors, all of which are uncertain and cannot be predicted. Given these uncertainties and new information that may continue to emerge about COVID-19 strains, the full extent of the impact of the COVID-19 pandemic cannot be accurately predicted at this time, and we remain unable to reasonably estimate the related impact to our business, operating results and financial condition, if any. We will continue to evaluate and actively monitor the impact of the COVID-19 pandemic on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have devoted substantially all of our financial resources and efforts to research and development and have incurred significant operating losses. As of September&#160;30, 2022, we had an accumulated deficit of $393.6&#160;million. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the preparation of our financial statements for the three and nine month period ended September&#160;30, 2022, we performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents may not be sufficient to fund our obligations for twelve months from the issuance of these financial statements. Our ability to execute our current business plan depends on our ability to obtain additional funding through equity offerings, debt and other non-dilutive financing alternatives, or potential licensing and collaboration arrangements. We may not be able to raise additional funding on terms acceptable to us, or at all, and any failure to raise funds as and when needed will compromise our ability to execute on our business plan.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">FINANCIAL OPERATIONS OVERVIEW</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, we have generated all of our revenues from our strategic partnerships with Mundipharma and Janssen, and our license agreement with Melinta. In the future, we may generate revenue from a combination of license fees and other upfront payments, other funded research and development agreements, milestone payments, product sales, government and other third-party funding and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter-to-quarter as a result of the timing of our achievement of nonclinical, clinical, regulatory and commercialization milestones, the timing and amount of payments relating to such milestones and the extent to which any of our products are approved and successfully commercialized. If we are unable to fund our development costs or we are unable to develop product candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenues and our results of operations and financial position would be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To date, our research and development expenses have related primarily to nonclinical development of our rezafungin acetate and our Cloudbreak platform, as well as clinical development of rezafungin acetate. Research and development expenses consist of wages, benefits and stock-based compensation for research and development employees, as well as the cost of scientific consultants, facilities and overhead expenses, laboratory supplies, manufacturing expenses and nonclinical and clinical trial costs. We accrue clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies or other activities within studies and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred and costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of the study or project and the invoices received from our external service providers. We adjust our accruals as actual costs become known.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may receive potential research and development funding through a partnership from the National Institute of Allergy and Infectious Diseases. We have evaluated the terms of the grants to assess our obligations and the classification of funding received. Amounts received for funded research and development are recognized in the statement of operations as a reduction to research and development expense over the grant period as the related costs are incurred to meet our obligations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several years as we continue to conduct nonclinical and clinical studies, expand our research and development pipeline and progress our product candidates through clinical trials. However, it is difficult to determine with certainty the duration, costs and timing to complete our current or future nonclinical programs and clinical trials of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact of the COVID-19 pandemic and other similar health crises;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">per patient trial costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients that participate in the trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of sites included in the trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the countries in which the trials are conducted;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the length of time required to enroll eligible patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of doses that patients receive;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the drop-out or discontinuation rates of patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">potential additional safety monitoring or other studies requested by regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the duration of patient follow-up;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the phase of development of the product candidate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and safety profile of the product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses by major program or category were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rezafungin</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">28,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cloudbreak platform</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6,252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Personnel costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,041&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54,074&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We typically deploy our employees, consultants and infrastructure resources across our programs. Thus, some of our research and development expenses are not attributable to an individual program but are included in other research and development expenses as shown above.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, legal, business development, commercial planning, and support functions. Other general and administrative expenses include facility and overhead costs not otherwise included in research and development expenses, consultant expenses, travel expenses and professional fees for auditing, tax, legal, and other services. We expect that general and administrative expenses will increase in the future as we expand our operating activities and incur additional costs associated with operating as a publicly traded company. These increases will likely include legal fees, accounting fees, directors&#8217; and officers&#8217; liability insurance premiums and costs associated with investor relations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other income and expense consist primarily of interest income and expense, and various income or expense items of a non-recurring nature.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We earn interest income from interest-bearing accounts and money market funds for cash and cash equivalents. Interest expense represents interest payable related to term loans and the amortization of debt issuance costs.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based upon unaudited financial statements that we have prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these unaudited financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities as of the date of the financial statements, and the revenues and expenses incurred during the reporting periods. We believe that the estimates, judgments and assumptions are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. To the extent there are material differences between these estimates, judgments or assumptions and actual results, our financial statements will be affected. Historically, revisions to our estimates have not resulted in a material change to our financial statements. While our significant accounting policies are more fully described in Note 2 to our consolidated financial statements contained in our Annual Report on Form 10-K, the significant accounting estimates that we believe are important to aid in fully understanding and evaluating our reported financial results include the following:</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We recognize revenue in accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;We only apply the five-step model to contracts when it is probable that we will collect the consideration we are entitled to in exchange for the goods or service we transfer to a customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and identify those that are performance obligations, and assess whether each promised good or service is distinct.&#160;We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, we must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in a contract, we recognize revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. We evaluate the measure of progress at each reporting period and, if necessary, adjust the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or a collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of milestones that are within our or a collaboration partner&#8217;s control, such as operational development milestones and any related constraint, and, if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to our estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, we will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, we have not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, we entered into the Mundipharma Collaboration Agreement with Mundipharma. We concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, we entered into the Janssen Collaboration Agreement with Janssen. We concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, we entered into the Melinta License Agreement with Melinta. We concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in August 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement, as well as progress towards completion of the research and development performance obligation related to the Melinta License Agreement, are best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. We periodically review and update the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to our estimates have no impact on our reported cash flows, the amount of revenue recorded in the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">period could be materially impacted. Revenue for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 to the financial statements for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;We accrue nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events. We periodically confirm the accuracy of these estimates with our service providers and make adjustments if necessary.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on the facts and circumstances known to us at that time. Our accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If possible, we obtain information regarding unbilled services directly from these service providers. However, we may be required to estimate these services based on other information available to us. If we underestimate or overestimate the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, our estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in our accruals.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We account for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance RSUs, or PRSUs, and employee stock purchase plan, or ESPP, rights by estimating the fair value on the date of grant. We estimate the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of our common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of our stock, (c) the expected term of the award, and (d) the expected dividend yield. We computed the historical volatility data using the daily close prices for our common stock during the equivalent period of the calculated expected term of our stock-based awards. We estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that we have not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We recognize forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_73"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended September&#160;30, 2022 and 2021 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the three months ended September&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40,744&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">20,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Collaboration revenue was $40.7 million for the three months ended September&#160;30, 2022 and $7.1 million for the three months ended September&#160;30, 2021. Revenue for the three months ended September&#160;30, 2022 included $25.9&#160;million of revenue recognized upon transfer of an intellectual property license to Melinta in August 2022. The remaining revenue for the three months ended September&#160;30, 2022 relates to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma, Janssen, and Melinta of $8.0&#160;million, $6.5&#160;million and $0.3&#160;million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenue for the three months ended September&#160;30, 2021 relates to ongoing research and development and clinical supply services provided to Mundipharma and Janssen of $3.3&#160;million and $3.8&#160;million, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses were $20.0 million for the three months ended September&#160;30, 2022 and $20.5&#160;million for the three months ended September&#160;30, 2021.&#160;The decrease in research and development expenses is primarily due to lower clinical expenses associated with the rezafungin clinical trials and lower consulting and personnel costs, offset by higher clinical expenses associated with our Cloudbreak antiviral platform.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative expenses were $5.8 million for the three months ended September&#160;30, 2022 and $4.6 million for the three months ended September&#160;30, 2021. The increase in general and administrative expenses is primarily due to amortization of contract costs related to obtaining the Melinta License Agreement offset by lower consulting and personnel costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other income (expense), net during the three months ended&#160;September&#160;30, 2022&#160;and September&#160;30, 2021 related primarily to interest expense in connection with our loan from Pacific Western Bank, offset by interest income generated from cash held in interest-bearing investments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the nine months ended September&#160;30, 2022 and 2021 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the nine months ended September&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">55,462</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">54,074</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,058</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">13,758</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Collaboration revenue was $54.1&#160;million for the nine months ended September&#160;30, 2022 and $42.3&#160;million for the nine months ended September&#160;30, 2021. Revenue for the nine months ended September&#160;30, 2022 included $25.9&#160;million of revenue recognized upon transfer of an intellectual property license to Melinta in August 2022. The remaining revenue for the nine months ended September&#160;30, 2022 relates to the achievement of milestones and ongoing research and development and clinical supply services provided to Mundipharma, Janssen and Melinta of $12.5&#160;million, $15.4&#160;million, and $0.3&#160;million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Revenue for the nine months ended September&#160;30, 2021 included $27.0&#160;million of revenue recognized upon transfer of an intellectual property license to Janssen in May 2021. The remaining revenue for the nine months ended September&#160;30, 2021 relates to ongoing research and development and clinical supply services provided to Mundipharma and Janssen of $8.4&#160;million and $6.9&#160;million, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and development expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses were $55.5&#160;million for the nine months ended September&#160;30, 2022 and $54.1&#160;million for the nine months ended September&#160;30, 2021.&#160;The increase in research and development expenses is primarily due to increased expense associated with our Cloudbreak antiviral platform and higher personnel costs, offset by lower clinical expenses associated with the rezafungin clinical trials.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">General and administrative expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">General and administrative expenses were $15.1&#160;million for the nine months ended September&#160;30, 2022 and $13.8&#160;million for the nine months ended September&#160;30, 2021. The increase in general and administrative expenses is primarily due to amortization of contract costs related to obtaining the Melinta License Agreement, offset by lower consulting and personnel costs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Other income (expense), net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Other income (expense), net during the nine months ended&#160;September&#160;30, 2022&#160;and September&#160;30, 2021 related primarily to interest expense in connection with our loan from Pacific Western Bank, offset by interest income generated from cash held in interest-bearing investments.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, as well as the cash flows generated from our partnerships with Mundipharma and Janssen, our license to Melinta, and equity and debt financings. We have devoted our resources to funding research and development programs, including research, preclinical and clinical development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to fund future operating needs will depend on a combination of equity, debt or other financing structures, receipt of payments under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, as well as potentially entering into other collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts. Our ability to raise additional capital may also be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, financial markets in the U.S. and worldwide resulting from the ongoing COVID-19 pandemic.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to $484.3&#160;million in development, regulatory and commercial milestone payments from Mundipharma for successful completion of certain activities over the next several years, as well as double-digit royalties in the teens on tiers of annual net sales. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to $237.0&#160;million in development and regulatory milestone payments from Janssen for successful completion of certain activities over the next several years, including but not limited to Janssen's decision to proceed with clinical development and initiation of a pivotal trial. In addition, we may be eligible to receive approximately $455.0&#160;million in commercial milestones as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are eligible to receive up to $430.0&#160;million in regulatory and commercial milestone payments from Melinta for successful completion of certain activities over the next several years, as well as tiered royalties on U.S. sales in the low double digits to mid-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On November 8, 2018, we entered into the controlled equity offering sales agreement with Cantor Fitzgerald &amp; Co, or the Sales Agreement, pursuant to which we may offer and sell, from time to time at our sole discretion, shares of our common stock having an aggregate offering price of up to $50.0&#160;million. As of September&#160;30, 2022, the aggregate offering price remaining under the Sales Agreement was $46.8 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our lease with Nancy Ridge Technology Center, L.P. expires on December 31, 2023 with options for two individual two-year extensions, which have not been exercised, and remain in effect and available to the Company. As of September&#160;30, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. Total undiscounted operating lease payments are $1.7 million as of September&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As discussed further below, we believe that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months. There are many factors that could impact our operating cash flow, most notably achievement of milestones under our Mundipharma Collaboration Agreement, Janssen Collaboration Agreement and Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are mindful that conditions in the current macroeconomic environment could affect our ability to achieve our goals. We operate and conduct clinical trials in countries that face economic volatility and weakness. Sustained weakness or further deterioration of the local economies and currencies and adverse effects of the impact of the ongoing COVID-19 pandemic may pose operational challenges in those countries. We will continue to monitor these conditions and will attempt to adjust our business plans, as appropriate, to mitigate macroeconomic risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services that generally provide for termination either on notice or after a notice period. Our material cash requirements include costs to complete agreed-upon activities under our Mundipharma Collaboration Agreement, Janssen Collaboration Agreement and Melinta License Agreement, as well as personnel and general and administrative support costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had $53.1 million in cash and cash equivalents. The following table shows a summary of our cash flows for the nine months ended September&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating activities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(7,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(10,325)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Investing activities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing activities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,615)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">7,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(9,195)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2,644)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in operating activities was $7.5 million for the nine months ended September&#160;30, 2022, compared to net cash used in operating activities of $10.3&#160;million for the nine months ended September&#160;30, 2021. Cash used in operating activities for the nine months ended September&#160;30, 2022 was primarily attributable to a net loss of $16.4 million, and included $2.8&#160;million for a milestone achieved in December 2021 under the Mundipharma Collaboration Agreement, which was received in January 2022, $3.0&#160;million for a milestone achieved in March 2022 under the Janssen Collaboration Agreement, which was received in May 2022, $11.1&#160;million for a milestone achieved in August 2022 under the Mundipharma Collaboration Agreement, which was received in September 2022, and the $30.0&#160;million upfront payment received in August 2022 pursuant to the Melinta License Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash used in operating activities for the nine months ended September&#160;30, 2021 was primarily attributable to a net loss of $25.7 million and included $11.1&#160;million for a milestone achieved in November 2020 under the Mundipharma Collaboration Agreement, which was received in January 2021, and the $27.0&#160;million upfront payment received in May 2021 pursuant to the Janssen Collaboration Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For all periods presented, the primary use of cash was to fund research and development activities for our product candidates, which activities and uses of cash we expect to continue to increase for the foreseeable future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our investing activities during the nine months ended September&#160;30, 2022 and 2021 consisted of purchases of property and equipment.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash used in financing activities during the nine months ended September&#160;30, 2022 primarily consisted of net proceeds of $1.7 million from the sale of 2,292,543 shares of common stock under the Sales Agreement, after deducting placement agent fees, offset by principal payments of $2.6 million made in connection with our loan from Pacific Western Bank and $0.7 million related to issuance costs for our 2021 underwritten public offering.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Net cash provided by financing activities during the nine months ended September&#160;30, 2021 primarily consisted of net proceeds of $11.0&#160;million from the sale of 4,577,115 shares of common stock under the Sales Agreement, after deducting placement agent fees, offset by principal payments of $3.3&#160;million made in connection with our loan from Pacific Western Bank.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital Requirements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months. Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. We plan to continue to fund our losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a smaller reporting company, we are not required to provide information typically disclosed under this item.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;4. CONTROLS AND PROCEDURES</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we are continuing to carry out an evaluation under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of September&#160;30, 2022 due to a material weakness in internal control over financial reporting described below.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An evaluation was also performed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Material Weakness in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We determined that our review control over the evaluation of applicable accounting standards and assessment of completeness and accuracy of valuation assumptions, related to non-routine transactions that include collaboration revenue, was not appropriately designed or operating effectively. While this improper design and operation did not result in a material error in the annual or interim financial statements, there is a reasonable possibility that a material misstatement in the annual or interim financial statements would not have been detected. Based on these factors, we concluded that the control deficiency noted above represents a material weakness.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Remediation of Material Weakness</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are committed to maintaining a strong internal control environment and implementing measures to ensure that the control deficiency identified above is remediated as soon as possible. Management is in the process of implementing a remediation plan, which includes adding additional layers of review by members of our management team regarding the evaluation of applicable accounting standards and completeness and accuracy of valuation assumptions related to non-routine transactions that include collaboration revenue. The remediation actions are also being monitored by the Audit Committee of our Board of Directors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1. LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_91"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;1A. RISK FACTORS</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_94"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the principal factors that make an investment in our securities speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below and should be carefully considered.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Our operations, business and financial results have been and could continue to be adversely impacted by the current public health pandemic related to COVID-19.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We depend heavily on the success of rezafungin, for which an NDA has been submitted to the FDA, and CD388, currently in Phase 1 and Phase 2a clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we experience delays or difficulties in enrolling patients in our clinical trials our receipt of necessary regulatory approvals could be delayed or prevented.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If clinical trials for rezafungin, CD388 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We may not be successful in our efforts to identify, discover, and develop potential product candidates through our Cloudbreak platform or otherwise.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We need substantial additional funding to complete the development of rezafungin and to advance CD388 and our Cloudbreak program.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We are dependent on our collaboration partners to provide funding to continue the development of rezafungin and CD388; for the commercialization of rezafungin outside Japan; and for the late-stage development, manufacturing, registration and commercialization of CD388. If the collaborations are not successful, we may not be able to complete the development of rezafungin and CD388, or capitalize on the full market potential for rezafungin and CD388.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be forced to suspend or terminate one or more of our preclinical Cloudbreak programs.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following risk factors, as well as the other information in this Quarterly Report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. When evaluating our business, you should consider all of the factors described as well as the other information in our Annual Report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The risk factors set forth below that are marked with an asterisk (*) contain changes to the similarly titled risk factors included in Item 1A of our Annual Report. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_100"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to the COVID-19 Pandemic</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our operations, business and financial results have been and could continue to be adversely impacted by the current public health pandemic related to COVID-19.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In January 2020, the World Health Organization, or WHO, announced a global health emergency because of a new strain of novel coronavirus known as COVID-19 and, in March 2020, the WHO declared the COVID-19 outbreak a pandemic, or the COVID-19 pandemic. The COVID-19 pandemic has resulted in significant governmental measures being implemented to control the spread of the virus, including quarantines, travel restrictions and business interruptions and shutdowns. These precautions have disrupted our business operations and prospects. For example, we have experienced, and expect to continue to experience, trial site activation and enrollment delays for the ReSPECT clinical trial due to facility restrictions, quarantines, travel restrictions, focus on COVID-specific trials and other obstacles. Our NDA for rezafungin may be adversely impacted by the pandemic if FDA personnel are redirected to pandemic-related product reviews or if FDA personnel are unable to travel to conduct manufacturing or clinical site inspections in conjunction with the review of our NDA. The COVID-19 outbreak and mitigation measures also have had and may continue to have an adverse impact on global economic conditions which could impair our ability to raise capital when needed. While the disruption from COVID-19 has had and we expect it to continue to have an adverse effect on our business, financial condition and results of operations, we are unable to predict the extent or nature of these impacts at this time. In addition, to the extent the ongoing COVID-19 outbreak continues to adversely affect our business, financial condition, results of operations and growth prospects, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this "Risk Factors" section.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_103"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Drug Discovery, Development and Commercialization</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We depend heavily on the success of rezafungin, for which an NDA has been submitted to the FDA, and CD388, currently in Phase 1 and Phase 2a clinical development, and we are very early in our efforts to develop other product candidates from our Cloudbreak program, none of which may be successful.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are currently conducting two Phase 3 clinical trials of rezafungin. We have completed the ReSTORE trial and conducted the primary analyses required for potential approval in U.S. and Europe but are continuing to enroll and treat patients in China to support Chinese regulatory filings. The U.S. Food and Drug Administration, or FDA, accepted for filing and granted Priority Review to our New Drug Application, or NDA, for rezafungin for the treatment of candidemia and invasive candidiasis, in September 2022. The FDA is planning to hold an advisory committee meeting to discuss the application. Even though the NDA has been accepted for filing, we may receive a Complete Response Letter rather than approval, including for reasons that may be identified during a meeting of the advisory committee. Additionally, the FDA may issue a Complete Response Letter if it does not agree that the clinical benefits outweigh the risks or if any of our clinical or manufacturing sites are found to be out of compliance with FDA requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ReSPECT trial is currently enrolling globally. We received IND clearance for CD388, our DFC for prevention and treatment of influenza, from the FDA in March 2022 and subsequently initiated a Phase 1 clinical trial. In September 2022, we initiated a Phase 2a trial of CD388 to evaluate the pre-exposure prophylactic activity of CD388 against influenza virus and a separate Phase 1 Japanese bridging study has been initiated. We are also conducting in vitro and in vivo preclinical studies of other product candidates from our Cloudbreak program for viral infections and oncology indications. Our assumptions about why rezafungin and CD388 are worthy of continued development, as well as our assumptions about the markets for rezafungin, CD388 or any other potential products from our Cloudbreak program, are based on data primarily collected by other companies. The timing and costs of our preclinical and clinical development programs, the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">likelihood of marketing approval for rezafungin and CD388, and the regulatory paths for marketing approval for additional products from our Cloudbreak program remain uncertain. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of rezafungin, CD388 and any other product candidates we may develop will depend on many factors, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact of the COVID-19 pandemic on our operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to secure adequate additional funding;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">agreement with regulatory authorities on study designs and other requirements for study initiation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful completion of preclinical studies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">successful enrollment and completion of clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">demonstration of safety and efficacy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">receipt of marketing approvals from applicable regulatory authorities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">negotiation of favorable indications and other key elements of the product labeling;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtaining and maintaining patent and trade secret protection and non-patent exclusivity for our product candidates and technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">launching commercial sales of the product candidates if and when approved;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acceptance of the product candidates, if and when approved, by patients, the medical community and third-party payors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">effectively competing with other therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a continued acceptable safety profile of the products following approval; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enforcing and defending intellectual property rights and claims.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we do not timely enroll the ReSPECT Phase 3 clinical trial, or if we are unable to secure significant additional funding, we will not be able to complete the clinical development plans for the prophylaxis indication for rezafungin. If we do not accomplish one or more of any of the other goals in a timely manner, or at all, we could experience significant delays or an inability to successfully complete the development of and commercialize our product candidates, which would harm our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in enrolling patients in our clinical trials our receipt of necessary regulatory approvals could be delayed or prevented.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may not be able to complete the ReSPECT clinical trial or the ongoing portion of the ReSTORE trial in China if we are unable to identify and enroll a sufficient number of eligible patients, as required by the FDA or similar regulatory authorities outside the U.S., or if we do not believe that the number of patients required by such regulatory authorities can be enrolled in a reasonable timeframe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our rezafungin Phase 3 clinical development program is a global program and, as such, our ability to timely enroll the clinical trials may be affected by many different factors specific to those global localities, such as, delays in our receipt of approval to commence trials in a particular country from applicable regulatory authorities and ethics committees, timely completion of clinical trial site initiation within each country, delays in local importation and receipt of necessary clinical trial supplies, and our ongoing compliance with local regulations, which may change during the course of the clinical trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the rezafungin clinical trials are heavily reliant on third-party contractors, including contractors that import clinical trial materials, and CROs that conduct and monitor our clinical trials, and interact with regional or local regulators and ethics committees on our behalf. If we experience significant difficulties with any of our key contractors such that we determine it is in the best interests of the clinical trials to replace a key contractor, this could result in a significant delay in enrollment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, timely enrollment in the ReSPECT trial is reliant on global clinical trial sites, most of which have been adversely affected by the COVID-19 global pandemic. For example, the COVID-19 global pandemic has significantly impacted our ability to activate sites and enroll patients in the ReSPECT trial in Europe and the U.S., resulting in substantial delays and increases in the cost of completing the trial. Our enrollment of patients in ReSTORE in China was </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">also delayed in part due to the pandemic. Some factors from the COVID-19 coronavirus outbreak that have adversely affected enrollment in our Phase 3 trials include:</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the diversion of healthcare resources away from the conduct of clinical trial matters to focus on pandemic concerns, including the attention of infectious disease physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the decision of some clinical trial sites to focus on the conduct of COVID-19 clinical trials;</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">limitations imposed by hospitals serving as our clinical trial sites that prohibit entry on hospital premises by persons other than those supporting the hospital's COVID-19 efforts;</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">limitations on travel that interrupt key trial activities, such as clinical trial site initiations and monitoring;</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">interruption in global shipping affecting the transport of clinical trial materials, such as investigational drug product and comparator drugs used in our trials; and</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">employee quarantine or isolation days that delay necessary interactions with local regulators, ethics committees and other important agencies and contractors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These and other factors arising from the COVID-19 coronavirus could worsen in countries that are already afflicted with the virus or could continue to spread to additional countries, each of which may further adversely impact our Phase 3 trials. The global outbreak of the COVID-19 coronavirus continues to evolve and the conduct of our Phase 3 trials may continue to be adversely affected, despite efforts to mitigate this impact.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, some of our competitors may have ongoing or new clinical trials for product candidates that would treat the same indications as rezafungin, or be used in the same patients and, therefore, patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment may also be affected by other factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">eligibility criteria, including regional or local practices that place additional limitations on patient eligibility;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">availability, safety and efficacy of approved medications or other investigational medications being studied clinically for the disease under investigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">perceived risks and benefits of rezafungin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">efforts to facilitate timely enrollment in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reluctance of physicians to encourage patient participation in clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the ability to monitor patients adequately during and after treatment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the proximity and availability of clinical trial sites for prospective patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">delays or failures in maintaining an adequate supply of quality drug product for use in clinical trials; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changing treatment patterns that may reduce the burden of disease which rezfungin addresses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our inability to enroll and retain a sufficient number of patients in a reasonable timeframe may require us to abandon the entire rezafungin Phase 3 clinical development program or terminate the ReSPECT trial or the ReSTORE trial in China. Enrollment delays have and will continue to result in increased development costs, which could cause the value of our company to decline and could limit our ability to obtain necessary additional financing.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials for rezafungin, CD388 or any other product candidates are delayed, terminated or suspended, or fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities, we may incur additional costs, or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A delay in starting or completing our clinical trials would materially impact our timelines and our ability to complete development of our product candidates in a timely manner or at all. For example, our entire rezafungin clinical development program has been severely impacted by the effects of the COVID-19 global pandemic. Additionally, our ability to complete our rezafungin Phase 3 development program is dependent on our ability to secure adequate additional funding.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A failure of one or more clinical trials could occur at any stage of testing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a particular clinical trial do not necessarily predict final results of that trial.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, preclinical and clinical data are often susceptible to multiple interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. For example, the historically observed high rate of correlation for clinical efficacy for anti-infectives based on preclinical data may not apply for our current or future product candidates, and any of the potential benefits that we anticipate for human clinical use may not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not know whether either the ReSPECT trial or the Phase 1 or Phase 2a trials of CD388 will be completed on schedule. We have experienced significant delays in these trials arising from the COVID-19 global pandemic. We may experience numerous other unforeseen events that could delay or prevent our ability to commence or complete our clinical trials, which could then delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial on our expected timeline, or at all, or conduct a clinical trial at a prospective trial site or in a given country;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may disagree with our interpretation of preclinical data, which may impact our ability to commence our trials on our expected timeline or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators may require that trials or studies be conducted, or sized or otherwise designed in ways, that were unforeseen in order to begin planned studies or to obtain marketing authorization;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials, modify planned clinical trial designs or abandon product development programs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">enrollment in these clinical trials may be slower than we anticipate, clinical sites may drop out of our clinical trials or participants may drop out of these clinical trials at a higher rate than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">regulators, institutional review boards or the data safety monitoring board assembled by us to oversee our rezafungin clinical trials may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks due to serious and unexpected side effects;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the FDA or comparable foreign regulatory authorities could require that we perform more studies than, or evaluate clinical endpoints other than, those that we currently expect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the supply of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be delayed or insufficient, or the quality of such materials may be inadequate; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we may be required to delay or terminate studies due to financial constraints.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If the FDA or similar regulatory authorities outside the U.S. do not agree with the design and implementation of our planned or ongoing clinical trials, including the safety database to support an NDA submission, or if we are unable to secure additional funding, we may not be able to complete the overall Phase 3 clinical development program for rezafungin as currently envisioned. If we do not accomplish one or more of any of the other goals in a timely manner, or at all, we could experience significant delays or an inability to successfully complete the development of and commercialize our product candidates, which would harm our business. If we are required to conduct additional clinical trials, or other tests of our product candidates beyond those that we currently contemplate, if we are unable to complete clinical trials of our product candidates or other tests successfully or in a timely manner, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be delayed in obtaining marketing approval for our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">not obtain marketing approval at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to additional post-marketing testing requirements; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">be subject to significant restrictions on reimbursement from public and/or private payors; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">have the product removed from the market after obtaining marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Product development costs will also increase if we experience delays in testing or in receiving marketing approvals. We do not know whether any clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates, could allow our competitors to bring products to market before we do, could increase competition from generics of the same class, and could impair our ability to successfully commercialize our product candidates, any of which may harm our business and results of operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If serious adverse reactions or unexpected characteristics of our product candidates are identified during development, we may need to abandon or limit our development of some or all of our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Because it is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval, the risk of each of our programs is high. If our product candidates are associated with undesirable side effects or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. For example, the PK properties, such as a longer half-life or less frequent dosing regimen, that differentiate rezafungin from other echinocandins could have side effects that we have not anticipated and the consequences of such side effects could be more severe than have been seen with other echinocandins that have shorter half-lives or more frequent dosing regimens, or are dosed at lower concentrations than we expect for rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, the treatment advantages that we are predicting for rezafungin, such as lower healthcare costs resulting from an ability to administer rezafungin once-weekly, which could allow earlier hospital discharge, or the predicted ability of rezafungin to be effective against resistant strains of fungal pathogens, may not be realized. For our DFCs, the bispecific mechanism of action, including the use of the immune system, may lead to side effects that are not anticipated based on the preclinical work we have conducted to date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the biotechnology industry, many agents that initially show promise in early stage testing may later be found to cause side effects that prevent further development of the agents. In addition, infections can occur in patients with co-morbidities and weakened immune systems, and there may be adverse events and deaths in our clinical trials that are attributable to factors other than investigational use of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited financial resources. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential than opportunities we pursue. For example, we believe that a supplemental NDA, or sNDA, filing for rezafungin adding the prophylaxis indication can be supported by one Phase 3 trial in prophylaxis, however, financial constraints may require us to delay our prophylaxis program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In support of the global effort to identify effective therapeutics to treat and prevent the COVID-19 coronavirus and stem the current global pandemic, we have expended financial resources to identify DFCs which may be effective in this area. In addition, we have recently expended financial resources on identification of DFCs targeting multiple potentially synergistic oncology targets. We have limited experience in identification and nonclinical and clinical testing of oncology therapeutics. Our resource allocation decisions may not result in us identifying valuable products or may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target markets for a particular product candidate or opportunity, we may relinquish valuable rights to that product candidate or opportunity through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or opportunity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, formulary committees, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If any of our product candidates receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by hospitals and hospital pharmacies, physicians, patients, third-party payors and others in the medical community for us to achieve commercial success. If our product candidates do not achieve an adequate level of acceptance, we may not generate sufficient product revenue to become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the efficacy and potential advantages compared to alternative therapies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size of the markets in the countries in which approvals are obtained;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terms, limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to offer any approved products for sale at competitive prices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of the target patient population to try new therapies or dosing regimens;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the willingness of physicians to prescribe these therapies and, in the case of rezafungin, transition to a once-weekly dosing regimen from traditional once-daily dosing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the strength of marketing and distribution support;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the success of competing products and the marketing efforts of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sufficient third-party payor coverage and adequate reimbursement; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the prevalence and severity of any side effects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates, if and when they are approved.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have a sales or marketing infrastructure. To achieve commercial success for any approved product, we must license the rights to third parties with such capabilities, develop a sales and marketing organization or outsource these functions to third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are risks involved both with establishing our own sales and marketing capabilities and with entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly and our investment would be lost if we cannot reposition our sales and marketing personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our product candidates on our own include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability of sales personnel to obtain access to physicians or to achieve adequate numbers of prescriptions for any future products; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we enter into arrangements with third parties to perform sales, marketing and distribution services, our product revenue or the profitability of these product revenues to us may be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell and market our product candidates or may be unable to do so on terms that are favorable to us. We may have little control over such third parties and any of them may fail to market and sell our products effectively, including by failing to devote the necessary resources and attention. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Regulatory incentives to develop drugs for treatment of infectious diseases have increased interest and activity in this area and will lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the indications on which we are focusing our product development efforts. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect that rezafungin will primarily compete with certain antifungal classes of drugs, which include polyenes, azoles and echinocandins. Approved branded echinocandin antifungal therapies include Cancidas (caspofungin, marketed by Merck&#160;&amp; Co.), Eraxis (anidulafungin, marketed by Pfizer, Inc.), and Mycamine (micafungin, marketed by Astellas Pharma US, Inc.). We expect that there will be generics of all of the current echinocandins available at the time of rezafungin market approval, which will create added competition.&#160;In addition, there are other generic products approved for candidemia, marketed by companies such as Baxter Healthcare Corporation, Mylan Inc. and Glenmark Generics Inc., among others. In addition to approved therapies, we expect that rezafungin will compete with product candidates that we are aware of in clinical development by third parties, such as SCY-078, being developed by Scynexis, Inc.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:115%">We expect that if we are successful in developing influenza product candidates identified through our Cloudbreak program, such product candidates will compete against approved and investigational agents for the treatment or prevention of viral influenza infections, including influenza vaccines, neuraminidase inhibitors such as Tamiflu, Relenza and Peramivir, and endonuclease inhibitors such as Xofluza. We may develop other product candidates through our Cloudbreak platform for the treatment or prevention of other serious diseases, such as the SARS-CoV-2 strains causing COVID-19, and various cancers.&#160;We are aware of a large number of approved and investigational therapies in these areas also.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our competitors may develop products that are more effective, safer, more convenient or less costly than any that we are developing or that would render our product candidates obsolete or non-competitive. Our competitors may also obtain marketing approval from the FDA or other regulatory authorities for their products sooner than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many of our competitors have significantly greater name recognition, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These same competitors may invent technology that competes with our rezafungin program, CD388, or our Cloudbreak platform.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">These third parties may compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-top:6.25pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analysis of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical studies. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6.25pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:18pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, these products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-top:6.3pt;padding-right:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. In the U.S., new and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product-licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial marketing approval is granted. As a result, we might obtain marketing approval for a drug in a particular country but then be subject to price regulations that delay its commercial launch, possibly for lengthy time periods, and negatively impact the revenue we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to commercialize and generate revenue from one or more product candidates, even if our product candidates obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health programs, private health insurers, integrated delivery networks and other third-party payors. Third-party payors decide which medications they will pay for and establish reimbursement levels. A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of payment for particular medications. Increasingly, third-party payors are requiring that drug companies provide predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, if reimbursement is available, the level of reimbursement may not be sufficient for commercial success. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and adequate reimbursement for newly approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or similar regulatory authorities outside the U.S. Moreover, eligibility for coverage and reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Coverage and reimbursement rates may vary according to the use of the drug and the medical circumstances under which it is used may be based on reimbursement levels already set for lower cost products or procedures or may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Commercial third-party payors often rely upon Medicare coverage policies and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded programs and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize our approved products and our overall financial condition. Further, coverage policies and third-party payor reimbursement rates may change at any time. Therefore, even if favorable coverage and reimbursement status is attained, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the commercialization of any product candidates we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and we will face an even greater risk if we commercially sell any products that receive marketing approval. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">decreased demand for any product candidates that we may develop;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant costs and distraction of management to defend any related litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the initiation of investigations by regulatory bodies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the inability to commercialize any products we may develop.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we have product liability insurance for our clinical trials, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage as we continue or expand our clinical trials and if we successfully commercialize any products. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees in our workplace, including those resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, chemical, hazardous or radioactive materials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify, discover, and develop potential product candidates through our Cloudbreak platform or otherwise.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Through our Cloudbreak platform, we are developing DFCs for the treatment and prevention of serious diseases, including influenza, the SARS-CoV-2 strains causing COVID-19, and various cancers. We have nominated the DFC CD388 as our lead development candidate for influenza.&#160;In applying our Cloudbreak platform, we may not be successful in identifying additional DFCs that could be developed as drug therapies. In addition, our Cloudbreak platform may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons. In particular, our research methodology used may not be successful in identifying compounds with sufficient potency, bioavailability or efficacy to be potential product candidates. In addition, our potential product candidates may, on further study, be shown to have harmful side effects or other negative characteristics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical expertise and human resources. For example, we have limited experience with the use of the Cloudbreak platform applied to viral pathogens and oncology </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">targets. A failure to optimize our expertise using the Cloudbreak platform for the development of our Cloudbreak program may limit our ability to successfully advance this program and identify future product candidates. Research programs to identify new product candidates also require substantial financial resources. We may choose to expend our financial resources on potential product candidates that ultimately prove to be unsuccessful. For example, in response to the immediate global pandemic crisis, we have expended financial resources to identify therapeutics to treat or prevent the COVID-19 coronavirus, and we may be unsuccessful in identifying such a DFC. If we are unable to identify successful product candidates from our Cloudbreak platform for preclinical and clinical development, we will have spent financial resources on programs that did not yield viable products and therefore generate product revenue, which would harm our financial position and adversely impact our stock price.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_106"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We need substantial additional funding to complete the development of rezafungin and to advance CD388 and our Cloudbreak program.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the preparation of our financial statements for the period ended September&#160;30, 2022, we performed an analysis of our ability to continue as a going concern. We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the next twelve months. Our ability to continue to fund the development of rezafungin through completion of our planned Phase 3 trials depends on our ability to obtain additional funding. Our ability to advance CD388 and other product candidates from our Cloudbreak program is also dependent on our ability to obtain additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we entered into the Mundipharma Collaboration Agreement, pursuant to which we granted Mundipharma exclusive commercialization rights to rezafungin outside the U.S. and Japan in exchange for a $30.0&#160;million upfront payment, near-term funding to support the global Phase 3 ReSTORE and ReSPECT trials, and the potential to receive development, regulatory and commercial milestone payments and double-digit royalties in the teens on tiers of annual net sales. The Mundipharma Collaboration Agreement requires, among other things, that we complete the rezafungin development program. On March 31, 2021, we entered into the Janssen Collaboration Agreement, to develop and commercialize our Cloudbreak DFCs for the prevention and treatment of seasonal and pandemic influenza. Under the collaboration, we will be responsible for the development and manufacturing of the first influenza DFC, CD388, into the clinic and through Phase 2 clinical development, and Janssen will be responsible for late-stage development, manufacturing, registration and global commercialization. We received an upfront payment of $27.0&#160;million. Janssen will fund all future research, development, manufacturing and commercialization for CD388, of which Janssen has funded $20.6&#160;million as of September&#160;30, 2022. On July 26, 2022, we entered into the Melinta License Agreement, pursuant to which we granted Melinta an exclusive license to develop, register and commercialize rezafungin in the U.S. in exchange for a $30.0&#160;million upfront payment and the potential to receive regulatory and commercial milestone payments and tiered royalties on U.S. sales in the low double digits to mid-teens. The Melinta License Agreement requires, among other things, that we complete the rezafungin development program. Our ability to meet our development obligations under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement depends on our ability to obtain additional funding.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There can be no assurance that additional funds will be available from any source or, if available, will be available on terms that are acceptable to us. There can also be no assurance that additional funds will be available to us without first obtaining the approval of our stockholders, which can be a difficult and lengthy process with an uncertain outcome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Even if we raise additional capital, our expenses may increase in connection with our ongoing activities beyond what is currently expected. Our future capital requirements will depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the ongoing effect of the COVID-19 global pandemic and the resulting impact on our rezafungin phase 3 clinical development program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing to complete our Phase 3 ReSPECT trial, the remaining Chinese portion of the ReSTORE trial and the CD388 Phase 1 and Phase 2a trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs, timing and outcome of any regulatory review of rezafungin, CD388 or future development candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to establish and maintain collaborations, when and if necessary, on favorable terms, if at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and timing of commercialization activities, including manufacturing, marketing, sales and distribution, for rezafungin or any future product candidates that receive marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the scope, progress, results and costs of drug discovery, preclinical development, manufacturing development, laboratory testing and clinical trials for our product candidates, for the Cloudbreak platform; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the extent to which we acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Identifying potential development candidates and conducting preclinical studies, manufacturing development and clinical trials are time consuming, expensive and uncertain processes that take years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales for any of our current or future product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenue, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accordingly, we need substantial additional funding in connection with our continuing operations and to achieve our goals. As of September&#160;30, 2022, we had cash and cash equivalents of $53.1 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate, it may make any additional debt or equity financing more difficult, more costly and more dilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional capital on attractive terms or at all, we may be forced to delay, reduce or eliminate our development programs, including CD388 or one or more of our other Cloudbreak DFC programs, be unable to continue the development of rezafungin, complete the ReSPECT Phase 3 clinical trial and meet our development obligations under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, or our other current and future license or collaboration agreements, and/or be forced to make reductions in spending, extend payment terms with suppliers, and/or liquidate or grant rights to assets where possible. Any of these actions could materially harm our business, results of operations and future prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity, debt or other financing structures, receipt of payments under the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, as well as potentially entering into other collaborations, strategic alliances or licensing arrangements with third parties or receiving government and/or charitable grants or contracts. In November 2018, we entered into the Sales Agreement which currently has an aggregate offering price of up to $50.0&#160;million, and, other than the Mundipharma Collaboration Agreement, the Janssen Collaboration Agreement and the Melinta License Agreement, it is our only current external source of potential financing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, we issued $9.0&#160;million of our common stock to Mundipharma in connection with entering into the Mundipharma Collaboration Agreement. In February 2020, we issued $30.0&#160;million of our common stock and Series X Preferred Stock upon the closing of a rights offering. In October 2021, we issued $38.5&#160;million of our common stock and Series X Preferred Stock upon the closing of concurrent but separate public offerings. As of September&#160;30, 2022, we have issued 13,443,622 shares of common stock pursuant to the Sales Agreement with an aggregate offering price of approximately $31.5&#160;million. To the extent that we raise additional capital through the sale of equity or convertible debt securities, like the sale of our common stock to Mundipharma, the sale of our common stock and Series X Preferred Stock issued in our rights offering, the sale of our common stock and Series X Preferred Stock in our concurrent public offerings or the sale of common stock under the Sales Agreement, your ownership interest will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may be secured by all or a portion of our assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds by entering into collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. On September 3, 2019, we licensed all rights to rezafungin outside of the U.S. and Japan to Mundipharma in exchange for certain payments and double-digit royalties in the teens on tiers of annual net sales. In March 2021, we granted exclusive worldwide rights to CD388 and other influenza DFCs to Janssen in exchange for certain payments and royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits. In July 2022, we licensed all rights to rezafungin inside of the U.S. to Melinta in exchange for certain payments and tiered royalties on U.S. sales in the low double digits to mid-teens. We may need to enter into similar agreements with other third parties for the development and commercialization of rezafungin outside of the Mundipharma and Melinta territories, or for the development of DFCs identified from our Cloudbreak program outside the scope of the Janssen Collaboration Agreement, which may require we relinquish valuable rights to these products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we raise funds through government grants and contracts, we may be subject to restrictions on our operations or certain unfavorable terms. U.S. government grants and contracts, if available, typically contain unfavorable termination provisions and are subject to audit and modification by the government at its sole discretion, which will subject us to additional risks. If we receive a U.S. government grant or contract, we would be required to comply with numerous laws and regulations relating to the formation, administration and performance of the grant or contract, which can make it more difficult for us to retain our rights under such grant or contract and result in increased costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are unable to raise additional funds through equity, debt or other financing structures, or through collaborations, strategic alliances or licensing arrangements with third parties, or through receiving government and/or charitable grants or contracts, we may be required to delay, reduce or terminate our rezafungin development program, including our ReSPECT Phase 3 clinical trial, be unable to meet our development obligations under the Mundipharma Collaboration Agreement and the Melinta License Agreement, and be unable to continue advancing the Cloudbreak program for non-influenza DFCs, or be forced to grant rights in the Cloudbreak program for non-influenza DFCs that we would otherwise prefer to retain for ourselves.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since our inception, and we anticipate that we will continue to incur substantial operating losses for the foreseeable future. We may never achieve or maintain profitability.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. Our net losses were $16.4 million and $25.7 million for the nine months ended September&#160;30, 2022 and 2021, respectively. As of September&#160;30, 2022, we had an accumulated deficit of $393.6 million. To date, we have financed our operations primarily through sale of our stock in public offerings and private placements, through borrowings under loan facilities, and through payments received in connection with the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement and Melinta License Agreement. We have devoted substantially all of our financial resources and efforts to research and development. We are currently conducting the ReSPECT and ReSTORE China Phase 3 clinical trials of rezafungin, Phase 1 and Phase 2a studies of CD388, and preclinical studies of our other DFCs. We expect that it will be many years, if ever, before we receive regulatory approval and have a product candidate available for commercialization. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">submit INDs to the FDA and equivalent filings to other regulatory authorities, and seek approval of our clinical protocols by institutional review boards at clinical trial sites;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">continue to advance rezafungin and CD388 through clinical development;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">continue the preclinical development of our other DFCs from our Cloudbreak platform or otherwise, and advance one or more of such product candidates into clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">seek marketing approvals for rezafungin, CD388 and other product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">establish or contract for a sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain marketing approval;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">maintain, expand and enforce our intellectual property portfolio;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">hire additional manufacturing, clinical, regulatory, quality assurance and scientific personnel;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">add operational, financial and management systems and personnel, including personnel to support product development; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">acquire or in-license other product candidates and technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize one or more products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those product candidates for which we may obtain marketing approval, and satisfying any post-marketing requirements. We may never succeed in these activities and, even if we do, may never generate revenue that is significant or large enough to achieve profitability.&#160;Our failure to become and remain profitable would decrease our value and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.*</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The recent global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the recent global financial crisis, could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. This is particularly true in Europe, which is undergoing a continued severe economic crisis. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, as a result of the COVID-19 pandemic and actions taken to slow its spread, the global credit and financial markets have recently experienced extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, rising inflation, increases in unemployment rates and uncertainty about economic stability. If the equity and credit markets continue to deteriorate, it may make any additional debt or equity financing more difficult, more costly and more dilutive.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The conflict between Russia and Ukraine could lead to disruption, instability and volatility in global markets and industries that could negatively impact our operations. The U.S. government and other governments in jurisdictions in which we operate have imposed severe sanctions and export controls against Russia and Russian interests and threatened additional sanctions and controls. The impact of these measures, as well as potential responses to them by Russia, is currently unknown and they could adversely affect our business, supply chain, partners or customers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for you to evaluate the success of our business to date and assess our future viability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We were founded in December 2012 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential development and product candidates, undertaking preclinical studies and conducting clinical trials. We have not yet demonstrated an ability to successfully complete large-scale, pivotal clinical trials required for regulatory approval of our product candidates, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop one new product from the time it is discovered to when it is commercially available. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history or if we had product candidates in advanced clinical trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors that may alter or delay our plans. We will need to continue to transition from a company with a research focus to a company capable of supporting late-stage development activities and, if a product candidate is approved, a company with commercial activities. We may not be successful in any step of such a transition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to continue to satisfy the applicable continued listing requirements of Nasdaq, our common stock could be delisted.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our common stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;CDTX.&#8221; In order to maintain this listing, we must continue to satisfy minimum financial and other continued listing requirements and standards. We cannot assure you that we will be able to continue to comply with the applicable listing standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we are not able to comply with applicable listing standards, our shares of common stock will be subject to delisting. The delisting of our common stock from trading on Nasdaq may have a material adverse effect on the market for, and liquidity and price of, our common stock and impair our ability to raise capital. Delisting from Nasdaq could also have other negative results, including, without limitation, the potential loss of confidence by customers and employees, the loss of institutional investor interest and fewer business development opportunities. In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Dependence on Third Parties</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our collaboration partners to provide funding to continue the development of rezafungin and CD388; for the commercialization of rezafungin outside Japan; and for the late-stage development, manufacturing, registration and commercialization of CD388. If the collaborations are not successful, we may not be able to complete the development of rezafungin and CD388, or capitalize on the full market potential for rezafungin and CD388.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, we licensed the rights to rezafungin outside of the U.S. and Japan to Mundipharma, a large international pharmaceutical company, and on July 26, 2022, we licensed the rights to rezafungin inside the U.S. to Melinta. Our ability to complete the development of rezafungin is dependent, in part, on funds provided by Mundipharma and Melinta. Additionally, our ability to receive payments from these arrangements will depend on Mundipharma&#8217;s and Melinta's ability to successfully commercialize rezafungin in their respective territories.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Mundipharma Collaboration Agreement and the Melinta License Agreement pose many risks to us, including that our collaborator, Mundipharma, and our licensee, Melinta:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">have significant discretion in determining the efforts and resources they will apply to commercializing rezafungin in their respective territories, and may not commit sufficient resources to the marketing and distribution of rezafungin;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may terminate the Mundipharma Collaboration Agreement at will and may terminate the Melinta License Agreement at will after July 26, 2023; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may be subject to changes in key personnel or strategic focus, have limited available funding or be subject to other external factors diverting resources or creates competing priorities, all of which could negatively impact the commercialization of rezafungin in their respective territories;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may independently develop, or develop with third parties, products that compete directly or indirectly with rezafungin if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may use our intellectual property or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may not agree with certain development decisions resulting in the delay or termination of the programs, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be involved in a business combination and the continued pursuit and emphasis on rezafungin could be delayed, diminished or terminated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be financially impacted by the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our ability to generate revenue under the Mundipharma Collaboration Agreement and the Melinta License Agreement is adversely impacted by these or any other risks, our right to receive additional payments from the Mundipharma Collaboration Agreement and the Melinta License Agreement, including our share of the revenues generated by net sales of rezafungin, if approved, could be insufficient to allow us to complete our rezafungin development program including the ReSPECT Phase 3 clinical trial, to achieve or maintain profitability or may result in rezafungin being less valuable to us than if we had not entered into the Mundipharma Collaboration Agreement and the Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, we licensed the exclusive worldwide rights to CD388 and other influenza DFCs to Janssen. Our ability to complete the development of CD388 is dependent, on funds provided by Janssen. Additionally, our ability to receive payments from this arrangement will depend in part on Janssen&#8217;s ability to successfully commercialize CD388.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Janssen Collaboration Agreement poses many risks to us, including that our collaborator, Janssen:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">has significant discretion in determining the efforts and resources it will apply to developing, manufacturing, registering and commercializing CD388;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may terminate the collaboration agreement at will, subject to certain limitations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may be subject to changes in key personnel or strategic focus, have limited available funding or be subject to other external factors diverting resources or creates competing priorities, all of which could negatively impact the development, manufacturing, registration and commercialization of CD388;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may independently develop, or develop with third parties, products that compete directly or indirectly with CD388 if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may use our intellectual property or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or proprietary information or expose us to potential litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">may not agree with certain development decisions resulting in the delay or termination of the program, or that result in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be involved in a business combination and the continued pursuit and emphasis on CD388 could be delayed, diminished or terminated; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">could be financially impacted by the COVID-19 pandemic.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our ability to generate revenue under the Janssen Collaboration Agreement is adversely impacted by these or any other risks, our right to receive additional payments under the Janssen Collaboration Agreement, including milestone payments and royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits, could be insufficient to allow us to achieve or maintain profitability or may result in CD388 being less valuable to us than if we had not entered into the Janssen Collaboration Agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may seek to selectively establish other collaborations and, if we are unable to establish them on commercially reasonable terms or at all, we may have to alter our research, clinical development and commercialization plans.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may seek to collaborate with other pharmaceutical and biotechnology companies to advance the Cloudbreak program for DFCs outside the scope of the Janssen Collaboration Agreement, or for the completion of development and commercialization of rezafungin in Japan. We may also seek funding from government grants or contracts to advance the Cloudbreak program for DFCs outside of the Janssen Collaboration Agreement. We cannot be certain that we will be successful in completing any such collaboration or obtaining any such government grants or contracts, or completing any of them on commercially reasonable terms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate pharmaceutical or biotech collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, on the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Those factors may include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the design or results of preclinical studies, CMC development activities or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the likelihood of approval by the FDA or similar regulatory authorities outside the U.S.;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential market for the product candidate in the territories that are the subject of the collaboration;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the costs and complexities of manufacturing and delivering such product candidate to patients;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the potential of competing products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">industry and market conditions generally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We also face significant competition for government grants and contracts for the Cloudbreak program, and there can be no assurances that such funding would be available to us if and when needed, or at all. For instance, government funding may be available only at certain phases of research and development, such as only after Phase 1 clinical trials have been completed. In order to advance the Cloudbreak program for DFCs outside of the Janssen Collaboration Agreement, we will need to obtain significant funding to complete IND-enabling studies, manufacturing development and Phase 1 clinical trials. Government grants and contracts may not be available to fund our activities at this earlier phase of the research and development process.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We intend to continue to rely on third parties to conduct our clinical trials and to conduct some aspects of our research and preclinical testing and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research or testing.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely and expect to continue to rely on third parties, such as CROs, contract manufacturers of clinical supplies, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and to conduct some aspects of our research and preclinical testing. Many of these third parties may terminate their </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">engagements with us at any time. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If we need to enter into alternative arrangements, it would delay our product development activities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other international regulatory authorities require us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a government-sponsored database, available at www.clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the ability of these third parties to conduct certain of their operations, including monitoring of clinical sites, may be limited by the COVID-19 pandemic, and to the extent that such third parties are unable to fulfil their contractual obligations as a result of the COVID-19 pandemic or government orders in response to the pandemic, we may have limited or no recourse under the terms of our contractual agreements with such third parties. Further, if any of the third parties with whom we engage were to experience shutdowns or other substantial disruptions due to the COVID-19 pandemic, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business and our results of operation and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have no experience manufacturing product candidates on a clinical or commercial scale and will be dependent on third parties for the manufacture of our product candidates. If we experience problems with any of these third parties, they could delay clinical development or marketing approval of our product candidates or our ability to sell any approved products.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have any manufacturing facilities. We currently rely, and expect to continue to rely, on third-party manufacturers for the manufacture of our product candidates for preclinical studies and clinical trials and for commercial supply of any of these product candidates should we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may be unable to establish agreements with third-party manufacturers for preclinical, clinical or commercial supply on terms favorable to us, or at all. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible breach of the manufacturing agreement by the third party, including the inability to supply sufficient quantities or to meet quality standards or timelines; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with current U.S. Good Manufacturing Practice requirements, or cGMPs, or similar regulatory requirements outside the U.S. Our failure, or the failure of our third-party manufacturers, to comply with cGMPs or other applicable regulations, even if such failures do not relate specifically to our product candidates or approved products, could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product that we develop may compete with other product candidates and products for access to these manufacturing facilities. There are a limited number of manufacturers that operate under cGMPs and that might be capable of manufacturing for us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers, including a failure that may not relate specifically to our product candidate or approved product or a failure due to the COVID-19 pandemic, could delay clinical development or marketing approval or adversely impact our ability to generate commercial sales. If any one of our current contract manufacturers cannot perform as agreed, we may be required to replace that manufacturer. Some of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials are located in countries affected by COVID-19, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">should they experience disruptions, such as temporary closures or suspension of services, we would likely experience delays in advancing these tests and trials.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently rely, and expect to continue to rely, on third parties to release, label, store and distribute drug supplies for our clinical trials. Any performance failure on the part of these third parties, including a failure that may not relate specifically to our product candidate or approved product, could delay or otherwise adversely impact clinical development or marketing approval of our product candidates or commercialization of our drugs, producing additional losses and depriving us of potential revenue.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Moreover, our manufacturers and suppliers may experience difficulties related to their overall businesses and financial stability, which could result in delays or interruptions of supply of our product candidates or approved products.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We do not have alternate manufacturing plans in place at this time. If we need to change to other manufacturers, the FDA and comparable foreign regulators may have to approve these manufacturers&#8217; facilities and processes prior to our use, which would require new testing and compliance inspections. In addition, the new manufacturers would have to be educated in or independently develop the processes necessary for production. This would result in delays and costs, and in the case of approved products, the potential loss of revenue.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_112"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to take full advantage of regulatory programs designed to expedite drug development or provide other incentives, our development programs may be adversely impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There are a number of incentive programs administered by the FDA and other regulatory bodies to facilitate development of drugs in areas of unmet medical need. In the U.S., rezafungin has been designated a Qualified Infectious Disease Product, or QIDP, a fast track product, and, with respect to the indication for treatment of candidemia and invasive candidiasis, rezafungin has also been designated as an orphan drug. Our product candidates may not qualify for, or maintain, designations under these or other similar incentive programs. For example, rezafungin may not receive orphan drug designation in the U.S. for the prophylaxis indication. Our inability to fully take advantage of these incentive programs may require us to run larger trials, incur delays, lose opportunities that may not otherwise be available to us, lose marketing exclusivity for which we would otherwise be eligible and incur greater expense in the development of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, our product candidates and our ability to generate revenue will be impaired.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, release, safety, efficacy, regulatory filings, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the U.S. and by comparable authorities in other countries. For example, in order to commence clinical trials of our product candidates in the U.S., we must file an IND and obtain FDA agreement to proceed. The FDA may place our development program on clinical hold and require further preclinical testing prior to allowing our clinical trials to proceed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must obtain marketing approval in each jurisdiction in which we market our products. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted a marketing application or received approval to market any of our product candidates from regulatory authorities in any jurisdiction. We have only limited experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. As a company we may not be able to prepare our contract manufacturers and clinical sites for inspection associated with NDA review, or appearing before an FDA advisory committee. Our NDA may receive a Complete Response Letter rather than approval. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each indication to establish the product candidate&#8217;s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process, testing and release and inspection of manufacturing facilities and personnel by the relevant regulatory authority. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the U.S. and elsewhere, is expensive, may take many years and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. We cannot assure you that we will ever obtain any marketing approvals in any jurisdiction. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical or other studies, changes in the manufacturing process or facilities or clinical trials. Moreover, approval by the FDA or an equivalent foreign authority does not ensure approval by regulatory authorities in any other countries or jurisdictions, but a failure to obtain marketing approval in one jurisdiction may adversely impact the likelihood of approval in other jurisdictions. In addition, varying interpretations of the data obtained from preclinical testing, manufacturing and product testing and clinical trials could delay, limit or prevent marketing approval of a product candidate. Additionally, any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The COVID-19 pandemic could also potentially affect the business of the FDA and comparable authorities in other countries, which could result in delays in meetings related to planned clinical trials and ultimately of reviews and approvals of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any product candidate for which we obtain marketing approval, along with the manufacturing processes and facilities, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of promotional materials and safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements for product facilities, quality assurance and corresponding maintenance of records and documents and requirements regarding the distribution of samples to physicians and related recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we do not comply with these restrictions, we may be subject to enforcement actions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown problems with our products, manufacturers or manufacturing processes and facilities or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on such products, manufacturers or manufacturing processes or facilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">restrictions on the labeling, marketing, distribution or use of a product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">requirements to conduct post-approval clinical trials, other studies or other post-approval commitments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">warning or untitled letters;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">withdrawal of the products from the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">recall of products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines, restitution or disgorgement of profits or revenue;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">refusal to permit the import or export of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">product seizure; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with customers, health care professionals and third-party payors may be subject to applicable healthcare laws, which could expose us to penalties, including administrative, civil or criminal penalties, damages, fines, imprisonment, exclusion from participation in federal healthcare programs such as Medicare and Medicaid, reputational harm, the curtailment or restructuring of our operations and diminished future profits and earnings.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Healthcare professionals and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with customers, healthcare professionals and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research, market, sell and distribute our medicines for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following, among others:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal healthcare anti-kickback statute, which prohibits persons and entities from, among other things, knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false claims laws, which impose criminal and civil penalties, including civil whistleblower or qui tam actions under the federal civil False Claims Act, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which imposes criminal and civil liability for, among other things, executing a scheme to defraud any healthcare benefit program and also imposes obligations, including mandatory contractual terms, on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates and their covered subcontractors that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the federal transparency requirements under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Affordable Care Act, which require, among other things, certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners), and teaching hospitals, and information regarding physician ownership and investment interests; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business activities, including sales or marketing arrangements and claims involving healthcare items or services including, in some states, those reimbursed by non-governmental third-party payors, including private insurers, some state laws which require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to payments or other transfers of value provided to physicians and other health care providers and entities, marketing expenditures, or drug pricing, state and local laws that require the registration of pharmaceutical sales representatives, and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs.&#160;Interpretations of standards of compliance under these laws and regulations are rapidly changing and subject to varying interpretations and it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other laws that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, exclusion from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">operations, any of which could diminish our future profits or earnings. If any of the physicians or other providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our information technology systems or sensitive information, or those of third parties upon which we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse consequences.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of our business, we may collect, store, use, transmit, receive, generate, transfer, disclose, make accessible, protect, secure, dispose of, share and otherwise process sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data (collectively, sensitive information). We are dependent upon our own or third-party information technology systems, infrastructure and sensitive information, including mobile technologies, to operate our business. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. The secure collection, storage, use, transmission and processing of such information is vital to our operations and business strategy. Any actual or perceived breach of our security measures or those of our third-party service providers, consultants, or contractors could adversely affect our business, operations, financial condition, and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cyberattacks, malicious internet-based activity, and online and offline fraud are prevalent and continue to increase. These threats are becoming increasingly difficult to detect. The procedures and controls we use to monitor cybersecurity threats and mitigate our exposure to such threats may not be sufficient to prevent security incidents, and our internal information technology systems and those of our third-party service providers, consultants, and contractors are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, public health crises (such as the COVID-19 global pandemic), telecommunication and electrical failures, theft as well as security incidents from inadvertent or intentional actions. These threats come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors. Some actors now engage and are expected to continue to engage in cyberattacks, including without limitation, nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of these attacks, including cyberattacks that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We and the third parties upon which we rely may be subject to additional threats, including, but not limited to, the deployment of harmful malware (including as a result of advanced persistent threat intrusions), ransomware, viruses, worms, denial-of-service attacks (such as credential stuffing), supply chain attacks, social engineering schemes (including through phishing attacks) and other means to affect service reliability and threaten the confidentiality, integrity and availability of sensitive information, which may compromise our, or our third-party service providers&#8217;, consultants&#8217;, or contractors&#8217; system infrastructure or lead to data leakage or misdirected payments to and from us. Ransomware attacks, including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, loss of data, loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the financial, operational and reputational impact of a ransomware attack it may be preferable to make extortion payments, but we may be unwilling or unable to do so (including, for example, if applicable laws or regulations prohibit such payments). Similarly, supply chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our platform, systems and networks or the systems and networks of third parties that support us and our services. Despite the security controls we have in place, such attacks are very difficult to avoid. Moreover, the prevalent use of mobile devices that access sensitive information increases the risk of security incidents. Additionally, the COVID-19 pandemic and our remote workforce poses increased risks to our information technology systems and data, as more of our employees work from home, utilizing network connections outside our premises. Future or past business transactions (such as acquisitions or integrations) could also expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities&#8217; systems and technologies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a security incident or other interruption.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A security incident or other interruption could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive information. A security incident or other interruption could disrupt our ability (and that of third parties upon whom we rely) to manufacture or deliver our products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are also required to comply with laws, rules, industry standards and regulations, policies and contracts that may require us to maintain the security of sensitive information. We may expend significant resources or modify our business activities (including our clinical trial activities) to try to protect against security incidents. While we have implemented security measures designed to protect against security incidents, there can be no assurance that these measures will be effective. We may be unable in the future to detect vulnerabilities in our information technology systems because such threats and techniques change frequently, are often sophisticated in nature, and may not be detected until after a security incident has occurred. Despite our efforts to identify and remediate vulnerabilities, if any, in our information technology systems, our efforts may not be successful. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Applicable data privacy and security laws, privacy policies and other data privacy and security obligations may require us to notify relevant stakeholders of security incidents. Such disclosures are costly, and the disclosures or the failure to comply with such requirements could lead to adverse consequences. If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced a security incident, we may also experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we may not have adequate insurance coverage for security incidents, including fines, judgments, settlements, penalties, costs, attorney fees and other impacts that arise out of incidents or breaches. We cannot assure you that any insurance coverage will adequately cover liabilities actually incurred or that insurance will continue to be available to us on economically reasonable terms, or at all. The successful assertion of one or more large claims against us that exceeds our available insurance coverage, or results in changes to our insurance policies (including premium increases or the imposition of large deductible or co-insurance requirements), could have an adverse effect on our business. Additionally, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations. Our risks are likely to increase as we continue to expand, grow our customer base, and process, store, and transmit increasingly large amounts of confidential, proprietary and sensitive information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and changing obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the ordinary course of business, we process sensitive information, including personal data, proprietary and confidential business data, trade secrets, intellectual property, data we collect about trial participants in connection with clinical trials, and sensitive third-party data. Our data processing activities subject us to numerous data privacy and security obligations, such as various foreign and domestic laws, regulations, guidance, industry standards, external and internal privacy and security policies, contracts, and other obligations that govern the processing of personal data by us and on our behalf.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the United States, federal, state, and local governments have enacted numerous data privacy and security laws, including data breach notification laws, personal data privacy laws, and consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act). For example, HIPAA, as amended by HITECH, and their respective implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information. Such laws may apply to us, our customers or our service providers. Most healthcare providers in the U.S., including institutions from which we may obtain customer data, are subject to data privacy and security regulations promulgated under HIPAA, as amended by HITECH. A person may be prosecuted for alleged HIPAA violations either directly or indirectly, such as under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial civil and criminal penalties and liabilities if we knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Additionally, the California Consumer Privacy Act of 2018, or CCPA, which took effect on January 1, 2020, gives California residents expanded rights to access and delete their personal data, opt out of certain personal data sharing, and receive detailed information about how their personal data is used. The CCPA also provides for civil penalties for violations (up to $7,500 per violation) and contains a private right of action for certain data breaches that is expected to increase litigation. Although the CCPA exempts some data processed in the context of clinical trials, the CCPA may increase our compliance costs and potential liability with respect to other personal data we maintain about California residents. In addition, it is anticipated that the California Privacy Rights Act of 2020, or CPRA, which goes into effect on January 1, 2023 will expand the CCPA. Additionally, the CPRA establishes a new California Privacy Protection Agency to implement and enforce the CPRA, which could increase the risk of enforcement. Some observers have noted that the CCPA and CPRA could mark </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">the beginning of a trend of states adopting more stringent privacy laws in the U.S., which could further increase our compliance costs, potential liability and adversely affect our business. For example, Virginia, Colorado, Utah and Connecticut have also passed comprehensive privacy laws, and similar laws are being considered in several other states. In addition, data privacy and security laws have been proposed at the federal, state, and local levels in recent years, which could further complicate compliance efforts. In addition, privacy advocates and industry groups have proposed, and may propose, standards with which we are legally or contractually bound to comply.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The global data protection landscape is also rapidly evolving, and we expect there will continue to be new and proposed laws, regulations, and industry standards concerning data privacy, data protection, and security. For example, the EU&#8217;s General Data Protection Regulation, or EU GDPR, the United Kingdom&#8217;s GDPR, or UK GDPR, Brazil&#8217;s General Data Protection Law (Lei Geral de Prote&#231;&#227;o de Dados Pessoais, or LGPD) (Law No. 13,709/2018), and China&#8217;s Personal Information Protection Law, or PIPL, impose strict requirements for processing personal data. We cannot yet determine the impact that such future laws, regulations and standards may have on our business. The EU GDPR and UK GDPR impose stringent requirements and to date, have increased compliance burdens on us, including by mandating burdensome documentation requirements and granting certain rights to individuals to control how we collect, use, disclose, retain and process their personal data. EU member states may allow enact additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of the EU GDPR (or UK GDPR) and the applicable national data protection laws of the EU member states may result in fines of up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. Further, the EU GDPR also provides for private litigation related to the processing of personal data that can be brought by classes of data subjects or consumer protection organizations authorized at law to represent the data subjects&#8217; interests.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain jurisdictions have enacted data localization laws and cross-border personal data transfer laws, which could make it more difficult to transfer personal data across jurisdictions (such as transferring or receiving personal data that originates in the EU or in other foreign jurisdictions). For example, absent appropriate safeguards or other circumstances, the EU GDPR generally restricts the transfer of personal data to countries outside of the European Economic Area, or EEA, that the European Commission does not consider to provide an adequate level of data privacy and security, such as the U.S. These requirements apply not only to third-party transactions, but also to transfers of personal data within our company, including employee information. The European Commission recently adopted new Standard Contractual Clauses, or SCCs, under the EU GDPR for personal data transfers outside the EEA. Currently, these SCCs are a valid mechanism to transfer personal data outside of the EEA. Additionally, the SCCs impose additional compliance burdens, such as conducting transfer impact assessments to determine whether additional security measures are necessary to protect the at-issue personal data. In addition, Switzerland and the UK similarly restrict personal data transfers outside of those jurisdictions to countries such as the United States that do not provide an adequate level of personal data protection. If we cannot implement a valid compliance mechanism for cross-border data transfers, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal data from Europe or other foreign jurisdictions. Loss of our ability to transfer personal data from Europe may reduce demand for our services from companies subject to European data protection laws and may also require us to increase our data processing capabilities in those jurisdictions at significant expense. Moreover, other countries outside of Europe (e.g. China, Brazil) have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to data privacy and security laws, we may be contractually subject to data privacy and security obligations, including industry standards adopted by industry groups and may become subject to new data privacy and security obligations in the future. For example, certain privacy laws, such as the GDPR and the CCPA, require our customers to impose specific contractual restrictions on their service providers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We may publish privacy policies and other documentation regarding our collection, processing, use and disclosure of personal data. Although we endeavor to comply with our published policies and other documentation, we may at times fail to do so, or may be perceived to have failed to do so. Despite our efforts, we may not be successful in achieving compliance if our personnel, customers, or service providers fail to comply with our policies and documentation. Such failures can subject us to potential foreign, local, state and federal action if they are found to be deceptive, unfair, or misrepresentative of our actual practices.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our obligations related to data privacy and security are quickly changing in an increasingly stringent fashion, creating some uncertainty as to the effective future legal framework. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms to ensure compliance with the new data privacy and security rules. Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Any failure or perceived failure by us, or third parties working on our behalf, to comply with applicable laws and regulations, any privacy and data security obligations pursuant to contract, our stated privacy or security policies, or obligations to customers or other third parties may result in governmental enforcement actions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(including fines, penalties, judgments, settlements, imprisonment of company officials and public censure), civil claims, litigation, damage to our brand and reputation and loss of goodwill (both in relation to existing customers and prospective customers), any of which could have a material adverse effect on our business, operations and financial performance. Moreover, despite our efforts, our personnel or third parties upon whom we rely may fail to comply with such obligations, which could negatively impact our business operations and compliance posture. For example, any failure by a third-party processor to comply with applicable law, regulations, or contractual obligations could result in adverse effects, including inability to or interruption in our ability to operate our business and proceedings against us by governmental entities or others.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations.&#160;Compliance with these legal standards could impair our ability to compete in domestic and international markets.&#160;We can face criminal liability and other serious consequences for violations, which can harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities.&#160;Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector.&#160;We may engage third parties for clinical trials outside of the U.S., to sell our products abroad once we enter a commercialization phase and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals.&#160;We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations.&#160;We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry in China is highly regulated and such regulations are subject to change which may affect approval and commercialization of our drugs.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Currently, we conduct the ReSTORE trial in China and have exclusively licensed the rights to commercialize rezafungin, our investigational drug studied in the ReSTORE trial, in China to our third-party collaborator, Mundipharma. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new drugs. For example, in order to conduct a clinical trial in China, sponsors must not only obtain the approval of the National Medical Product Administration of China, but also a separate approval from or filing with the Ministry of Science and Technology under the Administrative Regulations on Human Genetic Resources of the People's Republic of China, or HGR Regulation, for clinical trials involving HGR Materials or Information. Any failure to comply with these requirements could cause our ReSTORE trial to be suspended by governing authorities, may result in fines and also may constitute a breach under our agreements with third parties assisting us in the conduct of the trial in China, such as our CRO. In recent years, the regulatory framework in China regarding the pharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Certain changes or amendments to policy or law may result in increased compliance costs on our business or cause delays in the timely completion of the ReSTORE trial in China, or prevent the approval of rezafungin in China. Chinese authorities have become increasingly vigilant in enforcing laws in the pharmaceutical industry and any failure by us to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our clinical activities in China.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the U.S. and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system, including cost-containment measures, that could reduce or limit coverage and reimbursement for newly approved drugs, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For example, in March 2010, President Obama signed into law the Affordable Care Act, a sweeping law intended to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Affordable Care Act and subsequent regulations revised the definition of &#8220;average manufacturer price&#8221; for reporting purposes, which could increase the amount of Medicaid drug rebates to states. However, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap for single source and innovator multiple source drugs, beginning January 1, 2024. Further, the Affordable Care Act imposed a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance were also enacted under the Affordable Care Act, which may affect our business practices with healthcare practitioners. There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act, included a provision which repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructs certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in Affordable Care Act marketplaces through plan year 2025. The IRA also eliminates the &#8220;donut hole&#8221; under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how any additional healthcare reform measures of the Biden administration will impact the Affordable Care Act and our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This includes reductions to Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative amendments will remain in effect until 2031 unless additional congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Additionally, in January 2013, the President signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. In July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within ninety (90) days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. It is unclear whether this executive order or similar policy initiatives will be implemented in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">encourage importation from other countries and bulk purchasing. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. We expect that additional healthcare reform measures will be adopted within and outside the U.S. in the future, any of which could add difficulty to the regulatory approval processes for our product candidates or limit the amounts that governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. The continuing efforts of third-party payors to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability and the level of taxes that we are required to pay.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_115"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our efforts to protect the proprietary nature of the intellectual property related to rezafungin, CD388, our other Cloudbreak compounds or our other product candidates or compounds are not adequate, we may not be able to compete effectively in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to rezafungin and our other product candidates and compounds. Any involuntary disclosure to or misappropriation by third parties of our proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain and our commercial success will depend on our ability to obtain patents and maintain adequate protection for rezafungin, our DFCs and other compounds and product candidates in the U.S. and other countries. We currently hold issued U.S. utility and foreign patents and multiple pending U.S. utility patent applications, pending U.S. provisional patent applications and pending international, foreign national and regional counterpart patent applications covering various aspects of rezafungin and our DFCs. The patent applications may fail to result in issued patents in the U.S. or in foreign countries or jurisdictions. Even if the applications do successfully issue, third parties may challenge the patents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Further, the existing and/or future patents, if any, may be too narrow to prevent third parties from developing or designing around these patents. If the sufficiency of the breadth or strength of protection provided by the patent and patent applications we own with respect to rezafungin or our DFCs or the patents we pursue related to any of our other product candidates or compounds is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize the product candidates or compounds. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced, although a patent term extension or supplementary protection certificate having varied scope may be available in certain jurisdictions to compensate for some of the lost patent term. In addition, we do not know whether:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to make the inventions covered by each of our pending patent applications or our issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we were the first to file patent applications for these inventions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">others will independently develop similar or alternative technologies or duplicate any of our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our pending patent applications will result in issued patents;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any of our patents, once issued, will be valid or enforceable or will issue with claims sufficient to protect our products, or will be challenged by third parties;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any patents issued to us will provide us with any competitive advantages;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">we will develop additional proprietary technologies that are patentable; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the patents of others will have an adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">litigation. The U.S. Patent and Trademark Office, or USPTO, developed new regulations and procedures to govern administration of the Leahy-Smith Act and many of the substantive changes to patent law associated with the Leahy-Smith Act and, in particular, the first to file provisions, only became effective in March 2013. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable in one or more jurisdictions, inventions for which patents are difficult to enforce and any other elements of our drug discovery program that involve proprietary know-how, information and technology that is not covered by patents. Although we require all of our employees, consultants, advisers and third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or used in an unauthorized manner or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">There also may be challenges or other disputes concerning the inventorship, ownership or right to use our intellectual property. For example, our consultants and advisors may have obligations to assign certain inventions and/or know-how that they develop to third-party entities in certain instances, and these third parties may challenge our ownership or other rights to our intellectual property, which would adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">An inability to obtain, enforce and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S. We may encounter significant problems in protecting, enforcing and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent unauthorized material disclosure of the intellectual property related to our technologies to third parties or are otherwise unable to protect, enforce or defend our intellectual property, we will not be able to establish or, if established, maintain a competitive advantage in our markets, which could materially adversely affect our business, operating results and financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various foreign or jurisdictional governmental patent agencies in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm to pay these fees due to foreign patent agencies. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such noncompliance events are outside of our direct control for (1)&#160;non-U.S. patents and patent applications owned by us and, (2)&#160;if applicable in the future, patents and patent applications licensed to us by another entity. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may prevent or delay our drug discovery and development efforts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents with claims to materials, methods of manufacture or methods of treatment related to the use or manufacture of rezafungin, our DFCs and/or our other product candidates or compounds. If any third-party patents were held by a court of competent jurisdiction to cover the rezafungin or DFC manufacturing process, any molecules formed during these processes or the final products or any use thereof, the holders of any such patents may be able to block our ability to commercialize the product unless we obtained a license under the applicable patent or patents or until such patents expire. These same issues and risks arise in connection with any other product candidates we develop as well. We cannot predict whether we would be able to obtain a license on commercially reasonable terms, or at all. Any inability to obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">such a license under the applicable patents on commercially reasonable terms, or at all, would have a material adverse effect on our ability to commercialize the affected product until such patents expire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, third parties may obtain patents in the future and claim that our product candidates and/or the use of our technologies infringes upon these patents. Furthermore, parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case of willful infringement, obtain one or more licenses from third parties, pay royalties and/or redesign our infringing products, which may be impossible and/or require substantial time and monetary expenditure. In addition, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of one or more of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, or at all. In that event, we would not be able to further develop and commercialize such product candidates, which could harm our business significantly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be required to file lawsuits or take other actions to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Competitors may infringe our current or future patents. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our asserted patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Pursuit of these claims would involve substantial litigation expense and would be a substantial diversion of management and other employee resources from our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Interference proceedings or derivative proceedings provoked by third parties or brought by the USPTO may be necessary to determine the entitlement to patent protection with respect to our patents or patent applications. An unfavorable outcome could result in a loss of our patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms, or at all. Litigation or patent office proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent misappropriation of our trade secrets or confidential information, particularly in countries where the laws or legal process may not protect those rights as fully as in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Issued patents covering our product candidates and technologies could be found invalid or unenforceable if challenged in court or the USPTO.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technologies, the defendant could counterclaim that the patent covering our product candidate or our technology, as applicable, is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates or our technologies. The outcome following legal assertions of invalidity and/or unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art or that prior art that was cited during prosecution, but not relied on by the patent examiner, will not be revisited. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection directed to our product candidates or technologies. Such a loss of patent rights could have a material adverse impact on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involve both technological and legal complexity, and are therefore costly, time-consuming and inherently uncertain. In addition, the U.S. has implemented wide-ranging patent reform legislation, including patent office administrative proceedings that offer broad opportunities to third parties to challenge issued patents. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, the USPTO and foreign governmental bodies and tribunals, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"> Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> the U.S. Supreme Court held in 2013 that certain claims to DNA molecules are not patentable and lower courts have since been applying this case in the context of other types of biological subject matter. We cannot predict how future decisions by the courts, the U.S. Congress, the USPTO or foreign governmental bodies or tribunals may impact the value of our patent rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the U.S. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive and our intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. In addition, the laws and legal processes of some foreign countries do not protect intellectual property to the same extent as federal and state laws in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S. or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and further, may export otherwise infringing products to territories where we have patents but enforcement is not as strong as that in the U.S. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property in foreign jurisdictions. The legal systems of certain countries, particularly China and certain other developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put any of our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. The requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of any of our current or future patents, requiring us to engage in complex, lengthy and costly litigation or other proceedings. Certain countries in Europe and developing countries, including China and India, have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if any of our patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and trade names are not adequately protected, we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors, and academic or research institutions. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_118"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to U.S. Government Contracts and Grants</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to generate revenues from partnerships, government funding or other sources of funding, we may be forced to suspend or terminate one or more of our preclinical Cloudbreak programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In order to continue our Cloudbreak programs for DFCs outside the scope of the Janssen Collaboration Agreement, we will need to seek funding from partnerships, the government or other sources of funding. There can be no assurances that we will be able to obtain funding from partnerships, or enter into new contracts with the U.S. government or obtain other sources of funding to support such programs. The process of completing a partnership or obtaining government contracts is lengthy and uncertain and we will have to compete with other companies and institutions in each instance. Further, with respect to government contracting, changes in government budgets and agendas may result in a decreased and de-prioritized emphasis on supporting the discovery and development of anti-infective products. If we cannot obtain or maintain government or other funding for our Cloudbreak programs for DFCs outside the scope of the Janssen Collaboration Agreement, we may be forced to discontinue those programs.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our use of government funding adds uncertainty to our research and commercialization efforts and may impose requirements that increase our costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Contracts funded by the U.S. government and its agencies include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">terminate agreements, in whole or in part, for any reason or no reason;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">claim rights, including intellectual property rights, in products and data developed under such agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">audit contract-related costs and fees, including allocated indirect costs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspend or debar the contractor from doing future business with the government;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">control and potentially prohibit the export of products; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">pursue criminal or civil remedies under the Federal Civil Monetary Penalties Act and the federal civil False Claims Act and similar remedy provisions specific to government agreements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, government contracts contain additional requirements that may increase our costs of doing business, reduce our profits and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">specialized accounting systems unique to government contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">mandatory socioeconomic compliance requirements, including labor standards, anti-human-trafficking, non-discrimination, and affirmative action programs and environmental compliance requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If we fail to maintain compliance with these requirements, we may be subject to potential liability and to termination of our contracts.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the&#160;FDA, the Securities and Exchange Commission, or SEC,&#160;and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018 and ending on January 25, 2019, the U.S. government has shut down several times and certain regulatory authorities, such as the&#160;FDA and the SEC, have had to furlough critical&#160;FDA, SEC and other government&#160;employees and stop critical activities. If repeated or prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to audit by the U.S. government and a negative audit could adversely affect our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">U.S. government agencies routinely audit and investigate government contractors and recipients of Federal grants. These agencies review a contractor&#8217;s performance under its contracts, cost structure and compliance with applicable laws, regulations and standards.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Government agencies also review the adequacy of, and a contractor&#8217;s compliance with, its internal control systems and policies, including the contractor&#8217;s purchasing, property, estimating, compensation and management information systems. Any costs found to be improperly allocated to a specific contract will not be reimbursed, while such costs already reimbursed must be refunded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">termination of contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">forfeiture of profits;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension of payments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">fines; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">suspension or prohibition from conducting business with the U.S. government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, we could suffer serious reputational harm if allegations of impropriety were made against us, which could cause our stock price to decrease.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations affecting government contracts make it more expensive and difficult for us to successfully conduct our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We must comply with numerous laws and regulations relating to the formation, administration and performance of government contracts, which can make it more difficult for us to retain our rights under our government grant contracts. These laws and regulations affect how we conduct business with government agencies. Among the most significant government contracting regulations that affect our business are:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the Federal Acquisition Regulations, or FAR, and agency-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and include other requirements such as the Anti-Kickback Statute and Foreign Corrupt Practices Act;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">export and import control laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Any changes in applicable laws and regulations could restrict our ability to obtain new contracts, which could limit our ability to conduct our business and materially adversely affect our results of operations.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_121"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our ability to manage our business operations, to execute our strategic plan and to recruit talented employees may be adversely impacted by COVID-19.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Since early March 2020, we have taken precautionary measures intended to help minimize the risk of COVID-19 to our employees and their families. In accordance with state and federal guidelines, we have reduced those precautionary measures in 2022 and have permitted employees to return to the office, work remotely, or adopt hybrid schedules based on job responsibilities. Further measures may be taken as the COVID-19 outbreak continues. These measures could negatively affect our business. For instance, remote work may disrupt our operations, limit our ability to interact with and effectively manage our third-party manufacturers CROs or current and planned clinical trial sites. The measures taken now or in the future to contain the COVID-19 pandemic could negatively affect our ability to recruit and engage new employees and contractors necessary to the successful operation of our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain our senior management team and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are highly dependent upon our senior management team, as well as the other principal members of our research and development teams. All of our executive officers are employed &#8220;at will,&#8221; meaning we or they may terminate the employment relationship at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or employees. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, regulatory, quality assurance and sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisers, including scientific, regulatory, quality assurance and clinical advisers, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisers may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We expect to expand our operations, and may encounter difficulties in managing our growth, which could disrupt our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect to expand the scope of our operations, particularly in the areas of drug development, manufacturing, clinical, regulatory affairs, quality assurance and sales and marketing. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. We may not be able to effectively manage the expected expansion of our operations or recruit and train additional qualified personnel. Moreover, the expected expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In the future, we may enter into transactions to acquire other businesses, products or technologies and our ability to do so successfully is unproven. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may fail to strengthen our competitive position and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and non-disruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_124"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">The price of our stock may be volatile, and you could lose all or part of your investment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this report, these factors include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the market valuations of similar companies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the commencement, timing, enrollment or results of the current and planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter, "complete response" letter, or a request for additional information;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse results, suspensions, terminations or delays in pre-clinical or clinical trials;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial or development program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the impact of the COVID-19 pandemic on our business and industry as well as the global economy;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in laws or regulations applicable to our products, including but not limited to requirements for approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in the structure of healthcare payment systems or limitations on the ability of hospitals and outpatient treatment centers to receive adequate reimbursement for the purchase and use of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">adverse developments concerning our contract manufacturers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices or acceptable quality;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our inability to establish collaborations, if needed;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to commercialize our product candidates successfully, or at all;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">additions or departures of key scientific or management personnel;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">unanticipated serious safety concerns related to the use of our product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the introduction of new products or services offered by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">announcements of significant acquisitions, strategic partnerships, joint ventures, government grants or contracts or capital commitments by us or our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to effectively manage our growth;&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the size and growth of our fungal infection, bacterial infection or other target markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our ability to successfully enter new markets or develop additional product candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">actual or anticipated variations in quarterly operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our cash position and our ability to raise additional capital and the manner and terms on which we raise it, and the expectation of future fundraising activities by us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">publication of research reports or other media coverage about us or our industry or our therapeutic approaches in particular or positive or negative recommendations or withdrawal of research coverage by securities analysts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">overall performance of the equity markets;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">sales of our common stock by us or our stockholders in the future or the expectation of such sales;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the trading volume of our common stock;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">changes in accounting practices;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">ineffectiveness of our internal controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">disputes or other developments relating to proprietary rights, including patent rights, litigation matters and our ability to obtain patent protection for our technologies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">significant lawsuits, including patent or stockholder litigation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">general political and economic conditions; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">other events or factors, many of which are beyond our control.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, the stock market in general, and The Nasdaq Capital Market, pharmaceutical companies and companies in the anti-infective sector in particular, have experienced extreme price and volume fluctuations that may or may not have been related or proportionate to the operating performance of these companies or their product potential. Broad market and industry factors, such as the COVID-19 pandemic and actions taken to slow its spread, may negatively affect the market price of our common stock, regardless of our actual operating performance. You may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and are able to exert significant control over matters subject to stockholder approval.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our executive officers, directors and 5% stockholders&#160;and their affiliates currently beneficially own a significant percentage of our outstanding voting stock. These stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management devotes substantial time to compliance initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses. We are subject to the reporting requirements of the Securities Exchange Act of 1934, which require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Capital Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the political environment and the level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We expect the rules and regulations applicable to public companies to continue to result in substantial legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. These costs could decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, these rules and regulations could make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate financial statements on a timely basis could be impaired and our public reporting may be unreliable.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Based on our evaluation of the effectiveness of our internal control over financial reporting as of September&#160;30, 2022, we determined that we had a material weakness as of September&#160;30, 2022 because our review control over the evaluation of applicable accounting standards and assessment of completeness and accuracy of valuation assumptions, related to non-routine transactions that include collaboration revenue, was not appropriately designed or operating effectively. While this improper design and operation did not result in a material error in the annual or interim financial statements, there is a reasonable possibility that a material misstatement in the annual or interim financial statements would not have been detected. A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#8217;s annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are in the process of implementing a remediation plan. We have amended our process to add additional layers of review by members of our management team regarding the evaluation of applicable accounting standards and completeness and accuracy of valuation assumptions related to non-routine transactions that include collaboration revenue. The effectiveness of our process changes and overall remediation efforts is being assessed by management on an ongoing basis. The remediation actions are also being monitored by the Audit Committee of our Board of Directors. However, we cannot assure you that these efforts will remediate this material weakness in a timely manner, or at all, or that we will be able to maintain effective controls and procedures even if we remediate this material weakness. If we are unable to successfully remediate this material weakness, design or operate effective controls and procedures, or identify any future material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports and we may experience a loss of public confidence, which could have an adverse effect on our business, financial condition and the market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We are required to disclose changes made in our internal control procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are a &#8220;non-accelerated filer,&#8221; our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur additional expenses of remediation. In addition, if we are unable to remediate this material weakness, or if we are otherwise unable to conclude that our internal control over financial reporting is effective, we could lose investor confidence in the accuracy and completeness of our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">financial reports, the market price of our securities could decline, and we could be subject to sanctions or investigations by The Nasdaq Capital Market, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.*</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline. We had 71,181,197 shares of common stock outstanding as of September&#160;30, 2022.&#160;We are unable to predict the effect that sales may have on the prevailing market price of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Sales of our common stock by current stockholders may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate and may make it more difficult for you to sell shares of our common stock. In addition, shares of common stock that are either issuable upon the exercise of outstanding options or warrants or reserved for future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules and Rule 144 and Rule 701 under the Securities Act.&#160;If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Certain holders of our securities are entitled to rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">We believe, based on our current business plan, that our existing cash and cash equivalents will not be sufficient to fund our obligations for the twelve months following the filing of this report. Significant additional capital will be needed to continue our operations as currently planned, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities, new investors could gain rights, preferences and privileges senior to our existing stockholders and our existing stockholders may be materially diluted by such subsequent sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to our 2015 Equity Incentive Plan, or the 2015 EIP, our management is authorized to grant stock options to our employees, directors and consultants.&#160;The number of shares of our common stock reserved for issuance under the 2015 EIP will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by 4% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or a lesser number of shares determined by our board of directors. Additionally, the number of shares of our common stock reserved for issuance under our 2015 Employee Stock Purchase Plan, or the ESPP, will automatically increase on January&#160;1 of each year through and including January&#160;1, 2025, by the lesser of 1% of the total number of shares of our capital stock outstanding on December&#160;31 of the preceding calendar year or 490,336 shares. Unless our board of directors elects not to increase the number of shares available for future grant each year under the 2015 EIP and the ESPP, our stockholders may experience additional dilution, which could cause our stock price to fall.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of working capital and may not use it effectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our working capital. Because of the number and variability of factors that determine our use of our working capital, its ultimate use may vary substantially from its currently intended use. Our management might not apply our working capital in ways that ultimately increase the value of your investment. We expect to use our working capital to fund research and development activities and general operating expenses. The failure by our management to apply this working capital effectively could harm our business. Pending its use, we may invest our working capital in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply our working capital in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer or by a majority of the total number of authorized directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of not less than two-thirds of all outstanding shares of our voting stock then entitled to vote in the election of directors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">a requirement of approval of not less than two-thirds of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and&#160;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our certificate of incorporation or our bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This choice of forum provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could adversely affect our business and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">While the Delaware courts have determined that exclusive choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under current law, unused U.S. federal net operating losses generated in tax years beginning after December 31, 2017, will not expire and may be carried forward indefinitely, but the deductibility of such federal net operating losses in taxable years beginning after December 31, 2020, is limited to 80% of taxable income. It is uncertain if and to what extent various states will conform to federal tax laws. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. As a result of capital raising and other transactions that have occurred since our inception in 2012, we may or may not have experienced an &#8220;ownership change.&#8221; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2021, we had U.S. federal net operating loss carryforwards of approximately $306.8&#160;million, portions of which will begin to expire in 2033, and which could be limited if we experience an &#8220;ownership change.&#8221; In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and we may incur substantial costs to attempt to recover or reproduce the data. If any disruption or security breach resulted in a loss of or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, we could incur liability and/or the further development of our product candidates could be delayed.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity, public health crisis, pandemic diseases and other events beyond our control, the occurrence of which could materially harm our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Businesses located in California have, in the past, been subject to electrical blackouts as a result of a shortage of available electrical power and any future blackouts could disrupt our operations. We are also vulnerable to a major earthquake, wildfire, inclement weather and other natural and man-made disasters and public health crisis and pandemic diseases, such as coronavirus, and we have not undertaken a systematic analysis of the potential consequences to our business as a result of any such natural disaster, public health crisis or pandemic diseases and do not have an applicable recovery plan in place. In addition, if any of our third-party contract manufacturers are affected by natural disasters, such as earthquakes, power shortages or outages, floods, wildfire, public health crises, such as pandemics and epidemics, terrorism or other events outside of our control, our business and operating results could suffer. For example, as a result of the COVID-19 pandemic, we have experienced significant disruptions in the conduct of our clinical trials and our general business operations as the result of various federal, state and local stay-at-home, shelter-in-place and quarantine measures. We carry only limited business interruption insurance that would compensate us for actual losses from interruption of our business that may occur and any losses or damages incurred by us in excess of insured amounts could cause our business to materially suffer.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_127"></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_133"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i103e7621649e479aa89c7d0167cfd96f_136"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM&#160;5. OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.644%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.1(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.2(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515146688/d914065dex32.htm">Amended and Restated Bylaws of the Registrant, as currently in effect.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.3(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex312018-05x21.htm">Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.1(2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312515119340/d843130dex41.htm">Form of Common Stock Certificate of the Registrant.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.2(3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000119312516729294/d161044dex102.htm">Form of Warrant to Purchase Common Stock issued to Pacific Western Bank.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">4.3(4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1610618/000161061818000052/ex412018-05x21.htm">Form of Common Stock Purchase Warrant for First Private Placement.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012022-09.htm">Licen</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012022-09.htm">se Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012022-09.htm"> by and between the Registrant and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012022-09.htm">Melinta Therapeutics, LLC</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012022-09.htm">, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012022-09.htm">July 26</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:112%;text-decoration:underline" href="exhibit1012022-09.htm">, 2022.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1022022-09.htm">Employment offer letter between the Registrant and Taylor Sandison, dated March 22, 2017.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1032022-09.htm">Employment offer letter between the Registrant and Shane M. Ward, dated August 17, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1042022-09.htm">Employment offer letter between the Registrant and Preetam Shah, dated August 19, 2021.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3112022-09.htm">Certification of Principal Executive Officer required by Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3122022-09.htm">Certification of Principal Financial Officer required by Rule 13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3212022-09.htm">Certification of Principal Executive Officer required by Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit3222022-09.htm">Certification of Principal Financial Officer required by Rule 13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Instance Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">The cover page from the Company's Quarterly Report on Form 10-Q has been formatted in Inline</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Certain portions of this exhibit (indicated by asterisks) have been excluded pursuant to Item 601(b)(10) of Regulation S-K because they are both not material and are the type that the Registrant treats as private or confidential.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K, filed on April 24, 2015.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-202740), as amended, originally filed with the SEC on March 13, 2015.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant's Current Report on Form 8-K, filed on October 3, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Incorporated by reference to the Registrant's Current Report on Form 8-K, filed on May 21, 2018.</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i103e7621649e479aa89c7d0167cfd96f_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:6pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cidara Therapeutics, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: November 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date: November 3, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">/s/ Preetam Shah, Ph.D., MBA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D., MBA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">79</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit1012022-09.htm
<DESCRIPTION>MELINTA LICENSE AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i408bcc55b9e2401cbd5323c90a158ba2_1"></div><div style="min-height:95.76pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;*&#93;, HAS BEEN OMITTED BECAUSE IT IS BOTH (I)&#160;NOT MATERIAL AND (II)&#160;IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">LICENSE AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">THIS LICENSE AGREEMENT (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) dated as of July 26, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), is entered into between Cidara Therapeutics, Inc., a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), having a place of business at 6310 Nancy Ridge Drive, Suite 101, San    Diego, CA 92121, and Melinta Therapeutics, LLC, a Delaware limited liability company (together with its subsidiaries, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), having a place of business at 44 Whippany Road, Suite 280, Morristown, NJ 07960.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Cidara owns or has rights in the Compound (as defined below).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">WHEREAS, Melinta desires to obtain an exclusive license under Cidara&#8217;s rights to the Compound in the Territory (as defined below) on the terms and conditions set forth below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Agreement, the terms defined in this Section 1 shall have the respective meanings set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Acquiring Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Third Party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Acquiror</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that acquires a party through a Change of Control, together with any Affiliates of such Acquiror existing immediately prior to the consummation of the Change of Control.  For clarity, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Acquiring Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of a party shall exclude the party and all of its Affiliates existing immediately prior to the consummation of the Change of Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Actual Combination Product Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning provided in Section 1.82.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the prevention or prophylaxis of invasive fungal diseases in allogeneic blood and marrow transplant patients 18 years of age or older.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under common control with, such Person.  A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, more than fifty percent (50%) of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Melinta Expense Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in Section 5.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Anti-Corruption Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Foreign Corrupt Practices Act (15 U.S.C. &#167;&#167; 78dd-1, et seq.), the Organization for Economic Co-operation and Development (OECD) Convention on combating bribery of foreign public officials in international business transactions, and any other applicable anti-corruption laws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all applicable laws, statutes, code, ordinances, regulations, rules, guidelines, injunctions, judgments, orders, writs, stipulations, awards, arbitration awards, decrees, constitutions, treaties and other pronouncements having the effect of law, in each case, enacted, promulgated, issued, enforced or entered by any Governmental Authority applicable to a party or such party&#8217;s business, properties or assets, including, as applicable, Healthcare Laws, Anti-Corruption Laws and GLP, GCP or GMP.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a party, any of the following that occurs after the Effective Date&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">any single Third Party &#8220;person&#8221; or &#8220;group&#8221; (as such terms are defined below) (i)&#160;is or becomes, through one or a series of transactions, the &#8220;beneficial owner&#8221; (as defined below), directly or indirectly, of the then-outstanding shares of common stock of such party (or any direct or indirect parent entity or ultimate parent entity of such party) representing more than fifty percent (50%) of the total then-outstanding common stock (or foreign equivalent thereof) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Outstanding Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), (ii) is or becomes, through one or a series of transactions, the &#8220;beneficial owner&#8221;, directly or indirectly, of shares of securities, capital stock or other interests (including partnership interests) of such party (or any direct or indirect parent entity or ultimate parent entity of such party) then-outstanding and normally entitled (without regard to the occurrence of any contingency) to vote in the election of the directors, managers or similar supervisory positions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Outstanding Voting Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of such party (or any direct or indirect parent entity or ultimate parent entity of such party) representing more than fifty percent (50%) of the total voting power of all Outstanding Voting Stock of such party (or any direct or indirect parent entity or ultimate parent entity of such party) or (iii) has the power, directly or indirectly, to elect a majority of the members of the party&#8217;s (or any direct or indirect parent entities or ultimate parent entities of such party) board of directors (or similar governing body)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">such party (or any direct or indirect parent entity or ultimate parent entity of such party) enters into a merger, consolidation or similar transaction with a Person (whether or not such party (or any direct or indirect parent entity or ultimate parent entity of such party) is the surviving entity) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Business Combination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), in each case, unless, immediately following such Business Combination, the individuals and entities who were the beneficial owners, respectively, of the Outstanding Common Stock and Outstanding Voting Stock of such party (and the ultimate parent entity thereof) immediately prior to such Business Combination beneficially own, directly or indirectly, more than fifty percent (50%) of, respectively, (1) the then-outstanding shares of common stock (or foreign equivalent thereof) and (2) the combined voting power of the then-outstanding voting securities entitled to vote generally in the election of directors, of the corporation or other entity resulting from such Business Combination (and the ultimate parent entity thereof)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.12.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:8.5pt">such party (and its Affiliates) sells, exchanges or otherwise transfers to any Third Party, directly or indirectly (including through the transfer of shares (or other ownership interests) in Affiliates), in one or a series of transactions, the properties and assets representing all or substantially all of such party&#8217;s total assets (together with all or substantially all of the properties and assets of its Affiliates).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For the purpose of this definition of Change of Control, (x) &#8220;person&#8221; and &#8220;group&#8221; have the meanings given such terms under Sections 13(d) and 14(d) of the United States Securities Exchange Act of 1934 and the term &#8220;group&#8221; includes any group acting for the purpose of acquiring, holding or disposing of securities within the meaning of Rule 13d-5(b)(1) under the aforesaid Act&#59; (y) a &#8220;beneficial owner&#8221; shall be determined in accordance with Rule 13d-3 under the aforesaid Act&#59; and (z) the terms &#8220;beneficially owned&#8221; and &#8220;beneficially own&#8221; shall have meanings correlative to that of &#8220;beneficial owner.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Ex-Territory Licensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Cidara&#8217;s Third Party licensee of Product under any Cidara Out-License.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara General Manufacturing&#47;Formulation Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Licensed Patent Right that claims inventions that are necessary or useful for the manufacture or formulation of both (a) Compound or Product and (b) any compound that is not a Compound or any product that is not a Product.  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara In-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any agreement in effect as of the Effective Date (as modified, amended or restated as of the Effective Date) or during the Term, pursuant to which any Third Party has granted Cidara or any of its Controlled Affiliates any license with respect to any of the Licensed IP Rights in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Out-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any agreement, whether in effect on the Effective Date or entered into thereafter during the Term, pursuant to which Cidara or any of its Controlled Affiliates has granted or grants to any Third Party any license (or sublicense) of the Licensed IP Rights outside of the Territory, including, as of the Effective Date, the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Product-specific trademark REZZAYO selected by Cidara to be used for the Product in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any clinical trial in human subjects for which Melinta, its Affiliate, a Sublicensee or Cidara is the sponsor that is prospectively designed to measure the safety or efficacy of a Product and is subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to the licensing provisions of the Public Health Service Act (58 Stat. 632, as amended (42 U.S.C. 201 et seq.)).  Clinical Study may include pre- or post-Marketing Approval human clinical trials and human clinical trials related to post-marketing requirements.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">CMO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Third Party contract manufacturing organization.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a Product comprising a fixed-dose formulation of Compound and at least one Other Active&#59; or (b) a Product that is co packaged with at least one Other Active and sold and invoiced as a single unit for a single price.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialize</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercializing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means to import, have imported, promote, have promoted, market, have marketed, warehouse, have warehoused, distribute, have distributed, sell, have sold, offer to sell, and educate healthcare providers and customers about, the Product, including responsibility for pricing and reimbursement (including both commercial and government payors) and interacting with a Regulatory Authority in the Territory regarding any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.23</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 6.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.24</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercially Reasonable Efforts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to the efforts to be expended by a party with respect to any objective under this Agreement, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.25</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) rezafungin&#59; (b) the Lead Compound&#59; (c) &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.26</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Controlled</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to any intellectual property rights, the possession by a party or any of its Affiliates (whether by ownership, license, or otherwise, other than pursuant to this Agreement) of (a) with respect to any tangible Information, the legal authority or right to physical possession of such tangible Information, with the right to provide such tangible Information to the other party on the terms set forth herein, or (b) with respect to Patent Rights, intangible Information, or other intellectual property rights, the legal authority or right to assign, or grant a license, sublicense, access, authorization, or right to use (as applicable) to the other party under, such Patent Rights, intangible Information, or other intellectual property rights, on the terms set forth herein, in each case </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(clauses (a) and (b)), without breaching or otherwise violating the terms of any arrangement or agreement with a Third Party in existence as of the time such party or its Affiliates would first be required hereunder to grant the other party such assignment, access, authorization, right to use, license, or sublicense.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Controlled Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a party to this Agreement, any other Person that is controlled (as such term is defined in Section 1.6) by such party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.28</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cost of Goods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to Product supplied by or on behalf of Cidara hereunder, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.29</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Current Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Product containing the Lead Compound in the formulation for intravenous administration that is being investigated in the Lead Indication Trials as of the Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.30</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all results of research, preclinical and non-clinical studies, including in vitro, in vivo, and ex vivo studies, clinical trials and other testing of Compound or Product, and any and all other data generated by or on behalf of a party (including any of its Controlled Affiliates or its Sublicensees or Cidara Ex-Territory Licensees, as applicable) related to the development, manufacture or commercialization of Compound or Product, including biological, chemical, pharmacological, toxicological, safety, pharmacokinetic, clinical, CMC, analytical, quality control, mechanical, software, electronic and other data, results and descriptions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means activities relating to the pre-clinical and clinical drug development of Product toxicology, formulation, microbiology, non-clinical profile and clinical trials (including research to design clinical trials), whether pre- or post-Marketing Approval, and any other research and development activities with respect to Product, including Phase IV studies.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Develop</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall have a correlative meaning.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.32</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Development Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the budget of Cidara internal (on a fully-burdened basis) and out-of-pocket expenses for Development Plan activities set forth in the Development Plan as of the Effective Date, as such budget may be amended from time to time in accordance with Article 4 and Section 5.1.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the written plan attached hereto as Exhibit C for the conduct by or on behalf of Cidara of (a) the ReSPECT Trial and the other Clinical Study(ies) of the Current Product in the Lead Indications specified therein&#59; (b) the GLP-compliant studies of Compound specified therein&#59; and (c) the CMC development activities specified therein&#59; that, in each case (clauses (a) through (c)), are intended to support Marketing Approval for the Current Product in the Target Indication and the Additional Indication in the Territory, as such plan may be amended from time to time in accordance with Article 4 and Section 5.1.1.  Without limiting the generality of the foregoing, in no event shall the Development Plan be amended to include any activity that is not required for Marketing Approval for the Current Product in the Lead Indications in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.34</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.35</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expanded Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a)&#160;a Product for intravenous administration (including, without limitation, the Current Product) for one or more indications in the Field in addition to the Lead Indications&#59; (b)&#160;a Product containing the Lead Compound for intravenous administration, other than the Current Product, to the extent not managed entirely through a mutually agreed written change control procedure for amendments, variations or additions to the CMC-related portions of Marketing Approvals&#59; (c)&#160;a Product containing any Compound other than the Lead Compound&#59; (d)&#160;a Combination Product&#59; or (e)&#160;a Product in a formulation for non-intravenous administration (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, subcutaneous or oral administration).  For clarity, Expanded Product excludes a formulation of the Current Product intended for use in patients younger than 18&#160;years of age.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.36</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Food and Drug Administration of the United States, or the successor thereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.37</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Field</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all uses in humans and nonhuman animals.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Commercial Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the first commercial sale of any Product by a Selling Party to a Third Party (other than another Selling Party) for end use or consumption in the Territory, in an arm&#8217;s-length transaction, after the first NDA for any Product has been approved by the FDA.  Dispositions of Product for Clinical Study purposes or as registration samples, samples for the development of testing devices, and dispositions of Product for early or special access programs, named patient programs or compassionate use shall not constitute a First Commercial Sale.  In addition, the sale or disposition of Product by one Selling Party to another Selling Party for resale shall not constitute a First Commercial Sale.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.39</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means U.S. generally accepted accounting principles, consistently applied.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.40</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GCP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means current good clinical practices per international ethical and scientific quality standards established by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), as adopted by FDA, and regulations promulgated by FDA relating to designing, conducting, recording and reporting trials that involve the participation of human subjects&#59; in each case, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.41</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Generic Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a Product for which the FDA has approved an NDA filed by or on behalf of Cidara, Melinta or any of their respective Affiliates or sublicensees, any other medicinal product that&#58; (a) is sold in the Territory by a Third Party that is not a Selling Party and did not purchase or acquire such product in a chain of distribution that included any Selling Party&#59; and (b) for which the FDA has approved a new drug application pursuant to 21 U.S.C. 355(b)(2) or an Abbreviated New Drug Application (or successor application) pursuant to 21 U.S.C. 355(j), or any respective successor law, that (i) identified such Product as the reference listed drug and (ii) referred to or relied on (x) the approved NDA for such Product held by Cidara, Melinta or any of their respective Affiliates or (y) the data contained or incorporated by reference in such approved NDA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.42</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Global Development Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning provided in the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.43</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Global JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; as such term is defined in the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.44</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GLP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means current good laboratory practices as established by the FDA in 21 CFR Part 58 and as interpreted by relevant ICH guidelines, in each case, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.45</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GLP Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any non-clinical in vivo study of a Compound or Product (a) that is intended to comply with GLP or (b) the results of which would be required to be reported to any Regulatory Authority.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.46</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">GMP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means current good manufacturing practices as established by the FDA as interpreted by relevant ICH guidelines&#59; in each case, as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.47</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any applicable government authority, court, tribunal, arbitrator, agency, department, legislative body, commission or other instrumentality of (a) any government of any country or territory, (b) any nation, state, province, county, city or other political subdivision thereof or (c) any supranational body.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.48</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Healthcare Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any laws and implementing rules, regulations and guidance documents applicable to the Product, including but not limited to&#58; (a) the U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.), the Prescription Drug Marketing Act of 1987 (21 U.S.C. &#167;&#167; 331, 333, 353, 381), the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167; 335(a) et seq.), the U.S. Patent </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Act (35 U.S.C. &#167; 1 et seq.), the federal Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b(b)), the Anti-Inducement Law (42 U.S.C. &#167; 1320a-7a(a)(5)), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et.  seq.), the administrative False Claims Law (42 U.S.C. &#167; 1320a-7b(a)), the federal Civil Money Penalty law (42 U.S.C. &#167; 1320a-7a), Exclusion law (42 U.S.C. &#167; 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. &#167; 1320a-7h), the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (42 U.S.C. &#167;1320d et seq., 42 U.S.C. &#167; 300jj et seq.&#59; 42 U.S.C. &#167; 17901 et seq.), the Drug Supply Chain Security Act, the laws governing the Medicare Program (Title XVIII of the Social Security Act) including Medicare average sales price reporting (42 U.S.C. &#167; 1395w-3a), the Medicaid Program (Title XIX of the Social Security Act) including the collection and reporting requirements and the processing of any applicable rebate, chargeback or adjustment thereunder and under any state supplemental rebate program and the 340B drug pricing program (42 U.S.C. &#167; 256b), the Public Health Service Act (42 U.S.C. &#167; 256b), and the Federal Supply Schedule (38 U.S.C. &#167; 8126)&#59; (b) any state laws analogous to any of the foregoing&#59; and (c) any implementing rules, regulations, and guidance documents under any of the laws described in the preceding clauses (a) and (b)&#59; in each case (clauses (a) through (c)), to the extent applicable to the Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.49</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Expert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 14.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.50</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any and all tangible and intangible (a) techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, data (including biological, chemical, pharmacological, toxicological, safety, pharmacokinetic, clinical, CMC, analytical, quality control, mechanical, software, electronic and other data), results of research, preclinical and non-clinical studies (including in vitro, in vivo, and ex vivo studies), clinical trials and other testing, software and algorithms, and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material&#59; that, in each case, are not in the public domain.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.51</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Invention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any invention or discovery, whether or not patentable, that is made, conceived, generated or reduced to practice, in whole or in part, in the course and as a result of the conduct of the activities expressly contemplated by this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.52</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.53</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.54</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lead Compound</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means rezafungin acetate, the active pharmaceutical ingredient of rezafungin, with chemical formula&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">N</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,6-anhydro&#91;(4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">R</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)-4-hydroxy-2-&#91;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-(pentyloxy)&#91;1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-terphenyl&#93;-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-carboxamido&#93;-5-&#91;2-(trimethylazaniumyl)ethyl&#93;-L-ornithyl-L-threonyl-</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">trans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">-4-hydroxy-L-prolyl-(4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)-4-hydroxy-4-(4-hydroxyphenyl)-L-threonyl-L-threonyl-(3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">)-3-hydroxy-4-methyl-L-proline&#93; acetate, having the chemical structure set forth in Exhibit B attached hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.55</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lead Indication Trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the ReSTORE Trial and the ReSPECT Trial.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.56</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Lead Indications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Target Indication and the Additional Indication.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.57</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, collectively, the Licensed Patent Rights and the Licensed Know-How.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.58</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Information that is (a) Controlled by Cidara or any of its Controlled Affiliates as at the Effective Date or during the Term and (b) necessary or useful for the development, registration, manufacture, use or commercialization of the Compound, including Cidara Inventions&#59; but excluding&#58; (i) Licensed Patent Rights&#59; (ii) Mundipharma Expanded Product Independent Efficacy Data generated by or on behalf of Mundipharma or its Affiliates and other Cidara Ex-Territory Licensee Expanded Product Independent Efficacy Data generated by or on behalf of another Cidara Ex-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Territory Licensee, except, in each case, as expressly provided in Sections 3.4.1(a), 3.4.1(b) and 3.4.1(c)&#59; and (iii) Joint Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.59</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Patent Rights Controlled by Cidara or any of its Controlled Affiliates as of the Effective Date or during the Term that claim inventions that are necessary or useful for (a) the Development, registration, use or Commercialization of Compound or Product in the Territory, or (b) the Manufacture of Compound or Product worldwide&#59; but, in each case, excluding the Joint Patents.  The Licensed Patent Rights as of the Effective Date are listed on Exhibit A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.60</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.61</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">MAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an application or submission for approval to market a pharmaceutical product filed with the governing Regulatory Authority in any jurisdiction other than the U.S., including any application for a variation or amendment to any such application or submission filed with the governing Regulatory Authority in any jurisdiction other than the U.S.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.62</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all activities related to the production, manufacture, processing, filling, finishing, packaging (including Packaging), labeling, shipping and holding of the Product or any intermediate thereof prior to the delivery of the Product, including process development, process qualification and validation, scale-up, pre-clinical, clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance, including release of the Product, and quality control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.63</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Marketing Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) in the Territory, approval of an NDA by the FDA, or (b) in any jurisdiction outside of the Territory, approval of an MAA by the governing Regulatory Authority in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.64</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the activities related to the dissemination of scientific information, intake and fulfilment of medical information requests, and field based medical science liaison activities with respect to the Product, including&#58; (a) any associated activities of medical scientific liaisons and the provision of medical information services with respect thereto&#59; (b) medical advisory board meetings&#59; (c) conduct at scientific meetings&#59; (d) publications, including publications related to Clinical Studies&#59; (e) any health economics and outcomes research studies&#59; (f) any &#8220;real-world&#8221; or registry studies&#59; (g) any investigator initiated studies&#59; and (h) non-clinical or microbiology studies that are not required by the FDA for maintaining Marketing Approval of the Product.  For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Medical Affairs Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; excludes GLP Study and Clinical Study as defined herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.65</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Expanded Product Independent Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Melinta Independent Study of an Expanded Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Expanded Product Independent Efficacy Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means clinical efficacy data generated by or on behalf of Melinta in a Melinta Expanded Product Independent Study.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.67</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Expanded Product Independent Study Buy-In Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.68</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Expanded Product Independent Study Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.69</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Grantback IP Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Melinta Grantback Know-How and Melinta Grantback Patent Rights.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Grantback Know-How</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all Information and Data that&#58; (a) is generated, developed or obtained by or on behalf of Melinta or any of its Controlled Affiliates or Sublicensees during the Term in the development, registration, manufacture, use or commercialization of Compound or Product&#59; or (b) is otherwise Controlled by Melinta or any of its Controlled Affiliates during the Term and is necessary for, or is both useful for and actually used by Melinta or any of its Controlled Affiliates or Sublicensees in, the development, registration, manufacture, use or commercialization of Compound or Product&#59; in each case, including Melinta Inventions&#59; but, in each case, excluding&#58; (i) Melinta Grantback Patent Rights&#59; (ii) Melinta Expanded Product Independent Efficacy Data other than as expressly provided in Section 5.1.6&#59; and (iii) Joint Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.71</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Grantback License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.72</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Grantback Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all Patent Rights claiming Melinta Inventions&#59; and (b) all other Patent Rights Controlled by Melinta or any of its Controlled Affiliates that claim inventions that are necessary for, or both useful for and actually used by or on behalf of Melinta or any of its Controlled Affiliates or Sublicensees in, the development, registration, manufacture, use or commercialization of Compound or Product&#59; but, in each case, excluding Joint Patents.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.73</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Independent Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5.1.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.74</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 10.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.75</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mundipharma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Mundipharma Medical Company, a general exempted partnership established and existing under the laws of Bermuda, or its successor-in-interest under the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.76</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mundipharma Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain Collaboration and License Agreement by and between Mundipharma and Cidara, dated September 3, 2019, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.77</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mundipharma Expanded Product Independent Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.4.1(a).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mundipharma Expanded Product Independent Efficacy Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 3.4.1(b).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.79</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Mundipharma Licensed Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Licensed Patent Rights that are licensed to Cidara pursuant to the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.80</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) a New Drug Application (as more fully defined in 21 CFR 314.5, et seq.) filed with the FDA, or any successor application thereto in the U.S.&#59; or (b) with respect to a pharmaceutical product for which the FDA has approved a New Drug Application, an application to supplement or amend such New Drug Application to expand the approved label for such pharmaceutical product to include use of such pharmaceutical product for an additional indication.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.82</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#91;*&#93; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.83</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the gross sales price of the Product in the Territory invoiced by Melinta or its Affiliate or Sublicensees (in each case, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Selling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), less, to the extent specifically attributable to Product and actually incurred, allowed, paid or accrued, or otherwise specifically allocated to Product, by the Selling Party (if not previously deducted in calculating the amount invoiced), all in compliance with GAAP, consistently applied by the Selling Party&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">credits, allowances, discounts and rebates to, and chargebacks from the account of, such customers for nonconforming, damaged, outdated and returned Product&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">cash, quantity and trade discounts, rebates and other price reductions for the Product given to such customers under price reduction programs&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">sales, use, value-added and other direct taxes levied on the sale of Product to such customers and, in each case, actually paid, and as adjusted for rebates and refunds&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">customs duties, tariffs, surcharges and other governmental charges levied on the sale, transportation or delivery of Product to customers in the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">&#91;*&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">provided that, in each case (clauses (a) through (f)), (1) each such deduction is calculated in a manner consistent with the Selling Party&#8217;s customary practice for pharmaceutical products and in accordance with GAAP, consistently applied by the Selling Party, (2) each such deduction is directly allocable to Product, or apportioned on a good faith, fair and equitable basis to Product and other products of the Selling Party and its Affiliates such that Product does not bear a disproportionate portion of such deductions, and (3) no particular amount identified above shall be deducted more than once in calculating Net Sales (i.e., no &#8220;double counting&#8221; of deductions).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For clarification, sale or other disposition of Product by a Selling Party to another Selling Party for resale by such other Selling Party to a Third Party (other than a Selling Party) shall not be deemed a sale for purposes of this definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">,&#8221; provided that the subsequent resale is included in the computation of Net Sales.  In the event of any sale or other disposition of Product for any consideration other than exclusively monetary consideration on bona fide arm&#8217;s-length terms (including any sale or other disposition of Product by a Selling Party to another Selling Party for end use by such other Selling Party), then for purposes of calculating Net Sales under this Agreement, such Product shall be deemed to have been sold exclusively for cash at the weighted (by sales volume) average sale price of such Product in bona fide arm&#8217;s-length transactions (when sold alone, and not with other products) in the Territory during the applicable accounting period.  Transfers or dispositions of Product for charitable, research and development, clinical or humanitarian purposes, in all cases without consideration, shall be disregarded in determining Net Sales.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If a Product is sold as part of a Combination Product in a calendar quarter, Net Sales of such Product during such calendar quarter for the purpose of determining royalties and commercialization milestone payments due hereunder shall be calculated as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.63pt">In the event that both (x) a Single-Agent Product is sold separately in finished form during such calendar quarter and (y) the Other Active(s) in such Combination Product are sold separately in finished form during such calendar quarter, then Net Sales of such Product shall be determined by multiplying the actual Net Sales of the Combination Product calculated pursuant to the preceding provisions of this Section 1.82 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Actual Combination Product Net Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) during such calendar quarter by the fraction, A &#47; (A+B) where A is the weighted average sale price of such Single-Agent Product when sold separately in finished form during such calendar quarter, and B is the weighted average sale price of the Other Active(s) in the Combination Product when sold separately in finished form during such calendar quarter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.58pt">In the event that a Single-Agent Product is sold separately in finished form during such calendar quarter, but the Other Active(s) in such Combination Product are not sold separately in finished form during such calendar quarter, then Net Sales of such Product shall be calculated by multiplying the Actual Combination Product Net Sales of the Combination Product during </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">such calendar quarter by the fraction A &#47; C where A is the weighted average sale price of such Single-Agent Product when sold separately in finished form during such calendar quarter and C is the weighted average sale price of the Combination Product during such calendar quarter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:19.53pt">In the event that no Single-Agent Product is sold separately in finished form during such calendar quarter, but the Other Active(s) in such Combination Product are sold separately in finished form during such calendar quarter, Net Sales of such Product shall be calculated by multiplying the Actual Combination Product Net Sales of the Combination Product by the fraction (C B) &#47; C, where B is the weighted average sale price of the Other Active(s) in the Combination Product when sold separately in finished form during such calendar quarter, and C is the weighted average sale price of the Combination Product during such calendar quarter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:20.13pt">In the event that neither any Single-Agent Product is sold separately in finished form during such calendar quarter, nor the Other Active(s) in such Combination Product are sold separately in finished form during such calendar quarter, then the methodology for determining Net Sales of such Product shall be mutually agreed in writing by the parties in good faith based on the relative contributions of the Compound and the Other Active(s) in such Combination Product to the total value of the Combination Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.84</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Orange Book</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Approved Drug Products With Therapeutic Equivalence Evaluations as published by the FDA.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.85</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Other Active</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any active pharmaceutical ingredient other than Compound.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.86</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Out-of-Pocket Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means amounts paid by or on account of Melinta to the FDA and Third Party vendors, consultants, or contractors for services directly related to the Specified Melinta Activities.  For clarity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Out-of-Pocket Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; does not include payments for Melinta&#8217;s or its Affiliates&#8217; employee salaries, benefits, utilities, travel expenses &#91;*&#93;, general office supplies, insurance, information technology or capital expenditures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.87</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Package</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Packaging</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the labelling and secondary packaging of the Product, including inserts.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) all national, regional and international patents and patent applications filed in any country or jurisdiction, including without limitation provisional patent applications, (b) all patent applications filed either from such patents and patent applications or from a patent application claiming priority from either of these, including any continuation, continuation-in-part, division, provisional, converted provisional and continued prosecution applications, or any substitute applications, (c) any patent issued with respect to or in the future issued from any such patent applications including utility models, petty patents and design patents and certificates of invention, and (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, reexaminations and extensions (including any supplementary protection certificates, patent term extensions and the like) of the foregoing patents or patent applications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.89</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, Governmental Authority or any other form of entity not specifically listed herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.90</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Prior CDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that certain Mutual Confidentiality Agreement between the Parties dated February 14, 2022.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.91</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any product that contains or incorporates the Compound, including any line extensions or alternate dosage forms.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.92</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Product Filings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all INDs, NDAs, MAAs, Marketing Approvals, Regulatory Approvals, and other filings with, and formal submissions to, Regulatory Authorities, in each case, with respect to the development, manufacture, and marketing and sale of Product in any country or other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.93</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Qualified Cidara Out-License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) the Mundipharma Agreement&#59; or (b) &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.94</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 9.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.95</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Redacted Mundipharma Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning provided in Section 3.7</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.96</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, with respect to a pharmaceutical product in a particular jurisdiction, all approvals or other permissions from the applicable Regulatory Authority in such jurisdiction necessary to develop, market and sell such product in such jurisdiction, including approvals of INDs and Marketing Approvals, and pricing and reimbursement approvals if required for marketing or sale of such product in such jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.97</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Governmental Authority, including the FDA, that has authority over the development, manufacture or commercialization of pharmaceutical products in a given jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means all regulatory information, materials, data and results relating to the Product, including without limitation electronic common technical document (eCTD) dossier, stability data, in-vitro Product testing data and study data, data queries, data tables, reports and listings, case report forms, and trial master files generated during any pre-clinical or Clinical Study for Product.  Regulatory Data shall be deemed to be a &#8220;trade secret&#8221; as referenced to or defined under Section 101(35A) of the United States Bankruptcy Code.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.99</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Exclusivity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a pharmaceutical product other than a Patent, including orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, or pediatric exclusivity. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.100</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ReSPECT Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Phase 3 clinical trial of the Current Product described in Cidara Clinical Protocol No. CD101.IV.3.08, entitled &#8220;A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection Versus the Standard Antimicrobial Regimen to Prevent Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation,&#8221; as amended from time to time in accordance with this Agreement and the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.101</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">ReSTORE Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Phase 3 clinical trial of the Current Product in the Target Indication described in Cidara Clinical Protocol No. CD101.IV.3.05, entitled &#8220;A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection Versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia and&#47;or Invasive Candidiasis,&#8221; as amended from time to time in accordance with this Agreement and the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.102</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Rights of Reference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) in the U.S., a &#8220;right of reference or use,&#8221; as such term is defined in 21 C.F.R. 314.3(b)&#59; or (b) in any other country or jurisdiction, the equivalent authority to rely upon, and otherwise use, an investigation for the purpose of filing, and conducting a clinical trial under, an IND, or obtaining Marketing Approval or other Regulatory Approval, including the ability to make available the underlying raw data from the investigation for audit by the applicable Regulatory Authority in such country or other jurisdiction, if necessary.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.103</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, on a Product-by-Product basis, the earlier of&#58; (a) the end of the first calendar quarter in which one or more Generic Products for such Product account for &#91;*&#93; or more of aggregate unit sales of such Product and such Generic Product(s) in the Territory, as determined by reference to applicable sales data obtained from IQVIA or from such other independent source for such sales data as is generally recognized as a reliable source for pharmaceutical sales data in the Territory among major pharmaceutical companies&#59; and (b)&#160;the latest of&#58; (i)&#160;the expiration of the last-to-expire Valid Claim of the Licensed Patent Rights listed in the Orange Book for such Product (or, in the case of any Valid Claim of a pending patent application within the Licensed Patent Rights, if issued would be listable in the Orange Book) and that, in the absence of the License would be infringed by the manufacture, use, sale, offer for sale or importation of such Product in the Territory (it being agreed that in determining whether a Valid Claim of a pending patent application would be &#8220;infringed&#8221; for the purpose of this clause, and for the purpose of Section&#160;7.2.2, such claim shall be treated as if issued as then currently being prosecuted)&#59; (ii)&#160;expiration of all Regulatory Exclusivity for such Product in the Territory&#59; and (iii)&#160;ten (10) years from the First Commercial Sale of such Product in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.104</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.4 Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 14.4. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.105</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Selling Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning provided in Section 1.82.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.106</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Single-Agent Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a Product containing Compound as its sole active pharmaceutical ingredient.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.107</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Melinta Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means&#58; (a) preparing, obtaining, maintaining, and renewing Marketing Approval for the Current Product for the Target Indication in the Territory&#59; (b) preparing, obtaining, maintaining, and renewing Marketing Approval for the Current Product for the Additional Indication in the Territory&#59; (c) the conduct by or on behalf of Melinta of any post-marketing requirement or post-marketing commitment Clinical Study or other such study or analysis of the Current Product required to be conducted by the FDA as a condition of maintaining Marketing Approval for the Current Product in the Lead Indications in the Territory&#59; &#91;*&#93; (e) payment of applicable FDA-imposed prescription drug program fees and prescription drug user fees specifically with respect to the Current Product for the Lead Indications&#59; and (f) compliance by Melinta with the obligations imposed by U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167;&#167; 301 et seq.) and implementing rules and regulations thereunder on the holder of the Product Filings for the Current Product in a Lead Indication in the Territory, including but not limited to, the preparation and filing of annual reports with the FDA and other reports with respect to Current Product safety matters, including adverse events and quality complaints&#59; in each case, to the extent conducted by or on behalf of Melinta after the Transfer Date, in a commercially reasonable manner consistent with pharmaceutical industry norms and in compliance with Applicable Laws and the terms of this Agreement.  For clarity, the Specified Melinta Activities shall exclude, without limitation, (i) preparing and filing INDs and NDAs, and obtaining and maintaining Marketing Approvals, in the Territory for (A) the Current Product for any indication other than the Lead Indications, or (B) any Product other than the Current Product for any indication&#59; (ii) &#91;*&#93;&#59; (iii) the performance of Melinta&#8217;s safety and pharmacovigilance reporting obligations to Cidara under the PV Agreement&#59; (iv) compliance by Melinta with Healthcare Laws (except as expressly set forth in clause (f) of the preceding sentence) applicable to Melinta&#8217;s, its Affiliates&#8217; and Sublicensees&#8217; activities with respect to the Product&#59; and (v) any other activity not specifically set forth in clauses (a) through (f) of the first sentence of this Section 1.108.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.108</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Melinta Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) the internal expenses (not to exceed $&#91;*&#93; per calendar year), and (b) reasonable and documented Out-of-Pocket Expenses, that, in each case (clauses (a) and (b)), are incurred by Melinta on or after the Transfer Date directly in the performance of the Specified Melinta Activities and are reasonably allocable to the Current Product in the Lead Indications&#59; but excluding &#91;*&#93;.  To the extent that any Specified Melinta Activity &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.109</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicense</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a sublicense under the License, or grant of any other right, to market, promote and sell Product in the Field in the Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.110</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sublicensee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Third Party that has received a Sublicense, directly or indirectly through one or more tiers, from Melinta or any of its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.111</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the treatment of candidemia and invasive candidiasis in patients 18 years of age or older. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.112</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 11.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.113</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Territory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. and its territories and possessions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.114</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any Person other than Cidara, Melinta and their respective Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.115</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;  means 90 days after the earliest of&#58; (a) the date on which the FDA notifies Cidara of the approval of the NDA for the Current Product in the Additional Indication in the Territory&#59; (b) after the FDA delivers an Additional Indication CRL&#58; (i) if the JSC makes a unanimous Affirmative CRL Determination pursuant to Section&#160;5.1.1(a) or the Independent Expert makes an Affirmative CRL Determination pursuant to Section&#160;14.4, then the date that Cidara has completed each of the Additional Indication CRL Activities, and (ii) if the JSC makes a unanimous Negative CRL Determination pursuant to Section&#160;5.1.1(a) or the Independent Expert makes a Negative CRL Determination pursuant to Section&#160;14.4, then the date of such determination&#59; (c) the date on which, following the availability of complete topline efficacy data from the ReSPECT Trial, Cidara and Melinta jointly determine in good faith, based on the analysis of such topline efficacy data, that such data are insufficient to support the filing of an NDA for the Current Product in the Additional Indication in the Territory&#59; (d) the date on which Cidara and Melinta jointly determine that &#91;*&#93; or (ii)&#160;it is not commercially reasonable for Cidara to continue the conduct of the ReSPECT Trial&#59; and (e) if the ReSPECT Trial has not been completed by June&#160;30, 2028, the date on which Cidara notifies Melinta in writing that Cidara is terminating the ReSPECT Trial&#59; provided that in each case of clauses (a) through (e), following such date, (A) Cidara shall be responsible for any wind-down, close-out, reporting and other such obligations for the ReSPECT Trial required by Applicable Law, at Cidara&#8217;s sole expense, and (B) Cidara shall not be relieved of any other obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.116</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">U.S</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221; means the United States of America.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.117</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Valid Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (a) a claim of an issued and unexpired patent included within the Licensed Patent Rights in the Territory, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application that, if issued would be listable in the Orange Book, and has not been abandoned, finally rejected or expired without the possibility of appeal or re-filing and such patent application has not been pending for more than &#91;*&#93; from the filing date of the earliest patent application from which such claim derives priority.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">REPRESENTATIONS AND WARRANTIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Mutual Representations, Warranties and Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party hereby represents and warrants to the other party as of the Effective Date as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Such party is a corporation or limited liability company duly organized, validly existing and in good standing under the laws of the state in which it is incorporated or formed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Such party (a) has the corporate power and authority to enter into this Agreement and to perform its obligations hereunder, (b) is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and (c) has the full right, power and authority to grant all of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">licenses and rights granted to the other party under this Agreement.  This Agreement is legally binding upon such party and enforceable against such party in accordance with its terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">All necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by such party for the valid execution, delivery or performance of this Agreement by such party have been obtained, excluding Regulatory Approvals necessary for Commercialization or commercial Manufacture of the Compound or any Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">The execution and delivery of this Agreement by such party and the performance of such party&#8217;s obligations hereunder&#58; (a) do not conflict with or violate any requirement of Applicable Law&#59; and (b) subject to the other party&#8217;s compliance with the terms and conditions of this Agreement, including, in the case of Melinta, Section 3.7 hereof, do not conflict with, or constitute a default under, any contractual obligation of such party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:14pt">Neither such party nor any of its Controlled Affiliates involved in the performance of this Agreement has been excluded from participation in any government healthcare program, debarred or disqualified from or under any other federal program, convicted of any offense defined in 42 U.S.C. &#167; 1320a-7, or otherwise deemed ineligible for participation in any healthcare program, nor is such party aware of any pending or threatened actions against such party or any of its Controlled Affiliates that would give rise to any such exclusion, ineligibility, debarment, disqualification or conviction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, each party hereby agrees (x) to reasonably cooperate with the other party with respect to any investigation or audit by a Regulatory Authority or other Governmental Authority or meeting their respective compliance obligations arising under any Applicable Law, including without limitation Healthcare Laws, or otherwise relating to the performance of this Agreement, and (y) to comply in all material respects with all Applicable Law, including without limitation Healthcare Laws, pertaining to the performance of such party&#8217;s obligations or the exercise of such party&#8217;s rights under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Cidara hereby represents and warrants to Melinta as of the Effective Date as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.1&#160;&#160;&#160;&#160;Cidara (a) is the sole owner, or in the case of rights obtained under the Mundipharma Agreement is the exclusive licensee (except with respect to the Non-Exclusively Licensed Mundipharma Patent Claims (as defined in the Redacted Mundipharma Agreement), of which Cidara is a nonexclusive licensee), of the Licensed IP Rights, and except as expressly set forth in the Redacted Mundipharma Agreement (as defined below), has not granted to any Third Party any license or other interest in the Licensed IP Rights in the Territory, (b) is not aware of any pending or issued patent of any ikjm Third Party that would be infringed by the manufacture, use, sale, offer for sale or importation of any Compound or Product in the Territory, and (c) is not aware of any threatened or material infringement or misappropriation by a Third Party of the Licensed IP Rights in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.2&#160;&#160;&#160;&#160;As of the Effective Date, there are no Cidara In-Licenses other than the Mundipharma Agreement.  Cidara has provided Melinta with complete (other than the redactions in the Redacted Mundipharma Agreement) and correct copies of the Mundipharma Agreement as in effect on the Effective Date.  The Mundipharma Agreement is in full force and effect in accordance with its terms.  Cidara has not assigned the Mundipharma Agreement to any of its Affiliates or any Third Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.3&#160;&#160;&#160;&#160;In Developing the Product, Cidara has &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.4&#160;&#160;&#160;&#160;Cidara has only two Affiliates, both of which are Controlled Affiliates of Cidara&#58; (i) Cidara Therapeutics UK Limited&#59; and (ii) Cidara Therapeutics (Ireland) Limited.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2.5&#160;&#160;&#160;&#160;The Lead Compound as identified on Exhibit B is the drug substance that Cidara is using, and will use, in the Lead Indication Trials.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, Cidara hereby covenants to Melinta that&#58; (x) &#91;*&#93;&#59; (y) &#91;*&#93;, and (z) &#91;*&#93;.  During the Term, neither Cidara nor any of its Controlled Affiliates shall delegate or contract the performance of any activity under this Agreement that Cidara is responsible for performing to any Affiliate of Cidara that is not a Cidara-Controlled Affiliate, unless, in each case&#58; (i) none of Melinta&#8217;s rights hereunder are diminished or otherwise adversely affected as a result of such delegation or contracting&#59; (ii) each such Affiliate has made a present assignment in writing to Cidara or its Controlled Affiliate of all right, title and interest in and to any and all Inventions and Data generated or made by such Affiliate in the course of performing the delegated or contracted activities, as necessary for Cidara to grant to Melinta the full scope of licenses and rights to such Inventions (including Patent Rights claiming such Inventions) and Data expressly contemplated by this Agreement&#59; and (iii) each such Affiliate undertakes in writing obligations of confidentiality and nonuse regarding Confidential Information which are at least as stringent as those undertaken by the parties pursuant to Article 9.  In addition, during the Term, Cidara shall not transfer or assign, and shall not permit any of its Controlled Affiliates to transfer or assign, any Licensed IP Rights or Cidara&#8217;s interest in any Joint Patents or Joint Inventions to any Affiliate of Cidara that is not a Controlled Affiliate (except in conjunction with a permitted assignment by Cidara of this Agreement and all of Cidara&#8217;s rights and obligations hereunder in accordance with Section 15.3).  Cidara further acknowledges and agrees that any permitted Affiliate transferee of any Licensed IP Rights or Cidara&#8217;s interest in any Joint Patents or Joint Inventions will take such Licensed IP Rights or Cidara&#8217;s interest in such Joint Patents or Joint Inventions or the applicable rights thereunder subject to the terms of this Agreement, including the License, and Cidara shall obtain such permitted Affiliate transferee&#8217;s written acknowledgment of, and agreement to, the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Mutual Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In addition to any covenants made by it elsewhere in this Agreement, each party hereby covenants to the other party that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.1&#160;&#160;&#160;&#160;in the event that such party becomes aware that (i) it or any of its Affiliates has been debarred, suspended or is the subject of a conviction described in 21 U.S.C. &#167;335(a) or &#167;335(b) or any foreign equivalent thereof or has been excluded from participation in any government healthcare program, debarred or disqualified from or under any other federal program, convicted of any offense defined in 42 U.S.C. &#167; 1320a-7, or otherwise deemed ineligible for participation in any healthcare program, or (ii) if any action, suit, claim, investigation, or legal or administrative proceeding is pending or, to its actual knowledge, is threatened, relating to any such debarment, suspension, exclusion, disqualification, ineligibility or conviction, such party will immediately notify the other party in writing, and, to the extent such notice is referring to a such a debarment, suspension or conviction pursuant to clause (i), the other party may terminate this Agreement immediately upon written notice to the other party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if any of a party&#8217;s Affiliates, but not such party itself, is debarred, suspended or is the subject of a conviction described in 21 U.S.C. &#167;335(a) or &#167;335(b) or any foreign equivalent thereof or is excluded from participation in any government healthcare program, debarred or disqualified from or under any other federal program, convicted of any offense defined in 42 U.S.C. &#167; 1320a-7, or otherwise deemed ineligible for participation in any healthcare program, then such party may avoid termination of this Agreement by the other party by immediately terminating all rights, licenses and sublicenses (including any Sublicense) granted by such party to that Affiliate and notifying the other party thereof in writing&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.2.&#160;&#160;&#160;&#160;in the event that such party becomes aware that any Person that is performing activities hereunder on its behalf has been debarred, suspended or is the subject of a conviction described in 21 U.S.C. &#167;335(a) or &#167;335(b) or any foreign equivalent thereof or has been excluded from participation in any government healthcare program, debarred or disqualified from or under any other federal program, convicted of any offense defined in 42 U.S.C. &#167; 1320a-7, or otherwise deemed ineligible for participation in any healthcare program, or if any action, suit, claim, investigation, or legal or administrative proceeding is pending or, to its actual knowledge, is threatened, relating to any such debarment, suspension, exclusion, disqualification, ineligibility or conviction, such party will immediately notify the other party in writing and such party will cease, or cause its Affiliate to cease (as applicable), employing, contracting with, or retaining any such Person to perform any services relating to Product&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.3&#160;&#160;&#160;&#160;such party shall (i) maintain appropriate policies, practices and procedures to ensure its compliance with applicable Healthcare Laws, and (ii) track and report to applicable Regulatory Authorities information relating to pricing and&#47;or transfers of value to healthcare providers, teaching hospitals and other Third Parties with respect to its activities and&#47;or operations regarding each Product Commercialized by or on behalf of such party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.4&#160;&#160;&#160;&#160;any payments made by or on behalf of such party or any of its Affiliates to health care practitioners (HCPs) under or in connection with this Agreement will be on arm&#8217;s-length terms consistent with fair market value&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.5&#160;&#160;&#160;&#160;neither such party nor any of its Affiliates will, in connection with the exercise of such party&#8217;s rights or performance of its obligations under this Agreement, directly or indirectly through Affiliates or Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a public official or entity or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including such party and its Affiliates, nor will such party or any of its Affiliates directly or indirectly promise, offer or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a public official or entity or any other Person in connection with the exercise of such party&#8217;s rights or performance of such party&#8217;s obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.6&#160;&#160;&#160;&#160;neither such party nor any of its Affiliates (or any of their respective employees and contractors), in connection with the exercise of such party&#8217;s rights or performance of such party&#8217;s obligations under this Agreement, shall cause the other party to be in violation of Anti-Corruption Laws&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3.7&#160;&#160;&#160;&#160;such party shall immediately notify the other party if such party has any information that there is or is likely to be a violation of Anti-Corruption Laws in connection with the exercise of such party&#8217;s rights or performance of such party&#8217;s obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclaimer of Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly set forth in this Agreement, THE INTELLECTUAL PROPERTY RIGHTS PROVIDED BY EACH PARTY HEREUNDER ARE PROVIDED &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AS IS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;  Except as expressly set forth in this Agreement, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES.  EACH PARTY EXPRESSLY ACKNOWLEDGES THAT, DESPITE THE EFFORTS AND OBLIGATIONS REQUIRED BY THIS AGREEMENT, THE PARTIES MAY BE UNABLE TO MEET EXPECTED OR INTENDED TIMELINES FOR THE DEVELOPMENT OR COMMERCIALIZATION OR SALES OBJECTIVES OF COMPOUNDS OR PRODUCTS.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation of Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except in the case of breach of Article 9, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE LOSSES OR DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that this Section 2.5 shall not be construed to limit either party&#8217;s indemnification obligations under Article 12.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">LICENSE GRANTS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">License Grants to Melinta</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Cidara hereby grants to Melinta&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1.1&#160;&#160;&#160;&#160;an exclusive (even as to Cidara and its Affiliates, except as set forth in Section 3.2), royalty-bearing license (including the right sublicense through multiple tiers, subject to Section </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5.1), under the Licensed IP Rights, and Cidara&#8217;s interest in the Joint Patents, in each case, solely to Develop, register, use, sell, have sold, offer for sale, Commercialize and import Product in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusive License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that for purposes of the Exclusive License, the Licensed IP Rights exclude all Licensed Patent Rights existing outside of the Territory&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, to the extent that any Licensed IP Rights are non-exclusively licensed to Cidara by a Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Non-Exclusively Licensed Third Party IP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the Exclusive License granted by Cidara to Melinta under such Non-Exclusively Licensed Third Party IP shall be exclusive solely as between Cidara and Melinta, but shall otherwise be non-exclusive&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1.2&#160;&#160;&#160;&#160;a &#91;*&#93;, royalty-bearing license (but solely during the Term and pursuant to and in accordance with Section 3.6), with the right to sublicense, including the right to subcontract to a CMO, under the Licensed IP Rights, and Cidara&#8217;s interest in the Joint Patents, in each case, solely to make and have made Compound and Product anywhere in the world but solely to Develop, register, use, sell, have sold, offer for sale, Commercialize and import Product in the Field in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and, collectively with the Exclusive License, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  For clarity, notwithstanding the licenses granted in this Section 3.1, Cidara retains the right under the Licensed IP Rights to perform Cidara&#8217;s obligations under this Agreement and the Mundipharma Agreement and any other Cidara Out-Licenses &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1.3&#160;&#160;&#160;&#160;With respect to any Cidara Out-License that Cidara enters into after the Effective Date, Cidara shall use commercially reasonable efforts to ensure that such Cidara Out-License (a) &#91;*&#93;, and (b) &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Retained Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding the exclusivity of the Exclusive License, Cidara retains the non-exclusive right to practice the Licensed IP Rights and Joint Patents in the Territory solely for the purpose of performing&#58; (a) Cidara&#8217;s obligations with respect to Product in the Territory under this Agreement, including Development Plan activities in the Territory, the filing and maintenance of Product Filings in the Territory for such purpose, and the use of Product in the Territory for the foregoing purposes in the Territory&#59; and (b) Cidara&#8217;s obligations with respect to Product in the Territory under the Redacted Mundipharma Agreement, including Cidara&#8217;s responsibilities under the Global Development Plan in the Territory, the filing and maintenance of Product Filings in the Territory for such purpose, and the use of Product in the Territory for the foregoing purposes.  For clarity, Cidara retains the right to grant licenses under the Licensed IP Rights and Cidara&#8217;s interest in Joint Patents outside the Territory to its Third Party licensees that have the right to market, promote and sell Product outside the Territory, and to practice and grant licenses under the Licensed IP Rights and Cidara&#8217;s interest in Joint Patents to make and have made Product anywhere in the world, solely to Develop, register, use, sell, have sold, offer for sale, Commercialize and import Product in the Field outside the Territory, subject to the terms and conditions of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Grantback License to Cidara</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Melinta hereby grants to Cidara&#58; (a) an exclusive (even as to Melinta), royalty free, fully-paid, irrevocable, perpetual license, with the right to sublicense through multiple tiers of sublicense but only under a Qualified Cidara Out-License (provided that contracting with a Third Party service provider for services on a fee-for-service basis shall not be considered a sublicense), under the Melinta Grantback IP Rights and Melinta&#8217;s interest in Joint Patents, solely to Develop, register, use, sell, have sold, offer for sale, Commercialize and import Compound and Product outside of the Territory&#59; and (b) a non-exclusive, worldwide, royalty free, fully-paid, irrevocable, perpetual license, with the right to sublicense through multiple tiers of sublicense, under the Melinta Grantback IP Rights and Melinta&#8217;s interest in Joint Patents, to make and have made Compound and Product anywhere in the world solely to Develop, register, use, sell, have sold, offer for sale, Commercialize and import Product outside the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Grantback License</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The Melinta Grantback License shall survive any termination or expiration of this Agreement subject to Section 11.5.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Initial Delivery of Cidara Know-How&#59; Ongoing Know-How Exchange</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4.1&#160;&#160;&#160;&#160;Within 30 days after the Effective Date, Cidara shall, at no additional charge to Melinta, deliver to Melinta or its designated Affiliate such existing and available (in recorded form) Licensed Know-How in the possession of Cidara and&#47;or its Controlled Affiliates as is necessary or useful for or as otherwise reasonably requested by Melinta and its Affiliates to (A) exercise the License in accordance with this Agreement&#59; and (B) otherwise exercise Melinta&#8217;s rights and perform Melinta&#8217;s obligations under this Agreement.  Thereafter, on an ongoing basis during the Term, Cidara shall also disclose to Melinta or its designated Affiliate such additional Licensed Know-How arising after the Effective Date as is necessary or useful for or as otherwise reasonably requested by Melinta and its Affiliates to (1) exercise the License in accordance with this Agreement and (2) otherwise exercise Melinta&#8217;s rights and perform Melinta&#8217;s obligations under this Agreement.  Without limiting the generality of the foregoing, Cidara shall provide to Melinta true and complete copies of all written, graphic or electronic embodiments of Data generated by or on behalf of Cidara or any of its Affiliates or Cidara Ex-Territory Licensees, including, without limitation, all draft and final protocols and all final reports of any GLP Study or human clinical trial of Compound or Product in the Field conducted by or on behalf of Cidara and&#47;or its Affiliates or licensees (but subject to the following subclauses (a) &#8211; (c)), and all non-clinical, microbiology, pharmacology, toxicology, pharmacokinetic and other data with respect to Compound or Product, and Melinta shall have the right to use such disclosed Data solely within the scope of the License and as otherwise expressly permitted by this Agreement.  Notwithstanding the foregoing&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Melinta acknowledges that, subject to the terms and conditions of the Mundipharma Agreement, (i) &#91;*&#93;, and (ii) &#91;*&#93;.  In the event that Cidara &#91;*&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Melinta further acknowledges that if &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Melinta hereby acknowledges and agrees that&#58; (i) &#91;*&#93;&#59; (ii) &#91;*&#93;&#59; and (iii) &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4.2&#160;&#160;&#160;&#160;On an ongoing basis during the Term, Melinta shall disclose to Cidara such Melinta Grantback Know-How as is necessary for Cidara to (i) exercise the Melinta Grantback License in accordance with this Agreement or (ii) otherwise exercise Cidara&#8217;s rights and perform Cidara&#8217;s obligations under this Agreement, but subject in all cases to Section 5.1.5 and Section 5.1.6.  Without limiting the generality of the foregoing, Melinta shall provide to Cidara true and complete copies of all written, graphic or electronic embodiments of Data generated by or on behalf of Melinta or any of its Affiliates or Sublicensees, including, without limitation, all draft and final protocols and final reports of any GLP Study or Clinical Study of Compound or Product conducted by or on behalf of Melinta and&#47;or its Affiliates, and all non-clinical, microbiology, pharmacology, toxicology, pharmacokinetic and other data with respect to Compound or Product, and Cidara shall have the right to use and sublicense such disclosed Data solely within the scope of the Melinta Grantback License and as otherwise expressly permitted by this Agreement, including Sections 5.1.5 and 5.1.6 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5.1&#160;&#160;&#160;&#160;Melinta shall have the right to grant sublicenses under the Exclusive License through multiple tiers to&#58; (a) an Affiliate of Melinta&#59; or (b) a Third Party.  Any Sublicense granted to any Affiliate of Melinta or to any Third Party shall be in writing and shall be subject to, and consistent with, the terms and conditions of this Agreement.  Melinta shall be fully responsible for the compliance of its Affiliates and Sublicensees with the terms and conditions of this Agreement and shall remain solely liable for the performance of its obligations hereunder, notwithstanding the grant of any Sublicense.  Melinta shall promptly notify Cidara in writing of the execution of any Sublicense agreement and shall provide Cidara with a copy of such Sublicense agreement, and any amendment thereto, no later than 30 days following execution thereof&#59; provided, that Melinta may redact any confidential or financial information contained therein that is unnecessary for Cidara to ascertain compliance with this Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5.2&#160;&#160;&#160;&#160;Until the fifth (5th) anniversary of First Commercial Sale of the first Product in the Territory, neither Cidara nor Melinta shall, nor shall Cidara or Melinta cause or permit any of its Controlled Affiliates to, either directly or indirectly, itself or in collaboration with any Third Party, Develop, Manufacture for Development or Commercialization, or Commercialize any directly competitive therapeutic agent to Product in the Territory without the other party&#8217;s prior written consent.  For avoidance of doubt, a &#8220;directly competitive therapeutic agent&#8221; shall mean another product in the echinocandin class of drugs.  Notwithstanding the foregoing, in the event of a Change of Control of a party, the first sentence of this Section 3.5.2 shall not apply to any directly competitive therapeutic agent to Product that is&#58; (a) &#91;*&#93;&#59; (b) &#91;*&#93;&#59; or (c) &#91;*&#93;&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that, in each case (clauses (a), (b) and (c)), &#91;*&#93;.  Notwithstanding the foregoing, this Section&#160;3.5.2 shall not be construed to &#91;*&#93;.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5.3&#160;&#160;&#160;&#160;Melinta hereby acknowledges and agrees that neither Melinta nor its Affiliates or Sublicensee shall have any right to practice any Licensed IP Rights for any purpose other than as expressly authorized in this Agreement, and hereby covenants on behalf of itself and its Affiliates not to practice, and not to permit or cause any Sublicensee or Third Party contractor to, practice &#91;*&#93;, in each case (clauses&#160;(i) and (ii)), for any purpose other than as expressly authorized in this Agreement.  Melinta further covenants on behalf of itself and its Affiliates&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">not to Develop, register, use, sell, have sold or offer for sale or seek Regulatory Approval for Compound or Product outside of the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">without limiting the generality of Section 3.5.3(a), not to, and not to permit or cause any Affiliate to, (i) seek prospective purchasers for the Product outside of the Territory, (ii) engage in any advertising or educational activities relating to the Product expressly directed to prospective purchasers outside the Territory, (iii) solicit or accept orders for any Product from any prospective purchaser for sale outside the Territory, or (iv) sell or provide Compound or Product to any Sublicensee or other Third Party if Melinta or any of its Affiliates knows that Compound or Product sold or provided to such Sublicensee or other Third Party would be sold or transferred, directly or indirectly, for use outside of the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">not to conduct or have conducted any GLP Study or Clinical Study of Compound or Product, except in accordance with a protocol approved by the Global JSC in accordance with Article 3 of the Mundipharma Agreement&#59; &#91;*&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">except as otherwise mutually agreed by Melinta and Cidara (or Mundipharma or another Cidara Ex-Territory Licensee, as applicable) in writing as expressly provided in Sections&#160;3.4.1(b) and 3.4.1(c), &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">not to grant, or purport to grant, any Affiliate of Melinta or any Third Party any license or other right to do any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5.4&#160;&#160;&#160;&#160;Cidara hereby acknowledges and agrees that neither Cidara nor its Affiliates or sublicensee shall have any right to practice any Melinta Grantback IP Rights for any purpose other than as expressly authorized in this Agreement, and hereby covenants on behalf of itself and its Affiliates not to practice, and not to permit or cause any licensee or Third Party contractor to, practice &#91;*&#93;, in each case (clauses&#160;(i) and (ii)), for any purpose other than as expressly authorized in this Agreement.  Cidara further covenants on behalf of itself and its Affiliates and licensees&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">except as expressly permitted by this Agreement or otherwise necessary for the performance of Cidara&#8217;s obligations hereunder or under the Mundipharma Agreement, not to Develop, register, use or seek Regulatory Approval for Compound or Product in the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">not to sell, have sold or offer for sale Compound or Product in the Territory&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">without limiting the generality of Section 3.5.4(b), not to, and not to permit or cause any Affiliate to, (i) seek prospective purchasers for the Product in the Territory, (ii) engage in any advertising or educational activities relating to the Product directed to prospective purchasers in the Territory, (iii) solicit or accept orders for any Product from any prospective purchaser (other than a Selling Party as necessary to comply with Cidara&#8217;s obligations under Section 3.6 or the Supply Agreement) for sale in the Territory, or (iv) sell or provide Compound or Product to any licensee or sublicensee of Cidara or other Third Party if Cidara or any of its Affiliates knows that Compound or Product sold or provided to such licensee, sublicensee or other Third Party would be sold or transferred, directly or indirectly, for use in the Territory&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">not to conduct or have conducted any GLP Study or human clinical trial of Compound or Product, except pursuant to the Development Plan or the Global Development Plan or in accordance with a protocol approved by the Global JSC in accordance with Article 3 of the Mundipharma Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">except as expressly provided in Sections&#160;5.1.5 and 5.1.6, &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.02pt">not to grant, or purport to grant, any Affiliate of Cidara or any Third Party any license or other right to do any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cidara shall use commercially reasonable efforts to assist Melinta as Melinta reasonably requests with respect to taking any necessary actions at the Global JSC for the exercise of Melinta&#8217;s rights under this Agreement, including seeking approval of a protocol for a GLP Study or Clinical Study of Compound or Product pursuant to Article 3 of the Mundipharma Agreement &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5.5&#160;&#160;&#160;&#160;The parties acknowledge and agree that the restrictions set forth in this Section 3.5 and in Section 3.7 are considered by the parties to be reasonable for the purposes of protecting the goodwill and value of the Product.  Each party acknowledges that the other party may be irreparably harmed and that monetary damages may not provide an adequate remedy to the other party in the event that such party materially breaches any of the covenants contained in this Section 3.5, and Melinta acknowledges that Cidara may be irreparably harmed and that monetary damages may not provide an adequate remedy to Cidara in the event that Melinta materially breaches any of its obligations under Section 3.7.  Accordingly, any breach by a party (or its Affiliates or Sublicensees or licensees&#47;sublicensees, as applicable) of any provision of this Section 3.5 shall entitle the other party, and any breach by Melinta (or its Affiliates or Sublicensees) of any provision of Section 3.7 shall entitle Cidara, to seek injunctive and other equitable relief to secure the enforcement of these provisions, in addition to any other remedies (including damages) which may be available to such party at law or in equity or under any other provision of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing, Supply, and Quality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.1&#160;&#160;&#160;&#160;Within 60 days after the Effective Date, the parties shall reasonably negotiate and agree upon, and enter into, a supply agreement for the supply of the Product for Development and Commercialization in the Territory by Cidara to Melinta for a period ending no later than the December 31, 2026 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Supply Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) generally consistent with the terms set forth on Exhibit D hereto and below in this Section 3.6 and other customary and commercially reasonable terms to be negotiated in good faith by the parties&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the terms of the Supply Agreement (other than the supply price for Product) shall be consistent with, and designed to permit Cidara to comply with its obligations under, Cidara&#8217;s agreements with its CMOs for the Product (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara CMOs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and with the Mundipharma Agreement.  In addition, the Supply Agreement shall &#91;*&#93;, and Cidara shall &#91;*&#93;, provided that &#91;*&#93;.  Subject to the foregoing, the Supply Agreement shall provide for Melinta to forecast and purchase, and Cidara to supply, quantities of Product required by Melinta for Development and Commercialization in the Territory.  The supply price for Product supplied by or on behalf of Cidara pursuant to the Supply Agreement shall be&#58; (i)&#160;in the case of Product supplied for use in Clinical Studies and other Development and registration activities, equal to Cidara&#8217;s Cost of Goods&#59; and (ii)&#160;in the case of Product supplied for commercial distribution, equal to 110% of Cidara&#8217;s Cost of Goods. Cidara shall be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">responsible for the quality release of the Product under the terms of the Supply Agreement.  For clarity, the supply of Product to Melinta for the Development of the Product in the Territory does not limit the obligation of Cidara in Section 5.1 to perform Cidara&#8217;s obligations under, and in accordance with, the Development Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.2&#160;&#160;&#160;&#160;Subject to Section 3.7, the Supply Agreement shall also permit Melinta to request, at Melinta&#8217;s option, either&#58; (a) Cidara to conduct, or cause the applicable Cidara CMO to conduct, a full technology transfer of the manufacturing process for Product to Melinta or its designee (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Manufacturing Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) at Melinta&#8217;s sole cost, &#91;*&#93;&#59; and (b) to directly contract with the applicable Cidara CMO for the supply of Product, &#91;*&#93; on or before December 31, 2026, subject to the terms of the CMO supply agreements.  Melinta shall be solely responsible for the Manufacture of the Product for Development and Commercialization in the Territory upon the earlier of i) completion of the technology transfer set forth in the foregoing clause (a), and (ii) the execution of a supply agreement between Melinta and Cidara&#8217;s CMO, and for clarity no later than December 31, 2026.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6.3&#160;&#160;&#160;&#160;Within 60 days after the Effective Date of the Supply Agreement, the parties agree to negotiate in good faith and enter into a quality agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Quality Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) for the Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Compliance with Mundipharma Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta hereby acknowledges its receipt by email dated July 8, 2022, from Cidara to Melinta of a redacted copy of the Mundipharma Agreement, including all amendments thereto existing as of the Effective Date (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Redacted Mundipharma Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Melinta hereby&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7.1.&#160;&#160;&#160;&#160;acknowledges that the license and rights granted to it under this Agreement are subject to the licenses and rights granted by Cidara to Mundipharma, and the obligations of Cidara, under the Redacted Mundipharma Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7.2&#160;&#160;&#160;&#160;acknowledges and agrees that the exercise by or on behalf of Melinta, any of its Affiliates or any Sublicensee of the license and rights granted to Melinta hereunder, and the performance by or on behalf of Cidara of its obligations hereunder, are subject to restrictions under the Redacted Mundipharma Agreement, including&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;those provisions of the Mundipharma Agreement prohibiting the conduct by or on behalf of Cidara of certain activities with respect to Compound and Product without the prior approval of the Global JSC in accordance with Articles 3 and 4 of the Redacted Mundipharma Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Cidara&#8217;s negative covenants under Sections 2.7(d) and 2.7(e) of the Redacted Mundipharma Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7.3&#160;&#160;&#160;&#160;acknowledges that Cidara&#8217;s ability to comply with its obligations under (a) &#91;*&#93;, (b) &#91;*&#93;, (c) &#91;*&#93;, and (d) &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7.4&#160;&#160;&#160;&#160;covenants, on behalf of itself and its Affiliates, not to take any action, or omit to take any action, and not to permit or cause any Sublicensee or Third Party contractor to take any action, or omit to take any action, in connection with this Agreement that a reasonable Person in the pharmaceutical industry experienced in the negotiation, interpretation and performance of license agreements with respect to pharmaceutical products or product candidates, having read, and been advised by legal counsel regarding, the Redacted Mundipharma Agreement, would reasonably be expected to understand would cause Cidara to be in material breach of the Mundipharma Agreement or to be unable to materially comply with its obligations under the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of Section 365(n) of Title 11 of the United States Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Bankruptcy Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and any similar laws in any other country, all rights and licenses granted under or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">pursuant to any Section of this Agreement are rights to &#8220;intellectual property&#8221; (as defined in Section 101(35A) of the Bankruptcy Code).  The parties agree that Melinta, as licensee of such rights under this Agreement, will retain and may fully exercise all of its protections, rights, and elections under the Bankruptcy Code, including, but not limited to, its rights under Section 365(n) of the Bankruptcy Code to, in the event of the commencement of a bankruptcy proceeding by or against Cidara under the Bankruptcy Code and upon rejection of this Agreement by Cidara, elect to treat the Agreement as terminated or to retain its rights under this Agreement and under any agreement supplementary to this Agreement, to such intellectual property (including any embodiment of such intellectual property to the extent protected by applicable non-bankruptcy law).  Each party hereby acknowledges that any and all&#58; (a) &#91;*&#93;&#59; (b) &#91;*&#93;&#59; (c) &#91;*&#93;&#59; (d) pre-clinical research data and results&#59; (e) Licensed Know-How&#59; and (f) &#91;*&#93;, in each case ((a) through (f)), that relate to such intellectual property, constitute &#8220;embodiments&#8221; of such intellectual property pursuant to Section 365(n) of the Bankruptcy Code, and that Melinta will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it upon its written request therefor and election under Section 365(n)(1)(B) of the Bankruptcy Code to retain the license and the rights granted by Cidara to Melinta hereunder in the event of Cidara&#8217;s rejection of this Agreement.  The provisions of this Section 3.8 are without prejudice to any rights Melinta may have arising under the Bankruptcy Code, laws of other jurisdictions governing insolvency and bankruptcy, or other Applicable Law.  The parties agree that they intend the following rights to extend to the maximum extent permitted by Applicable Law, including for purposes of the Bankruptcy Code and any similar laws in any other jurisdiction the right to retain, receive, or access, as applicable any intellectual property (including all embodiments thereof) of Cidara.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">GOVERNANCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Steering Committee&#59; Responsibility</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within 60 days after the Effective Date, the parties shall establish a Joint Steering Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">JSC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) composed of an equal number of representatives (having the appropriate expertise and authority) of each of Cidara and Melinta.  The JSC shall meet at least four (4) times per year or at such greater frequency, in person or by means of teleconference or video conference, as mutually agreed by the parties.  Each party shall bear its own expenses of participating in meetings of the JSC.  The JSC&#8217;s overall responsibility shall be to encourage and facilitate the exchange of information between the parties contemplated by this Agreement, and to facilitate, coordinate and oversee the performance of the Development Plan and the Transfer Plan.  The specific responsibilities of the JSC shall be&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.1&#160;&#160;&#160;&#160;to review, discuss and approve amendments to the Development Plan (including the Development Budget)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.2&#160;&#160;&#160;&#160;to review and discuss the protocol (and material amendments or updates thereof) for the Clinical Studies in the Development Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.3&#160;&#160;&#160;&#160;to review and to discuss the approach to be taken with respect to the Global JSC to obtain approval of the protocol (and amendments or updates thereof) for each GLP Study of Compound and each Clinical Study of Product proposed to be conducted by or on behalf of Melinta or any of its Affiliates or Sublicensees, including all Melinta Independent Studies (as defined below)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.4&#160;&#160;&#160;&#160;to discuss and approve the Transfer Plan pursuant to Section 5.2&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.5&#160;&#160;&#160;&#160;to review, discuss and approve each Annual Melinta Expense Budget and any amendment thereto&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.6&#160;&#160;&#160;&#160;in accordance with Section 5.1.1(a), to review and discuss the &#91;*&#93; and make a unanimous &#91;*&#93;, a unanimous &#91;*&#93;, or a determination that no unanimous decision may be reached&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.7&#160;&#160;&#160;&#160;in accordance with Section 5.1.1(b), to review and discuss any proposed &#91;*&#93; and make a unanimous &#91;*&#93;, a unanimous &#91;*&#93;, or a determination that no unanimous decision may be reached&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.8&#160;&#160;&#160;&#160;to facilitate, coordinate and oversee the activities performed by the parties pursuant to the Development Plan and the Transfer Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.9&#160;&#160;&#160;&#160;to facilitate the exchange of Licensed Know-How and Melinta Grantback Know-How subject to and in accordance with Section 3.4&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.10&#160;&#160;&#160;&#160;to serve as the principal means by which (a) Melinta keeps Cidara reasonably informed regarding Melinta&#8217;s Development, Manufacture and Commercialization of Compound and Product in the Field in the Territory, and (b) Cidara keeps Melinta reasonably informed regarding (i) Cidara&#8217;s Development of Compound and Product in the Territory pursuant to the Development Plan and Manufacture of Compound and Product pursuant to the Supply Agreement, (ii) Cidara&#8217;s and its licensees&#8217; Development of Compound and Product in and outside of the Territory pursuant to the Global Development Plan, and (iii) Cidara&#8217;s and its licensees&#8217; Commercialization of Compound and Product in the Field outside of the Territory&#59; in each case (clauses (a) and (b)), including sharing of information and Data pursuant to Sections 3.4, 5.1.3, 5.1.5, 5.3.4, 5.3.5, and 5.3.6&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.1.11&#160;&#160;&#160;&#160;to carry out such other obligations as are expressly delegated to it under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the establishment and existence of the JSC, each party shall retain the rights, powers and discretion granted to it hereunder, and the JSC shall not be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly provided herein.  The JSC shall be disbanded at such time as is mutually agreed to in writing by the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Decision-Making&#59; Dispute Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Decisions within the scope of the JSC&#8217;s authority shall be made by unanimous vote, with each party&#8217;s representatives on the JSC collectively having one vote.  The presence of at least one of each party&#8217;s JSC representatives constitutes a quorum for the conduct of business at any JSC meeting, and no vote of the JSC may be taken without a quorum present.  If the JSC is unable to decide or resolve unanimously any matter within the scope of its authority set forth in Section 4.1, then, at the written request of either party, the issue shall be referred to the Chief Executive Officer of Cidara and the Chief Executive Officer of Melinta (in each case, such party&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Senior Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) who shall promptly meet and attempt in good faith to resolve such issue within 30 days.  If the Senior Executives cannot resolve such matter within 30 days of the date such matter is first referred to them, then, subject to the remainder of this Section 4.2 and Section 4.3&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.1&#160;&#160;&#160;&#160;except as provided in Section 4.2.3, &#91;*&#93;&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.2&#160;&#160;&#160;&#160;except as provided in Section 4.2.3, with respect to all other matters, &#91;*&#93;&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that &#91;*&#93; (a) &#91;*&#93;, (b) &#91;*&#93;, (c) &#91;*&#93;, or (d) &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.2.3&#160;&#160;&#160;&#160;any Section 14.4 Matter shall be resolved in accordance with Section 14.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The parties intend that all matters within the scope of the JSC&#8217;s decision-making authority shall be resolved by the parties in accordance with this Section 4.2, and, except as provided in Section 4.2.3, no matter within the scope of the JSC&#8217;s authority shall be subject to the dispute resolution mechanisms set forth in Article 14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Scope of Authority&#59; Exclusions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding the establishment and existence of the JSC, each party shall retain the rights, powers and discretion granted to it hereunder, and neither the JSC nor Melinta in the exercise of its final decision-making authority shall be delegated or vested with rights, powers or discretion unless such delegation or vesting is expressly provided herein.  In addition to any other exclusions from or limitations on its authority set forth in this Article 4 or elsewhere in this Agreement, the JSC shall have no right or authority&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.1&#160;&#160;&#160;&#160;to interpret, modify, amend, or waive compliance with any provision of, or any right or remedy under, this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.2&#160;&#160;&#160;&#160;to determine whether or not a party has complied with any of its obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.3&#160;&#160;&#160;&#160;to determine whether or not, or when, any milestone event set forth in Section 7.3 has been achieved&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.4&#160;&#160;&#160;&#160;to determine any issue in a manner that would conflict with the express terms of this Agreement&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.3.5&#160;&#160;&#160;&#160;to make any decision or approve any matter that is expressly stated to require the mutual written agreement of the parties or the written consent of one or both parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Alliance Managers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within 60 days after the Effective Date, each party shall appoint (and notify the other party of the identity of) a representative of such party to act as the primary point of contact for the parties with the objective of creating and maintaining collaborative, efficient, and responsive communications within and between Melinta and Cidara (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Alliance Manager</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  A party may replace its Alliance Manager on written notice to the other party and may designate a substitute to temporarily perform the functions of that Alliance Manager by written notice to the other party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">DEVELOPMENT AND REGULATORY ACTIVITIES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Development Activities</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.1&#160;&#160;&#160;&#160;Cidara shall, at its sole expense except as expressly set forth below, use Commercially Reasonable Efforts to conduct the activities, including the Clinical Studies (including the ReSPECT Trial), set forth in the Development Plan in the Territory.  Without limiting the foregoing, Cidara shall use Commercially Reasonable Efforts to complete all Development activities that are required by FDA for Marketing Approval for the Current Product for the Lead Indications in the Territory, including reasonably responding to and remediating any items raised in a Complete Response Letter from the FDA&#59; subject to the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;If the Current Product does not receive Marketing Approval in the Additional Indication in the Territory or &#91;*&#93;  In no event shall Cidara be obligated to perform &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.2&#160;&#160;&#160;&#160;If the FDA requires the conduct, prior to the Transfer Date, of any post-marketing requirement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PMR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or post-marketing commitment (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PMC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including but not limited to, a surveillance study of the Current Product in the Target Indication as a condition to obtaining or maintaining Marketing Approval for the Current Product in the Target Indication in the Territory, then (i) the parties shall discuss in good faith, and the JSC shall approve, an amendment to the Development Plan to add such PMR or PMC if such PMR or PMC qualifies as a Clinical Study, and (ii) Cidara shall use Commercially Reasonable Efforts to perform such PMR or PMC at Cidara&#8217;s sole expense.  For clarity, Cidara shall not be responsible for performing any Clinical Study of the Current Product in pediatric patients unless such Clinical Study is required by the FDA to obtain or maintain Marketing Approval of the Current Product in the Target Indication in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.3&#160;&#160;&#160;&#160;Until such time as Cidara has completed all activities allocated to it in the Development Plan, Cidara shall provide Melinta with &#91;*&#93; reports &#91;*&#93; that include &#91;*&#93;.  Cidara shall also provide Melinta reports of &#91;*&#93;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.4&#160;&#160;&#160;&#160;Melinta shall have the right to periodically review through the JSC and provide reasonable input on Development activities in connection with or related to the Clinical Studies set forth in the Development Plan, which Cidara shall consider in good faith.  Cidara shall promptly notify Melinta of any changes to the protocol or other Development activities in connection with the ReSPECT Trial in the Territory, which shall be discussed between the parties acting reasonably and in good faith through the JSC.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.5&#160;&#160;&#160;&#160;Subject to Sections 3.4.2, 3.5.3, 5.1.6, 5.1.8, 5.3.1, 5.3.2, 5.3.6, 5.3.7, Melinta shall have the right, but not the obligation, to conduct Development activities with respect to Compound and Product in the Territory, and to initiate, sponsor, or conduct (a) GLP Studies of Compound and (b) Clinical Studies of the Product, in each case (clauses (a) and (b)), in the Territory and at Melinta&#8217;s sole cost and expense (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Independent Study</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided that&#58; (i) the protocol for each such Melinta Independent Study shall be subject to the approval by the Global JSC in accordance with Article 3 of the Mundipharma Agreement&#59; (ii)&#160;Cidara shall have the right to disclose all final protocols and final reports of such Melinta Independent Study, and all Data with respect to Compound or Product disclosed by Melinta to Cidara pursuant to Section 3.4.2, to Mundipharma pursuant to the Mundipharma Agreement or a Third Party licensee of Cidara pursuant to any Qualified Cidara Out-License&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that neither Cidara, nor Mundipharma, nor any Third Party licensee of Cidara under a Qualified Cidara Out-License shall have any license or right to use any Melinta Expanded Product Independent Efficacy Data generated by or on behalf of Melinta or its Affiliates in support of any Product Filing or in the Commercialization of Product outside of the Territory, except, on a Melinta Expanded Product Independent Study-by-Melinta Expanded Product Independent Study basis as expressly set forth in Section&#160;5.1.6&#59; (iii) Melinta shall keep Cidara reasonably informed of the plans for, and the status, progress and results of, all Development and regulatory activities related to Compound, Product or any Melinta Independent Study, and Cidara shall have the right to disclose such information to Mundipharma pursuant to the Mundipharma Agreement or a Third Party licensee of Cidara pursuant to any Qualified Cidara Out-License, (iv) Melinta shall provide Cidara true and complete copies of all Product Filings pursuant to Section 5.3.3, and Cidara shall have the right to disclose such Product Filings to Mundipharma pursuant to the Mundipharma Agreement or a Third Party licensee of Cidara pursuant to any Qualified Cidara Out-License&#59; (v) Melinta shall timely provide to Cidara all information, data and documentation required under Section 4.4 or 4.5 of the Mundipharma Agreement and Cidara shall have the right to disclose such information, data and documentation for Mundipharma to exercise any of its options thereunder, and (vi) Melinta shall provide to Cidara such additional information, documentation and records within Melinta&#8217;s Control that are reasonably necessary for Cidara to comply with its obligations under the Redacted Mundipharma Agreement.  For clarity, Melinta Independent Study shall not include any studies that fall within Medical Affairs Activities.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.6&#160;&#160;&#160;&#160;At least &#91;*&#93; prior to the initiation of any Melinta Expanded Product Independent Study, Melinta shall offer to Cidara (which offer Cidara may extend to any Cidara Ex-Territory Licensee) the right to bear a share of the costs of such Melinta Expanded Product Independent Study based on the relative market sizes for Product in the respective territories of Cidara or such Cidara Ex-Territory Licensee and Melinta (to be mutually agreed in good faith) in exchange for the right to use the Melinta Expanded Product Independent Efficacy Data from such Melinta Expanded Product Independent Study in support of Product Filings outside of the Territory or in the Commercialization of Product outside of the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Cidara shall have no obligation to contribute to the costs of any Melinta Expanded Product Independent Study.  If, prior to initiation of any Melinta Expanded Product Independent Study, Melinta, on the one hand, and Cidara, Mundipharma and&#47;or another Cidara Ex Territory Licensee, on the other hand, enter into any agreement to share the costs of such Melinta Expanded Product Independent Study, then the Melinta Expanded Product Independent Efficacy Data for such Melinta Expanded Product Independent Study shall be included in the Melinta Grantback Know-How and Cidara shall have the right, and the right to grant to Cidara Ex-Territory Licensees the right, to use such Melinta Expanded Product Independent Efficacy Data in support of any Product Filing outside of the Territory or in the Commercialization of Product outside of the Territory.  If no such agreement is entered into with respect to a Melinta Expanded Product Independent Study, and any efficacy endpoint of such Melinta Expanded Product Independent Study is achieved, then, within &#91;*&#93; after the first availability of top-line results from such Melinta Expanded Product Independent Study, Melinta shall deliver such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">top-line results to Cidara, together with a written report of the reasonable and documented external costs and expenses incurred by Melinta to date in connection with such Melinta Expanded Product Independent Study or preparing, submitting, obtaining or maintaining Product Filings specific to such Melinta Expanded Product Independent Study (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Expanded Product Independent Study Costs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In such event, Cidara shall have the one-time right (which shall be transferable to Mundipharma or any other Cidara Ex-Territory Licensee), exercisable solely during the 60-day period after receipt of such top-line results and the report of Melinta Expanded Product Independent Study Costs, to notify Melinta that Cidara (or its transferee of such right) wishes to use the Melinta Expanded Product Independent Efficacy Data from such Melinta Expanded Product Independent Study, and pay Melinta an amount equal to &#91;*&#93;% of the Melinta Expanded Product Independent Study Costs of such Melinta Expanded Product Independent Study (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Expanded Product Independent Study Buy In Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including such Melinta Expanded Product Independent Study Costs incurred after the date of the written cost report delivered by Melinta to Cidara as described above in this Section 5.1.6.  Promptly upon written request by Cidara, Melinta shall deliver a written invoice to Cidara (or Cidara&#8217;s transferee of such right) for the applicable Melinta Expanded Product Independent Study Buy-In Fee, and Cidara (or such transferee) shall pay the invoiced amount within &#91;*&#93; of invoice.  Upon the exercise of such right with respect to the Melinta Expanded Product Independent Efficacy Data for a Melinta Expanded Product Independent Study (and subject to payment of the applicable Melinta Expanded Product Independent Study Buy In Fee), such Melinta Expanded Product Independent Efficacy Data shall be deemed included in the Melinta Grantback Know-How.  For clarity, except as expressly provided above in this Section 5.1.6, Cidara shall have no right to use Melinta Expanded Product Independent Efficacy Data from a Melinta Expanded Product Independent Study in support of any Product Filing outside of the Territory or in the Commercialization of Product outside of the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.7&#160;&#160;&#160;&#160;For clarity, and notwithstanding any other provision of this Agreement to the contrary, (a) the Development Plan shall not include any Development activity with respect to any Expanded Product, and (b) Melinta shall be solely responsible (but not obligated beyond the express obligations set forth in this Agreement) for the conduct of any Melinta Independent Study in accordance with this Agreement, at Melinta&#8217;s sole expense, and Melinta shall not have any right to deduct, offset or credit the costs incurred by Melinta in conduct such activity, or any portion thereof, against any of Melinta&#8217;s payment obligations to Cidara under this Agreement, unless such Melinta Independent Study falls within the scope of the Specified Melinta Activities, including Clinical Studies required as a PMR or PMC, and to the extent such costs are Specified Melinta Expenses and subject to Section&#160;5.5.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.8&#160;&#160;&#160;&#160;Melinta shall not conduct or have conducted, or cause or permit any Affiliate, Sublicensee or other Third Party to conduct, any GLP Study or Clinical Study of Compound or Product, except in accordance with a protocol approved by the Global JSC in accordance with Article 3 of the Mundipharma Agreement &#91;*&#93;.  Cidara shall reasonably cooperate in good faith with Melinta to obtain Global JSC approval of any such protocol, subject to the terms and conditions of the Mundipharma Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.9&#160;&#160;&#160;&#160;In conducting any Development activity, or any Manufacturing activity in connection with any Development activity, pursuant to this Agreement, each party shall comply with all Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.1.10&#160;&#160;&#160;&#160;In conformity with standard pharmaceutical and biotechnology industry practices and the terms and conditions of this Agreement, each party as applicable shall prepare and maintain, or shall cause to be prepared and maintained, complete and accurate written records, accounts, notes, reports and data (including Data) with respect to all Development and CMC activities of Products in the Field.  Such records shall fully and properly reflect all work done and results achieved in the performance of the development and CMC activities in good scientific manner appropriate for regulatory and patent purposes.  Each party shall document all GLP Studies and Clinical Studies in appropriate study records according to Applicable Law.  Each party may review such records (including, to the extent permitted by applicable data privacy laws, clinical study reports and case report forms) maintained by the other party at reasonable times, and upon reasonable notice, to obtain access to the original records to the extent such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">party has a license to use the Information, Data or Inventions contained in such records pursuant to the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;*&#93; after the submission of the Product Filing for the Additional Indication for the Product in the Territory or at such other time mutually agreed to by the parties, the parties shall discuss, primarily through the JSC, and mutually agree in writing on, a plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Transfer Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) setting forth activities to be performed by the parties to effectuate the orderly transfer of Development, regulatory and pharmacovigilance obligations for Products in the Territory from Cidara to Melinta to be completed on or before the Transfer Date.  Each party shall use Commercially Reasonable Efforts to perform its responsibilities under the Transfer Plan.  Without limiting the foregoing, following the Transfer Date, Melinta shall be solely responsible (but not obligated beyond the express obligations set forth in this Agreement), at its sole cost subject to offsetting the Specified Melinta Expenses against royalties pursuant to Section 7.2.1, for (a) maintaining and renewing all applicable Product Filings in the Territory for the Current Product for the Lead Indications, (b) preparing, obtaining, maintaining, and renewing all applicable Product Filings in the Territory for the Current Product for all indications other than the Lead Indications, (c) conducting post-marketing approval Clinical Studies or such other studies or analyses for the Current Product as part of any PMC or PMR for all indications (including the Target Indication and Additional Indication) in the Territory, and (d) all pharmacovigilance activities in the Territory, including Product recalls, regulatory audits, and the collection, investigation, reporting and exchange of information concerning the safety of the Product and responding to safety issues and requests to the FDA, except that Cidara will continue to provide Melinta with any information received by Cidara from its other licensees after the Transfer Date in connection with the Product that is necessary for Melinta to fulfill its responsibilities under this Section 5.2. Cidara shall be responsible for any and all remaining close-out, reporting, and other sponsor obligations for the Lead Indication Trials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.2.1&#160;&#160;&#160;&#160;On the Transfer Date (or at an earlier time at Melinta&#8217;s request if Cidara is unable to secure Marketing Approval for the Additional Indication as a result of bankruptcy or insolvency), Cidara shall assign and transfer, and hereby assigns and transfers, to Melinta all right, title and interest in and to all Product Filings for the Current Product in the Territory, to the extent permitted by Applicable Law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.1&#160;&#160;&#160;&#160;Prior to the Transfer Date, Cidara shall be the sole holder of Product Filings for the Current Product for the Target Indication or the Additional Indication in the Territory, and Cidara shall, at its sole cost and expense, be responsible for preparing, obtaining, maintaining, and renewing all applicable Product Filings and Marketing Approvals in its own name for the Current Product for the Target Indication or the Additional Indication in the Territory that are necessary for the Commercialization of the Current Product for the Lead Indications in the Territory, including, subject to Melinta&#8217;s compliance with its reporting obligations to Cidara under the PV Agreement, complying with all requirements, pre-approval, post-marketing or otherwise, imposed on the holder of such Product Filings to maintain the Marketing Approvals for the Current Product for the Lead Indications in good standing.  By way of example, such requirements shall include, but not be limited to, payment of user and filing fees, submission of annual reports, submission of safety reports, and satisfaction of post-marketing requirements and post-marketing commitments.  Following the Transfer Date, Melinta shall be the sole holder of the applicable Product Filings in the Territory, and Melinta shall be responsible for preparing, obtaining, maintaining, and renewing all NDAs and Marketing Approvals in its name for the Product in the Territory, including complying with all requirements, pre-approval, post-marketing or otherwise, imposed on the holder to maintain the Marketing Approvals in good standing, at its sole cost and expense (but subject to offsetting the Specified Melinta Expenses against royalties pursuant to Section 7.2.1).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.2&#160;&#160;&#160;&#160;Neither party shall take, and shall cause its Affiliates and Sublicensees not to take, any steps that would be expected to undermine the validity or status of compliance of any Marketing Approvals for the Product in the Territory.  Without limiting the foregoing, neither party shall withdraw any Marketing Approvals in the Territory for the Product without the other party&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.3&#160;&#160;&#160;&#160;Each party, as the holder of any applicable Product Filings or Marketing Approval for the Product in the Territory during the applicable period shall send to the other party a copy of any proposed Product Filing to any Regulatory Authority in the Territory no later than &#91;*&#93; prior to submission.  Each party shall promptly provide the other party true and complete copies of all applicable Product Filings for the Product in the Territory, and Cidara shall have the right to disclose such Product Filings to Mundipharma pursuant to the Mundipharma Agreement or a Cidara Ex-Territory Licensee pursuant to any Qualified Cidara Out-License.  &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.4&#160;&#160;&#160;&#160;Each party shall notify the other party of any material communication received from a Regulatory Authority in the Territory no later than &#91;*&#93; from the date of its receipt thereof.  Cidara shall notify Melinta of any material communications from any Regulatory Authority outside the Territory for which it becomes aware, including any material communication it receives from Mundipharma from any Regulatory Authority in the Major Markets in the Mundipharma Territory (each as defined in the Mundipharma Agreement) pursuant to the Mundipharma Agreement, solely to the extent such communications is reasonably expected to adversely impact the Product&#8217;s labeling or regulatory requirements in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.5&#160;&#160;&#160;&#160;Prior to the Transfer Date, Cidara shall (a) provide Melinta with reasonable advance notice of material meetings (including any Advisory Committee Meetings), conferences and discussions (whether in person or by telephonic or video conference) scheduled with FDA concerning the Product&#59; (b) to the extent not prohibited by Applicable Law, grant Melinta and its representatives the right to attend and participate in any such meetings, conferences or discussions (at Melinta&#8217;s cost and expense) and Cidara shall facilitate such participation&#59; and (c) consider in good faith in the preparation of such meetings, conferences or discussion, any reasonable input timely provided by or on behalf of Melinta.  If Melinta elects not to participate in such meetings, conferences or discussions, Cidara shall provide Melinta with written or oral summaries of such meetings, conferences or discussions promptly thereafter, and in all events, no later than &#91;*&#93; after the conclusion thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.6&#160;&#160;&#160;&#160;Each party shall inform the other party of any potential material changes that affect the Marketing Approval of the Product in the Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Material Variations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) as soon as such party identifies such Material Variation.  Material Variations includes but are not limited to the following&#58; changes to the product labeling related to efficacy or safety, changing or adding a manufacturing site, adding a new manufacturing step, changing the formulation of the Product, changing the specification of the Product, changing the primary packaging, changing storage conditions, changing the API manufacturer, or changing of the manufacturing process.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.7&#160;&#160;&#160;&#160;Each party shall promptly disclose to the other party any information that it receives pertaining to notices from a Regulatory Authority in the Territory of non-compliance with Applicable Law in connection with the Product.  Further, each party shall promptly notify the other party of any audit or inspection by a Regulatory Authority in the Territory in connection with the Product and shall provide a copy of any audit or inspection observations to such other party within &#91;*&#93; following receipt.  Each party shall have the right, but not the obligation, to participate in such audit or inspection.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.8&#160;&#160;&#160;&#160;Melinta shall use Commercially Reasonable Efforts to provide Cidara with all reasonable cooperation and informal, non-financial assistance and take all actions reasonably requested by Cidara (on behalf of itself or a Third Party licensee or sublicensee, including Mundipharma) that are necessary to enable Cidara or such Third Party licensee or sublicensee to obtain and maintain Regulatory Approvals for the Products outside the Territory (subject to Section 5.1.6), to cooperate with any inspection by any Regulatory Authority relating to the Products outside the Territory, or otherwise as necessary to perform Cidara&#8217;s obligations under the Mundipharma Agreement.  Melinta shall keep Cidara reasonably informed of the status, progress and results of all regulatory activities related to Product in the Territory, and Cidara shall have the right to disclose such information to Cidara Ex-Territory Licensees, subject to Section 5.1.6.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.3.9&#160;&#160;&#160;&#160;Subject to Section 5.1.6, Melinta hereby grants to Cidara the Rights of Reference to all Product Filings in the Territory, with the right to sublicense through multiple tiers of sublicense, for </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">28</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">the purposes of&#58; (a) obtaining and maintaining Marketing Approvals for Products outside the Territory&#59; (b) conducting or having conducted CMC activities in relation to Products&#59; and (c) complying with applicable pharmacovigilance and other regulatory requirements with respect to Products outside the Territory.  Melinta shall, promptly upon request of Cidara, file with applicable Regulatory Authorities such letters of authorization, access or cross-reference as may be necessary to accomplish the intent of this Section 5.3.9, which cooperation shall include the provision to Cidara or its designee by Melinta of the necessary certificates of pharmaceutical product, ancillary documents and supporting information (e.g., on reference pricing) required or requested by a Regulatory Authority outside the Territory.  Cidara hereby grants to Melinta the Rights of Reference to all Product Filings Controlled by Cidara or any of its Controlled Affiliates or Cidara Ex-Territory Licensee(s) (subject to any applicable exclusions of clinical efficacy data independently generated by such Cidara Ex-Territory Licensee(s)) for the purposes of&#58; (a) obtaining and maintaining Marketing Approvals for Products in the Territory&#59; (b) conducting or having conducted CMC activities in relation to Products&#59; and (c) complying with applicable pharmacovigilance and other regulatory requirements with respect to Products in the Territory.  Cidara shall, and shall cause its Third Party licensee (including Mundipharma) to, promptly upon request of Cidara, file with applicable Regulatory Authorities outside the Territory such letters of authorization, access or cross-reference as may be necessary to accomplish the intent of this Section 5.3.9.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pharmacovigilance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4.1&#160;&#160;&#160;&#160;Within &#91;*&#93; after the Effective Date, the parties agree to negotiate in good faith and enter into a pharmacovigilance agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PV Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which shall include mutually acceptable procedures governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions&#47;experiences, pregnancy reports and any other information concerning the safety of the Product, sufficient to permit each party to comply with its regulatory and other legal obligations within the applicable timeframes, shall be in accordance with U.S., EU and ICH guidelines, and shall be consistent with the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; (as such term is to be defined in the Mundipharma Agreement)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that at Cidara&#8217;s request, the parties shall cooperate in good faith with each other and with Mundipharma to make Melinta a party to the Pharmacovigilance Agreement in which case all references in this Agreement to the PV Agreement shall be deemed to refer to such &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Pharmacovigilance Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#8221;   The PV Agreement shall specify that each party shall be responsible for monitoring all clinical experiences with respect to Product in the course of Development activities of which such party is the regulatory sponsor.  The parties&#8217; respective responsibilities regarding the following shall also be set forth in the PV Agreement&#58; (a) filing all required reports with respect thereto (including quality complaints, adverse events and safety data)&#59; and (b) responding to safety issues and to all associated requests of Regulatory Authorities relating to Product in the Territory&#59; provided that Cidara shall be responsible for all monitoring and reporting obligations in respect of the Lead Indication Trials.  Prior to the Transfer Date, Cidara shall be responsible for the costs it incurs in complying with its monitoring and reporting obligations under the PV Agreement and in reporting relevant information to Melinta with respect to the Current Product for the Lead Indications.  Melinta shall be responsible for the costs it incurs in complying with its monitoring obligations under the PV Agreement and in reporting relevant information to Cidara with respect to the any other Product or indications.  Following the Transfer Date, Melinta shall be responsible for the costs it incurs in complying with its monitoring obligations under the PV Agreement and in reporting relevant information to Cidara with respect to the Current Product for the Lead Indications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4.2&#160;&#160;&#160;&#160;As between the parties, Cidara will hold, solely own and be solely responsible for maintaining the global safety database for Product, provisions concerning which (including Melinta&#8217;s right to reference such database) shall be included in the PV Agreement.  In addition, Cidara shall be responsible for the preparation and maintenance of the global developmental safety update reports, periodic safety update reports, risk management plans, signal detection activities, and the company core data sheet in respect of Product, subject to Melinta&#8217;s compliance with its monitoring obligations under the PV Agreement and its obligations thereunder to report relevant events to Cidara.  Pursuant to the terms of the PV Agreement, Melinta will collaborate with Cidara in respect of signaling, aggregate reporting and labelling activities.  Following the Transfer Date, Melinta shall be responsible for all associated safety reporting to FDA for the Product.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">29</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.4.3&#160;&#160;&#160;&#160;Subject to the terms of the PV Agreement&#58; (a) either party may audit relevant elements of the other party&#8217;s pharmacovigilance system to verify compliance with such party&#8217;s pharmacovigilance obligations&#59; and (b) if either party is subject to inspection of their pharmacovigilance system by a Regulatory Authority, the parties will collaborate in preparing for inspection and addressing any inspection questions and findings, detail of such collaboration to be contained in the PV Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Melinta Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No later than &#91;*&#93;, Melinta shall prepare in good faith and provide to Cidara a budget of Melinta&#8217;s good faith estimates of Specified Melinta Expenses, itemized by Specified Melinta Activity, for the next calendar year (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Annual Melinta Expense Budget</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and shall provide Cidara with reasonable supporting documentation for the Out-of-Pocket Expenses estimates in each Annual Melinta Expense Budget.  To the extent that any Specified Melinta Activity to be performed by Melinta will benefit or support both the Current Product and any other product under Development or Commercialization by or on behalf of Melinta or any of its Affiliates, Melinta&#8217;s good faith estimate of the corresponding Specified Melinta Expense shall be a fair, equitable and proportionate portion of the total estimated Out-of-Pocket Expenses for such Specified Melinta Activity.  At Cidara&#8217;s request within &#91;*&#93; after receipt of each Annual Melinta Expense Budget, the parties shall convene a meeting of the JSC to review and discuss such Annual Melinta Expense Budget.  Melinta shall act responsibly and prudently in contracting for Out-of-Pocket Expenses and incurring Specified Melinta Expenses, to the same extent as Melinta would if it were contracting for similar activities and incurring related expenses with respect to a Melinta product with respect to which Melinta was not entitled to offset such expenses against payments owed to a Third Party or otherwise to recover such expenses from a Third Party.  With respect to any applicable FDA-imposed prescription drug program fee or prescription drug user fee with respect to the Current Product for the Lead Indications, Melinta shall only include in Specified Melinta Expenses the amount Melinta is obligated to pay, net of any exemptions, reductions or refunds to which Melinta may be entitled, and if, after paying any such fee, Melinta receives a refund of any portion thereof, Specified Melinta Expenses not yet offset against royalties under Section 7.2.1 shall be reduced by the amount of such refund.  The Annual Melinta Expense Budget for a calendar year may be updated from time to time upon JSC approval as necessary to reflect &#91;*&#93;.  References in this Agreement to the Annual Melinta Expense Budget for a given calendar year shall, unless the context otherwise requires, be deemed to refer to the Annual Melinta Expense Budget for such calendar year as then in effect, including all applicable JSC-approved updates thereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">COMMERCIALIZATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">General Responsibilities</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1.1&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, Melinta, at its sole cost and expense, shall be responsible for Commercialization of the Product in the Territory and the conduct of all related Medical Affairs Activities for the Product in the Territory.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1.2&#160;&#160;&#160;&#160;Melinta shall use Commercially Reasonable Efforts to (a) following receipt of any Marketing Approval for the Product in the Territory, Commercialize the Product in the Field in the Territory for each indication for which Marketing Approval has been obtained in the Territory, and (b) maximize Net Sales of each Product in the Field in the Territory.  Subject to Melinta&#8217;s compliance with its obligations under the preceding sentence of this Section 6.1.2, Melinta shall have the right to determine &#91;*&#93; account targets, the methods of promoting and advertising the Product, the price and reimbursement strategy for the Product in the Territory, including Centers for Medicare &#38; Medicaid Services coding and reimbursement applications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.1.3&#160;&#160;&#160;&#160;No later than 30 days from the Effective Date, Cidara shall, make available to Melinta copies, whether electronic or otherwise, all vendor agreements, launch and sales plans, market research or any other commercialization plans, advertisements (including any &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Coming Soon</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; advertisements), scientific literature and any other documents or materials generated by or on behalf of Cidara in connection with Commercialization or Medical Affairs Activities for the Product in the Territory.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">30</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta shall prepare for Cidara&#8217;s review, a rolling twelve (12)-month plan describing the anticipated Commercialization strategy and activities to be conducted for the Product in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Melinta will submit the Commercialization Plan to Cidara for Cidara&#8217;s review prior to the anticipated date of receipt of each Marketing Approval for the Product in the Territory.  The Commercialization Plan shall describe the pre-launch, launch, and subsequent Commercialization of the Product, including the anticipated activities relating to education, messaging, branding, marketing and training for the Product in the Territory.  On an annual basis &#91;*&#93;, Melinta shall prepare and recommend amendments to the then-current Commercialization Plan to reflect any changes, re-prioritization of activities within, or additions to, the then-current Commercialization Plan, for &#91;*&#93; Cidara.  For clarity, and notwithstanding any other provision of this Agreement to the contrary, Cidara shall have no responsibility or obligation to perform any activity under the Commercialization Plan, and Melinta shall be solely responsible for all costs of performing the Commercialization Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">FINANCIAL CONSIDERATIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Upfront Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As soon as reasonably practicable after the Effective Date, but in no case later than thirty (30) days following the Effective Date, Melinta shall pay to Cidara thirty million dollars (USD $30,000,000).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms and conditions of this Agreement, Melinta shall pay to Cidara a royalty on aggregate annual Net Sales of all Product by Melinta, its Affiliates and Sublicensees in the Territory in each calendar year at the following incremental royalty rates, less the Specified Melinta Expenses that have accrued as of the date of the applicable calendar quarter in which such royalty is due, provided that in no event shall the total amount of Specified Melinta Expenses in any calendar year that Melinta is entitled to offset hereunder exceed 110% of the estimated Specified Melinta Expenses set forth in the Annual Melinta Expense Budget for such year (and provided that any amounts not fully offset in a calendar quarter will roll until the next calendar quarter until all Specified Melinta Expenses have been fully credited against such royalty payments)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;*&#93; percent (&#91;*&#93;%) of that portion of aggregate annual Net Sales of Products in the Territory up to &#91;*&#93;&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">&#91;*&#93; percent (&#91;*&#93;%) of that portion of aggregate annual Net Sales of Products in the Territory greater than &#91;*&#93; and up to &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">&#91;*&#93; percent (&#91;*&#93;%) of that portion of aggregate annual Net Sales of Products in the Territory greater than &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Royalty Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Royalties under Section 7.2.1 shall be payable on a Product-by-Product basis from the First Commercial Sale of a Product in the Territory until the expiration of the Royalty Term for such Product in the Territory&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that during any portion of the Royalty Term for a Product in the Territory when no Valid Claim of the Licensed Patent Rights would, in the absence of the License, be infringed (as construed in accordance with Section&#160;1.104) by the manufacture, use, sale, offer for sale or importation of such Product in the Territory, the royalties due Cidara under Section&#160;7.2.1 shall be reduced to &#91;*&#93;% of the amount otherwise payable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that Melinta or its Affiliate or Sublicensee (as applicable) is required to obtain one or more licenses under issued Patents of Third Parties (excluding Sublicensees) that are necessary for the manufacture, use, sale, offer for sale or import of Product in the Territory (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), &#91;*&#93;% of the royalties actually paid by Melinta or such Affiliate or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">31</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Sublicensee (as applicable) under such Third Party Licenses with respect to sales of such Product in such country for a calendar quarter will be creditable against the royalties payable by Melinta to Cidara with respect to Net Sales of such Product in such country for such calendar quarter&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that in no event will the royalties payable by Melinta to Cidara hereunder with respect to Net Sales of such Product for such calendar quarter be reduced by more than &#91;*&#93;% as a result of any and all such credits in the aggregate (but any portion of the royalties paid under Third Party Licenses with respect to sales of such Product that Melinta would have been entitled to credit against royalties payable to Cidara in the absence of the foregoing limitation on aggregate credits in any calendar quarter shall be carried over and applied against royalties payable to Cidara in respect of such Product in subsequent calendar quarters until the full deduction is taken)&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Melinta will not be entitled to credit any portion of royalties that are paid or payable by Melinta or its Affiliate or Sublicensee to any Third Party with respect to sales of a Combination Product in any country by reason of the inclusion in such Combination Product of any Other Active. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Regulatory Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;*&#93; days following the first achievement by Cidara (or, if Milestone Event #2 is achieved after the Transfer Date, the first achievement by Melinta, subject to the remainder of this Section&#160;7.3.1) of each of the milestone events set forth in the table below, Cidara shall provide Melinta (or, if Milestone Event #2 is achieved after the Transfer Date, subject to the remainder of this Section&#160;7.3.1, Melinta shall provide Cidara) with written notice of such achievement, and Melinta shall pay to Cidara the corresponding one-time, nonrefundable, noncreditable milestone payment set forth in such table within &#91;*&#93; days of such notice from Cidara (or, if Milestone Event #2 is achieved after the Transfer Date, subject to the remainder of this Section&#160;7.3.1, within 30&#160;days of such achievement)&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment (USD)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:19.75pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:19.75pt;padding-right:2.75pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For clarity, in the case that the Transfer Date occurs before Marketing Approval of the Current Product for the Additional Indication is obtained in the Territory, and Milestone Event #2 is achieved after the Transfer Date, then&#58; </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;if &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Milestones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;*&#93; following the end of the calendar &#91;*&#93; in which each of the milestone events set forth in the table below is first achieved (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Milestone Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Melinta shall provide Cidara with written notice of such achievement and shall pay to Cidara the corresponding one-time, nonrefundable, noncreditable milestone payment set forth in such table (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Commercialization Milestone Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) within &#91;*&#93; of such notice&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">32</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Event</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Milestone Payment (USD)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:19.75pt;padding-right:2.75pt;text-indent:-17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1. &#160;&#160;&#160;&#160;First calendar year in which aggregate annual Net Sales of all Products in the Territory equal or exceed </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:19.75pt;padding-right:2.75pt;text-indent:-17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2. &#160;&#160;&#160;&#160;First calendar year in which aggregate annual Net Sales of all Products in the Territory equal or exceed </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:19.75pt;padding-right:2.75pt;text-indent:-17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3. &#160;&#160;&#160;&#160;First calendar year in which aggregate annual Net Sales of all Products in the Territory equal or exceed </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt;padding-left:19.75pt;padding-right:2.75pt;text-indent:-17pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4. &#160;&#160;&#160;&#160;First calendar year in which aggregate annual Net Sales of all Products in the Territory equal or exceed </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If multiple Commercialization Milestone Events are achieved in any given calendar &#91;*&#93;, the Commercialization Milestone Payments corresponding to all of such achieved Commercialization Milestone Events shall be paid within &#91;*&#93; of the end of such calendar &#91;*&#93;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">PAYMENT&#59; RECORDS&#59; AUDITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Reports and Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Melinta Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Within &#91;*&#93; after the end of each calendar quarter during the Term following the Transfer Date, Melinta shall provide to Cidara a written statement setting forth the Specified Melinta Expenses incurred by Melinta during such calendar quarter, such statement to include a reasonably detailed breakdown of the components of such Specified Melinta Expenses and the Specified Melinta Activities to which such Specified Melinta Expenses are attributable (each such statement, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expense Report</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Melinta shall respond promptly to Cidara&#8217;s questions regarding any Expense Report delivered hereunder or reasonable requests for supporting documentation, including, without limitation, copies of agreements or work orders for Specified Melinta Activities performed by Third Parties (from which copies Melinta may redact confidential or proprietary information that is not necessary for Cidara to ascertain Specified Melinta Expenses).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Royalties under Section 7.2 shall be calculated and reported for each calendar quarter and shall be paid within &#91;*&#93; of the end of the calendar quarter.  Each payment of royalties shall be accompanied or preceded by a report of Net Sales in sufficient detail to permit confirmation of the accuracy of the payment made, including, on a Product-by-Product basis, the number of each type of Product sold, gross sales, Net Sales and itemized deductions from gross sales (by major category as set forth in the definition of Net Sales), details of any Net Sales adjustments for any Combination Product, the amount of Specified Melinta Expenses deducted pursuant to Section 7.2.1, credits taken pursuant to Section 7.2.3 on a Third Party License-by-Third Party License, and royalties payable, in each case on a Product-by-Product basis.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Manner and Place of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All payment amounts specified in this Agreement are expressed in U.S. dollars, and all payments by Melinta to Cidara under this Agreement shall be paid in U.S. dollars.  All payments owed under this Agreement shall be made by Melinta by wire transfer of immediately available funds to a bank and account designated in writing by Cidara, unless otherwise specified in writing by Cidara.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Audits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta shall keep, and shall cause its Affiliates and Sublicensees to keep, complete and accurate records pertaining to Out-of-Pocket Expenses and to the sale or other disposition of Products, in each case, in sufficient detail to permit Cidara to confirm the accuracy of all reports </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">delivered pursuant to Section 8.1 and payments due hereunder, for at least &#91;*&#93; full calendar years following the end of the calendar year to which they pertain.  Cidara shall have the right, once annually, to cause an independent, certified public accountant reasonably acceptable to Melinta to audit such records to confirm Specified Melinta Expenses, Net Sales, royalties and the timing of achievement of Commercialization Milestone Events, for a period covering not more than the preceding &#91;*&#93; full calendar years.  No audited period shall be subject to audit under this Section 8.3 more than once.  Such audits may be exercised during normal business hours upon reasonable prior written notice to Melinta, but no more frequently than once per year.  The auditor will execute a reasonable written confidentiality agreement with Melinta and will disclose to Cidara only such information as is reasonably necessary to provide Cidara with information regarding any actual or potential discrepancies between amounts reported and actually paid and amounts payable under this Agreement, and between the reported timing and actual timing of achievement of Commercialization Milestone Events.  The auditor will send a copy of the report to Melinta at the same time it is sent to Cidara.  The report sent to both parties will include the methodology and calculations used to determine the results.  If such audit reveals that Melinta has failed to accurately report information pursuant to Section 8.1 or to make any payment (or portion thereof) when due under this Agreement, then Melinta, within 30 days after receipt of the final audit report, shall pay to Cidara any underpaid amounts due under this Agreement, together with interest on such underpaid or late amounts calculated in accordance with Section 8.5.  Cidara shall bear the full cost of such audit unless such audit discloses an underpayment by Melinta of more than &#91;*&#93; of the amount due by Melinta for any calendar year under this Agreement, in which case Melinta shall bear the full cost of such audit.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Where any amount to be paid by Melinta to Cidara hereunder is subject to any withholding or similar tax, the parties shall use Commercially Reasonable Efforts to conduct all such acts (including the execution of all such documents) to enable them to take advantage of any applicable double taxation agreement or treaty.  If there is no applicable double taxation agreement or treaty, or if an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, Melinta shall timely remit such withholding or similar tax to the appropriate Governmental Authority, and Melinta will promptly furnish Cidara with proof of payment of such withholding or similar taxes as well as any official receipts issued by the applicable Governmental Authority or other evidence as is reasonably requested to establish that such withholding or similar taxes have been paid.  Any such amounts deducted by Melinta in respect of such withholding or similar tax shall be treated as having been paid by Melinta for purposes of this Agreement.  Melinta will provide Cidara such assistance as is reasonably required to obtain a refund of the withheld or similar taxes, or to obtain a credit with respect to such taxes paid.  Notwithstanding the foregoing, the parties acknowledge and agree that if Melinta (or its Affiliates, successor or assignee) is required to make a payment to Cidara subject to deduction or withholding of taxes, as described in this Section 8.4, and if the obligation to deduct or withhold taxes arises, or if the amount of such taxes required to be deducted or withheld is increased solely as a result of any action taken by Melinta or its Affiliates or a successor or assignee, including the assignment or transfer of this Agreement by Melinta pursuant to Section 15.3 or otherwise, or there is a change, whether by corporate continuance, merger or other means, in the tax residency of Melinta, or payments arise or are deemed to arise through a branch of Melinta (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Withholding Tax Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then notwithstanding anything to the contrary herein, the payment by Melinta (in respect of which such obligation to deduct or withhold taxes is required) shall be increased by the amount necessary to ensure that Cidara receives an amount equal to the same amount that it would have received had no Withholding Tax Action occurred.  Except as otherwise provided in this Agreement, all payments due under this Agreement are exclusive of value added taxes, sales taxes, consumption taxes and other similar taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indirect Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Notwithstanding anything to the contrary in this Agreement, Melinta shall be responsible for any Indirect Taxes as well as any transfer, documentary, sales use, stamp, registration, value added or other similar tax that is imposed with respect to the payments or the related transfer of rights or other property pursuant to the terms of this Agreement.  If the Indirect Taxes originally paid or otherwise borne by the paying party are in whole or in part subsequently determined not to have been chargeable, all reasonably necessary steps will be taken by the receiving party to receive a refund of these undue Indirect Taxes from the applicable Governmental Authority and any amount of undue Indirect Taxes repaid by such Governmental Authority to the receiving party will be transferred to the paying party within 45 days of receipt.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Late Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that any payment due under this Agreement is not made when due, simple interest shall accrue on the late payment at a rate per annum that is &#91;*&#93; basis points (i.e., &#91;*&#93; percentage points) above the then-current prime rate quoted by Citibank in New York City (or such other rate and source as the parties mutually agree in writing) for the period from the due date for payment until the date of actual payment&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that (a) in no event shall such rate exceed the maximum legal annual interest rate&#59; and (b) the payment of such interest shall not limit Cidara from exercising any other rights it may have as a consequence of the lateness of any payment due hereunder.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:27.75pt;text-decoration:underline">CONFIDENTIALITY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to Section 9.2, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of a party shall mean any Information disclosed or furnished by or on behalf of such party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the other party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) or its representatives pursuant to this Agreement or under the Prior CDA, whether in written, oral, visual, electronic or other form.  During the Term, and for a period of seven (7) years following the expiration or earlier termination hereof (or, with respect to Confidential Information that is a trade secret of the Disclosing Party, until such trade secret no longer qualifies as a trade secret under Applicable Law), the Receiving Party shall maintain in confidence, and shall not disclose and shall not use for any purpose, other than as expressly provided for in this Agreement, any Confidential Information of the Disclosing Party.  The Receiving Party shall only permit access to Confidential Information to those directors, officers, employees, permitted Sublicensees (in the case of Melinta), agents, consultants, clinical investigators or contractors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of the Receiving Party and its Affiliates, who, in each case, (a) have a need to know such information for the purpose of the Receiving Party&#8217;s exercise of its rights and performance of its obligations under this Agreement, (b) have been advised by the Receiving Party of the Receiving Party&#8217;s obligations under this Agreement, and (c) are contractually or legally bound by obligations of nondisclosure and nonuse at least as stringent as those contained herein.  The Receiving Party shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own, but no less than reasonable care, to ensure that its, and its Affiliates&#8217;, Representatives do not disclose or make any unauthorized use of the Confidential Information.  The Receiving Party shall be responsible for any failure by any of its or its Affiliates&#8217; Representatives which, if committed by the Receiving Party, would be a breach of this Agreement.  The Receiving Party shall notify the Disclosing Party promptly upon discovery of any unauthorized use or disclosure of the Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exceptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Confidential Information shall not include any information that the Receiving Party can demonstrate&#58; (a) is, or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known or available in the public domain&#59; (b) is known by the Receiving Party at the time of receiving such information from the Disclosing Party, as evidenced by its contemporaneously-maintained written records, with no restrictions on its use or disclosure&#59; (c) is hereafter furnished to the Receiving Party on a non-confidential basis by a Third Party, as a matter of right (i.e., without breaching any obligation such Third Party may have to the Disclosing Party)&#59; or (d) is independently discovered or developed by the Receiving Party, independently of the activities undertaken by the Receiving Party pursuant to this Agreement and without the use of, reliance on, or reference to Confidential Information of the Disclosing Party, as evidenced by the Receiving Party&#8217;s contemporaneously-maintained written records.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Permitted Disclosures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Receiving Party may disclose Confidential Information as expressly permitted by this Agreement, or if and to the extent such disclosure is necessary in the following instances&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3.1&#160;&#160;&#160;&#160;filing or prosecuting Patent Rights as permitted by this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3.2&#160;&#160;&#160;&#160;exercising or enforcing the Receiving Party&#8217;s rights or performing the Receiving Party&#8217;s obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3.3&#160;&#160;&#160;&#160;prosecuting or defending litigation as permitted by this Agreement&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">35</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3.4&#160;&#160;&#160;&#160;complying with applicable court orders or Applicable Laws, or the listing rules of any exchange on which the Receiving Party&#8217;s or its Affiliate&#8217;s securities are traded&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3.5&#160;&#160;&#160;&#160;in Product Filings that the Receiving Party has the right to file or maintain, or holds, as expressly set forth in this Agreement and related correspondence with Regulatory Authorities with respect thereto&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3.6&#160;&#160;&#160;&#160;disclosure to the Receiving Party&#8217;s Affiliates and to Sublicensees (or, in the case of Cidara, licensees or sublicensees) and potential Sublicensees (or, in the case of Cidara, potential licensees or sublicensees) of the Receiving Party, who, in each case, need to know such information in order for the Receiving Party to exercise its rights or perform its obligations under this Agreement, provided, in each case, that any such Affiliate, or actual or potential Sublicensee, licensee or sublicensee, agrees to be bound by terms of confidentiality and non-use at least as restrictive as those set forth in this Article 9&#59; and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, further</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that Cidara shall have the right to disclose Confidential Information of Melinta to Mundipharma as necessary to comply with its obligations under the Mundipharma Agreement, subject to the confidentiality provisions of the Mundipharma Agreement (without the need for any addition or different confidentiality agreement between Cidara and Mundipharma)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.3.7&#160;&#160;&#160;&#160;disclosure to Third Parties in connection with due diligence or similar investigations by such Third Parties, and disclosure to potential Third Party investors or other financing sources in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations of confidentiality and non-use.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#8217;s Confidential Information pursuant to Section 9.3.3 or 9.3.4, it will, except where impracticable or legally impermissible, (i) give reasonable advance notice to the Disclosing Party of such disclosure, (ii) use efforts to secure confidential treatment of such information at least as diligent as the Receiving Party would use to protect its own confidential information, but in no event less than reasonable efforts, and (iii) cooperate with any efforts by the Disclosing Party, at the Disclosing Party&#8217;s request and expense, to secure confidential treatment of such Confidential Information.  Disclosure by the Receiving Party of Confidential Information in accordance with any of the foregoing provisions of this Section 9.3 shall not, in and of itself, cause the information so disclosed to cease to be treated as Confidential Information under this Agreement, except to the extent that, by virtue of disclosure by the Receiving Party in full compliance with this Section 9.3, such information becomes generally known or available.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Terms of this Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided in this Article 9, each party agrees not to disclose to any Third Party the terms of this Agreement without the prior written consent of the other party hereto, except that each party may disclose the terms of this Agreement that are otherwise made public as contemplated by Section 9.5 or to the extent such disclosure is permitted under Section 9.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Public Announcements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5.1&#160;&#160;&#160;&#160;The parties will agree on the content of a press release which may be issued by Cidara (or jointly by the parties), the release of which the parties will coordinate in order to accomplish the same promptly upon execution and delivery of this Agreement.  Except to the extent already disclosed in a press release or other public communication issued in accordance with this Agreement, no public announcement concerning this Agreement, its subject matter or the transactions described herein shall be made, either directly or indirectly, by either party or its Affiliates, except as may be required by Applicable Law (including disclosure requirements of the U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)), judicial order, or stock exchange or quotation system rule, without first obtaining the approval of the other party and agreement upon the nature, text and timing of such announcement, which approval and agreement shall not be unreasonably withheld or delayed.  The party desiring to make any such voluntary public announcement shall provide the other party with a written copy of the proposed announcement in reasonably sufficient time prior to public release to allow the other party to comment </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">36</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">upon such announcement, prior to public release.  In the case of press releases or other public communications required to be made by law, judicial order or stock exchange or quotation system rule, the party making such press release or public announcement shall provide to the other party a copy of the proposed press release or public announcement in written or electronic form upon such advance notice as is practicable under the circumstances for the purpose of allowing the notified party to review and comment upon such press release or public announcement.  Under such circumstances, the releasing party shall not be obligated to delay making any such press release or public communication beyond the time when the same is required to be made.  Neither party shall be required to seek the permission of the other party to repeat any information regarding the terms of this Agreement or any amendment hereto that has already been publicly disclosed by such party or by the other party in accordance with this Section 9.5.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5.2&#160;&#160;&#160;&#160;Each party may make public statements regarding this Agreement in response to questions by the press, analysts, investors or those attending industry conferences or financial analyst calls, provided that any such public statement or press release&#58; (a) is not inconsistent with prior public disclosures or public statements made in accordance with Section 9.5.1 or as permitted by Section 9.3&#59; and (b) does not reveal (i) information regarding the terms of this Agreement that have not previously been disclosed in accordance with Section 9.5.1 or as permitted by Section 9.3 or (ii) nonpublic information about the other party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.5.3&#160;&#160;&#160;&#160;The parties shall coordinate in advance with each other in connection with the filing of this Agreement (including redaction of certain provisions of this Agreement) with the SEC or other governmental agency or any stock exchange on which securities issued by a party or its Affiliate are traded, and neither party shall make any such filing unless the parties have mutually agreed upon the provisions to be redacted (such agreement not to be unreasonably withheld).  Each party shall use reasonable efforts to seek and obtain confidential treatment for the provisions of this Agreement that the parties mutually agree to redact from such filing&#59; provided that each party shall ultimately retain ultimate discretion to disclose such information to the SEC or any stock exchange or other governmental agency (as the case may be) as such party determines, based on advice of legal counsel, is required to be so disclosed.  Except as expressly set forth in this Article 9, neither party (or its Affiliates) shall be obligated to consult with or obtain approval from the other party with respect to any filings with the SEC or any stock exchange or other governmental agency where such filings do not disclose Confidential Information of the other party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Scientific Publications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party recognizes that publications regarding results of Clinical Studies and studies conducted as part of Medical Affairs Activities carried out under this Agreement and other information regarding Product, including oral or poster presentations and abstracts (each of the foregoing, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), may be beneficial to both parties provided such Publications are&#58; (a) subject to reasonable controls to protect Confidential Information&#59; and (b) do not conflict with Cidara&#8217;s obligations under Section 7.7 of the Mundipharma Agreement as applicable.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">INTELLECTUAL PROPERTY</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For clarity, the provisions of this Article 10 shall not apply to Mundipharma Licensed Patent Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership of Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Inventorship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Inventorship of Inventions shall be determined in accordance with U.S. patent laws&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that constructive reduction to practice through the mere filing or prosecution of a patent application shall not constitute inventorship or give rise to any ownership rights.  For purposes of this Agreement, and notwithstanding any other provision of this Agreement to the contrary, neither Cidara, nor any of its Affiliates, nor any of its or their respective Representatives shall be considered employees, contractors or consultants of Melinta.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Ownership of Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The ownership of all Inventions shall be determined based on the principles of inventorship in accordance with U.S. patent laws.  Cidara shall solely own all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Inventions made solely by one or more employees, consultants or contractors of Cidara or any of its Affiliates, including all intellectual property rights therein and thereto (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Melinta shall solely own all Inventions made solely by one or more employees, consultants or contractors of Melinta or any of its Affiliates, including all intellectual property rights therein and thereto (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The parties shall jointly own all Inventions made jointly by, on the one hand, one or more employees, consultants or contractors of Cidara or any of its Affiliates, and, on the other hand, one or more employees, consultants or contractors of Melinta or any of its Affiliates, including all intellectual property rights therein and thereto (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and all Patent Rights claiming Joint Inventions (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Each party hereby assigns to the other party, without additional consideration, an undivided one-half ownership interest in and to all Joint Inventions and Joint Patents.  Subject to the terms and conditions of this Agreement, and except to the extent that a party has granted the other party an exclusive license under such party&#8217;s joint ownership interest in Joint Inventions and Joint Patents, each party shall have the right to practice, and to grant licenses under, such party&#8217;s own joint ownership interest in Joint Inventions and Joint Patents without the other party&#8217;s consent, and shall have no duty to account to the other party for such practice or license, and each party hereby waives any right it may have under the laws of any country to require such consent or accounting.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party shall cause all of its and its Affiliates&#8217; Representatives who perform activities for such party under this Agreement to be under an obligation to assign their rights, including all rights to priority and rights to file patent applications and&#47;or register designs, in any Inventions and Patent Rights and other intellectual property right, whether or not patentable, resulting therefrom to such party to effectuate the terms and conditions set forth in Section 10.1.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.1.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disclosure of Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party will promptly disclose to the other party all Inventions, including all invention disclosure or other similar documents submitted to such party by its or its Affiliates&#8217; Representatives relating to such Inventions, and will also promptly respond to reasonable requests from the other party for additional information relating to such Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Prosecution and Maintenance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For purposes of this Section 10.2, except as otherwise provided below, the terms &#8220;prosecution&#8221; and &#8220;maintenance&#8221; (including variations such as &#8220;prosecute&#8221; and &#8220;maintain&#8221;) shall mean, with respect to a Patent Right, the preparation, filing, prosecution and maintenance (including payment of any patent annuity fees) of such Patent Right, as well as re-examinations, reissues, appeals, post grant reviews (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PGR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), inter partes reviews (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">IPR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) and requests for patent term adjustments and patent term extensions with respect to such Patent Rights, together with the initiation or defense of interferences, oppositions and other similar proceedings with respect to the particular Patent Right, and any appeals therefrom.  For clarification, &#8220;prosecution&#8221; and &#8220;maintenance&#8221; (including variations such as &#8220;prosecute&#8221; and &#8220;maintain&#8221;) shall not include any other enforcement actions taken with respect to a Patent Right.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Licensed Patent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt;text-decoration:underline">Licensed Patent Rights (Other Than Cidara General Manufacturing&#47;Formulation Patents)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#91;*&#93; shall have the first right, but not the obligation, to prosecute and maintain Licensed Patent Rights, other than Cidara General Manufacturing&#47;Formulation Patents, in the Territory, using counsel of its own choice, at &#91;*&#93; sole expense.  &#91;*&#93; shall keep &#91;*&#93; reasonably informed of progress with regard to the prosecution and maintenance of all Licensed Patent Rights, other than Cidara General Manufacturing&#47;Formulation Patents, in the Territory, including any requests for patent term adjustments, patent term extensions, supplementary protection certificates or their equivalents.  In addition, &#91;*&#93; shall promptly provide &#91;*&#93; with drafts of all proposed substantive filings and correspondence to any patent authority to the extent related to such Licensed Patent Rights in the Territory for &#91;*&#93; review and comment prior to the submission of such proposed filings and correspondence.  &#91;*&#93; shall consider in good faith &#91;*&#93; comments related to such Licensed Patent Rights prior to submitting such filings and correspondence, provided that &#91;*&#93; provides such comments within &#91;*&#93; of receiving the draft filings and correspondence from &#91;*&#93;.  Notwithstanding the foregoing, the parties shall mutually agree upon the Licensed Patent Rights to include in the Orange Book for the Product in the Territory, provided that if the parties disagree </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">38</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">on whether any Licensed Patent Rights should be included in the Orange Book for the Product in the Territory, then such Licensed Patent Rights will be included in the Orange Book for the Product in the Territory.  In the event that &#91;*&#93; seeks to abandon or cease the prosecution or maintenance of any Licensed Patent Right covered by this Section 10.2.1(a) in the Territory (without initiation of the prosecution and maintenance of a substitution therefor), &#91;*&#93; shall provide reasonable prior written notice to &#91;*&#93; of such intention to abandon or cease such prosecution or maintenance (which notice shall be given no later than &#91;*&#93; prior to the next deadline for any action that must be taken with respect to any such Licensed Patent Right in the U.S. Patent and Trademark Office &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">USPTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  In such case, at &#91;*&#93; sole discretion, upon written notice to &#91;*&#93; from &#91;*&#93;, &#91;*&#93; may elect to continue the prosecution and maintenance of any such Licensed Patent Right in &#91;*&#93; name, at &#91;*&#93; sole cost and expense and by counsel of its own choice, and &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt;text-decoration:underline">Cidara General Manufacturing&#47;Formulation Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Cidara shall have the sole right, but not the obligation, to prosecute and maintain the Cidara General Manufacturing&#47;Formulation Patents in the Territory using counsel of its own choice, at Cidara&#8217;s sole expense. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#91;*&#93; shall have the first right, but not the obligation, to control and manage the prosecution and maintenance of all Joint Patents &#91;*&#93;, at its sole cost and expense and by counsel of its own choice.  &#91;*&#93; shall consult with &#91;*&#93; as to the prosecution and maintenance of Joint Patents reasonably prior to any deadline or action with any patent office, and shall furnish to &#91;*&#93; copies of all relevant drafts and documents reasonably in advance of such consultation.  &#91;*&#93; shall keep &#91;*&#93; reasonably informed of progress with regard to the prosecution and maintenance of Joint Patents and shall provide to &#91;*&#93; copies of all material patent office submissions within a reasonable amount of time following submission thereof by &#91;*&#93;.  In the event that &#91;*&#93; desires to abandon or cease the prosecution or maintenance of any Joint Patent in any country (without initiation of the prosecution and maintenance of a substitution therefor), &#91;*&#93; shall provide reasonable prior written notice to &#91;*&#93; of such intention to abandon (which notice shall, to the extent possible, be given no later than &#91;*&#93; prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office).  In such case, at &#91;*&#93; sole discretion, upon written notice to &#91;*&#93; from &#91;*&#93;, &#91;*&#93; may elect to continue the prosecution and maintenance of any such Joint Patent, at its sole cost and expense and by counsel of its own choice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation of the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party agrees to cooperate fully in the preparation, filing, prosecution and maintenance of Patent Rights pursuant to Section 10.2.  Such cooperation includes, but is not limited to&#58; (a) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as to effectuate the ownership of Inventions set forth in Section 10.1, and Patent Rights claiming or disclosing such Inventions, and to enable the other party to apply for and to prosecute patent applications in any country as permitted by Section 10.2, and (b) promptly informing the other party of any matters coming to such party&#8217;s attention that may affect the prosecution and maintenance of any such patent applications.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Third Party Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Each party shall notify the other party in writing within &#91;*&#93; (except as expressly set forth below) of becoming aware of any alleged or threatened infringement by a Third Party of any Licensed Patent Right or Joint Patent (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), including (a) any such alleged or threatened Infringement on account of a Third Party&#8217;s manufacture, use, import, offer for sale or sale of Products in the Field, and (b) any certification filed in the United States under 21 U.S.C. &#167;355(b)(2) or 21 U.S.C. &#167;355(j)(2) or similar provisions in other jurisdictions in connection with an ANDA (an Abbreviated New Drug Application in the United States or a comparable application for marketing approval under Applicable Law in any country other than the United States) or other NDA or MAA for a Product in the Field (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Certification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) ((a) and (b), collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Competitive Infringement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that each party shall notify the other party of any Patent Certification regarding any Licensed Patent Right or Joint Patent that it receives, and such party shall provide the other party with a copy of such Patent Certification, within &#91;*&#93; of receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Patents Other Than Cidara General Manufacturing&#47;Formulation Patent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  &#91;*&#93; shall have the first right, but not the obligation, to bring and control any action or proceeding </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">39</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">with respect to Competitive Infringement in the Field in the Territory of any Licensed Patent Right other than a Cidara General Manufacturing&#47;Formulation Patent, at its own expense and by counsel of its own choice, and &#91;*&#93; shall have the right, at its own expense, to be represented in any such action by counsel of its own choice at its own expense.  At &#91;*&#93; request, &#91;*&#93; shall join any action or proceeding brought by &#91;*&#93; under this Section 10.4.1, and &#91;*&#93; shall reimburse &#91;*&#93; cost and expenses, provided &#91;*&#93; is represented by counsel reasonably acceptable to &#91;*&#93;, and &#91;*&#93; hereby agrees that both &#91;*&#93; are acceptable to &#91;*&#93;.  If &#91;*&#93; fails to bring any such action or proceeding within (i) &#91;*&#93; following the notice of alleged infringement, or (ii) &#91;*&#93; before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, then &#91;*&#93; shall have the right to bring and control any such action, at its own expense and by counsel of its own choice, and &#91;*&#93; shall have the right, at its own expense, to be represented in any such action by counsel of its own choice.  &#91;*&#93; shall have the sole right, but not the obligation, to bring and control any action or proceeding with respect to Infringement of any such Licensed Patent Right, other than Competitive Infringement in the Field in the Territory, at its own expense and by counsel of its own choice, &#91;*&#93;.  Each party shall keep the other party reasonably informed of the status and progress of any action or proceeding brought by such party with respect to Competitive Infringement in the Field in the Territory of any Licensed Patent Right other than a Cidara General Manufacturing&#47;Formulation Patent, and shall provide the other party with drafts of all proposed substantive filings in such action or proceeding reasonably in advance of making such filings and consider the other party&#8217;s comments on such filings in good faith.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara General Manufacturing&#47;Formulation Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Cidara shall have the sole right, but not the obligation, to bring and control any action or proceeding with respect to Infringement of any Cidara General Manufacturing&#47;Formulation Patent, at its own expense and by counsel of its own choice.  With respect to any action or proceeding with respect to Competitive Infringement in the Field in the Territory of any Cidara General Manufacturing&#47;Formulation Patent, &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Joint Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta shall have the first right, but not the obligation, to bring and control any action or proceeding to enforce any Joint Patent with respect to Competitive Infringement in the Field in the Territory, at its own expense and by counsel of its own choice, and Cidara shall have the right, at its own expense, to be represented in any such action by counsel of its own choice.  Cidara shall have the first right, but not the obligation, to bring and control any action or proceeding to enforce any Joint Patent with respect to Competitive Infringement in the Field outside of the Territory, at its own expense and by counsel of its own choice, and Melinta shall have the right, at its own expense, to be represented in any such action by counsel of its own choice.  If the party having the first right to bring and control any action or proceeding to enforce any Joint Patent under this Section 10.4.2 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">First Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) fails to bring and control any such action or proceeding within (i) &#91;*&#93; following the notice of alleged infringement, or (ii) &#91;*&#93; before the time limit, if any, set forth in the appropriate laws and regulations for the filing of such actions, whichever comes first, then the other party shall have the right to bring and control any such action, at its own expense and by counsel of its own choice, and the First Party shall have the right, at its own expense, to be represented in any such action by counsel of its own choice.  In the case of Infringement of a Joint Patent, other than Competitive Infringement, the parties shall mutually agree in good faith on a case-by-case basis whether to jointly bring and control any action or proceeding to enforce such Joint Patent, or whether one party will bring and control any action or proceeding to enforce such Joint Patent, and, in each case, how the costs and expenses of such action or proceeding, and any recovery from such action or proceeding, will be allocated between the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event a party brings an infringement action in accordance with this Section 10.4 (such party, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the other party shall cooperate fully, including, if required to bring such action, the furnishing of a power of attorney or being named as a party.  The Enforcing Party shall not enter into any settlement or compromise of any action under this Section 10.4 that would impose any cost or liability on the other party, or admit the invalidity or unenforceability of any Patent Controlled by the other party, without such other party&#8217;s prior written consent, which may be withheld in such other party&#8217;s sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Recoveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise agreed by the parties in connection with a cost-sharing arrangement, any recovery as a result of any action or proceeding pursuant to this Section 10.4, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">whether by way of settlement or otherwise, shall first be used to reimburse the Enforcing Party for its documented, unreimbursed out-of-pocket costs and expenses (including court, attorneys&#8217; and professional fees) incurred in connection with such action or proceeding and then, following payment in full of all such costs to the Enforcing Party, to reimburse the non-Enforcing Party for its documented, unreimbursed out-of-pocket costs and expenses (including court, attorneys&#8217; and professional fees) incurred in connection with such action or proceeding.  Any remainder of the recovery after reimbursement of the litigation costs and expenses of the parties (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Remainder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall be retained by the Enforcing Party&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;any Remainder of a recovery realized by &#91;*&#93; as a result of any action brought and controlled by &#91;*&#93; pursuant to Section 10.4.1(a) or Section 10.4.2 that is specifically attributable to Competitive Infringement of a Licensed Patent Right or Joint Patent, shall be allocated as follows&#58; (A) to the extent it represents compensatory damages for such Competitive Infringement, &#91;*&#93;&#59; and (B) to the extent it represents special, exemplary, punitive, consequential or other noncompensatory damages (including treble damages) for such Competitive Infringement, &#91;*&#93;&#59; and in each case &#91;*&#93;&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;any Remainder of a recovery realized by &#91;*&#93; as a result of any action brought and controlled by &#91;*&#93; pursuant to Section 10.4.1(b) that is specifically attributable to Competitive Infringement of a Cidara General Manufacturing&#47;Formulation Patent, shall be allocated as follows&#58; (A) to the extent it represents compensatory damages for such Competitive Infringement, &#91;*&#93;&#59; and (B) to the extent it represents special, exemplary, punitive, consequential or other noncompensatory damages (including treble damages) for such Competitive Infringement, &#91;*&#93;&#59; and in each case &#91;*&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.4.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Other Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Cidara shall have the sole right, in its sole discretion, to enforce any Licensed Patent Right, &#91;*&#93; against any infringement that is not a Competitive Infringement in the Territory, and to retain all related recoveries.  If there is any infringement of any Joint Patent that is not a Competitive Infringement, then the parties shall mutually agree in good faith on a case-by-case basis whether to jointly bring and control any action or proceeding to enforce such Joint Patent, or whether one party will bring and control any action or proceeding to enforce such Joint Patent, and, in each case, how the costs and expenses of such action or proceeding, and any recovery from such action or proceeding, will be allocated between the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Term Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta shall have the sole discretion, after consultation with Cidara, to determine which Licensed Patent Rights (other than Cidara General Manufacturing&#47;Formulation Patents) or Joint Patents, if any, are extended with respect to any Product in the Territory pursuant to U.S. Drug Price Competition and Patent Term Restoration Act of 1984.  Cidara and Melinta shall each cooperate and use reasonable efforts to gain any such patent term extension in the Territory permitted under this Section 10.6.  All filings for such extensions shall be made by the party responsible for the prosecution of such Patent Rights.  For clarity, and notwithstanding the foregoing or any other provision of this Agreement, Melinta shall have no right to extend any Cidara General Manufacturing&#47;Formulation Patent with respect to a Product, and Cidara shall have no obligation to allow, or consider allowing, any Cidara General Manufacturing&#47;Formulation Patent to be extended with respect to any Product.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Patent Marking</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta shall mark (or cause to be marked) Product marketed and sold hereunder with appropriate Licensed Patent Right numbers or indicia to the extent required by Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta shall have the right to select the Product-specific trademark for use in connection with the marketing and sale of Product in the Territory (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), which may, but need not, be the Cidara Product Trademark.  Melinta shall consider in good faith Cidara&#8217;s suggestions regarding the selection of the Product Trademark but shall retain ultimate discretion as to such selection.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">41</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Cidara hereby assigns to Melinta all rights in and to the Cidara Product Trademark in the Territory.  During the Term, Melinta shall not use (or cause or permit any Affiliate or Sublicensee to use) the Cidara Product Trademark outside of the Territory.  Melinta shall be responsible for the failure by its Affiliates and Sublicensees to comply with this Section 10.7.1(a), including all relevant restrictions, limitations and obligations.  For so long as Melinta continues to use the Cidara Product Trademark with the Commercialization of the Product in the Territory, Melinta shall use Commercially Reasonable Efforts to prosecute and maintain the Cidara Product Trademark, and protect the goodwill associated with or attached to the Cidara Product Trademark.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Use of Other Product Trademark</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Melinta elects to use a Product Trademark other than the Cidara Product Trademark in connection with the marketing and sale of Product in the Territory, Melinta shall own all right, title and interest in and to such Product Trademark, and all goodwill associated with or attached to such Product Trademark arising out of the use thereof by Melinta, its Affiliates and Sublicensees shall vest in and inure to the benefit of Melinta.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.7.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event that Melinta elects to use the Cidara Product Trademark, each party shall promptly notify the other party in writing upon becoming aware of any infringement of the Cidara Product Trademark in the Territory.  Melinta shall control the enforcement of the Cidara Product Trademark in the Territory at its expense.  If Melinta uses a Product Trademark other than the Cidara Product Trademark in the Territory, Melinta shall control the enforcement of the Product Trademark in the Territory at its expense.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expiration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) shall begin on the Effective Date and, subject to earlier termination in accordance with Section 11.2 or Section 11.3, expire on the expiration of Melinta&#8217;s obligation to pay royalties to Cidara under Section 7.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Following such expiration (but not termination) of this Agreement Melinta shall have a fully paid-up, non-exclusive license under the Licensed Know-How to conduct research and to develop, make, have made, use, sell, offer for sale and import the Product in the Territory for use in the Field.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination by Melinta</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Following the first (1st) anniversary of the Effective Date, Melinta may terminate this Agreement, in its sole discretion, upon 90 days prior written notice to Cidara.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination for Material Breach</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Either party may terminate this Agreement upon written notice to the other party if such other party has materially breached any of its obligations (including a failure to perform with respect thereto) under this Agreement and has not cured such breach within 60 days (or 30 days with respect to any payment breach) after notice from the non-breaching party requesting cure of such breach&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, &#91;*&#93;.  Unless the breaching party has cured or remedied any such breach prior to the expiration of the applicable period, such termination shall become effective upon the breaching party&#8217;s receipt of the written notice of termination.  If the alleged breaching party contests in good faith the existence or materiality of any alleged non-payment breach, or the failure to cure, during any cure period, and initiates the dispute resolution procedure in accordance with Article 14, then the non-breaching party shall not have the right to terminate this Agreement under this Section 11.3, and the applicable cure period shall be tolled, until such dispute has been resolved in accordance with Article 14 with a determination that the breaching party has materially breached its obligations under this Agreement.  During the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the parties shall continue to perform all of their respective obligations hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent not prohibited under Applicable Law, Cidara shall have the right to terminate this Agreement upon &#91;*&#93; prior written notice to Melinta if Melinta or any of its Affiliates or Sublicensees, directly or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Licensed Patent Right, provided that if such proceeding is commenced by a Sublicensee of Melinta, then </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">42</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Cidara may not terminate this Agreement upon &#91;*&#93; prior written notice to Melinta pursuant to this Section 11.4 if Melinta either (a) terminates the rights of the relevant Sublicensee with respect to this Agreement or (b) causes such Sublicensee to, and such Sublicensee actually does, withdraw any such proceeding, in each case, within &#91;*&#93; after receipt by Melinta of such notice.  &#91;*&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Effect of Expiration or Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Upon termination (but not expiration) of this Agreement by either party pursuant to Section 11.2, 11.3 or 11.4, (a) all rights and licenses granted to Melinta hereunder shall immediately terminate and be of no further force and effect, (b) if this Agreement is terminated by Cidara pursuant to Section 11.3 or 11.4, each Sublicense granted by Melinta shall survive such termination and shall become a direct license by Cidara to such Sublicensee of Melinta, having the same scope as such Sublicense (and no greater than the rights granted by Cidara to Melinta hereunder), and on terms and conditions no less favorable to such Sublicensee than the terms and conditions of this Agreement, provided that (i) such Sublicensee is in good standing and is not in default of such Sublicense or any applicable obligations under this Agreement, and such Sublicensee is not a party in the applicable proceeding described in Section 11.4, (ii) if this Agreement is terminated by Cidara, such Sublicensee agrees in writing to be bound by the terms and conditions of such direct license, and (iii) Cidara will have no obligations under such direct license beyond those expressly set forth in this Agreement, and (c) if this Agreement is terminated by Melinta pursuant to Section 11.2, or by Cidara pursuant to Section 11.3 or 11.4, &#91;*&#93;, provided that &#91;*&#93;.  Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions of Sections 3.2, 9, 10, 11, 12 and 14 shall survive the expiration or termination of this Agreement.  Without limiting the foregoing, the parties will reasonably cooperate to effect a smooth transition following the effective date of termination of this Agreement, and Melinta shall&#58; (A) transfer or assign, or cause to be transferred or assigned, to Cidara or its designee (or to the extent not so assignable, take all reasonable actions to make available to Cidara or its designee the benefits of) all Product Filings in the Field in the Territory, whether held in the name of Melinta, its Affiliate or Sublicensee&#59; provided that prior to the effectiveness of the assignment of any Product Filing in the Field in the Territory that is not for a Lead Indication, the parties shall mutually agree upon the commercially reasonable compensation to be paid by Cidara to Melinta for such assignment, and if the parties are unable to reach agreement on such compensation, then the matter will be submitted for binding arbitration under Section 14.3, (B) either promptly wind-down any ongoing Development activities with respect to Products in an orderly fashion or promptly transition such Development activities to Cidara or its designee&#59; in each case, with due regard for patient safety and in compliance with all Applicable Laws&#59; (C) facilitate a smooth, orderly and prompt transition of any or all ongoing Manufacture and Commercialization activities with respect to Product to Cidara or its designee(s), and if Melinta had assumed responsibility for the Manufacture of Compound and Product and supply to Cidara, its Affiliates and licensees outside the Territory, use Commercially Reasonable Efforts to supply such quantities of Compound and Product as Cidara may reasonably require for the Development and Commercialization of Product in the Field, until &#91;*&#93;&#59; (D) transfer to Cidara all of Melinta&#8217;s right, title and interest in and to any and all Data Controlled by Melinta or any of its Affiliates relating to the Compound or Products, and provide a copy of the material tangible embodiments of such Data, any Melinta Grantback Know-How and any other material books, records, files and documents Controlled by Melinta to the extent related to the Compound or Products &#91;*&#93;&#59; and (E) transfer or assign, or cause to be transferred or assigned, to Cidara or its designee the Cidara Product Trademark, whether held in the name of Melinta, its Affiliate or Sublicensee.  Each party will execute all documents, or cause to be executed all documents, and take, or cause to be taken, all such further actions as may be reasonably requested by the other party in order to give effect to the foregoing clauses.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">INDEMNIFICATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Melinta</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Melinta hereby agrees to indemnify, defend and hold Cidara and its Affiliates and their respective directors, officers, employees and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Cidara Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any and all liabilities, expenses and&#47;or loss, including reasonable legal expense and attorneys&#8217; fees (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Losses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), to which any Cidara Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the extent such Losses arise directly or indirectly out of&#58; (a) the practice by Melinta or any of its Affiliates or Sublicensees of the License&#59; (b) the Development, Manufacture, use, Commercialization or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">43</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">exploitation of Compound or Product by or on behalf of Melinta or any of its Affiliates or Sublicensees&#59; (c) the breach by Melinta of any provision of this Agreement or the PV Agreement (including any warranty, representation, covenant or agreement made by Melinta herein or therein)&#59; (d) the negligence or willful misconduct of any Melinta Indemnitee (defined below), or (e) any negligent or willful misconduct act or omission of Melinta, its Affiliate, Sublicensee or Third Party contractor that causes Cidara to be in material breach of, or non-compliance with, the Mundipharma Agreement to the extent provided in Section 3.7&#59; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Cidara Indemnitee or the breach by Cidara of any provision of this Agreement, the PV Agreement or the Supply Agreement (including any warranty, representation, covenant or agreement made by Cidara herein or therein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnification by Cidara</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Cidara hereby agrees to indemnify, defend and hold Melinta and its Affiliates and their respective directors, officers, employees and agents (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Melinta Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) harmless from and against any and all Losses to which any Melinta Indemnitee may become subject as a result of any Claim to the extent such Losses arise directly or indirectly out of&#58; (a) the practice by Cidara or any of its Affiliates or Sublicensees of the Melinta Grantback License&#59; (b) the Development, Manufacture or use of Compound or Product by or on behalf of Cidara or any of its Affiliates or licensees prior to the Effective Date&#59; (c) the Development, Manufacture, use, Commercialization or other exploitation of Compound or Product by or on behalf of Cidara or any of its Affiliates or Third Party licensees outside the Territory&#59; (d) the performance by or on behalf of Cidara of the Development Plan&#59; (e) the breach by Cidara of any provision of this Agreement or the PV Agreement (including any warranty, representation, covenant or agreement made by Cidara herein or therein)&#59; or (f) the negligence or willful misconduct of any Cidara Indemnitee&#59; except, in each case, to the extent such Losses result from the negligence or willful misconduct of any Melinta Indemnitee or the breach by Melinta of any provision of this Agreement or the PV Agreement (including any warranty, representation, covenant or agreement made by Melinta herein or therein).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Procedure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event a party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnified Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) seeks indemnification for any Claim under Section 12.1 or 12.2, the Indemnified Party shall&#58; (a) inform the other party (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Indemnifying Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of such Claim as soon as reasonably practicable after it receives notice of the Claim (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of a Claim as provided in this Section 12.3 shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually damaged as a result of such failure to give notice)&#59; (b) permit the Indemnifying Party to assume direction and control of the defense of the Claim (including the right to settle the Claim solely for monetary consideration)&#59; and (c) cooperate as requested (at the expense of the Indemnifying Party) in the defense of the Claim.  If the Indemnifying Party does not assume control of such defense within 15 days after receiving notice of the Claim from the Indemnified Party, the Indemnified Party may control such defense and, without limiting the Indemnifying Party&#8217;s indemnification obligations, the Indemnifying Party shall reimburse the Indemnified Party for all reasonable and documented costs, including reasonable attorney fees, incurred by the Indemnified Party in defending itself within 30 days after receipt of any invoice therefor from the Indemnified Party.  The party not controlling such defense may participate therein at its own expense.  The party controlling such defense shall keep the other party advised of the status of such Claim and the defense thereof and shall consider recommendations made by the other party with respect thereto.  The Indemnified Party shall not agree to any settlement of such Claim without the prior written consent of the Indemnifying Party.  The Indemnifying Party shall not agree to any settlement of such Claim or consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party and its associated indemnitees (i.e., Cidara Indemnitees or Melinta Indemnitees, as applicable) from all liability with respect thereto, that imposes any liability or obligation on the Indemnified Party or that acknowledges fault by the Indemnified Party without the prior written consent of the Indemnified Party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">FORCE MAJEURE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each party shall be held excused from liability to the other party for failure or delay in fulfilling or performing any of its obligations under this Agreement (other than payment obligations to the other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">party) to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected party, including but not limited to fire, floods, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, pandemics, endemics, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any Governmental Authority, or any other event similar to those enumerated above.  Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the party has not caused such event(s) to occur.  The affected party shall provide written notice of any of its failure or delay in performance due to force majeure to the other party within 10 days after its occurrence.  All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">DISPUTE RESOLUTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exclusive Dispute Resolution Mechanism</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties agree that, except as expressly set forth in Article 4 or Section 14.4, the procedures set forth in this Article 14 shall be the exclusive mechanism for resolving any dispute, controversy, or claim between the parties that may arise from time to time pursuant to, arising out of or in connection with this Agreement, including any party&#8217;s rights or obligations hereunder or any questions regarding the formation, existence, validity, enforceability, performance, interpretation, tort, breach or termination hereof (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that cannot be resolved through good faith negotiation between the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Resolution by Senior Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of any Dispute, the parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation.  In the event that such Dispute is not resolved through such negotiation within 30 days after either party&#8217;s request, either party may, by written notice to the other party, refer the Dispute for attempted resolution by good faith negotiation between the Senior Executives within 30 days after such notice is received.  Except as set forth in Section 14.4, if any Dispute is not resolved by the Senior Executives within the above 30-day period, either party may, in its sole discretion, seek resolution of such Dispute in accordance with Section 14.3, and each party hereby expressly waives its right to seek resolution of such Dispute in a court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3.1&#160;&#160;&#160;&#160;Except for any Section 14.4 Matter (which shall be resolved solely in accordance with Section 14.4), with respect to any Disputes that are not resolved by the Senior Executives in accordance with Section 14.2, the Dispute shall be submitted by either party for resolution in arbitration administered by the American Arbitration Association (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AAA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) pursuant to its then current Commercial Arbitration Rules (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">AAA Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), except where they conflict with this Section 14.3, in which case this Section 14.3 shall control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3.2&#160;&#160;&#160;&#160;The arbitration shall be conducted in accordance with the AAA Rules by an arbitral tribunal of three neutral arbitrators&#59; provided that&#58; (i) no such arbitrator shall be current or former employee or director, or current stockholder, of either party, any of their respective Affiliates or any (sub)licensee&#59; (ii) each arbitrator shall have experience and familiarity with commercial licensing practices in the pharmaceutical and biotechnology industries&#59; and (iii) each arbitrator shall be a lawyer with at least 15 years&#8217; experience with a law firm or corporate law department of over 25 lawyers or who was a judge of a court of general jurisdiction.  Each party shall be entitled to nominate one arbitrator.  The other party may object to the nomination on grounds of bias, lack of subject matter experience, or any other legitimate grounds.  AAA will be the final decision maker if there is a dispute over the objection.  Once the party-nominated arbitrators are established, the two party-nominated arbitrators shall nominate a third arbitrator, who shall act as chairperson.  Each arbitrator shall abide by the Code of Ethics for Arbitrators in Commercial Disputes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3.3&#160;&#160;&#160;&#160;The seat, or legal place, of arbitration shall be New York, New York, and the language used in any such proceeding shall be English.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">45</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3.4&#160;&#160;&#160;&#160;Any arbitration conducted pursuant to the terms of this Agreement shall be governed by the Federal Arbitration Act (9 U.S.C. &#167;&#167; 1 et.  seq.).  The arbitrator(s) shall be guided, but not bound, by the CPR Protocol on Disclosure of Documents and Presentation of Witnesses in Commercial Arbitration (www.cpradr.org) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Protocol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  The parties will attempt to agree on modes of document disclosure, electronic discovery, witness presentation, etc.  within the parameters of the Protocol.  If the parties cannot agree on discovery and presentation issues, the arbitrator(s) shall decide on presentation modes and provide for discovery within the Protocol, understanding that the parties contemplate reasonable discovery.  The arbitral tribunal shall, in rendering an award, apply the substantive law of the State of New York, without giving effect to any conflicts of law provisions thereof that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction, and without giving effect to any of its rules or laws relating to arbitration.  The award shall include a written statement describing the essential findings and conclusions upon which the award is based, including the calculation of any damages awarded.  The arbitral tribunal&#8217;s authority to award special, incidental, consequential or punitive damages or lost profits shall be subject to the limitation set forth in Section 2.5, except to the extent the substantive laws of the State of New York, do not permit such limitation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3.5&#160;&#160;&#160;&#160;Except to the extent necessary to confirm or enforce an award or as may be required by Applicable Law, neither a party nor the arbitral tribunal may disclose the existence, content, or results of an arbitration without the prior written consent of both parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3.6&#160;&#160;&#160;&#160;The award rendered by the arbitral tribunal shall be final, binding and non-appealable (subject only to the parties&#8217; right to request correction of any errors in computation, clerical or typographical errors, or other errors of a similar nature, and the arbitral tribunal&#8217;s right to make any such correction on its own initiative, in each case, in accordance with the AAA Rules), and judgment upon the award may be entered in any court of competent jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.3.7&#160;&#160;&#160;&#160;Each party shall bear its own costs and attorney&#8217;s fees, and the parties shall equally bear the fees, costs, and expenses of the arbitrators and the arbitration proceedings, including costs and expenses of translators for the arbitration proceedings&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that the arbitrators may exercise discretion to award arbitration costs and translation costs, excluding attorney&#8217;s fees, to the prevailing party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Expedited Dispute Resolution of Certain Matters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event the JSC is unable to (a)&#160;make either a unanimous &#91;*&#93; in accordance with Section 5.1.1(a), or (b)&#160;make either a unanimous &#91;*&#93; in accordance with Section 5.1.1(b) (in each case (clauses&#160;(a) and (b)), a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 14.4 Matter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and the Senior Executives cannot resolve such Section 14.4 Matter within 30 days of the date such Section 14.4 Matter is first referred to them, then, upon the written request of either party, such Section 14.4 Matter will be referred to a neutral Third Party expert with relevant experience and expertise in performing cost-benefit analysis with respect to pharmaceutical development activities (e.g., IQVIA, L.E.K.) mutually agreed to by the parties in good faith (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Independent Expert</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; provided that if the parties are unable to reach agreement as to the Independent Expert, then each party shall promptly designate one neutral Third Party expert with such experience and expertise, and such experts shall select the Independent Expert by mutual agreement.  Within 10&#160;days following selection of the Independent Expert, each party shall submit to the Independent Expert&#58; (i)&#160;as applicable, (A)&#160;such party&#8217;s position as to whether the Independent Expert should make an &#91;*&#93; or (B)&#160;such party&#8217;s position as to whether the Independent Expert should make an &#91;*&#93;&#59; and (ii)&#160;such party&#8217;s written argument, not to exceed five pages in length, in favor of the reasonableness of its position (collectively (clauses&#160;(i) and (ii), such party&#8217;s &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Proposed Resolution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; of the applicable Section 14.4 Matter).  Within 15&#160;days following submission of the parties&#8217; respective Proposed Resolutions of such Section 14.4 Matter to the Independent Expert, the Independent Expert shall issue a written determination selecting the one (and only one) of such Proposed Resolutions that the Independent Expert determines to be the more reasonable of the two.  The Proposed Resolution selected by the Independent Expert shall be final and binding upon the parties, and determination of the Independent Expert shall be deemed, in the case of clause&#160;(A), as applicable, &#91;*&#93; in each case, based on the Proposed Resolution selected by the Independent Expert.  The Independent Expert&#8217;s sole authority shall be to select one of the Proposed Resolutions of such Section 14.4 Matter, as proposed by the applicable party, without </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">modification.  If one of the parties fails to submit its Proposed Resolution within 10&#160;days after the selection of the Independent Expert, then, provided the other party submitted its Proposed Resolution within such 10-day period, the Independent Expert must select the latter&#8217;s Proposed Resolution.  The parties shall share the fees and costs of the Independent Expert equally, regardless of which party&#8217;s Proposed Resolution is selected by the Independent Expert.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Injunctive Relief&#59; Court Actions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Either party may apply to the arbitral tribunal for interim injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved.  Either party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or other equitable relief in the context of a bona fide emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding any ongoing discussions between the parties or any ongoing arbitration proceeding.  In addition, either party may bring an action in any court of competent jurisdiction to resolve disputes pertaining to the scope, construction, validity, and enforceability of any patent, and no such claim shall be subject to arbitration pursuant to Section 14.3.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;padding-left:22.25pt;text-decoration:underline">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any consent, notice or report required or permitted to be given or made under this Agreement by one of the parties hereto to the other party shall be in writing, delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier, to the other party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise provided in this Agreement).  Notice shall be deemed sufficiently given for all purposes upon the earliest of&#58; (a) the date of actual receipt&#59; or (b) if delivered by overnight courier, the next business day the overnight courier regularly makes deliveries.</font></div><div style="padding-left:144pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Cidara&#58;&#160;&#160;&#160;&#160;6310 Nancy Ridge Dr.</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Suite 101</font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">San Diego, CA 92121 </font></div><div style="padding-left:216pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  General Counsel </font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">If to Melinta&#58;&#160;&#160;&#160;&#160;44 Whippany Road</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Suite 280</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Morristown, NJ 07960</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Attention&#58;  General Counsel</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law principles thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as expressly provided hereunder, neither party shall assign or otherwise transfer this Agreement or any of its rights or obligations hereunder without the prior written consent of the other party (which consent shall not be unreasonably withheld, conditioned or delayed)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that a party may, without such consent, assign this Agreement and its rights and obligations hereunder without the other party&#8217;s consent (a) to any Affiliate of such party, provided that the assigning party shall remain liable and responsible to the non-assigning party hereto for the performance and observance of all such duties and obligations by such Affiliate&#59; or (b) in connection with the transfer or sale of all or substantially all of such party&#8217;s business to which this Agreement relates, whether by merger, sale of stock, sale of assets or otherwise&#59; provided that in the event of a transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), the intellectual property rights of the acquiring party to such transaction (if other than one of the parties to this Agreement) shall not be included in the technology licensed hereunder or otherwise subject to this Agreement.  The rights and obligations of the parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the parties, and the name of a party appearing herein shall be deemed to include the name of such party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Section 15.3.  Any assignment not in accordance with this Agreement shall be void.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">47</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:95.76pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waivers and Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No change, modification, extension, termination or waiver of this Agreement, or any of the provisions herein contained, shall be valid unless made in writing and signed by duly authorized representatives of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement embodies the entire agreement between the parties and supersedes any prior representations, understandings and agreements between the parties regarding the subject matter hereof.  There are no representations, understandings or agreements, oral or written, between the parties regarding the subject matter hereof that are not fully expressed herein.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Any of the provisions of this Agreement which are determined to be invalid or unenforceable in any jurisdiction shall be ineffective to the extent of such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable the remaining provisions hereof and without affecting the validity or enforceability of any of the terms of this Agreement in any other jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The waiver by either party hereto of any right hereunder or the failure to perform or of a breach by the other party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar nature or otherwise.  Any waiver by a party of a particular provision or right shall be in writing, shall be as to a particular matter and, if applicable, for a particular period of time and shall be signed by an authorized representative of such party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Relationship Between the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors.  This Agreement does not create any partnership, joint venture or similar business relationship between the parties.  Neither party is a legal representative of the other party, and neither party shall assume or create, or purport to assume or create, any obligation, representation, warranty or guarantee, express or implied, on behalf of the other party for any purpose whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">No Third Party Beneficiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement is neither expressly nor impliedly made for the benefit of any party other than those executing it.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction.  All references in this Agreement to the singular shall include the plural where applicable.  The word &#8220;including&#8221; (and variations thereof) as used in this Agreement means including, without limiting the generality of any description preceding such term, and the word &#8220;or&#8221; has the inclusive meaning represented by the phrase &#8220;and&#47;or.&#8221;  Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection.  All references to days in this Agreement shall mean calendar days, unless otherwise specified.  Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either party, irrespective of which party may be deemed to have caused the ambiguity or uncertainty to exist.  This Agreement has been prepared in the English language and the English language shall control its interpretation.  In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral or other communications between the parties regarding this Agreement shall be in the English language.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in counterpart signature pages with the same effect as if both parties had signed the same signature page.  All such counterparts shall be deemed an original and shall, together with this Agreement in its entirety, constitute one and the same instrument.  Signatures to this Agreement transmitted by facsimile, by email in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;), or by any other means of electronic signature (including DocuSign) shall have the same effect as physical delivery of the paper document bearing original signature.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48</font></div><div><font><br></font></div></div></div><div id="i408bcc55b9e2401cbd5323c90a158ba2_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties have executed this Agreement effective as of the Effective Date.</font></div><div style="margin-bottom:24pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Melinta Therapeutics, LLC</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Christine Miller</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Christine Miller</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title President &#38; CEO</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font><br></font></div><div style="margin-bottom:24pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Cidara Therapeutics, Inc.</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58; &#47;s&#47; Jeff Stein </font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Name&#58; Jeff Stein</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title President &#38; CEO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">277176373 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><div id="i408bcc55b9e2401cbd5323c90a158ba2_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">LICENSED PATENT RIGHTS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="background-color:#d9d9d9;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:31.134%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:143%">277176373 v1</font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.843%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.978%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.025%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><div id="i408bcc55b9e2401cbd5323c90a158ba2_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">COMPOUND</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">DEVELOPMENT PLAN</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#91;*&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">EXHIBIT D</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SUPPLY AGREEMENT TERMS</font></div><div style="padding-left:5.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:39.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.250%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#2f5496;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#2f5496;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:5.35pt;padding-right:11.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:4.5pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:5.35pt;padding-right:11.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:4.5pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:39.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:5.35pt;padding-right:11.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.95pt;padding-left:5.35pt;padding-right:11.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:5.95pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:39.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.250%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:5.3pt;padding-left:5.35pt;padding-right:7.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:142%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:5.35pt;padding-right:7.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.8pt;padding-left:5.35pt;padding-right:7.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 6.35pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2.7pt;padding-left:5.35pt;padding-right:7.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;*&#93;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit1022022-09.htm
<DESCRIPTION>EXECUTIVE OFFICERS EMPLOYMENT AGREEMENT, AS AMENDED
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3df2cb015ca743d2ab61f6b3d6169b97_1"></div><div style="min-height:117.36pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY HAND DELIVERY AND EMAIL</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;  Employment Agreement </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Taylor&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This letter (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth the terms of your employment as the Chief Medical Officer of Cidara Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to Allison Lewis.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As of its effective date, this Agreement replaces and supersedes in its entirety any current or prior agreement or plan relating to your compensation (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prior Agreements</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) except that the terms of your Employee Confidential Information and Invention Assignment Agreement </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">executed on September 1, 2016 </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restrictive Covenant Agreement</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall continue to apply. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As the Company&#8217;s Chief Medical Officer you will report to the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This is a full-time employment position.  It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or part-time) unless you first obtain the approval of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which approval shall not be withheld unreasonably.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Salary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company will pay you a base salary payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be paid at the rate of $338,000 per year (on an annualized basis), subject to periodic review and adjustment at the Board&#8217;s discretion.  This is a full-time, exempt position, meaning that you are not eligible for overtime compensation. The annual base salary in effect at any given time shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will be eligible to participate in the Company&#8217;s amended and restated bonus plan.  Your bonus target percentage will be 35% of your Base Salary in effect at the end of the applicable year, based on achievement of individual and corporate performance objectives to be determined and approved by the Board or the Compensation Committee thereof. Bonuses are paid on an annual basis, after the close of the fiscal year and after determination by the Board (or the Compensation Committee thereof) of (i) the level of achievement of the applicable individual and corporate performance targets and (ii) the bonus earned by you (if any).   No bonus is guaranteed and, in addition to the other conditions for earning such compensation, you must remain an employee in good standing of the Company on the scheduled bonus payment date in order to be eligible for any bonus payment.  The Company&#8217;s bonus program will be the only incentive compensation, commissions, or other bonus program that will apply to you.  However, nothing in this paragraph will prevent you from participating in incentive compensation, commission plan, retention plan, or other bonus programs created after the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 2</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">commencement of your employment which is specifically designed to include you and&#47;or to which you are specifically invited to participate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Benefits&#47;Vacation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> You will continue to be eligible to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees including medical, dental, vision, disability, life and 401(k), all subject to the terms and conditions of such plans and programs.  Details of such benefits programs, including mandatory employee contributions, if any, and waiting periods, if applicable, will continue to be made available to you.  You will be entitled to accrue Paid Time Off (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with subject to the terms and conditions of the Company&#8217;s PTO policy (which includes a maximum accrual cap), as may be amended from time to time.   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">At-Will Employment&#59; Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your employment is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time, with or without Cause (as defined below) or advance notice. In the event of the ending of your employment for any reason and at any time, the Company shall pay you&#58; (i) any unpaid base salary through your last day of employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) any accrued but unused PTO, and (iii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to the Date of Termination and not yet reimbursed (together the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case at such time that is not within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into, do not revoke and comply with the terms of a separation agreement in a form provided by the Company which shall include a general release of claims against the Company and related persons and entities and must be returned to the Company and become effective no later than sixty days following your Date of Termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) the Company will provide you with the following termination benefits&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a lump sum cash payment equal to your Base Salary for a nine month period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), with the full cost of the monthly premium for such benefits paid by the Company until the earlier of (i) the date immediately following the expiration of the period of time following the Date of Termination equal to the Severance Period&#59; or (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you elect health care continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Health Care Benefit Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Health Care Benefit Payment shall be paid in monthly installments on the same schedule that the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 3</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">COBRA premiums would otherwise have been paid to the insurer and shall be equal to the amount, and paid for the same duration of time, that the Company would have otherwise paid for your COBRA benefits as described above (which amount shall be calculated based on the premium for the first month of coverage).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Change in Control Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case, within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into and do not revoke the Release, the Company will provide you with all of the termination benefits set forth in Section 7 above, on the same schedule as set forth in Section 7 above, except that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Severance Period shall be twelve months&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">you will also receive a lump sum cash amount equivalent to&#160;your target annual bonus for the year in which the Date of Termination occurs (calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable), multiplied by the quotient of twelve divided by twelve, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">in addition, the vesting of all equity compensation awards granted to you by the Company (or its successor), to the extent outstanding as of immediately prior to your termination, shall become fully vested and immediately exercisable by you.  Any stock options and other equity compensation awards that you hold as of your Date of Termination shall remain outstanding following your Date of Termination if and to the extent necessary to give effect to this Section 7(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, in no event shall you be entitled to benefits under both Section 6 and this Section 7.  If you are eligible for benefits under both Section 6 and this Section 7, you shall receive the benefits set forth in this Section 7 and such benefits will be reduced by any benefits previously provided to you under Section 6.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) your commission of any felony or commission of a crime involving dishonesty&#59; (ii) conduct by you in connection with your service to the Company that is fraudulent, unlawful or grossly negligent&#59; (iii) your willful failure or refusal to comply with lawful directives of the CEO or the Board&#59; (iv) willful breach by you of a written Company policy or your representations, warranties, covenants and&#47;or obligations under this Agreement  or any other agreement between you and the Company (including the Restrictive Covenant Agreement), which, if curable, is not cured by you within 30 days following your receipt of written notice from the Company detailing the nature of such breach&#59; and&#47;or (v) material misconduct by you which adversely impacts, discredits or damages the Company or any of its affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred upon the consummation of (i) the dissolution or liquidation of the Company&#59; (ii) the sale or disposition by the Company of all </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 4</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity&#59; (iii) a merger, reorganization or consolidation in which the Company consolidates with or merges into another corporation or entity, or any other corporation or entities consolidates with or merges into the Company, other than (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the voting securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, (B) a merger or consolidation which would result in a majority of the board of directors of the combined entity being comprised of members of the board of directors of the pre-transaction Company and the chief executive officer of the combined entity being the chief executive officer of the pre-transaction Company, in each case immediately following the consummation of such merger or consolidation, or (C) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no person becomes the beneficial owner, directly or indirectly, of a majority of the total voting power of all shares of then outstanding Common Stock&#59; (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transaction by a person or group of persons&#59; (v) an acquisition of more than 50% of the then outstanding voting securities of the Company by another entity or person in a single transaction&#59;  or (vi) any other acquisition of the business of the Company, as determined by the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any public offering, private placement of the Company&#8217;s securities or other capital raising event, or a merger effected solely to change the Company&#8217;s domicile shall not constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean that you have complied with the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (hereinafter defined) following the occurrence of any of the following events, without your prior written consent&#58; (i) a material reduction of at least 20% in your then-current Base Salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (ii) relocation of your principal place of employment to a place that increases your  one-way commute by more than 75 miles as compared to your then-current principal place of employment immediately prior to such relocation&#59; (iii) a material diminution in your primary duties, responsibilities or authorities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; in and of itself unless your new duties are materially reduced from the prior duties&#59; or (iv) a material diminution in the authority, duties or responsibilities of the supervisor to whom you are required to report, including, if applicable, a requirement that you report to a corporate officer or employee instead of reporting directly to the chief executive officer and&#47;or president of a corporation unless you are required to report directly to the board of directors of a corporation (or similar governing body with respect to an entity other than a corporation).  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean that (A) you have reasonably determined in good faith that a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; condition has occurred&#59; (B) you have notified the Company in writing of the first occurrence of the Good Reason condition within 90 days of the first occurrence of such condition&#59; (C) you have cooperated in good faith with the Company&#8217;s efforts, for a period of 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to remedy the condition&#59; (D) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (E) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 5</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Confidential Information and Restricted Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition of continued employment, you shall continue to abide by the Restrictive Covenant Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the terms of which are incorporated by reference herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Taxes&#59; Section 409A&#59; Section 280G.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the of the Internal Revenue Code of 1986, as amended and the regulations and other guidance thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20% additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service (as defined below), or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#8220;separation from service&#8221;. The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code.  If your Date of Termination occurs at a time when the Release could become effective in one of two different calendar years (for example, your Date of Termination occurs in December), to the extent necessary to avoid adverse taxation under Section 409A of the Code, the effective date of the Release (for purposes of timing of receiving your severance benefits) shall in all events be considered as occurring no sooner than the later of such two different calendar years.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The severance benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the Code or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A of the Code. To the extent that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 6</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any provision of this Agreement is ambiguous as to its exemption from or compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder are exempt from, or if not exempt from, comply with, Section 409A of the Code. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If any payment or benefit you will or may receive from the Company or otherwise, pursuant to this Agreement or otherwise constitutes a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code (such payment or benefit, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parachute Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and would be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Excise Tax</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then you shall be entitled to receive an additional payment or payments from the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Gross-Up Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) such that the net amount retained by you after deduction of any Excise Tax on the Parachute Payment, any Federal, state, and local income tax, employment tax and Excise Tax upon the payment provided by this Section&#160;11(c), shall be equal to the Parachute Payment. Subject to the provisions below, all determinations required to be made under this Section&#160;11(c) including whether a Gross-Up Payment is required and the amount of such Gross-Up Payment, shall be made at the Company&#8217;s expense by a nationally recognized accounting firm selected by the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Firm</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall provide detailed supporting calculations both to the Company and you within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or by you. For purposes of determining the amount of the Gross-Up Payment, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the Gross-Up Payment is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of your residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. The Gross-Up Payment, if any, as determined pursuant to this Section shall be paid to the relevant tax authorities as withholding taxes on your behalf at such time or times when each Excise Tax payment is due. Any determination by the Accounting Firm shall be binding upon the Company and you.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding the foregoing, the amount of the Gross-Up Payment in no event shall exceed $1,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Interpretation, Amendment and Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, including the Restrictive Covenant Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Dispute Resolution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To ensure the rapid and economical resolution of any disputes that may arise in connection with your employment, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to any statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment, or the termination of your employment, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by a single arbitrator and under the JAMS Employment Arbitration Rules &#38; Procedures (which are accessible on the JAMS&#8217; website at http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;, and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 7</font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">which will be provided to you on request).  The arbitration will be held in the JAMS&#8217; office closest to your assigned office location, or such other location as then-agreed by the parties.  You and the Company shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, the parties waive the right to resolve any such dispute through a trial by jury or judge or by administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will have the right to be represented by legal counsel at any arbitration proceeding.  The arbitrator shall&#58; (1) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding&#59; and (2) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based.  The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this section apply to a dispute, controversy, or claim sought to be resolved in accordance with these arbitration procedures.  The Company shall bear JAMS&#8217; arbitration fees and administrative costs in excess of the court filing fees that you would be required to pay if the dispute was litigated in civil court.  Nothing herein shall prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Initials for Section 12&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; TS   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenant Agreement) without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and a duly authorized officer of the Company. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation.&#8221; This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Other Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By signing this Agreement, you represent to the Company that you have no contractual commitments or other legal obligations that would or may prohibit you from performing your duties for the Company.  As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States.  </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:117.36pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Taylor Sandison</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">March 22, 2017</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 8</font></div><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please acknowledge, by signing below, that you have accepted this Agreement.  </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jeffrey Stein, Ph.D.                        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Jeffrey Stein, Ph.D.</font></div><div style="margin-top:3pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       President and Chief Executive Officer </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I have read and accept this employment offer&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Taylor Sandison, MD                                       </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Taylor Sandison, MD</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">March 23, 2017                                         </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Encl&#58; Exhibit A &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Confidential Information and Invention Assignment Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">     </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exhibit1032022-09.htm
<DESCRIPTION>EXECUTIVE OFFICERS EMPLOYMENT AGREEMENT, AS AMENDED
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i6e6825fbfde5432c83313a98cffdaa9e_1"></div><div style="min-height:100.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY EMAIL</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;  Employment Agreement </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Shane&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth the terms of your continued employment as the Chief Legal Officer of Cidara Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon commencement of your employment with the Company, which is expected to occur on August 25, 2021 (such actual date of commencement of employment, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), your duties under this Agreement shall be to serve as the Company&#8217;s Chief Legal Officer and you will report to the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This is a full-time employment position.  It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or part-time) unless you first obtain the approval of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which approval shall not be withheld unreasonably.  Notwithstanding the foregoing, you </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may continue providing limited consulting services to Bellicum Pharmaceuticals, Inc. and may also engage in religious, charitable and other community activities so long as such engagements and activities do not interfere or conflict with your obligations to the Company, as determined by the Board in its discretion. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your principal place of business shall be Newton, Massachusetts.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Salary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company will pay you a base salary payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be paid at the rate of $410,000 per year (on an annualized basis), subject to periodic review and adjustment at the Board&#8217;s discretion.  This is a full-time, exempt position, meaning that you are not eligible for overtime compensation. The annual base salary in effect at any given time shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will be eligible to participate in the Company&#8217;s amended and restated bonus plan.  Your bonus target percentage will be 40% of your Base Salary in effect at the end of the applicable year, based on achievement of individual and corporate performance objectives to be determined and approved by the Board or the Compensation Committee thereof. Any bonus for 2021 will be prorated for the number of calendar days you were employed by the Company in 2021. Bonuses are paid on an annual basis, after the close of the fiscal year and after determination by the Board (or the Compensation Committee thereof) of (i) the level of achievement of the applicable individual and corporate performance targets and (ii) the bonus earned by you (if any).   No bonus is guaranteed and, in addition to the other conditions for earning such compensation, you must remain an employee in good standing of the Company on the scheduled bonus payment date in order to be eligible for any bonus payment.  The Company&#8217;s bonus program will be the only incentive compensation, commissions, or other bonus program that will apply to you.  However, nothing in this paragraph will prevent you from participating in incentive compensation, commission plan, retention plan, or other bonus </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shane M. Ward </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 2</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">programs created after the commencement of your employment which is specifically designed to include you and&#47;or to which you are specifically invited to participate.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Stock Options.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As a material inducement for your employment, you will be granted a stock option to purchase 250,000 shares of the Company&#8217;s common stock, pursuant to the Company&#8217;s Inducement Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Your stock option will vest over a four year period with 25% of the shares vesting on the one year anniversary of your Start Date, and the remainder vesting in approximately equal monthly installments over the following 36 months, provided that you remain in Continuous Service (as defined in the Plan) through such vesting dates.  Your stock options will be subject to the terms and conditions set forth in the applicable Plan and its respective agreements.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Benefits&#47;Vacation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> You will continue to be eligible to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees including medical, dental, vision, disability, life and 401(k), all subject to the terms and conditions of such plans and programs.  Details of such benefits programs, including mandatory employee contributions, if any, and waiting periods, if applicable, will continue to be made available to you.  You will be entitled to accrue Paid Time Off (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with subject to the terms and conditions of the Company&#8217;s PTO policy (which includes a maximum accrual cap), as may be amended from time to time.   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Relocation Support. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If, during your employment, you and the Company mutually determine that your principal place of employment should be located at the Company's headquarters or another Company office, the Company shall provide relocation assistance to you consistent with its then current relocation policy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">At-Will Employment&#59; Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your employment is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time, with or without Cause (as defined below) or advance notice. In the event of the ending of your employment for any reason and at any time, the Company shall pay you&#58; (i) any unpaid base salary through your last day of employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) any accrued but unused PTO, and (iii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to the Date of Termination and not yet reimbursed (together the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case at such time that is not within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into, do not revoke and comply with the terms of a separation agreement in a form provided by the Company which shall include a general release of claims against the Company and related persons and entities and must be returned to the Company and become effective no later than sixty days following your Date of Termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) the Company will provide you with the following termination benefits&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a lump sum cash payment equal to your Base Salary for a nine month period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shane M. Ward </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 3</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), with the full cost of the monthly premium for such benefits paid by the Company until the earlier of (i) the date immediately following the expiration of the period of time following the Date of Termination equal to the Severance Period&#59; or (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you elect health care continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Health Care Benefit Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Health Care Benefit Payment shall be paid in monthly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer and shall be equal to the amount, and paid for the same duration of time, that the Company would have otherwise paid for your COBRA benefits as described above (which amount shall be calculated based on the premium for the first month of coverage).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Change in Control Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case, within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into and do not revoke the Release, the Company will provide you with all of the termination benefits set forth in Section 8 above, on the same schedule as set forth in Section 8 above, except that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Severance Period shall be twelve months&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">you will also receive a lump sum cash amount equivalent to&#160;your target annual bonus for the year in which the Date of Termination occurs (calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable), multiplied by the quotient of twelve divided by twelve, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">in addition, the vesting of all equity compensation awards granted to you by the Company (or its successor), to the extent outstanding as of immediately prior to your termination, shall become fully vested and immediately exercisable by you.  Any stock options and other equity compensation awards that you hold as of your Date of Termination shall remain outstanding following your Date of Termination if and to the extent necessary to give effect to this Section 8(c).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, in no event shall you be entitled to benefits under both Section 8 and this Section 9.  If you are eligible for benefits under both Section 8 and this Section 9, you shall receive the benefits set forth in this Section 9 and such benefits will be reduced by any benefits previously provided to you under Section 8.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) your commission of any felony or commission of a crime involving dishonesty&#59; (ii) conduct by you in connection with your service to the Company that is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shane M. Ward </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 4</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fraudulent, unlawful or grossly negligent&#59; (iii) your willful failure or refusal to comply with lawful directives of the Board&#59; (iv) willful breach by you of a written Company policy or your representations, warranties, covenants and&#47;or obligations under this Agreement  or any other agreement between you and the Company (including the Restrictive Covenant Agreement), which, if curable, is not cured by you within 30 days following your receipt of written notice from the Company detailing the nature of such breach&#59; and&#47;or (v) material misconduct by you which adversely impacts, discredits or damages the Company or any of its affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred upon the consummation of (i) the dissolution or liquidation of the Company&#59; (ii) the sale or disposition by the Company of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity&#59; (iii) a merger, reorganization or consolidation in which the Company consolidates with or merges into another corporation or entity, or any other corporation or entities consolidates with or merges into the Company, other than (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the voting securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, (B) a merger or consolidation which would result in a majority of the board of directors of the combined entity being comprised of members of the board of directors of the pre-transaction Company and the chief executive officer of the combined entity being the chief executive officer of the pre-transaction Company, in each case immediately following the consummation of such merger or consolidation, or (C) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no person becomes the beneficial owner, directly or indirectly, of a majority of the total voting power of all shares of then outstanding Common Stock&#59; (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transaction by a person or group of persons&#59; (v) an acquisition of more than 50% of the then outstanding voting securities of the Company by another entity or person in a single transaction&#59;  or (vi) any other acquisition of the business of the Company, as determined by the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any public offering, private placement of the Company&#8217;s securities or other capital raising event, or a merger effected solely to change the Company&#8217;s domicile shall not constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean that you have complied with the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (hereinafter defined) following the occurrence of any of the following events, without your prior written consent&#58; (i) a material reduction of at least 20% in your then-current Base Salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s similarly situated employees)&#59; (ii) relocation of your principal place of employment to a place that increases your  one-way commute by more than 75 miles as compared to your then-current principal place of employment immediately prior to such relocation&#59; (iii) a material diminution in your primary duties, responsibilities or authorities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; in and of itself unless your new duties are materially reduced from the prior duties&#59; or (iv) a material diminution in the authority, duties or responsibilities of the supervisor to whom you are required to report, including, if applicable, a requirement that you report to a corporate officer or employee instead of reporting directly to the chief executive officer and&#47;or president of a corporation unless you are required to report directly to the board of directors of a corporation (or similar governing body with respect to an entity other than a corporation).  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean that (A) you have reasonably determined in good faith that a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; condition has occurred&#59; (B) you have notified the Company in writing of the first occurrence of the Good </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shane M. Ward </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 5</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Reason condition within 90 days of the first occurrence of such condition&#59; (C) you have cooperated in good faith with the Company&#8217;s efforts, for a period of 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to remedy the condition&#59; (D) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (E) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Confidential Information and Restricted Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition of continued employment, you shall continue to abide by the Restrictive Covenant Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the terms of which are incorporated by reference herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Taxes&#59; Section 409A&#59; Section 280G.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the of the Internal Revenue Code of 1986, as amended and the regulations and other guidance thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20% additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service (as defined below), or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#8220;separation from service&#8221;. The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code.  If your Date of Termination occurs at a time when the Release could become effective in one of two different calendar years (for example, your Date of Termination occurs in December), to the extent necessary to avoid adverse taxation under Section 409A of the Code, the effective date of the Release (for purposes of timing of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shane M. Ward </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 6</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">receiving your severance benefits) shall in all events be considered as occurring no sooner than the later of such two different calendar years.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The severance benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the Code or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its exemption from or compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder are exempt from, or if not exempt from, comply with, Section 409A of the Code. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If any payment or benefit you will or may receive from the Company or otherwise, pursuant to this Agreement or otherwise constitutes a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code (such payment or benefit, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parachute Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and would be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Excise Tax</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then you shall be entitled to receive an additional payment or payments from the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Gross-Up Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) such that the net amount retained by you after deduction of any Excise Tax on the Parachute Payment, any Federal, state, and local income tax, employment tax and Excise Tax upon the payment provided by this Section&#160;12(c), shall be equal to the Parachute Payment. Subject to the provisions below, all determinations required to be made under this Section&#160;12(c) including whether a Gross-Up Payment is required and the amount of such Gross-Up Payment, shall be made at the Company&#8217;s expense by a nationally recognized accounting firm selected by the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Firm</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall provide detailed supporting calculations both to the Company and you within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or by you. For purposes of determining the amount of the Gross-Up Payment, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the Gross-Up Payment is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of your residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. The Gross-Up Payment, if any, as determined pursuant to this Section shall be paid to the relevant tax authorities as withholding taxes on your behalf at such time or times when each Excise Tax payment is due. Any determination by the Accounting Firm shall be binding upon the Company and you.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding the foregoing, the amount of the Gross-Up Payment in no event shall exceed $1,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Interpretation, Amendment and Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, including the Restrictive Covenant Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Dispute Resolution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To ensure the rapid and economical resolution of any disputes that may arise in connection with your employment, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to any statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shane M. Ward </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 7</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Agreement, your employment, or the termination of your employment, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by a single arbitrator and under the JAMS Employment Arbitration Rules &#38; Procedures (which are accessible on the JAMS&#8217; website at http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;, and which will be provided to you on request).  The arbitration will be held in the JAMS&#8217; office closest to your assigned office location, or such other location as then-agreed by the parties.  You and the Company shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, the parties waive the right to resolve any such dispute through a trial by jury or judge or by administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will have the right to be represented by legal counsel at any arbitration proceeding.  The arbitrator shall&#58; (1) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding&#59; and (2) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based.  The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this Section apply to a dispute, controversy, or claim sought to be resolved in accordance with these arbitration procedures.  The Company shall bear JAMS&#8217; arbitration fees and administrative costs in excess of the court filing fees that you would be required to pay if the dispute was litigated in civil court.  Nothing herein shall prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Initials for Section 14&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; SW   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenant Agreement) without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and a duly authorized officer of the Company. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation.&#8221; This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Other Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By signing this Agreement, you represent to the Company that you have no contractual commitments or other legal obligations that would or may prohibit you from performing your duties for the Company.  As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Shane M. Ward </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 17, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 8</font></div><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please acknowledge, by signing below, that you have accepted this Agreement.  </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jeffrey Stein, Ph.D.                        </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Jeffrey Stein, Ph.D.</font></div><div style="margin-top:3pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       President and Chief Executive Officer </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I have read and accept this employment offer&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Shane Ward                                                      </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Shane M. Ward</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">August 18, 2021                                        </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Encl&#58; Exhibit A &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential Information and Invention Assignment Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">     </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>exhibit1042022-09.htm
<DESCRIPTION>EXECUTIVE OFFICERS EMPLOYMENT AGREEMENT, AS AMENDED
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1fc749a89b6d466b92e30eb9973a9fc4_1"></div><div style="min-height:100.8pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.4</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">BY EMAIL</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;  Employment Agreement </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Preetam&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) sets forth the terms of your employment as the Chief Financial Officer and Chief Business Officer of Cidara Therapeutics, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As the Company&#8217;s Chief Financial Officer and Chief Business Officer you will report to the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  This is a full-time employment position.  It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or part-time) unless you first obtain the approval of the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which approval shall not be withheld unreasonably.  Notwithstanding the foregoing, you </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">may also engage in religious, charitable and other community activities so long as such engagements and activities do not interfere or conflict with your obligations to the Company, as determined by the Board in its discretion. Your principal place of business shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Secaucus, New Jersey.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Salary.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  The Company will pay you a base salary payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be paid at the rate of $415,000 per year (on an annualized basis), subject to periodic review and adjustment at the Board&#8217;s discretion.  This is a full-time, exempt position, meaning that you are not eligible for overtime compensation. The annual base salary in effect at any given time shall be referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will be eligible to participate in the Company&#8217;s amended and restated bonus plan.  Your bonus target percentage will be 40% of your Base Salary in effect at the end of the applicable year, based on achievement of individual and corporate performance objectives to be determined and approved by the Board or the Compensation Committee thereof. Any bonus for 2021 will be prorated for the number of calendar days you were employed by the Company in 2021. Bonuses are paid on an annual basis, after the close of the fiscal year  and after determination by the Board (or the Compensation Committee thereof) of (i) the level of achievement of the applicable individual and corporate performance targets and (ii) the bonus earned by you (if any).   No bonus is guaranteed and, in addition to the other conditions for earning such compensation, you must remain an employee in good standing of the Company on the scheduled bonus payment date in order to be eligible for any bonus payment  The Company&#8217;s bonus program will be the only cash incentive compensation, commissions, or other bonus program that will apply to you.  However, nothing in this paragraph will prevent you from participating in incentive compensation, commission plan, retention plan, or other bonus programs created after the commencement of your employment which is specifically designed to include you and&#47;or to which you are specifically invited to participate.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preetam Shah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 2</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Stock Options.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> As a material inducement for your employment, you will be granted a stock option to purchase 311,850 shares of the Company&#8217;s common stock, pursuant to the Company&#8217;s Inducement Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  Your stock option will vest over a four year period with 25% of the shares vesting on the one year anniversary of your Start Date, and the remainder vesting in approximately equal monthly installments over the following 36 months, provided that you remain in Continuous Service (as defined in the Plan) through such vesting dates.  Your stock options will be subject to the terms and conditions set forth in the applicable Plan and its respective agreements and shall commence vesting on your first date of employment with the Company.  If and as deemed advisable by the Compensation Committee and&#47;or the Board in its sole discretion, you shall also be eligible to receive appropriate additional annual equity incentive awards at such time, in such amounts in such types and with such terms as may be deemed appropriate by the Compensation Committee and&#47;or the Board and as per the Company&#8217;s compensation policy&#59; such additional grants, if any, are not guaranteed and are entirely discretionary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Performance Restricted Stock Units.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As a further material inducement for your employment, the Company will grant 50,000 performance Restricted Stock Units (&#8220;RSUs&#8221;) that will fully vest upon the first to occur of (i) completion of a successful financing(s) or (ii) business development deal no later than the end of the third quarter of 2022 resulting in the Company&#8217;s receipt of total cash proceeds in an amount forecasted to fund the Company through the end of the third quarter of 2023 , subject to terms and conditions in the RSU grant. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Relocation Support. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If, during your employment, you and the Company mutually determine that your principal place of employment should be located at the Company's headquarters or another Company office, the Company shall provide relocation assistance to you consistent with its then current relocation policy. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Your principal place of business shall be </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Secaucus, New Jersey.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Benefits&#47;Vacation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> You will be eligible to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees including medical, dental, vision, disability, life and 401(k), all subject to the terms and conditions of such plans and programs.  Details of such benefits programs, including mandatory employee contributions, if any, and waiting periods, if applicable, will continue to be made available to you.  You will be entitled to accrue Paid Time Off (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">PTO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in accordance with subject to the terms and conditions of the Company&#8217;s PTO policy (which includes a maximum accrual cap), as may be amended from time to time.   .</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">At-Will Employment&#59; Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your employment is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time, with or without Cause (as defined below) or advance notice. In the event of the ending of your employment for any reason and at any time, the Company shall pay you&#58; (i) any unpaid base salary through your last day of employment (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), (ii) any accrued but unused PTO, and (iii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to the Date of Termination and not yet reimbursed (together the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accrued Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case at such time that is not within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into, do not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preetam Shah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 3</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">revoke and comply with the terms of a separation agreement in a form provided by the Company which shall include a general release of claims against the Company and related persons and entities and must be returned to the Company and become effective no later than sixty days following your Date of Termination (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) the Company will provide you with the following termination benefits&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a lump sum cash payment equal to your Base Salary for a nine month period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Severance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">if elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), with the full cost of the monthly premium for such benefits paid by the Company until the earlier of (i) the date immediately following the expiration of the period of time following the Date of Termination equal to the Severance Period&#59; or (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA. Notwithstanding the foregoing, if the Company determines, in its sole discretion, that the Company cannot provide the COBRA premium benefits without potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof pay you a taxable cash amount, which payment shall be made regardless of whether you elect health care continuation coverage (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Health Care Benefit Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).  The Health Care Benefit Payment shall be paid in monthly installments on the same schedule that the COBRA premiums would otherwise have been paid to the insurer and shall be equal to the amount, and paid for the same duration of time, that the Company would have otherwise paid for your COBRA benefits as described above (which amount shall be calculated based on the premium for the first month of coverage).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Change in Control Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause (other than due to death or disability) or you resign your employment for Good Reason (as defined below), in either case, within the three months immediately preceding or the twelve months immediately following the consummation of a Change in Control (as defined below), in addition to the Accrued Obligations and provided you enter into and do not revoke the Release, the Company will provide you with all of the termination benefits set forth in Section 8 above, on the same schedule as set forth in Section 8 above, except that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">the Severance Period shall be twelve months&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">you will also receive a lump sum cash amount equivalent to&#160;your target annual bonus for the year in which the Date of Termination occurs (calculated by reference to your Base Salary rate in place immediately prior to the Date of Termination, but ignoring any decrease that forms the basis of your resignation for Good Reason, if applicable), multiplied by the quotient of twelve divided by twelve, which shall be paid to you on the first regular payroll date of the Company following the effective date of the Release, and in any event no later than March 15 of the year following the year in which the Date of Termination occurs&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">in addition, the vesting of all equity compensation awards granted to you by the Company (or its successor), to the extent outstanding as of immediately prior to your termination, shall become fully vested and immediately exercisable by you.  Any stock options </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preetam Shah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 4</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and other equity compensation awards that you hold as of your Date of Termination shall remain outstanding following your Date of Termination if and to the extent necessary to give effect to this Section 8(c). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the avoidance of doubt, in no event shall you be entitled to benefits under both Section 8 and this Section 9.  If you are eligible for benefits under both Section 8 and this Section 9, you shall receive the benefits set forth in this Section 9 and such benefits will be reduced by any benefits previously provided to you under Section 8.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58; (i) your commission of any felony or commission of a crime involving dishonesty&#59; (ii) conduct by you in connection with your service to the Company that is fraudulent, unlawful or grossly negligent&#59; (iii) your willful failure or refusal to comply with lawful directives of the Board&#59; (iv) willful breach by you of a written Company policy or your representations, warranties, covenants and&#47;or obligations under this Agreement  or any other agreement between you and the Company (including the Restrictive Covenant Agreement), which, if curable, is not cured by you within 30 days following your receipt of written notice from the Company detailing the nature of such breach&#59; and&#47;or (v) material misconduct by you which adversely impacts, discredits or damages the Company or any of its affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall be deemed to have occurred upon the consummation of (i) the dissolution or liquidation of the Company&#59; (ii) the sale or disposition by the Company of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity&#59; (iii) a merger, reorganization or consolidation in which the Company consolidates with or merges into another corporation or entity, or any other corporation or entities consolidates with or merges into the Company, other than (A) a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the voting securities of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, (B) a merger or consolidation which would result in a majority of the board of directors of the combined entity being comprised of members of the board of directors of the pre-transaction Company and the chief executive officer of the combined entity being the chief executive officer of the pre-transaction Company, in each case immediately following the consummation of such merger or consolidation, or (C) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no person becomes the beneficial owner, directly or indirectly, of a majority of the total voting power of all shares of then outstanding Common Stock&#59; (iv) the acquisition of all or a majority of the outstanding voting stock of the Company in a single transaction or a series of related transaction by a person or group of persons&#59; (v) an acquisition of more than 50% of the then outstanding voting securities of the Company by another entity or person in a single transaction&#59;  or (vi) any other acquisition of the business of the Company, as determined by the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any public offering, private placement of the Company&#8217;s securities or other capital raising event, or a merger effected solely to change the Company&#8217;s domicile shall not constitute a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean that you have complied with the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (hereinafter defined) following the occurrence of any of the following events, without your prior written consent&#58; (i) a reduction of 20% or more in your then-current Base Salary (unless pursuant to a salary reduction program applicable generally to the Company&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preetam Shah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 5</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">executives)&#59; (ii) relocation of your principal place of employment to a place that increases your  one-way commute by more than 75 miles as compared to your then-current principal place of employment immediately prior to such relocation&#59; (iii) a material diminution in your primary duties, responsibilities or authorities, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that a change in job position (including a change in title) shall not be deemed a &#8220;material reduction&#8221; in and of itself unless your new duties are materially reduced from the prior duties&#59; or (iv) a material diminution in the authority, duties or responsibilities of the supervisor to whom you are required to report, including, if applicable, a requirement that you report to a corporate officer or employee instead of reporting directly to the chief executive officer and&#47;or president of a corporation unless you are required to report directly to the board of directors of a corporation (or similar governing body with respect to an entity other than a corporation).  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean that (A) you have reasonably determined in good faith that a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; condition has occurred&#59; (B) you have notified the Company in writing of the first occurrence of the Good Reason condition within 90 days of the first occurrence of such condition&#59; (C) you have cooperated in good faith with the Company&#8217;s efforts, for a period of 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), to remedy the condition&#59; (D) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (E) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period Good Reason shall be deemed not to have occurred.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Confidential Information and Restricted Activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition of continued employment, you shall continue to abide by the Restrictive Covenant Agreement attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the terms of which are incorporated by reference herein.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Taxes&#59; Section 409A&#59; Section 280G.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409A of the of the Internal Revenue Code of 1986, as amended and the regulations and other guidance thereunder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred compensation subject to the 20% additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service (as defined below), or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preetam Shah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 6</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits shall be payable only upon your &#8220;separation from service&#8221;. The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). The Company and you intend that this Agreement will be administered in accordance with Section 409A of the Code.  If your Date of Termination occurs at a time when the Release could become effective in one of two different calendar years (for example, your Date of Termination occurs in December), to the extent necessary to avoid adverse taxation under Section 409A of the Code, the effective date of the Release (for purposes of timing of receiving your severance benefits) shall in all events be considered as occurring no sooner than the later of such two different calendar years.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The severance benefits under this Agreement are intended to qualify for an exemption from application of Section 409A of the Code or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its exemption from or compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder are exempt from, or if not exempt from, comply with, Section 409A of the Code. The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(h)</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.35pt">If any payment or benefit you will or may receive from the Company or otherwise, pursuant to this Agreement or otherwise constitutes a &#8220;parachute payment&#8221; within the meaning of Section 280G of the Code (such payment or benefit, a &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Parachute Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and would be subject to the excise tax imposed by Section&#160;4999 of the Code (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Excise Tax</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then you shall be entitled to receive an additional payment or payments from the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Gross-Up Payment</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) such that the net amount retained by you after deduction of any Excise Tax on the Parachute Payment, any Federal, state, and local income tax, employment tax and Excise Tax upon the payment provided by this Section&#160;11(c), shall be equal to the Parachute Payment. Subject to the provisions below, all determinations required to be made under this Section&#160;11(c) including whether a Gross-Up Payment is required and the amount of such Gross-Up Payment, shall be made at the Company&#8217;s expense by a nationally recognized accounting firm selected by the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Firm</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall provide detailed supporting calculations both to the Company and you within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or by you. For purposes of determining the amount of the Gross-Up Payment, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the Gross-Up Payment is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of your residence on the Date of Termination, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. The Gross-Up Payment, if any, as determined pursuant to this Section shall be paid to the relevant tax authorities as withholding taxes on your behalf at such time or times when each Excise Tax payment is due. Any determination by the Accounting Firm shall be binding upon the Company </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preetam Shah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 7</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and you.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Notwithstanding the foregoing, the amount of the Gross-Up Payment in no event shall exceed $1,000,000.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Interpretation, Amendment and Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, including the Restrictive Covenant Agreement and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. All questions concerning the construction, validity and interpretation of this Agreement will be governed by the laws of the State of California.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Dispute Resolution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  To ensure the rapid and economical resolution of any disputes that may arise in connection with your employment, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to any statutory claims, arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your employment, or the termination of your employment, will be resolved pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by law, by final, binding and confidential arbitration conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) by a single arbitrator and under the JAMS Employment Arbitration Rules &#38; Procedures (which are accessible on the JAMS&#8217; website at http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;, and which will be provided to you on request).  The arbitration will be held in the JAMS&#8217; office closest to your assigned office location, or such other location as then-agreed by the parties.  You and the Company shall be entitled to all rights and remedies that either would be entitled to pursue in a court of law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">By agreeing to this arbitration procedure, the parties waive the right to resolve any such dispute through a trial by jury or judge or by administrative proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will have the right to be represented by legal counsel at any arbitration proceeding.  The arbitrator shall&#58; (1) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding&#59; and (2) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#8217;s essential findings and conclusions on which the award is based.  The arbitrator, and not a court, shall also be authorized to determine whether the provisions of this section apply to a dispute, controversy, or claim sought to be resolved in accordance with these arbitration procedures.  The Company shall bear JAMS&#8217; arbitration fees and administrative costs in excess of the court filing fees that you would be required to pay if the dispute was litigated in civil court.  Nothing herein shall prevent either party from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration.  Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Employee Initials for Section 15&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">   &#47;s&#47; PS   </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenant Agreement) without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Preetam Shah</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">August 19, 2021</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Page 8</font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement may not be modified or amended, and no breach shall be deemed to be waived, unless agreed to in writing by you and a duly authorized officer of the Company. The headings and captions in this Agreement are for convenience only and in no way define or describe the scope or content of any provision of this Agreement. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; when used herein shall be deemed in each case to be followed by the words &#8220;without limitation.&#8221; This Agreement may be executed in two or more counterparts, each of which shall be an original and all of which together shall constitute one and the same instrument.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Other Terms.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  By signing this Agreement, you represent to the Company that you have no contractual commitments or other legal obligations that would or may prohibit you from performing your duties for the Company.  As with any employee, you must submit satisfactory proof of your identity and your legal authorization to work in the United States.  </font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Please acknowledge, by signing below, that you have accepted this Agreement.  </font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Very truly yours,</font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font><br></font></div><div style="padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Jeffrey Stein, Ph.D.                        </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;       Jeffrey Stein, Ph.D.</font></div><div style="margin-top:3pt;padding-left:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       President and Chief Executive Officer </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I have read and accept this employment offer&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Preetam Shah, Ph.D., MBA                              </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preetam Shah</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">August 19, 2021                                        </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Encl&#58; Exhibit A &#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Confidential Information and Invention Assignment Agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">     </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit3112022-09.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="icf3e650719904ad7aa4e3933b96eb871_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">PURSUANT TO RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">I, Jeffrey Stein, Ph.D., certify that&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit3122022-09.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SECURITIES EXCHANGE ACT OF 1934
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ife50f6c564a8405d88a9f213ef1ac65e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">PURSUANT TO RULE 13a-14(a) and 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">I, Preetam Shah, Ph.D., MBA, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">1. I have reviewed this quarterly report on Form 10-Q of Cidara Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">c. evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">d. disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>exhibit3212022-09.htm
<DESCRIPTION>CERTIFICATION OF CEO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8190baa03b9345d499458d178e2749d3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the quarterly report of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September&#160;30, 2022</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jeffrey Stein, Ph.D., President and Chief Executive Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167; 1350)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Jeffrey Stein, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The foregoing certification accompanies the Form 10-Q to which it relates, is being furnished solely pursuant to 18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>exhibit3222022-09.htm
<DESCRIPTION>CERTIFICATION OF CFO PURSUANT TO SARBANES-OXLEY ACT OF 2002
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ic2b2a8b496aa41a1b53009cd0e9f09df_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:27pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In connection with the quarterly report of Cidara Therapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">September&#160;30, 2022</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Preetam Shah, Ph.D., MBA, Chief Financial Officer and Chief Business Officer of the Company, certify, pursuant to the requirement in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Exchange Act&#8221;), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167; 1350)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, that, to my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act&#59; and</font></div><div style="margin-top:6pt;text-indent:54pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:6pt;text-indent:54pt"><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Date&#58; November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#47;s&#47; Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Preetam Shah, Ph.D., MBA</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Chief Financial Officer and Chief Business Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The foregoing certification accompanies the Form 10-Q to which it relates, is being furnished solely pursuant to 18 U.S.C. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#167;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;1350 and is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>cdtx-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a568bcbd-732c-4e03-9327-71091167a8dd,g:435374c1-7d67-4ed0-913a-245b913da5ec-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cdtx="http://cidara.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cidara.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cdtx-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://cidara.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATION" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION">
        <link:definition>0000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000009 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://cidara.com/role/DEBT">
        <link:definition>0000010 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000011 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANS" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS">
        <link:definition>0000012 - Disclosure - EQUITY INCENTIVE PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTS" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS">
        <link:definition>0000013 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>0000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>0000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>0000017 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>0000018 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSTables" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables">
        <link:definition>0000019 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSTables" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables">
        <link:definition>0000020 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>0000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="THECOMPANYANDBASISOFPRESENTATIONDetails" roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails">
        <link:definition>0000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
        <link:definition>0000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails">
        <link:definition>0000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails">
        <link:definition>0000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>0000026 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTAdditionalInformationDetails" roleURI="http://cidara.com/role/DEBTAdditionalInformationDetails">
        <link:definition>0000027 - Disclosure - DEBT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>0000028 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails">
        <link:definition>0000029 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSAdditionalInformationDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails">
        <link:definition>0000030 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails">
        <link:definition>0000031 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails">
        <link:definition>0000032 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>0000033 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails">
        <link:definition>0000034 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1">
        <link:definition>0000034 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails">
        <link:definition>0000035 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
        <link:definition>0000036 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails">
        <link:definition>0000037 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails">
        <link:definition>0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1">
        <link:definition>0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails">
        <link:definition>0000039 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" abstract="true" name="ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseAnnualRateIncrease" abstract="false" name="LesseeOperatingLeaseAnnualRateIncrease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" abstract="false" name="PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" abstract="true" name="MoreThanTenPercentVotingRightsClassesOfStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTransactionPotentialValue" abstract="false" name="CollaborativeArrangementTransactionPotentialValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_MelintaTherapeuticsIncMember" abstract="true" name="MelintaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_OperatingLeaseRightOfUseAmortization" abstract="false" name="OperatingLeaseRightOfUseAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" abstract="false" name="CollaborativeArrangementMaximumThirdPartyShareOfCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_SeriesXConvertiblePreferredStockMember" abstract="true" name="SeriesXConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_ClinicalSupplyServicesMember" abstract="true" name="ClinicalSupplyServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_ResearchAndDevelopmentServicesMember" abstract="true" name="ResearchAndDevelopmentServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" abstract="false" name="LesseeOperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_TwoThousandFifteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFifteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_WarrantsAggregateIntrinsicValueOutstanding" abstract="false" name="WarrantsAggregateIntrinsicValueOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_NumberOfOperatingLeaseOptionsForExtension" abstract="false" name="NumberOfOperatingLeaseOptionsForExtension" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementCostSharingPercentage" abstract="false" name="CollaborativeArrangementCostSharingPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" abstract="false" name="CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" abstract="false" name="ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_CollaborationAgreementNumberOfPerformanceObligations" abstract="false" name="CollaborationAgreementNumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_CommonStockWarrantMember" abstract="true" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_SaleOfStockConsiderationRemainingOnTransaction" abstract="false" name="SaleOfStockConsiderationRemainingOnTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseMonthlyRate" abstract="false" name="LesseeOperatingLeaseMonthlyRate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_JanssenPharmaceuticalsIncMember" abstract="true" name="JanssenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" abstract="true" name="DevelopmentRegulatoryAndCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_MundipharmaMedicalCompanyMember" abstract="true" name="MundipharmaMedicalCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_JanssenCollaborationAgreementMember" abstract="true" name="JanssenCollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" abstract="false" name="CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_NumberOfVotesEntitlementForEachShareHeld" abstract="false" name="NumberOfVotesEntitlementForEachShareHeld" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" abstract="false" name="LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" abstract="true" name="TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cdtx_RDFundingMember" abstract="true" name="RDFundingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_PublicStockOfferingMember" abstract="true" name="PublicStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_LicensesOfIntellectualPropertyMember" abstract="true" name="LicensesOfIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_AuthorizedSharesForFutureStockAwardsMember" abstract="true" name="AuthorizedSharesForFutureStockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_UpfrontPaymentMember" abstract="true" name="UpfrontPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_UnauditedInterimFinancialDataPolicyTextBlock" abstract="false" name="UnauditedInterimFinancialDataPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="cdtx_ClinicalDrugSupplyMember" abstract="true" name="ClinicalDrugSupplyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="cdtx_LesseeOperatingLeaseOptionRenewalTerm" abstract="false" name="LesseeOperatingLeaseOptionRenewalTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" abstract="false" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" abstract="false" name="IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_PaymentsRelatedToCollaborativeAgreements" abstract="false" name="PaymentsRelatedToCollaborativeAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" abstract="true" name="RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>cdtx-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a568bcbd-732c-4e03-9327-71091167a8dd,g:435374c1-7d67-4ed0-913a-245b913da5ec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f522be8e-2e09-4fa8-83a0-f014155cb0bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9d2859c3-2e83-48a3-a5bc-48eeff0944ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f522be8e-2e09-4fa8-83a0-f014155cb0bb" xlink:to="loc_us-gaap_StockholdersEquity_9d2859c3-2e83-48a3-a5bc-48eeff0944ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_267ba142-aae1-4fdb-9931-c213580ce4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f522be8e-2e09-4fa8-83a0-f014155cb0bb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_267ba142-aae1-4fdb-9931-c213580ce4b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0ca05202-9c5e-4c44-add5-ebec22999722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f522be8e-2e09-4fa8-83a0-f014155cb0bb" xlink:to="loc_us-gaap_Liabilities_0ca05202-9c5e-4c44-add5-ebec22999722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0395a2a3-2d14-4141-bca8-380f74d0f26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1e6c1393-1226-418e-906a-5d6e900986f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0395a2a3-2d14-4141-bca8-380f74d0f26e" xlink:to="loc_us-gaap_AssetsCurrent_1e6c1393-1226-418e-906a-5d6e900986f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0fcd36ad-1604-48ca-9c6c-ddb51a890447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0395a2a3-2d14-4141-bca8-380f74d0f26e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0fcd36ad-1604-48ca-9c6c-ddb51a890447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1046ffd6-d7db-4734-8cff-9e5407619686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0395a2a3-2d14-4141-bca8-380f74d0f26e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1046ffd6-d7db-4734-8cff-9e5407619686" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ecdb67d4-dce9-469d-a545-553e74b41a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0395a2a3-2d14-4141-bca8-380f74d0f26e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ecdb67d4-dce9-469d-a545-553e74b41a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bf3391a1-387e-42a5-825f-17f2a8965b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5132b5f9-75bc-445e-a5be-65c20087d7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bf3391a1-387e-42a5-825f-17f2a8965b0f" xlink:to="loc_us-gaap_LiabilitiesCurrent_5132b5f9-75bc-445e-a5be-65c20087d7bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_f0a6aa5c-eb59-45b6-ae54-59b2e1787722" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bf3391a1-387e-42a5-825f-17f2a8965b0f" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_f0a6aa5c-eb59-45b6-ae54-59b2e1787722" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d916cbc-f310-44b5-a561-57423931d93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bf3391a1-387e-42a5-825f-17f2a8965b0f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8d916cbc-f310-44b5-a561-57423931d93f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bfeb1df9-d4ff-4674-8e10-9dfa66e18fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ca1ce69a-50c0-4e78-b7e3-967a4d6597c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bfeb1df9-d4ff-4674-8e10-9dfa66e18fd2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ca1ce69a-50c0-4e78-b7e3-967a4d6597c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89bf277d-41a9-4535-85f7-b15150367838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bfeb1df9-d4ff-4674-8e10-9dfa66e18fd2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_89bf277d-41a9-4535-85f7-b15150367838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_615db4d5-21ab-4ad0-82c4-be99c832fc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bfeb1df9-d4ff-4674-8e10-9dfa66e18fd2" xlink:to="loc_us-gaap_CommonStockValue_615db4d5-21ab-4ad0-82c4-be99c832fc0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5dc45393-c0ec-4670-a152-30814be2f1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_bfeb1df9-d4ff-4674-8e10-9dfa66e18fd2" xlink:to="loc_us-gaap_PreferredStockValue_5dc45393-c0ec-4670-a152-30814be2f1c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d7ea4f78-48d5-4a98-b1b1-06eaca25e383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61c725c5-e74f-4020-8e96-59460f099870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7ea4f78-48d5-4a98-b1b1-06eaca25e383" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_61c725c5-e74f-4020-8e96-59460f099870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_11600d9c-6f71-4144-b022-72d994dc401a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7ea4f78-48d5-4a98-b1b1-06eaca25e383" xlink:to="loc_us-gaap_RestrictedCashCurrent_11600d9c-6f71-4144-b022-72d994dc401a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7e469e08-85bb-4e0e-9598-35e9f3a586b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7ea4f78-48d5-4a98-b1b1-06eaca25e383" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7e469e08-85bb-4e0e-9598-35e9f3a586b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2b4217ba-aa9d-4015-9300-2af228bf5fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d7ea4f78-48d5-4a98-b1b1-06eaca25e383" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2b4217ba-aa9d-4015-9300-2af228bf5fb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3693bfac-f914-4f2d-90a7-cc3e3418b0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d580fe0b-4a2e-4c05-8c79-89e94049a4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3693bfac-f914-4f2d-90a7-cc3e3418b0a9" xlink:to="loc_us-gaap_AccountsPayableCurrent_d580fe0b-4a2e-4c05-8c79-89e94049a4dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_736fa414-9322-404e-a0b8-d94778d4d762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3693bfac-f914-4f2d-90a7-cc3e3418b0a9" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_736fa414-9322-404e-a0b8-d94778d4d762" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_77b9394c-941e-4b2b-8377-2ad9144815bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3693bfac-f914-4f2d-90a7-cc3e3418b0a9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_77b9394c-941e-4b2b-8377-2ad9144815bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_7deab62d-882f-4c83-b6b4-cd1a7d09922d" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3693bfac-f914-4f2d-90a7-cc3e3418b0a9" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_7deab62d-882f-4c83-b6b4-cd1a7d09922d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_c9bfd7cc-90f9-49a7-8925-19ce0a16fcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3693bfac-f914-4f2d-90a7-cc3e3418b0a9" xlink:to="loc_us-gaap_LoansPayableCurrent_c9bfd7cc-90f9-49a7-8925-19ce0a16fcf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4bc86270-92e2-4db8-b3b7-94d5fd06fdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3693bfac-f914-4f2d-90a7-cc3e3418b0a9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4bc86270-92e2-4db8-b3b7-94d5fd06fdc6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d0b6f48-f36f-44b4-8ab1-887249960472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_06676f26-a6d9-4a08-8502-8a237d44f3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5d0b6f48-f36f-44b4-8ab1-887249960472" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_06676f26-a6d9-4a08-8502-8a237d44f3fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_de17ab80-b434-437b-af68-d8b56183cc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_5d0b6f48-f36f-44b4-8ab1-887249960472" xlink:to="loc_us-gaap_OperatingIncomeLoss_de17ab80-b434-437b-af68-d8b56183cc01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_251f2a79-642c-47fd-adde-af5289d51b70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c6765515-fabe-4592-b033-e56fcf497613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_251f2a79-642c-47fd-adde-af5289d51b70" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c6765515-fabe-4592-b033-e56fcf497613" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_685b6a92-1e0a-4bc3-b5e7-0cef673183e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_5574de6a-62db-47a3-9c7c-1ce6ac5a0c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_685b6a92-1e0a-4bc3-b5e7-0cef673183e5" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_5574de6a-62db-47a3-9c7c-1ce6ac5a0c72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_01e7e028-95bf-4481-babf-8848fa1b4903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_685b6a92-1e0a-4bc3-b5e7-0cef673183e5" xlink:to="loc_us-gaap_OperatingExpenses_01e7e028-95bf-4481-babf-8848fa1b4903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0b81f0fb-a4e9-40ab-b8eb-511cbc58b0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7a5dbf28-3fc4-4c1c-9ee7-5adfc8f345ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0b81f0fb-a4e9-40ab-b8eb-511cbc58b0d1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7a5dbf28-3fc4-4c1c-9ee7-5adfc8f345ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8a5658f0-aa60-41ea-afaf-7ff2fce9e5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_0b81f0fb-a4e9-40ab-b8eb-511cbc58b0d1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8a5658f0-aa60-41ea-afaf-7ff2fce9e5c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ea3ea8fe-7543-4ddc-8814-c8201666ef47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_3b19c0fb-9bd2-4228-bd25-83ff874e7680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ea3ea8fe-7543-4ddc-8814-c8201666ef47" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_3b19c0fb-9bd2-4228-bd25-83ff874e7680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_059f4a6e-9990-4007-9ce8-906762294e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_ea3ea8fe-7543-4ddc-8814-c8201666ef47" xlink:to="loc_us-gaap_NetIncomeLoss_059f4a6e-9990-4007-9ce8-906762294e40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c1d1412-5836-432a-b493-aa6168d2ceed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_976fbbee-90fc-40f0-88d6-eccf7d682dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c1d1412-5836-432a-b493-aa6168d2ceed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_976fbbee-90fc-40f0-88d6-eccf7d682dc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_604fe7a5-0a4d-4492-9355-f178900f1769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c1d1412-5836-432a-b493-aa6168d2ceed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_604fe7a5-0a4d-4492-9355-f178900f1769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_506b1f6c-c34a-447a-b2b3-239e77275246" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5c1d1412-5836-432a-b493-aa6168d2ceed" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_506b1f6c-c34a-447a-b2b3-239e77275246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4b297c0-1bee-4ca3-a1a9-f32c1dbcffa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f36163ca-2d56-4971-afdc-a5bad52d8632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4b297c0-1bee-4ca3-a1a9-f32c1dbcffa0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f36163ca-2d56-4971-afdc-a5bad52d8632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c5e34278-1e41-4ca7-98e9-c3c6fef430e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4b297c0-1bee-4ca3-a1a9-f32c1dbcffa0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c5e34278-1e41-4ca7-98e9-c3c6fef430e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_16c22c81-1c88-4662-b299-1b7eb8366048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4b297c0-1bee-4ca3-a1a9-f32c1dbcffa0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_16c22c81-1c88-4662-b299-1b7eb8366048" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_40cadaba-e2d5-44ef-a839-e0a951c299f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4b297c0-1bee-4ca3-a1a9-f32c1dbcffa0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_40cadaba-e2d5-44ef-a839-e0a951c299f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41f07b29-136d-4f95-b966-9e913f14aced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f3d745f-4893-43dc-a8ec-7cf3a1a44a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_41f07b29-136d-4f95-b966-9e913f14aced" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5f3d745f-4893-43dc-a8ec-7cf3a1a44a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b4f0fbad-07ff-47f9-b0ef-301be04348cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b4f0fbad-07ff-47f9-b0ef-301be04348cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c5362480-a5b6-4e8b-932f-e99b4763d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_c5362480-a5b6-4e8b-932f-e99b4763d02b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_c2c023e9-b72a-45ff-9a15-ef02e08b6ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_PaidInKindInterest_c2c023e9-b72a-45ff-9a15-ef02e08b6ac4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_40a35d90-b8e9-473f-b68e-c0375c3c4fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_40a35d90-b8e9-473f-b68e-c0375c3c4fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3e378d84-d266-4036-a6bf-68424e4ece88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_ShareBasedCompensation_3e378d84-d266-4036-a6bf-68424e4ece88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1b472cf2-b039-4d7c-a8b9-17d40467a4bf" xlink:href="cdtx-20220930.xsd#cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_1b472cf2-b039-4d7c-a8b9-17d40467a4bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_43a09366-22e7-41a0-a218-22fd083152f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_43a09366-22e7-41a0-a218-22fd083152f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b0b9d7e-c435-4077-8907-cf804ab0a218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_NetIncomeLoss_6b0b9d7e-c435-4077-8907-cf804ab0a218" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_15d4c745-80ba-4959-b565-dfd4d1a0cf55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_15d4c745-80ba-4959-b565-dfd4d1a0cf55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_0b6fc066-4408-4dbf-b2b0-dc18a4301b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_DepreciationAndAmortization_0b6fc066-4408-4dbf-b2b0-dc18a4301b4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_8b46d93d-4f80-4773-be94-beaeb203927f" xlink:href="cdtx-20220930.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_8b46d93d-4f80-4773-be94-beaeb203927f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2563b875-4c19-4f84-8b2f-6c3dd9d677dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2563b875-4c19-4f84-8b2f-6c3dd9d677dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_aa6d1bc7-a6f3-47ef-9010-5e5dd44c8894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0cb9ac6-c034-409a-9ff4-9538ef303553" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_aa6d1bc7-a6f3-47ef-9010-5e5dd44c8894" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d0a37493-82cb-439c-9dff-e8c052fd2689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_f5d2812f-bf05-4f29-b3d6-dff15b14a5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d0a37493-82cb-439c-9dff-e8c052fd2689" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_f5d2812f-bf05-4f29-b3d6-dff15b14a5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2b201eb3-9b63-4b94-bbab-80533607fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_d0a37493-82cb-439c-9dff-e8c052fd2689" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2b201eb3-9b63-4b94-bbab-80533607fdb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96b49390-0b83-4365-b517-31829d2ed48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_fc8c193b-0b9b-42fb-b771-13d620638ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96b49390-0b83-4365-b517-31829d2ed48b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_fc8c193b-0b9b-42fb-b771-13d620638ae2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe83df55-f736-45e1-9f3c-1d6d450792d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96b49390-0b83-4365-b517-31829d2ed48b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe83df55-f736-45e1-9f3c-1d6d450792d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f8bb4c5d-3607-4ada-8efe-e09b8d701c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96b49390-0b83-4365-b517-31829d2ed48b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_f8bb4c5d-3607-4ada-8efe-e09b8d701c18" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_e95ec28f-6e4f-4581-b8ee-ca4e4573541f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c42fd0a1-69cf-46bc-aedc-fe4856219c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e95ec28f-6e4f-4581-b8ee-ca4e4573541f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c42fd0a1-69cf-46bc-aedc-fe4856219c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3b7aeb30-9937-4062-b6ad-e4a5e211711d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_e95ec28f-6e4f-4581-b8ee-ca4e4573541f" xlink:to="loc_us-gaap_RestrictedCash_3b7aeb30-9937-4062-b6ad-e4a5e211711d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_174f8471-a4c3-4080-be73-2544bf3503fb" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_7fe82feb-f291-43df-ba8a-f0674d0226bd" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_174f8471-a4c3-4080-be73-2544bf3503fb" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_7fe82feb-f291-43df-ba8a-f0674d0226bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_d623997c-775c-4bfd-9ef3-6f7b237a4fa0" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_174f8471-a4c3-4080-be73-2544bf3503fb" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_d623997c-775c-4bfd-9ef3-6f7b237a4fa0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83e717ef-a463-472a-a74e-dac5e79e06c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a6ac98b1-a4ca-4a51-b7b6-d5d62a31196b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83e717ef-a463-472a-a74e-dac5e79e06c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a6ac98b1-a4ca-4a51-b7b6-d5d62a31196b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_58c6d527-e3f6-4672-a904-111a23239d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83e717ef-a463-472a-a74e-dac5e79e06c1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_58c6d527-e3f6-4672-a904-111a23239d20" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8c8701b-b649-4350-a7fd-c040af67a38d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3294e7d2-a0be-4e5b-a35d-065a4cfe578a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8c8701b-b649-4350-a7fd-c040af67a38d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3294e7d2-a0be-4e5b-a35d-065a4cfe578a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a05134e2-abe4-4d0c-8f50-7efdeaff3863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f8c8701b-b649-4350-a7fd-c040af67a38d" xlink:to="loc_us-gaap_OperatingLeaseLiability_a05134e2-abe4-4d0c-8f50-7efdeaff3863" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_734f3120-f5e3-4e86-b621-53193bc140cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c76d9e0-0c2f-47dc-922a-92a2d3d4427b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_734f3120-f5e3-4e86-b621-53193bc140cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c76d9e0-0c2f-47dc-922a-92a2d3d4427b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_174a4b31-3617-47e5-adea-f9af7e7a687c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_734f3120-f5e3-4e86-b621-53193bc140cb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_174a4b31-3617-47e5-adea-f9af7e7a687c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>cdtx-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a568bcbd-732c-4e03-9327-71091167a8dd,g:435374c1-7d67-4ed0-913a-245b913da5ec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i6d3f8dc7aea4430b8d4c0614330e9252_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:to="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f5eb10ac-de84-45f9-88fc-6c369263e5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f5eb10ac-de84-45f9-88fc-6c369263e5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7fd05da6-0713-43ae-849b-f66fce11b3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_RestrictedCashCurrent_7fd05da6-0713-43ae-849b-f66fce11b3c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dbb07df7-b892-4c30-a04b-de4895410266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dbb07df7-b892-4c30-a04b-de4895410266" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7a95790f-aa7d-45ff-b153-23019e012f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7a95790f-aa7d-45ff-b153-23019e012f1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6855cb1e-3313-46df-8e9c-eba08adbcf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_AssetsCurrent_6855cb1e-3313-46df-8e9c-eba08adbcf74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d5fe8740-2b39-4d3e-9647-9741cf3c6274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d5fe8740-2b39-4d3e-9647-9741cf3c6274" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06a09531-3c3b-42fa-bddd-374d841c06a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06a09531-3c3b-42fa-bddd-374d841c06a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_60a7fa53-0093-4324-bfb9-3148e2fc3d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_60a7fa53-0093-4324-bfb9-3148e2fc3d1f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_76f39450-6bb1-4dba-8a15-628cdf0566fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_Assets_76f39450-6bb1-4dba-8a15-628cdf0566fe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ce3ede63-809d-4721-8bad-259fcdadcf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_AccountsPayableCurrent_ce3ede63-809d-4721-8bad-259fcdadcf71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5cdc81b2-daaf-4337-be9d-cddd0147de19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5cdc81b2-daaf-4337-be9d-cddd0147de19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bfb5c96d-39e8-433a-a6ce-5ae4b6a18295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bfb5c96d-39e8-433a-a6ce-5ae4b6a18295" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_43752ef1-c42e-46bc-b127-b7911641e914" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_43752ef1-c42e-46bc-b127-b7911641e914" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9aa5fe01-b0bc-4d27-ba4a-acaef2e294e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9aa5fe01-b0bc-4d27-ba4a-acaef2e294e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_92e60491-af12-4050-b574-d40b7240e095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_LoansPayableCurrent_92e60491-af12-4050-b574-d40b7240e095" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_df6f6abe-af7b-4b8b-869c-7cb1b22dbf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_LiabilitiesCurrent_df6f6abe-af7b-4b8b-869c-7cb1b22dbf1c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_5d81f996-fbe0-4048-b56c-b79918f86cd7" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_5d81f996-fbe0-4048-b56c-b79918f86cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0eddac77-21ee-43e9-a99a-93835b3f6d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0eddac77-21ee-43e9-a99a-93835b3f6d71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c7ceed34-94de-4167-b98c-267982f7b3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_Liabilities_c7ceed34-94de-4167-b98c-267982f7b3b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2323e3b4-16f7-4f18-91c3-ef29d4ea55d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2323e3b4-16f7-4f18-91c3-ef29d4ea55d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8e921a99-2a27-4e9c-bb0f-a072ff87d279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_PreferredStockValue_8e921a99-2a27-4e9c-bb0f-a072ff87d279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_61579247-65f3-4341-b0a5-3aee213eb918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_CommonStockValue_61579247-65f3-4341-b0a5-3aee213eb918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1f80772e-dc93-4cbd-b90f-aae3a6eb974a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1f80772e-dc93-4cbd-b90f-aae3a6eb974a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19276f7f-b8d5-4b91-8d64-bd3feafdd5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19276f7f-b8d5-4b91-8d64-bd3feafdd5a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a803312a-a1f6-42b5-a2ce-3eff5b2d8a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_StockholdersEquity_a803312a-a1f6-42b5-a2ce-3eff5b2d8a3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b67c91a3-7f1c-4ef0-a839-a7aafc7c524d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b67c91a3-7f1c-4ef0-a839-a7aafc7c524d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ea4cfd3-2116-4aaf-afdf-80d4c4c3382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:to="loc_us-gaap_StatementTable_8ea4cfd3-2116-4aaf-afdf-80d4c4c3382b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_125e4f23-bae0-43a5-b4b5-22e8373bb52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8ea4cfd3-2116-4aaf-afdf-80d4c4c3382b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_125e4f23-bae0-43a5-b4b5-22e8373bb52e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_125e4f23-bae0-43a5-b4b5-22e8373bb52e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_125e4f23-bae0-43a5-b4b5-22e8373bb52e" xlink:to="loc_us-gaap_ClassOfStockDomain_125e4f23-bae0-43a5-b4b5-22e8373bb52e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa8555ff-00ab-482f-9c1a-7f23a129f745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_125e4f23-bae0-43a5-b4b5-22e8373bb52e" xlink:to="loc_us-gaap_ClassOfStockDomain_aa8555ff-00ab-482f-9c1a-7f23a129f745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_faf37de1-0724-4123-aa61-19e88caf8135" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_aa8555ff-00ab-482f-9c1a-7f23a129f745" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_faf37de1-0724-4123-aa61-19e88caf8135" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i7869fd6045964cbca95311c97d5bc77e_CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_77ff26e3-b229-4052-a87a-9ed6a1c14ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_77ff26e3-b229-4052-a87a-9ed6a1c14ebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_442c73ae-36e5-4d40-8785-30ddb8de659b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_442c73ae-36e5-4d40-8785-30ddb8de659b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3b1a088b-53e8-4407-9eea-ffedaf0beccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3b1a088b-53e8-4407-9eea-ffedaf0beccb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7eb7ef6e-93ba-4949-aff9-ba03c8a46ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7eb7ef6e-93ba-4949-aff9-ba03c8a46ad3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7378e4de-8d2d-467e-ba61-8552b1f38c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7378e4de-8d2d-467e-ba61-8552b1f38c1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a2427c0c-503d-4b94-8a77-37f35bfe7948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a2427c0c-503d-4b94-8a77-37f35bfe7948" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_94a5459f-45dd-4d4a-866c-5746661541d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockSharesIssued_94a5459f-45dd-4d4a-866c-5746661541d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_246f95a1-2adb-41ee-b9fb-50e1005b888b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_246f95a1-2adb-41ee-b9fb-50e1005b888b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ee1e153-7294-401d-a569-ca5109747a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_StatementTable_8ee1e153-7294-401d-a569-ca5109747a8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9690406f-e2aa-4440-8de6-78aeb6779901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8ee1e153-7294-401d-a569-ca5109747a8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9690406f-e2aa-4440-8de6-78aeb6779901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9690406f-e2aa-4440-8de6-78aeb6779901_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9690406f-e2aa-4440-8de6-78aeb6779901" xlink:to="loc_us-gaap_ClassOfStockDomain_9690406f-e2aa-4440-8de6-78aeb6779901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2883f99a-dc40-4bde-9829-99b975ee2dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9690406f-e2aa-4440-8de6-78aeb6779901" xlink:to="loc_us-gaap_ClassOfStockDomain_2883f99a-dc40-4bde-9829-99b975ee2dc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_789dce78-29b2-49c4-a5cc-661f914fca0d" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2883f99a-dc40-4bde-9829-99b975ee2dc4" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_789dce78-29b2-49c4-a5cc-661f914fca0d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="i9784bd5a0d2b4a0a865a0f9f4cf5b993_CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8ab53a3-352e-4cc2-b25d-8391b73af9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f8ab53a3-352e-4cc2-b25d-8391b73af9f2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_56f05a83-ab35-4315-bd80-0874e4030e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_56f05a83-ab35-4315-bd80-0874e4030e59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e3cd81fa-79ee-4206-9397-09ad94f24a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockholdersEquity_e3cd81fa-79ee-4206-9397-09ad94f24a27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b06e2ff-93e2-4de5-aa10-f72967854608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b06e2ff-93e2-4de5-aa10-f72967854608" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79d7e8e5-0b88-40e0-9f25-a6424519fa43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79d7e8e5-0b88-40e0-9f25-a6424519fa43" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0452cd4-35bb-4fd1-9ea2-8b8dc70f28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0452cd4-35bb-4fd1-9ea2-8b8dc70f28b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c6e755f-2492-48a4-a7b9-743534c7cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c6e755f-2492-48a4-a7b9-743534c7cbed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_68c40de4-4ab8-4fae-bcb0-6a0ae84ae0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_68c40de4-4ab8-4fae-bcb0-6a0ae84ae0cc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d916a662-5383-449a-902f-888c31fc5b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d916a662-5383-449a-902f-888c31fc5b80" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7660121-d390-4809-a9e1-5ef8cd1921c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7660121-d390-4809-a9e1-5ef8cd1921c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e4e41dbc-9381-4981-8578-cdcfb9756646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e4e41dbc-9381-4981-8578-cdcfb9756646" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_8d446858-36a5-41cd-95df-4d643c8ec0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_8d446858-36a5-41cd-95df-4d643c8ec0de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f583b49f-a3ed-4a4c-b839-4b9eb8963134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f583b49f-a3ed-4a4c-b839-4b9eb8963134" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b4162ff-c9b1-4ac9-b7f5-c8920bae5357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_NetIncomeLoss_0b4162ff-c9b1-4ac9-b7f5-c8920bae5357" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_917c6bad-0580-4312-ae6c-e4b98f50c4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2aac50e8-4c18-4a33-a646-37475fe3ffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_58c2e0c8-376f-415e-b63b-96561f23ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f8ab53a3-352e-4cc2-b25d-8391b73af9f2" xlink:to="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_02843ce4-0295-48a1-a0e1-636a9b4877a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_02843ce4-0295-48a1-a0e1-636a9b4877a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_02843ce4-0295-48a1-a0e1-636a9b4877a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_02843ce4-0295-48a1-a0e1-636a9b4877a4" xlink:to="loc_us-gaap_ClassOfStockDomain_02843ce4-0295-48a1-a0e1-636a9b4877a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8bcff19e-37c6-4e69-8066-407b2ac5d030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_02843ce4-0295-48a1-a0e1-636a9b4877a4" xlink:to="loc_us-gaap_ClassOfStockDomain_8bcff19e-37c6-4e69-8066-407b2ac5d030" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_5f9d3fba-e92a-47f4-a966-83e0a7f4982e" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8bcff19e-37c6-4e69-8066-407b2ac5d030" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_5f9d3fba-e92a-47f4-a966-83e0a7f4982e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a499e3c-82e0-495f-9c3d-ff626a74d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a499e3c-82e0-495f-9c3d-ff626a74d4bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5a499e3c-82e0-495f-9c3d-ff626a74d4bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a499e3c-82e0-495f-9c3d-ff626a74d4bd" xlink:to="loc_us-gaap_EquityComponentDomain_5a499e3c-82e0-495f-9c3d-ff626a74d4bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a499e3c-82e0-495f-9c3d-ff626a74d4bd" xlink:to="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_93020c93-b4bd-4ef8-af92-9254aa3fb95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_PreferredStockMember_93020c93-b4bd-4ef8-af92-9254aa3fb95f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_326108ca-0f29-43df-afc3-f3736f021353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_CommonStockMember_326108ca-0f29-43df-afc3-f3736f021353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c85fdb8c-566e-4151-969c-4e1ff90828ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c85fdb8c-566e-4151-969c-4e1ff90828ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bd3c243a-f03d-4040-bbd8-b2d4184c9a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_RetainedEarningsMember_bd3c243a-f03d-4040-bbd8-b2d4184c9a04" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended" id="i33e152633bb04e90b37624bdf8c8a25f_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb93432c-bf7b-4858-83b0-1e89cd2b6890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb93432c-bf7b-4858-83b0-1e89cd2b6890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_9f241b35-8b95-4974-b458-629beb08174e" xlink:href="cdtx-20220930.xsd#cdtx_CollaborationAgreementNumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:to="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_9f241b35-8b95-4974-b458-629beb08174e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b463feb-33fd-47b8-936f-ae4716902d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b463feb-33fd-47b8-936f-ae4716902d2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:to="loc_srt_CounterpartyNameAxis_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_b7f39b00-d6af-4a76-b941-6b026f4632f1" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_b7f39b00-d6af-4a76-b941-6b026f4632f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_7aa398f3-0118-4f50-a9e6-1db56473c23b" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_7aa398f3-0118-4f50-a9e6-1db56473c23b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_fc980bf3-fce3-4c25-82b9-5b5d3ac0f62c" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_fc980bf3-fce3-4c25-82b9-5b5d3ac0f62c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_406ba2a5-1082-477a-ac48-028a2439199f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_406ba2a5-1082-477a-ac48-028a2439199f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_406ba2a5-1082-477a-ac48-028a2439199f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_406ba2a5-1082-477a-ac48-028a2439199f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_406ba2a5-1082-477a-ac48-028a2439199f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98a29aba-b9b4-43a7-af22-83491106cc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_406ba2a5-1082-477a-ac48-028a2439199f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98a29aba-b9b4-43a7-af22-83491106cc57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenCollaborationAgreementMember_eac09376-b2ff-46b1-8640-39c912c96c88" xlink:href="cdtx-20220930.xsd#cdtx_JanssenCollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98a29aba-b9b4-43a7-af22-83491106cc57" xlink:to="loc_cdtx_JanssenCollaborationAgreementMember_eac09376-b2ff-46b1-8640-39c912c96c88" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13b80875-0a2e-4166-be97-d7faa7e98bf1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:to="loc_srt_RangeAxis_13b80875-0a2e-4166-be97-d7faa7e98bf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_13b80875-0a2e-4166-be97-d7faa7e98bf1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_13b80875-0a2e-4166-be97-d7faa7e98bf1" xlink:to="loc_srt_RangeMember_13b80875-0a2e-4166-be97-d7faa7e98bf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_13b80875-0a2e-4166-be97-d7faa7e98bf1" xlink:to="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bd1a2c96-ed2f-4fcf-b04a-706bfd1a71a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:to="loc_srt_MinimumMember_bd1a2c96-ed2f-4fcf-b04a-706bfd1a71a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_453f6e7c-63bb-416d-929a-c7d19a8d9465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:to="loc_srt_MaximumMember_453f6e7c-63bb-416d-929a-c7d19a8d9465" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="extended" id="i81abe4de4fb84fb89bcbe154360f1a85_SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d8cbd58-748b-4d41-9022-87f969bcce38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0005a9af-cdf9-459f-b692-ec9533a06ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d8cbd58-748b-4d41-9022-87f969bcce38" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0005a9af-cdf9-459f-b692-ec9533a06ee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c790d726-549f-4390-af3d-19f4e4d54358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d8cbd58-748b-4d41-9022-87f969bcce38" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c790d726-549f-4390-af3d-19f4e4d54358" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7b43752-931e-4293-9123-750640689efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c790d726-549f-4390-af3d-19f4e4d54358" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7b43752-931e-4293-9123-750640689efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d7b43752-931e-4293-9123-750640689efd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7b43752-931e-4293-9123-750640689efd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_d7b43752-931e-4293-9123-750640689efd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7b43752-931e-4293-9123-750640689efd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_89fbca43-7b61-4bcc-9567-56534774e4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:to="loc_us-gaap_WarrantMember_89fbca43-7b61-4bcc-9567-56534774e4cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7674dbfb-7bbb-46ad-960e-e1b4353a5374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7674dbfb-7bbb-46ad-960e-e1b4353a5374" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_f15d07da-d12d-48c4-a1b4-9bb12b284968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:to="loc_us-gaap_StockCompensationPlanMember_f15d07da-d12d-48c4-a1b4-9bb12b284968" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i40518adc2b054159972eda9c0ef62ce6_FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d856b2e2-6d05-4ae2-9221-1c3f0dd01119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d856b2e2-6d05-4ae2-9221-1c3f0dd01119" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9dfba42d-76fe-4028-ba80-65669fc200c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9dfba42d-76fe-4028-ba80-65669fc200c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bf168a46-2f95-41f6-99aa-2922524946d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:to="loc_us-gaap_RestrictedCash_bf168a46-2f95-41f6-99aa-2922524946d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3bfc8d99-6581-418c-ab4a-2482d26afa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3bfc8d99-6581-418c-ab4a-2482d26afa64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc4a1b6b-76d5-4179-ad0f-703619dde95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d856b2e2-6d05-4ae2-9221-1c3f0dd01119" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc4a1b6b-76d5-4179-ad0f-703619dde95a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61b3ef44-2285-4a7b-872d-804e2c306c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc4a1b6b-76d5-4179-ad0f-703619dde95a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61b3ef44-2285-4a7b-872d-804e2c306c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61b3ef44-2285-4a7b-872d-804e2c306c71_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61b3ef44-2285-4a7b-872d-804e2c306c71" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_61b3ef44-2285-4a7b-872d-804e2c306c71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61b3ef44-2285-4a7b-872d-804e2c306c71" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_798d694d-d745-4703-a832-592f8d192900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_798d694d-d745-4703-a832-592f8d192900" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4a346eed-9ec5-40b3-b7f7-c4b49ee25ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4a346eed-9ec5-40b3-b7f7-c4b49ee25ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a0b55522-15a9-4dd5-aeb9-53a60b780b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a0b55522-15a9-4dd5-aeb9-53a60b780b90" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#DEBTAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="extended" id="i1a5c69a50c424462bb7902be5eba33b2_DEBTAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_81c59d2c-8a5b-47a1-9c4a-f067737dcbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_81c59d2c-8a5b-47a1-9c4a-f067737dcbc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_073bf16c-0d84-41c8-a31f-26243394075b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_073bf16c-0d84-41c8-a31f-26243394075b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7f0403c0-617d-4cfe-b75a-c3bbb479f699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7f0403c0-617d-4cfe-b75a-c3bbb479f699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:to="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_235e8e32-36ec-43fb-a9f0-033d09c57e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_235e8e32-36ec-43fb-a9f0-033d09c57e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_235e8e32-36ec-43fb-a9f0-033d09c57e1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_235e8e32-36ec-43fb-a9f0-033d09c57e1b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_235e8e32-36ec-43fb-a9f0-033d09c57e1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0935d82-b008-45e2-ba40-a908a342fae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_235e8e32-36ec-43fb-a9f0-033d09c57e1b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0935d82-b008-45e2-ba40-a908a342fae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_9e2a39f8-bd06-4deb-81c0-252054d30e59" xlink:href="cdtx-20220930.xsd#cdtx_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c0935d82-b008-45e2-ba40-a908a342fae4" xlink:to="loc_cdtx_TermLoanMember_9e2a39f8-bd06-4deb-81c0-252054d30e59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_222760ed-793f-4d99-9578-0eb446988368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:to="loc_us-gaap_DebtInstrumentAxis_222760ed-793f-4d99-9578-0eb446988368" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_222760ed-793f-4d99-9578-0eb446988368_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_222760ed-793f-4d99-9578-0eb446988368" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_222760ed-793f-4d99-9578-0eb446988368_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_993c98ab-5765-4b24-ae92-df217a613fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_222760ed-793f-4d99-9578-0eb446988368" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_993c98ab-5765-4b24-ae92-df217a613fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_a5ce6e71-b7a6-4188-a8bb-32c0c2ccf7a0" xlink:href="cdtx-20220930.xsd#cdtx_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_993c98ab-5765-4b24-ae92-df217a613fd3" xlink:to="loc_cdtx_TermLoanAMember_a5ce6e71-b7a6-4188-a8bb-32c0c2ccf7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_687fb666-74ad-4610-b48e-568631e77fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:to="loc_us-gaap_VariableRateAxis_687fb666-74ad-4610-b48e-568631e77fcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_687fb666-74ad-4610-b48e-568631e77fcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_687fb666-74ad-4610-b48e-568631e77fcd" xlink:to="loc_us-gaap_VariableRateDomain_687fb666-74ad-4610-b48e-568631e77fcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_30305591-0c59-4097-abb4-635e56716661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_687fb666-74ad-4610-b48e-568631e77fcd" xlink:to="loc_us-gaap_VariableRateDomain_30305591-0c59-4097-abb4-635e56716661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_8daf6dc7-1c31-4aa6-a683-e6cf48e7fffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_30305591-0c59-4097-abb4-635e56716661" xlink:to="loc_us-gaap_PrimeRateMember_8daf6dc7-1c31-4aa6-a683-e6cf48e7fffc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended" id="if8fcd6c862c744a9bc5edc6e899a6842_STOCKHOLDERSEQUITYNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f1294998-c5f8-49c5-aa80-09b740674343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f1294998-c5f8-49c5-aa80-09b740674343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c8c5737f-9f90-47a6-8886-71806fbd8502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c8c5737f-9f90-47a6-8886-71806fbd8502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_2fc972b4-15df-483b-9bd2-cc67334ffa2b" xlink:href="cdtx-20220930.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_2fc972b4-15df-483b-9bd2-cc67334ffa2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e6757f7f-c6b8-4249-8914-da37bc7ae9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e6757f7f-c6b8-4249-8914-da37bc7ae9cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f52151da-3ca6-47e1-96cc-e4d0d0e0c63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f52151da-3ca6-47e1-96cc-e4d0d0e0c63d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c86d45fa-e7cc-4090-b300-e246adba5d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c86d45fa-e7cc-4090-b300-e246adba5d9b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_942f92ab-3c71-4e30-b96f-95e69d4b2efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_942f92ab-3c71-4e30-b96f-95e69d4b2efe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a8651cd1-6add-4dd3-bb61-d25dc3543330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a8651cd1-6add-4dd3-bb61-d25dc3543330" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b1fb8ada-d8b7-433a-acba-c323703fb5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b1fb8ada-d8b7-433a-acba-c323703fb5f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f68c3ee-0198-4c59-b1e3-9dd13f1fde0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f68c3ee-0198-4c59-b1e3-9dd13f1fde0d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ac508d3-5a63-403d-a1f1-d17eea7c53dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ac508d3-5a63-403d-a1f1-d17eea7c53dc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_85f85ff4-07ba-4a66-b663-770857b0b842" xlink:href="cdtx-20220930.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_85f85ff4-07ba-4a66-b663-770857b0b842" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_914c1176-f918-43ed-b6b3-89f465579e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_914c1176-f918-43ed-b6b3-89f465579e15" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_2b411dfa-67d4-49e1-8a7f-e7de360e41d2" xlink:href="cdtx-20220930.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_2b411dfa-67d4-49e1-8a7f-e7de360e41d2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_24fd66e5-08c6-49a9-b442-fbacd9a9b3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_24fd66e5-08c6-49a9-b442-fbacd9a9b3be" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9091c087-9123-47d5-94f5-cb54cbf2a16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9091c087-9123-47d5-94f5-cb54cbf2a16e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_741f602a-6b69-413b-87bd-204e76b9ba2e" xlink:href="cdtx-20220930.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_741f602a-6b69-413b-87bd-204e76b9ba2e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_92296089-ce89-4100-8334-8477ef9ec7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_92296089-ce89-4100-8334-8477ef9ec7bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92296089-ce89-4100-8334-8477ef9ec7bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_92296089-ce89-4100-8334-8477ef9ec7bf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_92296089-ce89-4100-8334-8477ef9ec7bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_92296089-ce89-4100-8334-8477ef9ec7bf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_ddb37907-9928-4f66-b742-cd374179d220" xlink:href="cdtx-20220930.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_ddb37907-9928-4f66-b742-cd374179d220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicStockOfferingMember_b5a076c5-6ede-4ffd-84a4-fc33dc84b507" xlink:href="cdtx-20220930.xsd#cdtx_PublicStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:to="loc_cdtx_PublicStockOfferingMember_b5a076c5-6ede-4ffd-84a4-fc33dc84b507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d5f102ff-d86d-4914-9305-75d899a70b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d5f102ff-d86d-4914-9305-75d899a70b7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_905bbf7b-ea59-413c-94e9-e65979b70f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_905bbf7b-ea59-413c-94e9-e65979b70f82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_905bbf7b-ea59-413c-94e9-e65979b70f82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_905bbf7b-ea59-413c-94e9-e65979b70f82" xlink:to="loc_us-gaap_EquityComponentDomain_905bbf7b-ea59-413c-94e9-e65979b70f82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6cabf0fb-8203-4f46-83b1-b564a0662188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_905bbf7b-ea59-413c-94e9-e65979b70f82" xlink:to="loc_us-gaap_EquityComponentDomain_6cabf0fb-8203-4f46-83b1-b564a0662188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0cfd04d7-e68d-4c9b-9116-627791208960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6cabf0fb-8203-4f46-83b1-b564a0662188" xlink:to="loc_us-gaap_CommonStockMember_0cfd04d7-e68d-4c9b-9116-627791208960" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d1726263-6dc5-4741-8312-589d15fc4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d1726263-6dc5-4741-8312-589d15fc4b25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1726263-6dc5-4741-8312-589d15fc4b25_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d1726263-6dc5-4741-8312-589d15fc4b25" xlink:to="loc_us-gaap_ClassOfStockDomain_d1726263-6dc5-4741-8312-589d15fc4b25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a657dc2-a5db-4217-b7a7-a16fdc4ebb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d1726263-6dc5-4741-8312-589d15fc4b25" xlink:to="loc_us-gaap_ClassOfStockDomain_3a657dc2-a5db-4217-b7a7-a16fdc4ebb8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_1ac1931c-9153-41d5-926b-5988199c0399" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3a657dc2-a5db-4217-b7a7-a16fdc4ebb8d" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_1ac1931c-9153-41d5-926b-5988199c0399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9872cb43-88b5-4518-8d7c-cc1397339e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9872cb43-88b5-4518-8d7c-cc1397339e67" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9872cb43-88b5-4518-8d7c-cc1397339e67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9872cb43-88b5-4518-8d7c-cc1397339e67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9872cb43-88b5-4518-8d7c-cc1397339e67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6c88610b-8f99-4778-a81e-af132f07e6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9872cb43-88b5-4518-8d7c-cc1397339e67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6c88610b-8f99-4778-a81e-af132f07e6cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_791c6af1-ee9e-439d-9d9a-e84b7f740afb" xlink:href="cdtx-20220930.xsd#cdtx_CommonStockWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6c88610b-8f99-4778-a81e-af132f07e6cc" xlink:to="loc_cdtx_CommonStockWarrantMember_791c6af1-ee9e-439d-9d9a-e84b7f740afb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_srt_RangeAxis_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba" xlink:to="loc_srt_RangeMember_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_672721eb-03d3-447f-be45-98f5d7a4fe91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba" xlink:to="loc_srt_RangeMember_672721eb-03d3-447f-be45-98f5d7a4fe91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_24f693d3-7d5d-480a-b8a3-91d68cac9713" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_672721eb-03d3-447f-be45-98f5d7a4fe91" xlink:to="loc_srt_WeightedAverageMember_24f693d3-7d5d-480a-b8a3-91d68cac9713" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="i1c79c443406f44938ec3d429d9510247_STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c9ad0085-92bc-459f-83f7-351efffe01c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9ecb7083-9d33-451d-ad3a-0f7f76b7a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_c9ad0085-92bc-459f-83f7-351efffe01c6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9ecb7083-9d33-451d-ad3a-0f7f76b7a99f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7893803a-951c-4348-99e2-cc3a5acfc6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_c9ad0085-92bc-459f-83f7-351efffe01c6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7893803a-951c-4348-99e2-cc3a5acfc6a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bfc752e-536c-4f00-af75-12027dff4c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7893803a-951c-4348-99e2-cc3a5acfc6a5" xlink:to="loc_us-gaap_AwardTypeAxis_9bfc752e-536c-4f00-af75-12027dff4c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bfc752e-536c-4f00-af75-12027dff4c57_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9bfc752e-536c-4f00-af75-12027dff4c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9bfc752e-536c-4f00-af75-12027dff4c57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9bfc752e-536c-4f00-af75-12027dff4c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b9db4fa4-7e44-4f9e-ad5e-061fae830336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_us-gaap_WarrantMember_b9db4fa4-7e44-4f9e-ad5e-061fae830336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_3f6e5f2d-030a-49e3-ae78-e04045b5dded" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_3f6e5f2d-030a-49e3-ae78-e04045b5dded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_68e79ed7-f5b8-4fe5-a847-4f68fa3ce841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_us-gaap_StockCompensationPlanMember_68e79ed7-f5b8-4fe5-a847-4f68fa3ce841" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_24ab0209-b380-4316-8228-8245390fb567" xlink:href="cdtx-20220930.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_24ab0209-b380-4316-8228-8245390fb567" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fc475a99-6120-4bf3-a09f-8099614d6b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_us-gaap_EmployeeStockMember_fc475a99-6120-4bf3-a09f-8099614d6b47" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended" id="i55f5e536fc06497caced8057d7b78e0c_EQUITYINCENTIVEPLANSAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_2f18e6da-2ba6-4b02-8960-c1a91ac1d769" xlink:href="cdtx-20220930.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_2f18e6da-2ba6-4b02-8960-c1a91ac1d769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ab60c471-298b-4011-8c0c-4d071346cd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ab60c471-298b-4011-8c0c-4d071346cd2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8ec403ea-90fa-4296-9da6-59e1f8f980bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8ec403ea-90fa-4296-9da6-59e1f8f980bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_32f82197-bb2c-441e-a9ee-2ad9ba7be19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_32f82197-bb2c-441e-a9ee-2ad9ba7be19f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_0bfe25b8-024c-447b-af4f-8dce413755cb" xlink:href="cdtx-20220930.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_0bfe25b8-024c-447b-af4f-8dce413755cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_567e4ff3-163f-40b2-8b56-4fbce61e1390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_567e4ff3-163f-40b2-8b56-4fbce61e1390" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f1829240-3950-4bed-8f98-72edb3a3066b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f1829240-3950-4bed-8f98-72edb3a3066b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_33b42a18-c795-40c4-8edf-5d9ee87e25d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_33b42a18-c795-40c4-8edf-5d9ee87e25d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9a1ff46a-c8ad-45b5-bae8-efc20ab30549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9a1ff46a-c8ad-45b5-bae8-efc20ab30549" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63d37d6c-fd55-4f8c-a77c-a7b6df71f44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63d37d6c-fd55-4f8c-a77c-a7b6df71f44b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_358e4b15-75d3-4ee5-b6be-5956df912c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_358e4b15-75d3-4ee5-b6be-5956df912c35" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d151bcf5-f504-4d7a-86c1-9589e2fa3c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d151bcf5-f504-4d7a-86c1-9589e2fa3c85" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a343f6cd-58a7-4461-9abd-c3683e2252b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a343f6cd-58a7-4461-9abd-c3683e2252b6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e1568cc6-75c4-4823-9a93-3bb0ed24513b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e1568cc6-75c4-4823-9a93-3bb0ed24513b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_af5956ac-6799-4508-a94c-36c22e4849ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_us-gaap_PlanNameAxis_af5956ac-6799-4508-a94c-36c22e4849ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_af5956ac-6799-4508-a94c-36c22e4849ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_af5956ac-6799-4508-a94c-36c22e4849ac" xlink:to="loc_us-gaap_PlanNameDomain_af5956ac-6799-4508-a94c-36c22e4849ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ebe9f92c-73b5-42db-b5e5-6b6760c8886f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_af5956ac-6799-4508-a94c-36c22e4849ac" xlink:to="loc_us-gaap_PlanNameDomain_ebe9f92c-73b5-42db-b5e5-6b6760c8886f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_9862ac62-b3e0-4522-a998-acefceb01af5" xlink:href="cdtx-20220930.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_ebe9f92c-73b5-42db-b5e5-6b6760c8886f" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_9862ac62-b3e0-4522-a998-acefceb01af5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_07f2a94b-60fc-486c-b676-9095ad93c511" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_srt_RangeAxis_07f2a94b-60fc-486c-b676-9095ad93c511" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_07f2a94b-60fc-486c-b676-9095ad93c511_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_07f2a94b-60fc-486c-b676-9095ad93c511" xlink:to="loc_srt_RangeMember_07f2a94b-60fc-486c-b676-9095ad93c511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_07f2a94b-60fc-486c-b676-9095ad93c511" xlink:to="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_daec9ea4-0454-4f07-8bc6-4a6bb53d5ac7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:to="loc_srt_MinimumMember_daec9ea4-0454-4f07-8bc6-4a6bb53d5ac7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d8d1e09-a64d-4d6b-90dc-aa538f3e1ce6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:to="loc_srt_MaximumMember_9d8d1e09-a64d-4d6b-90dc-aa538f3e1ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_964cd47c-f4bf-4e7f-9c0a-a44f290f2132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_964cd47c-f4bf-4e7f-9c0a-a44f290f2132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_964cd47c-f4bf-4e7f-9c0a-a44f290f2132_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_964cd47c-f4bf-4e7f-9c0a-a44f290f2132" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_964cd47c-f4bf-4e7f-9c0a-a44f290f2132_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_c77ab26b-d6f3-485d-918f-e1b608f1ad99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_964cd47c-f4bf-4e7f-9c0a-a44f290f2132" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_c77ab26b-d6f3-485d-918f-e1b608f1ad99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_9742aca5-6321-4ff1-9722-c463482d9034" xlink:href="cdtx-20220930.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c77ab26b-d6f3-485d-918f-e1b608f1ad99" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_9742aca5-6321-4ff1-9722-c463482d9034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_us-gaap_AwardTypeAxis_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_00a7c926-5fb0-43c5-816e-98502daf29ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:to="loc_us-gaap_EmployeeStockMember_00a7c926-5fb0-43c5-816e-98502daf29ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_4c02f365-df0a-4de8-ae9d-cf4095788025" xlink:href="cdtx-20220930.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_4c02f365-df0a-4de8-ae9d-cf4095788025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e9ceef5-8fd2-4f79-b7e9-9d58811984e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e9ceef5-8fd2-4f79-b7e9-9d58811984e0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended" id="i3180a887fad54c0a8d20f1ac26c0eca8_EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd98aa1d-79e3-4c3a-8a4d-78f99c34944b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd98aa1d-79e3-4c3a-8a4d-78f99c34944b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15e3d72b-0438-4064-a8ce-e8a85cce044e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15e3d72b-0438-4064-a8ce-e8a85cce044e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f40f0fc8-b237-4749-a0f3-ec39618eab69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f40f0fc8-b237-4749-a0f3-ec39618eab69" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d898e0d-fbc2-4880-9af1-d85bdfbaba09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d898e0d-fbc2-4880-9af1-d85bdfbaba09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82c6b33f-ffb7-4c58-a89c-9d223eab1a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6d6f31d-10d8-47f4-b52f-e4d187f2ed39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6d6f31d-10d8-47f4-b52f-e4d187f2ed39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab5ca7d3-3135-4597-b394-6016d321a7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab5ca7d3-3135-4597-b394-6016d321a7a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c1cc261c-6835-4b1b-a2d8-cbe406a18720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c1cc261c-6835-4b1b-a2d8-cbe406a18720" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8ee29753-8750-43fb-9593-8c298c3f08e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8ee29753-8750-43fb-9593-8c298c3f08e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5033c7e1-470f-4876-ba94-9eac212d1e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d82bb9eb-9f02-4d8b-8c70-5ce191a31f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d82bb9eb-9f02-4d8b-8c70-5ce191a31f67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d7fdd6f2-87ea-425d-9b55-18b88cd59ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d82bb9eb-9f02-4d8b-8c70-5ce191a31f67" xlink:to="loc_us-gaap_AwardTypeAxis_d7fdd6f2-87ea-425d-9b55-18b88cd59ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7fdd6f2-87ea-425d-9b55-18b88cd59ded_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d7fdd6f2-87ea-425d-9b55-18b88cd59ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7fdd6f2-87ea-425d-9b55-18b88cd59ded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a409923-69e0-4984-b892-836693c313cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d7fdd6f2-87ea-425d-9b55-18b88cd59ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a409923-69e0-4984-b892-836693c313cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_7ed94766-754e-4480-ac68-d7b29f7d541f" xlink:href="cdtx-20220930.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a409923-69e0-4984-b892-836693c313cf" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_7ed94766-754e-4480-ac68-d7b29f7d541f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i1a5124210f364a9f80473bd98fc79e4f_EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa001d8c-9bda-4c90-a1c1-5feeeabf394d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3c83c99f-79eb-49f4-8db7-2f678f6fd91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa001d8c-9bda-4c90-a1c1-5feeeabf394d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3c83c99f-79eb-49f4-8db7-2f678f6fd91f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae76ea60-c856-45ff-a470-57fab2440c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa001d8c-9bda-4c90-a1c1-5feeeabf394d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae76ea60-c856-45ff-a470-57fab2440c08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1da139ed-28c8-4f16-8316-bb73efe0cb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae76ea60-c856-45ff-a470-57fab2440c08" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1da139ed-28c8-4f16-8316-bb73efe0cb87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1da139ed-28c8-4f16-8316-bb73efe0cb87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1da139ed-28c8-4f16-8316-bb73efe0cb87" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1da139ed-28c8-4f16-8316-bb73efe0cb87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1da139ed-28c8-4f16-8316-bb73efe0cb87" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e3f5edf-2c73-4c88-b3f5-35d5182ac5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e3f5edf-2c73-4c88-b3f5-35d5182ac5e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ae3ba9f9-e9da-429c-844d-ca1e3ab1d583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ae3ba9f9-e9da-429c-844d-ca1e3ab1d583" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="extended" id="i6d0e6ad9bef7479498b17c5b9d975603_SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_dcefa9b4-5692-4855-b021-d3569d655e32" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_dcefa9b4-5692-4855-b021-d3569d655e32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_d206d6d8-eec9-427d-b5eb-40022482e942" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_d206d6d8-eec9-427d-b5eb-40022482e942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_14149a61-ab7d-424b-9464-733a185a9303" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_14149a61-ab7d-424b-9464-733a185a9303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_0f1ae8c1-bfa5-4ac0-9d5e-c04fc6f3bd19" xlink:href="cdtx-20220930.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_0f1ae8c1-bfa5-4ac0-9d5e-c04fc6f3bd19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7c04a19d-34cb-4d24-a0a2-db54b029fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7c04a19d-34cb-4d24-a0a2-db54b029fc38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_7732d525-f066-433e-8e7e-6a13144997ea" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_7732d525-f066-433e-8e7e-6a13144997ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_2fa7ff3b-906a-4a1c-9ef1-f46b64a8585d" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_2fa7ff3b-906a-4a1c-9ef1-f46b64a8585d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_a4e73ed0-35ca-4aa5-bbcf-6bcbdb241e29" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_a4e73ed0-35ca-4aa5-bbcf-6bcbdb241e29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_fe9b96e6-d0db-42c6-9a50-eb67e09bf75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostGross_fe9b96e6-d0db-42c6-9a50-eb67e09bf75b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_9f87abfb-65e9-4140-9bc9-58ec1c52acb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_9f87abfb-65e9-4140-9bc9-58ec1c52acb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_c53cd402-7fbf-4c98-a8a7-466c12ef9ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostNet_c53cd402-7fbf-4c98-a8a7-466c12ef9ef9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6e3b8de4-824a-423d-ba95-10f9098d7f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6e3b8de4-824a-423d-ba95-10f9098d7f60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d04689a5-257e-4b73-b4c5-7d8a34149f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d04689a5-257e-4b73-b4c5-7d8a34149f3e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_30977107-7bbc-4a10-8f57-912a275ae09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_30977107-7bbc-4a10-8f57-912a275ae09b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aaca684f-b64b-4453-afb8-14c4cea11068_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aaca684f-b64b-4453-afb8-14c4cea11068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_9942478f-1945-48be-99ea-ac72aa3ef402" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_9942478f-1945-48be-99ea-ac72aa3ef402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_50ee2be2-85f1-4392-a626-8b028b9f077d" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_50ee2be2-85f1-4392-a626-8b028b9f077d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_610ac895-7a1e-4f29-a51b-13f1d2c6f4bc" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_610ac895-7a1e-4f29-a51b-13f1d2c6f4bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1d5bc744-544a-4c21-809d-d09d7229bfa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:to="loc_us-gaap_RelatedPartyDomain_1d5bc744-544a-4c21-809d-d09d7229bfa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:to="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cf82d87a-4f3e-4174-95d6-3538912bba69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:to="loc_srt_AffiliatedEntityMember_cf82d87a-4f3e-4174-95d6-3538912bba69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c712b205-a39d-45b3-bf25-447ad85f49ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c712b205-a39d-45b3-bf25-447ad85f49ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_7be8e06a-30d3-4d5b-8ca4-129f858a4069" xlink:href="cdtx-20220930.xsd#cdtx_UpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_UpfrontPaymentMember_7be8e06a-30d3-4d5b-8ca4-129f858a4069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_be14a1a1-c39a-4d51-95ad-3f576d2bee95" xlink:href="cdtx-20220930.xsd#cdtx_RDFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_RDFundingMember_be14a1a1-c39a-4d51-95ad-3f576d2bee95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_3d6139a9-c2e7-42af-b1e0-15e455a003d2" xlink:href="cdtx-20220930.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_3d6139a9-c2e7-42af-b1e0-15e455a003d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:to="loc_srt_ProductsAndServicesDomain_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:to="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_106f0c44-732e-4d62-b4c9-962416af2d5c" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_106f0c44-732e-4d62-b4c9-962416af2d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_d9cc71a3-4dba-4dcd-b267-281294f659e9" xlink:href="cdtx-20220930.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_cdtx_MilestoneAchievementMember_d9cc71a3-4dba-4dcd-b267-281294f659e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_cc4c1bd8-a51b-4365-94f6-3d51aa2f97fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_us-gaap_RoyaltyMember_cc4c1bd8-a51b-4365-94f6-3d51aa2f97fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_b8cdd970-ce7d-4bf4-9f3e-54348994dc99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_b8cdd970-ce7d-4bf4-9f3e-54348994dc99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_5e2a8552-b0e7-4395-ab70-0f7e7e213ff9" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_5e2a8552-b0e7-4395-ab70-0f7e7e213ff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_308cf013-9a32-4740-8e47-008e74c107ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_308cf013-9a32-4740-8e47-008e74c107ae" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="extended" id="if8ebb8f1884a48c39b1429c98f728b0f_SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_dcefa9b4-5692-4855-b021-d3569d655e32" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_dcefa9b4-5692-4855-b021-d3569d655e32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_d206d6d8-eec9-427d-b5eb-40022482e942" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_d206d6d8-eec9-427d-b5eb-40022482e942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_14149a61-ab7d-424b-9464-733a185a9303" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_14149a61-ab7d-424b-9464-733a185a9303" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_0f1ae8c1-bfa5-4ac0-9d5e-c04fc6f3bd19" xlink:href="cdtx-20220930.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_0f1ae8c1-bfa5-4ac0-9d5e-c04fc6f3bd19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7c04a19d-34cb-4d24-a0a2-db54b029fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7c04a19d-34cb-4d24-a0a2-db54b029fc38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_7732d525-f066-433e-8e7e-6a13144997ea" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_7732d525-f066-433e-8e7e-6a13144997ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_2fa7ff3b-906a-4a1c-9ef1-f46b64a8585d" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_2fa7ff3b-906a-4a1c-9ef1-f46b64a8585d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_a4e73ed0-35ca-4aa5-bbcf-6bcbdb241e29" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_a4e73ed0-35ca-4aa5-bbcf-6bcbdb241e29" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_fe9b96e6-d0db-42c6-9a50-eb67e09bf75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostGross_fe9b96e6-d0db-42c6-9a50-eb67e09bf75b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_9f87abfb-65e9-4140-9bc9-58ec1c52acb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_9f87abfb-65e9-4140-9bc9-58ec1c52acb8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_c53cd402-7fbf-4c98-a8a7-466c12ef9ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostNet_c53cd402-7fbf-4c98-a8a7-466c12ef9ef9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6e3b8de4-824a-423d-ba95-10f9098d7f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6e3b8de4-824a-423d-ba95-10f9098d7f60" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d04689a5-257e-4b73-b4c5-7d8a34149f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d04689a5-257e-4b73-b4c5-7d8a34149f3e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_30977107-7bbc-4a10-8f57-912a275ae09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_30977107-7bbc-4a10-8f57-912a275ae09b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aaca684f-b64b-4453-afb8-14c4cea11068_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aaca684f-b64b-4453-afb8-14c4cea11068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_9942478f-1945-48be-99ea-ac72aa3ef402" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_9942478f-1945-48be-99ea-ac72aa3ef402" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_50ee2be2-85f1-4392-a626-8b028b9f077d" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_50ee2be2-85f1-4392-a626-8b028b9f077d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_610ac895-7a1e-4f29-a51b-13f1d2c6f4bc" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_610ac895-7a1e-4f29-a51b-13f1d2c6f4bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1d5bc744-544a-4c21-809d-d09d7229bfa1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:to="loc_us-gaap_RelatedPartyDomain_1d5bc744-544a-4c21-809d-d09d7229bfa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:to="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cf82d87a-4f3e-4174-95d6-3538912bba69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:to="loc_srt_AffiliatedEntityMember_cf82d87a-4f3e-4174-95d6-3538912bba69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_c712b205-a39d-45b3-bf25-447ad85f49ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_c712b205-a39d-45b3-bf25-447ad85f49ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_7be8e06a-30d3-4d5b-8ca4-129f858a4069" xlink:href="cdtx-20220930.xsd#cdtx_UpfrontPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_UpfrontPaymentMember_7be8e06a-30d3-4d5b-8ca4-129f858a4069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_be14a1a1-c39a-4d51-95ad-3f576d2bee95" xlink:href="cdtx-20220930.xsd#cdtx_RDFundingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_RDFundingMember_be14a1a1-c39a-4d51-95ad-3f576d2bee95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_3d6139a9-c2e7-42af-b1e0-15e455a003d2" xlink:href="cdtx-20220930.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_3d6139a9-c2e7-42af-b1e0-15e455a003d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:to="loc_srt_ProductsAndServicesDomain_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:to="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_106f0c44-732e-4d62-b4c9-962416af2d5c" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_106f0c44-732e-4d62-b4c9-962416af2d5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_d9cc71a3-4dba-4dcd-b267-281294f659e9" xlink:href="cdtx-20220930.xsd#cdtx_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_cdtx_MilestoneAchievementMember_d9cc71a3-4dba-4dcd-b267-281294f659e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_cc4c1bd8-a51b-4365-94f6-3d51aa2f97fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_us-gaap_RoyaltyMember_cc4c1bd8-a51b-4365-94f6-3d51aa2f97fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_b8cdd970-ce7d-4bf4-9f3e-54348994dc99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_b8cdd970-ce7d-4bf4-9f3e-54348994dc99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_5e2a8552-b0e7-4395-ab70-0f7e7e213ff9" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_5e2a8552-b0e7-4395-ab70-0f7e7e213ff9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended" id="i213b11080c68462295ce1539309ff867_SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0002f870-3b33-4bcc-9da4-5f870f19a402" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0002f870-3b33-4bcc-9da4-5f870f19a402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_63ecd74a-9c3d-417d-8c4c-d9c2ee054893" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_63ecd74a-9c3d-417d-8c4c-d9c2ee054893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_9f016d50-c1ea-4e79-8531-cadc30c2d656" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_9f016d50-c1ea-4e79-8531-cadc30c2d656" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_65f6a1d4-dd6c-4371-a2f7-ea7d2c110e33" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_61a02999-e794-4da3-8851-6e01f13a75dc" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_0acac072-fb53-47dc-80fa-64320468b9ae" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_0acac072-fb53-47dc-80fa-64320468b9ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_8d88e8bd-206c-4074-9dd9-19fae488e149" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_8d88e8bd-206c-4074-9dd9-19fae488e149" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e0704b2-66a2-4a32-bba7-e8ae2cc08ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e0704b2-66a2-4a32-bba7-e8ae2cc08ec8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f050605-d29f-4b6e-becd-48db9994327a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e0704b2-66a2-4a32-bba7-e8ae2cc08ec8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f050605-d29f-4b6e-becd-48db9994327a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_4f050605-d29f-4b6e-becd-48db9994327a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f050605-d29f-4b6e-becd-48db9994327a" xlink:to="loc_us-gaap_RelatedPartyDomain_4f050605-d29f-4b6e-becd-48db9994327a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d2c05b57-1bb2-4cb8-9463-af593305e083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f050605-d29f-4b6e-becd-48db9994327a" xlink:to="loc_us-gaap_RelatedPartyDomain_d2c05b57-1bb2-4cb8-9463-af593305e083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_ebe9c6e6-ffe2-4961-b17d-1f7e54b2c023" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d2c05b57-1bb2-4cb8-9463-af593305e083" xlink:to="loc_srt_AffiliatedEntityMember_ebe9c6e6-ffe2-4961-b17d-1f7e54b2c023" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:definitionLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended" id="i63ce701d90c64ae0bad6ba6459291860_SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ae1725c-c84e-48a9-9903-48f1a94bd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_cde562d1-081a-4dcb-b779-0b6b37373fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ae1725c-c84e-48a9-9903-48f1a94bd3b8" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_cde562d1-081a-4dcb-b779-0b6b37373fe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ae1725c-c84e-48a9-9903-48f1a94bd3b8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f63f526-251e-4d39-9eb3-d01060860d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f63f526-251e-4d39-9eb3-d01060860d64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7f63f526-251e-4d39-9eb3-d01060860d64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f63f526-251e-4d39-9eb3-d01060860d64" xlink:to="loc_us-gaap_RelatedPartyDomain_7f63f526-251e-4d39-9eb3-d01060860d64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_25267d7d-6160-4b14-aadc-e8a773a99ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f63f526-251e-4d39-9eb3-d01060860d64" xlink:to="loc_us-gaap_RelatedPartyDomain_25267d7d-6160-4b14-aadc-e8a773a99ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c15293f8-9c89-4dcf-83c5-a5c607753afd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_25267d7d-6160-4b14-aadc-e8a773a99ab5" xlink:to="loc_srt_AffiliatedEntityMember_c15293f8-9c89-4dcf-83c5-a5c607753afd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9b5395dd-284f-417f-bb7e-f5318e1a7508" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_srt_CounterpartyNameAxis_9b5395dd-284f-417f-bb7e-f5318e1a7508" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b5395dd-284f-417f-bb7e-f5318e1a7508_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9b5395dd-284f-417f-bb7e-f5318e1a7508" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b5395dd-284f-417f-bb7e-f5318e1a7508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9b5395dd-284f-417f-bb7e-f5318e1a7508" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_38f4c359-057d-4dfe-bdd7-8863ccd17810" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_38f4c359-057d-4dfe-bdd7-8863ccd17810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_ad81b596-7a78-4646-88ee-1abb51ef30c8" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_ad81b596-7a78-4646-88ee-1abb51ef30c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_bb21b8c1-47b3-4880-bdd3-5d8f023e9a49" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_bb21b8c1-47b3-4880-bdd3-5d8f023e9a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4987b4c2-b5d1-42ad-b075-6c554fb55f34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_srt_ProductOrServiceAxis_4987b4c2-b5d1-42ad-b075-6c554fb55f34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4987b4c2-b5d1-42ad-b075-6c554fb55f34_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4987b4c2-b5d1-42ad-b075-6c554fb55f34" xlink:to="loc_srt_ProductsAndServicesDomain_4987b4c2-b5d1-42ad-b075-6c554fb55f34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4987b4c2-b5d1-42ad-b075-6c554fb55f34" xlink:to="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_6bedba3e-6b03-4dad-86d1-208cba1262e3" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_6bedba3e-6b03-4dad-86d1-208cba1262e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalDrugSupplyMember_f7e76cc8-eed8-43b9-bbed-a4cb5498a2b7" xlink:href="cdtx-20220930.xsd#cdtx_ClinicalDrugSupplyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_ClinicalDrugSupplyMember_f7e76cc8-eed8-43b9-bbed-a4cb5498a2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_b31245f0-e5c8-488a-b772-ee11bfa1edcf" xlink:href="cdtx-20220930.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_b31245f0-e5c8-488a-b772-ee11bfa1edcf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_8775ac8a-fc12-4eeb-af80-f83537c3e560" xlink:href="cdtx-20220930.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_8775ac8a-fc12-4eeb-af80-f83537c3e560" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_67a7c43b-066a-441b-ab3f-0b1a3e510db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_67a7c43b-066a-441b-ab3f-0b1a3e510db3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_67a7c43b-066a-441b-ab3f-0b1a3e510db3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_67a7c43b-066a-441b-ab3f-0b1a3e510db3" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_67a7c43b-066a-441b-ab3f-0b1a3e510db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_67a7c43b-066a-441b-ab3f-0b1a3e510db3" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_6d04bf39-9de1-4a4f-b7d6-cd6950b92b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_6d04bf39-9de1-4a4f-b7d6-cd6950b92b06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_b826e696-701c-4e7a-a18a-57553ef0a1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:to="loc_us-gaap_TransferredOverTimeMember_b826e696-701c-4e7a-a18a-57553ef0a1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5ff1af85-ada1-4f87-b59b-4922ae193850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5ff1af85-ada1-4f87-b59b-4922ae193850" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ff1af85-ada1-4f87-b59b-4922ae193850_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5ff1af85-ada1-4f87-b59b-4922ae193850" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ff1af85-ada1-4f87-b59b-4922ae193850_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03006fdb-d4e2-42d2-b411-c62d15607982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5ff1af85-ada1-4f87-b59b-4922ae193850" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03006fdb-d4e2-42d2-b411-c62d15607982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_4255f75f-5e3b-4fb5-a8fb-746feadc8053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03006fdb-d4e2-42d2-b411-c62d15607982" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_4255f75f-5e3b-4fb5-a8fb-746feadc8053" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationRevenueMember_97f447af-47eb-49e5-beca-fbcad423a4ec" xlink:href="cdtx-20220930.xsd#cdtx_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="loc_cdtx_CollaborationRevenueMember_97f447af-47eb-49e5-beca-fbcad423a4ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>cdtx-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a568bcbd-732c-4e03-9327-71091167a8dd,g:435374c1-7d67-4ed0-913a-245b913da5ec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cdtx_CommonStockWarrantMember_65e40329-4913-4006-a8b1-5c9e57d93802_terseLabel_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_label_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:label id="lab_cdtx_CommonStockWarrantMember_documentation_en-US" xlink:label="lab_cdtx_CommonStockWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember" xlink:href="cdtx-20220930.xsd#cdtx_CommonStockWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CommonStockWarrantMember" xlink:to="lab_cdtx_CommonStockWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_61ac8749-7cd5-4f5b-b45f-27c23b278446_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_TypeOfRevenueExtensibleList_label_en-US" xlink:label="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRevenueExtensibleList" xlink:to="lab_us-gaap_TypeOfRevenueExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d65c8140-b36b-40b8-940b-4caaae26a5a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cf745a52-640a-4bbf-bee6-848657001cb4_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9056e882-9513-4e1f-a045-998d6b773554_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_14a59133-1bb6-4065-bc54-ea91ad46529b_terseLabel_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, and Commercial Milestones</link:label>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_label_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, And Commercial Milestones [Member]</link:label>
    <link:label id="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_documentation_en-US" xlink:label="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, Regulatory, And Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:href="cdtx-20220930.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:to="lab_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d9d8bc95-385f-4dd2-abdd-a80e8ec65b5f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0487cb65-0c79-4733-868c-b73fff879527_periodStartLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_cf51b61a-232e-416a-bbf5-0bd9a9223c6a_periodEndLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6814968a-3ca4-4669-b468-e080e74555fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_737f75b2-552b-463f-b07e-103de1768744_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from right offerings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_3c7e42ad-dbf0-411d-80e8-38c8743f0a1c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_174b150e-f334-452c-9ee7-8f0158084c94_verboseLabel_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 EIP</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand fifteen equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:href="cdtx-20220930.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_cdtx_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a9e93afe-79fb-4570-b2f1-f7e0cba2ab34_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_3a8535b5-43dc-451e-9a05-ec56b23f3726_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b10aed81-a22d-4fb8-a242-55661640ae3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_dc4a23c0-56db-4cbe-b080-31867fe07c2d_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_26403b8c-95fd-43a0-9d47-7689f32aa789_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for restricted share units vested (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_240ea5f8-5e7d-4e55-b6d9-39117834ec28_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable annual rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ac92296-8304-4928-86ec-b57e1bf979aa_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f352e780-119c-4c55-8d8a-0aaab784a2b7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_bd950a5c-27dc-4fb2-9d1d-54bdebce6aa3_terseLabel_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than 10% of voting power</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_label_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More Than Ten Percent Voting Rights Classes Of Stock [Member]</link:label>
    <link:label id="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_documentation_en-US" xlink:label="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">More than ten percent voting rights classes of stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:href="cdtx-20220930.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:to="lab_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d212ec4d-e35c-4732-ae26-da5f5673f8b3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) and comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0982f1bf-171a-41be-8dd3-a813b7f286c7_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_8c80b46d-9b3f-4ab9-9042-0e57a782ecd5_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_e43ba704-7177-4b4a-88be-cbc6ff556938_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic annual increase in shares authorized for issuance in equity incentive plan</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Number Of Shares Authorized For Issuance Percentage</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:href="cdtx-20220930.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c7567a3d-87a0-4615-be22-fcda645d0ac1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_40df5133-d0e2-45e7-861f-5ed8401c9f56_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3855094f-d3da-4a44-aca0-b4799dcec3de_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_1353ea10-c08b-4b27-ba7f-cbd218b1b4be_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_3052767b-415e-47da-9689-912407fa2faf_terseLabel_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Data</link:label>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited Interim Financial Data [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unaudited interim financial data.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:href="cdtx-20220930.xsd#cdtx_UnauditedInterimFinancialDataPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:to="lab_cdtx_UnauditedInterimFinancialDataPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_ddffeed5-1413-4877-88ef-399aa1a2a0da_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9f658447-98d1-4398-b31a-aaf469cde4b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b285ad71-38f5-4f10-ae36-a23b468b0001_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_afa26aea-2525-4908-ba97-75a343341268_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_8a0a1726-bcfa-484c-af76-89528c882beb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5ca561fc-240e-405e-8544-48267b26a6a0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_226ffb0c-d2c1-4a7d-95d7-40ed6238565c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, net</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_6061b9e9-01a3-4c05-9168-ad2917520255_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated unrecognized share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_de3f0ede-41a6-4466-93a6-b62827f0d870_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_42002d2d-6006-453f-b36d-2d4634770a65_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_46b33186-5e8e-41fe-86bd-7290b5536a4d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_56f2dc7f-b884-4a3b-83eb-3c23679e4c46_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_fc5fa663-6c28-4700-bbad-3d0d0aa20500_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_402b88b1-0f29-48fd-a0f7-a8c95c9bfbc7_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards available under the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_ed56537c-6ba8-4cee-b2b5-5d83e84b1337_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_d9246517-0fbe-41e0-a078-51c27790b3b3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_d52c6aa4-e905-4840-bf27-4c533e130055_terseLabel_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_label_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use, Amortization</link:label>
    <link:label id="lab_cdtx_OperatingLeaseRightOfUseAmortization_documentation_en-US" xlink:label="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization" xlink:href="cdtx-20220930.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_OperatingLeaseRightOfUseAmortization" xlink:to="lab_cdtx_OperatingLeaseRightOfUseAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a5f574b8-bac6-4669-8e7c-9d5bb9c0f7b6_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_33040d06-d2c7-41dc-a839-d9f433683a76_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_002b50c8-5da6-4645-8790-2f81e3324006_verboseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_47c11e3f-a4ab-4d18-a029-79425fb8653d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c43f67db-7876-471b-978b-02b70779fd5c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_520a03a4-619d-4792-8be8-80edc1d8da8a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_72ff3a44-1b50-4a7a-a2c3-6feddb9c2dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c5580810-31e9-4c53-812e-8991f3cd0021_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_519d3f63-55c7-4bf2-9730-35bcf3f69d47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_bca28a97-c028-4860-b100-b9b2b3170110_terseLabel_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical and Clinical Trial Accruals</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_label_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:label id="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_documentation_en-US" xlink:label="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:href="cdtx-20220930.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:to="lab_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1c5cebcc-cf7f-4c48-8bd6-b17599840d6b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c08c5b5b-72f7-41e3-b4ea-c1372cc280f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_559e9240-b01e-4aed-b216-95fd3ef9809a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d4d462cd-6c5c-47be-b44f-a0e520973b54_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_96c727d3-43e2-4db4-9dd8-de0c059a4e1f_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage increase in base rent annual</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rate Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:to="lab_cdtx_LesseeOperatingLeaseAnnualRateIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_73d52db6-a398-4b80-aab1-811be14e72b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_adf2a3c8-b122-43ad-b4fb-7e391440feed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_JanssenCollaborationAgreementMember_58ffdba7-23a6-456a-abd3-3bc75ef79d82_terseLabel_en-US" xlink:label="lab_cdtx_JanssenCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration Agreement</link:label>
    <link:label id="lab_cdtx_JanssenCollaborationAgreementMember_label_en-US" xlink:label="lab_cdtx_JanssenCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration Agreement [Member]</link:label>
    <link:label id="lab_cdtx_JanssenCollaborationAgreementMember_documentation_en-US" xlink:label="lab_cdtx_JanssenCollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenCollaborationAgreementMember" xlink:href="cdtx-20220930.xsd#cdtx_JanssenCollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_JanssenCollaborationAgreementMember" xlink:to="lab_cdtx_JanssenCollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_d7ffbccb-25e5-435e-9338-320052c95ddd_terseLabel_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized for future stock awards</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_label_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Shares For Future Stock Awards [Member]</link:label>
    <link:label id="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember_documentation_en-US" xlink:label="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized Shares For Future Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:href="cdtx-20220930.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:to="lab_cdtx_AuthorizedSharesForFutureStockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_96f7d063-0674-49ec-935b-5c59ab023733_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d73719b4-d68e-4bad-9735-d1f8f501510f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d46c5082-7745-4df5-bab8-435c1ba920bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_e294b01b-2f85-4af2-b12a-3e918fcb752c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a3e08645-c06e-4f1a-b1bc-d26ddea2f42e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_01c630c3-253e-409e-b564-5f95af02fa06_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_821adb8d-43b8-4291-b8ef-c46943935735_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a5f2e688-084d-4393-b6b7-da9838cfea8c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_c66e4b33-4677-4790-b082-7ed866373d08_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred at Point in Time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_aaa50415-f5c2-4774-9dd3-2802b5a5a11c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_9eb8634d-4673-41dd-9221-78a8fcfd2fe8_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0708760b-5d0d-4b3e-a34e-044511044bee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_168d68da-4e39-4ea7-b8f7-c7c60ca89f6f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_98f9820a-92cd-414b-bc47-f423ce4a6db3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e9d943db-545a-4a38-aefd-a066949eb66e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bf51b4a5-be1a-4f6e-a9b9-94f8941354f2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_99727447-639d-4ca8-be8d-92a49987e68c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_baace7a3-5790-4d0b-b5b9-f7654058dc3e_terseLabel_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units And Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units and Performance-based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:href="cdtx-20220930.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_373e35ed-d064-49cb-ba9a-b376d7653d4c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_5e8944cb-7a10-4be1-aacc-764aa74cfc5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b8bfe1b2-a2e9-4878-a2f4-bf1c9873bac8_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a3643e18-1428-4618-87c7-46589cc244b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_16dd3f60-f4dd-41c4-8bb7-377f882aa215_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of term loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_569c7771-b0e5-4110-8439-2eba308ef5d9_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b11e3e75-8ad1-4dfb-b74b-38732c82ae09_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_20132394-2ba5-47b9-8f25-beb19a526280_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs for underwritten public offering</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_49ba61b1-89a2-4efb-8613-aa062cdb3962_verboseLabel_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_2f7e6906-cfb9-4eed-a7ba-fcdae110e3f9_terseLabel_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_label_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_cdtx_SeriesXConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SeriesXConvertiblePreferredStockMember" xlink:to="lab_cdtx_SeriesXConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_0a85f712-5eaf-4b00-be19-e235c1740c16_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_023740b0-7dc3-4f4e-8eb1-697a5fce280b_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_44ebb515-9e10-4f59-92f2-a5173e2d22aa_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_885ac95f-3263-47ed-a2bc-e0853942a1da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_b98c9e86-e43b-4738-adb8-ca458356d840_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8ea3cf83-b67f-4661-9848-1b6196924862_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_0c4807a9-1f29-425a-ab43-21a1ad3d0a6e_totalLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b0299cc6-f03e-4560-b21c-7b2b5f63ad81_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_2274ceb8-03fb-417e-bc83-861d35547fd4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d3e875e4-2d65-486a-9574-5d477b33ce05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_2fc26d76-cefa-49f6-96d7-14900dda6257_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2cca1b41-3771-4dc5-b780-c6b09a0c506a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_ad22a8da-b8b9-4f09-af93-42531817367b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_ce554adf-2cec-46b4-a63c-be10062d33a0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations_c361f560-a1f5-4e91-8b56-6be066bad375_terseLabel_en-US" xlink:label="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations_label_en-US" xlink:label="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number of Performance Obligations</link:label>
    <link:label id="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations_documentation_en-US" xlink:label="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:href="cdtx-20220930.xsd#cdtx_CollaborationAgreementNumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:to="lab_cdtx_CollaborationAgreementNumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_dce6e954-2019-48b0-9ec1-f6ce9977391b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ab5a482c-0c91-4f42-aed0-5e3298162419_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_b6edb162-da3b-4c53-8b7b-dd41754b644e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e0dfa641-f4a8-4311-bf7c-b686ee79076e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_1b35e1bf-8eaf-43e3-8d2f-1b2ff4fe6b85_terseLabel_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, aggregate intrinsic value, outstanding</link:label>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding_documentation_en-US" xlink:label="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:href="cdtx-20220930.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:to="lab_cdtx_WarrantsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2652b3b0-bd71-44c5-aa1b-af9ee5bf28ce_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period to recognize unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e98fc35e-d25c-4e9c-84f1-52153b2bae1d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3a619de6-dc6f-43e6-a62e-cded4b2c0a82_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e307f159-3035-4689-a18a-f748ba8e0129_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1720529f-25a9-4266-9520-a4c14e477854_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_f3dbbe75-3df9-41a6-ae5a-97aa9fcf106d_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Election to proceed notice, period post delivery of results</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:to="lab_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_9b9253f1-5309-49d4-8982-be0b078f907d_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, maximum cost share</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Third Party Share Of Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:to="lab_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_078ab7af-225c-4c8e-8fe5-ffe80b87bce7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9987daf9-a40b-4a43-b19b-6ce4e089f3e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f54f77eb-2f74-4b1b-abb6-07b30be497ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f5e1d7ec-9fbd-4c4a-b8aa-90e01769b085_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_944ffca1-d5fe-42e0-9f79-16b3dd925afc_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_c007ef17-f2d7-4f37-b932-03a7a9f7efc4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_9bfe2e8b-08ca-4360-a864-cc65c0e18b42_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative agreement</link:label>
    <link:label id="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_b826157f-4082-466a-ac75-71a060496a1b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e5cf900c-571b-4e16-ab4c-368ea9f12228_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e135c62a-b4c8-40cc-959e-d63e6a6d52db_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_dbfdd4bf-e83d-45f5-ad4c-ab6093bd07e7_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_ca62a7fe-184c-4302-b3de-b463877a6631_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c682cacf-950f-4770-b547-6f4ecd534b7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7dd02c66-1fea-4bc8-9318-6e711d38e548_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_6ca1dc9d-c7c5-46ae-891e-440e5d110465_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_fadcd32d-c784-470f-abca-86e947e6ce95_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_5eb0a8f6-f881-44f1-8f03-9dd9c3ecbe97_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_9f65f2f7-2d9c-4892-9a0c-611b9c0fd05a_periodStartLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opening balance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_fa5827b8-3b82-422d-954f-f60828e3b1d9_periodEndLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing balance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_fa295384-0fa0-4c5d-96a9-d8277b43fe8e_netLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_25559712-08cb-41f7-959f-5404edfd25d4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7fba8734-dc1a-429d-8081-4d5293b7aadf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_14cce314-191f-409c-a7df-f3daeae38d78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1763d23a-818d-49b7-8903-d13e95d8f98a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fcede21f-f769-408c-86cd-2f5ded91773d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and money market accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_593739a0-ff0e-4737-9dd1-0e4d972e7041_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_7303b032-8f99-48cf-9ccf-ff836d7a6028_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic increase in number of shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ef00ca6-8d47-4675-8f41-031cb804df33_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a561a5a9-1ede-4baf-9da1-6facefbfaac8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_e00cafa8-a301-4792-9f76-06e29472129e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_92356369-9375-4be1-bb42-7de1e6843d06_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings (loss) per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7839bfb1-4b0a-44b6-8ef7-179eda18ebba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_2f9f5e8a-caa9-4c10-9c92-5132aa620d23_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_label_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:label id="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension_documentation_en-US" xlink:label="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Lease Options For Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:href="cdtx-20220930.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:to="lab_cdtx_NumberOfOperatingLeaseOptionsForExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_ff6a2f19-92a5-4fb3-acb1-6544e2c704fe_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_d03949ec-74f6-4d70-895c-ae334d852147_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, gross</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e5692008-8136-462a-80a4-60f962f25ce5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_4ffe61e9-bad2-400b-bca1-efe3f723d255_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e8cc57ad-d949-4dcb-8197-e16e4864196d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_1c2e824e-2d1f-4b06-ba82-3199785261a1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_3d30e0a9-9f04-48ee-8c2c-e8fbee51df95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_cf0856d0-ce9f-4605-908e-6833fb0dab2b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_235f728c-aa8e-45dc-accc-aef26e684116_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of costs to obtain a contract with a customer</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_af93c421-a2d8-4022-b765-536186bf0c70_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized contract cost, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_5cadf578-5d23-4e9b-a949-06c0ebc17870_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Incremental Borrowing Rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:to="lab_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_558b9f14-9804-4266-a33f-73e83c102c0e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_60d1c93f-0463-44e8-be0f-df8981301c8b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_2d187750-b221-472c-a348-75f74711c4db_terseLabel_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration remaining on transaction</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_label_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Remaining on Transaction</link:label>
    <link:label id="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction_documentation_en-US" xlink:label="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Remaining on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:href="cdtx-20220930.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:to="lab_cdtx_SaleOfStockConsiderationRemainingOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_66b2cd4e-b128-42f9-a2c7-d38d95966674_terseLabel_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to collaborative agreement</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_label_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:label id="lab_cdtx_PaymentsRelatedToCollaborativeAgreements_documentation_en-US" xlink:label="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Related To Collaborative Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:href="cdtx-20220930.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:to="lab_cdtx_PaymentsRelatedToCollaborativeAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b86c50ee-e62e-4fc5-9185-a8da8bd262a0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c5ebd760-197c-4f0e-beb5-1e2b81562651_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized share-based compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_f85e4f23-6ed6-4b0d-9b51-80d5772aeef4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_2b38fd64-810f-4575-af04-4e1d0c222688_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limit on employee's payroll deductions as a percentage of eligible compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_df921422-3e57-49b9-8c0e-7e6de458afb9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5f2b44e7-2a6a-45c1-8508-c25bdc520f8d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c0b3578d-dbdc-4fec-bc02-acf7754aff18_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_68771db8-faf2-4877-ad1f-5c4304f2b891_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_6907eddb-1887-4971-82f2-638d72ebc7a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a04692e8-4779-4d01-9dc4-63e9b51c1950_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_ab3b3b34-8b7f-4b78-b257-4dde809e361f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9e8079aa-9fa3-42f1-a02a-267d4ae81696_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_ec186146-2a3b-4805-8c7a-38881a962f80_terseLabel_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes for each share held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_label_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Entitlement For Each Share Held</link:label>
    <link:label id="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld_documentation_en-US" xlink:label="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes entitlement for each share held.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:href="cdtx-20220930.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:to="lab_cdtx_NumberOfVotesEntitlementForEachShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2489c6ff-7573-4e8c-9e02-7d15d25675aa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_015142cf-ab69-49f7-a54d-28c3d40068fb_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_13240494-318a-4ded-9f63-a4e58c8d0387_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_632580ed-ca14-4140-bef9-ffab892ea884_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs incurred but not yet paid</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_96e2780a-5995-4328-a9f8-eaccb20a335a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e873ec51-a179-4a06-80c1-6c71614d7995_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_28e945c0-4826-49d7-b609-d9d42f6f4f34_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued for each preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_754a9801-1291-4ecc-bc0e-e236d920689b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_fcdb5fb8-41f3-48d9-a147-4f9a597af54f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_980e991a-7522-43b8-9496-feda3808e6cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_8696fc58-d66f-438f-af26-d5b66633ce74_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_758fd203-595f-42ff-8af7-affb9bed44d7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_143a31c6-acf6-4f2b-b3ec-b3bbc3862ad8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_74c48bcc-95a5-48fd-a03e-69df6486d809_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_214de909-c084-4d14-92cb-31314cec0709_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_67b0f84a-1208-4d65-8d8c-42a038b95679_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75c06743-b0b9-4ad5-947f-faf6ce1ad75e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_e7538ed6-d98e-49f8-8e7c-926dc4003144_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_48063d12-d728-4115-bbfc-457cb2f6cd2a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f495175a-6bc7-42f1-9497-d3b5b06dfa62_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e8828b23-836f-4983-b522-75e7e43dbc25_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_2a3f19cd-0695-4ee6-997d-48ba48b31c26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e35f0e9e-e031-4a32-be9f-8409933a7661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_05b5a61a-4c00-42b0-8033-edfe6ed107cf_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_e0dd9300-7627-4526-9de1-f4ab3e3a9b06_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7ee0ad8c-9a54-4977-b767-da87edff6b98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_6d2d8992-8e58-4827-b5a3-1b24b74b4ae1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_9a07609a-bc8d-4e68-a593-742b1d9fc90f_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, potential transaction value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction, Potential Value</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTransactionPotentialValue_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction, Potential Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:to="lab_cdtx_CollaborativeArrangementTransactionPotentialValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_07a0122e-185c-4f89-825b-755794a127b0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_bfd4e702-296e-491a-b026-932703718554_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_540eaa60-2bb7-4cd0-9b29-fc06f93cabb4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, other current assets, and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_393182e6-c5ce-47a6-9f9e-e7192965c67e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4a21ce94-32af-4046-85b5-7f80e01030ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a0f311bd-1281-44db-ad5c-b4db1822d336_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d6b36748-9201-48c8-85d9-bc834aea3396_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_e6cc0f43-3faf-450a-98c5-0e79ce1aee4c_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received in advance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets_2ca8c7de-1db8-4047-b7a1-ff304b9c3422_terseLabel_en-US" xlink:label="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses and other current assets</link:label>
    <link:label id="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" xlink:href="cdtx-20220930.xsd#cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_1230d283-d502-4263-a00e-43b207c80239_terseLabel_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Melinta Therapeutics, Inc.</link:label>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_2ce5913e-e5f5-4138-90b7-57a6eb7947fa_verboseLabel_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Melinta</link:label>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_label_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Melinta Therapeutics Inc [Member]</link:label>
    <link:label id="lab_cdtx_MelintaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_cdtx_MelintaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Melinta Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MelintaTherapeuticsIncMember" xlink:to="lab_cdtx_MelintaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_03ba0ecb-24bf-4698-9e3d-308d38249933_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b226328d-ebd5-4e43-bb92-8840f802464f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6f1f5546-4020-425e-9eb9-5db6c9dc8456_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_a347cc74-ce91-4638-bc8c-af657c5b1beb_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_be69bbaf-8109-40f3-9632-3811a6085ea9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66ec917d-d1b9-464b-85b8-be119876d588_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_81c91793-bcd8-4de3-9425-a0d9159f4f20_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of participating securities:</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Available to Common Shareholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:to="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_63cc76a3-71d5-45e5-971d-41f4de93c737_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_52ee8724-bf9c-4b75-8521-8288176baba8_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bd470114-9775-45a6-8175-33af0b0d7ccc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted net earnings (loss) per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_71a64467-b610-44a7-aff1-2a0208102541_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f174d3cb-0569-4635-979e-7f76b040b4bd_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_c829edb6-4390-4b36-8b09-b01dc2d317de_negatedTerseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from performance obligations satisfied during reporting period</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_aac0c783-1014-41c8-9c70-3cf537a2d015_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 200,000,000 shares authorized at September&#160;30, 2022 and December&#160;31, 2021; 71,181,197 shares issued and outstanding at September&#160;30, 2022 and 67,863,674 shares issued and outstanding at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_5ae5d4af-a52a-4658-a390-11947df0978b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_f39a6d6d-cb52-475a-b847-8e442c36a6e3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3a88da1d-cc39-4f9a-b54e-b5aedcee0e01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_c29bcfee-a7ec-40d7-a033-8b9b6e04e1a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_839c1be7-a462-4a88-b750-4e24d02e3cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Financial Instruments Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_af852c0f-647e-4289-a54e-784f4825550d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ecc369a9-7c9c-4764-bfb8-9bf8e740dce4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a3a3ea58-657b-49f4-b654-be26d2a95e31_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_488d13ac-c054-4865-b934-3a8aea2e590c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8622031-a4f6-41a8-8f64-f625b126b42d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_163b4130-59e8-43de-b89f-60ecbb12cb20_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_c0760d3e-449d-4bce-8bb1-2c007b4532c6_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option renewal term</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option Renewal Term</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Option Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseOptionRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:to="lab_cdtx_LesseeOperatingLeaseOptionRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_5a2500dd-84b1-492b-be69-b5d95724731b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d170e5d1-286b-46e4-abc4-7f02fa1321af_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_a4a3e229-759a-4323-bc53-8d1447af180c_terseLabel_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base rent per month</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_label_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:label id="lab_cdtx_LesseeOperatingLeaseMonthlyRate_documentation_en-US" xlink:label="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:to="lab_cdtx_LesseeOperatingLeaseMonthlyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_522eeea2-100e-4913-881a-334749611916_terseLabel_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Services</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_label_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:label id="lab_cdtx_ClinicalSupplyServicesMember_documentation_en-US" xlink:label="lab_cdtx_ClinicalSupplyServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Supply Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember" xlink:href="cdtx-20220930.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClinicalSupplyServicesMember" xlink:to="lab_cdtx_ClinicalSupplyServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_89a2a13b-4f15-425b-ac6e-be5e2c530ef2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d3b13eef-dcf2-457c-ab2d-faa8f798fdb8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_PublicStockOfferingMember_279e578f-e412-46bf-81a2-e173a25d0f68_terseLabel_en-US" xlink:label="lab_cdtx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:label id="lab_cdtx_PublicStockOfferingMember_label_en-US" xlink:label="lab_cdtx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering [Member]</link:label>
    <link:label id="lab_cdtx_PublicStockOfferingMember_documentation_en-US" xlink:label="lab_cdtx_PublicStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicStockOfferingMember" xlink:href="cdtx-20220930.xsd#cdtx_PublicStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_PublicStockOfferingMember" xlink:to="lab_cdtx_PublicStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_33d674b6-8fc5-4ecd-b737-a3b91e3b57ab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_80fd477e-555c-423e-85e3-3a3dc36fcf55_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_12079e12-1db6-4de0-83b4-2443730904b2_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2ea65a4b-5cb2-4972-b0d8-fab9d4c9894c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5ff046c8-9e57-41d1-b011-9fb6d9fec366_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ac1cf6cf-37c9-4c44-86ab-871f3e318898_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a35287a5-907d-4111-a0c4-a6512db06d46_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_9a5ee081-876d-4ca4-847c-f3818f7d410a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_86fa2148-c1fb-4ff8-8aba-82ba06d86f3f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowed from the lender</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_06eafd7b-26cd-496b-a0e5-8c68f749b11f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of shares pursuant to Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_ee64e8e6-2353-40e8-bd64-025b522873ee_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_7bd4e99d-c390-46d4-b35b-1c27049aef2a_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) and comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f918d817-b774-4dd4-8a1d-40524e0fb4a5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_148b1612-db48-45db-a01d-8c150e0da4b4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_aecf94d9-5829-4ec3-8fe7-b81d1d60d730_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d4959435-1693-49c0-8f66-ad0e498e6e84_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3fb66ba6-92d3-4f95-945d-36b11f3b5f80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Life in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e86606d5-3489-4117-9e7c-b8f346690613_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_c89f4687-8fa4-415e-8875-edfdc5b60d0b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price of stock option as percentage of estimated fair value of shares on date of grant</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e6bbfaca-5239-45a3-9474-9105848926b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Employee Stock Purchase Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e083f2ff-6d0e-49f3-9429-22647d660322_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_319d56c5-33d5-4f22-87d4-d171fe7cb89b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_766a8123-4ea1-4c50-aeaf-712cdbc3032a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0cf8e57c-1817-448e-9a56-7d927e4ba902_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_668efee2-42f3-4423-94bf-1d5591a32a25_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_73645689-0e19-4b73-9d0c-6df2ed51930c_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ffc5746a-9769-49e8-b29b-900c25ddf9c4_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_de8fd221-e716-4c73-bb90-9794a241de8b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_6689ae60-35f4-4f94-956c-c5658455f41e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_6d8cde02-6cb0-4709-b336-1fbe92615b0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal repayments of Term Loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_090a21bd-da24-459b-a09d-dba329f1e065_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_6dc8bbd6-2e59-40fe-a7e8-4c394b47968f_terseLabel_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Services</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_label_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:label id="lab_cdtx_ResearchAndDevelopmentServicesMember_documentation_en-US" xlink:label="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:href="cdtx-20220930.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ResearchAndDevelopmentServicesMember" xlink:to="lab_cdtx_ResearchAndDevelopmentServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ClinicalDrugSupplyMember_62336d88-132f-4024-8d82-45cf759a6330_terseLabel_en-US" xlink:label="lab_cdtx_ClinicalDrugSupplyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Drug Supply</link:label>
    <link:label id="lab_cdtx_ClinicalDrugSupplyMember_label_en-US" xlink:label="lab_cdtx_ClinicalDrugSupplyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Drug Supply [Member]</link:label>
    <link:label id="lab_cdtx_ClinicalDrugSupplyMember_documentation_en-US" xlink:label="lab_cdtx_ClinicalDrugSupplyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Drug Supply</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalDrugSupplyMember" xlink:href="cdtx-20220930.xsd#cdtx_ClinicalDrugSupplyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ClinicalDrugSupplyMember" xlink:to="lab_cdtx_ClinicalDrugSupplyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8ff959a1-691f-40bc-875c-33b1c233d4fd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_201fc7b7-4cb5-4a48-a16f-2d08ce238b95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_08d18df3-69aa-4c57-88d7-330d3dd602e2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_cf468af5-c704-43ce-85c9-30da879cfdec_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4f518368-d280-434c-9915-787a33c4c0bd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_b62c5ccc-4f7c-4c3b-9221-0c2e4c525534_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_44dc3576-6d6b-4e0b-b2af-74cf12dce701_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_9441a766-d8b2-4d10-8fca-7d1bd3f604d5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_7343cf12-070e-4581-b87d-6c3e8039a2d6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_d46145f6-ede3-4aea-a14a-c340bac8d067_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add back allocation of earnings to participating securities</link:label>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_label_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:to="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_50b475d2-05c7-4c51-be56-74e7f49df27d_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost sharing percentage</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cost Sharing Percentage</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementCostSharingPercentage_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Cost Sharing Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:to="lab_cdtx_CollaborativeArrangementCostSharingPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_0184a115-d24e-4480-8ed4-bec5b8a29a85_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_0e251369-3584-4d4e-aa1c-307368263fd3_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options, RSUs and PRSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_b1aa4567-9f2c-44ac-a860-c602e00833ae_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, RSUs and PRSUs issued and outstanding</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ebb84818-3247-443d-b91a-e364dc4e6cbe_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_48465d2c-01b1-4458-9dfa-703cb29c600d_terseLabel_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting power threshold</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_label_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:label id="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_documentation_en-US" xlink:label="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:href="cdtx-20220930.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:to="lab_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6116d0fa-6904-40ad-8d8b-da29dff8efdb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_197d3976-b853-4645-9456-5dab41ac5902_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_24ab81cd-17e7-46d9-8c1e-29275e3bdeb9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_b6cc0c9a-6498-44e6-8312-2c6056189099_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and money market accounts</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_7a4476b0-f54d-40b9-be4a-c27664068b3f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_91487fea-67a4-420d-89c7-cccfadddb70f_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f019d4a5-0a0d-47ba-9723-ed9cc54e3b82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaidInKindInterest_47db84d5-1504-43b2-82e1-e5d104cec3d7_terseLabel_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_PaidInKindInterest_label_en-US" xlink:label="lab_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaidInKindInterest" xlink:to="lab_us-gaap_PaidInKindInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_b63acfa2-ca1c-4826-bc8b-f465bac29345_terseLabel_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="cdtx-20220930.xsd#cdtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_1c6a315f-4666-4de3-9bfc-9c07d0269eaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RDFundingMember_404b8786-a2f1-4121-8900-6d9efad7d3a3_terseLabel_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Funding</link:label>
    <link:label id="lab_cdtx_RDFundingMember_label_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Funding [Member]</link:label>
    <link:label id="lab_cdtx_RDFundingMember_documentation_en-US" xlink:label="lab_cdtx_RDFundingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Funding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember" xlink:href="cdtx-20220930.xsd#cdtx_RDFundingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RDFundingMember" xlink:to="lab_cdtx_RDFundingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c2535546-f0df-4a9e-bdf9-6ac8abe4c271_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1080dfef-2abb-4077-899c-d873a4e17b76_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_766123db-492a-4be1-960a-105296a318b7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LicensesOfIntellectualPropertyMember_15db11e8-c842-432c-8cfd-dca37ff4935d_terseLabel_en-US" xlink:label="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License of Intellectual Property</link:label>
    <link:label id="lab_cdtx_LicensesOfIntellectualPropertyMember_label_en-US" xlink:label="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses Of Intellectual Property [Member]</link:label>
    <link:label id="lab_cdtx_LicensesOfIntellectualPropertyMember_documentation_en-US" xlink:label="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses Of Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LicensesOfIntellectualPropertyMember" xlink:to="lab_cdtx_LicensesOfIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b8f38382-d5e7-458a-884e-37ccf360e7f5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_f2e98185-cc35-47bc-9fd5-67f528c0b68c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_191e1b03-ac94-4f0f-8b20-26924bb446a7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_5e568f1f-1fc9-4441-bfa1-64c3f5a45fa6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_60321daf-2e85-4db8-ae7b-35586059ad14_terseLabel_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum ownership following conversion</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_label_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:label id="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_documentation_en-US" xlink:label="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:href="cdtx-20220930.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:to="lab_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7a3667b9-2a29-4091-a185-b321e3c7c00f_terseLabel_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_label_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer</link:label>
    <link:label id="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_documentation_en-US" xlink:label="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:href="cdtx-20220930.xsd#cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:to="lab_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2cc3bcc9-342d-4062-a83f-afefd78fafa8_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7de2a05e-3eca-43fc-a017-29c858edcd71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5e4d87bc-6ca6-4122-913b-4f21f555b36a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4c381a48-54a5-4591-897c-70babbdb1970_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6800eb03-a1d3-4643-8efe-8fa2e01f59fd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_4203019f-3241-467b-b5cc-125592b1c8b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_UpfrontPaymentMember_d143aa48-4d90-4a72-8ab8-89f8156aeaf9_terseLabel_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_label_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment [Member]</link:label>
    <link:label id="lab_cdtx_UpfrontPaymentMember_documentation_en-US" xlink:label="lab_cdtx_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember" xlink:href="cdtx-20220930.xsd#cdtx_UpfrontPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_UpfrontPaymentMember" xlink:to="lab_cdtx_UpfrontPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_c9504c67-9358-4448-84f2-6e6262feaafd_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_20d7d14b-45b7-40c6-96c8-500a7fefebcf_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_93d2fd6f-28fa-4884-8458-daf5acd96f76_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_19f217c2-6013-4c84-a2d7-66a05a94f060_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_42aaaf5f-3956-4d5a-a36a-d21cf106da07_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute basic net earnings (loss) per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0459b4e1-37a6-4050-9ca4-23e85f94c3e2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic net earnings (loss) per share - common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_7377f31b-024b-4087-9d5d-6cba894c4199_terseLabel_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_label_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:label id="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_documentation_en-US" xlink:label="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:href="cdtx-20220930.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:to="lab_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TermLoanMember_360d0492-fd8e-4625-9184-bd87c5c74de7_terseLabel_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_cdtx_TermLoanMember_label_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanMember_documentation_en-US" xlink:label="lab_cdtx_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember" xlink:href="cdtx-20220930.xsd#cdtx_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanMember" xlink:to="lab_cdtx_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6b9659d2-90b4-4300-bd05-11c61962d78c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_31946bfb-cac2-448c-9f70-6feca78453a7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_83af47e5-03d1-4568-8347-fd8794834311_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_a250be8c-e5f3-4a37-9204-f9965a9dbe13_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5c11b279-e73d-46d7-9bd3-3b679501c5b1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_12fc2703-1ce5-4520-8b9f-02be3fd681b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_5b514cbf-7c06-46d7-b6d8-e3e7e30d5e82_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_bc783395-2a34-4cec-8370-237142b484b6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_335ef653-2e16-483e-82a3-6bd76fc646c3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_5dc5e47d-9e61-492a-b051-e439f3053df1_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bb64e6a4-6227-4e1d-8377-2c87c730e190_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_8d7938ce-4177-4c72-bf57-08a9a2ae7388_terseLabel_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease and short-term lease term included within operating lease cost (greater than)</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_label_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:label id="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_documentation_en-US" xlink:label="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:href="cdtx-20220930.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:to="lab_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_27bf3783-c9a9-4695-80e1-c26a71ef3fd4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_abb61d54-43dc-4245-8304-0a3d40b55b83_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0b579b39-f433-4568-9f75-775c039304d4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_34fa368c-0cf5-4f44-9c33-b57cb48e00b4_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1db3245d-a0f7-41b7-8943-3042eda5ec25_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY INCENTIVE PLANS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_e6330135-f9bd-4710-9dd1-c4f8b047d68b_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series X Convertible Preferred Stock, as converted (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_e2285b0f-f7a3-45ea-a449-66905978e3ec_terseLabel_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_9c83acee-75bd-4cd1-8ec5-b82cff83d99d_verboseLabel_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_cdtx_JanssenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_JanssenPharmaceuticalsIncMember" xlink:to="lab_cdtx_JanssenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_16be4606-64f2-4301-bcc1-101b50f25ca4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_532783a1-ca42-4ea0-a283-bf69ff8dbc9a_terseLabel_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_label_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</link:label>
    <link:label id="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_documentation_en-US" xlink:label="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:to="lab_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_46e67dc5-d6f0-4d13-8d6a-1c56d1885320_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_a482f086-f36b-43de-b247-11e77b1654b7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_07f8ec3a-44d4-4cd6-aa53-8c65fbeee428_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_12fe7762-1ef0-4b75-b470-24ebb23fadbe_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_14f879aa-0432-4c35-9c65-41478d7db7ff_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_001601b5-5ed5-4779-87ee-dc6558dd993a_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options, RSUs, PRSUs, and ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d93e1df-2cf6-4c8e-a927-7394b2403787_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_dc903ec3-f2cc-4ada-a5c3-3e71bf29b843_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c97d890b-1592-44f6-9e64-ee5c8254017f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEVEL 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_e0ba7e95-e260-43bf-8840-fecd076746f5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_faaeef63-3f67-4fee-ab4a-1951b16325ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ab428ef7-354e-41b5-b864-7a2b0daca017_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_234598bc-3fa6-4447-b856-e01e3abeb38a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings (loss) per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_2eef4c2d-7af1-4647-8924-b729b5239c65_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ab10969e-c630-49ac-ab21-e870c5fcf307_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_5359948a-0953-40ea-adbe-5732d8eb04e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs for underwritten public offering</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_8b9b7369-f1b6-455d-8cbd-1e0ccbb53e42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Reserved for Future Issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1fe5c277-4be9-48a1-9941-caea624537b1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_555f942e-5505-435a-a6c4-b14769275461_terseLabel_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination provisions, required period of written notice</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_label_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</link:label>
    <link:label id="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_documentation_en-US" xlink:label="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:to="lab_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MilestoneAchievementMember_30d04713-d934-4113-b097-636b943aed15_terseLabel_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_label_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_cdtx_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_cdtx_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember" xlink:href="cdtx-20220930.xsd#cdtx_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MilestoneAchievementMember" xlink:to="lab_cdtx_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_9c310e83-5ac3-43bd-a8bf-5f630f2c680f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ce9eea88-13e1-4a25-b3f5-c6a363f3e96b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term for stock options to be granted</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_bef81816-35f0-4278-84cb-97a2c2541679_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of earnings to participating securities</link:label>
    <link:label id="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_label_en-US" xlink:label="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Participating Securities, Distributed and Undistributed Earnings (Loss), Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:to="lab_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_d681398e-72eb-4a4e-a0ed-81d9ca0d906d_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_d42da77b-3e48-4ae8-92b5-4163a3c8bc55_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_e706073b-6a54-463e-94e3-f1dd6f3cb3ce_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0772ac0f-3e5a-4ee7-89c2-fcdc7cdeef75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ca8b8854-431a-477f-aa48-ef436d54df1b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_884122a6-e91a-4592-b86e-31eb4b9f5235_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b3885fe8-806c-49ed-8d16-202bf5673781_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_326d9ef2-0f32-4e74-8fb7-06e0bdd24011_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_320eea08-acaf-4ea2-ae89-4a0ba0650e5d_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_fe07b853-16c1-4655-93e6-f0f5b416f433_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_92ce52d4-c577-4336-b1f7-8be9c7539b95_terseLabel_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_label_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:label id="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_documentation_en-US" xlink:label="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:href="cdtx-20220930.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:to="lab_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_33ddbc7e-2caf-41be-a6f4-07ddfd6169ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs and PRSUs vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_78972559-bb59-4a98-9ccc-5d43afb5b084_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_49d41c5d-852e-43eb-b856-3269cb4a59f1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3b82d50d-3337-47c2-b413-915d728e5ad9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_22ee7d78-fd7e-4ebb-8361-656926614c39_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_decb3632-37ce-459c-906b-7b4ef0b7d3ee_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_016561ad-133a-4014-bf39-b72547c73f7f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_403c6e61-9279-4888-8fff-8799a349a59b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_48b6cebb-d01e-4316-affd-de5744a06f84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_cc55b227-9e6f-4ad7-93b6-d8609e8afa9e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT AGREEMENTS AND CONTRACTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_43d3f99d-94cb-4402-a920-10bb2fdfd203_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_db68f996-24ce-4e48-ac83-187f5d9d3388_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ba02cace-4e3a-4b40-b129-b6b84468622d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_4752f999-2361-483e-bf0a-c3f3bf6ec86e_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_e2b33e87-82d4-43d9-ada8-de0eaa6ccdf3_terseLabel_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mundipharma Medical Company</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_2d8f4172-2eb2-4afa-8974-bbc36b900381_verboseLabel_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mundipharma</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_label_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:label id="lab_cdtx_MundipharmaMedicalCompanyMember_documentation_en-US" xlink:label="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mundipharma Medical Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_MundipharmaMedicalCompanyMember" xlink:to="lab_cdtx_MundipharmaMedicalCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_244cfde8-b726-4ad6-8942-8d39439aceff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_178dce85-1ae0-40b5-aeda-d10f650e3c44_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_72fed5b8-42fb-4199-b351-88c6a6dcb288_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3aa5bbe2-d73f-4deb-8406-9394fda4be82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20a3ba22-a559-4e75-8b59-f80eb2bd1468_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_c9d610b4-0c01-44d7-a9da-c0546ba5bbe9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_9edab6ab-0dfb-40f7-9462-3ad990eb9a68_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_TermLoanAMember_feeac408-c950-4a99-a0ad-a653d9bd2875_verboseLabel_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term A Loan</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_label_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_cdtx_TermLoanAMember_documentation_en-US" xlink:label="lab_cdtx_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember" xlink:href="cdtx-20220930.xsd#cdtx_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_TermLoanAMember" xlink:to="lab_cdtx_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b899a15d-5a14-4f18-acd6-afb2b6db4d9b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0acd4f81-4d1d-443d-8f1e-4d15e58fdaee_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_b0cdd30a-0258-42a7-8166-cd5ce62af29c_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0b398679-67b4-41d2-bbf4-ecb0dfebcc6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Earnings (loss) Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_23dc9d77-0619-4189-b0e1-509098c1af98_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain" xlink:to="lab_us-gaap_ConversionOfStockNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_648c81e9-ed9e-42e3-ae2a-f69dbcb1e59e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset obtained in exchange for lease liability</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b68df7a2-4273-49fc-8286-25e86dae494b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">THE COMPANY AND BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cdtx_CollaborationRevenueMember_label_en-US" xlink:label="lab_cdtx_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_cdtx_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_cdtx_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationRevenueMember" xlink:href="cdtx-20220930.xsd#cdtx_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cdtx_CollaborationRevenueMember" xlink:to="lab_cdtx_CollaborationRevenueMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>cdtx-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:a568bcbd-732c-4e03-9327-71091167a8dd,g:435374c1-7d67-4ed0-913a-245b913da5ec-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cidara.com/role/Cover" xlink:type="simple" xlink:href="cdtx-20220930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://cidara.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_efb40df0-4549-4ed9-836d-b3c20b0326f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_DocumentType_efb40df0-4549-4ed9-836d-b3c20b0326f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_9c05cfbb-aa9a-4d83-8267-3628309ce8a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_DocumentQuarterlyReport_9c05cfbb-aa9a-4d83-8267-3628309ce8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_355591ef-a514-4c70-ba46-bf42a8423d9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_DocumentPeriodEndDate_355591ef-a514-4c70-ba46-bf42a8423d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6e45c46a-9639-49ae-8971-b7581c566792" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_DocumentTransitionReport_6e45c46a-9639-49ae-8971-b7581c566792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f4c6311c-6dbf-41e0-8582-885a9fbf6db1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityFileNumber_f4c6311c-6dbf-41e0-8582-885a9fbf6db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fd133a05-b3c8-4e49-9af2-5a2abec8e58d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityRegistrantName_fd133a05-b3c8-4e49-9af2-5a2abec8e58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_8b932f1c-8e3f-4ec0-a349-b51ae06c28a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_8b932f1c-8e3f-4ec0-a349-b51ae06c28a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f7341b02-0700-4e48-b055-3832631e4838" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityTaxIdentificationNumber_f7341b02-0700-4e48-b055-3832631e4838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_613f3ddc-1d10-4c3e-8d18-14bb372aab81" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityAddressAddressLine1_613f3ddc-1d10-4c3e-8d18-14bb372aab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_706dd4ab-3d6b-474a-8409-9f829c47a523" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityAddressAddressLine2_706dd4ab-3d6b-474a-8409-9f829c47a523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f779771-a734-4f47-ba29-56c6c5392ff6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityAddressCityOrTown_8f779771-a734-4f47-ba29-56c6c5392ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_dafb58c3-2295-4d45-b851-a585d450ad4a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityAddressStateOrProvince_dafb58c3-2295-4d45-b851-a585d450ad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_080322e3-c0e3-46f8-9b09-1340e9af4c62" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityAddressPostalZipCode_080322e3-c0e3-46f8-9b09-1340e9af4c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8a9a1cde-7ea3-4e96-82ba-f217e4062752" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_CityAreaCode_8a9a1cde-7ea3-4e96-82ba-f217e4062752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b35a5ca1-597e-4b80-8184-f5605b16346c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_LocalPhoneNumber_b35a5ca1-597e-4b80-8184-f5605b16346c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_37f52c82-94c9-4bb0-ac45-f3e93cf844ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_Security12bTitle_37f52c82-94c9-4bb0-ac45-f3e93cf844ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_51189f12-08a5-4ef7-9176-2ee4a4c1f85f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_TradingSymbol_51189f12-08a5-4ef7-9176-2ee4a4c1f85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3cea4aa2-c718-419f-8f2b-34e2271f2399" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_SecurityExchangeName_3cea4aa2-c718-419f-8f2b-34e2271f2399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_58d505ce-a350-45a3-ab2b-95a9ea958f37" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityCurrentReportingStatus_58d505ce-a350-45a3-ab2b-95a9ea958f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e6017ed5-5e9e-4973-9f13-0b5b3852f048" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityInteractiveDataCurrent_e6017ed5-5e9e-4973-9f13-0b5b3852f048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ff4f2687-a7c1-4aa4-831d-0df3bcfd161a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityFilerCategory_ff4f2687-a7c1-4aa4-831d-0df3bcfd161a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4ad26d11-b305-4564-a07c-4e7ab441760b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntitySmallBusiness_4ad26d11-b305-4564-a07c-4e7ab441760b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b1299ccd-5bbf-41e3-ac27-60b10902f4a4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityEmergingGrowthCompany_b1299ccd-5bbf-41e3-ac27-60b10902f4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d309f0bc-9fd4-45da-b729-a532d5a8089b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityShellCompany_d309f0bc-9fd4-45da-b729-a532d5a8089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_61e03392-a577-4761-84fc-3991dc56f252" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_61e03392-a577-4761-84fc-3991dc56f252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c6bc063a-ea6f-48eb-a301-65d139e8ae9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_AmendmentFlag_c6bc063a-ea6f-48eb-a301-65d139e8ae9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e0ffdb54-d838-4bd9-8330-be10500a8f09" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_DocumentFiscalYearFocus_e0ffdb54-d838-4bd9-8330-be10500a8f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_106c202a-8681-46d1-b210-10fec7e8cc6d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_106c202a-8681-46d1-b210-10fec7e8cc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3b2718ce-44d3-4e0f-81c9-64f951448eb8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_EntityCentralIndexKey_3b2718ce-44d3-4e0f-81c9-64f951448eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_983308a0-969c-4010-a93d-b46af7c8b7c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d755a2dd-e853-400a-a3f6-28831d2620de" xlink:to="loc_dei_CurrentFiscalYearEndDate_983308a0-969c-4010-a93d-b46af7c8b7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8463d6b9-1f92-4166-a8b6-507d88596867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ea4cfd3-2116-4aaf-afdf-80d4c4c3382b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8463d6b9-1f92-4166-a8b6-507d88596867" xlink:to="loc_us-gaap_StatementTable_8ea4cfd3-2116-4aaf-afdf-80d4c4c3382b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_125e4f23-bae0-43a5-b4b5-22e8373bb52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ea4cfd3-2116-4aaf-afdf-80d4c4c3382b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_125e4f23-bae0-43a5-b4b5-22e8373bb52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa8555ff-00ab-482f-9c1a-7f23a129f745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_125e4f23-bae0-43a5-b4b5-22e8373bb52e" xlink:to="loc_us-gaap_ClassOfStockDomain_aa8555ff-00ab-482f-9c1a-7f23a129f745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_faf37de1-0724-4123-aa61-19e88caf8135" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_aa8555ff-00ab-482f-9c1a-7f23a129f745" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_faf37de1-0724-4123-aa61-19e88caf8135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ea4cfd3-2116-4aaf-afdf-80d4c4c3382b" xlink:to="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:to="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f5eb10ac-de84-45f9-88fc-6c369263e5d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f5eb10ac-de84-45f9-88fc-6c369263e5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7fd05da6-0713-43ae-849b-f66fce11b3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_RestrictedCashCurrent_7fd05da6-0713-43ae-849b-f66fce11b3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dbb07df7-b892-4c30-a04b-de4895410266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dbb07df7-b892-4c30-a04b-de4895410266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7a95790f-aa7d-45ff-b153-23019e012f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7a95790f-aa7d-45ff-b153-23019e012f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6855cb1e-3313-46df-8e9c-eba08adbcf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8f4e0901-5a9b-4976-8ccd-4d08e34ffb1f" xlink:to="loc_us-gaap_AssetsCurrent_6855cb1e-3313-46df-8e9c-eba08adbcf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d5fe8740-2b39-4d3e-9647-9741cf3c6274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d5fe8740-2b39-4d3e-9647-9741cf3c6274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_06a09531-3c3b-42fa-bddd-374d841c06a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_06a09531-3c3b-42fa-bddd-374d841c06a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_60a7fa53-0093-4324-bfb9-3148e2fc3d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_60a7fa53-0093-4324-bfb9-3148e2fc3d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_76f39450-6bb1-4dba-8a15-628cdf0566fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a2ddc4be-7122-41da-a17f-d08336c7c17b" xlink:to="loc_us-gaap_Assets_76f39450-6bb1-4dba-8a15-628cdf0566fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_741e4afc-8eff-45fa-804c-44519804d96d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ce3ede63-809d-4721-8bad-259fcdadcf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_AccountsPayableCurrent_ce3ede63-809d-4721-8bad-259fcdadcf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5cdc81b2-daaf-4337-be9d-cddd0147de19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5cdc81b2-daaf-4337-be9d-cddd0147de19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bfb5c96d-39e8-433a-a6ce-5ae4b6a18295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bfb5c96d-39e8-433a-a6ce-5ae4b6a18295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_43752ef1-c42e-46bc-b127-b7911641e914" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_43752ef1-c42e-46bc-b127-b7911641e914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9aa5fe01-b0bc-4d27-ba4a-acaef2e294e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9aa5fe01-b0bc-4d27-ba4a-acaef2e294e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_92e60491-af12-4050-b574-d40b7240e095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_LoansPayableCurrent_92e60491-af12-4050-b574-d40b7240e095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_df6f6abe-af7b-4b8b-869c-7cb1b22dbf1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0aff496c-3272-44c7-a41b-b455cd82a5a0" xlink:to="loc_us-gaap_LiabilitiesCurrent_df6f6abe-af7b-4b8b-869c-7cb1b22dbf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_5d81f996-fbe0-4048-b56c-b79918f86cd7" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_5d81f996-fbe0-4048-b56c-b79918f86cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0eddac77-21ee-43e9-a99a-93835b3f6d71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0eddac77-21ee-43e9-a99a-93835b3f6d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c7ceed34-94de-4167-b98c-267982f7b3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_Liabilities_c7ceed34-94de-4167-b98c-267982f7b3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2323e3b4-16f7-4f18-91c3-ef29d4ea55d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2323e3b4-16f7-4f18-91c3-ef29d4ea55d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8e921a99-2a27-4e9c-bb0f-a072ff87d279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_PreferredStockValue_8e921a99-2a27-4e9c-bb0f-a072ff87d279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_61579247-65f3-4341-b0a5-3aee213eb918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_CommonStockValue_61579247-65f3-4341-b0a5-3aee213eb918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1f80772e-dc93-4cbd-b90f-aae3a6eb974a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1f80772e-dc93-4cbd-b90f-aae3a6eb974a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19276f7f-b8d5-4b91-8d64-bd3feafdd5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19276f7f-b8d5-4b91-8d64-bd3feafdd5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a803312a-a1f6-42b5-a2ce-3eff5b2d8a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_628594bc-9991-4737-80b6-b5ca24f41d2e" xlink:to="loc_us-gaap_StockholdersEquity_a803312a-a1f6-42b5-a2ce-3eff5b2d8a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b67c91a3-7f1c-4ef0-a839-a7aafc7c524d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a7360fcf-69e8-4efb-b4f9-eb44b22d03e3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b67c91a3-7f1c-4ef0-a839-a7aafc7c524d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1292ea61-f834-4f49-a4bb-da19b58bc158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8ee1e153-7294-401d-a569-ca5109747a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1292ea61-f834-4f49-a4bb-da19b58bc158" xlink:to="loc_us-gaap_StatementTable_8ee1e153-7294-401d-a569-ca5109747a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9690406f-e2aa-4440-8de6-78aeb6779901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ee1e153-7294-401d-a569-ca5109747a8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9690406f-e2aa-4440-8de6-78aeb6779901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2883f99a-dc40-4bde-9829-99b975ee2dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9690406f-e2aa-4440-8de6-78aeb6779901" xlink:to="loc_us-gaap_ClassOfStockDomain_2883f99a-dc40-4bde-9829-99b975ee2dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_789dce78-29b2-49c4-a5cc-661f914fca0d" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2883f99a-dc40-4bde-9829-99b975ee2dc4" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_789dce78-29b2-49c4-a5cc-661f914fca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8ee1e153-7294-401d-a569-ca5109747a8b" xlink:to="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_77ff26e3-b229-4052-a87a-9ed6a1c14ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_77ff26e3-b229-4052-a87a-9ed6a1c14ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_442c73ae-36e5-4d40-8785-30ddb8de659b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_442c73ae-36e5-4d40-8785-30ddb8de659b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3b1a088b-53e8-4407-9eea-ffedaf0beccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3b1a088b-53e8-4407-9eea-ffedaf0beccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7eb7ef6e-93ba-4949-aff9-ba03c8a46ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7eb7ef6e-93ba-4949-aff9-ba03c8a46ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7378e4de-8d2d-467e-ba61-8552b1f38c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7378e4de-8d2d-467e-ba61-8552b1f38c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a2427c0c-503d-4b94-8a77-37f35bfe7948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a2427c0c-503d-4b94-8a77-37f35bfe7948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_94a5459f-45dd-4d4a-866c-5746661541d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockSharesIssued_94a5459f-45dd-4d4a-866c-5746661541d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_246f95a1-2adb-41ee-b9fb-50e1005b888b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63017725-b220-4777-8cde-dfa27f7ee4b6" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_246f95a1-2adb-41ee-b9fb-50e1005b888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRevenueExtensibleList_c45d115f-1a77-4119-a36f-599bcd9b9c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRevenueExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_TypeOfRevenueExtensibleList_c45d115f-1a77-4119-a36f-599bcd9b9c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_047c081c-c2b7-4e4e-94db-d7c363849b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_047c081c-c2b7-4e4e-94db-d7c363849b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_33c48eff-30e7-4b8c-a148-793c224525b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_33c48eff-30e7-4b8c-a148-793c224525b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5a7cd44e-5fab-405d-a261-1ad3a8ddec62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_33c48eff-30e7-4b8c-a148-793c224525b9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5a7cd44e-5fab-405d-a261-1ad3a8ddec62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c8acae4b-9bac-42ff-98f8-07d5ee11ad05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_33c48eff-30e7-4b8c-a148-793c224525b9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c8acae4b-9bac-42ff-98f8-07d5ee11ad05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b138b6cc-bf87-40bb-89c5-d585769aabcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_33c48eff-30e7-4b8c-a148-793c224525b9" xlink:to="loc_us-gaap_OperatingExpenses_b138b6cc-bf87-40bb-89c5-d585769aabcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a977b9a1-9f24-42ff-a898-85a26117eb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_OperatingIncomeLoss_a977b9a1-9f24-42ff-a898-85a26117eb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b2ac8a0-0228-458b-9bca-7cf85ab763d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b2ac8a0-0228-458b-9bca-7cf85ab763d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e5e5a788-9abb-48a6-b9b5-c542acbab9be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b2ac8a0-0228-458b-9bca-7cf85ab763d2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e5e5a788-9abb-48a6-b9b5-c542acbab9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1343c16c-efa2-46a9-8d62-1f767de4d767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_1b2ac8a0-0228-458b-9bca-7cf85ab763d2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1343c16c-efa2-46a9-8d62-1f767de4d767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0c33eff-1ddc-4748-8fb6-c3341d48bc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f0c33eff-1ddc-4748-8fb6-c3341d48bc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0456b8d-5131-4edd-9742-5e92c54db47f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_NetIncomeLoss_a0456b8d-5131-4edd-9742-5e92c54db47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_9e9147d1-c7ba-4f00-b382-3b7fd4db817b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_9e9147d1-c7ba-4f00-b382-3b7fd4db817b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5fbc8fd4-6a22-4fdc-8258-9e3bff602f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_5fbc8fd4-6a22-4fdc-8258-9e3bff602f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_79fe779a-7f3d-4f8d-94ed-c35a02deeafa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_EarningsPerShareBasic_79fe779a-7f3d-4f8d-94ed-c35a02deeafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_67de9687-ff1d-454c-8105-e6427292a9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_67de9687-ff1d-454c-8105-e6427292a9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b55a6b71-0f09-4115-a757-f6834856d343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b55a6b71-0f09-4115-a757-f6834856d343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d8bc5e3-aaf4-45f1-8f2c-b32845f5d156" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1bc3b795-05f8-4f00-a182-9c93df2f915b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3d8bc5e3-aaf4-45f1-8f2c-b32845f5d156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cc839ff3-8247-4c11-97b0-a87d30851531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cc839ff3-8247-4c11-97b0-a87d30851531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4fa9e94-31a3-44e1-95ed-35935740338c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cc839ff3-8247-4c11-97b0-a87d30851531" xlink:to="loc_us-gaap_NetIncomeLoss_a4fa9e94-31a3-44e1-95ed-35935740338c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cc839ff3-8247-4c11-97b0-a87d30851531" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_4c8a9676-2187-4d6b-8846-a0b673bcc133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:to="loc_us-gaap_ShareBasedCompensation_4c8a9676-2187-4d6b-8846-a0b673bcc133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_13860917-dbe8-4df2-abc2-a01687f7f451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_13860917-dbe8-4df2-abc2-a01687f7f451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_OperatingLeaseRightOfUseAmortization_e4c457f7-a609-4e38-8620-3b0fa1d292e9" xlink:href="cdtx-20220930.xsd#cdtx_OperatingLeaseRightOfUseAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:to="loc_cdtx_OperatingLeaseRightOfUseAmortization_e4c457f7-a609-4e38-8620-3b0fa1d292e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_61e0e8ba-51d6-498b-bc3a-923cbda5c651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:to="loc_us-gaap_DepreciationAndAmortization_61e0e8ba-51d6-498b-bc3a-923cbda5c651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaidInKindInterest_85236ae1-931a-4e10-aae7-909c1e95902f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaidInKindInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:to="loc_us-gaap_PaidInKindInterest_85236ae1-931a-4e10-aae7-909c1e95902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1b1965ba-4334-42fd-ab7e-b7fd24125882" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1b1965ba-4334-42fd-ab7e-b7fd24125882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f943785c-975b-43d5-b9c3-89372c44c40e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbf5e083-113a-4f00-9e3f-2ea1728d2e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbf5e083-113a-4f00-9e3f-2ea1728d2e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_db968c4d-e4ff-4ed8-a6e5-5ae78fb67b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_db968c4d-e4ff-4ed8-a6e5-5ae78fb67b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_beafbbe8-f86f-4334-b57c-b687575a1a09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_beafbbe8-f86f-4334-b57c-b687575a1a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e83761d7-606e-48cd-99d5-59e1dd955ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e83761d7-606e-48cd-99d5-59e1dd955ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6c7d3a8b-a5a7-4e36-8bab-7848e5e96160" xlink:href="cdtx-20220930.xsd#cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:to="loc_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_6c7d3a8b-a5a7-4e36-8bab-7848e5e96160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_efd50038-02fe-47f6-8427-c4663978906e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_21488c5d-7701-422e-96fd-5fe1ee05ae45" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_efd50038-02fe-47f6-8427-c4663978906e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7700851d-b638-41d8-a75c-e633bc3326f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_cc839ff3-8247-4c11-97b0-a87d30851531" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7700851d-b638-41d8-a75c-e633bc3326f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_91593bf6-1f7f-4e52-8673-55ba73a3cf63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_91593bf6-1f7f-4e52-8673-55ba73a3cf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8526f7e-9038-4a06-ae6f-b3070fa6d633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_91593bf6-1f7f-4e52-8673-55ba73a3cf63" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8526f7e-9038-4a06-ae6f-b3070fa6d633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_280a48c3-348e-4290-967a-b15810c00cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_91593bf6-1f7f-4e52-8673-55ba73a3cf63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_280a48c3-348e-4290-967a-b15810c00cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3cb8efd4-c277-4f00-b504-8a97a7854b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3cb8efd4-c277-4f00-b504-8a97a7854b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1b7c296-f1f3-48b9-80f0-75584d3e3d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3cb8efd4-c277-4f00-b504-8a97a7854b6b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1b7c296-f1f3-48b9-80f0-75584d3e3d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_684c38c5-72d8-4fec-a8ed-7c134f46ae25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3cb8efd4-c277-4f00-b504-8a97a7854b6b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_684c38c5-72d8-4fec-a8ed-7c134f46ae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_da0eb5e3-297d-4086-8754-89e8f1dafe48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3cb8efd4-c277-4f00-b504-8a97a7854b6b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_da0eb5e3-297d-4086-8754-89e8f1dafe48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_595fb591-b55d-429f-bd47-79ef8b7771e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3cb8efd4-c277-4f00-b504-8a97a7854b6b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_595fb591-b55d-429f-bd47-79ef8b7771e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07ea0d7-fde8-43e1-9ec2-e879cf3e9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_3cb8efd4-c277-4f00-b504-8a97a7854b6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d07ea0d7-fde8-43e1-9ec2-e879cf3e9f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf1f2458-0dac-4f2c-9b55-6c79aa9cefd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bf1f2458-0dac-4f2c-9b55-6c79aa9cefd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d49c5f9-c395-4f2b-942f-ff3c40f0cca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8d49c5f9-c395-4f2b-942f-ff3c40f0cca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ff8ca59-3a59-44b5-852f-89abb9327cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ff8ca59-3a59-44b5-852f-89abb9327cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_392fe2bb-171e-48b7-84b4-8e38995fbda1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_392fe2bb-171e-48b7-84b4-8e38995fbda1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b0bfb450-4ea4-4478-8230-5da671357b29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_392fe2bb-171e-48b7-84b4-8e38995fbda1" xlink:to="loc_us-gaap_InterestPaidNet_b0bfb450-4ea4-4478-8230-5da671357b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_336be542-88fe-49e8-9aa2-36952360148a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_336be542-88fe-49e8-9aa2-36952360148a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e5fe3d17-d80d-4a69-8069-03731bb1fd56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_336be542-88fe-49e8-9aa2-36952360148a" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_e5fe3d17-d80d-4a69-8069-03731bb1fd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_39bc61cd-cae5-4d5b-9aa8-3a614669ca3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d262941b-ade9-496a-8456-f6d6b6ed8786" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_39bc61cd-cae5-4d5b-9aa8-3a614669ca3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_06da6b45-9baf-4fd5-a708-abb44d2b15ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_39bc61cd-cae5-4d5b-9aa8-3a614669ca3e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_06da6b45-9baf-4fd5-a708-abb44d2b15ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets_fc2bce32-e864-429c-a9bb-9dd3488f41d1" xlink:href="cdtx-20220930.xsd#cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_39bc61cd-cae5-4d5b-9aa8-3a614669ca3e" xlink:to="loc_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets_fc2bce32-e864-429c-a9bb-9dd3488f41d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9cf9336d-20f5-463d-859a-fbcbfb534074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_39bc61cd-cae5-4d5b-9aa8-3a614669ca3e" xlink:to="loc_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_9cf9336d-20f5-463d-859a-fbcbfb534074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="cdtx-20220930.xsd#CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e5b05207-a9ce-409e-a920-6ef4505cdda5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e5b05207-a9ce-409e-a920-6ef4505cdda5" xlink:to="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_02843ce4-0295-48a1-a0e1-636a9b4877a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:to="loc_us-gaap_StatementClassOfStockAxis_02843ce4-0295-48a1-a0e1-636a9b4877a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8bcff19e-37c6-4e69-8066-407b2ac5d030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_02843ce4-0295-48a1-a0e1-636a9b4877a4" xlink:to="loc_us-gaap_ClassOfStockDomain_8bcff19e-37c6-4e69-8066-407b2ac5d030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_5f9d3fba-e92a-47f4-a966-83e0a7f4982e" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8bcff19e-37c6-4e69-8066-407b2ac5d030" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_5f9d3fba-e92a-47f4-a966-83e0a7f4982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5a499e3c-82e0-495f-9c3d-ff626a74d4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5a499e3c-82e0-495f-9c3d-ff626a74d4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5a499e3c-82e0-495f-9c3d-ff626a74d4bd" xlink:to="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_93020c93-b4bd-4ef8-af92-9254aa3fb95f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_PreferredStockMember_93020c93-b4bd-4ef8-af92-9254aa3fb95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_326108ca-0f29-43df-afc3-f3736f021353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_CommonStockMember_326108ca-0f29-43df-afc3-f3736f021353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c85fdb8c-566e-4151-969c-4e1ff90828ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c85fdb8c-566e-4151-969c-4e1ff90828ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bd3c243a-f03d-4040-bbd8-b2d4184c9a04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a8f7e366-1f07-4558-b96a-372813e47019" xlink:to="loc_us-gaap_RetainedEarningsMember_bd3c243a-f03d-4040-bbd8-b2d4184c9a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f8ab53a3-352e-4cc2-b25d-8391b73af9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_164931ed-cdbc-4628-8060-57dc7899df85" xlink:to="loc_us-gaap_StatementLineItems_f8ab53a3-352e-4cc2-b25d-8391b73af9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f8ab53a3-352e-4cc2-b25d-8391b73af9f2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_56f05a83-ab35-4315-bd80-0874e4030e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_56f05a83-ab35-4315-bd80-0874e4030e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e3cd81fa-79ee-4206-9397-09ad94f24a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockholdersEquity_e3cd81fa-79ee-4206-9397-09ad94f24a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b06e2ff-93e2-4de5-aa10-f72967854608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b06e2ff-93e2-4de5-aa10-f72967854608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79d7e8e5-0b88-40e0-9f25-a6424519fa43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_79d7e8e5-0b88-40e0-9f25-a6424519fa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0452cd4-35bb-4fd1-9ea2-8b8dc70f28b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f0452cd4-35bb-4fd1-9ea2-8b8dc70f28b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c6e755f-2492-48a4-a7b9-743534c7cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c6e755f-2492-48a4-a7b9-743534c7cbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_68c40de4-4ab8-4fae-bcb0-6a0ae84ae0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_68c40de4-4ab8-4fae-bcb0-6a0ae84ae0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d916a662-5383-449a-902f-888c31fc5b80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_d916a662-5383-449a-902f-888c31fc5b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7660121-d390-4809-a9e1-5ef8cd1921c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e7660121-d390-4809-a9e1-5ef8cd1921c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e4e41dbc-9381-4981-8578-cdcfb9756646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_e4e41dbc-9381-4981-8578-cdcfb9756646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_8d446858-36a5-41cd-95df-4d643c8ec0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_8d446858-36a5-41cd-95df-4d643c8ec0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f583b49f-a3ed-4a4c-b839-4b9eb8963134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f583b49f-a3ed-4a4c-b839-4b9eb8963134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0b4162ff-c9b1-4ac9-b7f5-c8920bae5357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_NetIncomeLoss_0b4162ff-c9b1-4ac9-b7f5-c8920bae5357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_917c6bad-0580-4312-ae6c-e4b98f50c4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_917c6bad-0580-4312-ae6c-e4b98f50c4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2aac50e8-4c18-4a33-a646-37475fe3ffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_StockholdersEquity_2aac50e8-4c18-4a33-a646-37475fe3ffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_58c2e0c8-376f-415e-b63b-96561f23ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_010e6cf9-6396-4d7c-b9b9-efe7f2af2300" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_58c2e0c8-376f-415e-b63b-96561f23ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="simple" xlink:href="cdtx-20220930.xsd#THECOMPANYANDBASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6d2b42aa-1a8a-4cdd-8f61-74d554470eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_72d86b18-cc35-45e0-bc98-d6afb003f3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6d2b42aa-1a8a-4cdd-8f61-74d554470eca" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_72d86b18-cc35-45e0-bc98-d6afb003f3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9610857d-7352-45f7-934c-1e01b27e40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4b892368-ec2f-42cc-b37f-1db8e690a68d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9610857d-7352-45f7-934c-1e01b27e40fb" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4b892368-ec2f-42cc-b37f-1db8e690a68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="cdtx-20220930.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c173040b-be8e-475d-8f98-6acf4815eafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_6734bb18-9604-47e2-89fb-f06dd9c1b011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c173040b-be8e-475d-8f98-6acf4815eafb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_6734bb18-9604-47e2-89fb-f06dd9c1b011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBT" xlink:type="simple" xlink:href="cdtx-20220930.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ce014b5d-6f66-497a-b190-311e2162e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_24b1de6b-0bce-4373-a9ae-9d0c961a7e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce014b5d-6f66-497a-b190-311e2162e6fe" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_24b1de6b-0bce-4373-a9ae-9d0c961a7e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="cdtx-20220930.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_00892354-ef12-48ce-9d2f-1957636788bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6c569fa4-4f05-4a53-8c4a-c48e4b20bcc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_00892354-ef12-48ce-9d2f-1957636788bb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6c569fa4-4f05-4a53-8c4a-c48e4b20bcc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c296eaa2-f034-4ea8-b0a5-022fe82428bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_849343b6-91b1-40aa-81fd-f8c36b34233d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c296eaa2-f034-4ea8-b0a5-022fe82428bd" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_849343b6-91b1-40aa-81fd-f8c36b34233d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTS"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6dd0b195-809f-4275-8f72-432ff84330cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e2198f9a-0ad1-4d7f-a5ef-674564a2eb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6dd0b195-809f-4275-8f72-432ff84330cc" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_e2198f9a-0ad1-4d7f-a5ef-674564a2eb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33d132b7-69f9-41de-9e44-c76416c619a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_873f437e-976e-4107-92e9-1eb057b58c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_33d132b7-69f9-41de-9e44-c76416c619a9" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_873f437e-976e-4107-92e9-1eb057b58c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_30f4ea0a-7c60-4762-ad58-6fdc2aec1ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_30f4ea0a-7c60-4762-ad58-6fdc2aec1ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_68d34d76-01e0-4098-a9ed-9b9179a7951f" xlink:href="cdtx-20220930.xsd#cdtx_UnauditedInterimFinancialDataPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_cdtx_UnauditedInterimFinancialDataPolicyTextBlock_68d34d76-01e0-4098-a9ed-9b9179a7951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d7b2bffb-74b8-4f14-b0e5-a8b38435fc03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d7b2bffb-74b8-4f14-b0e5-a8b38435fc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_d2068102-3d9a-4588-afc5-34cd298b34c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_UseOfEstimates_d2068102-3d9a-4588-afc5-34cd298b34c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0f2a968d-a6ea-41ab-b4f9-1eb6842929a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_0f2a968d-a6ea-41ab-b4f9-1eb6842929a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3b561768-c1f9-4fc1-b2c0-51b1febba7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3b561768-c1f9-4fc1-b2c0-51b1febba7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9ceb4c98-9f13-4bfa-b87a-3be68bd93890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_9ceb4c98-9f13-4bfa-b87a-3be68bd93890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_da688cc8-b390-47d3-b96c-ef659a920509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_da688cc8-b390-47d3-b96c-ef659a920509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_3f62c9f6-78cf-4030-98ce-dd25c18e43a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_3f62c9f6-78cf-4030-98ce-dd25c18e43a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5d7debdc-5741-479b-bce7-5b2185630088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5d7debdc-5741-479b-bce7-5b2185630088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_eb4f1bb4-df63-4c48-b1b4-aa2fc6b617e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_eb4f1bb4-df63-4c48-b1b4-aa2fc6b617e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_7abde651-4141-4c47-b537-89f529a4f1af" xlink:href="cdtx-20220930.xsd#cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock_7abde651-4141-4c47-b537-89f529a4f1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f50bc0b3-c006-40d5-990b-af07af0e42f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f50bc0b3-c006-40d5-990b-af07af0e42f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0da76bd8-f40c-4cda-89f4-eb9967ba847d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0da76bd8-f40c-4cda-89f4-eb9967ba847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2b75b49d-1092-4c0c-a3e8-e5726076806f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_2b75b49d-1092-4c0c-a3e8-e5726076806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c922915-3b77-4439-ae68-8331418ce3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e5e7e59-c004-46c0-b4fb-724c0930ae4d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_7c922915-3b77-4439-ae68-8331418ce3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_143dd01d-eb2c-4d7d-9e43-74f698a5a300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b5091b70-380a-44de-b8da-3e30b9ae44c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_143dd01d-eb2c-4d7d-9e43-74f698a5a300" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b5091b70-380a-44de-b8da-3e30b9ae44c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3b33fd8c-3d58-4f1e-956d-5689fd7deaee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_143dd01d-eb2c-4d7d-9e43-74f698a5a300" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3b33fd8c-3d58-4f1e-956d-5689fd7deaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="cdtx-20220930.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2016c7b3-5b82-4311-897f-6ccde1dda2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_408576d1-1ee5-44c1-a1cd-0526d92f19db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2016c7b3-5b82-4311-897f-6ccde1dda2cb" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_408576d1-1ee5-44c1-a1cd-0526d92f19db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="cdtx-20220930.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9fba0086-5d04-49fd-827d-6b9f0e04b90b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_9810eb82-7007-4025-b4af-63d4f40ecef2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9fba0086-5d04-49fd-827d-6b9f0e04b90b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_9810eb82-7007-4025-b4af-63d4f40ecef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_102d505d-c05a-4d9f-a880-cccdeb8fa581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0f5d1544-2386-4b18-a43d-b7e8ea6bfcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_102d505d-c05a-4d9f-a880-cccdeb8fa581" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0f5d1544-2386-4b18-a43d-b7e8ea6bfcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e4d33c2e-23f6-489d-8b6c-1d9861c4a7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_102d505d-c05a-4d9f-a880-cccdeb8fa581" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e4d33c2e-23f6-489d-8b6c-1d9861c4a7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eee74080-8f87-4a6f-b5a0-4bb3b696cd59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_102d505d-c05a-4d9f-a880-cccdeb8fa581" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_eee74080-8f87-4a6f-b5a0-4bb3b696cd59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f5b81fa-34af-4ad9-ab9e-1e2231373173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_c8b2e2a7-e396-44bf-900b-448d953882d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0f5b81fa-34af-4ad9-ab9e-1e2231373173" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_c8b2e2a7-e396-44bf-900b-448d953882d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c15c8b12-f34a-474e-8f48-65d19ffd1bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8d63abc1-b9d0-4741-9589-ca909704b2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c15c8b12-f34a-474e-8f48-65d19ffd1bc9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8d63abc1-b9d0-4741-9589-ca909704b2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_28f32231-076b-4831-aca7-79f7604f8056" xlink:href="cdtx-20220930.xsd#cdtx_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c15c8b12-f34a-474e-8f48-65d19ffd1bc9" xlink:to="loc_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock_28f32231-076b-4831-aca7-79f7604f8056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#THECOMPANYANDBASISOFPRESENTATIONDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef0fac5c-2c6d-4e4b-84c3-c7ad8466a86c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dc77a1bf-40fa-4cca-a331-966b561bcf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef0fac5c-2c6d-4e4b-84c3-c7ad8466a86c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dc77a1bf-40fa-4cca-a331-966b561bcf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7397166f-1ed0-4b6c-b39c-bb2aa8355d18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef0fac5c-2c6d-4e4b-84c3-c7ad8466a86c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7397166f-1ed0-4b6c-b39c-bb2aa8355d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_692a8798-a785-4087-b2c2-1ad24c20b5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef0fac5c-2c6d-4e4b-84c3-c7ad8466a86c" xlink:to="loc_us-gaap_NumberOfOperatingSegments_692a8798-a785-4087-b2c2-1ad24c20b5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ed87d339-ddbd-4468-a034-f453734464c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ed87d339-ddbd-4468-a034-f453734464c3" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:to="loc_srt_CounterpartyNameAxis_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_57d702a0-77b2-4b3c-a061-cf3fd16a7bdd" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_b7f39b00-d6af-4a76-b941-6b026f4632f1" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_b7f39b00-d6af-4a76-b941-6b026f4632f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_7aa398f3-0118-4f50-a9e6-1db56473c23b" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_7aa398f3-0118-4f50-a9e6-1db56473c23b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_fc980bf3-fce3-4c25-82b9-5b5d3ac0f62c" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_90bb72a8-bace-4507-b41f-c71bb1287c16" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_fc980bf3-fce3-4c25-82b9-5b5d3ac0f62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_406ba2a5-1082-477a-ac48-028a2439199f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:to="loc_us-gaap_TypeOfArrangementAxis_406ba2a5-1082-477a-ac48-028a2439199f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98a29aba-b9b4-43a7-af22-83491106cc57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_406ba2a5-1082-477a-ac48-028a2439199f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98a29aba-b9b4-43a7-af22-83491106cc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenCollaborationAgreementMember_eac09376-b2ff-46b1-8640-39c912c96c88" xlink:href="cdtx-20220930.xsd#cdtx_JanssenCollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_98a29aba-b9b4-43a7-af22-83491106cc57" xlink:to="loc_cdtx_JanssenCollaborationAgreementMember_eac09376-b2ff-46b1-8640-39c912c96c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_13b80875-0a2e-4166-be97-d7faa7e98bf1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:to="loc_srt_RangeAxis_13b80875-0a2e-4166-be97-d7faa7e98bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13b80875-0a2e-4166-be97-d7faa7e98bf1" xlink:to="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bd1a2c96-ed2f-4fcf-b04a-706bfd1a71a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:to="loc_srt_MinimumMember_bd1a2c96-ed2f-4fcf-b04a-706bfd1a71a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_453f6e7c-63bb-416d-929a-c7d19a8d9465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e96aff4a-6883-46e7-9a27-72bc4013f59f" xlink:to="loc_srt_MaximumMember_453f6e7c-63bb-416d-929a-c7d19a8d9465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_49a35055-7e70-4a24-afb7-9de46834b5fd" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb93432c-bf7b-4858-83b0-1e89cd2b6890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_fb93432c-bf7b-4858-83b0-1e89cd2b6890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_9f241b35-8b95-4974-b458-629beb08174e" xlink:href="cdtx-20220930.xsd#cdtx_CollaborationAgreementNumberOfPerformanceObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:to="loc_cdtx_CollaborationAgreementNumberOfPerformanceObligations_9f241b35-8b95-4974-b458-629beb08174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b463feb-33fd-47b8-936f-ae4716902d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_0f26f090-2b58-494f-96bb-5af2e24cbab2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0b463feb-33fd-47b8-936f-ae4716902d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5ea9fae1-1c1f-4bb7-8316-eceff49c88f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5bcde954-e3ba-4aa6-8a9a-eed2921e3f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5ea9fae1-1c1f-4bb7-8316-eceff49c88f6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5bcde954-e3ba-4aa6-8a9a-eed2921e3f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d05cd56-cf79-4efa-9e6f-bc1328787c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5bcde954-e3ba-4aa6-8a9a-eed2921e3f14" xlink:to="loc_us-gaap_NetIncomeLoss_8d05cd56-cf79-4efa-9e6f-bc1328787c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_8eeefa9b-a8e6-49db-aaae-993513527bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5bcde954-e3ba-4aa6-8a9a-eed2921e3f14" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic_8eeefa9b-a8e6-49db-aaae-993513527bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b3deebda-3e81-4bf2-8535-e0c4d1d3580b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5bcde954-e3ba-4aa6-8a9a-eed2921e3f14" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b3deebda-3e81-4bf2-8535-e0c4d1d3580b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_0b9b6610-1488-47a4-a1ab-5951a8373367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5ea9fae1-1c1f-4bb7-8316-eceff49c88f6" xlink:to="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_0b9b6610-1488-47a4-a1ab-5951a8373367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_12c73e5a-8bfd-4b47-b261-1459e6872e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_0b9b6610-1488-47a4-a1ab-5951a8373367" xlink:to="loc_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted_12c73e5a-8bfd-4b47-b261-1459e6872e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_599a335b-28cc-4099-8887-8b990247f163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract_0b9b6610-1488-47a4-a1ab-5951a8373367" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_599a335b-28cc-4099-8887-8b990247f163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_20bdf2d7-9c1d-464b-a7c8-8d0ea9ac9ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5ea9fae1-1c1f-4bb7-8316-eceff49c88f6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_20bdf2d7-9c1d-464b-a7c8-8d0ea9ac9ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d8603e01-f7e5-47eb-aa1b-f22b88a085da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_20bdf2d7-9c1d-464b-a7c8-8d0ea9ac9ae9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d8603e01-f7e5-47eb-aa1b-f22b88a085da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4fa137ec-e473-435f-ad4b-cd4040f7783a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5ea9fae1-1c1f-4bb7-8316-eceff49c88f6" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4fa137ec-e473-435f-ad4b-cd4040f7783a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_178138ea-4dd9-4a2f-b144-1d272e302af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4fa137ec-e473-435f-ad4b-cd4040f7783a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_178138ea-4dd9-4a2f-b144-1d272e302af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5de89f73-41fb-4860-b9df-5a1a42e34c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4fa137ec-e473-435f-ad4b-cd4040f7783a" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_5de89f73-41fb-4860-b9df-5a1a42e34c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6247e05d-f07c-44d5-a5fa-7621e40ec16b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4fa137ec-e473-435f-ad4b-cd4040f7783a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6247e05d-f07c-44d5-a5fa-7621e40ec16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ec1425d7-f7db-4233-8160-a704add1dc88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4fa137ec-e473-435f-ad4b-cd4040f7783a" xlink:to="loc_us-gaap_EarningsPerShareBasic_ec1425d7-f7db-4233-8160-a704add1dc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_992765fb-18f5-47a1-bfe0-1d637dceb8fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_4fa137ec-e473-435f-ad4b-cd4040f7783a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_992765fb-18f5-47a1-bfe0-1d637dceb8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_37396cea-7b24-4289-ad7f-db03bf7398a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c790d726-549f-4390-af3d-19f4e4d54358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37396cea-7b24-4289-ad7f-db03bf7398a9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c790d726-549f-4390-af3d-19f4e4d54358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7b43752-931e-4293-9123-750640689efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c790d726-549f-4390-af3d-19f4e4d54358" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7b43752-931e-4293-9123-750640689efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_d7b43752-931e-4293-9123-750640689efd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_89fbca43-7b61-4bcc-9567-56534774e4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:to="loc_us-gaap_WarrantMember_89fbca43-7b61-4bcc-9567-56534774e4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_7674dbfb-7bbb-46ad-960e-e1b4353a5374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_7674dbfb-7bbb-46ad-960e-e1b4353a5374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_f15d07da-d12d-48c4-a1b4-9bb12b284968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_8dde48f1-1d83-4144-9a2f-33d95a56a64a" xlink:to="loc_us-gaap_StockCompensationPlanMember_f15d07da-d12d-48c4-a1b4-9bb12b284968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d8cbd58-748b-4d41-9022-87f969bcce38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c790d726-549f-4390-af3d-19f4e4d54358" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d8cbd58-748b-4d41-9022-87f969bcce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0005a9af-cdf9-459f-b692-ec9533a06ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_5d8cbd58-748b-4d41-9022-87f969bcce38" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0005a9af-cdf9-459f-b692-ec9533a06ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b3a95d79-a205-4066-b264-853b90f09ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc4a1b6b-76d5-4179-ad0f-703619dde95a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b3a95d79-a205-4066-b264-853b90f09ca5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc4a1b6b-76d5-4179-ad0f-703619dde95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61b3ef44-2285-4a7b-872d-804e2c306c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc4a1b6b-76d5-4179-ad0f-703619dde95a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61b3ef44-2285-4a7b-872d-804e2c306c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_61b3ef44-2285-4a7b-872d-804e2c306c71" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_798d694d-d745-4703-a832-592f8d192900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_798d694d-d745-4703-a832-592f8d192900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_4a346eed-9ec5-40b3-b7f7-c4b49ee25ce2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_4a346eed-9ec5-40b3-b7f7-c4b49ee25ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a0b55522-15a9-4dd5-aeb9-53a60b780b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c6a94dac-2f0f-4fa5-b5fe-492ed75ef46a" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a0b55522-15a9-4dd5-aeb9-53a60b780b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d856b2e2-6d05-4ae2-9221-1c3f0dd01119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc4a1b6b-76d5-4179-ad0f-703619dde95a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d856b2e2-6d05-4ae2-9221-1c3f0dd01119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d856b2e2-6d05-4ae2-9221-1c3f0dd01119" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9dfba42d-76fe-4028-ba80-65669fc200c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9dfba42d-76fe-4028-ba80-65669fc200c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bf168a46-2f95-41f6-99aa-2922524946d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:to="loc_us-gaap_RestrictedCash_bf168a46-2f95-41f6-99aa-2922524946d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3bfc8d99-6581-418c-ab4a-2482d26afa64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_03cd4c63-9d30-43f6-a757-2e9b3dcecace" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3bfc8d99-6581-418c-ab4a-2482d26afa64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#DEBTAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/DEBTAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ce21be75-20a2-456a-941a-eb384b4e192e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce21be75-20a2-456a-941a-eb384b4e192e" xlink:to="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_235e8e32-36ec-43fb-a9f0-033d09c57e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_235e8e32-36ec-43fb-a9f0-033d09c57e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c0935d82-b008-45e2-ba40-a908a342fae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_235e8e32-36ec-43fb-a9f0-033d09c57e1b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c0935d82-b008-45e2-ba40-a908a342fae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanMember_9e2a39f8-bd06-4deb-81c0-252054d30e59" xlink:href="cdtx-20220930.xsd#cdtx_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_c0935d82-b008-45e2-ba40-a908a342fae4" xlink:to="loc_cdtx_TermLoanMember_9e2a39f8-bd06-4deb-81c0-252054d30e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_222760ed-793f-4d99-9578-0eb446988368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:to="loc_us-gaap_DebtInstrumentAxis_222760ed-793f-4d99-9578-0eb446988368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_993c98ab-5765-4b24-ae92-df217a613fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_222760ed-793f-4d99-9578-0eb446988368" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_993c98ab-5765-4b24-ae92-df217a613fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TermLoanAMember_a5ce6e71-b7a6-4188-a8bb-32c0c2ccf7a0" xlink:href="cdtx-20220930.xsd#cdtx_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_993c98ab-5765-4b24-ae92-df217a613fd3" xlink:to="loc_cdtx_TermLoanAMember_a5ce6e71-b7a6-4188-a8bb-32c0c2ccf7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_687fb666-74ad-4610-b48e-568631e77fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:to="loc_us-gaap_VariableRateAxis_687fb666-74ad-4610-b48e-568631e77fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_30305591-0c59-4097-abb4-635e56716661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_687fb666-74ad-4610-b48e-568631e77fcd" xlink:to="loc_us-gaap_VariableRateDomain_30305591-0c59-4097-abb4-635e56716661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_8daf6dc7-1c31-4aa6-a683-e6cf48e7fffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_30305591-0c59-4097-abb4-635e56716661" xlink:to="loc_us-gaap_PrimeRateMember_8daf6dc7-1c31-4aa6-a683-e6cf48e7fffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_dabfd904-92e8-41ff-b363-b6383f260769" xlink:to="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_81c59d2c-8a5b-47a1-9c4a-f067737dcbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_81c59d2c-8a5b-47a1-9c4a-f067737dcbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_073bf16c-0d84-41c8-a31f-26243394075b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_073bf16c-0d84-41c8-a31f-26243394075b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7f0403c0-617d-4cfe-b75a-c3bbb479f699" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_595d1223-2156-4269-8eb0-40f963768948" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7f0403c0-617d-4cfe-b75a-c3bbb479f699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_db895b06-22f5-4e4b-9342-a9689217f2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_db895b06-22f5-4e4b-9342-a9689217f2b1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_92296089-ce89-4100-8334-8477ef9ec7bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_92296089-ce89-4100-8334-8477ef9ec7bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_92296089-ce89-4100-8334-8477ef9ec7bf" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_ddb37907-9928-4f66-b742-cd374179d220" xlink:href="cdtx-20220930.xsd#cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:to="loc_cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember_ddb37907-9928-4f66-b742-cd374179d220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PublicStockOfferingMember_b5a076c5-6ede-4ffd-84a4-fc33dc84b507" xlink:href="cdtx-20220930.xsd#cdtx_PublicStockOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:to="loc_cdtx_PublicStockOfferingMember_b5a076c5-6ede-4ffd-84a4-fc33dc84b507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_d5f102ff-d86d-4914-9305-75d899a70b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d2d5c85c-b551-4f90-b977-c729234f9e33" xlink:to="loc_us-gaap_OverAllotmentOptionMember_d5f102ff-d86d-4914-9305-75d899a70b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_905bbf7b-ea59-413c-94e9-e65979b70f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_905bbf7b-ea59-413c-94e9-e65979b70f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6cabf0fb-8203-4f46-83b1-b564a0662188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_905bbf7b-ea59-413c-94e9-e65979b70f82" xlink:to="loc_us-gaap_EquityComponentDomain_6cabf0fb-8203-4f46-83b1-b564a0662188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0cfd04d7-e68d-4c9b-9116-627791208960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6cabf0fb-8203-4f46-83b1-b564a0662188" xlink:to="loc_us-gaap_CommonStockMember_0cfd04d7-e68d-4c9b-9116-627791208960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d1726263-6dc5-4741-8312-589d15fc4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d1726263-6dc5-4741-8312-589d15fc4b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3a657dc2-a5db-4217-b7a7-a16fdc4ebb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d1726263-6dc5-4741-8312-589d15fc4b25" xlink:to="loc_us-gaap_ClassOfStockDomain_3a657dc2-a5db-4217-b7a7-a16fdc4ebb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_1ac1931c-9153-41d5-926b-5988199c0399" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3a657dc2-a5db-4217-b7a7-a16fdc4ebb8d" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_1ac1931c-9153-41d5-926b-5988199c0399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9872cb43-88b5-4518-8d7c-cc1397339e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9872cb43-88b5-4518-8d7c-cc1397339e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6c88610b-8f99-4778-a81e-af132f07e6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9872cb43-88b5-4518-8d7c-cc1397339e67" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6c88610b-8f99-4778-a81e-af132f07e6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CommonStockWarrantMember_791c6af1-ee9e-439d-9d9a-e84b7f740afb" xlink:href="cdtx-20220930.xsd#cdtx_CommonStockWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_6c88610b-8f99-4778-a81e-af132f07e6cc" xlink:to="loc_cdtx_CommonStockWarrantMember_791c6af1-ee9e-439d-9d9a-e84b7f740afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_srt_RangeAxis_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_672721eb-03d3-447f-be45-98f5d7a4fe91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7425ca9f-bd7f-4cdb-9fb4-1631f82103ba" xlink:to="loc_srt_RangeMember_672721eb-03d3-447f-be45-98f5d7a4fe91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_24f693d3-7d5d-480a-b8a3-91d68cac9713" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_672721eb-03d3-447f-be45-98f5d7a4fe91" xlink:to="loc_srt_WeightedAverageMember_24f693d3-7d5d-480a-b8a3-91d68cac9713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_35aad55c-8a59-495d-bccf-4df4608c79d3" xlink:to="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f1294998-c5f8-49c5-aa80-09b740674343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f1294998-c5f8-49c5-aa80-09b740674343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c8c5737f-9f90-47a6-8886-71806fbd8502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_c8c5737f-9f90-47a6-8886-71806fbd8502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_2fc972b4-15df-483b-9bd2-cc67334ffa2b" xlink:href="cdtx-20220930.xsd#cdtx_SaleOfStockConsiderationRemainingOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_SaleOfStockConsiderationRemainingOnTransaction_2fc972b4-15df-483b-9bd2-cc67334ffa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_e6757f7f-c6b8-4249-8914-da37bc7ae9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_e6757f7f-c6b8-4249-8914-da37bc7ae9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f52151da-3ca6-47e1-96cc-e4d0d0e0c63d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f52151da-3ca6-47e1-96cc-e4d0d0e0c63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c86d45fa-e7cc-4090-b300-e246adba5d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_c86d45fa-e7cc-4090-b300-e246adba5d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_942f92ab-3c71-4e30-b96f-95e69d4b2efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedPerTransaction_942f92ab-3c71-4e30-b96f-95e69d4b2efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a8651cd1-6add-4dd3-bb61-d25dc3543330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a8651cd1-6add-4dd3-bb61-d25dc3543330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b1fb8ada-d8b7-433a-acba-c323703fb5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b1fb8ada-d8b7-433a-acba-c323703fb5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f68c3ee-0198-4c59-b1e3-9dd13f1fde0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_4f68c3ee-0198-4c59-b1e3-9dd13f1fde0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ac508d3-5a63-403d-a1f1-d17eea7c53dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ac508d3-5a63-403d-a1f1-d17eea7c53dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_85f85ff4-07ba-4a66-b663-770857b0b842" xlink:href="cdtx-20220930.xsd#cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion_85f85ff4-07ba-4a66-b663-770857b0b842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_914c1176-f918-43ed-b6b3-89f465579e15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_914c1176-f918-43ed-b6b3-89f465579e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_2b411dfa-67d4-49e1-8a7f-e7de360e41d2" xlink:href="cdtx-20220930.xsd#cdtx_NumberOfVotesEntitlementForEachShareHeld"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_NumberOfVotesEntitlementForEachShareHeld_2b411dfa-67d4-49e1-8a7f-e7de360e41d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_24fd66e5-08c6-49a9-b442-fbacd9a9b3be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_24fd66e5-08c6-49a9-b442-fbacd9a9b3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9091c087-9123-47d5-94f5-cb54cbf2a16e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9091c087-9123-47d5-94f5-cb54cbf2a16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_741f602a-6b69-413b-87bd-204e76b9ba2e" xlink:href="cdtx-20220930.xsd#cdtx_WarrantsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a5847851-3966-4a94-81f3-1d4c442788a4" xlink:to="loc_cdtx_WarrantsAggregateIntrinsicValueOutstanding_741f602a-6b69-413b-87bd-204e76b9ba2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b017b0bb-ec11-4317-bedd-b9a81f2616ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7893803a-951c-4348-99e2-cc3a5acfc6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b017b0bb-ec11-4317-bedd-b9a81f2616ab" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7893803a-951c-4348-99e2-cc3a5acfc6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9bfc752e-536c-4f00-af75-12027dff4c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7893803a-951c-4348-99e2-cc3a5acfc6a5" xlink:to="loc_us-gaap_AwardTypeAxis_9bfc752e-536c-4f00-af75-12027dff4c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9bfc752e-536c-4f00-af75-12027dff4c57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b9db4fa4-7e44-4f9e-ad5e-061fae830336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_us-gaap_WarrantMember_b9db4fa4-7e44-4f9e-ad5e-061fae830336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_SeriesXConvertiblePreferredStockMember_3f6e5f2d-030a-49e3-ae78-e04045b5dded" xlink:href="cdtx-20220930.xsd#cdtx_SeriesXConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_cdtx_SeriesXConvertiblePreferredStockMember_3f6e5f2d-030a-49e3-ae78-e04045b5dded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_68e79ed7-f5b8-4fe5-a847-4f68fa3ce841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_us-gaap_StockCompensationPlanMember_68e79ed7-f5b8-4fe5-a847-4f68fa3ce841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_24ab0209-b380-4316-8228-8245390fb567" xlink:href="cdtx-20220930.xsd#cdtx_AuthorizedSharesForFutureStockAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_cdtx_AuthorizedSharesForFutureStockAwardsMember_24ab0209-b380-4316-8228-8245390fb567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fc475a99-6120-4bf3-a09f-8099614d6b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba062894-45da-45a1-994f-e275693163eb" xlink:to="loc_us-gaap_EmployeeStockMember_fc475a99-6120-4bf3-a09f-8099614d6b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_c9ad0085-92bc-459f-83f7-351efffe01c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7893803a-951c-4348-99e2-cc3a5acfc6a5" xlink:to="loc_us-gaap_ClassOfStockLineItems_c9ad0085-92bc-459f-83f7-351efffe01c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9ecb7083-9d33-451d-ad3a-0f7f76b7a99f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_c9ad0085-92bc-459f-83f7-351efffe01c6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9ecb7083-9d33-451d-ad3a-0f7f76b7a99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e977b35-0377-4842-bd41-3a53cad73081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e977b35-0377-4842-bd41-3a53cad73081" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_af5956ac-6799-4508-a94c-36c22e4849ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_us-gaap_PlanNameAxis_af5956ac-6799-4508-a94c-36c22e4849ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ebe9f92c-73b5-42db-b5e5-6b6760c8886f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_af5956ac-6799-4508-a94c-36c22e4849ac" xlink:to="loc_us-gaap_PlanNameDomain_ebe9f92c-73b5-42db-b5e5-6b6760c8886f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_9862ac62-b3e0-4522-a998-acefceb01af5" xlink:href="cdtx-20220930.xsd#cdtx_TwoThousandFifteenEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_ebe9f92c-73b5-42db-b5e5-6b6760c8886f" xlink:to="loc_cdtx_TwoThousandFifteenEquityIncentivePlanMember_9862ac62-b3e0-4522-a998-acefceb01af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_07f2a94b-60fc-486c-b676-9095ad93c511" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_srt_RangeAxis_07f2a94b-60fc-486c-b676-9095ad93c511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_07f2a94b-60fc-486c-b676-9095ad93c511" xlink:to="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_daec9ea4-0454-4f07-8bc6-4a6bb53d5ac7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:to="loc_srt_MinimumMember_daec9ea4-0454-4f07-8bc6-4a6bb53d5ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9d8d1e09-a64d-4d6b-90dc-aa538f3e1ce6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4b4e2bdf-8014-4930-ae20-50a4bd701bc5" xlink:to="loc_srt_MaximumMember_9d8d1e09-a64d-4d6b-90dc-aa538f3e1ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_964cd47c-f4bf-4e7f-9c0a-a44f290f2132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_964cd47c-f4bf-4e7f-9c0a-a44f290f2132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_c77ab26b-d6f3-485d-918f-e1b608f1ad99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_964cd47c-f4bf-4e7f-9c0a-a44f290f2132" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_c77ab26b-d6f3-485d-918f-e1b608f1ad99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_9742aca5-6321-4ff1-9722-c463482d9034" xlink:href="cdtx-20220930.xsd#cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_c77ab26b-d6f3-485d-918f-e1b608f1ad99" xlink:to="loc_cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember_9742aca5-6321-4ff1-9722-c463482d9034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_us-gaap_AwardTypeAxis_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_45f9f93d-9dc0-4fbf-b31a-8c3d6c70c8be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_00a7c926-5fb0-43c5-816e-98502daf29ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:to="loc_us-gaap_EmployeeStockMember_00a7c926-5fb0-43c5-816e-98502daf29ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_4c02f365-df0a-4de8-ae9d-cf4095788025" xlink:href="cdtx-20220930.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_4c02f365-df0a-4de8-ae9d-cf4095788025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e9ceef5-8fd2-4f79-b7e9-9d58811984e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d98c0f13-3908-48ab-83e2-d57cd001245c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e9ceef5-8fd2-4f79-b7e9-9d58811984e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10d618bf-9dd4-4dd3-bbe8-c804e6d651a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_2f18e6da-2ba6-4b02-8960-c1a91ac1d769" xlink:href="cdtx-20220930.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage_2f18e6da-2ba6-4b02-8960-c1a91ac1d769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ab60c471-298b-4011-8c0c-4d071346cd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ab60c471-298b-4011-8c0c-4d071346cd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8ec403ea-90fa-4296-9da6-59e1f8f980bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8ec403ea-90fa-4296-9da6-59e1f8f980bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_32f82197-bb2c-441e-a9ee-2ad9ba7be19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_32f82197-bb2c-441e-a9ee-2ad9ba7be19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_0bfe25b8-024c-447b-af4f-8dce413755cb" xlink:href="cdtx-20220930.xsd#cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold_0bfe25b8-024c-447b-af4f-8dce413755cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_567e4ff3-163f-40b2-8b56-4fbce61e1390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_567e4ff3-163f-40b2-8b56-4fbce61e1390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f1829240-3950-4bed-8f98-72edb3a3066b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_f1829240-3950-4bed-8f98-72edb3a3066b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_33b42a18-c795-40c4-8edf-5d9ee87e25d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_33b42a18-c795-40c4-8edf-5d9ee87e25d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9a1ff46a-c8ad-45b5-bae8-efc20ab30549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_9a1ff46a-c8ad-45b5-bae8-efc20ab30549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63d37d6c-fd55-4f8c-a77c-a7b6df71f44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_63d37d6c-fd55-4f8c-a77c-a7b6df71f44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_358e4b15-75d3-4ee5-b6be-5956df912c35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_358e4b15-75d3-4ee5-b6be-5956df912c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d151bcf5-f504-4d7a-86c1-9589e2fa3c85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_d151bcf5-f504-4d7a-86c1-9589e2fa3c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a343f6cd-58a7-4461-9abd-c3683e2252b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a343f6cd-58a7-4461-9abd-c3683e2252b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e1568cc6-75c4-4823-9a93-3bb0ed24513b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ef17bbc3-76a4-481a-9a31-5c6452445232" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e1568cc6-75c4-4823-9a93-3bb0ed24513b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd32f34d-77eb-489a-9118-94436442b679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d82bb9eb-9f02-4d8b-8c70-5ce191a31f67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dd32f34d-77eb-489a-9118-94436442b679" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d82bb9eb-9f02-4d8b-8c70-5ce191a31f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d7fdd6f2-87ea-425d-9b55-18b88cd59ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d82bb9eb-9f02-4d8b-8c70-5ce191a31f67" xlink:to="loc_us-gaap_AwardTypeAxis_d7fdd6f2-87ea-425d-9b55-18b88cd59ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a409923-69e0-4984-b892-836693c313cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d7fdd6f2-87ea-425d-9b55-18b88cd59ded" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a409923-69e0-4984-b892-836693c313cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_7ed94766-754e-4480-ac68-d7b29f7d541f" xlink:href="cdtx-20220930.xsd#cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a409923-69e0-4984-b892-836693c313cf" xlink:to="loc_cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember_7ed94766-754e-4480-ac68-d7b29f7d541f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d82bb9eb-9f02-4d8b-8c70-5ce191a31f67" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd98aa1d-79e3-4c3a-8a4d-78f99c34944b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_dd98aa1d-79e3-4c3a-8a4d-78f99c34944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15e3d72b-0438-4064-a8ce-e8a85cce044e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15e3d72b-0438-4064-a8ce-e8a85cce044e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f40f0fc8-b237-4749-a0f3-ec39618eab69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_f40f0fc8-b237-4749-a0f3-ec39618eab69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d898e0d-fbc2-4880-9af1-d85bdfbaba09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8d898e0d-fbc2-4880-9af1-d85bdfbaba09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82c6b33f-ffb7-4c58-a89c-9d223eab1a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_9a55f522-db5c-4d0e-bcec-3909db4638ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_82c6b33f-ffb7-4c58-a89c-9d223eab1a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2b6bef7e-eed5-464c-b55d-0a80ecf8295c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6d6f31d-10d8-47f4-b52f-e4d187f2ed39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6d6f31d-10d8-47f4-b52f-e4d187f2ed39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab5ca7d3-3135-4597-b394-6016d321a7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ab5ca7d3-3135-4597-b394-6016d321a7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c1cc261c-6835-4b1b-a2d8-cbe406a18720" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c1cc261c-6835-4b1b-a2d8-cbe406a18720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8ee29753-8750-43fb-9593-8c298c3f08e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_8ee29753-8750-43fb-9593-8c298c3f08e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5033c7e1-470f-4876-ba94-9eac212d1e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_55e55f6a-9ec6-4fab-a92a-73a81b800644" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5033c7e1-470f-4876-ba94-9eac212d1e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_71db094e-c12e-4cf9-9c03-2ab5d0cb5c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_71db094e-c12e-4cf9-9c03-2ab5d0cb5c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_364e216e-63f9-4f92-ac1a-68e0a67f197f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_71db094e-c12e-4cf9-9c03-2ab5d0cb5c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_364e216e-63f9-4f92-ac1a-68e0a67f197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19ee079d-82a8-4ac3-b36f-ed9f458a3b31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_71db094e-c12e-4cf9-9c03-2ab5d0cb5c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19ee079d-82a8-4ac3-b36f-ed9f458a3b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cf97659b-1fc4-44f9-af21-a035af37f607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_71db094e-c12e-4cf9-9c03-2ab5d0cb5c74" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cf97659b-1fc4-44f9-af21-a035af37f607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_45187fdf-45b7-42a9-91db-f106ad1cf979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_71db094e-c12e-4cf9-9c03-2ab5d0cb5c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_45187fdf-45b7-42a9-91db-f106ad1cf979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3170ece5-cb36-4a45-abb6-305b90992d31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_71db094e-c12e-4cf9-9c03-2ab5d0cb5c74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3170ece5-cb36-4a45-abb6-305b90992d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fadda8da-698a-4881-b320-00582e667f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fadda8da-698a-4881-b320-00582e667f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8b2dd825-e943-4693-82a4-5b55fa6b73b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8b2dd825-e943-4693-82a4-5b55fa6b73b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50e03249-4389-4f94-8666-eeffddcfb137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50e03249-4389-4f94-8666-eeffddcfb137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1daeef2e-f706-482c-877b-248e40fe0b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50e03249-4389-4f94-8666-eeffddcfb137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1daeef2e-f706-482c-877b-248e40fe0b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9e143412-760e-45c5-b1a1-8e9b149f6e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50e03249-4389-4f94-8666-eeffddcfb137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9e143412-760e-45c5-b1a1-8e9b149f6e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44b7722c-ab46-4b1f-a807-1ae14b7b5901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50e03249-4389-4f94-8666-eeffddcfb137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_44b7722c-ab46-4b1f-a807-1ae14b7b5901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1622247-7e8f-4b09-a73b-df880adc8b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50e03249-4389-4f94-8666-eeffddcfb137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e1622247-7e8f-4b09-a73b-df880adc8b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4752256c-c2f3-4369-ab39-5e2956c6cf29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50e03249-4389-4f94-8666-eeffddcfb137" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4752256c-c2f3-4369-ab39-5e2956c6cf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b8640fe5-d366-42ef-bdb7-4501b9ac5381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_b8640fe5-d366-42ef-bdb7-4501b9ac5381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28acfac5-7eac-4506-9da0-f9ba65a08be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_28acfac5-7eac-4506-9da0-f9ba65a08be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7b6059b-d43c-4ce6-aab1-c44e17c987f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7b6059b-d43c-4ce6-aab1-c44e17c987f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eee8d2fe-944e-4f61-9bcf-3f6874714401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7b6059b-d43c-4ce6-aab1-c44e17c987f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_eee8d2fe-944e-4f61-9bcf-3f6874714401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6410277e-5b91-4815-85ea-efd74850d737" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7b6059b-d43c-4ce6-aab1-c44e17c987f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6410277e-5b91-4815-85ea-efd74850d737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_12cb4ab7-d8a0-47e6-81a6-3bc5b6eae4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e7b6059b-d43c-4ce6-aab1-c44e17c987f9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_12cb4ab7-d8a0-47e6-81a6-3bc5b6eae4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_8200db28-23ca-4ce7-8f05-c41d8f2b7e40" xlink:href="cdtx-20220930.xsd#cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7184a14b-a69c-4e2d-ba82-c6be8d77e1a2" xlink:to="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_8200db28-23ca-4ce7-8f05-c41d8f2b7e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89eb7198-400a-44be-a96a-c47c8c4d9e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_8200db28-23ca-4ce7-8f05-c41d8f2b7e40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89eb7198-400a-44be-a96a-c47c8c4d9e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2be01fcc-f0f3-4550-8f76-dfac69498f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_8200db28-23ca-4ce7-8f05-c41d8f2b7e40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2be01fcc-f0f3-4550-8f76-dfac69498f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c35f67ff-e383-4442-9b04-0563e7a01b05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract_8200db28-23ca-4ce7-8f05-c41d8f2b7e40" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c35f67ff-e383-4442-9b04-0563e7a01b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6a6026-c882-4b8e-9281-03e8a046cbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae76ea60-c856-45ff-a470-57fab2440c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ca6a6026-c882-4b8e-9281-03e8a046cbba" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae76ea60-c856-45ff-a470-57fab2440c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1da139ed-28c8-4f16-8316-bb73efe0cb87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae76ea60-c856-45ff-a470-57fab2440c08" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1da139ed-28c8-4f16-8316-bb73efe0cb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1da139ed-28c8-4f16-8316-bb73efe0cb87" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e3f5edf-2c73-4c88-b3f5-35d5182ac5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3e3f5edf-2c73-4c88-b3f5-35d5182ac5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ae3ba9f9-e9da-429c-844d-ca1e3ab1d583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df976110-c48e-4f39-bf09-315fb3bcf0e0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ae3ba9f9-e9da-429c-844d-ca1e3ab1d583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa001d8c-9bda-4c90-a1c1-5feeeabf394d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ae76ea60-c856-45ff-a470-57fab2440c08" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa001d8c-9bda-4c90-a1c1-5feeeabf394d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3c83c99f-79eb-49f4-8db7-2f678f6fd91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_aa001d8c-9bda-4c90-a1c1-5feeeabf394d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3c83c99f-79eb-49f4-8db7-2f678f6fd91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a31b8876-1511-438d-9e1e-f903984cde6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a31b8876-1511-438d-9e1e-f903984cde6d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_aaca684f-b64b-4453-afb8-14c4cea11068" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_9942478f-1945-48be-99ea-ac72aa3ef402" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_9942478f-1945-48be-99ea-ac72aa3ef402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_50ee2be2-85f1-4392-a626-8b028b9f077d" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_50ee2be2-85f1-4392-a626-8b028b9f077d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_610ac895-7a1e-4f29-a51b-13f1d2c6f4bc" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1ffc0834-d507-4f26-a2f9-38795e70fa2d" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_610ac895-7a1e-4f29-a51b-13f1d2c6f4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1d5bc744-544a-4c21-809d-d09d7229bfa1" xlink:to="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_cf82d87a-4f3e-4174-95d6-3538912bba69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3c3c626d-134d-4b71-8274-1f833087e3e0" xlink:to="loc_srt_AffiliatedEntityMember_cf82d87a-4f3e-4174-95d6-3538912bba69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_c712b205-a39d-45b3-bf25-447ad85f49ac" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_UpfrontPaymentMember_7be8e06a-30d3-4d5b-8ca4-129f858a4069" xlink:href="cdtx-20220930.xsd#cdtx_UpfrontPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_UpfrontPaymentMember_7be8e06a-30d3-4d5b-8ca4-129f858a4069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RDFundingMember_be14a1a1-c39a-4d51-95ad-3f576d2bee95" xlink:href="cdtx-20220930.xsd#cdtx_RDFundingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_RDFundingMember_be14a1a1-c39a-4d51-95ad-3f576d2bee95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_3d6139a9-c2e7-42af-b1e0-15e455a003d2" xlink:href="cdtx-20220930.xsd#cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_922d702c-6602-48eb-baa1-e72bb0712b17" xlink:to="loc_cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember_3d6139a9-c2e7-42af-b1e0-15e455a003d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f77a1f85-987d-40ff-b0d1-c9ce2dbe927e" xlink:to="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_106f0c44-732e-4d62-b4c9-962416af2d5c" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_106f0c44-732e-4d62-b4c9-962416af2d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MilestoneAchievementMember_d9cc71a3-4dba-4dcd-b267-281294f659e9" xlink:href="cdtx-20220930.xsd#cdtx_MilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_cdtx_MilestoneAchievementMember_d9cc71a3-4dba-4dcd-b267-281294f659e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_cc4c1bd8-a51b-4365-94f6-3d51aa2f97fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7b64157-52a1-4cdc-8a93-749e3b338344" xlink:to="loc_us-gaap_RoyaltyMember_cc4c1bd8-a51b-4365-94f6-3d51aa2f97fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_b8cdd970-ce7d-4bf4-9f3e-54348994dc99" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_5e2a8552-b0e7-4395-ab70-0f7e7e213ff9" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_cbdf025e-d0c0-422e-aa7b-809a6bfbd5cf" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_5e2a8552-b0e7-4395-ab70-0f7e7e213ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_308cf013-9a32-4740-8e47-008e74c107ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_308cf013-9a32-4740-8e47-008e74c107ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3b0b7a82-d18c-4b9b-bcca-9ddc75db6fc3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementCostSharingPercentage_dcefa9b4-5692-4855-b021-d3569d655e32" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementCostSharingPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementCostSharingPercentage_dcefa9b4-5692-4855-b021-d3569d655e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_d206d6d8-eec9-427d-b5eb-40022482e942" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost_d206d6d8-eec9-427d-b5eb-40022482e942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_14149a61-ab7d-424b-9464-733a185a9303" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTransactionPotentialValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementTransactionPotentialValue_14149a61-ab7d-424b-9464-733a185a9303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_0f1ae8c1-bfa5-4ac0-9d5e-c04fc6f3bd19" xlink:href="cdtx-20220930.xsd#cdtx_PaymentsRelatedToCollaborativeAgreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_PaymentsRelatedToCollaborativeAgreements_0f1ae8c1-bfa5-4ac0-9d5e-c04fc6f3bd19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7c04a19d-34cb-4d24-a0a2-db54b029fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_7c04a19d-34cb-4d24-a0a2-db54b029fc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_7732d525-f066-433e-8e7e-6a13144997ea" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability_7732d525-f066-433e-8e7e-6a13144997ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_2fa7ff3b-906a-4a1c-9ef1-f46b64a8585d" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults_2fa7ff3b-906a-4a1c-9ef1-f46b64a8585d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_a4e73ed0-35ca-4aa5-bbcf-6bcbdb241e29" xlink:href="cdtx-20220930.xsd#cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice_a4e73ed0-35ca-4aa5-bbcf-6bcbdb241e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_fe9b96e6-d0db-42c6-9a50-eb67e09bf75b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostGross_fe9b96e6-d0db-42c6-9a50-eb67e09bf75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_9f87abfb-65e9-4140-9bc9-58ec1c52acb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_9f87abfb-65e9-4140-9bc9-58ec1c52acb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_c53cd402-7fbf-4c98-a8a7-466c12ef9ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_CapitalizedContractCostNet_c53cd402-7fbf-4c98-a8a7-466c12ef9ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_6e3b8de4-824a-423d-ba95-10f9098d7f60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_6e3b8de4-824a-423d-ba95-10f9098d7f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d04689a5-257e-4b73-b4c5-7d8a34149f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_d04689a5-257e-4b73-b4c5-7d8a34149f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_30977107-7bbc-4a10-8f57-912a275ae09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6d549c8-64ae-4b1e-a403-9efb568b5f20" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_30977107-7bbc-4a10-8f57-912a275ae09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8268aca3-e62e-4886-904a-3c558215b687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e0704b2-66a2-4a32-bba7-e8ae2cc08ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8268aca3-e62e-4886-904a-3c558215b687" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e0704b2-66a2-4a32-bba7-e8ae2cc08ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f050605-d29f-4b6e-becd-48db9994327a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e0704b2-66a2-4a32-bba7-e8ae2cc08ec8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f050605-d29f-4b6e-becd-48db9994327a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d2c05b57-1bb2-4cb8-9463-af593305e083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_4f050605-d29f-4b6e-becd-48db9994327a" xlink:to="loc_us-gaap_RelatedPartyDomain_d2c05b57-1bb2-4cb8-9463-af593305e083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_ebe9c6e6-ffe2-4961-b17d-1f7e54b2c023" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d2c05b57-1bb2-4cb8-9463-af593305e083" xlink:to="loc_srt_AffiliatedEntityMember_ebe9c6e6-ffe2-4961-b17d-1f7e54b2c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2e0704b2-66a2-4a32-bba7-e8ae2cc08ec8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0002f870-3b33-4bcc-9da4-5f870f19a402" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_0002f870-3b33-4bcc-9da4-5f870f19a402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_63ecd74a-9c3d-417d-8c4c-d9c2ee054893" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance_63ecd74a-9c3d-417d-8c4c-d9c2ee054893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_9f016d50-c1ea-4e79-8531-cadc30c2d656" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized_9f016d50-c1ea-4e79-8531-cadc30c2d656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_65f6a1d4-dd6c-4371-a2f7-ea7d2c110e33" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward_224f6b32-ab5b-45fc-b55d-b520ae64c9ae" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_65f6a1d4-dd6c-4371-a2f7-ea7d2c110e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_61a02999-e794-4da3-8851-6e01f13a75dc" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent_61a02999-e794-4da3-8851-6e01f13a75dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_0acac072-fb53-47dc-80fa-64320468b9ae" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent_0acac072-fb53-47dc-80fa-64320468b9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_8d88e8bd-206c-4074-9dd9-19fae488e149" xlink:href="cdtx-20220930.xsd#cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e718f6f3-0a51-420c-a238-e56bdbad5f9c" xlink:to="loc_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability_8d88e8bd-206c-4074-9dd9-19fae488e149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ebf637e-c4d1-45d9-afe8-5ee3a0ff4314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ebf637e-c4d1-45d9-afe8-5ee3a0ff4314" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f63f526-251e-4d39-9eb3-d01060860d64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f63f526-251e-4d39-9eb3-d01060860d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_25267d7d-6160-4b14-aadc-e8a773a99ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7f63f526-251e-4d39-9eb3-d01060860d64" xlink:to="loc_us-gaap_RelatedPartyDomain_25267d7d-6160-4b14-aadc-e8a773a99ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_c15293f8-9c89-4dcf-83c5-a5c607753afd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_25267d7d-6160-4b14-aadc-e8a773a99ab5" xlink:to="loc_srt_AffiliatedEntityMember_c15293f8-9c89-4dcf-83c5-a5c607753afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9b5395dd-284f-417f-bb7e-f5318e1a7508" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_srt_CounterpartyNameAxis_9b5395dd-284f-417f-bb7e-f5318e1a7508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9b5395dd-284f-417f-bb7e-f5318e1a7508" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MundipharmaMedicalCompanyMember_38f4c359-057d-4dfe-bdd7-8863ccd17810" xlink:href="cdtx-20220930.xsd#cdtx_MundipharmaMedicalCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:to="loc_cdtx_MundipharmaMedicalCompanyMember_38f4c359-057d-4dfe-bdd7-8863ccd17810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_JanssenPharmaceuticalsIncMember_ad81b596-7a78-4646-88ee-1abb51ef30c8" xlink:href="cdtx-20220930.xsd#cdtx_JanssenPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:to="loc_cdtx_JanssenPharmaceuticalsIncMember_ad81b596-7a78-4646-88ee-1abb51ef30c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_MelintaTherapeuticsIncMember_bb21b8c1-47b3-4880-bdd3-5d8f023e9a49" xlink:href="cdtx-20220930.xsd#cdtx_MelintaTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a9dfe4-d4b2-4e50-b1a7-2f957a2d16e6" xlink:to="loc_cdtx_MelintaTherapeuticsIncMember_bb21b8c1-47b3-4880-bdd3-5d8f023e9a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4987b4c2-b5d1-42ad-b075-6c554fb55f34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_srt_ProductOrServiceAxis_4987b4c2-b5d1-42ad-b075-6c554fb55f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4987b4c2-b5d1-42ad-b075-6c554fb55f34" xlink:to="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LicensesOfIntellectualPropertyMember_6bedba3e-6b03-4dad-86d1-208cba1262e3" xlink:href="cdtx-20220930.xsd#cdtx_LicensesOfIntellectualPropertyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_LicensesOfIntellectualPropertyMember_6bedba3e-6b03-4dad-86d1-208cba1262e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalDrugSupplyMember_f7e76cc8-eed8-43b9-bbed-a4cb5498a2b7" xlink:href="cdtx-20220930.xsd#cdtx_ClinicalDrugSupplyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_ClinicalDrugSupplyMember_f7e76cc8-eed8-43b9-bbed-a4cb5498a2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ResearchAndDevelopmentServicesMember_b31245f0-e5c8-488a-b772-ee11bfa1edcf" xlink:href="cdtx-20220930.xsd#cdtx_ResearchAndDevelopmentServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_ResearchAndDevelopmentServicesMember_b31245f0-e5c8-488a-b772-ee11bfa1edcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_ClinicalSupplyServicesMember_8775ac8a-fc12-4eeb-af80-f83537c3e560" xlink:href="cdtx-20220930.xsd#cdtx_ClinicalSupplyServicesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7ed0e8b-7426-4f40-a3d5-af3103da0fdb" xlink:to="loc_cdtx_ClinicalSupplyServicesMember_8775ac8a-fc12-4eeb-af80-f83537c3e560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_67a7c43b-066a-441b-ab3f-0b1a3e510db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_67a7c43b-066a-441b-ab3f-0b1a3e510db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_67a7c43b-066a-441b-ab3f-0b1a3e510db3" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_6d04bf39-9de1-4a4f-b7d6-cd6950b92b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_6d04bf39-9de1-4a4f-b7d6-cd6950b92b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_b826e696-701c-4e7a-a18a-57553ef0a1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_4da405c0-b673-49c7-b234-e5b0907841dd" xlink:to="loc_us-gaap_TransferredOverTimeMember_b826e696-701c-4e7a-a18a-57553ef0a1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5ff1af85-ada1-4f87-b59b-4922ae193850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5ff1af85-ada1-4f87-b59b-4922ae193850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03006fdb-d4e2-42d2-b411-c62d15607982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5ff1af85-ada1-4f87-b59b-4922ae193850" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03006fdb-d4e2-42d2-b411-c62d15607982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_4255f75f-5e3b-4fb5-a8fb-746feadc8053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_03006fdb-d4e2-42d2-b411-c62d15607982" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_4255f75f-5e3b-4fb5-a8fb-746feadc8053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ae1725c-c84e-48a9-9903-48f1a94bd3b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3301e910-8154-4d03-a97a-ed074125bbf8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ae1725c-c84e-48a9-9903-48f1a94bd3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_cde562d1-081a-4dcb-b779-0b6b37373fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5ae1725c-c84e-48a9-9903-48f1a94bd3b8" xlink:to="loc_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer_cde562d1-081a-4dcb-b779-0b6b37373fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c76498fc-ee32-433d-8128-6ed3f1ca7575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c76498fc-ee32-433d-8128-6ed3f1ca7575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseMonthlyRate_714f7c56-b02e-4f4b-9a36-448bbfdf3883" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseMonthlyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_cdtx_LesseeOperatingLeaseMonthlyRate_714f7c56-b02e-4f4b-9a36-448bbfdf3883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_0aa94291-d8da-4ebe-9aaa-00a52e4649ea" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseAnnualRateIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_cdtx_LesseeOperatingLeaseAnnualRateIncrease_0aa94291-d8da-4ebe-9aaa-00a52e4649ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_6369cd0a-8b05-4881-86d6-5824cd323f75" xlink:href="cdtx-20220930.xsd#cdtx_NumberOfOperatingLeaseOptionsForExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_cdtx_NumberOfOperatingLeaseOptionsForExtension_6369cd0a-8b05-4881-86d6-5824cd323f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_ab90c9df-756d-4339-855b-f85bcc45bc55" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseOptionRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_cdtx_LesseeOperatingLeaseOptionRenewalTerm_ab90c9df-756d-4339-855b-f85bcc45bc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_61b87415-b59f-4c74-b3b3-4bb9a2a9b677" xlink:href="cdtx-20220930.xsd#cdtx_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate_61b87415-b59f-4c74-b3b3-4bb9a2a9b677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0f9992dc-f2aa-4bd7-9d70-82bd78578e42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0f9992dc-f2aa-4bd7-9d70-82bd78578e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_29e677e5-63ea-4398-a7ad-96edbd2c2211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_us-gaap_OperatingLeasePayments_29e677e5-63ea-4398-a7ad-96edbd2c2211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_dde8cf8f-70cc-44b6-9c37-ebe27eed2388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_us-gaap_OperatingLeaseCost_dde8cf8f-70cc-44b6-9c37-ebe27eed2388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_c0f75e0f-feab-4d3f-ae6d-67e261fc414c" xlink:href="cdtx-20220930.xsd#cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6b849a42-358b-406e-997e-62992ac29370" xlink:to="loc_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost_c0f75e0f-feab-4d3f-ae6d-67e261fc414c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b1eb98b-4934-46e7-a5ea-2cbb774e0ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_19094528-52f0-4ec2-8002-45847f56d7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b1eb98b-4934-46e7-a5ea-2cbb774e0ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_19094528-52f0-4ec2-8002-45847f56d7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0f365369-a94e-46c3-9fc7-1e88b18abdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b1eb98b-4934-46e7-a5ea-2cbb774e0ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0f365369-a94e-46c3-9fc7-1e88b18abdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d4a53393-ecc4-4468-97f8-a2cc0de94e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b1eb98b-4934-46e7-a5ea-2cbb774e0ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d4a53393-ecc4-4468-97f8-a2cc0de94e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_848c9d2c-1237-4c9d-9ca3-5ed55b1d676e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b1eb98b-4934-46e7-a5ea-2cbb774e0ba0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_848c9d2c-1237-4c9d-9ca3-5ed55b1d676e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_c38839ff-12ac-45cc-bec1-1d1fcaa12e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9b1eb98b-4934-46e7-a5ea-2cbb774e0ba0" xlink:to="loc_us-gaap_OperatingLeaseLiability_c38839ff-12ac-45cc-bec1-1d1fcaa12e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="cdtx-20220930.xsd#COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9a975df-a177-4760-8289-71b538f36862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_7466bf0c-5777-4a01-aecb-a70d0a56eae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9a975df-a177-4760-8289-71b538f36862" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_7466bf0c-5777-4a01-aecb-a70d0a56eae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2aa6aa72-7407-4808-955d-0a895e9588df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9a975df-a177-4760-8289-71b538f36862" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2aa6aa72-7407-4808-955d-0a895e9588df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_86a9aefc-a103-47ef-a934-46c7350c1db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9a975df-a177-4760-8289-71b538f36862" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_86a9aefc-a103-47ef-a934-46c7350c1db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d7d334e6-cc6d-4679-8946-8db61b713051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e9a975df-a177-4760-8289-71b538f36862" xlink:to="loc_us-gaap_OperatingLeaseLiability_d7d334e6-cc6d-4679-8946-8db61b713051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337491824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CIDARA THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1537286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6310 Nancy Ridge Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">752-6170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.0001 Per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CDTX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,618,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001610618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337865888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,078<span></span>
</td>
<td class="nump">$ 59,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,042<span></span>
</td>
<td class="nump">5,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,779<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">63,899<span></span>
</td>
<td class="nump">71,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,295<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">66,858<span></span>
</td>
<td class="nump">75,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,244<span></span>
</td>
<td class="nump">1,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">8,162<span></span>
</td>
<td class="nump">10,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">4,859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current deferred revenue</a></td>
<td class="nump">15,249<span></span>
</td>
<td class="nump">13,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,049<span></span>
</td>
<td class="nump">34,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">24,398<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">57,791<span></span>
</td>
<td class="nump">53,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 200,000,000 shares authorized at September&#160;30, 2022 and December&#160;31, 2021; 71,181,197 shares issued and outstanding at September&#160;30, 2022 and 67,863,674 shares issued and outstanding at December&#160;31, 2021</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">402,649<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(393,589)<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">9,067<span></span>
</td>
<td class="nump">21,573<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">66,858<span></span>
</td>
<td class="nump">75,325<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337360400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337500304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Revenue, Product and Service [Extensible Enumeration]</a></td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
<td class="text">Collaboration Revenue [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="nump">$ 40,744<span></span>
</td>
<td class="nump">$ 7,076<span></span>
</td>
<td class="nump">$ 54,069<span></span>
</td>
<td class="nump">$ 42,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">20,041<span></span>
</td>
<td class="nump">20,505<span></span>
</td>
<td class="nump">55,462<span></span>
</td>
<td class="nump">54,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,780<span></span>
</td>
<td class="nump">4,607<span></span>
</td>
<td class="nump">15,058<span></span>
</td>
<td class="nump">13,758<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,821<span></span>
</td>
<td class="nump">25,112<span></span>
</td>
<td class="nump">70,520<span></span>
</td>
<td class="nump">67,832<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">14,923<span></span>
</td>
<td class="num">(18,036)<span></span>
</td>
<td class="num">(16,451)<span></span>
</td>
<td class="num">(25,485)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net income (loss) and comprehensive income (loss)</a></td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(18,083)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="num">(25,664)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) and comprehensive income (loss)</a></td>
<td class="nump">14,978<span></span>
</td>
<td class="num">(18,083)<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="num">(25,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Allocation of earnings to participating securities</a></td>
<td class="num">(3,081)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="nump">$ 11,897<span></span>
</td>
<td class="num">$ (18,083)<span></span>
</td>
<td class="num">$ (16,422)<span></span>
</td>
<td class="num">$ (25,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used to compute basic net earnings (loss) per common share (in shares)</a></td>
<td class="nump">70,217,985<span></span>
</td>
<td class="nump">49,533,956<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">48,402,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted net earnings (loss) per common share (in shares)</a></td>
<td class="nump">88,592,568<span></span>
</td>
<td class="nump">49,533,956<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">48,402,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2740-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126928961&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238336906352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,422)<span></span>
</td>
<td class="num">$ (25,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,859<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of costs to obtain a contract with a customer</a></td>
<td class="nump">1,772<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_OperatingLeaseRightOfUseAmortization', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">7,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, other current assets, and other assets</a></td>
<td class="num">(1,662)<span></span>
</td>
<td class="nump">713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(670)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Deferred revenue</a></td>
<td class="nump">7,314<span></span>
</td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(850)<span></span>
</td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,471)<span></span>
</td>
<td class="num">(10,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">11,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="num">(720)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal repayments of Term Loan</a></td>
<td class="num">(2,593)<span></span>
</td>
<td class="num">(3,333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,615)<span></span>
</td>
<td class="nump">7,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(9,195)<span></span>
</td>
<td class="num">(2,644)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">62,273<span></span>
</td>
<td class="nump">42,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">40,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of shares pursuant to Employee Stock Purchase Plan</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets', window );">Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses and other current assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred financing costs incurred but not yet paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_OperatingLeaseRightOfUseAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_OperatingLeaseRightOfUseAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238333640272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Series X Convertible Preferred Stock</div></th>
<th class="th">
<div>Series X Convertible Preferred Stock </div>
<div>Preferred Stock</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 10,715<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 345,411<span></span>
</td>
<td class="num">$ (334,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,876,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,327,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, net of issuance costs</a></td>
<td class="nump">8,589<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">8,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(18,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,292)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2021</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">354,879<span></span>
</td>
<td class="num">(352,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,288,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2020</a></td>
<td class="nump">10,715<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">345,411<span></span>
</td>
<td class="num">(334,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,876,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(25,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2021</a></td>
<td class="num">(1,158)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">359,201<span></span>
</td>
<td class="num">(360,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,621,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2021</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">354,879<span></span>
</td>
<td class="num">(352,992)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,288,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, net of issuance costs</a></td>
<td class="nump">2,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock for exercise of options</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">10,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2021</a></td>
<td class="nump">15,789<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">358,065<span></span>
</td>
<td class="num">(342,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,506,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, net of issuance costs</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(18,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,044,278<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2021</a></td>
<td class="num">(1,158)<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">359,201<span></span>
</td>
<td class="num">(360,364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,621,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 21,573<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="nump">67,863,674<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, net of issuance costs</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(18,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Mar. 31, 2022</a></td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">400,398<span></span>
</td>
<td class="num">(395,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Dec. 31, 2021</a></td>
<td class="nump">$ 21,573<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">398,733<span></span>
</td>
<td class="num">(377,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Dec. 31, 2021</a></td>
<td class="nump">67,863,674<span></span>
</td>
<td class="nump">67,863,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock for exercise of options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(16,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2022</a></td>
<td class="nump">$ 9,067<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">402,649<span></span>
</td>
<td class="num">(393,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, beginning at Mar. 31, 2022</a></td>
<td class="nump">$ 4,957<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">400,398<span></span>
</td>
<td class="num">(395,448)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, beginning (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,049,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under Employee Stock Purchase Plan</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs for underwritten public offering</a></td>
<td class="num">(720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(13,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Jun. 30, 2022</a></td>
<td class="num">(7,961)<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">400,599<span></span>
</td>
<td class="num">(408,567)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,238,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,664,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Public offering of common stock, net of issuance costs</a></td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock for restricted share units vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">14,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance, ending at Sep. 30, 2022</a></td>
<td class="nump">$ 9,067<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 402,649<span></span>
</td>
<td class="num">$ (393,589)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance, ending (in shares) at Sep. 30, 2022</a></td>
<td class="nump">71,181,197<span></span>
</td>
<td class="nump">71,181,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238338680112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">THE COMPANY AND BASIS OF PRESENTATION</a></td>
<td class="text">THE COMPANY AND BASIS OF PRESENTATION<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. The Company is focused on infectious diseases and oncology. The Company&#8217;s lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections. In addition, the Company is using its Cloudbreak&#174; platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. This technology couples potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. The Company's most advanced DFC program is CD388, a highly potent, long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting the SARS-CoV-2 strains causing COVID-19 and multiple solid tumor oncology indications.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At September&#160;30, 2022, the Company had an accumulated deficit of $393.6 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company had cash and cash equivalents of $53.1 million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options, estimated collaboration expenses and incurred expenses related to the Company's collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company's collaboration and license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238339335392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash represented cash that the Company was required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 4 for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at September&#160;30, 2022 or December&#160;31, 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTIzOA_4025d4e0-b32b-4383-8a9a-aee6ae64d94d">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the FASB ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a License Agreement, or the Melinta License Agreement, with Melinta Therapeutics, LLC, or Melinta. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in August 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 for additional information.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Earnings (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the guidance in FASB ASC 260, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series X Preferred Stock (see Note 5). Basic net earnings per share is then calculated by dividing income allocable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net earnings per share using the more dilutive of the (1) if-converted method or contingently issuable share method, as applicable, or (2) the two-class method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the if-converted method. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net earnings (loss) per common share (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(18,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,664)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator for basic net earnings (loss) per share - net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(18,083)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of participating securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Add back allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(18,083)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator for basic net earnings (loss) per share - common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,217,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49,533,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48,402,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock, as converted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs, PRSUs, and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">88,592,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49,533,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48,402,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,442,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,442,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,041,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,356,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,086,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,356,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,558,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,316,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40,788,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,316,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238338889568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">None of the Company&#8217;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238338913824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Term Loan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $10.0&#160;million&#160;from the Lender, or the Term A Loan. The Term A Loan bore interest at a variable annual rate equal to the greater of (i) 4.5% or (ii) the Lender's prime interest rate plus 0.75%, and matured on July 3, 2022. The Term A Loan had an interest-only period through April 3, 2020, which was followed by equal monthly principal payments and was paid in full on July 5, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238340236144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Controlled Equity Sales Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp; Co, or the Sales Agreement. During the nine months ended September&#160;30, 2022 and 2021, the company sold 2,308,435 and 4,492,034 shares of common stock, respectively, for net proceeds of approximately $1.7&#160;million and $10.9&#160;million, respectively, after deducting placement agent fees. As of September&#160;30, 2022, the aggregate offering price remaining under the Sales Agreement is $46.8 million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2021 Public Offering</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On October 13, 2021, the Company completed concurrent but separate public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common stock, at a price to the public of $1.55 per share, and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share, for aggregate gross proceeds of $38.5&#160;million. The Company received total net proceeds of $35.8&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the amended and restated certificate of incorporation, the Company&#8217;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at September&#160;30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On August 12, 2020, at the request of certain holders, 52,241 shares of the Company&#8217;s Series X Convertible Preferred Stock were converted to an aggregate of 522,410 shares of the Company&#8217;s common stock. As of September&#160;30, 2022 and December&#160;31, 2021, shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The specific terms of the Series X Convertible Preferred Stock are as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Conversion: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 10 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Dividends:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company's common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Liquidation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Upon the liquidation, dissolution, or winding up of the company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Voting:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company had 200,000,000 shares of common stock authorized as of September&#160;30, 2022. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#8217;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#8217;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, warrants to purchase 12,517,328 shares of the Company's common stock were outstanding with a weighted average exercise price of $6.82 per share.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The warrants had no intrinsic value at September&#160;30, 2022 and December&#160;31, 2021. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Reserved for Future Issuance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,086,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,470,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,710,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,436,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">986,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">680,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,485,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43,289,438&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238340244560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY INCENTIVE PLANS</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2020 Inducement Incentive Plan and 2015 Equity Incentive Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In December 2020, the Company's board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by 4% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTQ2NQ_548f15b5-a1d8-4cd3-872c-e2f333fda6b9">three</span>- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">2015 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2015, the Company&#8217;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;1%&#160;of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31, (ii)&#160;490,336&#160;shares, or (iii) such lesser number as determined by the Company&#8217;s board of directors.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The ESPP allows substantially all employees to purchase the Company&#8217;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#8217;s payroll deductions under the ESPP are limited to 15% of the employee&#8217;s eligible compensation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">During the nine months ended&#160;September&#160;30, 2022 and 2021, 184,219 shares and 145,696 shares, respectively, were issued pursuant to the ESPP. As of September&#160;30, 2022, total unrecognized compensation expense related to the ESPP was approximately $0.3&#160;million. This unrecognized compensation cost is expected to be recognized over approximately 0.6 years.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,174,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,471,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,032,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(320,532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,292,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs and PRSUs granted during the nine months ended September&#160;30, 2021 was $2.28 per share. The total fair value of RSUs and PRSUs vested during the nine months ended September&#160;30, 2022 and 2021 was approximately $1.6 million and $0.4 million, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At September&#160;30, 2022, estimated unrecognized compensation expense related to RSUs and PRSUs grants was approximately $1.7 million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">in Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,296,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,014,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,516,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,794,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.46</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,794,645&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,749,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted by the Company during the nine months ended September&#160;30, 2022 and 2021 was $0.51 and $1.43 per share, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, total unrecognized share-based compensation expense related to unvested stock options was approximately $2.8 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.0 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238333624048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS AND CONTRACTS</a></td>
<td class="text">SIGNIFICANT AGREEMENTS AND CONTRACTS<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Mundipharma Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#8217;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#8209;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Mundipharma Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product in the Mundipharma Territory, at Mundipharma&#8217;s sole cost.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#8209;bearing license to develop, register and commercialize the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, subject to the Company&#8217;s retained right as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#8209;exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#8217;s territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company retained the exclusive right to develop, register and commercialize the Mundipharma Licensed Product, Subcutaneous Product and Other Products in Japan, or the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Mundipharma Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of the execution of the Mundipharma Collaboration Agreement, the parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#8217;s Global Development Cost share of $31.2&#160;million. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible for double-digit royalties in the teens on tiers of annual net sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSTORE Trial and the ReSPECT Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company's patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million, research and development funding of $32.2&#160;million, plus milestones achieved of $13.9&#160;million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$17.9&#160;million&#160;in September 2019 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company's initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company determined that as of&#160;September&#160;30, 2022, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In November 2020, the Company achieved a $11.1&#160;million milestone under the Mundipharma Collaboration Agreement, which is recorded as long-term deferred revenue as of September&#160;30, 2022 because the rights to consideration is not expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. In December 2021 and August 2022, the Company achieved milestones of $2.8&#160;million and $11.1&#160;million, respectively, under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in January 2022 and September 2022, respectively.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;No&#160;royalty revenue was recognized during the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Janssen Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs (previously called Antiviral Drug Conjugates, or AVCs) based on the Company's Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 Challenge Study. Unless otherwise agreed by the parties, the Company will be responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company will be the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Within 90 days after delivery by the Company to Janssen of results of the Phase 2 Challenge Study and all then-available data from other clinical trials of the Development Candidate conducted under the Research Plan, or the Election Period, Janssen will be obligated to notify the Company of Janssen&#8217;s election to proceed with further clinical development of Products, such notice, an Election to Proceed Notice. If Janssen fails to deliver an Election to Proceed Notice prior to expiration of the Election Period, the Company will have the right to terminate the Janssen Collaboration Agreement upon written notice to Janssen. If Janssen provides an Election to Proceed Notice prior to expiration of the Election Period, then the parties will continue any then-ongoing Research Plan activities to completion, and Janssen will otherwise be solely responsible for the development, manufacture and commercialization of Products, at Janssen&#8217;s sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#8217;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#8217;s DFC technology more broadly. The Company&#8217;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company is eligible for reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting Research Plan activities. The Company will also be eligible to receive up to an additional $695.0&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. In addition to the Company&#8217;s right to terminate the Janssen Collaboration Agreement for Janssen&#8217;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">prior to the completion of all Research Plan activities and the Company&#8217;s delivery to Janssen of all Research Plan deliverables, upon 90 days&#8217; written notice to the Company, provided that if any clinical trial under the Research Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after completion of the Phase 2 Challenge Study and before expiration of the Election Period, immediately upon written notice to the Company; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt">after delivery of the Election to Proceed Notice, upon 90 days&#8217; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million, research and development funding of $61.2&#160;million, plus milestones achieved of $3.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $27.0&#160;million in May 2021 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The research and development services to be performed represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company's initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company determined that as of the latest financial statement date all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are not included in the transaction price. At the end of each </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In March 2022, the Company achieved a $3.0&#160;million milestone under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in May 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the three and nine months ended September&#160;30, 2022 and 2021.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Melinta License Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Pursuant to the Melinta License Agreement, the Company granted Melinta an exclusive, royalty&#8209;bearing license (including the right to sublicense through multiple tiers), to develop, register and commercialize the Melinta Licensed Product for all uses in humans and non-human animals in the Melinta Territory, subject to the Company&#8217;s retained right, as described below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Non-Compete Covenant</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">. Until the fifth anniversary of the first commercial sale of the first Melinta Licensed Product in the Melinta Territory, neither the Company nor Melinta, nor any of their respective majority-owned subsidiaries may, directly or indirectly, itself or in collaboration with any Third Party, develop, manufacture for development or commercialization, or commercialize any product in the echinocandin class of drugs in the Melinta Territory without the other party&#8217;s prior written consent, subject to certain provisions in connection with a change of control of a party.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Commercialization.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Melinta will be solely responsible for the commercialization of rezafungin in the Melinta Territory, at its sole expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s Retained Rights.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company retains the non-exclusive right to practice the intellectual property rights licensed to Melinta in the Melinta Territory solely for the purpose of performing its obligations under the Melinta License Agreement and Mundipharma Collaboration Agreement. The Company also retains the right to grant licenses under the intellectual property rights licensed to Melinta to third parties to which the Company has granted licenses or rights to market, promote and sell Melinta Licensed Product outside the Melinta Territory, to make and have made Melinta Licensed Product anywhere in the world solely to develop, register, use, sell, have sold, offer for sale, commercialize and import Melinta Licensed Product outside the Melinta Territory, subject to the terms of the Melinta License Agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Continued Development and Regulatory Activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company will be responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that includes, among other activities, (a) completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the U.S. Food and Drug Administration, or FDA, of a supplemental New Drug Application, or NDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the Company&#8217;s ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain chemistry, manufacturing and controls activities for the Melinta Licensed Product, and (f) all other development activities that are required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company will remain the holder of all FDA submissions, including the rezafungin IND and NDA. The FDA submissions will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated supplemental NDA for the Prophylaxis Indication, after which Melinta will be responsible for performing all activities that may be necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta&#8217;s sole expense, subject to Melinta&#8217;s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket expenses incurred by Melinta.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Supply and Transfer of CMC activities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Until Melinta assumes responsibility for the manufacture and supply of the Melinta Licensed Product for development and commercialization in the Melinta Territory, which it may do by direct purchase from the Company&#8217;s contract manufacturing organizations for the Melinta Licensed Product or by having a manufacturing </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">technology transfer to Melinta or its designee performed at Melinta&#8217;s sole expense, which, in either case, will be no later than December 31, 2026, the Company will be responsible for the manufacture and supply of the Melinta Licensed Product for development and commercialization by Melinta in the Melinta Territory, and during such period, shall supply Melinta Licensed Product to Melinta pursuant to the terms of a supply agreement to be negotiated by the parties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Financial Terms.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Upon execution of the Melinta License Agreement the total potential transaction value is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestones. In addition, the Company is eligible for tiered royalties on U.S. sales in the low double digits to mid-teens.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Termination.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> Either party may terminate the Melinta License Agreement for uncured material breach by the other party. After July 26, 2023, Melinta may terminate the Melinta License Agreement at will. The Company may terminate the Melinta License Agreement if Melinta or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the patent rights licensed to Melinta by the Company.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The license to the Company&#8217;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$25.9&#160;million&#160;in August 2022 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> The Company is required to provide research and development services, at its sole expense, as described under the Melinta Development Plan, which represents a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Clinical Supply Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company's obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services. Revenue related to the clinical supply services performance obligation recognized during the three and nine months ended September&#160;30, 2022 was immaterial.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;The Company determined that as of&#160;September&#160;30, 2022, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. No revenue related to milestones was recognized during the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Royalties.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;No royalty revenue was recognized during the three and nine months ended September&#160;30, 2022.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Costs to Obtain a Contract with a Customer</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $2.0&#160;million upon execution of the Melinta License Agreement in accordance with ASC 340. The Company incurred these costs in connection with all the performance obligations identified in the Melinta License Agreement and allocated the capitalized contract costs to performance obligations on a relative basis (i.e., in proportion to the transaction price allocated to each </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">performance obligation) to determine the period of amortization. Amortization during the three and nine months ended September&#160;30, 2022 was $1.8&#160;million and is included within general and administrative expenses in the Company's condensed consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022, the remaining balance of the asset recognized from costs to obtain the Melinta License Agreement was $0.2&#160;million.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the nine months ended&#160;September&#160;30, 2022&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,005)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred revenue, September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, aggregate transaction price allocated to performance obligations that are unsatisfied is $18.0&#160;million, $39.5&#160;million, and $3.8&#160;million under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. These amounts are expected to be recognized over 2.3 years, 1.3 years, and 2.3 years which represent the remaining research periods under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company recorded $0.5&#160;million and $4.5&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our contract revenues disaggregated by collaborator and timing of revenue recognition and excludes royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,388&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,393&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238427541440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">On July 14, 2021, the Company entered into a sixth amendment to its lease with Nancy Ridge Technology Center, L.P. which extended the term of the lease by an additional 24 months and increases the base rent to $103,733 per month effective January 1, 2022, subject to 3% increases every January. The lease expires on December 31, 2023 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of September&#160;30, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. The incremental borrowing rate used in measuring the Company's lease liability was 10.8%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of September&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company's operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the weighted average remaining lease term was 1.3 years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Cash paid for amounts included in the present value of operating lease liabilities was $1.0 million and $0.7&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating lease costs were $1.0 million and $0.9&#160;million for the nine months ended September&#160;30, 2022 and 2021 respectively. These costs are primarily related to the Company's long-term operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337085488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At September&#160;30, 2022, the Company had an accumulated deficit of $393.6 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At September&#160;30, 2022, the Company had cash and cash equivalents of $53.1 million. Based on the Company&#8217;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#8217;s obligations for twelve months from the issuance of these financial statements. The Company&#8217;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#8217;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#8217;s business, operating results and financial condition and the Company&#8217;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, </span></div>financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_UnauditedInterimFinancialDataPolicyTextBlock', window );">Unaudited Interim Financial Data</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Data</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#8217;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods ended September&#160;30, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#8217;s condensed consolidated financial statements relate to estimating the fair value of the Company&#8217;s stock options, estimated collaboration expenses and incurred expenses related to the Company's collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company's collaboration and license agreements. Although the estimates are based on the Company&#8217;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Restricted cash represented cash that the Company was required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 4 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at September&#160;30, 2022 or December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTIzOA_4025d4e0-b32b-4383-8a9a-aee6ae64d94d">three</span> to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the FASB ASC 740,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#8217;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes revenue is accordance with ASC Topic 606,&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#8217;s or a </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#8217;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#8217;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In July 2022, the Company entered into a License Agreement, or the Melinta License Agreement, with Melinta Therapeutics, LLC, or Melinta. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in August 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#8217;s estimates have no impact on the Company&#8217;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See Note 7 for additional information.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock', window );">Preclinical and Clinical Trial Accruals</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Trial Accruals</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#8220;simplified&#8221; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Net Earnings (Loss) Per Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows the guidance in FASB ASC 260, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series X Preferred Stock (see Note 5). Basic net earnings per share is then calculated by dividing income allocable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net earnings per share using the more dilutive of the (1) if-converted method or contingently issuable share method, as applicable, or (2) the two-class method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the if-converted method. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#8217;s stock option plans. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each </span></div>reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preclinical And Clinical Trial Accrued Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_UnauditedInterimFinancialDataPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial data.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_UnauditedInterimFinancialDataPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238338636144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Earnings (loss) Per Common Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net earnings (loss) per common share (in thousands, except share and per share data):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(18,083)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,664)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(3,081)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator for basic net earnings (loss) per share - net income (loss) attributable to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,897&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(18,083)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of participating securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Add back allocation of earnings to participating securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">14,978&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(18,083)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(16,422)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(25,664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator for basic net earnings (loss) per share - common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">70,217,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49,533,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48,402,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock, as converted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs, PRSUs, and ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">189,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">88,592,568&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">49,533,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">69,170,865&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">48,402,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic net earnings (loss) per common share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted net earnings (loss) per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(0.53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Earnings (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per share because doing so would be anti-dilutive (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,442,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,442,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,041,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,356,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,086,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,356,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">22,558,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,316,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">40,788,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">33,316,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238336888176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Instruments Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following tables summarize the Company&#8217;s financial instruments measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LEVEL 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,078&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and money market accounts</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">59,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted cash and money market accounts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">62,273&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337368448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Common stock reserved for future issuance is as follows (in common stock equivalent shares):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:70.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.517%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">12,517,328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Series X Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">18,184,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Stock options, RSUs and PRSUs issued and outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">10,086,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">9,470,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Authorized for future stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,710,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,436,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Awards available under the ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">986,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">680,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,485,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">43,289,438&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337260992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes RSU and PRSU activity during the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of<br/>RSUs and PRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,174,087&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,471,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,032,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">RSUs and PRSUs canceled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(320,532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.06&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,292,194&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2022:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Contractual Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">in Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Intrinsic Value (in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,296,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,014,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">0.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Options canceled</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(1,516,146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,794,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.46</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Vested and expected to vest at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">8,794,645&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">6.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Exercisable at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5,749,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">5.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238427624384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the nine months ended&#160;September&#160;30, 2022&#160;(in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Opening balance, December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">32,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Payments received in advance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">11,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Revenue from performance obligations satisfied during reporting period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(4,005)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Closing balance, September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of deferred revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">15,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term portion of deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">24,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total deferred revenue, September&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">39,647&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents our contract revenues disaggregated by collaborator and timing of revenue recognition and excludes royalty revenue (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,019&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,512&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,388&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,213&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Mundipharma</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Janssen</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Melinta</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from Collaboration and License Agreements:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Point in Time:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">License of Intellectual Property</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Drug Supply</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Over Time:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical Supply Services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Revenue from Collaboration and License Agreements</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,393&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238338690240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of September&#160;30, 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Present value of lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,621&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The balance sheet classification of the Company's operating lease is as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current portion of lease liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Total operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">1,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337347360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY AND BASIS OF PRESENTATION (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (393,589)<span></span>
</td>
<td class="num">$ (377,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 53,078<span></span>
</td>
<td class="nump">$ 62,273<span></span>
</td>
<td class="nump">$ 40,305<span></span>
</td>
<td class="nump">$ 42,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337540864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - obligation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Janssen Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations', window );">Number of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborationAgreementNumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborationAgreementNumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cdtx_JanssenCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cdtx_JanssenCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337281424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 14,978<span></span>
</td>
<td class="num">$ (13,119)<span></span>
</td>
<td class="num">$ (18,281)<span></span>
</td>
<td class="num">$ (18,083)<span></span>
</td>
<td class="nump">$ 10,711<span></span>
</td>
<td class="num">$ (18,292)<span></span>
</td>
<td class="num">$ (16,422)<span></span>
</td>
<td class="num">$ (25,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic', window );">Allocation of earnings to participating securities</a></td>
<td class="num">(3,081)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common stockholders</a></td>
<td class="nump">11,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,422)<span></span>
</td>
<td class="num">(25,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract', window );"><strong>Effect of participating securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted', window );">Add back allocation of earnings to participating securities</a></td>
<td class="nump">3,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions</a></td>
<td class="nump">$ 14,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (18,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,422)<span></span>
</td>
<td class="num">$ (25,664)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic net earnings (loss) per share - common shares outstanding (in shares)</a></td>
<td class="nump">70,217,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,533,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">48,402,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Series X Convertible Preferred Stock, as converted (in shares)</a></td>
<td class="nump">18,184,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Common stock options, RSUs, PRSUs, and ESPP (in shares)</a></td>
<td class="nump">189,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding (in shares)</a></td>
<td class="nump">88,592,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,533,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,170,865<span></span>
</td>
<td class="nump">48,402,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings (loss) per common share (in dollars per share)</a></td>
<td class="nump">$ 0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2740-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337138288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">22,558,661<span></span>
</td>
<td class="nump">33,316,375<span></span>
</td>
<td class="nump">40,788,887<span></span>
</td>
<td class="nump">33,316,375<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">12,517,328<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,442,780<span></span>
</td>
<td class="nump">18,184,720<span></span>
</td>
<td class="nump">10,442,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Common stock options, RSUs and PRSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">10,041,333<span></span>
</td>
<td class="nump">10,356,267<span></span>
</td>
<td class="nump">10,086,839<span></span>
</td>
<td class="nump">10,356,267<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238332786304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">$ 53,078<span></span>
</td>
<td class="nump">$ 59,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">LEVEL 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">59,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,593<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">53,078<span></span>
</td>
<td class="nump">62,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">LEVEL 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">LEVEL 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash and money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238332714176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Additional Information (Details) - Term Loan - Term A Loan<br></strong></div></th>
<th class="th">
<div>Oct. 03, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Borrowed from the lender</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Variable annual rate</a></td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember', window );">Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Prime interest rate</a></td>
<td class="nump">0.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=cdtx_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cdtx_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238335741056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 13, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 12, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of stock, proceeds | $</a></td>
<td class="nump">$ 35,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NumberOfVotesEntitlementForEachShareHeld', window );">Number of votes for each share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember', window );">Common Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_WarrantsAggregateIntrinsicValueOutstanding', window );">Warrants, aggregate intrinsic value, outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember', window );">Common Stock Warrant | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrant (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">774,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,818,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from right offerings | $</a></td>
<td class="nump">$ 38,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,947,759<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued for each preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion', window );">Maximum ownership following conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember', window );">Controlled Equity Sales Agreement, Cantor Fitzgerald and Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,308,435<span></span>
</td>
<td class="nump">4,492,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_SaleOfStockConsiderationRemainingOnTransaction', window );">Consideration remaining on transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicStockOfferingMember', window );">Public Stock Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">17,064,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="nump">2,225,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfVotesEntitlementForEachShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes entitlement for each share held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfVotesEntitlementForEachShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_SaleOfStockConsiderationRemainingOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Remaining on Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_SaleOfStockConsiderationRemainingOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_WarrantsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Aggregate Intrinsic Value, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_WarrantsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=cdtx_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cdtx_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238332731200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">45,485,232<span></span>
</td>
<td class="nump">43,289,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">12,517,328<span></span>
</td>
<td class="nump">12,517,328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember', window );">Series X Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">18,184,720<span></span>
</td>
<td class="nump">18,184,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Stock options, RSUs and PRSUs issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">10,086,839<span></span>
</td>
<td class="nump">9,470,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember', window );">Authorized for future stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">3,710,000<span></span>
</td>
<td class="nump">2,436,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Awards available under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total (in shares)</a></td>
<td class="nump">986,345<span></span>
</td>
<td class="nump">680,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_SeriesXConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_AuthorizedSharesForFutureStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238332576128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term for stock options to be granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold', window );">Voting power threshold</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of employee stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 1.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic annual increase in shares authorized for issuance in equity incentive plan</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Limit on employee's payroll deductions as a percentage of eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,219<span></span>
</td>
<td class="nump">145,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember', window );">Restricted Stock Units and Performance-based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Estimated unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.83<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs and PRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period to recognize unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember', window );">More than 10% of voting power</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Price of stock option as percentage of estimated fair value of shares on date of grant</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Automatic increase in number of shares available for issuance (in shares)</a></td>
<td class="nump">490,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage', window );">Automatic annual increase in shares authorized for issuance in equity incentive plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cdtx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337249488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details) - Restricted Stock Units and Performance-based Restricted Stock Units - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs and PRSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,174,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs and PRSUs granted (in shares)</a></td>
<td class="nump">1,471,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">RSUs and PRSUs vested (in shares)</a></td>
<td class="num">(1,032,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs and PRSUs canceled (in shares)</a></td>
<td class="num">(320,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">1,292,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 2.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs granted (in dollars per share)</a></td>
<td class="nump">0.83<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs vested (in dollars per share)</a></td>
<td class="nump">1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">RSUs and PRSUs canceled (in dollars per share)</a></td>
<td class="nump">2.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238336917728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">8,296,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">2,014,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares)</a></td>
<td class="num">(1,516,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">8,794,645<span></span>
</td>
<td class="nump">8,296,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">8,794,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">5,749,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share)</a></td>
<td class="nump">2.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">2.74<span></span>
</td>
<td class="nump">$ 3.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">6 years 5 months 15 days<span></span>
</td>
<td class="text">6 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">6 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">5 years 3 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract', window );"><strong>Total Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238337156128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">$ 901<span></span>
</td>
<td class="nump">$ 3,032<span></span>
</td>
<td class="nump">$ 2,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">443<span></span>
</td>
<td class="nump">425<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 1,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238329169168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 03, 2019</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,744,000<span></span>
</td>
<td class="nump">$ 7,076,000<span></span>
</td>
<td class="nump">$ 54,069,000<span></span>
</td>
<td class="nump">$ 42,347,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,772,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementCostSharingPercentage', window );">Cost sharing percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability', window );">Long-term portion of deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember', window );">Mundipharma Medical Company | Affiliated Entity | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost', window );">Collaborative agreement, maximum cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults', window );">Election to proceed notice, period post delivery of results</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice', window );">Termination provisions, required period of written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable, related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | R&amp;D Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember', window );">Janssen Pharmaceuticals, Inc. | Affiliated Entity | Development, Regulatory, and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 695,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized contract cost, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized contract cost, amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized contract cost, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="nump">$ 460,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | Affiliated Entity | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | Affiliated Entity | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | Affiliated Entity | Milestone Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | Affiliated Entity | Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | Affiliated Entity | Upfront Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_PaymentsRelatedToCollaborativeAgreements', window );">Payments related to collaborative agreement</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember', window );">Melinta Therapeutics, Inc. | Affiliated Entity | Development, Regulatory, and Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_CollaborativeArrangementTransactionPotentialValue', window );">Collaborative agreement, potential transaction value</a></td>
<td class="nump">$ 430,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementCostSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Cost Sharing Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementCostSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Third Party Share Of Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_CollaborativeArrangementTransactionPotentialValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Transaction, Potential Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_CollaborativeArrangementTransactionPotentialValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_PaymentsRelatedToCollaborativeAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Related To Collaborative Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_PaymentsRelatedToCollaborativeAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126928961&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=cdtx_LicensesOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=cdtx_LicensesOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238336897616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward', window );"><strong>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Opening balance</a></td>
<td class="nump">$ 13,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Closing balance</a></td>
<td class="nump">15,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">15,249<span></span>
</td>
<td class="nump">$ 13,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">24,398<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability', window );">Total deferred revenue</a></td>
<td class="nump">39,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward', window );"><strong>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Opening balance</a></td>
<td class="nump">32,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance', window );">Payments received in advance</a></td>
<td class="nump">11,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized', window );">Revenue from performance obligations satisfied during reporting period</a></td>
<td class="num">(4,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Closing balance</a></td>
<td class="nump">39,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">$ 39,647<span></span>
</td>
<td class="nump">$ 32,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238330399712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,744<span></span>
</td>
<td class="nump">$ 7,076<span></span>
</td>
<td class="nump">$ 54,069<span></span>
</td>
<td class="nump">$ 42,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,019<span></span>
</td>
<td class="nump">3,270<span></span>
</td>
<td class="nump">12,468<span></span>
</td>
<td class="nump">8,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma | License of Intellectual Property | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
<td class="nump">3,033<span></span>
</td>
<td class="nump">7,965<span></span>
</td>
<td class="nump">7,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Mundipharma | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="nump">792<span></span>
</td>
<td class="nump">598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,512<span></span>
</td>
<td class="nump">3,806<span></span>
</td>
<td class="nump">15,388<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen | License of Intellectual Property | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">2,072<span></span>
</td>
<td class="nump">11,235<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Janssen | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">3,337<span></span>
</td>
<td class="nump">3,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Melinta | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Melinta | License of Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="nump">$ 25,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Melinta | License of Intellectual Property | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,885<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,885<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Melinta | Clinical Drug Supply | Transferred at Point in Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Melinta | Research and Development Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | Melinta | Clinical Supply Services | Transferred over Time | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126928961&amp;loc=SL5834089-161433<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_LicensesOfIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ClinicalDrugSupplyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ClinicalDrugSupplyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cdtx_ClinicalSupplyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238329155408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 14, 2021 </div>
<div>USD ($) </div>
<div>option</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseMonthlyRate', window );">Base rent per month</a></td>
<td class="nump">$ 103,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease', window );">Percentage increase in base rent annual</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_NumberOfOperatingLeaseOptionsForExtension', window );">Number of options to extend | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseOptionRenewalTerm', window );">Option renewal term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost', window );">Variable lease and short-term lease term included within operating lease cost (greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseAnnualRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rate Increase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseAnnualRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseMonthlyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseMonthlyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeOperatingLeaseOptionRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option Renewal Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeOperatingLeaseOptionRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cdtx_NumberOfOperatingLeaseOptionsForExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operating Lease Options For Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cdtx_NumberOfOperatingLeaseOptionsForExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cdtx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238339366784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">1,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 1,621<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140238343347664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 1,491<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liability</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">1,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">344<span></span>
</td>
<td class="nump">$ 1,322<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 1,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>cdtx-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cdtx="http://cidara.com/20220930"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cdtx-20220930.xsd" xlink:type="simple"/>
    <context id="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3ea934756b6a4b36acc5dce537f5d6cd_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="ia4364c8090e34068aa4c7347a141f4a0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib5225fdc3f334ed69fa883c887f70abe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08d686bd4def4018a3689e8e8c4201a4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8c7723f16324a4fad5896b06b8f70ee_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1455ccf570fa408797a81a114aeef838_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1541d551c68f4ed2b3a7797a2421af03_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a6f6259262c4efcb61b27512dc283e6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i42a96ee88a724103bd21dea2ce351a6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bdf276fab234f5793b92dd0eab61737_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3cb92875f7444accb8df71f69d1e6823_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i098de05c0a73424893e619674f8ede0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i439485f4e8e2471190cf787925ce765f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id549c6dc162445b0a8b51e25ba53845f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie8bf3279b1814f298a5a4e543dffe461_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ddfea5cb5ac4dbba5969c5c32dc405f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idcfbfe674ada4806903f264b16edff10_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3fd27b6890e4826a59b299ceb905038_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i160c27cee64e434eabaaa10605b89946_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9cb81e64d8f846e1b7b1aedc4305a63b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idc647f0b1f5d4ee99cd69cc22038ac7b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i70591917e30b4422865fea663b0f796f_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3a186807702543a3b16705ccfa44e627_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5122efa490e14a07b68b1661470c2d68_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26800230236f4cc9bc3aac4ee89d9783_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if1a3f0c9c39f4de6bf503a1bbe64da16_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib82d7061381343cf8fd9d02f13182140_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i956248bf259a4879bbb53a8a82a26ec7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a529f48c1e14479a8bac0af6684dfed_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iba7ab5417525497fb3acb2513449bdd2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb414282b9dc4b85bc63049a4f25a84f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31de05b5ec874e73a1ec0902444ca46e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i109b1669ef4d446f8220b8cba5c0ae2e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3dea2fc105bf4d31866b9f83d65b2932_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="icf881d2c650347459458b36b03ca94d0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i864469b8adce4fbb956b05333e046b7e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i693eb172a4d347d0b0a8944c52cb7b00_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5738d3cb61f1420b9d7309c2a207e112_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i94201b3baa82482bbac00a56f5e155fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idd091b6d62174e4d8d75ae1cf5dc7c1a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic0d525f23739440fbefcb160732067b9_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibc56da2da39740feb3ec19fc507a66e8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i07c2a73a148b485f89fc5f997009213f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if133fdbf28ba4b219f3f376b31de78bf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic6911289ff2c4b749f20e55b06a07c49_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i87017a31f5664b1b9432ba825c9cffd3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7c805b66507a4ce5a2a3ea7b4ce88a7c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id436a614bbc4407580ad8a47424abedc_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4453b17a58014dc49d268e838656cf76_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i40678b795d7a4f77b2887ee7e28b9d6b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ica9486a33c544927bc063333539cd357_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc5f7c9d49964f0c9dd7ecb39b9e7a9a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i89f47ece2c56488f873e04e2b611b0a9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib177b93cb8ec46ba81e03a7d526bc97b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i7d7d33deac174ca1acff18720307d200_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5347a69850cb4e3a9c600e3f046564c5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id376015bef2f4799bc27e985203d46bd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60d1ea8a7959445a95096c4b864be06d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i818d0f7b825449cda1e49ae8b91e0960_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i94ee68c9bbb94758b8465a6d2c6abd10_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id1d162d88a05494b9a13cdb4bb8b29d6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i55632fa7f7f64ff2a296fb450fc05947_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6abcad7d8034ab09ccfc1455cc8aca2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie8d3b55bd5de40eab1cd422f39bee135_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i39f7d4a95df44e80aad5a7828af660e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3728c48f4fff45e48fd89bdb795841d3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cdtx:JanssenCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie84641f18b5b49039831316c6a1bf0a1_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="ib67565edcae74a3cb712ae982e16c451_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie4bdc30657f14452b62cb74aaa0c1c02_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9489bd66399422eba3c70350fb1aec6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1eba19ec547f41fe9cb7fcf6f8323c4e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53017c7a53ac41bba664c2e94189573a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if5bb1e9a932d46abbb6c2af18fe748bf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8290788acae94198a642171a08cb981e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67bd62ef1d93442c8672b744fb64dba0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea096aaf8a964de0a3100d448444ba50_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5e6c2025ff77482496d4861d17864fb7_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89983bfbaa774a6089ebf1552008beed_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib71ae47f80d7456fa74d8430a1187edd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic90bb450d4b14645876a8c40853f0f80_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6c9e1bc6d28645a0a88c59ae7c3b268d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id64416d06cee4e5ca72c5b5ca3dd7cdf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if9923c3f04494ea08d78070db565dec5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d1ba8de76cf4d50a911304fc4244f77_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2787b199372343b4b03ee56c6d782676_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i052c13aef942486698daafbe3f173f65_I20161003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-03</instant>
        </period>
    </context>
    <context id="i959c564f9e4f4f058243fb9d370aa5de_D20161003-20161003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cdtx:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">cdtx:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-03</startDate>
            <endDate>2016-10-03</endDate>
        </period>
    </context>
    <context id="ifb67d01a4acc4c67a09bea73d61871ed_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf66717d514a49d7b24e502df0f65ed9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae88c6865e4e458ba163ba5e2108e78e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id488125f97f9422c86fe3f9a0f62e61e_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cdtx:PublicStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="i44b0440e80904930ac842fa7429f8b17_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="i2873a315ee3b49fb92caf5729891639a_I20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="idd41362b50874d8d8249094d91ca90f6_I20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-13</instant>
        </period>
    </context>
    <context id="i5df29006f187417e816e2158bd2f9209_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="if7f37a17eb6a463698c6b8c41d120df5_D20211013-20211013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-10-13</startDate>
            <endDate>2021-10-13</endDate>
        </period>
    </context>
    <context id="i94af5aa812844c758cdfa1475671e9a6_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i7dc162d67bbe4dca8bd989529e6ae2b3_D20200812-20200812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-12</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="i43db71acffc7473da141de0be728b1f4_D20200812-20200812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-12</startDate>
            <endDate>2020-08-12</endDate>
        </period>
    </context>
    <context id="i13ec61aa3e0b43378a90a84041d66908_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86b952768f264a7b874692f258aa5053_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i62d149e810834aceba4d99488eae77db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf327b331dbc430d85c195531d36f8df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fe30b7973da4dffb8da105c119dfe8b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">cdtx:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia5324603762448499a4ae28f38d54d1b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8d844b63d15b429cbac3aefd54d810e1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic05c4f78a48f4a4dbf218b042d1d1f6e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i541af1a514f347a69bd1214db5ee6761_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:SeriesXConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38ddb97add1a4265b3f354df1f33347f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i782d88c1c80c43aeb3ee3636280e0ec3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i31cc8c5f67c647a8bb8f8d484fb20097_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i445ea361a0534f34b979c1b9c39c0ee4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:AuthorizedSharesForFutureStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i036bdcca976a44cf9a1566845a5fb841_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1395be4faaed4f909c2d9d668463d93d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib506537ee0944bfcbcb6c12ae798c59c_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cdtx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i7005c05e48314e688d999cdea4698c80_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i5b111eb9e1724eb4b52920f38d9f5ac1_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i12b01287deb64faf84f4daa9f17bb5e0_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">cdtx:MoreThanTenPercentVotingRightsClassesOfStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i71ef06f8cb854b7abf2c1ca8ca9f0400_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="ide919cb038934f0c97c7be8388a351c8_D20150301-20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="i56e4c68ba76241baa53301e647eb569c_I20150331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i967a2fb933ca4d77a5793520831dca91_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad586f67e1e64183ba99bd648dfdad0f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc7909cccd3141d4980af143ffea9363_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9912047c193415f8d530486835fc858_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if4c2b554012041d29eba537838cbb84c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia0437175fbfa46dbba01f38007dbede7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cdtx:RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idfeff9f96ab8411fa8bca991c8031822_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1dcbfc97d2f34fb9a0872c85a82593c5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8cfddad092a44527821fd2ac2ffc91ed_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i96c9f00db2034a07ab38792b24541941_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i244171b35f434cc39f5129662239663e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3c6df55d735d4a3584f2bf2d709732de_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19798a6430cc425eaf630f93c7d82742_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id0e07da4e20844708da921b1866aff4a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9746cabdad4f4ba5ad36b76a394afa49_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib6bd1aaba9504281a7c3adc36f4d33c8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iecd9ae8d02994db09c6c17d85d05eb8e_D20190903-20190903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-03</startDate>
            <endDate>2019-09-03</endDate>
        </period>
    </context>
    <context id="ia9b69a06369d4a8e88c985f8b0d67518_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2ab15c514b9d45d58fb7d77080e63dbd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib8e503d246dc400e926a1ee2b976a58e_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifc0df86722f14e688642f553eeef0df3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i083a9e97a9064a748f3e9e13753ecc2e_D20211201-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i050a34311f2f464091d42f5ee44e4c79_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="ie658ef0290234febab93dba91faae5e1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3a4ea630ca944ade94e8636670a33f15_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i161035ba306c4c2cbad3a08836c61a30_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80867d87eba64530a2fb32636e6cfb8f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9170170c08441b781c4c6d06c63beeb_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i294b1ca2af214dad80eaf69f5050931a_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:RDFundingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i58a391d92ba84000b49895803c8b0101_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5ec5bff221b34504b1e0fbb18258fed7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iae8af69b23b64ece8613fb9204fc9c4b_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i34737c9c45ac487189c88b240a304577_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i5a85bab3728d4eada2f9bcaf61036888_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ad6fb4866e44519aefef3041cf4c2cb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i577b14f0889b45eb8cb9da83fcc52acf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b2539318f504eba964d023b1f0971c9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id3992b0eb8484b4aaf5f1a209d2603dc_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="ib906710cf3274c668e80b30f6e1ec734_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:UpfrontPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="if3f48f173a7046749372f5bdca47960e_D20220726-20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cdtx:DevelopmentRegulatoryAndCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-26</startDate>
            <endDate>2022-07-26</endDate>
        </period>
    </context>
    <context id="ifd947fb9100e419d90d6c2dfa4983059_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i693aca7e97aa4503a8037a869333ca1b_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i1a7f54e53e964d7c9958ac2b8a920ce5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2ce9bdb2fb7b4bf88fc587dee9f5a817_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:MilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id1b5450d72e34c33b4dec3e66a44b756_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iabd098fd38fd419896b25481459eb489_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic5c7726e1d4f43d6ada81fc4d023fd3d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaa27a7d5291744e8a8982d3d8fd39e8b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ief418486b3fd4aeaa1b3a28dde7a1f60_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i810b267149e44965acbf595fbb6b9e33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ac7381acc7e4e059c3e2321b8b15239_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8c38f20f22ba485bb4c251fc607c0a9e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i18d550357dd0498aa73e25001de9cc1a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iefc06d4abeb64a938a55a63bbfcfedc8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ief933a73262047ada7ce3fa9a403b153_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i74e6e40b20bd48d29415c8c3c7305f97_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9c1d8dcb1b3c4b8bacd38918de4039b1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib709c1ffb8854bb481421062c0b218f9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iab1678b723954fb2a37229ed7298c334_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i04cff27d9bb54d1fa6f4a32a4b7398df_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia9f4882fb39748e396fbfb4e6f2141a1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2363ec926c83422882f201f395e6418e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia89c179f7606467791e1ccda6296e332_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ied8bda146b1e42518db4ad5b9607da40_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2a13d205acea4035b1472638de599302_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i608d2c0acd8a446f97ea23de80771ca2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if86142a8002b4fb3bfa67f3114a2168c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifdb93712507e4b0d9bcf6e602fc11d8f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4b76d577a5a04ef2a426145c4efdec1f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i330a14431e6c447f850339e8183a87c2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib64ac500c81045e0900ce23c27023a2c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ee636604f0544608be83b816d561a04_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie8993710e84743d28a95a4b2457fa9cb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if43870715ac94163bfa487cc20cc7a5c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia26a535ba45543e8a02c93c70be14f9c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i791e53caa07d4e4ea55fd15972c74a19_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ef6e2feb31a41178bada54e92855b1b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3a540ce1f4734c1b8df74de8131b45d3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7fb8ca4cb3f04e0ebddd7c2383d433d7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if8e5492e892a4011aeca081fc7b607fa_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i05496cda0e33452896f54514996a1288_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iad9574638cde472faee405847f9f3e1a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i586689ef6a80408b93ad64b72f84c672_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i04ff76c144cd4408a9a52fbbc69b19cf_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a54ee7566ce41918832cd3479ef935e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i805c213b2c0743b087c75996e2d88021_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i62d5577ed469475da80b700a69f04f2c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8c636231d35f4bf0971afbbb890c922e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c2b515fd83f4999933be813beb65c48_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcd3b7ed4d6b4262a23a7634c2c7aff2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib9fb95774ab143ebafe375c57e2fac61_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iefed914e0ec24b92964d9459ffc3d327_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id406989deae044f4acf764c75f7ad87b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:LicensesOfIntellectualPropertyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic04da1d4150b40a8abe55e454e756c44_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c71d7b0754c47a8818fc47cb60bf5b8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i605912304b144c4bba382814666efe0a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib370fe55235440b19f13161583777fca_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibc3e4af26d3548a0905d4625e4c6960f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8777634ed6ab43ceb831077cb1ba1505_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalDrugSupplyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf075aa78dbb48cb952fb65ae88fc07a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9c01b6b14c1a485fb20538cac3587498_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ida8b4e5a23a9418d8c44be5a1e0e74a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i515a17efa892472b86a77214dfa7ef7b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if41b2c7dcf954060af28af4c157705cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib77a7ee0b23046cc9cb75730e07ea8c6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ica341a5f24ad4bcab2e21eea5d444a9d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i76dc324051474558a170627d6a003711_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d4f5d1f93e04d73aa48631d7518db9c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06d0c3d06b8544eda7efed1647c21a9c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3011064556b748619173464bff0d68e3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9776e033e33d450695fa795370df723c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cdtx:ClinicalSupplyServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i940b58f0b39b440d929568bd00af95e5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if417d192e5eb43008abe45d33168ea61_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id433e60fe208470fa98c4a38610c659c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a3ec63d2d654bbe9108ebb110c10485_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i661d0dfb1ecb4a8e85c58f301a66b3bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:JanssenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idef1c49cdd9a44d09573c601607368e6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MelintaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie6a10d1d7b8341e48e7157fc9809cb9e_D20190903-20190903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cdtx:MundipharmaMedicalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-03</startDate>
            <endDate>2019-09-03</endDate>
        </period>
    </context>
    <context id="ib12d63d710f14cf2a688757cc358ebca_I20210714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001610618</identifier>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="segment">
        <measure>cdtx:segment</measure>
    </unit>
    <unit id="obligation">
        <measure>cdtx:obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>cdtx:vote</measure>
    </unit>
    <unit id="option">
        <measure>cdtx:option</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY18zLTEtMS0xLTQyMzY3_3a4b0bc1-0e3c-4f83-a97c-4f0ec06484d4">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY180LTEtMS0xLTQyMzY3_0893f1c2-493a-4f28-ba96-de411f67e669">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY181LTEtMS0xLTQyMzY3_08b10f97-dc3b-41f6-ae0c-6f6540276527">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY182LTEtMS0xLTQyMzY3_7bd02998-a920-4fbc-be16-c8272fbf3258">0001610618</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80L2ZyYWc6M2ZmYTMzZmExMDNiNGZmYTkxNmExY2UyYjE1NGNlZmIvdGFibGU6ODdjYjA0ZGRiNTU4NGY4MjhhZDVlOTQ4MTIzMTVjYWMvdGFibGVyYW5nZTo4N2NiMDRkZGI1NTg0ZjgyOGFkNWU5NDgxMjMxNWNhY183LTEtMS0xLTQyMzY3_c2c01c33-f539-430f-a6a7-ad46a9395723">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_011b2109-21a8-464f-bb1e-33d79328bc43">http://cidara.com/20220930#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_278b3e2b-3ca4-47d9-97c2-0c16a9fc93d4">http://cidara.com/20220930#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_be7bbebb-4238-4090-b165-d91c10c23ad7">http://cidara.com/20220930#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0wLTEtMS00MjM2Nw_f777ca9d-6e93-4f97-b8fd-af359bd8aa31">http://cidara.com/20220930#CollaborationRevenueMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i55632fa7f7f64ff2a296fb450fc05947_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTIzOA_4025d4e0-b32b-4383-8a9a-aee6ae64d94d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7005c05e48314e688d999cdea4698c80_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTQ2NQ_548f15b5-a1d8-4cd3-872c-e2f333fda6b9">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cdtx:CollaborativeArrangementCostSharingPercentage
      contextRef="ie6a10d1d7b8341e48e7157fc9809cb9e_D20190903-20190903"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81Mi9mcmFnOjQwMWMxNTdjMWU0YTQwZjRiY2VkYzljMzI0OGI3MTdkL3RleHRyZWdpb246NDAxYzE1N2MxZTRhNDBmNGJjZWRjOWMzMjQ4YjcxN2RfNTM_64166873-704d-4fa8-8988-1cbbe7e1c510"
      unitRef="number">0.50</cdtx:CollaborativeArrangementCostSharingPercentage>
    <dei:DocumentType
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODc4_0a614a74-3ede-413b-a760-3445350e4c24">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NWY2MTU1YjI2NjhlNDg0NmI2MmU4YTk5YjdlOTc3MjYvdGFibGVyYW5nZTo1ZjYxNTViMjY2OGU0ODQ2YjYyZThhOTliN2U5NzcyNl8wLTAtMS0xLTQyMzY3_924ce57b-b042-4b40-b5cc-65ee14337c56">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xMzU_535fa9e6-f04a-459d-a05a-419aef07ce23">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6YTUxMzNmNmEyNGI2NDhhODhmYmE0NzY1MDE4MTlhZWIvdGFibGVyYW5nZTphNTEzM2Y2YTI0YjY0OGE4OGZiYTQ3NjUwMTgxOWFlYl8wLTAtMS0xLTQyMzY3_a5898101-8d60-4889-90ab-b63a5d05622b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgz_4f38336c-4a2c-4101-92e5-07748a6e3c07">001-36912</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODc5_92df4576-a419-4b20-80e7-4c986dad503e">CIDARA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8wLTAtMS0xLTQyMzY3_1b97eadc-5fcb-492b-95bb-af1642eef5ff">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8wLTUtMS0xLTQyMzY3_a6b9be63-8996-4347-b559-c95665882d9c">46-1537286</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8zLTAtMS0xLTQyMzY3_5e66dfde-ef80-4f81-80a2-385bb3e1f76c">6310 Nancy Ridge Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV8zLTMtMS0xLTQyMzY3_62002cfe-55c9-485a-92d2-c670ed933cc4">Suite 101</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTAtMS0xLTQyMzY3_4db9bd7e-c7bf-4735-9595-8929aab2cca7">San Diego,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTEtMS0xLTQyMzY3_d0e422a5-4195-4f16-8968-29b451ce5f57">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTItMS0xLTQyMzY3_8ad313ff-9ae3-4c39-9337-4aea32e600ab">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTUtMS0xLTQyMzY3_3c8b78ca-89e5-4b95-829d-6c8b23c83e4f">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6NzMzMWNkNDI2YWY0NGYwM2I0ODQ1NmIzNzgyZDA0ODUvdGFibGVyYW5nZTo3MzMxY2Q0MjZhZjQ0ZjAzYjQ4NDU2YjM3ODJkMDQ4NV80LTYtMS0xLTQyMzY3_2b381d2a-3444-47dc-a998-b0725823b341">752-6170</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6MWU5ZjNjNDNiNDA5NDNkMmI2YjFlNjlmYjAyYzkwZmIvdGFibGVyYW5nZToxZTlmM2M0M2I0MDk0M2QyYjZiMWU2OWZiMDJjOTBmYl8xLTAtMS0xLTQyMzY3_52322cf2-de9f-4996-8707-39cd7ea02ee9">Common Stock, Par Value $0.0001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6MWU5ZjNjNDNiNDA5NDNkMmI2YjFlNjlmYjAyYzkwZmIvdGFibGVyYW5nZToxZTlmM2M0M2I0MDk0M2QyYjZiMWU2OWZiMDJjOTBmYl8xLTItMS0xLTQyMzY3_6f11d7fc-a0a8-4a43-90fe-b8d98d68b901">CDTX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6MWU5ZjNjNDNiNDA5NDNkMmI2YjFlNjlmYjAyYzkwZmIvdGFibGVyYW5nZToxZTlmM2M0M2I0MDk0M2QyYjZiMWU2OWZiMDJjOTBmYl8xLTQtMS0xLTQyMzY3_43f5112f-7d82-4561-a8f6-01e59fee9a5c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgw_2d873fa6-f055-4e44-a96a-9d08c7b12ecb">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgx_bba2f01b-4dc5-40f1-9659-eb491de74cf0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6ZGI1MDc5ZDIwMmVlNDI0ZTkwOTU0ODZjYjQzOTczOTcvdGFibGVyYW5nZTpkYjUwNzlkMjAyZWU0MjRlOTA5NTQ4NmNiNDM5NzM5N18yLTAtMS0xLTQyMzY3_9fc38916-7d11-4f46-a78b-7590b120e615">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6ZGI1MDc5ZDIwMmVlNDI0ZTkwOTU0ODZjYjQzOTczOTcvdGFibGVyYW5nZTpkYjUwNzlkMjAyZWU0MjRlOTA5NTQ4NmNiNDM5NzM5N18yLTQtMS0xLTQyMzY3_91dd4496-01ca-4a6f-bbb8-c274a4391449">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGFibGU6ZGI1MDc5ZDIwMmVlNDI0ZTkwOTU0ODZjYjQzOTczOTcvdGFibGVyYW5nZTpkYjUwNzlkMjAyZWU0MjRlOTA5NTQ4NmNiNDM5NzM5N180LTQtMS0xLTQyMzY3_8de11e3c-d05f-4006-8653-7b0b2be444a3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODgy_524116e8-bb4c-4007-bf72-0f07101190cb">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3ea934756b6a4b36acc5dce537f5d6cd_I20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODIy_8a2fdcec-75e8-4b39-b1ce-fd2150241ec9"
      unitRef="shares">71618091</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODUw_23e7add0-450d-48cd-88cb-4126784e4caa"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xL2ZyYWc6MzE3Y2QzNWVjYzg5NGZiODg1MzkxZWZjMDc4NjM1MGIvdGV4dHJlZ2lvbjozMTdjZDM1ZWNjODk0ZmI4ODUzOTFlZmMwNzg2MzUwYl8xODUw_84ad136b-49cc-4eec-952d-5ddcadeb53b2"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNC0xLTEtMS00MjM2Nw_a9d2478f-da0c-4a44-bcb9-4af811b2b81f"
      unitRef="usd">53078000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNC0zLTEtMS00MjM2Nw_64268cb1-b76c-47ba-9bd3-deb2cf8e2ea2"
      unitRef="usd">59680000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNS0xLTEtMS00MjM2Nw_6a5b943b-f620-404a-b85f-b9a268e98827"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNS0zLTEtMS00MjM2Nw_bc30d3b3-8dcf-4b49-9f29-7661163fae15"
      unitRef="usd">2593000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNi0xLTEtMS00MjM2Nw_4961c698-6496-419c-bafa-633457de3dd3"
      unitRef="usd">5042000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNi0zLTEtMS00MjM2Nw_85f81e96-7bdd-470e-a041-097accdf2f6c"
      unitRef="usd">5356000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNy0xLTEtMS00MjM2Nw_257537f6-02da-4472-a43c-bc6e4d4752b6"
      unitRef="usd">5779000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfNy0zLTEtMS00MjM2Nw_2ce08f2e-1819-420c-bd4d-ebeffe65f813"
      unitRef="usd">4069000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOC0xLTEtMS00MjM2Nw_e99b6d7f-dec3-44dd-98a8-d10c43081810"
      unitRef="usd">63899000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOC0zLTEtMS00MjM2Nw_d6305344-77fa-4ce4-b6c2-e5044b314090"
      unitRef="usd">71698000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOS0xLTEtMS00MjM2Nw_dc6d30b5-e3ed-49ea-91bb-3e3dee3de8b6"
      unitRef="usd">173000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfOS0zLTEtMS00MjM2Nw_285fd04a-39b7-4d28-b4b7-40594d5eefb4"
      unitRef="usd">256000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTAtMS0xLTEtNDIzNjc_77ad1a5a-9e9d-40a0-b780-9ea082b3dbe1"
      unitRef="usd">1491000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTAtMy0xLTEtNDIzNjc_10a6e9e2-fa69-4be8-98ca-09aaf76215f8"
      unitRef="usd">2287000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTEtMS0xLTEtNDIzNjc_4ea5d6f2-63f0-4204-83c4-a50f940279cd"
      unitRef="usd">1295000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTEtMy0xLTEtNDIzNjc_f4f39644-aeba-4b7c-ad5e-fbb1cec92f2d"
      unitRef="usd">1084000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTItMS0xLTEtNDIzNjc_6d70413e-962f-4378-82dd-4fd54fbcde8b"
      unitRef="usd">66858000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTItMy0xLTEtNDIzNjc_7d36c14d-0645-4d5a-be25-65e76d2a676d"
      unitRef="usd">75325000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTYtMS0xLTEtNDIzNjc_ae8b9b80-8166-4552-8141-4098ff9c9c51"
      unitRef="usd">4244000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTYtMy0xLTEtNDIzNjc_887c47c9-bb30-4de0-ac54-34a85aa7e1ed"
      unitRef="usd">1301000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTctMS0xLTEtNDIzNjc_5f3d32d7-780f-4770-ad1a-3b571892265c"
      unitRef="usd">8162000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTctMy0xLTEtNDIzNjc_dcabccc8-27c6-4f45-a17c-00173482fc9e"
      unitRef="usd">10198000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTgtMS0xLTEtNDIzNjc_afdb1152-5e41-4986-96ed-d2e592332140"
      unitRef="usd">4117000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTgtMy0xLTEtNDIzNjc_9331c799-63ba-409b-a808-6cc330169e35"
      unitRef="usd">4859000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTktMS0xLTEtNDIzNjc_d191e78c-3580-4c37-b962-5a904aad528a"
      unitRef="usd">15249000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMTktMy0xLTEtNDIzNjc_a5cab5f8-65b0-43e5-93b3-f4abc9884a98"
      unitRef="usd">13920000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMS0xLTEtNDMxNjE_2b87fe1f-00b4-434f-acb2-c9fbaba5f7fc"
      unitRef="usd">1277000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMy0xLTEtNDMxNjE_ede654c5-bf70-4044-b6b2-674edee5f2f7"
      unitRef="usd">1148000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMS0xLTEtNDIzNjc_e56f6185-3f6d-4e5c-b357-5350cda5d23e"
      unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjAtMy0xLTEtNDIzNjc_ffa9ac20-f0c4-4566-bdf2-b80ee6b4795d"
      unitRef="usd">2591000</us-gaap:LoansPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjItMS0xLTEtNDIzNjc_99f69754-ea09-4d22-9195-9406d88ac675"
      unitRef="usd">33049000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjItMy0xLTEtNDIzNjc_a3b22c1b-754b-4b43-a77f-a1028e1b2b07"
      unitRef="usd">34017000</us-gaap:LiabilitiesCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjMtMS0xLTEtNDIzNjc_ad7400bf-9b1f-487b-b6a8-8bb69d1a3813"
      unitRef="usd">24398000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjMtMy0xLTEtNDIzNjc_18f9a57c-dffa-411c-804b-e10f15616586"
      unitRef="usd">18413000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjQtMS0xLTEtNDIzNjc_cc603157-7632-45d1-ae7d-ba9c831e3af7"
      unitRef="usd">344000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjQtMy0xLTEtNDIzNjc_d4e565c6-61e8-47a0-bfb7-df67fbe5eea3"
      unitRef="usd">1322000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjUtMS0xLTEtNDIzNjc_7fd00986-d878-40f5-a96b-c3f8c59ce7d1"
      unitRef="usd">57791000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjUtMy0xLTEtNDIzNjc_fbbc3527-4548-4180-990b-c7a7b9126fbe"
      unitRef="usd">53752000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjYtMS0xLTEtNDIzNjc_e101f2db-60c7-4267-84e2-c56e17041699"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjYtMy0xLTEtNDIzNjc_91d2afff-7b84-4121-83cb-4bc4da4de3fb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8yMg_389f3a30-a477-42b1-9230-6b61fda4de8e"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8yMg_b039281c-5322-448e-8b03-a432723991b4"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8zNg_7e8fdd94-1cd7-4876-81dc-c3e424d3d322"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjpjNDcxOGY5YzI2ZmU0ZTgyOTQzYTUxOGRmNjhiY2ExMF8zNg_dd92e960-c30e-468e-bfd2-a6d6c0388de4"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMS0xLTEtNDIzNjc_a86833c2-0131-40ac-b53b-a6f8d30c51c4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjgtMy0xLTEtNDIzNjc_6d52b54e-b7ca-4524-a1a3-d222525c27de"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV80Mw_262757f3-5ecd-4486-ad1f-c7598a681631"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV80Mw_4fb31243-83e4-4c9b-bbc7-8cf8cb4813f2"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV81Nw_423f430d-4302-4b05-958d-f62125ddb26d"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV81Nw_e137cc0d-b41c-462d-b0a1-f25eaefd051e"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV85Mg_2501dd97-5d39-4f4c-abf6-bf9b4b7307a2"
      unitRef="shares">1870713</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV85Mg_4fd7ff97-3cf0-40f2-a8af-11ec68b87ea9"
      unitRef="shares">1870713</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV8xMTM_59487669-2bbc-4d6d-8213-7290175db536"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjphMjljYWNlMDFhODU0YjA2OGJhZTgwYTZkNzgzNzAwOV8xMTM_7688b69a-ad36-435d-a644-57024c568bb8"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMS0xLTEtNDIzNjc_41a90ef2-821f-4161-a0b8-1cb3e80f3bf4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMjktMy0xLTEtNDIzNjc_fb7d53bf-0758-4279-8a23-30a2981d9826"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xOQ_23e7add0-450d-48cd-88cb-4126784e4caa"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xOQ_84ad136b-49cc-4eec-952d-5ddcadeb53b2"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8zMw_73da8890-124f-4bb9-a205-bc9ab0c40c8b"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8zMw_e56b4d62-2a31-4fb5-8893-11ecc4bf502b"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl82OA_4e4db261-a89e-47d4-98af-3ccd4bda0a3e"
      unitRef="shares">71181197</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl82OA_546c15d0-6993-4177-b81f-8eb87b19843a"
      unitRef="shares">71181197</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xMTE_a9b63c23-93b8-4836-ac2b-07c686465fc9"
      unitRef="shares">67863674</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMC0xLTEtNDIzNjcvdGV4dHJlZ2lvbjplMTliNzJmODNlZmY0ZWY3OWY4MDI4NGE5NzRmZmU4Yl8xMTE_c4096338-8e79-4528-a04a-63575c4fc81f"
      unitRef="shares">67863674</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMS0xLTEtNDIzNjc_21a6d905-bb15-44cd-959b-df677f5f6557"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzAtMy0xLTEtNDIzNjc_93b26415-c766-4a19-9aaa-9c4130436235"
      unitRef="usd">7000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzEtMS0xLTEtNDIzNjc_47c0c3aa-20f7-4c9b-bc90-a32a3578707b"
      unitRef="usd">402649000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzEtMy0xLTEtNDIzNjc_67ffb368-41df-4b2c-976c-48e0d8f74d2d"
      unitRef="usd">398733000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzItMS0xLTEtNDIzNjc_19a6ed5d-5743-4d50-aad5-19c4ebb02bcc"
      unitRef="usd">-393589000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzItMy0xLTEtNDIzNjc_f0ee4572-7169-490e-97d7-2eb82a5d5f77"
      unitRef="usd">-377167000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzMtMS0xLTEtNDIzNjc_600efc73-7849-440a-afe7-ced8b0ab9d5c"
      unitRef="usd">9067000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzMtMy0xLTEtNDIzNjc_aa116c1d-83a3-4ec3-8d06-4f378f9a10a0"
      unitRef="usd">21573000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzQtMS0xLTEtNDIzNjc_0fccc072-7997-4d15-99ed-caa119c2e0e4"
      unitRef="usd">66858000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xNi9mcmFnOmY4OTc3NjI1OTA3NTRlNmZiNzBlN2I1ZTQxNTg1NmIzL3RhYmxlOjdmNzVjY2Y2NzdmMjQ5NWJiZTMxNzE3ZWI1OGY1YWY5L3RhYmxlcmFuZ2U6N2Y3NWNjZjY3N2YyNDk1YmJlMzE3MTdlYjU4ZjVhZjlfMzQtMy0xLTEtNDIzNjc_1f74a5e9-533d-45a3-862a-964ab553f1a4"
      unitRef="usd">75325000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0xLTEtMS00MjM2Nw_2ac52b5f-1f66-4eb9-9061-bf6555734413"
      unitRef="usd">40744000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy0zLTEtMS00MjM2Nw_358256ed-e3bc-41a8-9750-06e7ad68e7bb"
      unitRef="usd">7076000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy01LTEtMS00MjM2Nw_4acaffc1-06d7-448f-baad-5c3d4ae3076c"
      unitRef="usd">54069000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMy03LTEtMS00MjM2Nw_246f6779-974f-45fa-97b6-40e74a78c4ae"
      unitRef="usd">42347000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC0xLTEtMS00MjM2Nw_77f832cb-0cab-4af9-8e6b-8a4df04208d0"
      unitRef="usd">40744000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC0zLTEtMS00MjM2Nw_043f4d9c-ea1d-4d4d-b381-d3e18b70cec4"
      unitRef="usd">7076000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC01LTEtMS00MjM2Nw_c5c11dd4-cf0f-4abc-8094-39d7e05f67d6"
      unitRef="usd">54069000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNC03LTEtMS00MjM2Nw_85628603-1e51-465c-81a3-7e5452645db3"
      unitRef="usd">42347000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi0xLTEtMS00MjM2Nw_7026519a-df37-43fc-878e-b303b53e6c77"
      unitRef="usd">20041000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi0zLTEtMS00MjM2Nw_8c72a3e1-f8be-4aca-af2e-0fad27f7c543"
      unitRef="usd">20505000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi01LTEtMS00MjM2Nw_81f37e87-f780-4735-9e2c-71b20b9ef4b1"
      unitRef="usd">55462000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNi03LTEtMS00MjM2Nw_3cd790e1-ef39-45b2-b94b-f28a8ad79f1f"
      unitRef="usd">54074000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy0xLTEtMS00MjM2Nw_cd18f71d-438c-4ef0-b7ab-4a2d253b18ce"
      unitRef="usd">5780000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy0zLTEtMS00MjM2Nw_2b63b90a-78dd-4327-bd7d-c7a6650c9993"
      unitRef="usd">4607000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy01LTEtMS00MjM2Nw_ec7dd365-77f0-45d0-9e87-0f16ee603102"
      unitRef="usd">15058000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfNy03LTEtMS00MjM2Nw_616a5f76-75d0-484d-a026-cae733b69862"
      unitRef="usd">13758000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC0xLTEtMS00MjM2Nw_220c3c49-b8fd-4ff5-81d6-37f956e0472b"
      unitRef="usd">25821000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC0zLTEtMS00MjM2Nw_75bfc9a7-504c-4bd7-b362-bcd003595af7"
      unitRef="usd">25112000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC01LTEtMS00MjM2Nw_7c95b08d-c690-4651-a2ff-0007a4868c7f"
      unitRef="usd">70520000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOC03LTEtMS00MjM2Nw_f0970184-33a0-4a99-957e-dd07de2504a8"
      unitRef="usd">67832000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS0xLTEtMS00MjM2Nw_541e8531-2435-4104-a2a7-cc94c2224b3f"
      unitRef="usd">14923000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS0zLTEtMS00MjM2Nw_c3310585-4d3b-4af0-aefb-a157dc68c931"
      unitRef="usd">-18036000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS01LTEtMS00MjM2Nw_3597e9b8-a0f2-4651-8256-2456a5c921d2"
      unitRef="usd">-16451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfOS03LTEtMS00MjM2Nw_429f3c6b-0ec6-41c0-b38a-c1bfaaeae2b3"
      unitRef="usd">-25485000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtMS0xLTEtNDIzNjc_d89198ee-16dd-44a5-bd1a-5eff7ddac052"
      unitRef="usd">55000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtMy0xLTEtNDIzNjc_ae3a8805-f874-4b95-ae74-cc18d3d802e6"
      unitRef="usd">-47000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtNS0xLTEtNDIzNjc_1f0b16db-b883-403e-abd1-f23a277ca8aa"
      unitRef="usd">29000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTEtNy0xLTEtNDIzNjc_2d5b42d3-1515-48b7-9295-900e3270c94f"
      unitRef="usd">-179000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItMS0xLTEtNDIzNjc_fd163b56-d02f-4c6e-8921-2fd3791d6663"
      unitRef="usd">55000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItMy0xLTEtNDIzNjc_71826f99-8877-42b5-b0b5-e990c168ff84"
      unitRef="usd">-47000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItNS0xLTEtNDIzNjc_e71a5dce-24d8-46d4-b630-e97c9b98cb8b"
      unitRef="usd">29000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTItNy0xLTEtNDIzNjc_7064ade1-1346-477e-8885-0b047a15ea3d"
      unitRef="usd">-179000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMS0xLTEtNDIzNjc_a03a8234-392f-4c3d-83dd-de06b394cc0a"
      unitRef="usd">14978000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMS0xLTEtNDIzNjc_e98118b6-9db8-49da-a44f-672c020f71bc"
      unitRef="usd">14978000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMy0xLTEtNDIzNjc_5d178df8-65f1-4c36-afb8-5f76d9da6bf5"
      unitRef="usd">-18083000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtMy0xLTEtNDIzNjc_71204ca7-d86d-49b5-8843-c27b90838725"
      unitRef="usd">-18083000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNS0xLTEtNDIzNjc_210d593f-b54f-4c38-b4fb-5e1b814673ba"
      unitRef="usd">-16422000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNS0xLTEtNDIzNjc_8f54952b-483e-48cb-83d6-5cad3372d671"
      unitRef="usd">-16422000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNy0xLTEtNDIzNjc_e479cc2b-fc0d-4dfc-8fbe-4a039f437803"
      unitRef="usd">-25664000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTMtNy0xLTEtNDIzNjc_ee776232-ced5-4db5-8fc5-3cbe431a51cf"
      unitRef="usd">-25664000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtMS0xLTEtNDIzNjc_6e261422-e566-4015-9594-cf70c8d33218"
      unitRef="usd">3081000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtMy0xLTEtNDIzNjc_94cc0080-93e0-4a73-913b-6304a294480b"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtNS0xLTEtNDIzNjc_29c20057-961e-4b11-9042-6061f7acc181"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTQtNy0xLTEtNDIzNjc_983aa547-33d2-4a1d-a133-860504bfebb2"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtMS0xLTEtNDIzNjc_67c9c26f-7aad-49ac-a014-6047b27a61cb"
      unitRef="usd">11897000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtMy0xLTEtNDIzNjc_9c81812a-9375-4d42-970c-eba4e377b8c8"
      unitRef="usd">-18083000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtNS0xLTEtNDIzNjc_2c6810eb-929b-4d3b-9a6b-edd8f4262e0a"
      unitRef="usd">-16422000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTYtNy0xLTEtNDIzNjc_37cd46e1-85b3-4dab-894a-46aa4f49f6e6"
      unitRef="usd">-25664000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctMS0xLTEtNDIzNjc_04cac45a-c07f-491f-9415-7f154be1ff87"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctMy0xLTEtNDIzNjc_fc89585b-a28b-4c61-acb6-b39ac3ff68b9"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctNS0xLTEtNDIzNjc_155c0897-d948-430b-858e-381f0cbf7736"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTctNy0xLTEtNDIzNjc_29fbbc98-6bac-47c6-bf92-7ca2f949b05b"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtMS0xLTEtNDIzNjc_c5b37227-2a9c-4b66-9064-f9b7cce3a2d2"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtMy0xLTEtNDIzNjc_7623328b-b2de-474b-a981-7fa9cad3387f"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtNS0xLTEtNDIzNjc_4f5ad4a6-f67a-4eaf-b123-80700bc6e28b"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMTgtNy0xLTEtNDIzNjc_286e0eeb-c4d1-4747-9360-de2de739f950"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtMS0xLTEtNDIzNjc_d3ba94be-ba4d-49c7-8e8f-a50e0e4dabc0"
      unitRef="shares">70217985</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtMy0xLTEtNDIzNjc_b196dffb-c6bc-439b-b0a3-818ce27ca9f8"
      unitRef="shares">49533956</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtNS0xLTEtNDIzNjc_005ecc98-b91b-48b7-91c6-540e9541c0a4"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjAtNy0xLTEtNDIzNjc_d8d17f0f-0691-402d-a03e-b8114d616389"
      unitRef="shares">48402095</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtMS0xLTEtNDIzNjc_7b19a23c-87c8-4c45-9e84-0555268510d6"
      unitRef="shares">88592568</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtMy0xLTEtNDIzNjc_e4a20d25-0f28-455d-a411-26a96cb2e994"
      unitRef="shares">49533956</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtNS0xLTEtNDIzNjc_a554538e-82e1-450b-ac5a-584c8b10b5a5"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8xOS9mcmFnOmE3ZGRhOTQwNWEyZDRhMWJiYTM0ZTZmMWVlZmQxNzgzL3RhYmxlOmJjMGE1NmY0MWNjNDQ5Yzk5ZDc1ZjVlYjIzZWQ2ZGQ2L3RhYmxlcmFuZ2U6YmMwYTU2ZjQxY2M0NDljOTlkNzVmNWViMjNlZDZkZDZfMjEtNy0xLTEtNDIzNjc_f9775731-d8d8-4b97-8fe0-9642f0215a6e"
      unitRef="shares">48402095</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMy0xLTEtMS00MjM2Nw_7ffa5daa-3c83-4118-bcd7-aac46156998c"
      unitRef="usd">-16422000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMy0zLTEtMS00MjM2Nw_699eb247-9aa7-417c-80cd-4bf69b4d779d"
      unitRef="usd">-25664000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNS0xLTEtMS00MjM2Nw_39c61ee3-c2dd-45a7-b20d-98b03c8a0498"
      unitRef="usd">2859000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNS0zLTEtMS00MjM2Nw_d554c854-3d0d-42bf-8b99-b17638fdbe30"
      unitRef="usd">2651000</us-gaap:ShareBasedCompensation>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0xLTEtMS00MzQ4Mg_856dc14a-0c93-48ad-ad91-34b00fcdc4a3"
      unitRef="usd">1772000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0zLTEtMS00MzQ4Mg_23b07f18-be7e-4f76-8394-2da2dcf0c735"
      unitRef="usd">0</us-gaap:CapitalizedContractCostAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0xLTEtMS00MzQwMw_9501eb89-611d-4037-a889-09386f0b5f27"
      unitRef="usd">796000</cdtx:OperatingLeaseRightOfUseAmortization>
    <cdtx:OperatingLeaseRightOfUseAmortization
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0zLTEtMS00MzQwMw_76dd04f0-3720-48ef-a4b3-8775f7ed5497"
      unitRef="usd">669000</cdtx:OperatingLeaseRightOfUseAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0xLTEtMS00MjM2Nw_65e7493e-87f2-4bdf-bdda-f59580e8c395"
      unitRef="usd">114000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNi0zLTEtMS00MjM2Nw_b7f582ff-e60e-47d9-900d-8216af046049"
      unitRef="usd">152000</us-gaap:DepreciationAndAmortization>
    <us-gaap:PaidInKindInterest
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0xLTEtMS00MjM2Nw_f7933b85-2085-4e4d-86cc-d4a8f1f23c5d"
      unitRef="usd">1000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNy0zLTEtMS00MjM2Nw_527bcb6d-6920-4dfc-a63e-712d8e059364"
      unitRef="usd">10000</us-gaap:PaidInKindInterest>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfOC0xLTEtMS00MjM2Nw_dc545046-d617-4dfb-859e-76b8db0513b7"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfOC0zLTEtMS00MjM2Nw_70723ba7-c019-4630-8d93-44db3c283b1d"
      unitRef="usd">2000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTEtMS0xLTEtNDIzNjc_3e701712-0e5e-4d8e-abdd-c1c4d29c3bed"
      unitRef="usd">-314000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTEtMy0xLTEtNDIzNjc_9af47669-97ed-4ccc-aef0-ef742dc7c9ff"
      unitRef="usd">-7303000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTItMS0xLTEtNDIzNjc_d7a937e1-e662-409c-b52e-9b9761e377cd"
      unitRef="usd">1662000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTItMy0xLTEtNDIzNjc_5c8ed821-c88f-471d-9458-5317e99e59f1"
      unitRef="usd">-713000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTMtMS0xLTEtNDIzNjc_ccf55b14-124e-496f-abc5-a6b45fd71c99"
      unitRef="usd">-1037000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTMtMy0xLTEtNDIzNjc_b4e44674-ec83-47ed-b5fd-3c1f158e8628"
      unitRef="usd">-811000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTQtMS0xLTEtNDIzNjc_d5892b7b-accb-415c-9588-7ea3b031a502"
      unitRef="usd">-670000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTQtMy0xLTEtNDIzNjc_3474fd7f-6fda-473a-a5d3-d46ce5823793"
      unitRef="usd">6000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTUtMS0xLTEtNDIzNjc_fe1d7cef-f1b9-46c1-ac16-dbc7a61f6de0"
      unitRef="usd">7314000</cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTUtMy0xLTEtNDIzNjc_690c86f6-4a95-46d6-b259-06e29b3a2a7b"
      unitRef="usd">5274000</cdtx:IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTYtMS0xLTEtNDIzNjc_4cdf9c6c-8fa1-4f29-91a3-2215d852aef9"
      unitRef="usd">-850000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTYtMy0xLTEtNDIzNjc_c1af558f-2e45-4e2f-8692-315adef6b687"
      unitRef="usd">-630000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTctMS0xLTEtNDIzNjc_813007e6-21db-484e-aeee-a42ddabca981"
      unitRef="usd">-7471000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMTctMy0xLTEtNDIzNjc_4ea2d4da-d7df-48a9-abc9-fc53c1ebd94b"
      unitRef="usd">-10325000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjAtMS0xLTEtNDIzNjc_a766d77b-c4f4-49e0-8aee-1822eeb28634"
      unitRef="usd">109000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjAtMy0xLTEtNDIzNjc_4b4f7dc2-5cf5-4dfe-837b-8bb83eeceb20"
      unitRef="usd">41000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjEtMS0xLTEtNDIzNjc_ce701b2d-4fb9-4820-a5e6-90247bfc0f51"
      unitRef="usd">-109000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjEtMy0xLTEtNDIzNjc_60d03f68-7b5d-4a66-a820-12d2e43cad68"
      unitRef="usd">-41000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjUtMS0xLTEtNDIzNjc_b770e116-a7ec-46bb-b847-6576d9ca6bd4"
      unitRef="usd">1698000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjUtMy0xLTEtNDIzNjc_d2677185-b2d0-4389-ac04-4b4b23f7a528"
      unitRef="usd">11049000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjYtMS0xLTEtNDIzNjc_8db47348-0d1c-4cec-b4c2-0b3dbfe15fb7"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjYtMy0xLTEtNDIzNjc_6ba0ed48-594f-48ac-ad28-4b74cbe4f4d1"
      unitRef="usd">6000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjctMS0xLTEtNDIzNjc_e039df7a-25a9-47fc-83ec-2a68349586a6"
      unitRef="usd">720000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjctMy0xLTEtNDIzNjc_a38e8d36-eb31-4214-b7c9-a86e8b55963b"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjgtMS0xLTEtNDIzNjc_6f31b541-c556-4452-97ae-e0d88d712ec0"
      unitRef="usd">2593000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjgtMy0xLTEtNDIzNjc_ea7d9ce2-e272-4f72-9209-77dcdf476cc9"
      unitRef="usd">3333000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjktMS0xLTEtNDIzNjc_a8a01bc1-44ba-4e1f-b6fb-778acd67bfb5"
      unitRef="usd">-1615000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMjktMy0xLTEtNDIzNjc_7f0926e6-4a59-4e78-a68b-910fbafb17c0"
      unitRef="usd">7722000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzAtMS0xLTEtNDIzNjc_00ce9262-97cb-460e-8344-e27a9bfa9ebb"
      unitRef="usd">-9195000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzAtMy0xLTEtNDIzNjc_31110cca-3b50-4fbb-b1d3-b34d2e7bbd66"
      unitRef="usd">-2644000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzEtMS0xLTEtNDIzNjc_38345cac-cf88-422f-b7bf-8e83ecf4a22e"
      unitRef="usd">62273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1541d551c68f4ed2b3a7797a2421af03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzEtMy0xLTEtNDIzNjc_e9cf67dd-60ba-4097-8bf5-8cdda3bbe17f"
      unitRef="usd">42949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzItMS0xLTEtNDIzNjc_e4caab9a-e465-43f3-9a0f-1caf894047db"
      unitRef="usd">53078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1a6f6259262c4efcb61b27512dc283e6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzItMy0xLTEtNDIzNjc_908f0865-977c-4fc5-b908-30b2c67c9773"
      unitRef="usd">40305000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzUtMS0xLTEtNDIzNjc_568d5d9b-ef1e-4ac9-98fc-adfaee18617f"
      unitRef="usd">40000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzUtMy0xLTEtNDIzNjc_d42c1f76-1eed-45e1-9c61-70ce73e5defd"
      unitRef="usd">190000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzgtMS0xLTEtNDIzNjc_587830e3-1e91-4732-bb46-c070fd327509"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfMzgtMy0xLTEtNDIzNjc_e4cb2ae8-9ece-43a3-b536-2822bc08c044"
      unitRef="usd">2341000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDAtMS0xLTEtNDIzNjc_e7c84200-682f-4efd-904b-19ab4f34a667"
      unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDAtMy0xLTEtNDIzNjc_b3e6517c-bf0c-4524-b160-9b8a1c0d1406"
      unitRef="usd">252000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDEtMS0xLTEtNDIzNjc_0c61e215-7103-4127-a9a3-7a5301b3a5b6"
      unitRef="usd">10000</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets>
    <cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDEtMy0xLTEtNDIzNjc_1a0e531a-593a-4562-b307-c6a8baeeb2b2"
      unitRef="usd">0</cdtx:ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDMtMS0xLTEtNDI1MzI_4fa81166-1da3-4ebd-b038-a2087ba914e0"
      unitRef="usd">0</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yMi9mcmFnOjcxNzhkNDAxMjY4NjRhM2Q4Y2JjMmRjOTQ0Zjc5NDA4L3RhYmxlOjMzN2UzZGNkNmJiODQyYjA4ODRiMTM4N2NkMTlmZGQxL3RhYmxlcmFuZ2U6MzM3ZTNkY2Q2YmI4NDJiMDg4NGIxMzg3Y2QxOWZkZDFfNDMtMy0xLTEtNDI1MzI_401fa832-5dd0-48b0-bbe8-49df5ee9d934"
      unitRef="usd">64000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i42a96ee88a724103bd21dea2ce351a6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0yLTEtMS00MjM2Nw_d08c4859-adb6-4f16-8209-7c7f0e0ebbe4"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i42a96ee88a724103bd21dea2ce351a6b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy00LTEtMS00MjM2Nw_ee41e5c5-4a20-4d4a-a9f6-b7f855929e25"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8bdf276fab234f5793b92dd0eab61737_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy02LTEtMS00MjM2Nw_bac1fc5c-9893-4c52-b3ea-54f7aee0cff0"
      unitRef="shares">67863674</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8bdf276fab234f5793b92dd0eab61737_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy04LTEtMS00MjM2Nw_56269de5-3526-4477-944d-cea5f80b9f16"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cb92875f7444accb8df71f69d1e6823_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0xMC0xLTEtNDIzNjc_58303de9-f35d-4485-883f-a0198f40e99e"
      unitRef="usd">398733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i098de05c0a73424893e619674f8ede0d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0xMi0xLTEtNDIzNjc_ecae09f8-d4b6-46df-9d41-c54f440c0766"
      unitRef="usd">-377167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMy0xNi0xLTEtNDIzNjc_40755ac3-767b-4e48-80cc-94d086df85fe"
      unitRef="usd">21573000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i439485f4e8e2471190cf787925ce765f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfNi02LTEtMS00MjM2Nw_3c3bad82-0c0d-47de-969f-1fec56e9ffe7"
      unitRef="shares">644265</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id549c6dc162445b0a8b51e25ba53845f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfNi0xMC0xLTEtNDIzNjc_0ae5b416-54c2-4b32-a922-b197d2f148f3"
      unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfNi0xNi0xLTEtNDIzNjc_4959a338-7a69-43be-bf68-83e45b75dd5b"
      unitRef="usd">500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i439485f4e8e2471190cf787925ce765f_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfOC02LTEtMS00MjM2Nw_1afa0593-bb81-4cab-b282-83d7622a8823"
      unitRef="shares">541308</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="id549c6dc162445b0a8b51e25ba53845f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfOS0xMC0xLTEtNDIzNjc_7b0920ba-844e-4014-b496-e5aa7a5a65bd"
      unitRef="usd">1165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfOS0xNi0xLTEtNDIzNjc_b9b4459a-40ab-417c-be27-6eaf40b5cf8d"
      unitRef="usd">1165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="ie8bf3279b1814f298a5a4e543dffe461_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTAtMTItMS0xLTQyMzY3_f90094a9-0c52-4315-81e1-b3a2c86da187"
      unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie27d9f024187488a8f2739c2c86c0122_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTAtMTYtMS0xLTQyMzY3_3736b5cc-1ee4-4683-a525-cae716c1bc50"
      unitRef="usd">-18281000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3ddfea5cb5ac4dbba5969c5c32dc405f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMi0xLTEtNDIzNjc_5305ef2f-0222-45d5-8f44-57f06d4d1ba0"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3ddfea5cb5ac4dbba5969c5c32dc405f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtNC0xLTEtNDIzNjc_b5d7e936-5c4d-4682-baa2-8b3c23d6b58f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idcfbfe674ada4806903f264b16edff10_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtNi0xLTEtNDIzNjc_7eebcd3a-3760-4a9b-83e7-3c9f5b0a1ca7"
      unitRef="shares">69049247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idcfbfe674ada4806903f264b16edff10_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtOC0xLTEtNDIzNjc_ac209f9c-5210-47dc-9423-d6996098aede"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3fd27b6890e4826a59b299ceb905038_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMTAtMS0xLTQyMzY3_33f2d029-e580-4c29-ae1d-d9e887cd84d6"
      unitRef="usd">400398000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i160c27cee64e434eabaaa10605b89946_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMTItMS0xLTQyMzY3_52c218e6-bda7-4a16-bf04-a73005e79769"
      unitRef="usd">-395448000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cb81e64d8f846e1b7b1aedc4305a63b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTEtMTYtMS0xLTQyMzY3_bf4ffbfc-68a8-4ff0-9dbc-a5a28b1ca498"
      unitRef="usd">4957000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="idc647f0b1f5d4ee99cd69cc22038ac7b_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTYtNi0xLTEtNDIzNjc_d41fc9e6-1743-432d-8917-31878c31238a"
      unitRef="shares">5042</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idc647f0b1f5d4ee99cd69cc22038ac7b_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTctNi0xLTEtNDIzNjc_258b7846-4394-4605-8590-86ea8bb933f9"
      unitRef="shares">184219</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i70591917e30b4422865fea663b0f796f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTctMTAtMS0xLTQyMzY3_12b387e9-cf01-498a-b076-0ef5d847ce3c"
      unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTctMTYtMS0xLTQyMzY3_3897fb80-2ccd-4083-8571-fa7f43aeb705"
      unitRef="usd">69000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i70591917e30b4422865fea663b0f796f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTgtMTAtMS0xLTQyMzY3_9c99c0b7-d11c-47a3-b0bc-cc47000db808"
      unitRef="usd">852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTgtMTYtMS0xLTQyMzY3_2b0fac4f-a63f-4579-8148-ab4fa8625368"
      unitRef="usd">852000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i70591917e30b4422865fea663b0f796f_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTktMTAtMS0xLTQyMzY3_42a4f2e4-b21e-4eed-a5e8-b5fecbecb896"
      unitRef="usd">720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMTktMTYtMS0xLTQyMzY3_4e217383-d4f8-4d03-b05a-2982c9cc4042"
      unitRef="usd">720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="i5122efa490e14a07b68b1661470c2d68_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjAtMTItMS0xLTQyMzY3_a4a78b1a-c98f-4588-8fc5-e150a9b51c1c"
      unitRef="usd">-13119000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3a186807702543a3b16705ccfa44e627_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjAtMTYtMS0xLTQyMzY3_694c7127-56d1-4aaf-bc68-ae6fb2014287"
      unitRef="usd">-13119000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i26800230236f4cc9bc3aac4ee89d9783_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMi0xLTEtNDIzNjc_3e9518dc-aa76-439d-8d6f-4774b99db1f9"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i26800230236f4cc9bc3aac4ee89d9783_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtNC0xLTEtNDIzNjc_45e655d4-df67-4c8f-894a-3608af22717d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if1a3f0c9c39f4de6bf503a1bbe64da16_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtNi0xLTEtNDIzNjc_5e4231f4-5e14-43d9-8edb-44fc1458650b"
      unitRef="shares">69238508</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if1a3f0c9c39f4de6bf503a1bbe64da16_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtOC0xLTEtNDIzNjc_47a5642b-f775-42be-9b23-4b9b313b82fd"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib82d7061381343cf8fd9d02f13182140_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMTAtMS0xLTQyMzY3_e4c0fe1a-f8cf-44f2-ae80-09b284faeea9"
      unitRef="usd">400599000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i956248bf259a4879bbb53a8a82a26ec7_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMTItMS0xLTQyMzY3_972dcf9a-afd4-45d0-b68f-2caf9c1bc98d"
      unitRef="usd">-408567000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2a529f48c1e14479a8bac0af6684dfed_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjEtMTYtMS0xLTQyMzY3_fb5b35ef-b3df-41bf-ab39-b0e26d53c28e"
      unitRef="usd">-7961000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="iba7ab5417525497fb3acb2513449bdd2_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjQtNi0xLTEtNDIzNjc_205d533e-416c-46b9-9ee4-d5ed1f0a3538"
      unitRef="shares">1664170</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idb414282b9dc4b85bc63049a4f25a84f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjQtMTAtMS0xLTQyMzY3_9fabd33d-11fb-4ba8-a3de-9e5447decd7f"
      unitRef="usd">1208000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjQtMTYtMS0xLTQyMzY3_ee60e396-b373-445f-aa87-bc70936cbf6b"
      unitRef="usd">1208000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iba7ab5417525497fb3acb2513449bdd2_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjYtNi0xLTEtNDIzNjc_89b793eb-e598-4bee-ae57-3752d5280163"
      unitRef="shares">278519</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="idb414282b9dc4b85bc63049a4f25a84f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjctMTAtMS0xLTQyMzY3_7d9b928d-54de-4f3e-bb19-997dc8425a83"
      unitRef="usd">842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjctMTYtMS0xLTQyMzY3_a8d24193-64e9-4b5a-8125-f0b5f3709bb3"
      unitRef="usd">842000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="i31de05b5ec874e73a1ec0902444ca46e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjgtMTItMS0xLTQyMzY3_9ae52d06-598d-4891-a52e-5a81baad5459"
      unitRef="usd">14978000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjgtMTYtMS0xLTQyMzY3_c58898f5-1fb6-448c-922f-e99e8ef30799"
      unitRef="usd">14978000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i109b1669ef4d446f8220b8cba5c0ae2e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMi0xLTEtNDIzNjc_b37af4f9-da53-4c36-90b8-7fd7eccd4867"
      unitRef="shares">1818472</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i109b1669ef4d446f8220b8cba5c0ae2e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktNC0xLTEtNDIzNjc_5f3c0cb5-8be0-4e45-8128-e9d782b01d0d"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3dea2fc105bf4d31866b9f83d65b2932_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktNi0xLTEtNDIzNjc_3084870a-2c5a-4512-a0fe-3f058678f756"
      unitRef="shares">71181197</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3dea2fc105bf4d31866b9f83d65b2932_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktOC0xLTEtNDIzNjc_d0af73eb-ad1a-48ee-b00c-af53b301a8d7"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icf881d2c650347459458b36b03ca94d0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMTAtMS0xLTQyMzY3_f59110bb-945c-4ae5-8cf4-aea4c661a794"
      unitRef="usd">402649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i864469b8adce4fbb956b05333e046b7e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMTItMS0xLTQyMzY3_305d5d3a-5f54-40b5-8f52-e94b6dc01167"
      unitRef="usd">-393589000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOmY0NDM1MjdiODViOTQ4ZDU5NTIzYWZjODk5ZTdmMTIwL3RhYmxlcmFuZ2U6ZjQ0MzUyN2I4NWI5NDhkNTk1MjNhZmM4OTllN2YxMjBfMjktMTYtMS0xLTQyMzY3_2f379e03-ea8b-4362-80d8-41cd0be2599a"
      unitRef="usd">9067000</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i693eb172a4d347d0b0a8944c52cb7b00_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0yLTEtMS00MjM2Nw_81dd1989-ad7c-44cf-8de8-8b69e8ab747a"
      unitRef="shares">1044278</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i693eb172a4d347d0b0a8944c52cb7b00_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy00LTEtMS00MjM2Nw_323a9ae1-e8e7-4fc1-9b90-64660752dbc4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5738d3cb61f1420b9d7309c2a207e112_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy02LTEtMS00MjM2Nw_924a1a0d-39e2-4623-a7b0-23be92598888"
      unitRef="shares">44876408</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5738d3cb61f1420b9d7309c2a207e112_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy04LTEtMS00MjM2Nw_abafdea8-b0c4-4ef1-9dec-418f5bbe44cd"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i94201b3baa82482bbac00a56f5e155fd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0xMC0xLTEtNDIzNjc_292992d4-39ed-4c39-a98c-1aeb71b89772"
      unitRef="usd">345411000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idd091b6d62174e4d8d75ae1cf5dc7c1a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0xMi0xLTEtNDIzNjc_293ee1a2-385a-4d25-98bb-d3562afd53a6"
      unitRef="usd">-334700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1541d551c68f4ed2b3a7797a2421af03_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMy0xNi0xLTEtNDIzNjc_84cef082-006f-451d-91f5-48b676b68e9e"
      unitRef="usd">10715000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi02LTEtMS00MjM2Nw_5dae4945-3d4b-41fb-a0eb-2233a0313b43"
      unitRef="shares">3327706</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi04LTEtMS00MjM2Nw_bdd4bece-529e-4659-bd24-20e0e178e8f9"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic0d525f23739440fbefcb160732067b9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi0xMC0xLTEtNDIzNjc_7c3fe6aa-1ec2-4d50-bb14-d54a77b881f6"
      unitRef="usd">8588000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNi0xNi0xLTEtNDIzNjc_9355d67c-a448-4186-9fff-bd8955d46715"
      unitRef="usd">8589000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNy02LTEtMS00MjM2Nw_a577f08c-e501-4a60-bf27-56a3aacf037e"
      unitRef="shares">486</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic0d525f23739440fbefcb160732067b9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNy0xMC0xLTEtNDIzNjc_093d938f-3332-43a5-a95c-3d900c887ed4"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfNy0xNi0xLTEtNDIzNjc_28377a17-afb8-4e66-aecf-455850240bb9"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i2654fc2a4fcd482787080addea259ea4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfOC02LTEtMS00MjM2Nw_97019a3b-b911-4ff6-998d-21e6759cf705"
      unitRef="shares">84070</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ic0d525f23739440fbefcb160732067b9_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfOS0xMC0xLTEtNDIzNjc_dd800bc4-689d-4243-87b2-92a47651a7cb"
      unitRef="usd">879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfOS0xNi0xLTEtNDIzNjc_812356db-5602-4276-81c0-efb57aa8a16d"
      unitRef="usd">879000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="ibc56da2da39740feb3ec19fc507a66e8_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTAtMTItMS0xLTQyMzY3_7aee7e9c-a078-4412-a590-7054fe210a1a"
      unitRef="usd">-18292000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i891ad55377db46c8bcfe6cd0c72c0273_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTAtMTYtMS0xLTQyMzY3_259f7bef-1295-4659-9945-3d389dad72ed"
      unitRef="usd">-18292000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i07c2a73a148b485f89fc5f997009213f_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMi0xLTEtNDIzNjc_08b2e9cc-f470-4af1-885f-c6fc7a72b45d"
      unitRef="shares">1044278</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i07c2a73a148b485f89fc5f997009213f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtNC0xLTEtNDIzNjc_2635b74a-d111-4a81-9306-6e3ef3fe17f7"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if133fdbf28ba4b219f3f376b31de78bf_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtNi0xLTEtNDIzNjc_349131cc-9284-4997-9d7a-1a586a35e44e"
      unitRef="shares">48288670</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if133fdbf28ba4b219f3f376b31de78bf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtOC0xLTEtNDIzNjc_800576a8-fd2e-40fc-9e8c-ee2223730c1f"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic6911289ff2c4b749f20e55b06a07c49_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMTAtMS0xLTQyMzY3_f36fe1e3-e190-4bee-8ea9-e827f4473f90"
      unitRef="usd">354879000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87017a31f5664b1b9432ba825c9cffd3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMTItMS0xLTQyMzY3_cbf28bb4-5098-4a7e-8b57-b00f026bcd86"
      unitRef="usd">-352992000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7c805b66507a4ce5a2a3ea7b4ce88a7c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTEtMTYtMS0xLTQyMzY3_061ddf80-cf83-431c-994a-1a7ba753f8be"
      unitRef="usd">1892000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTItNi0xLTEtNDIzNjc_e0ad3655-f874-46c5-9964-6e05b0fbb041"
      unitRef="shares">1050928</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTItMTAtMS0xLTQyMzY3_c912a864-9e45-4fb7-ab22-4dcb51621270"
      unitRef="usd">2058000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTItMTYtMS0xLTQyMzY3_f193bc90-5a2f-4735-9969-9ba87a0b4624"
      unitRef="usd">2058000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTMtNi0xLTEtNDIzNjc_c88d6927-3445-419a-95b9-bd181320e771"
      unitRef="shares">2444</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTMtMTAtMS0xLTQyMzY3_d06aed50-1dca-4ee3-b254-bf478cf4494e"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTMtMTYtMS0xLTQyMzY3_52c32994-162e-4ed5-ad0a-fbd3b1b32847"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTQtNi0xLTEtNDIzNjc_e7d7195a-d6ad-441d-a7b6-27dc19265a76"
      unitRef="shares">18530</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i8ef7074c446f4b1e8dc8d6eb439bed8e_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTUtNi0xLTEtNDIzNjc_f81775de-4f53-4d7b-ba61-d892326101f3"
      unitRef="shares">145696</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTUtMTAtMS0xLTQyMzY3_1d8dc775-8a47-4cea-be76-895f00e7fdf8"
      unitRef="usd">252000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTUtMTYtMS0xLTQyMzY3_03574b80-4802-4c4b-bb63-16108eece205"
      unitRef="usd">252000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i9e27bb397ff54773ad04f0e2a7358931_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTYtMTAtMS0xLTQyMzY3_312bc336-7de3-4cdb-a7dd-daf8182b2f72"
      unitRef="usd">871000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTYtMTYtMS0xLTQyMzY3_620b2810-50ba-4c61-88ce-67c20ee8373b"
      unitRef="usd">871000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="i4453b17a58014dc49d268e838656cf76_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTctMTItMS0xLTQyMzY3_f4ef645f-1361-4007-b4c8-e88651548c10"
      unitRef="usd">10711000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id436a614bbc4407580ad8a47424abedc_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTctMTYtMS0xLTQyMzY3_bfe35f88-f7e8-4026-a215-ee28c44ccedc"
      unitRef="usd">10711000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i40678b795d7a4f77b2887ee7e28b9d6b_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMi0xLTEtNDIzNjc_4caf6bbd-6f3b-439f-9ae3-f1227e65708b"
      unitRef="shares">1044278</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i40678b795d7a4f77b2887ee7e28b9d6b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtNC0xLTEtNDIzNjc_e09dde7b-22c9-45f0-b816-89b99e7a71ca"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ica9486a33c544927bc063333539cd357_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtNi0xLTEtNDIzNjc_5aa3b9a0-9d42-47ec-841f-89827f85e047"
      unitRef="shares">49506268</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ica9486a33c544927bc063333539cd357_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtOC0xLTEtNDIzNjc_a53245b3-060f-4e8f-9a21-93834e40f8db"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc5f7c9d49964f0c9dd7ecb39b9e7a9a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMTAtMS0xLTQyMzY3_b42a1ed0-1ae3-4a04-be1e-a97f21b990ad"
      unitRef="usd">358065000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i89f47ece2c56488f873e04e2b611b0a9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMTItMS0xLTQyMzY3_538b7e77-3f3c-42b5-9e3a-9bc6958d17a4"
      unitRef="usd">-342281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib177b93cb8ec46ba81e03a7d526bc97b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTgtMTYtMS0xLTQyMzY3_9f9eaae2-c0d2-4b67-a5fd-3b6690d88985"
      unitRef="usd">15789000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7d7d33deac174ca1acff18720307d200_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTktNi0xLTEtNDIzNjc_3bd2158e-778e-4fb4-b4ad-3067f178fc99"
      unitRef="shares">113400</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5347a69850cb4e3a9c600e3f046564c5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTktMTAtMS0xLTQyMzY3_095cb1a2-664d-40a7-b6c4-a77eb8728f8c"
      unitRef="usd">235000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMTktMTYtMS0xLTQyMzY3_b1f2c3bd-914c-4206-811c-8fd0f20f8354"
      unitRef="usd">235000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i7d7d33deac174ca1acff18720307d200_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjItNi0xLTEtNDIzNjc_8fa475a3-1ae8-4e8f-bb97-c8866d47433c"
      unitRef="shares">1875</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="i5347a69850cb4e3a9c600e3f046564c5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjMtMTAtMS0xLTQyMzY3_d23db4c1-9ad5-4cb9-9e91-863067eef05d"
      unitRef="usd">901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjMtMTYtMS0xLTQyMzY3_78ee9a12-a412-4994-aff5-f70e4cad9e3d"
      unitRef="usd">901000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="id376015bef2f4799bc27e985203d46bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjQtMTItMS0xLTQyMzY3_1c1f33e8-b99c-47e4-ab30-a3526575f411"
      unitRef="usd">-18083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjQtMTYtMS0xLTQyMzY3_003f9738-b95a-43ac-9504-74700c5dda48"
      unitRef="usd">-18083000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i60d1ea8a7959445a95096c4b864be06d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMi0xLTEtNDIzNjc_62b25723-fbeb-4ad3-a227-c2d5877a83d4"
      unitRef="shares">1044278</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i60d1ea8a7959445a95096c4b864be06d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtNC0xLTEtNDIzNjc_265a4f97-7446-417c-9a9d-addf77125d95"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i818d0f7b825449cda1e49ae8b91e0960_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtNi0xLTEtNDIzNjc_85482cde-8b03-4a14-9e43-9b8f96eac4a2"
      unitRef="shares">49621543</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i818d0f7b825449cda1e49ae8b91e0960_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtOC0xLTEtNDIzNjc_50fdd2d5-ba85-4f97-938d-857225bb0edd"
      unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i94ee68c9bbb94758b8465a6d2c6abd10_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMTAtMS0xLTQyMzY3_ba20f416-757c-423a-9fb7-6a473371ac94"
      unitRef="usd">359201000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id1d162d88a05494b9a13cdb4bb8b29d6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMTItMS0xLTQyMzY3_9c55ff95-0616-4e10-b329-f7164f44df60"
      unitRef="usd">-360364000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1a6f6259262c4efcb61b27512dc283e6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8yNS9mcmFnOjY3ZjQ1OGUyNGIxYzRiN2RhYzY3M2QzNDM1NTAzMGRkL3RhYmxlOjcyNTBmNWNhMmI4MzQ1MDc5MjE2NThjMDRkZDIzZjY1L3RhYmxlcmFuZ2U6NzI1MGY1Y2EyYjgzNDUwNzkyMTY1OGMwNGRkMjNmNjVfMjUtMTYtMS0xLTQyMzY3_25fb5ee5-5ffc-46d4-a205-231b83d041a7"
      unitRef="usd">-1158000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgxMg_5ca039d6-dc60-48f8-be71-061ad6cf5f55">THE COMPANY AND BASIS OF PRESENTATION&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cidara Therapeutics, Inc., or the Company, was originally incorporated in Delaware in December 2012 as K2 Therapeutics, Inc., and its name was changed to Cidara Therapeutics, Inc. in July 2014. The Company is a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to transform the standard of care for patients facing serious diseases. The Company is focused on infectious diseases and oncology. The Company&#x2019;s lead product candidate is rezafungin acetate, an intravenous formulation of a novel echinocandin antifungal. Rezafungin is being developed as a once-weekly, high-exposure therapy for the first-line treatment and prevention of serious, invasive fungal infections. In addition, the Company is using its Cloudbreak&#xae; platform to develop a potential new class of drugs called drug-Fc conjugates, or DFCs, for the prevention and treatment of serious diseases. This technology couples potent inhibitors to a human antibody fragment to create long-acting DFCs designed to inhibit multiple disease targets. The Company's most advanced DFC program is CD388, a highly potent, long-acting antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. Additional programs are targeting the SARS-CoV-2 strains causing COVID-19 and multiple solid tumor oncology indications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company formed wholly-owned subsidiaries, Cidara Therapeutics UK Limited, in England, and Cidara Therapeutics (Ireland) Limited, in Ireland, in March 2016 and October 2018, respectively, for the purpose of developing its product candidates in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At September&#160;30, 2022, the Company had an accumulated deficit of $393.6 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, the Company had cash and cash equivalents of $53.1 million. Based on the Company&#x2019;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s obligations for twelve months from the issuance of these financial statements. The Company&#x2019;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#x2019;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to estimating the fair value of the Company&#x2019;s stock options, estimated collaboration expenses and incurred expenses related to the Company's collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company's collaboration and license agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgyMA_c0eccd48-9772-4567-86f7-3424b9eda3d0">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. The Company has experienced net losses and negative cash flows from operating activities since its inception. At September&#160;30, 2022, the Company had an accumulated deficit of $393.6 million. The Company expects to continue to incur net losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, the Company had cash and cash equivalents of $53.1 million. Based on the Company&#x2019;s current business plan, management believes that existing cash and cash equivalents will not be sufficient to fund the Company&#x2019;s obligations for twelve months from the issuance of these financial statements. The Company&#x2019;s ability to execute its operating plan depends on its ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business. However, the Company&#x2019;s current working capital, anticipated operating expenses and net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that these financial statements are issued. The condensed consolidated financial statements do not include any adjustments for the recovery and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third party funding, and potential licensing or collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to the Company. Even if the Company raises additional capital, it may also be required to modify, delay or abandon some of its plans which could have a material adverse effect on the Company&#x2019;s business, operating results and financial condition and the Company&#x2019;s ability to achieve its intended business objectives. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In addition to the foregoing, the Company is monitoring closely the impact of the COVID-19 pandemic on its business and has taken steps designed to protect the health and safety of its employees while continuing its operations. Given the level of uncertainty regarding the duration and impact of the COVID-19 pandemic on capital markets and the United States, or U.S., economy, the Company is currently unable to assess the impact of the COVID-19 pandemic on its future access to capital. The Company is continuing to monitor the spread of COVID-19 and its potential impact on the Company's operations. The full extent to which the COVID-19 pandemic will impact the Company's business, results of operations, &lt;/span&gt;&lt;/div&gt;financial condition, clinical trials, and preclinical research will depend on future developments that are highly uncertain, including actions taken to contain or treat COVID-19 and their effectiveness, as well as the economic impact on national and international markets.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfMTg0Mw_16ddd025-5188-43cb-b9d3-e8f01a3bcb22"
      unitRef="usd">-393600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfMjE1Mg_d721119b-3196-4af9-8a8d-759f6716614c"
      unitRef="usd">53100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <cdtx:UnauditedInterimFinancialDataPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgwOQ_2d536841-0239-4254-8ff7-4a21f62aa54f">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Data&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements are unaudited and have been prepared by the Company in accordance with U.S. generally accepted accounting principles, or GAAP, as found in the Accounting Standards Codification, or ASC, of the Financial Accounting Standards Board, or FASB.&#160;Certain information and footnote disclosures normally included in the Company&#x2019;s annual financial statements have been condensed or omitted. These interim condensed consolidated financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</cdtx:UnauditedInterimFinancialDataPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgyOQ_0a96f892-b20f-44cf-821a-847eda6a1138">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgwNA_0d67af6e-f820-4ee1-bd71-af4c390c8a95">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company&#x2019;s condensed consolidated financial statements relate to estimating the fair value of the Company&#x2019;s stock options, estimated collaboration expenses and incurred expenses related to the Company's collaboration and license agreements, certain accruals, including those related to nonclinical and clinical activities, and the stand-alone selling price of performance obligations associated with the Company's collaboration and license agreements. Although the estimates are based on the Company&#x2019;s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzgwNQ_7da9e192-351e-4615-9b72-cf693226af22">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, the Chief Executive Officer, in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zMS9mcmFnOjJiZjdlOGJlMjFiNjRjNDZhMjY3OWRiM2UzNjQ3NWRhL3RleHRyZWdpb246MmJmN2U4YmUyMWI2NGM0NmEyNjc5ZGIzZTM2NDc1ZGFfNzc4Mw_ef15ef32-e4b6-4342-8729-4fd250f46a2a"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0OTg_b668e61c-b088-4088-9ebd-6c050e4821a2">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Restricted cash represented cash that the Company was required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 4 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at September&#160;30, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTIzOA_4025d4e0-b32b-4383-8a9a-aee6ae64d94d"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the FASB ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue is accordance with ASC Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company entered into a License Agreement, or the Melinta License Agreement, with Melinta Therapeutics, LLC, or Melinta. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#x2019;s estimates have no impact on the Company&#x2019;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Earnings (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the guidance in FASB ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series X Preferred Stock (see Note 5). Basic net earnings per share is then calculated by dividing income allocable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net earnings per share using the more dilutive of the (1) if-converted method or contingently issuable share method, as applicable, or (2) the two-class method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the if-converted method. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#x2019;s stock option plans. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net earnings (loss) per common share (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(18,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Numerator for basic net earnings (loss) per share - net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(18,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of participating securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Add back allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(18,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Denominator for basic net earnings (loss) per share - common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70,217,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49,533,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48,402,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock, as converted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs, PRSUs, and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;88,592,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49,533,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48,402,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Diluted net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,442,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,442,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,041,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,356,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,086,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,356,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,558,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33,316,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40,788,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33,316,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODk_0e08f6dc-e788-43eb-b1df-52d07c874f1c">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company considers all short-term investments purchased with a maturity of three months or less when acquired to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Restricted cash represented cash that the Company was required to maintain on hand in order to maintain compliance with an operating covenant in the Third Amendment to the Company's Loan Agreement with Pacific Western Bank.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 4 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODM_76121518-abcc-41fa-adb7-05db3c017966">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at their net invoice value and are not interest bearing. The Company reserves specific receivables when collectability is no longer probable. These reserves are re-evaluated on a regular basis and are adjusted, as needed. Once a receivable is deemed to be uncollectable, such balance is recorded as an allowance for credit losses. No such allowance existed at September&#160;30, 2022 or December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MDE_b1adad8d-88f3-42d6-a279-18499371cfb5">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company records property and equipment at cost, which consists of lab equipment, computer equipment and software, office equipment, furniture and fixtures and leasehold improvements.&#160;Property and equipment is depreciated using the straight-line method over the estimated useful lives (generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTIzOA_4025d4e0-b32b-4383-8a9a-aee6ae64d94d"&gt;three&lt;/span&gt; to seven years).&#160;Leasehold improvements are amortized over the lesser of their useful life or the remaining lease term, including any renewal periods that are deemed to be reasonably assured.&#160;Repair and maintenance costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib6abcad7d8034ab09ccfc1455cc8aca2_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTI0NA_5f7f1c9c-5085-4e1e-bf6f-f6ed9becf779">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0NzU_80231646-11cd-4af1-8077-de6333d1cc42">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the FASB ASC 740,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 740, in reporting deferred income taxes. ASC 740 requires a company to recognize deferred tax assets and liabilities for expected future income tax consequences of events that have been recognized in the Company&#x2019;s condensed consolidated financial statements. Under this method, deferred tax assets and liabilities are determined based on temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in the years in which the temporary differences are expected to reverse. Valuation allowances are provided if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions pursuant to ASC 740, which prescribes a recognition threshold and measurement process for financial statement recognition of uncertain tax positions taken or expected to be taken in a tax return. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0NzQ_8b0c51ca-e1e9-48b9-a4ac-121a873f3b3d">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue is accordance with ASC Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or Topic 606, which applies to all contracts with customers, except for elements of certain contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments.&#160;Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services.&#160;To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.&#160;The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.&#160;At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.&#160;The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations. The estimation of the stand-alone selling price(s) may include estimates regarding forecasted revenues or costs, development timelines, discount rates, and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. Any change made to estimated progress towards completion of a performance obligation and, therefore, revenue recognized will be recorded as a change in estimate. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in a contract, the Company recognizes revenues from the transaction price allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from the allocated transaction price. The Company evaluates the measure of progress at each reporting period and, if necessary, adjusts the measure of performance and related revenue or expense recognition as a change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being reached. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company&#x2019;s or a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of milestones that are within its or a collaboration partner&#x2019;s control, such as operational developmental milestones and any related constraint, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which will affect collaboration revenues and earnings in the period of adjustment. Revisions to the Company&#x2019;s estimate of the transaction price may also result in negative collaboration revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties,&#160;including commercial milestone payments based on the level of sales, and a license is deemed to be the predominant item to which the royalties relate, the Company will recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied. To date, the Company has not recognized any royalty revenue from collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a Collaboration and License Agreement, or the Mundipharma Collaboration Agreement, with Mundipharma Medical Company, or Mundipharma. The Company concluded that there were three performance obligations under the Mundipharma Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in September 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company entered into an exclusive worldwide license and collaboration agreement, or the Janssen Collaboration Agreement, with Janssen Pharmaceuticals, Inc., or Janssen, one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson. The Company concluded that there were three performance obligations under the Janssen Collaboration Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in May 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In July 2022, the Company entered into a License Agreement, or the Melinta License Agreement, with Melinta Therapeutics, LLC, or Melinta. The Company concluded that there were three performance obligations under the Melinta License Agreement: the license, the research and development services, and the clinical supply services, and that the obligations are distinct from each other. Revenue associated with the license was recognized upon delivery in August 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company concluded that progress towards completion of the research and development and clinical supply performance obligations related to the Mundipharma Collaboration Agreement and the Melinta License Agreement, is best measured in an amount proportional to the collaboration expenses incurred and the total estimated collaboration expenses. The Company periodically reviews and updates the estimated collaboration expenses, when appropriate, which may adjust revenue recognized for the period. While such changes to the Company&#x2019;s estimates have no impact on the Company&#x2019;s reported cash flows, the amount of revenue recorded in the period could be materially impacted. Revenue from research and development services for the Janssen Collaboration Agreement is recognized based on actual amounts billed as the underlying services are provided and billed at market rates. The transaction prices to be recognized as revenue under both the Mundipharma Collaboration Agreement and the Janssen Collaboration Agreement consist of upfront payments, estimated reimbursable research and development and clinical supply costs, and milestones achieved to date. The transaction price to be recognized as revenue under the Melinta License Agreement consists of an upfront payment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Potential future payments for variable consideration, such as clinical, regulatory or commercial milestones, will be recognized when it is probable that, if recorded, a significant reversal will not take place. Potential future royalty payments will be recorded as revenue when the associated sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;See Note 7 for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="ie8d3b55bd5de40eab1cd422f39bee135_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDM5NA_c2727a6e-9daf-46d4-90fd-085b2f83c824"
      unitRef="obligation">3</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="i39f7d4a95df44e80aad5a7828af660e0_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDQxMg_6d5d355f-5975-4fa9-bebd-90cbf807f055"
      unitRef="obligation">1</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="i3728c48f4fff45e48fd89bdb795841d3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDQwNA_95338466-d888-4e25-ad33-e1a49d29e16f"
      unitRef="obligation">3</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <cdtx:CollaborationAgreementNumberOfPerformanceObligations
      contextRef="ie84641f18b5b49039831316c6a1bf0a1_I20220731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTA5OTUxMTY1MDM4MQ_68dc9fff-dbe9-45f8-95a9-3d381ff94bf0"
      unitRef="obligation">3</cdtx:CollaborationAgreementNumberOfPerformanceObligations>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0Nzc_7dd6f8dc-6ce8-428a-aa23-3ccaf18a1daa">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of wages, benefits and stock-based compensation charges for research and development employees, scientific consultant fees, facilities and overhead expenses, laboratory supplies, manufacturing expenses, and nonclinical and clinical trial costs.&#160;The Company accrues nonclinical and clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Costs incurred in purchasing technology assets and intellectual property are charged to research and development expense if the technology has not been conclusively proven to be feasible and has no alternative future use.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MDk_e790aafc-8076-440f-bd20-c1fce4b2d0ed">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preclinical and Clinical Trial Accruals&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company makes estimates of its accrued expenses as of each balance sheet date in the financial statements based on the facts and circumstances known at that time. Accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred and fees that may be associated with services provided by contract research organizations, or CROs, clinical trial investigational sites and other clinical trial-related activities. Payments under certain contracts with such parties depend on factors such as successful enrollment of patients, site initiation and the completion of clinical trial milestones. In accruing for these services, the Company estimates the time period over which services will be performed and the level of effort to be expended in each period. If possible, the Company obtains information regarding unbilled services directly from these service providers. However, the Company may be required to estimate these services based on other available information. If the Company underestimates or overestimates the activities or fees associated with a study or service at a given point in time, adjustments to research and development expenses may be necessary in future periods. Historically, estimated accrued liabilities have approximated actual expense incurred. Subsequent changes in estimates may result in a material change in accruals.&lt;/span&gt;&lt;/div&gt;</cdtx:PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODU_3bd9cc6e-373a-4d42-9d1d-f29dc235e4bc">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company accounts for stock-based compensation expense related to stock options, restricted stock units, or RSUs, performance-based RSUs, or PRSUs, and Employee Stock Purchase Plan, or ESPP, rights by estimating the fair value on the date of grant. The Company estimates the fair value of stock options granted to employees and non-employees using the Black-Scholes option pricing model. The fair value of RSUs and PRSUs granted to employees is estimated based on the closing price of the Company's common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The assumptions included in the Black-Scholes option pricing model include (a) the risk-free interest rate, (b) the expected volatility of the Company's stock, (c) the expected term of the award, and (d) the expected dividend yield. The Company computed the expected volatility data using the daily close prices for the Company's common stock during the equivalent period of the calculated expected term of the Company's stock-based awards. The Company estimated the expected life of employee stock options using the &#x201c;simplified&#x201d; method, whereby the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods within the expected life of the option are based on the yields of zero-coupon U.S. treasury securities. The expected dividend yield of zero reflects that the Company has not paid cash dividends since inception and do not intend to pay cash dividends in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;For awards subject to time-based vesting conditions, including those with a graded vesting schedule, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees, (i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management believes the performance criteria is probable of being met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures related to stock-based compensation as they occur and any compensation cost previously recognized for awards for which the requisite service has not been completed is reversed in the period that the award is forfeited.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMTQxOTU_301e24d9-adb0-4030-a569-fc23f1d15a86"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MTA_df2a334f-a24e-4a2a-8291-c5c526f5b003">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Earnings (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows the guidance in FASB ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;, or ASC 260, which establishes standards regarding the computation of earnings per share, or EPS, by companies that have issued securities other than common stock that contractually entitle the holder to participate in dividends and earnings of a company. The guidance requires earnings to be hypothetically allocated between the common, preferred, and other participating stockholders based on their respective rights to receive non-forfeitable dividends, whether or not declared. Participating securities include Series X Preferred Stock (see Note 5). Basic net earnings per share is then calculated by dividing income allocable to common stockholders (after the reduction for any preferred stock and assuming current income for the period had been distributed) by the weighted-average number of common shares outstanding for the period. The Company calculates diluted net earnings per share using the more dilutive of the (1) if-converted method or contingently issuable share method, as applicable, or (2) the two-class method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing the net loss allocable to common shares by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss allocable to common shares by the weighted-average number of common shares and dilutive stock equivalents outstanding for the period determined using the if-converted method. Dilutive common stock equivalents are comprised of warrants, Series X Convertible Preferred Stock, RSUs, PRSUs and options outstanding under the Company&#x2019;s stock option plans. In loss periods, basic and diluted net loss per share are identical because the otherwise dilutive potential common shares become anti-dilutive and are therefore excluded.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0ODc_adae7156-8a4f-455f-ba47-760f1a191a46">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted net earnings (loss) per common share (in thousands, except share and per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(18,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(3,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Numerator for basic net earnings (loss) per share - net income (loss) attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(18,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of participating securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Add back allocation of earnings to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;14,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(18,083)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(16,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(25,664)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Denominator for basic net earnings (loss) per share - common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;70,217,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49,533,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48,402,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock, as converted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs, PRSUs, and ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;189,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;88,592,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;49,533,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;69,170,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;48,402,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Basic net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Diluted net earnings (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(0.53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy0xLTEtMS00MjM2Nw_6939b52a-2bf0-4d77-9f73-4cb2f5369ea6"
      unitRef="usd">14978000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy0zLTEtMS00MjM2Nw_90f8034a-befb-48fe-b961-dcc3ebc0a54e"
      unitRef="usd">-18083000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy01LTEtMS00MjM2Nw_9cd06061-0654-4386-b6f2-772a201873cb"
      unitRef="usd">-16422000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMy03LTEtMS00MjM2Nw_597dbc56-5a36-478c-a8fb-f680aa3a34d0"
      unitRef="usd">-25664000</us-gaap:NetIncomeLoss>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC0xLTEtMS00MjM2Nw_e3196023-a2f8-4625-a46b-4b5dc8510a05"
      unitRef="usd">3081000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC0zLTEtMS00MjM2Nw_ea8497dc-1dd3-4974-88f1-6045e6f84a81"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC01LTEtMS00MjM2Nw_25108109-0ae4-4e95-8548-5a8d8a7d5205"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNC03LTEtMS00MjM2Nw_bdbf3a6b-0f9d-439c-bf40-baf73060e3a5"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi0xLTEtMS00MjM2Nw_3c542116-f22d-46d4-87ff-69557e33cf3e"
      unitRef="usd">11897000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi0zLTEtMS00MjM2Nw_26ff5761-973d-4375-ab59-7cd55501fd58"
      unitRef="usd">-18083000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi01LTEtMS00MjM2Nw_8ded41fd-4f52-46a6-a410-31d55e25306d"
      unitRef="usd">-16422000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfNi03LTEtMS00MjM2Nw_9fb42532-9c11-4dec-9aa4-2e3ff83d7ecd"
      unitRef="usd">-25664000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS0xLTEtMS00MjM2Nw_f5ff9e9f-8e5e-46bf-aabd-bff9340f5dde"
      unitRef="usd">-3081000</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS0zLTEtMS00MjM2Nw_66d257fa-3108-4fe0-8999-ac8125e44ed4"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS01LTEtMS00MjM2Nw_cb73d282-ab2f-4085-9b0a-27a224fca174"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfOS03LTEtMS00MjM2Nw_931b93e5-9014-4695-919c-a9bbc369f966"
      unitRef="usd">0</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtMS0xLTEtNDIzNjc_5e69638b-02a5-4a22-8033-d2e1f0cf8efa"
      unitRef="usd">14978000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtMy0xLTEtNDIzNjc_e7625468-2ee7-4747-84bc-d4c3e2e9b2b9"
      unitRef="usd">-18083000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtNS0xLTEtNDIzNjc_050dc154-3eea-479e-98a4-4abf7f693f25"
      unitRef="usd">-16422000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTAtNy0xLTEtNDIzNjc_0fddf889-faab-4d86-af51-9178111b2697"
      unitRef="usd">-25664000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtMS0xLTEtNDIzNjc_36339af6-862a-4979-addf-8c36b40eb9a1"
      unitRef="shares">70217985</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtMy0xLTEtNDIzNjc_2af04f23-af66-4471-836d-57416ead6a76"
      unitRef="shares">49533956</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtNS0xLTEtNDIzNjc_af8312d4-cf18-4a1b-8491-08dd5031a6a4"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTMtNy0xLTEtNDIzNjc_2aaad562-cdc8-4d74-a706-9e83b34bdb0d"
      unitRef="shares">48402095</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtMS0xLTEtNDIzNjc_5d636103-b09b-43c7-ad19-0b390a895d2e"
      unitRef="shares">18184720</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtMy0xLTEtNDIzNjc_cc336232-ed67-4ba7-a756-f66a8b5d344c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtNS0xLTEtNDIzNjc_7503c4ea-92a2-46da-9d61-3f283c60fc93"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTUtNy0xLTEtNDIzNjc_015209c4-c4ba-4e11-add0-dea2ac609e4b"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtMS0xLTEtNDIzNjc_0c66528e-3d75-4de9-8194-a6c2e024aee3"
      unitRef="shares">189863</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtMy0xLTEtNDIzNjc_2d1654a0-8467-4ce7-8aa2-ee8e479e7ecc"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtNS0xLTEtNDIzNjc_7cc92876-a8fc-430f-9a63-9f16df87277e"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTYtNy0xLTEtNDIzNjc_581b637c-c81c-42a6-a513-6ce9b81f5dd2"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctMS0xLTEtNDIzNjc_94bd9f9d-8139-42d7-93a1-c10bb16f0a23"
      unitRef="shares">88592568</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctMy0xLTEtNDIzNjc_e361949f-439b-4f8e-867a-07f0123ef7ff"
      unitRef="shares">49533956</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctNS0xLTEtNDIzNjc_e0df65c8-8ee6-4ba2-9f87-01489206fe77"
      unitRef="shares">69170865</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTctNy0xLTEtNDIzNjc_4b9d1963-360d-460d-b051-4d017fb9f05a"
      unitRef="shares">48402095</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktMS0xLTEtNDIzNjc_4ffb8023-3688-4bc5-af2f-d0d182938337"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktMy0xLTEtNDIzNjc_6ccddc71-39a5-46eb-af68-659f16d0f243"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktNS0xLTEtNDIzNjc_f878a014-671b-4399-b157-b7cf7b1f8c9b"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMTktNy0xLTEtNDIzNjc_0ae76e87-80a4-4281-834e-2b705a2176eb"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtMS0xLTEtNDIzNjc_e59a8483-b5e4-468b-967e-4695a30a8ee2"
      unitRef="usdPerShare">0.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtMy0xLTEtNDIzNjc_c052d192-c81c-43e5-809a-46678872096f"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtNS0xLTEtNDIzNjc_6d82f322-12bf-4c09-b0bf-53699b982bfc"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjM0N2MzODg3MDU5ZDRkYzU4NDFhZDJkNmU3ZTM1ZTVlL3RhYmxlcmFuZ2U6MzQ3YzM4ODcwNTlkNGRjNTg0MWFkMmQ2ZTdlMzVlNWVfMjAtNy0xLTEtNDIzNjc_ce1d78bb-0546-4037-b043-e1605993718b"
      unitRef="usdPerShare">-0.53</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MDA_4c5e4c6c-b86a-478a-960e-be93225f0b13">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net earnings (loss) per share because doing so would be anti-dilutive (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,442,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,442,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,041,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,356,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,086,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,356,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;22,558,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33,316,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;40,788,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;33,316,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib67565edcae74a3cb712ae982e16c451_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi0xLTEtMS00MjM2Nw_13f6efe7-f86d-480b-80a8-1bfa27ae49d5"
      unitRef="shares">12517328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie4bdc30657f14452b62cb74aaa0c1c02_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi0zLTEtMS00MjM2Nw_06bf9296-aa0a-41af-b3eb-d06ad85093b9"
      unitRef="shares">12517328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia9489bd66399422eba3c70350fb1aec6_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi01LTEtMS00MjM2Nw_24078329-198f-465b-a08d-7a361c1a204b"
      unitRef="shares">12517328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1eba19ec547f41fe9cb7fcf6f8323c4e_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMi03LTEtMS00MjM2Nw_056d55c3-b663-4e41-b0c3-4afb22b4cf28"
      unitRef="shares">12517328</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i53017c7a53ac41bba664c2e94189573a_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy0xLTEtMS00MjM2Nw_4bf788a4-63d0-4319-932a-b841d809cd2c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if5bb1e9a932d46abbb6c2af18fe748bf_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy0zLTEtMS00MjM2Nw_b5ec3546-78b6-4c5c-906d-1bafe6a7420f"
      unitRef="shares">10442780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8290788acae94198a642171a08cb981e_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy01LTEtMS00MjM2Nw_eb9e806d-d8e7-439e-b48d-905f1b559e50"
      unitRef="shares">18184720</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67bd62ef1d93442c8672b744fb64dba0_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfMy03LTEtMS00MjM2Nw_4d2420d5-4e0c-4e65-aad2-c00c25d8e319"
      unitRef="shares">10442780</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iea096aaf8a964de0a3100d448444ba50_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC0xLTEtMS00MjM2Nw_cbdb7af1-6f03-4e58-8af7-794a84c77ff8"
      unitRef="shares">10041333</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5e6c2025ff77482496d4861d17864fb7_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC0zLTEtMS00MjM2Nw_b4cc1704-ae43-4b2f-8073-55ba390de92e"
      unitRef="shares">10356267</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i89983bfbaa774a6089ebf1552008beed_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC01LTEtMS00MjM2Nw_fb9c2826-720e-4a6e-a28c-4dba1c72d8ba"
      unitRef="shares">10086839</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib71ae47f80d7456fa74d8430a1187edd_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNC03LTEtMS00MjM2Nw_1188a598-a3d5-4ceb-85fd-04e84e11e52a"
      unitRef="shares">10356267</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS0xLTEtMS00MjM2Nw_3e134dac-445f-42cf-bf9f-cc17012f6848"
      unitRef="shares">22558661</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS0zLTEtMS00MjM2Nw_e3af9e45-f9df-4089-88a9-1a2e87434882"
      unitRef="shares">33316375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS01LTEtMS00MjM2Nw_c78ed389-c43a-43fa-929a-c4fc9ea84b74"
      unitRef="shares">40788887</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RhYmxlOjcyMjMxMGUyYTJlMTQzMTU5NTdkNzQ0MzI4MjFiMmM1L3RhYmxlcmFuZ2U6NzIyMzEwZTJhMmUxNDMxNTk1N2Q3NDQzMjgyMWIyYzVfNS03LTEtMS00MjM2Nw_e9cfc881-8e14-4340-8387-c712abca0985"
      unitRef="shares">33316375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA1MTE_b8899ce2-3eb2-481e-8059-3e4f79f1e0ad">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10 issued by the FASB with respect to fair value reporting for financial assets and liabilities. The guidance defines fair value, provides guidance for measuring fair value and requires certain disclosures. The guidance does not apply to measurements related to share-based payments. The guidance discusses valuation techniques such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, lease liability, and a term loan. Fair value estimates of these instruments are made at each &lt;/span&gt;&lt;/div&gt;reporting period end based on relevant market information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and therefore cannot be determined with precision. The carrying amount of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and accrued liabilities are generally considered to be representative of their respective fair values because of the short-term nature of those instruments.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNC9mcmFnOmMyNWEzN2ZjZmRiZjQxMzU4ZmM5NjM2NDRlNDNmMzkxL3RleHRyZWdpb246YzI1YTM3ZmNmZGJmNDEzNThmYzk2MzY0NGU0M2YzOTFfMjA0OTE_1f53dbb8-d202-453a-b44b-6d75c8f013b4">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, "Accounting for Convertible Instruments and Contracts in an Entity's Own Equity," simplifies the accounting for certain convertible instruments by removing the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature. As a result, more convertible debt instruments will be reported as a single liability instrument with no separate accounting for embedded conversion features. Additionally, this ASU amends the diluted EPS calculation for convertible instruments by requiring the use of the if-converted method. The treasury stock method is no longer available. Entities may adopt this ASU using either a full or modified retrospective approach, and it is effective for interim and annual reporting periods beginning after December 15, 2021. Early adoption is permitted for interim and annual reporting periods beginning after December 15, 2020. The Company adopted ASU 2020-06 effective January 1, 2022. The adoption of this standard did not have a material impact on the Company's condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RleHRyZWdpb246NzYwMzMwNjM4YTBkNGE4N2E2ZTVjOGY4NGNlZTZlZThfMTczNw_ef749914-4c2d-4903-8baa-d28af852277e">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company follows ASC 820-10, Fair Value Measurements and Disclosures, which among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Level 3: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions, which reflect those that a market participant would use.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company classifies investments in money market funds within Level 1 as the prices are available from quoted prices in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;None of the Company&#x2019;s non-financial assets or liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RleHRyZWdpb246NzYwMzMwNjM4YTBkNGE4N2E2ZTVjOGY4NGNlZTZlZThfMTczMA_f681fb5a-cdfa-49e8-8716-8438d2744a75">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company&#x2019;s financial instruments measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;LEVEL 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;53,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;59,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Restricted cash and money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;62,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy0xLTEtMS00MjM2Nw_41e937a3-b945-4c0b-9c44-e2999321fd83"
      unitRef="usd">53078000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic90bb450d4b14645876a8c40853f0f80_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy0zLTEtMS00MjM2Nw_1fd8f597-51a3-46fa-8c22-1672ab789953"
      unitRef="usd">53078000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6c9e1bc6d28645a0a88c59ae7c3b268d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy01LTEtMS00MjM2Nw_153bae6c-9e2f-4e4a-9f98-a9b60aa24873"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id64416d06cee4e5ca72c5b5ca3dd7cdf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMy03LTEtMS00MjM2Nw_64da0b73-db36-4e92-b219-445d040182cd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS0xLTEtMS00MjM2Nw_12b60ef0-d365-4206-8ce5-7406792cf1af"
      unitRef="usd">53078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic90bb450d4b14645876a8c40853f0f80_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS0zLTEtMS00MjM2Nw_de957591-8fed-4046-90dc-c710c0bfac53"
      unitRef="usd">53078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6c9e1bc6d28645a0a88c59ae7c3b268d_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS01LTEtMS00MjM2Nw_d8c73fd0-6968-4b8b-85f7-0e8fe97e1aaa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id64416d06cee4e5ca72c5b5ca3dd7cdf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfNS03LTEtMS00MjM2Nw_f5a0f589-1877-4873-b749-17607ca4be23"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtMS0xLTEtNDIzNjc_eb98042a-d29e-4c63-aa75-45bc84a1bebd"
      unitRef="usd">59680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if9923c3f04494ea08d78070db565dec5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtMy0xLTEtNDIzNjc_5855e430-7952-4735-b465-8d6d28d9a30f"
      unitRef="usd">59680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1d1ba8de76cf4d50a911304fc4244f77_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtNS0xLTEtNDIzNjc_5b896caf-8b30-4563-9655-f4fe06077587"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2787b199372343b4b03ee56c6d782676_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTMtNy0xLTEtNDIzNjc_8521844e-56d5-4ded-9c34-cca263e4a928"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RestrictedCash
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtMS0xLTEtNDIzNjc_905f1aa9-c3da-4264-80fc-42a92d23c124"
      unitRef="usd">2593000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="if9923c3f04494ea08d78070db565dec5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtMy0xLTEtNDIzNjc_2f9b7a95-b10d-4d42-aaed-c9097ddaf8f8"
      unitRef="usd">2593000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i1d1ba8de76cf4d50a911304fc4244f77_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtNS0xLTEtNDIzNjc_b57985fe-7951-4d68-b35c-576097284452"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i2787b199372343b4b03ee56c6d782676_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTQtNy0xLTEtNDIzNjc_fdd98738-e902-4f8f-ac65-605a550d7239"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtMS0xLTEtNDIzNjc_352055fd-b754-4cdf-84a4-471fbdead07f"
      unitRef="usd">62273000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if9923c3f04494ea08d78070db565dec5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtMy0xLTEtNDIzNjc_566bfff0-315b-4525-9b43-889d02772a8d"
      unitRef="usd">62273000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1d1ba8de76cf4d50a911304fc4244f77_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtNS0xLTEtNDIzNjc_2a77f940-e28e-4c7f-9ccb-5944ebbda008"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2787b199372343b4b03ee56c6d782676_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl8zNy9mcmFnOjc2MDMzMDYzOGEwZDRhODdhNmU1YzhmODRjZWU2ZWU4L3RhYmxlOmI5YjM3Yzk0MWIzZjRkYWM4NmI0ODA2NDA4YTVmZTQwL3RhYmxlcmFuZ2U6YjliMzdjOTQxYjNmNGRhYzg2YjQ4MDY0MDhhNWZlNDBfMTUtNy0xLTEtNDIzNjc_52e20a37-e78a-4024-9bfb-af3c4250cbe3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfMTI1NA_22e71a83-b485-4604-9a2e-4c9eeaf5b8f6">DEBT&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Term Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On October 3, 2016, the Company entered into a loan and security agreement, or the Loan Agreement, with Pacific Western Bank, as the collateral agent and a lender, or the Lender, pursuant to which the Company has borrowed $10.0&#160;million&#160;from the Lender, or the Term A Loan. The Term A Loan bore interest at a variable annual rate equal to the greater of (i) 4.5% or (ii) the Lender's prime interest rate plus 0.75%, and matured on July 3, 2022. The Term A Loan had an interest-only period through April 3, 2020, which was followed by equal monthly principal payments and was paid in full on July 5, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i052c13aef942486698daafbe3f173f65_I20161003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfMjQ1_cee4916d-01a5-4dcb-8f20-860097b48ce1"
      unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i052c13aef942486698daafbe3f173f65_I20161003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfMzI2_a17b00ec-40a5-4c0d-924a-3620bf7536d8"
      unitRef="number">0.045</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i959c564f9e4f4f058243fb9d370aa5de_D20161003-20161003"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80MC9mcmFnOjI0NWU3ZjdiNzA3MDQ5NjM4N2JlOGI4ZDY4ZmI1ZjljL3RleHRyZWdpb246MjQ1ZTdmN2I3MDcwNDk2Mzg3YmU4YjhkNjhmYjVmOWNfNTQ5NzU1ODE3NjIw_98a6459c-89b7-4392-93a4-7b22f3207b81"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzNA_70383b46-de09-496b-8d4f-38eb1f216d27">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Controlled Equity Sales Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company began to sell shares of common stock under a controlled equity sales agreement with Cantor Fitzgerald &amp;amp; Co, or the Sales Agreement. During the nine months ended September&#160;30, 2022 and 2021, the company sold 2,308,435 and 4,492,034 shares of common stock, respectively, for net proceeds of approximately $1.7&#160;million and $10.9&#160;million, respectively, after deducting placement agent fees. As of September&#160;30, 2022, the aggregate offering price remaining under the Sales Agreement is $46.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On October 13, 2021, the Company completed concurrent but separate public offerings of 17,064,511 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,225,805 shares of common stock, at a price to the public of $1.55 per share, and 774,194 shares of its Series X Convertible Preferred Stock at a price to the public of $15.50 per share, for aggregate gross proceeds of $38.5&#160;million. The Company received total net proceeds of $35.8&#160;million, after deducting underwriting discounts, commissions, and other expenses payable by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the amended and restated certificate of incorporation, the Company&#x2019;s board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding. The Company had 10,000,000 shares of preferred stock authorized at September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company designated 5,000,000 shares of preferred stock as Series X Convertible Preferred Stock with a par value of $0.0001 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On August 12, 2020, at the request of certain holders, 52,241 shares of the Company&#x2019;s Series X Convertible Preferred Stock were converted to an aggregate of 522,410 shares of the Company&#x2019;s common stock. As of September&#160;30, 2022 and December&#160;31, 2021, shares of preferred stock designated as Series X Convertible Preferred Stock totaled 4,947,759.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The specific terms of the Series X Convertible Preferred Stock are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Conversion: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Each share of Series X Convertible Preferred Stock is convertible at the option of the holder into 10 shares of common stock. Holders are not permitted to convert Series X Convertible Preferred Stock into common stock if, after conversion, the holder, its affiliates, and any other person whose beneficial ownership of common stock would be aggregated with the holder's for purposes of Section 13(d) or Section 16 of the Exchange Act, would beneficially own more than 9.99% of the number of shares of common stock outstanding immediately after the conversion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Dividends:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Holders of Series X Convertible Preferred Stock are not entitled to receive any dividends except to the extent that dividends are paid on the Company's common stock. If dividends are paid on shares of common stock, holders of Series X Convertible Preferred Stock are entitled to participate in such dividends on an as-converted basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Liquidation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Upon the liquidation, dissolution, or winding up of the company,&#160;each holder of Series X Convertible Preferred Stock will participate pari passu with any distribution of proceeds to holders of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"&gt;Voting:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Shares of Series X Convertible Preferred Stock will generally have no voting rights, except as required by law and except that the consent of the holders of a majority of the outstanding Series X Convertible Preferred Stock will be required to amend the terms of the Series X Convertible Preferred Stock, if such action would adversely alter or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Convertible Preferred Stock, or to increase or decrease (other than by conversion) the number of authorized shares of Series X Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Series X Convertible Preferred Stock for liability or equity classification under ASC&#160;480,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;,&#160;and determined that equity treatment was appropriate because the Series X Convertible Preferred Stock did not meet the definition of liability instruments defined thereunder as convertible instruments. Additionally, the Series X Convertible Preferred Stock is not redeemable for cash or other assets (i) on a fixed or determinable date, (ii) at the option of the holder, and (iii) upon the occurrence of an event that is not solely within control of the Company. As such, the Series X Convertible Preferred Stock is recorded as permanent equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company had 200,000,000 shares of common stock authorized as of September&#160;30, 2022. Holders of outstanding shares of common stock are entitled to one vote for each share held of record on all matters submitted to a vote of the holders of common stock. Subject to the rights of the holders of any class of the Company&#x2019;s capital stock having any preference or priority over common stock, the holders of common stock are entitled to receive dividends that are declared by the Company&#x2019;s board of directors out of legally available funds. In the event of a liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in the net assets remaining after payment of liabilities, subject to prior rights of preferred stock, if any, then outstanding. The common stock has no preemptive rights, conversion rights, redemption rights or sinking fund provisions, and there are no dividends in arrears or default. All shares of common stock have equal distribution, liquidation and voting rights, and have no preferences or exchange rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, warrants to purchase 12,517,328 shares of the Company's common stock were outstanding with a weighted average exercise price of $6.82 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The warrants had no intrinsic value at September&#160;30, 2022 and December&#160;31, 2021. The intrinsic value of a common stock warrant is the difference between the market price of the common stock at the measurement date and the exercise price of the warrant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,086,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,470,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,710,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,436,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;986,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;680,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,485,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;43,289,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ifb67d01a4acc4c67a09bea73d61871ed_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjgx_45c9c964-5eda-43e2-9e02-447ec7fe09c0"
      unitRef="shares">2308435</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icf66717d514a49d7b24e502df0f65ed9_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjg4_cfdedb3b-9f4b-4b20-af0b-fed6cb4037a3"
      unitRef="shares">4492034</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ifb67d01a4acc4c67a09bea73d61871ed_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMzYz_d10cd139-e0c8-40d6-b27d-bcf5b0384616"
      unitRef="usd">1700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="icf66717d514a49d7b24e502df0f65ed9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMzcw_df444bcf-1938-4d89-afde-cf0c227ecb7e"
      unitRef="usd">10900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <cdtx:SaleOfStockConsiderationRemainingOnTransaction
      contextRef="iae88c6865e4e458ba163ba5e2108e78e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTA0_f6b7e2ba-8471-4485-a29d-eb76678270a6"
      unitRef="usd">46800000</cdtx:SaleOfStockConsiderationRemainingOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="id488125f97f9422c86fe3f9a0f62e61e_D20211013-20211013"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjE2_b3daee5e-9c9a-473d-9d5b-0a85a1459523"
      unitRef="shares">17064511</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i44b0440e80904930ac842fa7429f8b17_D20211013-20211013"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNzQw_cdc584b1-91b7-4c5d-a555-87ff4ae8ad31"
      unitRef="shares">2225805</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2873a315ee3b49fb92caf5729891639a_I20211013"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNzk1_cf86481f-e4d7-44e5-bf69-2c6e5be02339"
      unitRef="usdPerShare">1.55</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="idd41362b50874d8d8249094d91ca90f6_I20211013"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfODEz_f1a8213b-d42c-465a-96bf-2783f21e691f"
      unitRef="shares">774194</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="idd41362b50874d8d8249094d91ca90f6_I20211013"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfODk1_88f35efc-c30b-4874-8e4e-c4d035adec4c"
      unitRef="usdPerShare">15.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i5df29006f187417e816e2158bd2f9209_D20211013-20211013"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfOTQx_2620ed82-e8c6-4681-ba69-f0c82cf83c67"
      unitRef="usd">38500000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="if7f37a17eb6a463698c6b8c41d120df5_D20211013-20211013"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfOTg4_32212c33-adb4-4027-b861-1daae9396ef6"
      unitRef="usd">35800000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTI3Ng_6d478240-0ec0-4365-830e-c8e6cc210cc7"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTcyMA_5ddb78f5-a60c-48fb-9cab-6f162f10f87c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i94af5aa812844c758cdfa1475671e9a6_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTgwMw_2af8489e-a1e9-42cb-9a61-a9c34d0ed8a8"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i94af5aa812844c758cdfa1475671e9a6_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTg5Mg_c5bca2f5-7a70-4d8a-b1b8-ca529e7934f6"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i7dc162d67bbe4dca8bd989529e6ae2b3_D20200812-20200812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMTk2MQ_0ef16366-c3af-48ad-b487-8b03becfd21c"
      unitRef="shares">52241</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i43db71acffc7473da141de0be728b1f4_D20200812-20200812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjA1OQ_df39b83c-6c36-4ae8-bf20-9129a40c28bd"
      unitRef="shares">522410</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjIwMg_423f430d-4302-4b05-958d-f62125ddb26d"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i08d686bd4def4018a3689e8e8c4201a4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjIwMg_e137cc0d-b41c-462d-b0a1-f25eaefd051e"
      unitRef="shares">4947759</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="ib8c7723f16324a4fad5896b06b8f70ee_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjM5Ng_2929a1d6-3f56-4f92-a8a0-42d46752ece6"
      unitRef="shares">10</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion
      contextRef="i13ec61aa3e0b43378a90a84041d66908_D20220101-20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfMjc2NQ_0d9c5e5d-c903-4b48-ad68-d20d9bdaba5b"
      unitRef="number">0.0999</cdtx:ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNDc3NQ_ca75a3c8-ef3f-4b4a-98fe-823f79b7ba14"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <cdtx:NumberOfVotesEntitlementForEachShareHeld
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzNg_6d3ed90e-c65e-47ef-a91c-88bf0e128895"
      unitRef="vote">1</cdtx:NumberOfVotesEntitlementForEachShareHeld>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i86b952768f264a7b874692f258aa5053_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTg2MQ_20742c0d-117f-49ff-81b8-03b42aa3fdd7"
      unitRef="shares">12517328</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i62d149e810834aceba4d99488eae77db_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTg2MQ_e63e81e1-716d-4c56-a7a8-a045205a0825"
      unitRef="shares">12517328</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="idf327b331dbc430d85c195531d36f8df_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTk2MA_797eb87b-5ac8-497f-8145-d9682542a343"
      unitRef="usdPerShare">6.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3fe30b7973da4dffb8da105c119dfe8b_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNTk2MA_c9fe452d-2471-45e1-8b4e-5432d076b5b3"
      unitRef="usdPerShare">6.82</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding
      contextRef="i86b952768f264a7b874692f258aa5053_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzMQ_2f820548-d0d3-4644-b0ca-7e11a5ea292f"
      unitRef="usd">0</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <cdtx:WarrantsAggregateIntrinsicValueOutstanding
      contextRef="i62d149e810834aceba4d99488eae77db_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzMQ_7173aca2-3660-4db6-92ca-a1d36f233feb"
      unitRef="usd">0</cdtx:WarrantsAggregateIntrinsicValueOutstanding>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RleHRyZWdpb246OTQwZDRhNWNiMzNjNGQ3MmFiMjU5NzIzYjZlMGI2MzJfNjMzMw_3d471d36-a96e-419b-96cf-e0d83aa5629b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Common stock reserved for future issuance is as follows (in common stock equivalent shares):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;12,517,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Series X Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;18,184,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Stock options, RSUs and PRSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;10,086,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;9,470,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Authorized for future stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,710,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,436,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Awards available under the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;986,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;680,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;45,485,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;43,289,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia5324603762448499a4ae28f38d54d1b_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMS0xLTEtMS00MjM2Nw_b2e769f4-8312-4b8c-a358-b2858cc0172e"
      unitRef="shares">12517328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8d844b63d15b429cbac3aefd54d810e1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMS0zLTEtMS00MjM2Nw_a707365c-8a9e-4a22-b82c-8fc9e089ae62"
      unitRef="shares">12517328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic05c4f78a48f4a4dbf218b042d1d1f6e_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMi0xLTEtMS00MjM2Nw_8bedb6f4-5a01-43e9-90dc-c0ad7cd34713"
      unitRef="shares">18184720</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i541af1a514f347a69bd1214db5ee6761_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMi0zLTEtMS00MjM2Nw_e4e08ef7-dd3c-4a21-9a8c-2cc757e61a8c"
      unitRef="shares">18184720</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i38ddb97add1a4265b3f354df1f33347f_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMy0xLTEtMS00MjM2Nw_e95f37a5-ea74-4c6f-8601-a017991b171e"
      unitRef="shares">10086839</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i782d88c1c80c43aeb3ee3636280e0ec3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfMy0zLTEtMS00MjM2Nw_47b5cb6b-69a7-4d71-9feb-d1a5a674a3be"
      unitRef="shares">9470178</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i31cc8c5f67c647a8bb8f8d484fb20097_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNC0xLTEtMS00MjM2Nw_1dba26ad-f43f-4977-8faa-b3b7f62b242b"
      unitRef="shares">3710000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i445ea361a0534f34b979c1b9c39c0ee4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNC0zLTEtMS00MjM2Nw_88dc6cdc-5822-4ef7-b5cb-f9b06dd788c5"
      unitRef="shares">2436984</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i036bdcca976a44cf9a1566845a5fb841_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNS0xLTEtMS00MjM2Nw_cd6841a9-e84a-4a75-bdac-63b12d14082f"
      unitRef="shares">986345</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1395be4faaed4f909c2d9d668463d93d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNS0zLTEtMS00MjM2Nw_fb6414f4-0b78-4578-948e-8d0e3e921079"
      unitRef="shares">680228</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNi0xLTEtMS00MjM2Nw_3f38c0f5-7acd-49f7-b88a-513b3445fc77"
      unitRef="shares">45485232</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80My9mcmFnOjk0MGQ0YTVjYjMzYzRkNzJhYjI1OTcyM2I2ZTBiNjMyL3RhYmxlOjc3MTM2MmVkNDk3NzQ0Y2I5MzM1ZDNiMjgwYTA4N2MzL3RhYmxlcmFuZ2U6NzcxMzYyZWQ0OTc3NDRjYjkzMzVkM2IyODBhMDg3YzNfNi0zLTEtMS00MjM2Nw_5d071744-cab0-49da-b362-3d9fe9c65819"
      unitRef="shares">43289438</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU4Nw_beb3c26a-7cf6-4e8c-8904-06c0dae2a7d3">EQUITY INCENTIVE PLANS&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2020 Inducement Incentive Plan and 2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company's board of directors approved and adopted the 2020 Inducement Incentive Plan, or 2020 IIP. Under the 2020 IIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who were not previously employees or directors of the Company, or who are returning to employment following a bona fide period of non-employment with the Company, as an inducement material to such persons entering into employment with the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company&#x2019;s board of directors and stockholders approved and adopted the 2015 Equity Incentive Plan, or 2015 EIP. Under the 2015 EIP, the Company may grant stock options, stock appreciation rights, restricted stock, RSUs, and other awards to individuals who are employees, officers, directors or consultants of the Company. The number of shares of stock available for issuance under the 2015 EIP is automatically increased each January 1 by 4% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31 or such lesser number as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Terms of stock award agreements, including vesting requirements, are determined by the board of directors, subject to the provisions of the 2020 IIP and 2015 EIP. Stock options granted by the Company generally vest over a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTQ2NQ_548f15b5-a1d8-4cd3-872c-e2f333fda6b9"&gt;three&lt;/span&gt;- or four-year period. Certain stock options are subject to acceleration of vesting in the event of certain change of control transactions. The stock options may be granted for a term of up to 10 years from the date of grant. The exercise price for stock options granted under the 2020 IIP and 2015 EIP must be at a price no less than 100% of the fair value of the shares on the date of grant, provided that for an incentive stock option granted to an employee who at the time of grant owns stock representing more than 10% of the voting power of all classes of stock of the Company, the exercise price shall be no less than 110% of the value on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;In March 2015, the Company&#x2019;s board of directors and stockholders approved and adopted the 2015 Employee Stock Purchase Plan, or the ESPP.&#160;The number of shares of stock available for issuance under the ESPP will be automatically increased each January 1 by the lesser of (i)&#160;1%&#160;of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31, (ii)&#160;490,336&#160;shares, or (iii) such lesser number as determined by the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The ESPP allows substantially all employees to purchase the Company&#x2019;s common stock through a payroll deduction at a price equal to 85% of the lower of the fair market value of the stock as of the beginning or the end of each purchase period.&#160;An employee&#x2019;s payroll deductions under the ESPP are limited to 15% of the employee&#x2019;s eligible compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;During the nine months ended&#160;September&#160;30, 2022 and 2021, 184,219 shares and 145,696 shares, respectively, were issued pursuant to the ESPP. As of September&#160;30, 2022, total unrecognized compensation expense related to the ESPP was approximately $0.3&#160;million. This unrecognized compensation cost is expected to be recognized over approximately 0.6 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PRSU activity during the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs and PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,174,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,471,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,032,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(320,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,292,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of RSUs and PRSUs granted during the nine months ended September&#160;30, 2021 was $2.28 per share. The total fair value of RSUs and PRSUs vested during the nine months ended September&#160;30, 2022 and 2021 was approximately $1.6 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2022, estimated unrecognized compensation expense related to RSUs and PRSUs grants was approximately $1.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Contractual Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,296,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,014,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,516,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,794,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,794,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,749,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The intrinsic value of a stock option is the difference between the market price of the common stock at the measurement date and the exercise price of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted by the Company during the nine months ended September&#160;30, 2022 and 2021 was $0.51 and $1.43 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, total unrecognized share-based compensation expense related to unvested stock options was approximately $2.8 million. This unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage
      contextRef="ib506537ee0944bfcbcb6c12ae798c59c_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTA2MA_c4d665df-1960-4a54-8b2f-5cd71fe5b279"
      unitRef="number">0.04</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i5b111eb9e1724eb4b52920f38d9f5ac1_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU4Mw_5522586b-d137-40fa-8dad-411cf6aefec6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTY1OA_6ddb87c1-4d45-400c-b509-112afa26d4a0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTc5NA_d909eb50-1ce9-4e35-bd7e-f05127a0ac48"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold
      contextRef="i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMTk3Nw_47cf3486-8e7e-4d7c-849d-280107a1bb6a"
      unitRef="number">0.10</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i12b01287deb64faf84f4daa9f17bb5e0_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjA4MQ_5134d5a5-eb4e-423a-b4bd-f7b1e4ce5279"
      unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage
      contextRef="i71ef06f8cb854b7abf2c1ca8ca9f0400_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjQyNw_588b2c8b-c106-4aea-9254-4221acc2a35d"
      unitRef="number">0.01</cdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ide919cb038934f0c97c7be8388a351c8_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjU0Mw_736bda93-607e-4588-8ec9-194009427ba7"
      unitRef="shares">490336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i71ef06f8cb854b7abf2c1ca8ca9f0400_D20150301-20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjc2NA_97a91835-0879-4647-9d38-9a876e57a30a"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="i56e4c68ba76241baa53301e647eb569c_I20150331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMjkzNw_3da9ed12-c4d4-4453-8f2b-aa31780e56e2"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i967a2fb933ca4d77a5793520831dca91_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzAxOQ_0f8b64e1-d897-472e-a748-0da213575c3e"
      unitRef="shares">184219</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iad586f67e1e64183ba99bd648dfdad0f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzAzMw_8d76c552-f168-4355-a928-684f0ed7047f"
      unitRef="shares">145696</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i036bdcca976a44cf9a1566845a5fb841_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzE4MA_861dcfd5-79e8-4c41-888b-0c59f71f78fd"
      unitRef="usd">300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i967a2fb933ca4d77a5793520831dca91_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzI2OA_905f0cff-782b-4a35-897a-1200bc4a0ebb">P0Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU5MQ_358ede85-b44b-4ecb-94da-928ed42a5015">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU and PRSU activity during the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs and PRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,174,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,471,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,032,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;RSUs and PRSUs canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(320,532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,292,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icc7909cccd3141d4980af143ffea9363_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMS0xLTEtMS00MjM2Nw_8c092b43-dace-42da-a7c0-dd5f58a163d6"
      unitRef="shares">1174087</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="icc7909cccd3141d4980af143ffea9363_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMS0zLTEtMS00MjM2Nw_d2cd3bec-4c1a-4b8c-9d17-f0f5a13057ac"
      unitRef="usdPerShare">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMi0xLTEtMS00MjM2Nw_23592bed-4c26-4e23-9b03-7cbfec5cdc05"
      unitRef="shares">1471454</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMi0zLTEtMS00MjM2Nw_5161b3f2-096d-4e08-95d6-9af4fcfe3a55"
      unitRef="usdPerShare">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMy0xLTEtMS00MjM2Nw_12155d64-bc92-46ac-a235-7f9c968512c2"
      unitRef="shares">1032815</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfMy0zLTEtMS00MjM2Nw_308d755c-8a01-42b2-880d-1011d74d5fd3"
      unitRef="usdPerShare">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNC0xLTEtMS00MjM2Nw_8a847463-312c-4037-9c9a-e1495fb0ad57"
      unitRef="shares">320532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNC0zLTEtMS00MjM2Nw_c207924d-690e-4b62-94b6-ac703545c709"
      unitRef="usdPerShare">2.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if4c2b554012041d29eba537838cbb84c_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNS0xLTEtMS00MjM2Nw_13569443-06ad-4001-97c3-adcd6c70fc77"
      unitRef="shares">1292194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if4c2b554012041d29eba537838cbb84c_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjUwNzU3NjBhZTJlZjRlNTJhODEzZTJhMzdlZDY4MGY0L3RhYmxlcmFuZ2U6NTA3NTc2MGFlMmVmNGU1MmE4MTNlMmEzN2VkNjgwZjRfNS0zLTEtMS00MjM2Nw_518ed4ab-54f8-4e44-a550-262ca9456345"
      unitRef="usdPerShare">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia0437175fbfa46dbba01f38007dbede7_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzQ4NA_918fe7dc-d564-4123-858f-88d680f27736"
      unitRef="usdPerShare">2.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="id9912047c193415f8d530486835fc858_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzU5OQ_2bce7b24-5e45-4201-8153-6dae13e0f6ca"
      unitRef="usd">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ia0437175fbfa46dbba01f38007dbede7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzYwNg_c10e42f8-d92b-4ed4-9149-b7d75254987b"
      unitRef="usd">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if4c2b554012041d29eba537838cbb84c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfMzcyNg_98dc351f-c07c-4bdf-adc2-192f766196c4"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU4OQ_59a1ad4b-d68d-4b23-924e-957b2862f936">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Number of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Contractual Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;in Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Total Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Intrinsic Value (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,296,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,014,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;0.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(1,516,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,794,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;8,794,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5,749,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;5.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS0xLTEtMS00MjM2Nw_a34dd35f-6f32-4f67-a3ed-2ca89cbccf12"
      unitRef="shares">8296091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS0zLTEtMS00MjM2Nw_dbd28340-6583-4397-b36a-ec064dff92ec"
      unitRef="usdPerShare">3.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="idfeff9f96ab8411fa8bca991c8031822_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS01LTEtMS00MjM2Nw_51c06d59-5e02-4c0e-98ea-b69adaac0646">P6Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib5225fdc3f334ed69fa883c887f70abe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMS03LTEtMS00MjM2Nw_d19c0ebf-f971-4342-8166-2ebf04ab6172"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMi0xLTEtMS00MjM2Nw_f574c807-a71d-4a7b-87dc-52d2091c99d9"
      unitRef="shares">2014700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMi0zLTEtMS00MjM2Nw_4bcfae37-f797-43ae-a362-8a36faa7fe57"
      unitRef="usdPerShare">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMy0xLTEtMS00MjM2Nw_67c92403-7b61-4195-bb15-6d867ee86a45"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfMy0zLTEtMS00MjM2Nw_4021e420-6f69-4c40-ab98-664d0b739576"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNC0xLTEtMS00MjM2Nw_4bfbd8ff-867e-492e-8f02-c972145864c8"
      unitRef="shares">1516146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNC0zLTEtMS00MjM2Nw_b8aec5ae-6d73-4d6c-b8b9-c18c747b6def"
      unitRef="usdPerShare">2.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS0xLTEtMS00MjM2Nw_16fa153f-0240-45a5-9270-d8b31fda8d57"
      unitRef="shares">8794645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS0zLTEtMS00MjM2Nw_18f6d3d2-e92a-437b-aacc-06b5a7b74b7c"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS01LTEtMS00MjM2Nw_554a9525-5773-4158-bf53-efd2d22f00db">P6Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNS03LTEtMS00MjM2Nw_562598bc-3efe-4bb8-ad2b-f559089d064b"
      unitRef="usd">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi0xLTEtMS00MjM2Nw_8eace611-8c8a-4690-9adc-3423a99d44fc"
      unitRef="shares">8794645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi0zLTEtMS00MjM2Nw_d4138b93-1f79-4732-8ab7-cd386c22e1ac"
      unitRef="usdPerShare">2.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi01LTEtMS00MjM2Nw_7ffbf194-860d-4e96-807e-ecfb0d30aa4c">P6Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNi03LTEtMS00MjM2Nw_5c4cc29d-079c-4d53-a9d7-98513334ff24"
      unitRef="usd">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy0xLTEtMS00MjM2Nw_78643fe9-b8d5-489a-8565-a4a7c6b5be35"
      unitRef="shares">5749660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy0zLTEtMS00MjM2Nw_c0b4845e-4132-4b25-8802-e4747fa22b92"
      unitRef="usdPerShare">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy01LTEtMS00MjM2Nw_64274f82-4ff1-46e2-827f-055152e57661">P5Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOmJlY2FiZTZjOTYyMzRkMjk5ZmQ2ZTlkMDk3N2QyOTY5L3RhYmxlcmFuZ2U6YmVjYWJlNmM5NjIzNGQyOTlmZDZlOWQwOTc3ZDI5NjlfNy03LTEtMS00MjM2Nw_27f7bb53-8638-49a8-8379-08f05cdc5b49"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDExNw_718a17e6-560f-48a5-8735-39c1078a05c7"
      unitRef="usdPerShare">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDEyNA_d1c58d03-e7e5-4bf2-a169-f69f6b747232"
      unitRef="usdPerShare">1.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNTQ5NzU1ODE4ODQy_07f556cb-acf7-4aa0-a9e8-c4244caf7695"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1dcbfc97d2f34fb9a0872c85a82593c5_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNTQ5NzU1ODE4OTYw_7246ff31-70ba-4cf3-9741-5a9c47f43b81">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RleHRyZWdpb246OTI0ZTljZmJiMWFkNDA3OWI0ZmI1NDFlNjE4YzQxZjNfNDU3OA_465bd83e-3454-4e1c-b4c8-58f84a28d1c6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for restricted shares, RSUs, PRSUs, stock options, and the ESPP has been reported in the statements of operations as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;3,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8cfddad092a44527821fd2ac2ffc91ed_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi0xLTEtMS00MjM2Nw_a6b3b8fe-392d-4e40-8ba6-66a165077dfa"
      unitRef="usd">443000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96c9f00db2034a07ab38792b24541941_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi0zLTEtMS00MjM2Nw_22b42a38-d7cc-41fb-abe5-baa36f7eb662"
      unitRef="usd">425000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i244171b35f434cc39f5129662239663e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi01LTEtMS00MjM2Nw_0c661a8d-83bd-4428-95d3-8ba2c7e5b4b7"
      unitRef="usd">1366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3c6df55d735d4a3584f2bf2d709732de_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMi03LTEtMS00MjM2Nw_1c7722ac-3ccb-4704-8388-f68b70e05642"
      unitRef="usd">1215000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19798a6430cc425eaf630f93c7d82742_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy0xLTEtMS00MjM2Nw_3e7d37ad-e320-4402-8539-6a4a21d8c012"
      unitRef="usd">399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id0e07da4e20844708da921b1866aff4a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy0zLTEtMS00MjM2Nw_1f484507-e749-4ac4-8128-8bcc9a7aeeac"
      unitRef="usd">476000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9746cabdad4f4ba5ad36b76a394afa49_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy01LTEtMS00MjM2Nw_2c6b11a1-7e45-4b37-bb36-47990b30573d"
      unitRef="usd">1666000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib6bd1aaba9504281a7c3adc36f4d33c8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfMy03LTEtMS00MjM2Nw_035daae3-2898-42d6-87b2-9d3dc3a86342"
      unitRef="usd">1436000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1455ccf570fa408797a81a114aeef838_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC0xLTEtMS00MjM2Nw_375cacb0-b50e-494a-933b-83d8ab51afdd"
      unitRef="usd">842000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf99262b5e5e42338fbae8524fbead35_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC0zLTEtMS00MjM2Nw_de423ab9-60e1-4ba7-833f-fa9c3f650ce7"
      unitRef="usd">901000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC01LTEtMS00MjM2Nw_1e7768dd-dec0-4a8f-8fb0-9d82963fc78e"
      unitRef="usd">3032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80Ni9mcmFnOjkyNGU5Y2ZiYjFhZDQwNzliNGZiNTQxZTYxOGM0MWYzL3RhYmxlOjgwYzEwMmRhYzY4ZTQ3Yzk5YjI3ZDQwMzMyMzExMzU3L3RhYmxlcmFuZ2U6ODBjMTAyZGFjNjhlNDdjOTliMjdkNDAzMzIzMTEzNTdfNC03LTEtMS00MjM2Nw_a2bdc306-1977-449b-bd48-ebc2208c2695"
      unitRef="usd">2651000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjIwNTk_263fa3fc-691a-4967-8007-4e5ef3b73c29">SIGNIFICANT AGREEMENTS AND CONTRACTS&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mundipharma Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On September 3, 2019, the Company entered into the Mundipharma Collaboration Agreement with Mundipharma, a related party, for a strategic collaboration to develop and commercialize rezafungin in an intravenous formulation, or the Mundipharma Licensed Product, for the treatment and prevention of invasive fungal infections.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Under the Mundipharma Collaboration Agreement, the Company is responsible for leading the conduct of an agreed global development plan, or the Global Development Plan, that includes the Company&#x2019;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the treatment of candidemia and/or invasive candidiasis, or the ReSTORE Trial, and the Company&#x2019;s ongoing Phase&#160;3 pivotal clinical trial of the Mundipharma Licensed Product for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the ReSPECT Trial, as well as specified GLP-compliant non&#x2011;clinical studies and chemistry, manufacturing and controls, or CMC, development activities for the Mundipharma Licensed Product. Mundipharma is responsible for performing all development activities, other than Global Development Plan activities, that may be necessary to obtain and maintain regulatory approvals for the Mundipharma Licensed Product in the Mundipharma Territory, at Mundipharma&#x2019;s sole cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Pursuant to the Mundipharma Collaboration Agreement, the Company granted Mundipharma an exclusive, royalty&#x2011;bearing license to develop, register and commercialize the Mundipharma Licensed Product outside of the U.S. and Japan, or the Mundipharma Territory, subject to the Company&#x2019;s retained right as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company also granted Mundipharma an option to obtain exclusive licenses to develop, register and commercialize rezafungin in a formulation for subcutaneous administration, or Subcutaneous Product, and in formulations for other &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;modes of administration, or Other Products, in the Mundipharma Territory, subject to similar retained rights of the Company to conduct mutually agreed global development activities for such products. In addition, the Company granted Mundipharma a co&#x2011;exclusive, worldwide license to manufacture the Mundipharma Licensed Product and rezafungin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Until the seventh anniversary of the first commercial sale of the Mundipharma Licensed Product in the Mundipharma Territory, each party has granted the other party an exclusive, time-limited right of first negotiation to obtain a license to any anti-fungal product (other than Mundipharma Licensed Product, Subcutaneous Product and Other Products) that such party proposes to out-license in the other party&#x2019;s territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company retained the exclusive right to develop, register and commercialize the Mundipharma Licensed Product, Subcutaneous Product and Other Products in Japan, or the Company Territory, and Mundipharma has granted the Company certain licenses under Mundipharma-controlled technology and jointly-developed technology to develop, register and commercialize Mundipharma Licensed Product, Subcutaneous Product and Other Products in the Company Territory and to manufacture such products and rezafungin worldwide.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of the execution of the Mundipharma Collaboration Agreement, the parties have agreed to share equally (50/50) the costs of Global Development Plan activities, or Global Development Costs, subject to a cap on Mundipharma&#x2019;s Global Development Cost share of $31.2&#160;million. The total potential transaction value is $568.4&#160;million, including an equity investment, an up-front payment, global development funding, and certain development, regulatory, and commercial milestones. The Company is also eligible for double-digit royalties in the teens on tiers of annual net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Either party may terminate the Mundipharma Collaboration Agreement for uncured material breach by the other party. Mundipharma may terminate the Mundipharma Collaboration Agreement at will, provided that if Mundipharma terminates the Mundipharma Collaboration Agreement in its entirety prior to the last visit of the last patient in both the ReSTORE Trial and the ReSPECT Trial, Mundipharma will continue to be liable for its share of Global Development Costs as described above. The Company may terminate the Mundipharma Collaboration Agreement if Mundipharma or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the Company's patent rights licensed to Mundipharma, or upon an insolvency event of Mundipharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million, research and development funding of $32.2&#160;million, plus milestones achieved of $13.9&#160;million. The common stock issued pursuant to the Mundipharma Stock Purchase Agreement was determined to be issued at fair market value after applying a lack of marketability discount as Mundipharma received restricted shares. Therefore, no additional premium or discount was allocated to the transaction price of the Mundipharma Collaboration Agreement for the share issuance. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Mundipharma Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Mundipharma during September 2019, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$17.9&#160;million&#160;in September 2019 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company and Mundipharma share equally in the costs of ongoing rezafungin clinical development in the Mundipharma Territory up to the specified cap, which represents a distinct performance obligation. The Company records these cost-sharing payments due from Mundipharma as collaboration revenue. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company's initial obligation to supply rezafungin for ongoing clinical development in the Mundipharma Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company determined that as of&#160;September&#160;30, 2022, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In November 2020, the Company achieved a $11.1&#160;million milestone under the Mundipharma Collaboration Agreement, which is recorded as long-term deferred revenue as of September&#160;30, 2022 because the rights to consideration is not expected to be satisfied within one year. The Company received payment for this milestone in January 2021. Mundipharma is entitled to credit the full amount of this milestone payment toward future royalties payable to the Company, subject to a limit on the amount by which royalty payments to the Company may be reduced in any quarter. If Mundipharma has not fully credited the amount of such milestone payment toward royalties payable to the Company before the earlier of (i)&#160;December&#160;31, 2024 and (ii)&#160;termination of the Mundipharma Collaboration Agreement by Mundipharma, the Company will be obligated to refund the uncredited portion of such milestone payment to Mundipharma on the earlier of such dates. In December 2021 and August 2022, the Company achieved milestones of $2.8&#160;million and $11.1&#160;million, respectively, under the Mundipharma Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with these milestones has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for these milestones in January 2022 and September 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;No&#160;royalty revenue was recognized during the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company and Janssen entered into the Janssen Collaboration Agreement to develop and commercialize one or more DFCs (previously called Antiviral Drug Conjugates, or AVCs) based on the Company's Cloudbreak platform, for the prevention and treatment of influenza, including CD388 and CD377, or the Products. The effectiveness of the Janssen Collaboration Agreement, including the effectiveness of the terms and conditions described below, was subject to the expiration or earlier termination of all applicable waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, or HSR. HSR clearance was obtained on May 12, 2021 and the Janssen Collaboration Agreement became effective on the same date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company and Janssen will collaborate in the research, preclinical development and early clinical development of CD388 or another mutually-agreed influenza DFC development candidate, or, in each case, the Development Candidate, under a mutually-agreed research and development plan, or the Research Plan, with the objective of advancing such Development Candidate through the completion of mutually-agreed Phase 1 clinical trials and the first Phase 2 Challenge Study. Unless otherwise agreed by the parties, the Company will be responsible for performing, or having performed, all investigational new drug application, or IND, -enabling studies and clinical trials under the Research Plan, and the Company will be the IND holder for the Research Plan clinical trials. Both parties will be responsible for conducting certain specified chemistry, manufacturing and controls development activities under the Research Plan. Janssen will be solely responsible, and reimburse the Company, for internal full-time equivalent and out-of-pocket costs incurred by the Company in performing Research Plan activities in accordance with a mutually-agreed budget.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Within 90 days after delivery by the Company to Janssen of results of the Phase 2 Challenge Study and all then-available data from other clinical trials of the Development Candidate conducted under the Research Plan, or the Election Period, Janssen will be obligated to notify the Company of Janssen&#x2019;s election to proceed with further clinical development of Products, such notice, an Election to Proceed Notice. If Janssen fails to deliver an Election to Proceed Notice prior to expiration of the Election Period, the Company will have the right to terminate the Janssen Collaboration Agreement upon written notice to Janssen. If Janssen provides an Election to Proceed Notice prior to expiration of the Election Period, then the parties will continue any then-ongoing Research Plan activities to completion, and Janssen will otherwise be solely responsible for the development, manufacture and commercialization of Products, at Janssen&#x2019;s sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Upon the effectiveness of the Janssen Collaboration Agreement, the Company granted Janssen an exclusive, worldwide, royalty-bearing license to develop, register and commercialize Products, subject to the Company&#x2019;s retained right to conduct Research Plan activities as described above. In addition, the Company granted Janssen an exclusive right of first negotiation until December 31, 2021, to negotiate and enter into a separate definitive agreement pursuant to which the parties would collaborate in the research and development of DFCs for the treatment or prevention of respiratory syncytial virus. This right of first negotiation expired on December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Compete Covenant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. The Company will covenant that, except for the performance of Research Plan activities, from the effectiveness of the Janssen Collaboration Agreement until the fifth anniversary of the completion of all Research Plan activities and the Company&#x2019;s delivery to Janssen of all Research Plan deliverables, the Company and its affiliates will not directly or indirectly (including through any third-party contractor or through or in collaboration with any third-party licensee) develop, file any IND or application for marketing approval for, or commercialize any DFC that binds influenza or influenza viral proteins at therapeutic levels, except that the Company has the right to conduct limited internal research of such DFCs for the purposes of generating data to support patent filings and improving and further developing the Company&#x2019;s DFC technology more broadly. The Company&#x2019;s non-compete covenant described above will not apply to any DFC that demonstrates high specificity for a virus other than the influenza virus and does not possess significant activity against the influenza virus.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Terms&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Upon the effectiveness of the Janssen Collaboration Agreement, Janssen paid the Company an upfront payment of $27.0&#160;million. As of the execution of the Janssen Collaboration Agreement, the Company is eligible for reimbursement by Janssen of up to $58.2&#160;million in research and development costs incurred in conducting Research Plan activities. The Company will also be eligible to receive up to an additional $695.0&#160;million in development, regulatory and commercial milestone payments, as well as royalties on tiers of annual net sales at rates from the mid-single digits to the high-single digits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. In addition to the Company&#x2019;s right to terminate the Janssen Collaboration Agreement for Janssen&#x2019;s failure to deliver the Election to Proceed Notice prior to expiration of the Election Period, the Janssen Collaboration Agreement includes standard termination provisions upon material breach, insolvency or safety concerns. In addition, Janssen may terminate the Janssen Collaboration Agreement for convenience as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;prior to the completion of all Research Plan activities and the Company&#x2019;s delivery to Janssen of all Research Plan deliverables, upon 90 days&#x2019; written notice to the Company, provided that if any clinical trial under the Research Plan is ongoing at the time of such termination, such clinical trial will be completed in accordance with the terms of the Janssen Collaboration Agreement;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;after completion of the Phase 2 Challenge Study and before expiration of the Election Period, immediately upon written notice to the Company; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:14.68pt"&gt;after delivery of the Election to Proceed Notice, upon 90 days&#x2019; written notice to the Company, which termination may be of the Janssen Collaboration Agreement in its entirety or on a country-by-country or Product-by-Product basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of $27.0&#160;million, research and development funding of $61.2&#160;million, plus milestones achieved of $3.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Janssen Collaboration Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Janssen in May 2021, therefore the Company recognized the revenue related to this performance obligation in the amount of $27.0&#160;million in May 2021 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The research and development services to be performed represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company's initial obligation to supply drug supply for ongoing development represents a distinct performance obligation. The Company recognizes revenue based on actual amounts incurred as the underlying services are provided and billed at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company determined that as of the latest financial statement date all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are not included in the transaction price. At the end of each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. In March 2022, the Company achieved a $3.0&#160;million milestone under the Janssen Collaboration Agreement that the Company deems to be tied to all the performance obligations identified in the original agreement. Revenue associated with the milestone has been allocated proportionately to the original transaction price which was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In conjunction with the performance obligations already delivered, revenue is recognized based on the progress of these performance obligations, the unrecognized portion is recorded as deferred revenue at the reporting period end and will be recognized as revenue over the remaining progress of these performance obligations. The Company received payment for this milestone in May 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur. No royalty revenue was recognized during the three and nine months ended September&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Melinta License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 26, 2022, the Company entered into the Melinta License Agreement with Melinta under which the Company granted Melinta an exclusive license to develop and commercialize products that contain or incorporate rezafungin, or the Melinta Licensed Product, in the U.S., or the Melinta Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Pursuant to the Melinta License Agreement, the Company granted Melinta an exclusive, royalty&#x2011;bearing license (including the right to sublicense through multiple tiers), to develop, register and commercialize the Melinta Licensed Product for all uses in humans and non-human animals in the Melinta Territory, subject to the Company&#x2019;s retained right, as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Compete Covenant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;. Until the fifth anniversary of the first commercial sale of the first Melinta Licensed Product in the Melinta Territory, neither the Company nor Melinta, nor any of their respective majority-owned subsidiaries may, directly or indirectly, itself or in collaboration with any Third Party, develop, manufacture for development or commercialization, or commercialize any product in the echinocandin class of drugs in the Melinta Territory without the other party&#x2019;s prior written consent, subject to certain provisions in connection with a change of control of a party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Commercialization.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Melinta will be solely responsible for the commercialization of rezafungin in the Melinta Territory, at its sole expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Retained Rights.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company retains the non-exclusive right to practice the intellectual property rights licensed to Melinta in the Melinta Territory solely for the purpose of performing its obligations under the Melinta License Agreement and Mundipharma Collaboration Agreement. The Company also retains the right to grant licenses under the intellectual property rights licensed to Melinta to third parties to which the Company has granted licenses or rights to market, promote and sell Melinta Licensed Product outside the Melinta Territory, to make and have made Melinta Licensed Product anywhere in the world solely to develop, register, use, sell, have sold, offer for sale, commercialize and import Melinta Licensed Product outside the Melinta Territory, subject to the terms of the Melinta License Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Continued Development and Regulatory Activities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company will be responsible, at its sole expense, for conducting an agreed upon development plan, or the Melinta Development Plan, that includes, among other activities, (a) completion of the ongoing ReSPECT Phase 3 pivotal clinical trial for the prophylaxis of invasive fungal infections in adult allogeneic blood and marrow transplant recipients, or the Prophylaxis Indication, (b) preparation and submission to the U.S. Food and Drug Administration, or FDA, of a supplemental New Drug Application, or NDA, for the Melinta Licensed Product in the Prophylaxis Indication, (c) site close-out activity worldwide (outside of China) for the Company&#x2019;s ReSTORE Phase 3 pivotal clinical trial for the treatment of candidemia and invasive candidiasis, or the Treatment Indication, (d) certain nonclinical studies and other nonclinical activities, (e) certain chemistry, manufacturing and controls activities for the Melinta Licensed Product, and (f) all other development activities that are required by the FDA to obtain marketing approval of the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company will remain the holder of all FDA submissions, including the rezafungin IND and NDA. The FDA submissions will transfer to Melinta on a transfer date determined based on the status of the ReSPECT trial and the associated supplemental NDA for the Prophylaxis Indication, after which Melinta will be responsible for performing all activities that may be necessary to maintain NDA approvals for the Melinta Licensed Product in the Treatment Indication and the Prophylaxis Indication in the Melinta Territory, at Melinta&#x2019;s sole expense, subject to Melinta&#x2019;s right to deduct from royalties payable to the Company the internal expenses (not to exceed a specified dollar amount per calendar year) and certain out-of-pocket expenses incurred by Melinta.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Supply and Transfer of CMC activities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Until Melinta assumes responsibility for the manufacture and supply of the Melinta Licensed Product for development and commercialization in the Melinta Territory, which it may do by direct purchase from the Company&#x2019;s contract manufacturing organizations for the Melinta Licensed Product or by having a manufacturing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;technology transfer to Melinta or its designee performed at Melinta&#x2019;s sole expense, which, in either case, will be no later than December 31, 2026, the Company will be responsible for the manufacture and supply of the Melinta Licensed Product for development and commercialization by Melinta in the Melinta Territory, and during such period, shall supply Melinta Licensed Product to Melinta pursuant to the terms of a supply agreement to be negotiated by the parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Terms.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Upon execution of the Melinta License Agreement the total potential transaction value is $460.0&#160;million, including a $30.0&#160;million upfront payment and up to $430.0&#160;million in regulatory and commercial milestones. In addition, the Company is eligible for tiered royalties on U.S. sales in the low double digits to mid-teens.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Termination.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; Either party may terminate the Melinta License Agreement for uncured material breach by the other party. After July 26, 2023, Melinta may terminate the Melinta License Agreement at will. The Company may terminate the Melinta License Agreement if Melinta or any of its affiliates or sublicensees, directly or indirectly through any third party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any of the patent rights licensed to Melinta by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company determined the transaction price is equal to the up-front fee of&#160;$30.0&#160;million. The transaction price was allocated to the performance obligations on the basis of the relative stand-alone selling price estimated for each performance obligation. In estimating the stand-alone selling price for each performance obligation, the Company developed assumptions that required judgment and included forecasted revenues, expected development timelines, discount rates, probabilities of technical and regulatory success, costs to continue the research and development efforts and costs for manufacturing clinical supplies. A description of the distinct performance obligations identified under the Melinta License Agreement, as well as the amount of revenue allocated to each distinct performance obligation, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The license to the Company&#x2019;s intellectual property, bundled with the associated know-how, represents a distinct performance obligation. The license and associated know-how was transferred to Melinta in August 2022, therefore the Company recognized the full revenue related to this performance obligation in the amount of&#160;$25.9&#160;million&#160;in August 2022 as collaboration revenue in its condensed consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt; The Company is required to provide research and development services, at its sole expense, as described under the Melinta Development Plan, which represents a distinct performance obligation. The Company concluded that progress towards completion of the performance obligation related to the research and development services is best measured in an amount proportional to the research and development expenses incurred and the total estimated research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical Supply Services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company's obligation to supply rezafungin for ongoing clinical development in the Melinta Territory represents a distinct performance obligation.&#160;The Company concluded that progress towards completion of the performance obligations related to the clinical supply services is best measured in an amount proportional to the clinical supply services expenses incurred and the total estimated clinical supply services. Revenue related to the clinical supply services performance obligation recognized during the three and nine months ended September&#160;30, 2022 was immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;The Company determined that as of&#160;September&#160;30, 2022, all remaining potential milestone payments are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company's control or are otherwise constrained under the variable consideration guidance. Therefore, these payments have been fully constrained and are therefore not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate the probability of achievement of each milestone and any related constraint. No revenue related to milestones was recognized during the three and nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;&#160;As the license is deemed to be the predominant item to which sales-based royalties relate, the Company will recognize revenue when the related sales occur.&#160;No royalty revenue was recognized during the three and nine months ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:120%"&gt;Costs to Obtain a Contract with a Customer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company incurred costs to a third party to obtain the Melinta License Agreement and capitalized $2.0&#160;million upon execution of the Melinta License Agreement in accordance with ASC 340. The Company incurred these costs in connection with all the performance obligations identified in the Melinta License Agreement and allocated the capitalized contract costs to performance obligations on a relative basis (i.e., in proportion to the transaction price allocated to each &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;performance obligation) to determine the period of amortization. Amortization during the three and nine months ended September&#160;30, 2022 was $1.8&#160;million and is included within general and administrative expenses in the Company's condensed consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022, the remaining balance of the asset recognized from costs to obtain the Melinta License Agreement was $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the nine months ended&#160;September&#160;30, 2022&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Opening balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Closing balance, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;24,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred revenue, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, aggregate transaction price allocated to performance obligations that are unsatisfied is $18.0&#160;million, $39.5&#160;million, and $3.8&#160;million under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively. These amounts are expected to be recognized over 2.3 years, 1.3 years, and 2.3 years which represent the remaining research periods under the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company recorded $0.5&#160;million and $4.5&#160;million in accounts receivable associated with the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents our contract revenues disaggregated by collaborator and timing of revenue recognition and excludes royalty revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost
      contextRef="iecd9ae8d02994db09c6c17d85d05eb8e_D20190903-20190903"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNDMzMg_c0381fe3-2e33-47b3-861b-d77cca19fd60"
      unitRef="usd">31200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="iecd9ae8d02994db09c6c17d85d05eb8e_D20190903-20190903"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNDM3Nw_f280fe59-3304-42e5-a72d-7df29be6cab0"
      unitRef="usd">568400000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="ia9b69a06369d4a8e88c985f8b0d67518_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTcwMg_68857dc1-d766-4dd6-81df-44ea20f8f91e"
      unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost
      contextRef="ia9b69a06369d4a8e88c985f8b0d67518_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTc1MA_8bbb0934-3af7-4532-8e60-2c3b300d7fb4"
      unitRef="usd">32200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i2ab15c514b9d45d58fb7d77080e63dbd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODM4MjU1_b835576e-e849-477c-afcb-2937013f0d2d"
      unitRef="usd">13900000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ib8e503d246dc400e926a1ee2b976a58e_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNzIyMQ_c0472bbf-759e-4058-bb66-3656f10b204a"
      unitRef="usd">17900000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
      contextRef="ifc0df86722f14e688642f553eeef0df3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfOTAyMw_a9383f60-375a-417c-b71a-345eadffa2b7"
      unitRef="usd">11100000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i083a9e97a9064a748f3e9e13753ecc2e_D20211201-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfOTkzMw_fc1c10a1-cbff-4f82-8619-ca640610890d"
      unitRef="usd">2800000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i050a34311f2f464091d42f5ee44e4c79_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODM3MDEw_a6d4ec90-4545-4614-a221-93d2fab9f981"
      unitRef="usd">11100000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ie658ef0290234febab93dba91faae5e1_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_308991fa-1ae8-47e0-a4c0-5fca39baf69e"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3a4ea630ca944ade94e8636670a33f15_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_4b5423f1-111d-4cd5-a840-b0a192a6bc17"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i161035ba306c4c2cbad3a08836c61a30_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_ac1e554f-d18a-4558-9459-239651ed56ed"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i80867d87eba64530a2fb32636e6cfb8f_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTA5MTM_fa40b235-5c59-4a80-9bff-71bdf30a303d"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults
      contextRef="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTI5NjA_c6f05680-51bc-4b09-8392-4bb395fecb97">P90D</cdtx:CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="ib9170170c08441b781c4c6d06c63beeb_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTU4MDY_8b02492f-16c4-4dc0-9adb-fd8e072ac9b0"
      unitRef="usd">27000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="i294b1ca2af214dad80eaf69f5050931a_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTU5MzE_1f104634-a8f8-4bea-aab1-2cc262dec971"
      unitRef="usd">58200000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="i58a391d92ba84000b49895803c8b0101_D20210331-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTYwODI_c0da4563-268d-46ca-aad0-42fcd34afb00"
      unitRef="usd">695000000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice
      contextRef="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTY4Mjg_c6138a77-a187-42b7-a51a-527ad76a80c4">P90D</cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice>
    <cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice
      contextRef="i8c20299262eb4c75ac12c928dd909ec3_D20210331-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTcyNjQ_c6138a77-a187-42b7-a51a-527ad76a80c4">P90D</cdtx:CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="i5ec5bff221b34504b1e0fbb18258fed7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTc1NDI_b3a239c8-1614-40a4-8c79-ea34464000d9"
      unitRef="usd">27000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost
      contextRef="i5ec5bff221b34504b1e0fbb18258fed7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTc1ODY_2c8107a5-e4ca-4c73-bac4-d29fcf208cc8"
      unitRef="usd">61200000</cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iae8af69b23b64ece8613fb9204fc9c4b_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTc2MTg_b4d33315-55b2-453f-8f32-1188363c3fe0"
      unitRef="usd">3000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i34737c9c45ac487189c88b240a304577_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMTg3MjI_bc54e6ea-47b8-4242-83e5-f40da148215d"
      unitRef="usd">27000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iae8af69b23b64ece8613fb9204fc9c4b_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjAwMTI_b4d33315-55b2-453f-8f32-1188363c3fe0"
      unitRef="usd">3000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i5a85bab3728d4eada2f9bcaf61036888_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_0c9cfa60-5b27-498c-987a-6573fe284ad2"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i6ad6fb4866e44519aefef3041cf4c2cb_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_a0068196-6eb2-486e-83fd-c9976e161abf"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i577b14f0889b45eb8cb9da83fcc52acf_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_c6352be1-e906-478d-9989-bbab6c8c6e7f"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i4b2539318f504eba964d023b1f0971c9_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjA5ODQ_e20c2493-2bf0-4acb-9aac-3d1a887f0fdc"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="id3992b0eb8484b4aaf5f1a209d2603dc_D20220726-20220726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5ODQy_8e4df3f8-745e-459b-b2de-9bd58f798458"
      unitRef="usd">460000000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="ib906710cf3274c668e80b30f6e1ec734_D20220726-20220726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5ODU4_8ba59393-79e6-48a9-b993-bfee864db17c"
      unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <cdtx:CollaborativeArrangementTransactionPotentialValue
      contextRef="if3f48f173a7046749372f5bdca47960e_D20220726-20220726"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5ODcz_7a07d1ac-153a-427c-8b99-cea8902649e8"
      unitRef="usd">430000000</cdtx:CollaborativeArrangementTransactionPotentialValue>
    <cdtx:PaymentsRelatedToCollaborativeAgreements
      contextRef="ifd947fb9100e419d90d6c2dfa4983059_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODY5OTE5_b2b1ae55-9f8a-4986-b787-ec8a334ceea1"
      unitRef="usd">30000000</cdtx:PaymentsRelatedToCollaborativeAgreements>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i693aca7e97aa4503a8037a869333ca1b_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODcwNTM5_50db25bf-c048-4c55-bf09-220927b5f108"
      unitRef="usd">25900000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i1a7f54e53e964d7c9958ac2b8a920ce5_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzcx_71432a90-f773-4407-97cc-d3e93f446f49"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i2ce9bdb2fb7b4bf88fc587dee9f5a817_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzcx_98b8f510-8636-4d1e-80e1-6a2676b6c63c"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="id1b5450d72e34c33b4dec3e66a44b756_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzgy_35950f02-dccc-4cb9-be6f-8d8793a1fd14"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iabd098fd38fd419896b25481459eb489_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczMzgy_978d5b5f-955c-4e27-99ef-209c01eb1499"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:CapitalizedContractCostGross
      contextRef="ic5c7726e1d4f43d6ada81fc4d023fd3d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMzg0ODI5MDc1OTI3MQ_386574fd-e1f7-451e-8fed-5201c6b372a3"
      unitRef="usd">2000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="iaa27a7d5291744e8a8982d3d8fd39e8b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc3OTM0_dbc0f4b7-ecbc-4adb-be48-81b3d7ff899a"
      unitRef="usd">1800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="ief418486b3fd4aeaa1b3a28dde7a1f60_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc3OTM0_dc36500e-b66c-4da9-9fe3-039a7ad88035"
      unitRef="usd">1800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="ic5c7726e1d4f43d6ada81fc4d023fd3d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODczOTY1_e81122e1-690a-4181-9428-980ed094ebf2"
      unitRef="usd">200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjIwNTg_4509d9ea-71e6-4d89-b92c-fdfc7a49c59a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the activity in the Company's contract liabilities (recorded as deferred revenue on the balance sheet) pertaining to the Mundipharma Collaboration Agreement, Janssen Collaboration Agreement, and Melinta License Agreement during the nine months ended&#160;September&#160;30, 2022&#160;(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Opening balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;32,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Payments received in advance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;11,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Revenue from performance obligations satisfied during reporting period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(4,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Closing balance, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;15,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Long-term portion of deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;24,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total deferred revenue, September&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;39,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents our contract revenues disaggregated by collaborator and timing of revenue recognition and excludes royalty revenue (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Mundipharma&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Melinta&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from Collaboration and License Agreements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Point in Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;License of Intellectual Property&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Drug Supply&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Over Time:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and Development Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical Supply Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Revenue from Collaboration and License Agreements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="i810b267149e44965acbf595fbb6b9e33_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfMC0xLTEtMS00MjM2Nw_ae5a60a5-07bd-426c-b54c-38470848f510"
      unitRef="usd">32333000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance
      contextRef="i7ac7381acc7e4e059c3e2321b8b15239_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfMS0xLTEtMS00MjM2Nw_9922597b-e8b5-49ec-8e3d-af05e59b7da6"
      unitRef="usd">11319000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized
      contextRef="i7ac7381acc7e4e059c3e2321b8b15239_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfMy0xLTEtMS00MjM2Nw_755e926a-24e0-4f0c-bfe2-38720a2ea9e9"
      unitRef="usd">4005000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="i8c38f20f22ba485bb4c251fc607c0a9e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfNC0xLTEtMS00MjM2Nw_b4b8d217-e402-442f-9663-47e72385f5a3"
      unitRef="usd">39647000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfNi0xLTEtMS00MjM2Nw_4603133e-8c30-4c1e-b378-c7668f61c1c6"
      unitRef="usd">15249000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfNy0xLTEtMS00MjM2Nw_b13f26fc-4ba2-4805-89d3-b3cca92012d1"
      unitRef="usd">24398000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent>
    <cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjBiZjU0MWVmNmU4MzRjNjE4YmQ1MDg2ZjE0MTMwZTAzL3RhYmxlcmFuZ2U6MGJmNTQxZWY2ZTgzNGM2MThiZDUwODZmMTQxMzBlMDNfOC0xLTEtMS00MjM2Nw_a79ac1e2-f835-4c78-b976-f5b14aa3cfff"
      unitRef="usd">39647000</cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i18d550357dd0498aa73e25001de9cc1a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE0NTI_ff167815-8a24-4748-be5e-5217c7a3575b"
      unitRef="usd">18000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iefc06d4abeb64a938a55a63bbfcfedc8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE0NTk_9660aa1f-3a64-449c-8e95-d2a8115a7653"
      unitRef="usd">39500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ief933a73262047ada7ce3fa9a403b153_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc2MDMw_8b2dc4de-888a-45f3-afe1-3928ab9ddfbe"
      unitRef="usd">3800000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i18d550357dd0498aa73e25001de9cc1a_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc2MTE0_63f35d2e-a3b5-42a9-8b35-e1a3b00d9463">P2Y3M18D</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="iefc06d4abeb64a938a55a63bbfcfedc8_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE2MDg_94749e54-2af0-4672-bf41-57e6e1be1c31">P1Y3M18D</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ief933a73262047ada7ce3fa9a403b153_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfNTQ5NzU1ODc2MTIy_0aa89908-f713-419f-8dc6-0d7d280cced4">P2Y3M18D</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i74e6e40b20bd48d29415c8c3c7305f97_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE3NzI_5a40c607-ad34-4c13-a98e-155d0856fd11"
      unitRef="usd">500000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i9c1d8dcb1b3c4b8bacd38918de4039b1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RleHRyZWdpb246NDFmYWM4N2NkNDk5NDFmOGIwOTA5ZjRmZGY3OWE0MGVfMjE3Nzk_4d89fb46-110b-44cd-8f3f-5b8fbb7cf6de"
      unitRef="usd">4500000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ib709c1ffb8854bb481421062c0b218f9_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0xLTEtMS00NTUzNg_f6a23065-0026-4831-87c7-57cbab96c833"
      unitRef="usd">3252000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iab1678b723954fb2a37229ed7298c334_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0zLTEtMS00NTUzNg_967c4225-ce11-4922-bec7-425b59af6730"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i04cff27d9bb54d1fa6f4a32a4b7398df_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC01LTEtMS00NTI2Mg_46e28102-ff46-48d5-b517-f1f9670aac4e"
      unitRef="usd">25885000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ia9f4882fb39748e396fbfb4e6f2141a1_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC03LTEtMS00NTUzNg_dc692ff0-42f9-48f8-9cfa-e35f33ecf52c"
      unitRef="usd">3252000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i2363ec926c83422882f201f395e6418e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC05LTEtMS00NTUzNg_5e3c0487-cb7b-4140-99c2-790cf748e947"
      unitRef="usd">816000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ia89c179f7606467791e1ccda6296e332_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0xMS0xLTEtNDUyODY_d2c553b2-80c8-4b57-8245-121c16f41d5d"
      unitRef="usd">25885000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ied8bda146b1e42518db4ad5b9607da40_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0xLTEtMS00NTUzNg_b07b81da-212c-4a75-beec-c7bd610fdf58"
      unitRef="usd">459000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i2a13d205acea4035b1472638de599302_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0zLTEtMS00NTUzNg_e9a3243f-c273-48bf-a76f-4f649872aa53"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i608d2c0acd8a446f97ea23de80771ca2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS01LTEtMS00NTUzNg_d852f934-440f-4589-b78d-155e4b3b2e36"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="if86142a8002b4fb3bfa67f3114a2168c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS03LTEtMS00NTUzNg_92996eaf-9b3b-485f-a509-1387b7622377"
      unitRef="usd">459000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ifdb93712507e4b0d9bcf6e602fc11d8f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS05LTEtMS00NTUzNg_3506f375-aa6b-4e93-a109-0f2443cbc19c"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i4b76d577a5a04ef2a426145c4efdec1f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0xMS0xLTEtNDU1MzY_b3190583-c8d9-47d0-a31b-6a59309fc6bf"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i330a14431e6c447f850339e8183a87c2_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0xLTEtMS00MjM2Nw_2123704e-11b2-46ff-b268-2dc1f9e3d2c5"
      unitRef="usd">3945000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ib64ac500c81045e0900ce23c27023a2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNy0zLTEtMS00NTUzNg_7fd15465-6d92-40cf-9550-df7f92c23e81"
      unitRef="usd">6250000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i9ee636604f0544608be83b816d561a04_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC0zLTEtMS00MjM2Nw_e4f09204-9c61-4f33-922b-475ec6c31320"
      unitRef="usd">328000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ie8993710e84743d28a95a4b2457fa9cb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC01LTEtMS00MjM2Nw_7b2d79c5-2ed5-43ce-909d-88579ef60900"
      unitRef="usd">7965000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="if43870715ac94163bfa487cc20cc7a5c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNy05LTEtMS00NTUzNg_c90c65d0-af5d-4371-ab4a-0e130c57ddc3"
      unitRef="usd">11235000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ia26a535ba45543e8a02c93c70be14f9c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNC03LTEtMS00MjM2Nw_c9e9cc04-1784-4cb9-a209-708d2e866ae3"
      unitRef="usd">328000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i791e53caa07d4e4ea55fd15972c74a19_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0xLTEtMS00MjM2Nw_144e4078-3b68-4fb3-ba5e-566cd99417f2"
      unitRef="usd">363000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i9ef6e2feb31a41178bada54e92855b1b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOC0zLTEtMS00NTUzNg_7e832faa-b8d2-48e3-8677-ca299e18730c"
      unitRef="usd">262000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3a540ce1f4734c1b8df74de8131b45d3_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS0zLTEtMS00MjM2Nw_11b2b132-a466-4225-9f67-798da3b36e24"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i7fb8ca4cb3f04e0ebddd7c2383d433d7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS01LTEtMS00MjM2Nw_75d1305a-6a56-4596-9945-1b16414beefc"
      unitRef="usd">792000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="if8e5492e892a4011aeca081fc7b607fa_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOC05LTEtMS00NTUzNg_4090914b-cd19-4702-baff-b67b05d851f0"
      unitRef="usd">3337000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i05496cda0e33452896f54514996a1288_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNS03LTEtMS00MjM2Nw_9a897145-5381-4620-ab38-fab2fa50e37f"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iad9574638cde472faee405847f9f3e1a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi0xLTEtMS00MjM2Nw_e1dcb2c3-0ab9-4bbc-a75d-caa6b8421947"
      unitRef="usd">8019000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i586689ef6a80408b93ad64b72f84c672_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOS0zLTEtMS00NTI3Mg_37792259-99ac-4412-b0b0-c8005c43e948"
      unitRef="usd">6512000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i04ff76c144cd4408a9a52fbbc69b19cf_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi0zLTEtMS00MjM2Nw_a1b76dcb-a0c0-45ea-939e-82e6464f8b5b"
      unitRef="usd">26213000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i6a54ee7566ce41918832cd3479ef935e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi01LTEtMS00MjM2Nw_586f7f21-1ba7-4c90-879f-c8d2f52182e5"
      unitRef="usd">12468000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i805c213b2c0743b087c75996e2d88021_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfOS05LTEtMS00NTI5NA_580c641f-74c1-49d4-aa21-b3207a1b879b"
      unitRef="usd">15388000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i62d5577ed469475da80b700a69f04f2c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOjgzMjA0NDhkMjIzYjQ5Y2VhNDAzYmNhZWE5ZjliZGM2L3RhYmxlcmFuZ2U6ODMyMDQ0OGQyMjNiNDljZWE0MDNiY2FlYTlmOWJkYzZfNi03LTEtMS00MjM2Nw_c8e3faed-bed7-4e9f-ae2a-d582b22c5f4e"
      unitRef="usd">26213000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i8c636231d35f4bf0971afbbb890c922e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC0xLTEtMS00MjM2Nw_3cabd0df-6d20-4f3d-8f14-34a714342278"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i1c2b515fd83f4999933be813beb65c48_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC0zLTEtMS00NTU1MQ_b89d67ad-4ae3-465a-9e41-da8193438f09"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="idcd3b7ed4d6b4262a23a7634c2c7aff2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC0zLTEtMS00MjM2Nw_53c07258-01bb-4494-9807-22d76363dfd7"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ib9fb95774ab143ebafe375c57e2fac61_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC01LTEtMS00MjM2Nw_cab04173-a11c-40ea-948f-595154468bb4"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="iefed914e0ec24b92964d9459ffc3d327_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC05LTEtMS00NTU1MQ_597078df-9630-47c4-922b-b362fb8a7391"
      unitRef="usd">27000000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="id406989deae044f4acf764c75f7ad87b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNC03LTEtMS00MjM2Nw_51bcd273-2639-443d-bc8a-b9dc843f11df"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ic04da1d4150b40a8abe55e454e756c44_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS0xLTEtMS00MjM2Nw_af7828cd-d610-49d7-b253-b1a8bbdb849e"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i4c71d7b0754c47a8818fc47cb60bf5b8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS0zLTEtMS00NTU1MQ_187844d4-5d1f-4790-acea-ed09a7282dfc"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i605912304b144c4bba382814666efe0a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS0zLTEtMS00MjM2Nw_51c82890-6b23-4f32-b309-1366d1c01c81"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ib370fe55235440b19f13161583777fca_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS01LTEtMS00MjM2Nw_d189edf0-3ee1-4ee8-9725-4f5998bb1b3f"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibc3e4af26d3548a0905d4625e4c6960f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS05LTEtMS00NTU1MQ_5ba7751d-2dbe-4ac4-ac55-fe24d66d2109"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i8777634ed6ab43ceb831077cb1ba1505_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNS03LTEtMS00MjM2Nw_8be6b002-89e2-4b48-8e03-d54ebbd2c9ba"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ibf075aa78dbb48cb952fb65ae88fc07a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy0xLTEtMS00NTU1MQ_e52a0492-31d9-4909-8ebe-57216ffe08dc"
      unitRef="usd">3033000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i9c01b6b14c1a485fb20538cac3587498_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy0zLTEtMS00NTU1MQ_7f10042b-2dbb-411c-9f17-c199358deaed"
      unitRef="usd">2072000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ida8b4e5a23a9418d8c44be5a1e0e74a0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy01LTEtMS00NTU1MQ_83964d41-7314-4009-8640-a727727eca9c"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i515a17efa892472b86a77214dfa7ef7b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy03LTEtMS00NTU1MQ_b2b76610-f35c-4a0e-b620-849093c3c503"
      unitRef="usd">7795000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="if41b2c7dcf954060af28af4c157705cb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy05LTEtMS00NTU1MQ_620d1bf8-96a4-4083-a88a-4e872358e1d4"
      unitRef="usd">3747000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ib77a7ee0b23046cc9cb75730e07ea8c6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfNy0xMS0xLTEtNDU1NTE_5fc5f94a-e265-4fa9-92c2-666f8927f1ed"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="ica341a5f24ad4bcab2e21eea5d444a9d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC0xLTEtMS00NTU1MQ_435fc8a0-9623-4ddf-b706-fbdcac69285b"
      unitRef="usd">237000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i76dc324051474558a170627d6a003711_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC0zLTEtMS00NTU1MQ_c80876ab-2cef-4397-b9ae-3b75ce9eec62"
      unitRef="usd">1734000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i6d4f5d1f93e04d73aa48631d7518db9c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC01LTEtMS00NTU1MQ_0cc6e4b7-c3a1-4351-af6b-be22ea9525a0"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i06d0c3d06b8544eda7efed1647c21a9c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC03LTEtMS00NTU1MQ_8c6e9b1b-c11d-4b29-96de-1ceaab6e1bf8"
      unitRef="usd">598000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i3011064556b748619173464bff0d68e3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC05LTEtMS00NTU1MQ_d92d3fac-b40f-4d12-b0c9-5d404a264392"
      unitRef="usd">3207000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i9776e033e33d450695fa795370df723c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOC0xMS0xLTEtNDU1NTE_01decfa7-4172-46bb-824d-ba9e2766f8ff"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i940b58f0b39b440d929568bd00af95e5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS0xLTEtMS00MjM2Nw_8cf470d7-011c-4d65-899a-f87618220ded"
      unitRef="usd">3270000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="if417d192e5eb43008abe45d33168ea61_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS0zLTEtMS00NTU1MQ_53a9cc0e-ab07-447d-be1d-e711e3a9bc8d"
      unitRef="usd">3806000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="id433e60fe208470fa98c4a38610c659c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS0zLTEtMS00MjM2Nw_76e54f82-0009-447f-9fde-fc41d2639534"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i0a3ec63d2d654bbe9108ebb110c10485_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS01LTEtMS00MjM2Nw_a9f6c517-3f04-432e-a597-c75bf36e7e5c"
      unitRef="usd">8393000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="i661d0dfb1ecb4a8e85c58f301a66b3bb_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS05LTEtMS00NTU1MQ_15c88f2b-4621-48a7-b2da-292449b10723"
      unitRef="usd">33954000</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
      contextRef="idef1c49cdd9a44d09573c601607368e6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl80OS9mcmFnOjQxZmFjODdjZDQ5OTQxZjhiMDkwOWY0ZmRmNzlhNDBlL3RhYmxlOmVmNDBmMTZkNTEzNTQ3M2U5NDJjYWVhZTUyMjc2ZTVmL3RhYmxlcmFuZ2U6ZWY0MGYxNmQ1MTM1NDczZTk0MmNhZWFlNTIyNzZlNWZfOS03LTEtMS00MjM2Nw_94214be8-0f2d-4bc7-b561-6be86af84f96"
      unitRef="usd">0</us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3Nw_bfa07b7f-c056-4046-b702-6433c6d87a5d">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;On July 14, 2021, the Company entered into a sixth amendment to its lease with Nancy Ridge Technology Center, L.P. which extended the term of the lease by an additional 24 months and increases the base rent to $103,733 per month effective January 1, 2022, subject to 3% increases every January. The lease expires on December 31, 2023 with options for two individual two-year extensions, as described in the original lease agreement, which have not been exercised, and remain in effect and available to the Company. As of September&#160;30, 2022, the Company was not reasonably certain that it would exercise the extension options, and therefore did not include these options in the determination of the total lease term for accounting purposes. The incremental borrowing rate used in measuring the Company's lease liability was 10.8%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of September&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company's operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the weighted average remaining lease term was 1.3 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the present value of operating lease liabilities was $1.0 million and $0.7&#160;million for the nine months ended September&#160;30, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $1.0 million and $0.9&#160;million for the nine months ended September&#160;30, 2022 and 2021 respectively. These costs are primarily related to the Company's long-term operating lease, but also include immaterial amounts for variable leases and short-term leases with terms greater than 30 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The Company enters into contracts in the normal course of business with vendors for research and development activities, manufacturing, and professional services. These contracts generally provide for termination either on notice or after a notice period.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ib12d63d710f14cf2a688757cc358ebca_I20210714"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMjI1_e6f44ce9-3edf-4d45-b259-b2ca0d2c92f6">P24M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <cdtx:LesseeOperatingLeaseMonthlyRate
      contextRef="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMjU5_3e168c72-a819-4bb4-a736-9f9163084745"
      unitRef="usd">103733</cdtx:LesseeOperatingLeaseMonthlyRate>
    <cdtx:LesseeOperatingLeaseAnnualRateIncrease
      contextRef="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMzEw_14146d8f-97c4-4fb6-8cf3-bd4dbcd47ce3"
      unitRef="number">0.03</cdtx:LesseeOperatingLeaseAnnualRateIncrease>
    <cdtx:NumberOfOperatingLeaseOptionsForExtension
      contextRef="ib12d63d710f14cf2a688757cc358ebca_I20210714"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMzk0_b67e7805-c672-433a-a1cf-f29481d41832"
      unitRef="option">2</cdtx:NumberOfOperatingLeaseOptionsForExtension>
    <cdtx:LesseeOperatingLeaseOptionRenewalTerm
      contextRef="i0563d3151aee4946be6325655f1f8e6d_D20210714-20210714"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3MQ_47faa439-5207-4d7a-a3eb-c75f42f02af0">P2Y</cdtx:LesseeOperatingLeaseOptionRenewalTerm>
    <cdtx:LesseeOperatingLeaseIncrementalBorrowingRate
      contextRef="ib12d63d710f14cf2a688757cc358ebca_I20210714"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfODQ4_8657ea41-296f-4ba7-a6ec-135cb4bc8e46"
      unitRef="number">0.108</cdtx:LesseeOperatingLeaseIncrementalBorrowingRate>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3Mg_d9b7e79b-f61e-4d51-8bc5-bbc8823757b5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company's operating lease as of September&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Present value of lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMC0xLTEtMS00MjM2Nw_1bcdad18-a2b2-4fab-8243-2412e1433289"
      unitRef="usd">340000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMS0xLTEtMS00MjM2Nw_cd6379c4-a41d-40ff-9ec3-d545ccfd5c05"
      unitRef="usd">1400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMi0xLTEtMS00MjM2Nw_5ff5125a-7659-4c5e-9615-db0f0bdffb37"
      unitRef="usd">1740000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfMy0xLTEtMS00MjM2Nw_7cc94d4a-8f16-437b-8702-3e050b509e74"
      unitRef="usd">119000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjViNmVlZWZlMDQyMDQ2MTA4YzNjMDI0MzM0YzQ0MWVmL3RhYmxlcmFuZ2U6NWI2ZWVlZmUwNDIwNDYxMDhjM2MwMjQzMzRjNDQxZWZfNC0xLTEtMS00MjM2Nw_52aab868-c5a1-45fa-960b-9b69974a43e1"
      unitRef="usd">1621000</us-gaap:OperatingLeaseLiability>
    <cdtx:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTg3NQ_2ce520da-ce7a-4125-a9f1-4f2606c1522f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"&gt;The balance sheet classification of the Company's operating lease is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.620%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Current portion of lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;Total operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"&gt;1,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cdtx:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfMS0xLTEtMS00MjM2Nw_ef4d20e5-1837-4a75-8cb0-ee57dc297e56"
      unitRef="usd">1491000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfMy0xLTEtMS00MjM2Nw_f595a43e-0e52-489d-aa1e-daf082e92f30"
      unitRef="usd">1277000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfNC0xLTEtMS00MjM2Nw_5b81eec3-56f3-4f1a-8f32-42b355c9ad3e"
      unitRef="usd">344000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RhYmxlOjg5MzExY2EwMDIyMzQ2Y2I5YjA0NGZiZDViOTk4MzY0L3RhYmxlcmFuZ2U6ODkzMTFjYTAwMjIzNDZjYjliMDQ0ZmJkNWI5OTgzNjRfNS0xLTEtMS00MjM2Nw_2d6a7f41-9a5d-4f0a-a9d3-0cd2114234be"
      unitRef="usd">1621000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia4364c8090e34068aa4c7347a141f4a0_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTE3Mg_ae0445f1-f3dc-4c65-b441-f24ecd358ddc">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeasePayments
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTI2Mw_47371e0f-d77d-4675-b84e-483a90ab8df6"
      unitRef="usd">1000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTI3MA_1679b9d3-207d-4931-872f-45dfd8d85a38"
      unitRef="usd">700000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseCost
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTM0OQ_fe1bb856-c4b0-4293-bce2-8b2a2e975e66"
      unitRef="usd">1000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3e58202bf58244cebc5c9862415e0c2a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTM1Ng_62c32ce1-62c3-4209-9cdd-e55cac63aeb6"
      unitRef="usd">900000</us-gaap:OperatingLeaseCost>
    <cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost
      contextRef="ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjEwM2U3NjIxNjQ5ZTQ3OWFhODljN2QwMTY3Y2ZkOTZmL3NlYzoxMDNlNzYyMTY0OWU0NzlhYTg5YzdkMDE2N2NmZDk2Zl81NS9mcmFnOmJiYTE4MTIyMzdmYzQ0ZTY4ZmNjOWE0NmExMmZjMGY2L3RleHRyZWdpb246YmJhMTgxMjIzN2ZjNDRlNjhmY2M5YTQ2YTEyZmMwZjZfMTU4Nw_0d3c057b-24ef-4b61-8946-b1d3fb4a03ec">P30D</cdtx:LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>55
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MLS)IIN%\!V[EQ!T/<9XB![$R![%*.<A,4V$2 [E@(97U:W3$YUXF3>[[ FS
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MQQCHW]><J_V%>=5R>+4V_Q]02P,$%     @ 8HMC53W=L](C P   @P  !@
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MK(MT$,9 SZ\X5T\=4P969?_T#U!+ P04    " !BBV-5\R*:4>4%  "(&P
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MZ_6U&,)T7?+,OAP0SK%(?_&%<,1VG)'E%[?=+9YN;^<1Q3Y/E"$,%@7"0:(
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M@#ZWDRXM=,P)T^49?HSM0H^/7JNAML.?5. 8DWS)"H/*0X5>;KJ'1#M3F&3
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MM_! ^/BE)H.X!,8Q4_)GH8+*66IT!L#.DJ(L4F18%P@*L6)6FCDLP\C,=/N
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MT&W%\ FEZ+-=0[1P/CG/PZ+SQJY@I9KB=,=#KRE7PO"2S'(RBR50K2$P@]T
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M6#08';>01F"B3X4G[>F]R^PBCB2:X+LM9N\#?_HK60TPG;.T_D-I*D."YD2
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MAP;@_:)$F_8WM$#W7P$N_@M02P,$%     @ 8HMC5=U_$E"7"    1D  !D
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MR?L&1842?T(0^MXC,J+/14"L5K91#JSTW&>EB4><8F*,RR1'J866$LR*CY@
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M#^A6XZDT-P""I4^(TDOL#L/N'KOPQL0@YXI^]M:@P4>T;#"4>D3U"."GVT:
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M'^L=JSGS=G!J8L+@>'VND/ILN.R\CW$F@C=\'V2XYPB@$I_#@([V=5/D>]*
MH9SM^&'F$57\1&+.$-W/4X0;=<.8R139RAFKX>LJ6_):=L1""HK6O;7[L^Q5
MK%O[4[VM#.WXM[3<?>O^]6=3U3V7_ ^DJ#>DK+@\ K3T4U<<1AYB#V3)C.1
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M)ZJ>5(,!]#W:T[M_8 /_\Y0O_@]02P,$%     @ 8HMC50GN!/$?!0  ZPT
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M+W=O<FMS:&5E=',O<VAE970R,"YX;6S55]MNXS80_96!-M@F@+J6*,F7;&+
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M)=/A[0D3JRI_WR^5I=?##]?T7*-V ?2]4,KN)BY!\P_ \ =02P,$%     @
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M;"]W;W)K<VAE971S+W-H965T,C,N>&ULQ9IM;^HV%,>_BI5)TR;=-21 6SI
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MUW@7D2I>MV-8AM<]T(%:&_U9)PYRRJR>O)%CXYN*$*I+A60;@K+YH&PC4+8
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M+8 MM*;.V@1@VRZ@!-Q?6=Z?B\\4TB1:&P#\@0[ C'URR0X]P#%YM0/ -BT
M/MS=#VI@"FF2K'=__);M/VAE9'7_MX76U%D[ /QN"X"M>@!;:$V=M0O MFT
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MSE4H$5AYHE%.!%WK0X$G*@3-]' %1(I4&<C["TK%RT2=,]3G2J.?4$L#!!0
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MWETEB&Y19_+3#_;0^D7%UJ289TA,XMXON?=UZI-/B$: MR; &[;_!9"-@)X
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MT&HW;XC6+=&ZYU\XL,]S;UOW^$R2'L&]ZIFL-: A7J_$Z]4FT>^V%M"A&FU
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M12K(#JCM63]C?247:KPA3.I%D#(2\,!\E]2BP5/VL%-YV^='.3_ZOVW,HT&
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MT^M96>J/_F9'DXVH%J*:0#6):@K5(E33J&90+4:U!-4LI;D]HTX_]@8'OTQ
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M7@#_1YRKEXEV4+;@@W\ 4$L#!!0    ( &.+8U49.:U!' L  /V2   9
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MI;!J_\"S^P?VPGK,6FG[!EO+ &H[0&D42F-0&H?2!(IFBE3;(][@Y*42ZF!
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MX5X7YRO[!EK+"&HF0&D,2N-0FD#13!EI,R$XHH/6P17Z/2S/LN]@ZW,KU/.
MTBB4QJ T#J4)%,T\*+0E$YR\AU8 M5"@- *E42B-06D<2A,HFJE:;:$$1_?0
MLF>V5AO4^H#2:+#?T<H+A\-Z$ZV&L+W+YH-(PDHR?\M0VPKA$?VS])WHQ?M<
M)VW?J;8B@]((E$:A- :E<2A-H&CF@: MF?#D[;-"J.L"I1$HC4)I#$KC4)I
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M%R#+/"?BY1HSOALXOO-Z\$ WJ3(';M0OR 87J!Z+N= [M_:2T!R9I)R!P/7
M&?J]ZZZQMP8_*.[DP1I,)"O.G\QFD@P<SPC"#&-E/!#]VN((L\PXTC+^['TZ
M-:4!'JY?O=_:V'4L*R)QQ+.?-%'IP/GL0()K4F;J@>^^XSZ>CO$7\TS:)^SV
MMIX#<2D5S_=@K2"GK'J3YWT>#@!!< 00[ &!U5T1695CHDC4%WP'PEAK;V9A
M0[5H+8XR4Y2%$OHKU3@5C>ZGT\ER>C-;+F X&\/H?K:<S+[=S$:3FP5<PC#G
M)5,7L*2:? .$)?#(8A1*UUN] %_#B,@4;G5Q):P%S^&^0$&4,;Y#G2XX'Z,V
MSN0G. /*8)GR4FHWLN\JK=^H<..]UNM*:W!$ZP*+*VAY%Q!X00"/BS&<GWWZ
MUXVKPZ]S$-0Y"*S?UK$<\#RG2G>:DC; $6=&/[*8HH0QE7'&92D0?@U74@G=
M2+^;Q%<D[682<[EZLB Q#AQ]>R2*+3K1QP]^Z'T]$4*K#J%URGMD,M*DJ4*%
M%F7NYS9JM;V^NVV@:M=4[?>H6DU4%:IS0.6WO2-<G9JK<Y)KR17)H&2)KH'I
M0TR U^V5V?8JR(NM7).DSEM)W6/AA[6D\*2D.Y2R!Y.\*(T:?0E05U,UL8=O
MV"]]_TLS>[=F[YYDGYO680JV)"O1W+[WD]!]TP)^&/C_R7 /)H@9QE,B-I1)
M[7ZM8=Y55X<AJ@%7;10O[%!9<:5'E%VF^I^ PACH[VO.U>O&S*GZ+Q/]!5!+
M P04    " !CBV-5KXJG[]("  !S!P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S.2YX;6RM55U/VS 4_2M6AB8F#?+9E+$V$J1LJ[061,KV,.W!36];"\?.
M;*>%?S_;"5$IH=NDO21V<L_QN>?:UX,M%_=R#:#00T&9'#IKI<ISUY7Y&@HL
M3WD)3/]9<E%@I:=BY<I2 %Y84$'=P/-BM\"$.<G ?KL1R8!7BA(&-P+)JBBP
M>+P$RK=#QW>>/MR2U5J9#VXR*/$*,E!WY8W0,[=E69 "F"2<(0'+H7/AGZ>Q
MB;<!WPALY<X8F4SFG-^;R7@Q=#PC""CDRC!@_=I "I0:(BWC5\/IM$L:X.[X
MB?V3S5WG,L<24DZ_DX5:#YTS!RU@B2NJ;OGV"S3Y] Q?SJFT3[1M8CT'Y954
MO&C 6D%!6/W&#XT/.P _>@40-(#@;P%A PAMHK4RF]8(*YP,!-\B8:(UFQE8
M;RQ:9T.8J6*FA/Y+-$XEZ?5D,IY-KJ:S#%U,1RB]GL[&T\]7TW1\E:$3E%5E
M24&736&*+C'%+ >4V?TU9O4F,M4X'H'"A,IW&G*7C=#QT3MTA A#LS6O)&8+
M.7"5EFL6=?-&VF4M+7A%6@;E*0J]]RCP@J #GAZ&CR#7<-_"_>=P5YO4.A6T
M3@66+WS-*5X41!DG)-()H90S1=@*6$Y HA&1.>6R$H!^7,RE$GI__NS*N5XD
MZE[$G-ES6>(<AHX^E!+$!ISD[1L_]CYV.?"?R)[Y$;9^A(?8D^L2!#8.( KZ
M'"%A#LP)7YY4>H*E!-65?LT96T[383:)'WW0Y=GLIO4R* C.^FW0,[E1*S<Z
M*#>MA-"U0R47=L?R9:.;$CPGE*C'+KDU9V]7;M#O[\GM"/*CLVZYO59N[Z#<
MKW_6UGNQ;!A%>])Z+^T.S6'JDA:WTN*#TF;<] *^5_Z#4N.7,N)@O^H'5_W7
MS>SNM$1S'4VP6!$FM=BEIO=.^]H94;?X>J)X:;ODG"O=<^UPK6]%$"9 _U]R
MKIXFIO&V]VSR&U!+ P04    " !CBV-5Y/952#H#  #N$P  #0   'AL+W-T
M>6QE<RYX;6S=6%UOVC 4_2M1NDZM-#5 UI2L@+0A59JT397:A[U5ACC!DF-G
MCNE@OWZ^=@@?]46L#QLLJ,2^Q^?<8_NF<3NH]9+3AQFE.EB47-3#<*9U]2&*
MZNF,EJ2^DA45!LFE*HDV755$=:4HR6H@E3SJ=3I)5!(FPM% S,N[4M?!5,Z%
M'H9)&PK<[7,V#+O)^S!P<F.9T6'X=/'VQUSJVS>!NY^].SOK/%W>[L8O+' 9
M1E[1ZP-$KSKF0I4MBLDGA\GO$\>D;[:E[?!S(^2(YQBM[Z&9+&LF=#!R>M!T
M]LS&"D?-?H\&N13K;8]#%S"924F#9\*'X9AP-E$,6#DI&5^Z< \"4\FE"K2I
M-V.E"Y'ZEX.[K@>EV.B43$AE<[L,[GO2#-\!5CTPR#AO#?9"%Q@-*J(U5>+.
M=.Q@&WP!!4W[<5D9AX4BRV[O.EP3[,TDF4B54=6FZ8:KT&C :0YV%"MF<->R
MB@#46I:FD3%22$&LAQ6C:1C9*>7\ 9[3[_F6]B+?V-,.[*AHF\90TW0RK@/Z
MFVI.>U,V?I5N4+%GJ3_-S72$[4.MT'M%<[:P_47>&L#4N[@ZJ2J^_,A9(4KJ
M)G]PPM& K'C!3"KVRV2#4IF: %5A\$R59M/-R$]%JD>ZT*MR6N2XY]X)>OZ[
MZUQ0017AFZ9-[1_S*K_:<7SSKRS;WRJ[AKT>FY?OL9N\/@63R2F8/(F:[)^"
MR?3X3<;'Z3%J#AD;)YFM<TP;#>"\. R_P<F4KY,&DSGCFHFF-V-91L6+XXR1
MUV1B_IC9TC?C,YJ3.=>/+3@,U^VO-&/S,FU'W<-"-*/6[2\PO6[2'E9-+B8R
MNJ#9N.FJ8F*;@6F8K,T%A%WDSEY^!.,XS(\ AN7!'& <Q\+R_$_SZ:/S<1CF
MK>]%^BBGCW(<RX>,[0?+X^>DYO+/-$WC.$FP%1V/O0[&V+HE"?SXU3!OP,#R
M0*8_6VM\M_$*V5\'V)[NJQ!LIG@E8C/%UQH0_[H!(TW]NXWE 0:V"UCM0'Y_
M'J@I/R>.85<Q;]@3C"-IBB%0B_X:31)D=1+X^/<'>TKB.$W]"&!^!W&,(? T
MX@CF #Q@2!S;]^#.^RA:O:>B]7_X1K\!4$L#!!0    ( &.+8U67BKL<P
M !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6
MH@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.
MD4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,
M<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW'
M]I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 8XMC
M51XF6+"& P  H1H   \   !X;"]W;W)K8F]O:RYX;6S%F=]OHC <P/^5AJ?=
MPPX!=3\RES#$C9R")VBRIZ5"G<V@-07=W?[Z*W!F)3>_N9?&)VF+Y=.6?C]M
MN7OGXFW-^1OZ5>2L'!G;JMK=FF:9;DF!R^]\1Y@LV7!1X$HFQ:M9[@3!6;DE
MI"IRT^[UAF:!*3/N[XYUS86I)GA%THIR)C/KC!4E[^5G>9U$!UK2-<UI]7MD
M--<Y,5!!&2WH!\E&1L] Y9:_/W%!/SBK<!ZG@N?YR+#:@A41%4W_R8YKR 2O
MRR:GPNL%EB C8]B3%6ZH**OFCJ9^+!D/1-[<IO85G]"\(F*,*_(H^'Y'V6M=
MC6R%J32CZ8?C;]N)M^)_NI%O-C0E8Y[N"\*JMA\%R6M 5F[IKC00PP49&1X_
M$%&W1SX@R-JV51)*Z2EQ2V6!"+(&3R<*RP@K28;D5<ESFDF.##W@'+.4( 72
M!B#M,T*^V JD T Z9X&,:QSY5P6R#T#VSPC9Z<D! #DX)Z2C0 X!R*%>R.3)
M1UXTF[OA,W+#,7IPXR!&T03-%W[LAPKD%0!YI1<R7LYF[N*YQHJ#QS"8!)X;
M)LCUO&@9)H$">0U 7NN%G+C! JW<Z=)',]^-EPM_YH=)K,#= ' W>N'&_D.B
M1NH>%*I[FD<SB;P?3]%T["_B%^3_7 ;)L\H&:D2S1UH:%(2>'+M@Y:/YU W5
M,;0@?UB:!=)Y^1\7?ON&-?/6B\+. $,&L70K))K-@J3+%H2/?N@%?J<O(8-8
MFA4"QI2.0BS((99FB<"8JD0LR"*69HV<"'[H0BY;<U*JF)!'+-TB^2+T'!F_
MJ9"01RS-(ODZ!GV)"1G%TJP4,!AU)I -V<;6;!LP&*$+%1,2CZU9/. ZK-N;
MX Y&MX' <-17,2$#V9H-!&,.5$S(0?99'314,2$'V9H=="JX7Z)X7Q18Q80<
M9&MV4+W&E4QNEM&Z#.<H8&U%,M6=Z9"#[',XZ!*%6 AY\T'%A"QD:[;0"<Q8
M5IWM:Y)/3,A"MF8+G9#E\350SU0@"SF:+702LYE!ZB&: UG(.<OVYR]F]X0*
MLI"CV4*G,9NW4\4$3])T6PA<(:EK=P>RD*/;0B"FZG0'LI"C>R<$8JI.=R +
M.9HM!*\W+U5,R$*.9@N!F-V9#EG(T6PA&+,SA2 +.8V%S.,GD8QL*"-9*!]1
MROP4Y^E<H/JG/>+I#^J=U6:?YY[,B]B4X^SXA>7X=>C^#U!+ P04    " !C
MBV-50+O#+8<!  "\%P  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
MS=C+;L(P$(7A5T%Y )R9X5H!JV[85KQ !.8B<E/LJO#VC6 !!W71#?)91;:5
MR;_Z%'GQY<LBGIHZ'$]M&%RJL@[+[!AC^^%<V!Y]581AT_JZ/]DW757$?MD=
M7%MLS\7!.\WSB>N>9V2KQ?/,P>;:^O],;/;[T]9_-MOORM?QC\'NI^G.X>A]
MS :;HCOXN,S<I7QL!W=[R+"?G W6NV76K7>2N=1!"D&:/L@@R-('C2!HE#YH
M#$'C]$$3")JD#YI"T#1]T R"9NF#YA T3Q\D.<J8$R2]8$V@M2#70N"U(-A"
M(+8@V4)@MB#:0J"V(-M"X+8@W$(@MR#=0F"W(-Y"H+>BWDJ@MZ+>2J"WOOQL
M$^BMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z&VHMQ'H;:BW
M$>AMJ+<1Z&TOER4$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H;ZFWOU#O$
M:^G#H^>^QMO(=U(=^W?]X_.WY7T3<1[=<'9P6;_Z!5!+ P04    " !CBV-5
M_WEJDI\!   =&   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-F<UN@S 0A%\%
M<8V"8[M-?Y3DTO;:YM 7<&$)*( MVTF3MZ\A/U*K%"5*I<X%"[P[,WBE[P"3
M]ZTA%VWJJG'3N/#>/#+FTH)JY1)MJ D[N;:U\N'6+IA1Z5(MB(G1:,Q2W7AJ
M_-"W&O%L\DRY6E4^>MF$QZ[4S32V5+DX>MH5ME[36!E3E:GR89^MF^R'RW#O
MD(3.KL85I7&#4!"SDP[MSN\&^[ZW-5E;9A3-E?6OJ@Y5;%,QY[<5N:1?XD1&
MG>=E2IE.5W5H29RQI#)7$/FZ2G:B@WYG'TZ8=E=^M7\GTV<8*N=6&Q<F9NER
MN\-(VNZA"4)D?=G_BD?'('WU^U$[[8RR,[W#\7YJN^SFX5BW7'_&WV=\U+\P
MAP#)(4%RW(#DN 7),0;)<0>2XQXDQP-(#CY""8)"5(Z"5(["5(X"58Y"58Z"
M58["58X"5HY"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5H%"5HE"5HE"
M5HE"5HE"5HE"5HE"5HE"5HE"5HE"5OF?9/W0>OG7'ZS;-:E5V1S\6?=78/8%
M4$L! A0#%     @ 8HMC50=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !BBV-5>GYA/>X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !BBV-5F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( &*+8U5)HF%2^@4  ,X?   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !BBV-5D?S]F"\&  !F&P  &               @($]#@  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 8HMC53W=L](C P   @P  !@
M             ("!HA0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( &*+8U7S(II1Y04  (@;   8              " @?L7  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !BBV-50GN2$&T'  !(
M(0  &               @($6'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ 8HMC50S+O$WW#P  J[P  !@              ("!N24
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( &*+8U48^,9Q
MP0T  +TD   8              " @>8U  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !BBV-5QEP:5O$<   F7   &
M@('=0P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 8HMC
M57C!=@M?!0  '@T  !@              ("!!&$  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( &*+8U77LPC"+0,  -H&   9
M      " @9EF  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ 8HMC51"=9Q5V"P  %B   !D              ("!_6D  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !BBV-5W7\24)<(   !&0
M&0              @(&J=0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( &*+8U45J='#.AX  +:%   9              " @7A^  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 8HMC5;TG(< &
M!@  V@T  !D              ("!Z9P  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !BBV-5?C-]AQXB  "J<@  &0
M@($FHP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( &*+
M8U4)[@3Q'P4  .L-   9              " @7O%  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ 8HMC5<V0#AT  P  &@<  !D
M         ("!T<H  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !BBV-5#M0SK1\#  !X!@  &0              @($(S@  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &*+8U5J!H)&OP0  +8+
M   9              " @5[1  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ 8HMC55 :?&T !0  [0P  !D              ("!5-8
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !BBV-54?YM
M W(#   ,"   &0              @(&+VP  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( &*+8U4PYWR]. ,  &L*   9
M  " @33?  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M8HMC53JF$?K>!   \B0  !D              ("!H^(  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !BBV-5VWP &(H&  "@*P  &0
M            @(&XYP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( &*+8U6?YAK-/@0  '\6   9              " @7GN  !X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 8HMC57P$N9^M P
MQQ(  !D              ("![O(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !BBV-5PQ)626P"  !X!@  &0              @('2
M]@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( &*+8U7$
MWLB5'PD  "I6   9              " @77Y  !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ 8HMC5:LFF7;P P  8Q(  !D
M     ("!RP(! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &.+8U4M%FK&,A0  '%: 0 9              "
M@;T; 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 8XMC
M5?7T'5P$!   C@\  !D              ("!)C ! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " !CBV-5&3FM01P+  #]D@  &0
M        @(%A- $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( &.+8U7BNB('/P0  ',1   9              " @;0_ 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 8XMC53HEY\N^ @  <08
M !D              ("!*D0! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " !CBV-5KXJG[]("  !S!P  &0              @($?1P$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( &.+8U7D]E5(
M.@,  .X3   -              "  2A* 0!X;"]S='EL97,N>&UL4$L! A0#
M%     @ 8XMC59>*NQS     $P(   L              ( !C4T! %]R96QS
M+RYR96QS4$L! A0#%     @ 8XMC51XF6+"& P  H1H   \
M ( !=DX! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &.+8U5 N\,MAP$
M +P7   :              "  2E2 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( &.+8U7_>6J2GP$  !T8   3              "
M >A3 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     O "\ P P  +A5 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>251</ContextCount>
  <ElementCount>246</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - EQUITY INCENTIVE PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANS</Role>
      <ShortName>EQUITY INCENTIVE PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - EQUITY INCENTIVE PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSTables</Role>
      <ShortName>EQUITY INCENTIVE PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/EQUITYINCENTIVEPLANS</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cidara.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails</Role>
      <ShortName>THE COMPANY AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - DEBT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/DEBTAdditionalInformationDetails</Role>
      <ShortName>DEBT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails</Role>
      <ShortName>SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cdtx-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: cdtx:CollaborativeArrangementCostSharingPercentage, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  cdtx-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="cdtx-20220930.htm">cdtx-20220930.htm</File>
    <File>cdtx-20220930.xsd</File>
    <File>cdtx-20220930_cal.xml</File>
    <File>cdtx-20220930_def.xml</File>
    <File>cdtx-20220930_lab.xml</File>
    <File>cdtx-20220930_pre.xml</File>
    <File>exhibit1012022-09.htm</File>
    <File>exhibit1022022-09.htm</File>
    <File>exhibit1032022-09.htm</File>
    <File>exhibit1042022-09.htm</File>
    <File>exhibit3112022-09.htm</File>
    <File>exhibit3122022-09.htm</File>
    <File>exhibit3212022-09.htm</File>
    <File>exhibit3222022-09.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="636">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cdtx-20220930.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "contextCount": 251,
   "dts": {
    "calculationLink": {
     "local": [
      "cdtx-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cdtx-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cdtx-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cdtx-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cdtx-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cdtx-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 393,
   "entityCount": 1,
   "hidden": {
    "http://cidara.com/20220930": 1,
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 12
   },
   "keyCustom": 31,
   "keyStandard": 215,
   "memberCustom": 22,
   "memberStandard": 25,
   "nsprefix": "cdtx",
   "nsuri": "http://cidara.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://cidara.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - DEBT",
     "role": "http://cidara.com/role/DEBT",
     "shortName": "DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - EQUITY INCENTIVE PLANS",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANS",
     "shortName": "EQUITY INCENTIVE PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - EQUITY INCENTIVE PLANS (Tables)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSTables",
     "shortName": "EQUITY INCENTIVE PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION (Details)",
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ComprehensiveIncomeNetOfTax",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted EPS (Details)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Computation of Basic and Diluted EPS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Summary of Financial Instruments Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i052c13aef942486698daafbe3f173f65_I20161003",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - DEBT - Additional Information (Details)",
     "role": "http://cidara.com/role/DEBTAdditionalInformationDetails",
     "shortName": "DEBT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i052c13aef942486698daafbe3f173f65_I20161003",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "if7f37a17eb6a463698c6b8c41d120df5_D20211013-20211013",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "if7f37a17eb6a463698c6b8c41d120df5_D20211013-20211013",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockConsiderationReceivedPerTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i871e9ccbcb2a4afea3b491f311e0c0a8_D20150301-20150331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "icc7909cccd3141d4980af143ffea9363_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "icc7909cccd3141d4980af143ffea9363_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ib5225fdc3f334ed69fa883c887f70abe_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "EQUITY INCENTIVE PLANS - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "iecd9ae8d02994db09c6c17d85d05eb8e_D20190903-20190903",
      "decimals": "-5",
      "lang": "en-US",
      "name": "cdtx:CollaborativeArrangementMaximumThirdPartyShareOfCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ib5225fdc3f334ed69fa883c887f70abe_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Summary of Contract Liability Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "cdtx:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "role": "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
     "shortName": "SIGNIFICANT AGREEMENTS AND CONTRACTS - Revenues Disaggregated by Timing of Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "iad9574638cde472faee405847f9f3e1a_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ib12d63d710f14cf2a688757cc358ebca_I20210714",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ib12d63d710f14cf2a688757cc358ebca_I20210714",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Amount, Timing and Uncertainty of Cash Flows from Operating Lease (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cdtx:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ia4364c8090e34068aa4c7347a141f4a0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)",
     "role": "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i1455ccf570fa408797a81a114aeef838_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i693eb172a4d347d0b0a8944c52cb7b00_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "role": "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "i2654fc2a4fcd482787080addea259ea4_D20210101-20210331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - THE COMPANY AND BASIS OF PRESENTATION",
     "role": "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION",
     "shortName": "THE COMPANY AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://cidara.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cdtx-20220930.htm",
      "contextRef": "ieb378ae20898418fbaa068b97e5617f9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "cdtx_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdtx_AuthorizedSharesForFutureStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Authorized Shares For Future Stock Awards",
        "label": "Authorized Shares For Future Stock Awards [Member]",
        "terseLabel": "Authorized for future stock awards"
       }
      }
     },
     "localname": "AuthorizedSharesForFutureStockAwardsMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ClinicalDrugSupplyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Drug Supply",
        "label": "Clinical Drug Supply [Member]",
        "terseLabel": "Clinical Drug Supply"
       }
      }
     },
     "localname": "ClinicalDrugSupplyMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ClinicalSupplyServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Supply Services [Member]",
        "label": "Clinical Supply Services [Member]",
        "terseLabel": "Clinical Supply Services"
       }
      }
     },
     "localname": "ClinicalSupplyServicesMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_CollaborationAgreementNumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number of Performance Obligations",
        "label": "Collaboration Agreement, Number of Performance Obligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPerformanceObligations",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdtx_CollaborativeArrangementCostSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Cost Sharing Percentage",
        "label": "Collaborative Arrangement, Cost Sharing Percentage",
        "terseLabel": "Cost sharing percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementCostSharingPercentage",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results",
        "label": "Collaborative Arrangement, Election To Proceed Notice, Period Post Delivery Of Results",
        "terseLabel": "Election to proceed notice, period post delivery of results"
       }
      }
     },
     "localname": "CollaborativeArrangementElectionToProceedNoticePeriodPostDeliveryOfResults",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Third Party Share Of Cost",
        "label": "Collaborative Arrangement, Maximum Third Party Share Of Cost",
        "terseLabel": "Collaborative agreement, maximum cost share"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumThirdPartyShareOfCost",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice",
        "label": "Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice",
        "terseLabel": "Termination provisions, required period of written notice"
       }
      }
     },
     "localname": "CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdtx_CollaborativeArrangementTransactionPotentialValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Transaction, Potential Value",
        "label": "Collaborative Arrangement, Transaction, Potential Value",
        "terseLabel": "Collaborative agreement, potential transaction value"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPotentialValue",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrant [Member]",
        "label": "Common Stock Warrant [Member]",
        "terseLabel": "Common Stock Warrant"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]",
        "label": "Controlled Equity Sales Agreement, Cantor Fitzgerald And Company [Member]",
        "terseLabel": "Controlled Equity Sales Agreement, Cantor Fitzgerald and Company"
       }
      }
     },
     "localname": "ControlledEquitySalesAgreementCantorFitzgeraldAndCompanyMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion",
        "label": "Convertible Preferred Stock, Maximum Ownership Percentage Following Conversion",
        "terseLabel": "Maximum ownership following conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMaximumOwnershipPercentageFollowingConversion",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development, Regulatory, And Commercial Milestones",
        "label": "Development, Regulatory, And Commercial Milestones [Member]",
        "terseLabel": "Development, Regulatory, and Commercial Milestones"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercialMilestonesMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer",
        "label": "Increase (Decrease) In Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_JanssenCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Collaboration Agreement",
        "label": "Janssen Collaboration Agreement [Member]",
        "terseLabel": "Janssen Collaboration Agreement"
       }
      }
     },
     "localname": "JanssenCollaborationAgreementMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_JanssenPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Inc.",
        "label": "Janssen Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Janssen Pharmaceuticals, Inc.",
        "verboseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_LesseeOperatingLeaseAnnualRateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rate Increase",
        "label": "Lessee, Operating Lease, Annual Rate Increase",
        "terseLabel": "Percentage increase in base rent annual"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRateIncrease",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_LesseeOperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Incremental Borrowing Rate",
        "label": "Lessee Operating Lease Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_LesseeOperatingLeaseMonthlyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rate",
        "label": "Lessee, Operating Lease, Monthly Rate",
        "terseLabel": "Base rent per month"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRate",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_LesseeOperatingLeaseOptionRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option Renewal Term",
        "label": "Lessee, Operating Lease, Option Renewal Term",
        "terseLabel": "Option renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionRenewalTerm",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdtx_LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost",
        "label": "Lessee, Variable Lease And Short-Term Leases, Term Of Lease Included In Operating Lease Cost",
        "terseLabel": "Variable lease and short-term lease term included within operating lease cost (greater than)"
       }
      }
     },
     "localname": "LesseeVariableLeaseAndShortTermLeasesTermOfLeaseIncludedInOperatingLeaseCost",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cdtx_LicensesOfIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licenses Of Intellectual Property [Member]",
        "label": "Licenses Of Intellectual Property [Member]",
        "terseLabel": "License of Intellectual Property"
       }
      }
     },
     "localname": "LicensesOfIntellectualPropertyMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_MelintaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Melinta Therapeutics Inc",
        "label": "Melinta Therapeutics Inc [Member]",
        "terseLabel": "Melinta Therapeutics, Inc.",
        "verboseLabel": "Melinta"
       }
      }
     },
     "localname": "MelintaTherapeuticsIncMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement [Member]",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone Achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_MoreThanTenPercentVotingRightsClassesOfStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "More than ten percent voting rights classes of stock.",
        "label": "More Than Ten Percent Voting Rights Classes Of Stock [Member]",
        "terseLabel": "More than 10% of voting power"
       }
      }
     },
     "localname": "MoreThanTenPercentVotingRightsClassesOfStockMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_MundipharmaMedicalCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mundipharma Medical Company [Member]",
        "label": "Mundipharma Medical Company [Member]",
        "terseLabel": "Mundipharma Medical Company",
        "verboseLabel": "Mundipharma"
       }
      }
     },
     "localname": "MundipharmaMedicalCompanyMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_NumberOfOperatingLeaseOptionsForExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Operating Lease Options For Extension",
        "label": "Number Of Operating Lease Options For Extension",
        "terseLabel": "Number of options to extend"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseOptionsForExtension",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdtx_NumberOfVotesEntitlementForEachShareHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of votes entitlement for each share held.",
        "label": "Number Of Votes Entitlement For Each Share Held",
        "terseLabel": "Number of votes for each share held"
       }
      }
     },
     "localname": "NumberOfVotesEntitlementForEachShareHeld",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cdtx_OperatingLeaseRightOfUseAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use, Amortization",
        "label": "Operating Lease, Right-Of-Use, Amortization",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAmortization",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_PaymentsRelatedToCollaborativeAgreements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Related To Collaborative Agreements",
        "label": "Payments Related To Collaborative Agreements",
        "terseLabel": "Payments related to collaborative agreement"
       }
      }
     },
     "localname": "PaymentsRelatedToCollaborativeAgreements",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]",
        "label": "Preclinical And Clinical Trial Accrued Costs [Policy Text Block]",
        "terseLabel": "Preclinical and Clinical Trial Accruals"
       }
      }
     },
     "localname": "PreclinicalAndClinicalTrialAccruedCostsPolicyTextBlock",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdtx_ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses And Other Current Assets",
        "label": "Proceeds From Public Offering, Net Of Issuance Costs, Prepaid Expenses And Other Current Assets",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ProceedsFromPublicOfferingNetOfIssuanceCostsPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_PublicStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Stock Offering",
        "label": "Public Stock Offering [Member]",
        "terseLabel": "Public Stock Offering"
       }
      }
     },
     "localname": "PublicStockOfferingMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_RDFundingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "R&amp;D Funding",
        "label": "R&amp;D Funding [Member]",
        "terseLabel": "R&amp;D Funding"
       }
      }
     },
     "localname": "RDFundingMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Services [Member]",
        "label": "Research And Development Services [Member]",
        "terseLabel": "Research and Development Services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock Units and Performance-based Restricted Stock Units [Member]",
        "label": "Restricted Stock Units And Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units and Performance-based Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability",
        "totalLabel": "Total deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "order": 1.0,
       "parentTag": "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Current",
        "netLabel": "Current portion of deferred revenue",
        "periodEndLabel": "Closing balance",
        "periodStartLabel": "Opening balance",
        "terseLabel": "Current deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityCurrent",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails": {
       "order": 2.0,
       "parentTag": "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue",
        "verboseLabel": "Long-term portion of deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Payments Received In Advance",
        "terseLabel": "Payments received in advance"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityPaymentsReceivedInAdvance",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Revenue from performance obligations satisfied during reporting period"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiabilityRollForward",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability",
        "label": "Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability",
        "terseLabel": "Long-term portion of deferred revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_SaleOfStockConsiderationRemainingOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Remaining on Transaction",
        "label": "Sale of Stock, Consideration Remaining on Transaction",
        "terseLabel": "Consideration remaining on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationRemainingOnTransaction",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cdtx_SeriesXConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series X Convertible Preferred Stock [Member]",
        "label": "Series X Convertible Preferred Stock [Member]",
        "terseLabel": "Series X Convertible Preferred Stock",
        "verboseLabel": "Series X Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesXConvertiblePreferredStockMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award automatic increase in number of shares authorized for issuance percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Number Of Shares Authorized For Issuance Percentage",
        "terseLabel": "Automatic annual increase in shares authorized for issuance in equity incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInNumberOfSharesAuthorizedForIssuancePercentage",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Ownership Percentage, Threshold",
        "terseLabel": "Voting power threshold"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOwnershipPercentageThreshold",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cdtx_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A [Member]",
        "label": "Term Loan A [Member]",
        "verboseLabel": "Term A Loan"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]",
        "label": "Total Aggregate Intrinsic Value Of Stock Options Granted [Abstract]",
        "terseLabel": "Total Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "TotalAggregateIntrinsicValueOfStockOptionsGrantedAbstract",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cdtx_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "verboseLabel": "2015 EIP"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_UnauditedInterimFinancialDataPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial data.",
        "label": "Unaudited Interim Financial Data [Policy Text Block]",
        "terseLabel": "Unaudited Interim Financial Data"
       }
      }
     },
     "localname": "UnauditedInterimFinancialDataPolicyTextBlock",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cdtx_UpfrontPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment",
        "label": "Upfront Payment [Member]",
        "terseLabel": "Upfront Payment"
       }
      }
     },
     "localname": "UpfrontPaymentMember",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cdtx_WarrantsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Aggregate Intrinsic Value, Outstanding",
        "label": "Warrants, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Warrants, aggregate intrinsic value, outstanding"
       }
      }
     },
     "localname": "WarrantsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://cidara.com/20220930",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://cidara.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r291",
      "r431",
      "r432",
      "r433",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r39",
      "r83",
      "r84",
      "r208",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r207",
      "r243",
      "r293",
      "r294",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r487",
      "r489",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r190",
      "r207",
      "r243",
      "r293",
      "r294",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r487",
      "r489",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r157",
      "r188",
      "r189",
      "r279",
      "r280",
      "r448",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r157",
      "r188",
      "r189",
      "r279",
      "r280",
      "r448",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r182",
      "r187",
      "r188",
      "r189",
      "r190",
      "r207",
      "r243",
      "r283",
      "r293",
      "r294",
      "r328",
      "r329",
      "r330",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r487",
      "r489",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r182",
      "r187",
      "r188",
      "r189",
      "r190",
      "r207",
      "r243",
      "r283",
      "r293",
      "r294",
      "r328",
      "r329",
      "r330",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r487",
      "r489",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r38",
      "r39",
      "r83",
      "r84",
      "r208",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r440",
      "r442",
      "r445",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r436"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r159",
      "r160"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r20",
      "r82",
      "r432",
      "r433",
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable, related parties"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r340",
      "r341",
      "r342",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r258",
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedTerseLabel": "Issuance costs for underwritten public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r53",
      "r65",
      "r227",
      "r408"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r12",
      "r81",
      "r143",
      "r151",
      "r155",
      "r170",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r366",
      "r369",
      "r388",
      "r434",
      "r436",
      "r465",
      "r476"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r26",
      "r81",
      "r170",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r366",
      "r369",
      "r388",
      "r434",
      "r436"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r86",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "THE COMPANY AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Capitalized contract cost, amortization",
        "verboseLabel": "Amortization of costs to obtain a contract with a customer"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostGross": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Capitalized contract cost, gross"
       }
      }
     },
     "localname": "CapitalizedContractCostGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Capitalized contract cost, net"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r10",
      "r67"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and money market accounts"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r68",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r61",
      "r67",
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r61",
      "r397"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r78",
      "r81",
      "r108",
      "r112",
      "r119",
      "r123",
      "r125",
      "r131",
      "r132",
      "r133",
      "r170",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r241",
      "r242",
      "r246",
      "r250",
      "r258",
      "r388",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r267",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r361",
      "r362",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "SIGNIFICANT AGREEMENTS AND CONTRACTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r469",
      "r482"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r191",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r87",
      "r88",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r436"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized at September\u00a030, 2022 and December\u00a031, 2021; 71,181,197 shares issued and outstanding at September\u00a030, 2022 and 67,863,674 shares issued and outstanding at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r41",
      "r43",
      "r44",
      "r50",
      "r471",
      "r484"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Net income (loss) and comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]",
        "terseLabel": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]",
        "terseLabel": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r241",
      "r242",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series X Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r17",
      "r18",
      "r253",
      "r259",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common stock issued for each preferred stock (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r77",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r221",
      "r228",
      "r229",
      "r231",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "DEBT"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r80",
      "r85",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r233",
      "r234",
      "r235",
      "r409",
      "r466",
      "r467",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Prime interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r204",
      "r232",
      "r233",
      "r407",
      "r409",
      "r410"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Borrowed from the lender"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Variable annual rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32",
      "r80",
      "r85",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r232",
      "r233",
      "r234",
      "r235",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r32",
      "r80",
      "r85",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r259",
      "r263",
      "r264",
      "r265",
      "r406",
      "r407",
      "r409",
      "r410",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r70",
      "r71",
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Deferred financing costs incurred but not yet paid"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r65",
      "r179"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r334",
      "r335",
      "r337",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "EQUITY INCENTIVE PLANS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r51",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r105",
      "r108",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r381",
      "r382",
      "r472",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net earnings (loss) per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r51",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100",
      "r108",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r381",
      "r382",
      "r472",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net earnings (loss) per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period to recognize unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Estimated unrecognized share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized share-based compensation expense, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP",
        "verboseLabel": "Awards available under the ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r46",
      "r47",
      "r48",
      "r87",
      "r88",
      "r89",
      "r92",
      "r101",
      "r103",
      "r130",
      "r174",
      "r258",
      "r266",
      "r340",
      "r341",
      "r342",
      "r355",
      "r356",
      "r380",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r430",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r384",
      "r385",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r219",
      "r232",
      "r233",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r385",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value, Hierarchy"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r219",
      "r284",
      "r285",
      "r290",
      "r292",
      "r385",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "LEVEL 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r219",
      "r232",
      "r233",
      "r284",
      "r285",
      "r290",
      "r292",
      "r385",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "LEVEL 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r219",
      "r232",
      "r233",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r385",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "LEVEL 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r219",
      "r232",
      "r233",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r181",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r45",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r64",
      "r420"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, other current assets, and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock": {
     "auth_ref": [
      "r117",
      "r118",
      "r125"
     ],
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock",
        "terseLabel": "Series X Convertible Preferred Stock, as converted (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r125",
      "r297"
     ],
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Common stock options, RSUs, PRSUs, and ESPP (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r60",
      "r62",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Amount, Timing and Uncertainty of Cash Flows from Operating Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r423"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r81",
      "r152",
      "r170",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r367",
      "r369",
      "r370",
      "r388",
      "r434",
      "r435"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r81",
      "r170",
      "r388",
      "r436",
      "r468",
      "r479"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r30",
      "r81",
      "r170",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r367",
      "r369",
      "r370",
      "r388",
      "r434",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "terseLabel": "Current portion of term loan"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r32",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r61",
      "r63",
      "r66"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r40",
      "r42",
      "r48",
      "r49",
      "r66",
      "r81",
      "r91",
      "r96",
      "r97",
      "r98",
      "r99",
      "r102",
      "r103",
      "r121",
      "r143",
      "r150",
      "r153",
      "r154",
      "r156",
      "r170",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r382",
      "r388",
      "r470",
      "r483"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "totalLabel": "Net income (loss) and comprehensive income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r99",
      "r105",
      "r106",
      "r122",
      "r125",
      "r143",
      "r150",
      "r153",
      "r154",
      "r156"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income (loss) attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r107",
      "r113",
      "r114",
      "r115",
      "r116",
      "r122",
      "r125"
     ],
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Numerator for diluted net earnings (loss) per share - net income (loss) attributable to common stockholders after assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r98",
      "r104",
      "r128",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r340",
      "r341",
      "r342",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r404",
      "r405",
      "r411",
      "r412",
      "r413",
      "r414",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r449",
      "r450",
      "r451",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r143",
      "r150",
      "r153",
      "r154",
      "r156"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r419",
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease payments",
        "totalLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAmountTimingandUncertaintyofCashFlowsfromOperatingLeaseDetails",
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of lease liability",
        "verboseLabel": "Current portion of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r417",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESSupplementalBalanceSheetInformationDetails",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r422",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/COMMITMENTSANDCONTINGENCIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Non-cash financing activities:"
       }
      }
     },
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaidInKindInterest": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Paid-in-Kind Interest",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "PaidInKindInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
     "auth_ref": [
      "r120",
      "r122"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
        "negatedTerseLabel": "Allocation of earnings to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
        "label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted",
        "negatedTerseLabel": "Add back allocation of earnings to participating securities"
       }
      }
     },
     "localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Issuance costs for underwritten public offering"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Balance, ending (in shares)",
        "periodStartLabel": "Balance, beginning (in shares)",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r436"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from right offerings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r57",
      "r339"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r180",
      "r436",
      "r473",
      "r481"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r180",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r291",
      "r431",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r291",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r291",
      "r431",
      "r433",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Principal repayments of Term Loan"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r346",
      "r447",
      "r508"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r10",
      "r73",
      "r464",
      "r477"
     ],
     "calculation": {
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash and money market accounts"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSSummaryofFinancialInstrumentsMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r10",
      "r73"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r266",
      "r436",
      "r478",
      "r496",
      "r501"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/THECOMPANYANDBASISOFPRESENTATIONDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r87",
      "r88",
      "r89",
      "r92",
      "r101",
      "r103",
      "r174",
      "r340",
      "r341",
      "r342",
      "r355",
      "r356",
      "r380",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
     "auth_ref": [
      "r360",
      "r363"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
        "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
        "terseLabel": "Revenue from collaborative agreement",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Sale of stock, proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Shares sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Offering price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of Outstanding Potentially Dilutive Securities Excluded from Calculation of Diluted Net Earnings (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSNarrativeDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSSummaryofContractLiabilityActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Summary of Collaborative Agreement Liabilities and Revenues Disaggregated by Timing of Revenue Recognition"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Earnings (loss) Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r332",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Instruments Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r295",
      "r296",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r304",
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units and Performance-based Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r78",
      "r131",
      "r132",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r250",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r238",
      "r239",
      "r240",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "RSUs and PRSUs canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs and PRSUs canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs and PRSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs and PRSUs granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs and PRSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "RSUs and PRSUs vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of RSUs and PRSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "RSUs and PRSUs vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Limit on employee's payroll deductions as a percentage of eligible compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Automatic increase in number of shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life in Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of employee stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r323",
      "r324",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofRestrictedStockUnitsandPerformancebasedRestrictedStockUnitsActivityDetails",
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r303",
      "r325",
      "r326",
      "r327",
      "r328",
      "r331",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Term for stock options to be granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Price of stock option as percentage of estimated fair value of shares on date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r74",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r78",
      "r81",
      "r108",
      "r112",
      "r119",
      "r123",
      "r125",
      "r131",
      "r132",
      "r133",
      "r170",
      "r193",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r241",
      "r242",
      "r246",
      "r250",
      "r258",
      "r388",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r36",
      "r46",
      "r47",
      "r48",
      "r87",
      "r88",
      "r89",
      "r92",
      "r101",
      "r103",
      "r130",
      "r174",
      "r258",
      "r266",
      "r340",
      "r341",
      "r342",
      "r355",
      "r356",
      "r380",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r430",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r130",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Common stock options, RSUs and PRSUs issued and outstanding",
        "verboseLabel": "Stock options, RSUs and PRSUs issued and outstanding"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r35",
      "r222",
      "r258",
      "r259",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Series X Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r258",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r258",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Public offering of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r18",
      "r19",
      "r258",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of common stock for restricted share units vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r258",
      "r266",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)",
        "terseLabel": "Issuance of common stock for exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://cidara.com/role/EQUITYINCENTIVEPLANSSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r258",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of shares pursuant to Employee Stock Purchase Plan",
        "verboseLabel": "Issuance of common stock under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r258",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r258",
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock for exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r23",
      "r24",
      "r81",
      "r166",
      "r170",
      "r388",
      "r436"
     ],
     "calculation": {
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets",
      "http://cidara.com/role/CondensedConsolidatedStatementsofChangesinConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r242",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r254",
      "r255",
      "r257",
      "r266",
      "r268",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flows:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service [Axis]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r279",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service [Domain]"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred at point in time.",
        "label": "Transferred at Point in Time [Member]",
        "terseLabel": "Transferred at Point in Time"
       }
      }
     },
     "localname": "TransferredAtPointInTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred over Time [Member]",
        "terseLabel": "Transferred over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SIGNIFICANTAGREEMENTSANDCONTRACTSRevenuesDisaggregatedbyTimingofRevenueRecognitionDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Undistributed Earnings (Loss) Available to Common Shareholders, Diluted [Abstract]",
        "terseLabel": "Effect of participating securities:"
       }
      }
     },
     "localname": "UndistributedEarningsLossAvailableToCommonShareholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/DEBTAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common stock warrants",
        "verboseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/STOCKHOLDERSEQUITYScheduleofCommonStockReservedforFutureIssuanceDetails",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAntidilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r107",
      "r125"
     ],
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used to compute diluted net earnings (loss) per common share (in shares)",
        "totalLabel": "Denominator for diluted net earnings (loss) per share - adjusted weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r105",
      "r125"
     ],
     "calculation": {
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used to compute basic net earnings (loss) per common share (in shares)",
        "verboseLabel": "Denominator for basic net earnings (loss) per share - common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://cidara.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveIncomeLoss",
      "http://cidara.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESComputationofBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2740-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=126928961&loc=SL5834089-161433"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r509": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r510": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r511": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r512": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r513": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r514": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r515": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001610618-22-000085-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001610618-22-000085-xbrl.zip
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ML;_6;O>&^=1;QWG2H1*G28H3TXI;3D6,W('!T(9YFX1B1ANT,A?=W^9:BN8
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M]OH:'3H1@N2@N,HRBW$_:$6U\5H[!L1R D)=M%X0%]G7.=S =E9B]2L4[$S
MZ(O[9V3%A(R^U<)9QQ73 :(-EB7C/!(V.K-2:UW-*,Q>>19'?J<_HR!MD,F!
MEC(""&IL3#$A'5.?R@FR!7%:*_F=O?S.Q#M&M\%12$1KXR"OX/+.!*MY\EXP
MZQ>AWV$EO_,AOS.I2 #'!#><ZB0(1&>-A$ PU*.)&$6]J2K"*OF=YXJPP(UA
MCB#Q@@8'UB:1J$4Y#4P2'OR%_#)97+R81_G]U@1];+>Z0]L\C'U[7$K5KR93
M3-Y3IJX>^J#I7"(5)3[O%@Y>2ATU<9PD&6GTBD,E4]5<[J+(<N()=***6T5
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MEUPR3@,7"5PB1E&+@8#3AGC#V,@1HA>1 *T48,:IV:J[^R_B$M+[AT5T8FQ
M/7."BA0T3V#P/\Y=K@UST4GA05=LL.1L,(=SQ$O!0@O)!L$'[K)O'*0#)IEE
MW"K)P3.O;$JL8H,E<H[GAH(J*IA#*G F.8.!,EA'@4=G4^1*>*$B2]9+.J8"
M6E'!DCH&RZZ5"QPFW#=I,#DVB"D&0W,!N6?@##,2@@%A4O(\<*8J-EAR-JC"
MA+GU#:;/!@&(--J$:",!2&!]4A*\$DG9H)6KV* *$RJ'Y)>@ D\@6!J "N*
M6&U=%"*"@%QJX0&JC,&2.P;+V!E^@4.#Z2<*T.[3H!Q1 CPHJS75"5]X)XE+
MPE4S"!4#5%O2+'6J4!)A*.,$7"XO!N<LUTQ3D%+&%(FM&* *!Q:<=BKU_\9,
M 5<DH=?/N  @CII$.:JFT%PIE;RML@&5 [!PFKC (<#TDP#.\P@V,1F0 K0E
MAH@ DHD(7AI)4L4 %0-4(< RIP$UFGK)(09I'7 ?G>;H\"OOJ+-4$%$Q0!4"
M+#CM5.K_#0<@$26L53HX!]H[D]<62V&CULD3564 EJG7_+STFJDB@?G+!1A/
MJ)..@J<6M$B.$<&UMYX+K<!4DP$5$3Q.TZDJ()@O(@A6.X@B+R P0'70'L#A
M>QI)5&!)101+1 0+&8TLF!NRD"P@*&J\BLEJPT QIZ55BE$(R>*G5:'@4K'
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M7#_:CX5-*$K/;/NS/1NL/+U^8WA7XW& +" 3>H"YW7'D&SNH?%]%R_W09OP
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M9<Z36C<.JS3)(Z=)1B/_IFV[0XRO-BX&OQ&'%4O]"$O=+ML(7@9.G"@BCZ$
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M%0*%A0#&.4F/& :&M(I1.^TXSJ?+"%LXE-F\I(;"/QO!/W67V"C\LT3^F?*
MDY$<DTZ#M10E#S@@,(XSH,PH;HP,.%1;*10U*:GJ*>=D))0,+H*_KN%+:L:R
M=5$>\3^^#WBAIMJIR<U((QZII\1+D I%8%(F:O+8 +5<8J4)$=QM;:LV%@O7
M[2KI&8T#;XVBHH!W!>"=TA7>&>N<4T"D2WY-9!P,E@X0PHF"%8E.AZ0K4!LO
M?CQU W,T'E-8N/Y9+C53=>NM3J/:T NQ4T<-C8UDJKIDQM[9>;=_&<+KW&>X
M,-9R&>O#;"0F>HLQ)\!#CK]H)4"+X,&3P#6AE&"&<B0&XR9EIY?C)<V2&P7$
MJP7QE.S0E&(GM09!<V8HTA:,0@J$<Y0B+'2@/(-8\;KJWY1P1CU;DC[$D![Y
MUB!\"KV+.W:LGKQ;M*C8<'[TY?GK\1#_-NB?[>8^VK:?C\1]"CN#@>E]"/EL
M_=X7U[W(PW?CM;U1OL2_.J.3W8MA&J8PN"*XRT)OM=/;QQF-XK'&02H'E"L$
MS%$)5HLD68Q&S!C/B3+)J^)MPII4C+#$1)HA4@KXUPK\4]K&<&<LCTG,<)O
M3P,'G?NJ)-JW3BO%C%8)_+2MR<(-V4I(I59Q<]X?5-CNQTG=CJO-F\L24UEA
MN8["5TOCJ]/K]3K29Y_NO2<VK4L!1T#(LL17+()QEH#3T1IK>)315<=K90FH
M;!Z"EU.OHR!XJ0B^O(G@X(/@S'&PR6:YZ6*N,9H0+&2R: @\DB@S@C%K4D/J
M$DVY(3A&87#6ZO9-KT14EBHU_DA#_,/4M=(,M@9I,7:% A=18,6!1N&!!>[
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MN)II5\VQX<[%Z*0_2)3LYXL4E+FX\KGX]?##>QE4]%XSP,[+G#<E0&'OP-'
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MTC EE)-Q:UNB-B<+1_H+[C<(][4'(PKNEXG[Z?!#1#I),<6 4I-P;[0&S64
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MTU'D*KYW)*HUC/4V."FM0D*N,?@](6T2NCP/@V_ARA,S" M4:Z!IW'W_(L=
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M#+M\C>-$ 3V,C/AT/%VX:%;^[_^/"O[SX 0FGR@Z;28"<S@!#H/7PRLF_M/
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M78T:?11/L(3A:CI;8L XZ#8=Q>.U<&\L&A#/?L,CQJ,/Z= WL#]&R2*A4X&
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MK7'645V?L"#]</5$9^R?4N^UHO4*-R7E!W;/[+"V$,Y596WK:4!6.TKYF%$
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MJN^VC>Y=>=;\:&B#GAOT?"1OT@8]'P<]YT-UI'0@T1@Q(AP"PU0@XSA#6IN
MJ5+4ZK!!SPUZ;M!SK3U[FP0%#PV<\TX^:I5*AF,4J<YQURHAX[U#PG >G0L6
MXWL_Q-\@YP8Y-\AYOT[6#7(^.'+.4TX:*;9,H:BT11Q3#I0S.603@VU/8._B
M0^5V^8'(6;RU_RKUM5_6];S_-5._OGJ=9;S5&=HRUNF*W[6>\*Q(9]U^*W_A
MMUYLPS>_QDD1[JQ$4[^J!XPG/[$.QC8<7/V3V9KK2TN+/PXBE"KLA,_60)_^
M-W>Z:" !W5>2$LE-Y,I8JXU7 1.I? I&ID..7XQ^=#Q.#W%FCR)RO6B_@.C!
MP'ZS[7-[T7_QK]GI@+F8GOO5IJV>I)?_U_6@N24C6/Y+HA^NROW"%?TROWRK
M\7]GQ' 69:-CH*2@K]IH3G1RUF*IG5$ M03XS^&KDD"+8((FF;1F ?95=(,)
MJAY T[^WN_[+CP5/O/O'"#QW\-X_']GGD]#:N]QFNZ_>B;T3 $+ZG_;^FQW^
M^=4G_OETAWP^:9\ $+;C_[R_^/Q/.'.4R]V3=^3S03C=HSOP.W^^!VWO7AZQ
M3Z<?^:>3XR][)\>GGT[^/MW_9P^ <(?L;1]2&A6QFB''M4!<8L ^2S-_-#':
M))Q.LMKH  1BV,Z[3X@!-CK/4N2<*^Z,QQA,=$.,#LH&_J(184<Z@RD?](;Q
MQ<M7KW\_6,26:1&<PYEZ)6YZS,WB?G\R6QKZK34 X/$K2/%![)TV_NK:SNPX
M'Z^_UV+8?J>Q[P?=D@@CY\$@LMD8',?&']U3Z,1%H\!J#(U69]!MV$8;QE$"
M4/O1#WNMP47#'O5B/(6O-1O=7OEI'FMC>_+V>6MPW'AK?2N!!O\3^]!@I_&[
M[7QI-FR__ +&"'M%[.5SM2/X37D"/"QV8-^;M%N_/!OV^D,+WX(>G1^W_/%,
MAX^A3=@P>]USZ/5_W8*T84$]83:"X42YEA)$R]H$^WTBBB59G(5$ KBR:=*V
ML_?G,E#9Z?1!X//X_[0^;I_F^-S5G(7R9P,?^.YA3H%HB P($YNCSL%6U8EB
MI"7&1@$>^4A@O\5;5UW) X5HPZOJ1>IU3V<DIA:@HHG;13ZW&@>S;V29B5G*
M0=K[@WRN:QM?+2A8)F*V VC4;O1 1AOQ?_.?('JY11#R++>-;FK\TOJU<:6T
MP6*#ACV.P.W48W@//?LP@'_"V]C+] A4:RQEB/YL8G:Y0P\M40[CZ('8VU*B
M-"!#N45,4NR2$DP&G6F'6)"R_Y-EZ)<6K/%$KOZ[WSCKM4ZGI*8(R%E[V+^E
M)!AAO) \ 4-,/&&A*6?)F< 4ME:$F)E,)0GH3B+QN^VW^A_.0%C#?N?O6JJS
M?)"?5R#V#J#=RX]D_]7K/*;S0Z.MY+ 02!NG$) +B@RS'"E':6(4*Z<!@_"6
M6B(=S>I2AAT,\UX)Z_V?8?NBVE I7<2:8PO;6V<L-ZC;@6^?P0[>#2!?8",>
M'3>V0;;:=1.X66]TY["Y)=@LR^;F+FHP.@59.LXM]%H=WSJ#=\[L15[W?NE6
M_M&9;>4]O)&&[?:X?Z+NWYP-L-326]&682_6S8@0#VY$?!B R7#<;0,D]/.M
MM<'%7G<0U]"L&/MDON#=-^_PIX._3SZ=[%Y^NGS_9>_R/\>?3G;(_H&_V*4[
M]//![RW0NHMY#=L_>%=\.'O_[+5V+_=.]MZ\8[NG?[9V3SZ"-NU<?CKYW-Y]
MLP-:]Y\$O[\$LT)AIIGC$I@.-H@;"7M[X DQ'1U)($R!JGFS(@;,'9!^^"GA
MG%H;+6R."M11!-@MR;Q9\>%@_X__]W_V_WKU^OV'XIQ1_VZ\?O=QY^#3'8R-
MFQ\^VUGF*: UH4P*!M^G%GX/:D%HD,IP%JXT3AY$&6YIG?P!W^@!H@">5++;
M^ #[07_"W]?2:MGI-#[$LT&5P ^TT\P:+2X>05> H_4CP%W_V +*9H[FNZ>
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M)=-$#L6>6)/_/6]'[J0K?G15=.[Q'88U/:0SF[,?MLZR-Z35J8[I)CTH9X3
MS-#$A>)RQI2G(G)_M?YWV KE%/2'4+3,4<IZMR<=:>90EI+-L;R 304 MBCZ
M\&R$#_7=]F;E+"C'OS4M6W6=SUOM]LSBPM\M^ >H4WUV4&0X'PJ[X8C^C8.S
M0#"F!&M&1)_(RO_=S5%#/P1I/HQ5=?65.@+&T"MTX=A^S<#3^%H&, X7J$$&
MC*3L2F_UJBPW;7M>F-$(@HYK1@_JVL\H-$/IJ^/[QJD]*=$THP^GMYK5.^SB
MI"/9JYJC@$ISMS;^@.O5X0$U):HXE UY>RM[7KLD$NLU5LG&\Y/G7157YUU=
MDQ2J2Q/+W#E1S*,BS?(YK^E_"8&?Q/0TIP)])H$]8%UTSRM-;"Y$Y0#ZYGTW
M%"LD-U>9$8/;*5/^[14A/;]4QE.Q0]S%%(/\=8Z43@5<]&\%9NOKG!IG[<RG
MY<7Z6]DYE9<#S% 'MFA&S=XH&8YOPVXZ#KFJ+V-O?_BCVK2YQLW9K->/%%2Z
M? Y>P58/2C)L@8$'0/]7/9X\^A+G5D7(_X#MLIZDO(N%F#</^$:H=K)ZG@<Y
ME625;@BVOY*; W0J<QH7O1W6L6HK+64 ,IU)_6F,U4890,$ZK1'_F:QR:YPA
ML%]]IQ*87JQS(\WZT::^O=78'E^MS.D 5NY:JU]Z!F_$>%K"E[/<>=L_SB)7
M:6Y=6C$GU,S,O%'2VU<J7LU<^1W0S-BL4C)>X^"K7"KP+?C:<$13N[ZZN.QC
M%>H'ZC(V9NH.PGZ8-^7,(<%>J%-$S1V2E?.PO*7?;OQ@7N5\[N6X*WN;;"<_
MO)*")Q.]_4=%EM<W='M-8BVK>=H<**U^O_.59WOO#KU5PC*O44PL9?>314:G
MB#0P*&6<<K 2.:W"2I&6,SZGZ3#+ZXZSMZ9]*=/6PU7MSKD<KA0X,'GFP]/N
ME(1RJ=P5%^CH@CE8A['_NNI3247=[>73E"*(_Q/;LQ((FN:S%)X#.(%5];.)
M7<Y5F8/Q60PF1]]+$1%7,2%KB$=:NX0CH5H;\>)EMQ,7Q2TO:]G,XN3 ZA@F
M.0M*!?EE-P.C$F:\)"_H#]WDJ,%6#2R:LK.>LP]#=Q+]V U7L>]E!G"G9FY7
M!G;8LPSVM?"".9Y%._]JPNX+D>^U:C/Z:SG&F';*7=/1!6T8^10G3K>RV^:O
M@1RW;6WIKWAG)E^.R40F'A5G@OUJ6^V*3 !Q 7*R4^WSU;9>W %7>::F'%-H
M>':[,55KW+/Y)D7F4I5Y$0<C C/)8%3YL^NDO-,4K%PMZ$_6M$SWU*K.!<L4
M)T+VF%UQN6"FN_EB42<W"4SK+#L$QK;:Q"0:OY4)V6G%GT9/!T.ZU?F2NY]G
MM;+;IFZC%9Y8^X^GEA6FP4*';:]?,;9DA^T!,*6K\W 65U"5R'C:4]><7K/R
MQ#E?47YKY$::OF:257!T6E5]]TFRJL8_,(\6N/9:TJN[1X*=U\.:R=5R.W:F
MI3."*JD3E=PJIQ67AB8J@*<)+-CJ["PCY'ZJ9WJ_]SZ/<'^B51N*MCQ[UU&.
M>J58<9IC?@A0%,1-2DCG(&_,7$Z:S%((ZK:Q7)(&PDW4!&O&K8_.\F ,USK:
MJ%1P*\=R;5;V.U8V2@9+$ E2N20']T(BJZQ&%O-<S]QB38$%$=H41#497;SQ
MO&*4Z=RY8!7&/$VUZ^L?%1)EP@[;ECV:R@U5I>:X:S*.Q*ARC)'@? Y*U,(3
M(P2\9C+ID)8+VT(RCJ6B]KKN84G/,?ZP7W_:)S^QB'VAN]N'"FP;P&V'A,V)
M2HW*X,$%"D:"< %^L%)*X/:+RE)DV$'S+ !VI.1TL 3#RA(34M1N^=ZP6=3[
M6%1O4@2$"(B6C(X"$$0['I'@C :LI!,.%E5N:;H"8JSY+:!,M\=4YEH'TV*6
MC^_F+\7*'XG?]BC4:Z<#Y+G3;_ER%^VJS6YCYV?NDC1L9%RC@ -#7'*.'/86
MJ4B(%=%26(Y;57S];N*R6=+O7%)%%+/>4L2DS'<.G40YYQZR93NG##8&]^)E
MI[L"]+1&LUY?.KWZ.O8UEDYED<\W59P1LZ2G6O-\,E".:EIIY'YQ<7 >8^56
M *C[4O(*U7QG,&_MUV<@I]'FDC/%SY!/2$:F^A+*-)@@V-,TD-]':/AK?9+\
MYS#77FJ,4F(ME'EYR/H__CB&X3C/TN\7A3S\S%5_=L\/60 . )J'K)$1<6(<
M,M(G%(%G,]CF)#5NOHK/NNSM?TPK5F]:RE(E9:U:RK+23BYT-'XI1X53O\V'
M>J#W61DK ^C7E2Y]B#+@4HYY$K-32D"70IEG_?C;Z(]_AU;_K&TO?FMURCC*
MC_Y=MU4'^N1!SY5_+@$\U<=UQ(LQ6UJP'/22:T%/JE;7\3!;)1YFKJ)U]9G"
M6X:)*S_&6^3*SZYKEM M0>2=FKW^,\'HPW16K=1LJ;5=SS&L8I:&4JY]'+54
ME?/&N9CW5'O7?+6N_+T8E75ET>_[T*6;XA-+!-6D2!/LF"58*H/H?('T9S\-
M(X;0 '(PF@4R,PLW2,5B[7CO8TQIOOK[].!SH-B##OUF-,4+:'H^[]2>7U=Z
M\YAK+"R<Y*R$:K1"8]3]Z0G!C2734HX$UF%>;AF1 +#%)69*4LXU-\9R8"TZ
M,1T$#^0*O\;U$0E_5&> 56#"B$W]V>U57&I$I9ZUJ_3XT^FW]OZ)9[L'NW3W
M].\O>Z^^L+U+^#W=$4!DR.=70'E.CLX_'6SS/2 XH]_ LX:?Z4>Y=^F_P5.
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M^G>_T>T<=?.SWQX#TZM3?C;.6E]+LD\/(\\[-JP=S-DHS_1UR[UDM>%7/E=
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M;15I(Q<+XS0G-%?ILB@N8#WQ!JE50$&*:;3L9&R>/U;F%RY1:(W^ #Y@F.0
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MF+#[HX^W_$19(S33#$D=*L25T<AJ^*N-(:B*>TLD*']V(WFLS%]).N;N(S"
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M"RYC4QN"E91IP:.EADE*=?"2:N48X]LCN-8,F.QDUJUDUN<EF:4KZ3BE KE
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M#KU57(=[$UG7B(UNI.M#<#S8(\1+BZ7@CDNC%%$1_N!LA6T4MDO /0&.7T[
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MJ8BN],B"*UQ_G(3/+R R>P2C_V\G":"52W9:"RZ%XFK3K<'(K2TWTL"[Q_X
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MAY<H :-HIE'>5HF8)O]"C@JV V#HA%U3*R<[3V&:4HO-QZ*\W=/62?&Z%:7
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M<?3D^.M<0&.[_(9]>?H V+A';!Q\82_>4@JA1Q_UE?=304&]JC*J&L8O/!#
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MP&2VFDCII5:H.O03%6@LY*_3E.22.\D?#;;(W6F0/1$7K _->@:[$5'D[O)
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M;*5&-?%.4CO'= $%<0G_D/$L[.XL"%NXC94$\M1W 5'=E0LBM5R262QM>HI
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MI&!'[DOZ"5LIG3]3W2C+""MY0@O# BW8;N_]8I^GMNUQKY=KH>-]U\8]NE%
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M6'A!2Q?61 \($ =+.68LK_6HM9Q-MP3Q)7XDPJ ^Q;'G>E ' S@L^D::_KA
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M#L(-RO);V*+DPJBZ7CP]!:"SKK<J$\([U+P>7#T<?F$ET^M75@_P78N>;?!
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M5SIDWK$" JTF<$P,EL6+,1/5-W^+%I[/WK7E7=Z5:QO'0Q$VOEG+G=.$3)Y
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M^#_:)?EJNW&O\@Q$:L;UI<5(#/-K;1=%SFO4#*,<8Y'A3+I,\+[7D7I$'3U
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M46&@'<)2?T*)]MTU.)&15Q8M%TWMHTZ%/SW%GYX*MS;OZ7 S4?:5M;/M;D/
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M:Q;C603Z11@PVR;]*#$\6LPX]%./P9M:I3!;M"0,(SZ0WAHIWPH:N[3WWXZ
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M!4)20N8UPQG-$1NFD:9^7(X+??P%:7P/-FA/:5H!I=CA22_3](HY)\T[^'S
ML?=7UG.E[M0H ];\3"+CG!.)3S,=A$H SR$X96B3R Q:SDE_8$>.W]B4%1HW
M+CM69!3D!UTV%,.U(H&[Z)[&:WO;\Z02Z\]K<6O&M!%$RC:#':4)-Z\Y[7L-
MV/-.M'16D1*!K23A&F;0(=5LZ[VNZ*$+JDF)CT(G3 ZD8$]8%<W=PG.8?AHK
MGF+7064ZD_<=^(S*DK19+TJ(=QZ4PFB!M,+],V4JJ]E5W]WR6PA*$@*KE<=
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M.VIT ]*T+%% K K]/NG$X\-'3L_V0!C,@DE@K)'8+)8L>L/#IKV6 HMVF!3
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M5$RXG=Z1HIPA>\2\GLA'K;1!'MWJ/T,%-'9J%Y!CK-W9]_2TL2:F3Z$WIE2
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M%(Y%5!ZL,]0T96KR$9H7NS]!%:4OP4"2IB=3B]0ER_2MH.6!I*22P*$NPSK
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MK5PLV"%N&,\_%R!L)G:#E@2IY1\,._K\TW0\ECOP]-@[%=40((9!6A2$4DP
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M9(X@Y@:ZI09&V),+%63MOL>A A$'AI1AK%U!'# J?<65!B/\.! 4OCL.R 4
M227-VVCS 7E4UQYWOJ>.?5MR>]2%BKADT$:-:S%XP"G,B&SVGMZC"+8<BM2
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M'DTGR<YG \9K:VJW:3P+JD_N;8U,65(K"_JUJY^7?P*^];>?_@]02P,$%
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M)L$CF88:@1E> CK)I&SMKNPYN+]_G0Y;*:1UO="*:0RR&-1%9&"2A=HX1D)
MZP"98DI'G:>N_"-.#3D8BG2EE2Y.P5EOWVMQU>5?A@,=6H_90M&U:7Q!#<$I
M6ZOA7 DRH5.MYXO= ^<9\ZFULAI6J4RI?MV>;!;2N IES#+QJC#&5T'A$!GM
M)Q#)"R+WAQMP0CCZ0VGI68GZ=LK2DDUH]6<^8^)TJ9T.<IM?G7T['?Y G-\?
M2U)6!^_!D.4'*A;:'UD-L3#O#5?91-4ZAK  QC/F4"OE+$V%:W3%,[M1>//N
MQ:MWG]_\X]6'MR?O/IWD//W$</IF4(:CLZD,M[C+6?L96UW:;+>B6[<S6A>-
MY$N5Q(SR-H6$V3%MLXW6(4N]M9_6L?N]C-[7@5<LW,:8)%A#AK=R/( /DH-.
M1FFAZ/^R>5GLUJBWL_0W?3R= <.JO?1FD$9(/WTSN#F%[OJ0H./A\@;BNB=M
M3Q3NT-"F(6(='4.G!-2Z)T@\^)H?G>?F*-_O/.QK"0>XA;>E^$WOXU$PI8M;
MJXT77O_X!XXG5XWD>2]$P^B(XR"\BZ 8Y^ 22Z RLUPJD_+MEH+[VV$6X'\V
ME-^[\KN*3\>'UQ)OK^75G]_ZLS$]LY7T'";%))(<62&K3W@#/M.[J3WRXHIW
M+'82E&X!_GE2>.=J[Z*ER:8+^7 ^2E_#54/:N;R)BU.F)T5-+/068A3T/JJ:
MQ^T1083L8[ 1>?.4E>Y6<V3X?HC1,'ZQG<6U8 3$9V+M^.OP-/=8+"AJ1(\)
M55=D(X1"'KO+"1675NNTXGS<+N ]&^X>B(8[*"?<>%&77L%UC.#.K IM+*I2
M>P\;6<B"BN0*1$U.08D)#4<N?>N>)!TNY]F0_="HT<6PT4V7=C&VYRH8>A['
M:=2?=I+[&";8(^=7>*$82*]K1!1SK3AS8 7F*(-DQNP\ 63#M1SYO@]2=# 7
M]=XY>3?"^E<6UFD8C'M21B4"=Y"LU_2.)@4.<P&=R:9REDZMW/KJ94.HSX^J
M.U!I!_-8KY#AZ#O9\(N%^*YF3(QK.='T:O+S<!).YW_^8CB>O!M._A,G'S$-
MOPRN;C:GGS3[1^\G7W'T^6L8S)I\CGL^\%*4"9!<R% 3*R &=( E"1:B9%KY
MQES>VV*?W=OP.&C5P=3:SA8^VTY>#T<7WZJ_QWM&9FFS25"RIMVCN 3!VOI'
M-+E87I1J;=SL=H7'-^=P"-3!R-V-A3UK,_EF,)Z,SJ>Y%[<W@K]/IRB]N0B]
MWJJ'G?[P)1F"KT-_-)VKU)/:H8I\VE]:@D+4=8HC@O::!.&Y2+)Y_=2A+/[9
MO60'(_FU:-=R0G'WDOC'=(.ZE,1TB[I>=N::QU0T%,U(>=D&<"9Q\-IY%#4[
MTCV>M^V^E1Y?K<,C5!?CF#>/1&^V;P2I9#$I@W;!@E*&EAIBAB2-DRB$%K%U
MN<F.EWA\<PZ(0BWG5G?O(TZGRUSX@\BU<2D9.F!3U8B0M$HO0<;(, NEN7PT
M'M+\PI[=ZW%X=.EBEO=<H?K&Z>:SLG;.LN$N%O"Y3B7/9%[&B Z28PI--IJ'
M#B>P;@=^5^TC]KWC[T79A]*9XK(28EI<'$KU>$("8VLW2,T<!*\22).$0.64
M#ZW;H,X__P#Z4NR2 <-&FN@@R?)6?<PJ:#IJ/W$(C2,VU\P2%6\AUNZ5C1%]
M\2*!E;7=K\@1HD9=YYM;PY)SSK3.(CR +@M=Z7@=:;9N<OSYC^'GK\/S<1CD
MU_TR01Q<NO<UVZK_'>?J9+TS(B0C($IDM&0A:,F>UIVP)(R,DTQ62JA;XZ&[
MMYZW4<YP!Y+MK"$RLT40A2,85A(92"9!72-XYG7(7B;-F[5>?;Y'^>8R;YAH
M?KM[Z2HPGE[[Y+6$OZ3][B:2Z[!]LHH*1<RUC)@3(VG7A8""@69!Q6P9CVFE
M</V^%;A2^^06^EM'8(WU]AM)ZNS\['**;L#DD3Q3IG3M@L,LN)@,J&!BU#+K
MD%;*&'M <S<>NK]VR6N)?=A"9HV/S8N\Q<OS.[O,D7D(1F6HQ?M$PIP@!"U=
MD<@3KA3D?TAY\P]]A,K;6&:=C &MS87J;G/5:O+W0?^_S_$E7F6@SKJI&96R
ML@F*HI->H:7C/K$ 0:DB/"N"-R^57Q7;\[2@.M5@%V,G;^.<;^BX K2NIDXM
MA[6GJ5.=Z/,ATFRIC%WL3',0D[4AU@%ZV11))H_.X+DK@#P:Y@HGLZ=U+N[.
M>?+0$*I]TV0=';0.U_PV'&'-M/B,@XN"N'\,:^']=%[3>-HK&2_;;%^>LU:)
MD((&(P4G(ZEP\%8(2,I(Y43V3*J5HC;K/WL/O>=;Z6VX.Z%WT,GC9C]8I8LO
M7M8A6XG5,K$"4?( +LELDF7)Q=:M. ZME_@>S93-=;&/DM5-6J.MLJ9CY_&U
M.H^O19-=M'#>1,>/I?-X]BZQPB5(SQP=#"%"S:N"K&W*C'&A=.LK[<?#V[4Z
MCQ\<;==1;0=T7=3XD;%@DQ<&=(FU46C2X+A!\$XSD0.9IJ7UW>G3[<JYEGY7
MZ,JYCG):]R+_B./)J)\F%XENY-1,QG7%.)KVCQRDF606_=IE8"XQ4:31D$MM
MB)W)0@GH,Z2BF-?6.296NZ#=&LHSIM<>=-GUSC7+N;QL=(P^(19Z,4H6M,=;
M#]&BIRU?.\>Y=PI;=R99"N89TZRMHI;>+7?88?C3^=E9&/T8ED5O0;CQLL1E
M+\M)FO2_]R<_&C<F[@):\W[&G<OO5AMDR1T+SMD2LJ;=*;@LB+0A"9,8IN 6
MMD'N N3>NR>+6OE7+ )BUJ",2A"USD R(4D4)_SN'8;.NB=W7R]V50OP<7AZ
M^GHXJO^HYT-MNRUH$XQZVC@4(29,=8NL\V*,='@P_6,W6N$!GEUMF;^[@L.M
M"71(S9177^VL5U@OD_D0 L]@ZP0<E23YVT'17UWQ/DGEV[>6V-GB'M%+L@.6
M[OZ%VH!B^XCZ->H"T.,:9;8B E.2#'%F% 27:+=SP>F4D"GU> Z=FVL[ODE[
M>9.V(%A7C:5W4//?*XH55I*#**0%996'P(H$3-(;[C#$VS,O#OA%NKFVXXNT
MEQ=I"X)UD-/5W3I)"P7[\TMUV7F'+$.)28!RCH$/A4-V.N820PSL\;Q+=Y9W
M?)WV\CIM1[-#:J:]MC'K1#)1R@*E1-HZDG9T!OL$/@LA:>/@@3^>]^E>?^D@
MM?!@OY/YET=KI+?'!/!8\_I+B!"\"&!E<#PZ1@:4>GRZ6D<$CVA_?#1AHLXH
M^*A\W]7%T4NFYDR2_\]9)K?%%D7Z% 509>YL$9CE(]PRGU)GJT,@_P&^R&LQ
M]U&]O6LW$2/K,]@L07))6[*NDWZD5V 8-UD*'FQH/I'\4!9_?(\/\SWNDL./
M.'JVPJ[&4Q*&)S"N"B)R4J>@_2U%5,P$VMG$P4P':KWXX\M\F"]SEQQ^C!&\
M\Q&.'Y:"0Q3>:@G.UODVLD3PVM-?D_ NR<(</AX'=YV5'U_CPWR-.V/OXXP9
M/BP#S:1,%CDY%ZR <M9 #&24> Q)<)$YVD>8?K'F^[N![IH5YV4G8O1(U"M,
M@,HN$O\L YV0>QXD+Z;YK*UGV#]UJYC>7I1]*/U3;]9(95MR-D70GHEUMG0M
M0R9! G?1N92UGV;<-J7K$ZO&78L#]U;CKJ.+1U/-N,*:CM6X:U7CKD63G90U
M;J#CQ\)?%Q3S7D@POO;"]$Y!=)Z6*HWQ,DDN4R<3ZA\%;]>JQCTXVJZCVM:=
M4[:OR+.8O;*F3AQ0"$HY!B$9!]E&X8O-6O%;Q#Q65[:C0]OJRG5TN;0XH,O:
MN MC:3CK*A-O2_[5G_5+;%WVMMY3VU>T;;'J6\5J/&@NE."L2*."+XXI*V/V
MKB3K497%Q6KK/7\'4W5.3J<?U*_]C&Y/B*PC4L;7_ED(C/'L$NWQF7;[Y(G2
M/''0!1%#+-*KUGY%XR5L[6?-GC0_>W:!]GHR.9F\+[68(=*V4Q2X'"T(<AM<
M,27[V_OX]@[82LAVOZWODX-W/+/VVNNBK.O*BVTCNYE'&] :#(9!<MJ TJ5
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MHI@&H0R3P"B*<*?=J;'+1SWCJ_4]TQXM@I3+0C0G[*_S1Y*9!@?N@G>:22Z
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M2 -*A,^M#\W&U6%JDV='A1YG:2./O\51VW1'=<3I\%C* LN,!1J) YD*UFB
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MERGQ8YAKG S4>%$[1M+TR&:V,B&M-U'O]#%IV^F;O+C[7BDU=+Z,0*8R$IA
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M^OKR3I'0O(GI06GD)Q&!,65)DYT^16D">4@CZL5<DCBP>=W-NIT:!6P*;=V
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M2)P!A)S:M-?2T=;@6S5:EFM3F^UM?VK_+HR>T>NZ6I5N.S%';*NA9\#Y(&^
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M--])[-G\I@-6-VX* ];0CN9.2+/*KD$;HN?,930"L4O'0*,RR66%#UG#X8Y
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MQID: 7PR#[/KC^_V!,^^X_-R%_*E.O?KVTC[ -N$)BKA,0),4 RPCC4@',8
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M$%>YCSLJ77G#<<A8_@_HV5YM^?Q<;,I:(>5J<&$'4V88M9X1Q#3.50IB)!.
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M!*Y&8*_6P/5/&[F:?S5[/BR,%*]5J5@;9/_TC2UJ.6U!:B4?FMQ1A*3D(E<
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M>&ULY+U9=UM)<B[Z[E]1M\_KC:Z<!R_;9[$HJLUKE4A3K&[[O&#E*,$& 1D
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M,<U7O$3OB8Y9@S<E8Q4X 4>$Q]4@C)6"$J:>.R#8:R-[AIY^V@-V!Z!JLF\
M1Q@-?G7#>/+]:TG$HV4]FW])TWLR&VAGI;8$@P>G8[&F&3R5&%5P@O$AH2S3
MVLF^+<CJI\-@=ZBJK8D&P'6?>&6D#)XFX+Q86%4"T60#).^(<=&'K)^KGSW8
MO>ZG&6&'9FAOZ>X/C<G<C2K9G<G7-)W_.!\Y%,<X%F?N:PE/T90.HLS):$&
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M<:CZ+N5A&,X'U#*-KET&;Z($@>L#3%0"?.0YN1QC_7JMEZGJ-WCK"%Z5E=$
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M/1%KOK9:&]B2'R0B178V60&\M*44(B'Q$B,A+BV76A#.3>T3@MT3O=V=8_:
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M[<$XSQ+4KVVIAHN'UJ6>$MHS*N].?KG<QX8L_MV!)N/QNRM9B-*G]DY7=QC
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M5D1D0Z1ZR>;M],9^\PK=(ZP[\;>W@[XT+?==FKOA:*]]=-M'=SSO]TD.FHJ
M4B;9!1F !15!).'!B, A:!>-4,H9]8?L-WY1-#-.<54@=13"]=7U(AGR+N5A
M&,X',6CMJ"\WQ7.9/AL<.(XKS"I56JSXD&WM?I4O4_5'B$=VP=SC"[!5]=9
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MIZ*?!<^>4F_"M[W/R>D8D9EF\V)&/\W+.*KS- U%6Y_3@&A>CKP#D&@$KK:
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MMOX132Z6%Z5:GXNP5PY[GB-[K&:W.YH&8&M;*^?N7?]B.;]9E4H\W77^6(W
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MO*0PXU8BHZ#02LP,I*Z#5 )Y?;'.'C8QQ1R%XBB:N>/MT=3OW,!A [MC#0_
MI7\AC_K'?+98C KZZ T:R"R32R:2 1\T XS&(O.Q6-WVL-C7Z&F$5'^T2&U=
M9<.%W\G5;+Y<=^8;^>)LB"6"T>A!<<7JO'8/VF'B28N08MN18@.RFB4AV.^*
MQJTU.%Q0?L;E*&F9LF(";(FE]N!U$%RPH(Q)7& AB>VI=)"H:0;!XTV$M:RO
M 2"O437&R*",+J,")VHK$"'KL&2O@;/BF7?9%M-^XY0&A#7#X_$FPKK3XJ%
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MM0PE-X'/<518;J3/MRLL-Q%NS_ XK:\3<7Y=A?$Y7-V.4_!12Z\SQ8%.E9J
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MB2@O@(F#6&Z PYW#WG#DX6Y7"'GXBJ)YG2?D/-P^2M*T6! MG'IWG7!?&2_
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M;EUB01EB.E+>T ::4J88WD "9\YU+F(LL#S$XY+I(A/3(FH"R'=+F/JN!9H
M)H!N&Z# X,/?R\VM9)C5KA*5TS+9+IRFB,6CW"F+ZRNP;C0<M!QY6;F!$)(V
MNE6M]58IEQV6R_?\)2Z,9V6"-0"<VL_$/#!8=WNQ=>*GG,KXZ[:!))4#%M]L
M, JGW[QL4T.JCM:KVE)L:DC_P'+6J=C%,RD6]01B.ZO11I:423:9L[]SL#/<
MPC1M_FO"Y4K\P1]8%50A'N-2*E%_Y/:F]NAQ<KO$[;LEO,NZYQ\1V5)(WB^R
M24?PL<C9+ON@;RF3OT62*]R%XW9I+@7X49, ;T(1JS<%LO#"/AG5H.W^NR2-
M F">0@O]*F?1.@ ]LLP6'.=ZA170MJ"X1!)].C&NR/Y@-K_J8J'8V^&/_YO\
MQ=]PE8>[;YYMF>$L=665]_9WWCS=(C\O*6]*=M:2EY]&'>HHZL6E'@;<[T&!
M>DVY 0$URL:*FSG!]#A>-;%5]5_@YA.4S(HLW4 [-&%+<F>ZI?,KR,TL"#G-
MN])<&^O_;3/4 D30[;$]TPS<L;N$*Q@ A?O?-L>G&'-OCO:F)FB]HVV4J2X<
M<;347LAZP49W8<6,Q6"5 I(SAFL.)48+-;"J.=8,>(N+;"62?\0A0@?!GPO/
M_^+=$/:,86D7ZDLPNB-O(O@NN&.Q4'VQ9DD42$08"^M#&2R$;8K->%!M5FB'
MBS1$KV B'8-1B.67E0?8C%4.O>Q#5%]2U??4#DJ!/ "C2:(S@@00V\6"JKBW
M3?%XJ:#;:HQJ+1E79<KZ\MJ[:9*(=0,7PZ[^;M @)6R2+N%69>E>)@&7[*DA
MV"LU#:I,'M]=J6?O#]_>U,2MR8<T_J!4=[K#C*B75LV"UVH9.9NITY*!/-8&
M?J.Z4N09V/+J/+0_$_14]<S[M2+2LNSW].<L;4KUUCM+!)L6H=O,"U-""Y2"
MM#MGJE+K7Q'P 9@&8A[&VJEFM>8,3130)3R8+RS%ID4$(E]A&\_E&EA7$]X;
M""P)+#(-J0V:ARXQ=36]AKJN>6&&DM:,L-H6L%F,&^16,I2R#.'IN)6N?I(U
M.FM:\I4E(#H)H-PRG8PQWJI#XPQ! ]*F;O4">!QU_TN\%*=,[%;%!/V!1F+P
M<GM<E>N"@80]40!ME@9C?6]O:*GU>*A WK<$K]&, >N$Q$^4<<(B!WV%Z((!
M:A2@C+QWRO?*4YC"([;)1:IHC& JR&&[K-QY,]#H&,#E;I"/P@?8&!IMZ5J*
MLLP&92@<N!Q&F2:,(:.?;GF5D]ST>; P\-%01IP8[)5'&(DU@5?1CW8<YST&
MB2./T<(W+.?1+(>=X_!<W9BD#-,IOS(MH/ ,]0C2Y]4FRW9-:HZH(>;*7(2N
M-;C1;3QK@Y3:9'4V_2'O31+NMR?O4JI-=\A<"V*AQA?<GY<DYTO-B1]^MOMS
M/C;IO4_$_IUWQ7+[)';>BTYXFQ^$XW.X Q31']K>I/@^%6T?)5DWDHC^BF2]
MR8![%%E_2+TX)US^[I5F./5!JCQ[,D?K/Y<RM=II^R^7O_RZMA3]R%_N#O]Y
MW<7DN!?%?[I?0H,\A^HHT'=I'-=A9JPI5X6$&?HWF:#W<K61]9 D7KCFBIS%
ME"R?U1)W9;#M6Y33-&33LG=7Q><RSAZZ"[$A4F)G):\SHZ9J(7BT23&>8D]'
M]#5G#O" F9UO3"%XF KLSQ*_7_OEU>5$/,,G7[]R^K'=^T=YH6J%2JTYRZ9N
MZ1X9:!<PK>W$L-/$[BO$8'6RN=K"S*PWZN;K30+I'V3W,KN^"]S^0>;2_LY^
M?ZAWDR/Y!ZFWHW5#%$>OU0Y11<\J4:-*=?%6YOFKBH_6D;0/KBA2XOY!LOY;
MJE)_BNQ?67_4SY+$UYM\OD?QF$Y&3!_L4#SL#_UN<N@>2;^;[B+/3+F;Y)7U
M*->@<'2!9*7KVX(&4;EBJ%Z ?N,Z*GP?@18AY@N,XF,#*?@*BS <@?4&49@A
M_"'WF NIZD V@=7=7T%C>2?2>1%XKH(?R0H?-;(D!4K>IC(->)AUGSVL_O63
M>KW)BWGLR3'4T)TSQ,:'2-$'"X<GBKR)G 0="^F!,"-'TP)_F(C\3HBX1.R4
M_DBH"]3,$D[6E8"#-Y_ P=AWG;W=X5N[#WI_CL0F%>;11^)E9$,^T/O%*#O]
MH>M-&LS3T'7GTB#7H.])C^A[DP_S:/KN.CI4"S"1]JI&ZG>L)6*DJ$619H47
MZT*L?NOQ;S;)&&L1_]EQ=^!=K() >OYQ6E#%E\9"V0)^/D^ S*<%Q@14!1(P
M\[VA<_3^TMD?'NP<N@ZP^4S\MC.HPJ6H8F,)M,+F;@EM158$JJP*1$<II4!4
M*QO;P67@AKM9Z.L7DS#BFF6TS1LGZ%8!;N -60&?V491>#%<OMRX0G"#(!'-
M1:/J=0350&.B6UO&3/.FZB\.=4Q77LTA&L<S:-]A_]"^WW0QV-\[3*XW70Q*
MZU5V>K/,F[C<>K(1Y,B5%W6C+M=  =RD298Y&0X,D7/\*EA,#7\#X^\)7%<-
MX9= IVO1\:T*'&^WBZJO!"$8@5Z<YEWPK2 ^$J@7KM*Z8>0HPE%Q(' BU%^\
M/$_#28$>>X'7J?TK)3Z 1"[2%--+X6-RAW\LO)#R##S?3PO\ I,B=&)F^15P
MCZ_ !30$@RRU+ZT9[/>4"O(7J;@-DR(C!0NO9PT+GN<CEHI*W?3F21'GFK0&
M-#ZZ,)F#/H*X1JPM?1B-+K#30IPA0&J<1Q(4SY3\E\9!2N F?5^1TYO:4O0P
M?7^#NEI"7?6Q[SI!K^")QY,$?P=AYN.)8]"/5$PXR2IA@!8$'KL1F)^6.=,T
MF4O,&+H#Q(/+FKP/:Y_,19J1\AXG,9Q*S'$G6++ FP.I(#<I<@YS\(OR(HV-
MPX^LH;X [DZZM/5#WGLOFQ%$7)P31AQ:<JD7"+/_KMY\TR6"U8!42*2_3'?9
M4"+E!MBC-"=+=,#AW<KM:.+=I-X\Z]5F^UW:;%H'4N$HK=!%C,)";,-5\MSQ
MO@9A2HX&[RN,) *YS #CN+-X,RI^%\9XK^RMQTU12DJ<TBI0A6#.@5Z) #<+
M'CTE+"!#7*F8 H'TBPR"+I&!//.T95@8@R! H#)Z\.QIADP[9<9NGW5&MT.'
MD!<YZN<Z;;@.]=9=)&FN@81M:$V+;@S)5"V'7NV\Z-+.5^'5=39V7U9[VIW5
M/MS9W6M:[C^VU,^TL+H "V,^9?[N;/F1!](DDVTYTJ2XF2$ '!AG6\,!7TA"
M(M"B/LRT9<=VGH<Y[[%(+8O-.- KEMJ;O>'K'S/)/S"5?X'HMZA+H"1I]ALS
M*\,7@7::!H^V$V%*>ZU38KFI[=^R?<TA@ 5R1KB<N:8';#4! >C!2%S\#Y<?
M(#8=F^<3#X95-=*5\B4G)MTP9;.:9EON[D7CI9"=>EB0P-=H?$^$AQCQH.S!
M4^4(T3DC_]0^>3U;"="XM8_8>Y0*&.)FIMH^#QB<$-6*"4@.)YNAG3X1QKBG
MB I5^B6X&15;7SO!G*UP1^RX^!KI"0J2 I>&U%*J3)2 @E-K>'T)JVMXP:F.
MU; &EFI5+5/>!5N\8EY9A2((Z9]O*O_ ZA<]=B([ 31=1F&GZUF8!LIS8Q=K
MEB\>R/UFVH)]$7.*/M%+Z) 6*0Q;2.(-):R?GD:G?7Z=\,^ZBNQ+C)G5L&*2
M(8QJG*MM#3,580N4KH7NLB+7=41Z3CN.<\)7B%N)TTIARX<0W53&.(F9!D(F
M/EI40A5(&;4]A>,?BQR9=^7JV)D [W&FB+X,C%QQ>Y"I\0V* Y'.,QL:_L&C
M6_=(8,03XY$KSL2 "KGB&D4W,S*5TPR[H1,@I(=$C='BDG1B8( S#[CG!)-#
MLR0*2DN(KT7#777(9((16%FWE([ZVR0JY@CC"OJW=R/--^V]+[T[O&_E4:_W
MI*&_=3=3(_(BV$D6!WC<2:B6)50=FMLNQI>!9V3ITG-$2+5P+)( ^V+A:Z=H
M)22EK<VJE(<V"4M-UV#2XJA*=78V2NRL@&,8HMD#M*GVCW0;W 54;1BX-RGR
M,I6ZUD:%62INO%0>K4 @@3)\K#E3_9!%)\ *#+5D<O<SDO[$)[!<8*(0H2VR
M\O! P'$"]>"W BX6J6L=BRH=2M)@KT+E/NU@DKO%0M\L>9HLO8@0G,O]%%3%
M)*R* *4QA@=X2R0(M'X%8<GRZ=3[:FFG'OJUT"6:K0X2/,)2.CAX/DLI[)*E
M]&H?%Z(D>4B>47'NUE=,S;F"ZR.Q/;K!'ZMDF F@0M@MBES)=B+L69JO)BC2
M8I?<Y>^<N!;A(HLMYEIT4Q-98];;'WJS%!WMY\"2!4S@;)',"R#P1;34[)-\
M:^7GR ;%M4%;1%U-SUN Y2)4EQ,&-3?*F2Y;VWFSYVQU6CD;\7(TS;X3>IN*
MTZZF2FEY3E-/MM 9@4I\\/I'9VOT?]X-G#MD6/!=F)7E_@HIWWAZC!!_/!7C
M 7KWP)&T'+(V<OWCP_N6DO=YF76'N/7>SN&;9F[]1$S:I1;JC^'0J)#^25S:
MXJT-7/HA;&D5YY9CW"0HJ!/QMJ<)"L^TG \20UH*'75( G&=Y!H":,7QZKL,
MZ8X0&;[=.6Q1^>.D:U+D#[[VV85']1AO'3F@1,JC[,JSW%D=SMV<\ >?\-O.
M'/"]W9UAVP$7(=$/>FZ?Z*3'TDWT'!8]5W[FLR3@]E-3RH!H< NVLX-Y(?-E
M//03DV/Q+@W)+RK/,D7<"$O,BB#*3FDR&T-I?]RW$Q-^C4TO#'"8*MI99ZFD
MSR!/,!>$4HA6'+V>>#^'.V\V^$QKN6+.4R\&_OPN2;YTP.-B53*,5'T:U;%=
MJ#CZ+WB$KN$4> M*'G#&OQ7A+1YR$"UC)'/9. ]]WH6"NS']X_I#Z!LXI_4(
MW6*=W:%TZFY)8ZJFQ,#R8JHWA7=-<%9)A/Z0\09;:3TR+O+M9+I]D?A?0$49
M?UU@1587G.6*H.=<B$!U2!J3U50;Z!HSJ9Y@]3-J-W;."FBA09)FG/ %9I9'
MF>V$K@I*$AR71%8IZ,ZM.J>KTO_VBNN=A&D*8AIJOJB^H-W==IV>ILK#== 6
M=T@NNTX'K%869O(71\P74;(49"G"AF"(?R)B,:5:%V")42CSGU,P*1'@CE?
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MF9]L1\4M;'E>9'C+I6<F85;>MR0?K6M_NF*>H+.?.:7+,?R2EXG06S-GZ^N
M4?9U7:^?) OJ(VA!NUAZ<ZTA&8$^V!CU-D2]UXQ*KV,BS8U2J6)(")6E4$Y^
MM*2#+;D\( 7C(L%15>/^*UM!5O >*B>EVEYR);^0AO)RP.DB,%JV *)(M[!4
M\Y&X#?C3'QLMICM)Q)#F(=XC]Z5V"KH&*']9VQW2JNIQBL/>SAZGW=3_[6;P
M5B:I5+S=1('&X?W,+FZ52GBO>ULG/?_%W-J@6;51G5P[ZM["7C=*5DKN8M1
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MGL#NG1E!/03L\>:XB.1+LO1.1?/A+FR4,M'MZDN9$?O[AQ)"PGR>#-18D&W
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M_A'2>+MCJ48PA*I[A7U"/6Z49!\_5:-JT.!K32=:0CWZT'SK//WA[IMG4QJ
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M:(C84Y=T,U!^F/J2I99N\%36ID6Y+\/2PEPG.:;G7@H@-1X WB)TJJKX$IR
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M59-=A8NWHN3"Q-Y(Y5/H>-1YEERQIIN-%HP5WK2%N%;\121-ADXSD-4]B+O
M36I$\JW+HYY5'+[>&>ZT<97F- R-YX@^(LX9L@!"P[PQ@XAR2BKZG48X;7A2
M.7)D2,-T>;;-3&VEN@_N;OVM$S^?>1-;3<V5=:"EE+!V8&RW)=%<)OU=E;/7
M[Z<1^SA9'H)J,=N*GCTKL5(KI%;*A7I$\_.>54.V$4H^2TK)(JM3[^ ZBA*J
M!"^56[YRSQ1$JE5LT@I];K=5M3$/&=_03CY\<"IXYNS38P_470_@$'W*.)ZT
M[GW%0@2+A;S?5OY:*:LK<_9V7F\%'&#"/SG=ZB_'=%L-R;84/A/PG(1D-CTD
M6EI%EW2KR))N%5)2^@R"YM8G_5G_5B@$3;?N ^O?=;5SSIV>52XU>483\HLW
M_/:-\/[6>RE!UR(.M<&MK:A:1'">G7-Q(=+,N*]D-PH"-B7HZP"V-EUBB0;L
M!8*G!NI2Y;N0;\Y%N@ [1(8$32L557M>@_JN,_C*RR5H;"8+TKA7!R)U!KPM
M,^\610S,)7!E(@HVK0] 2+&6& &OBF!%"G@O9D/=>&F@P\GWR7@N8[-2J";4
MTT*7.=+Y(^10>2EOKM%,&=E>9<>J/-&5DI.W'&XL8I5%:677WL\-VF/Y??%R
MO'E97HYW7OPE+1:Y_[QIDAPKM'/P=6CIU>%63!+ZFC*-AT-%H9_C$"G]*B=U
M_B@)Q MP.9KUIA%WP46@$\6S$-[BI9@)G:FJ:YD<!QPJQU)A2MIDD\@"73'V
MD0;HV&0LZ(R%X29CX5NNIYUG1(J*9!0-?4Q2H8B5D*^)+: >0#[&@@4X* $,
M0(_ \%L>!G*GJM1%/7JX.]S:/QQI.Z%RB <R>ZH2/+%*4*B^PW8S4.G!RIHU
M*CA"=25D904+&+@AC/9YX&&4S@15L41U$OQ<F3@=B9KSH#+\4J,S[!*G\RE(
MCW#9DVR/M<Z;&Q[+MU:@\-G:GL]13U,)'IXS,7=2L%V0%YFM<>\&5B#3&9JM
MLZ#94D0S%;^VDH3VS+F\,J2DPLEB\]PBG8P"N"'WXF:M1VY&;34:NN>8NA$3
M#J-H)_TI,1ZJ.ZXJ4AHIU"YMP>>:]G>:G)KOD^Y*.+W2\Y$+U4G."H=C9SAK
M%T "#,I%;4T1!E;58\Z8!F)<MYU 8R\!-/Q 3==]ZE#]%EZ*C> \&1*&;XHH
METEZ:+[7.J);20'3P2IP,QRL:D,%EPYD+C+)([%Z1UP&U@]S$$**N5A-"15+
M6;T[-C-[T*E2SD:KO(TX!>K^7(O%G:Y,5\6@H%WFR.\6)RGR+XAFDG'O$2X_
M@U&E:%$.6!UH'[9J*%AIPKAJL92/-//FR'&FW,8B0MN(RA2)BR49*!,9V6MJ
M5KK_4P#3O:623NFHQ[..=ZEV(3*;B,--C,UB^%\CY]H:#K;>K>!?ZLA7G<)4
MI+K*Y5]U$=?X8+6_9SO+4K*EXMHLU3&\(5&G'(UP>GX%1N$+)2'E4.VV4@R&
MF#*:S@K)0*H@O)#5P%\+N"-0WNB;!+8CQ@< @TXBF)K/E&$8B6MJYT>&V9QZ
M=^T2$RY>$@W)=3;-LXPH)V86*-8V][Z&\V*N69P-1E=^JQVCG%;LC3:1LEHQ
MME?$D(4A'9=#L+?"5?!!6;78DYYV/\^OG+:<^X<-##&M94&7(!307K[/IM[^
M4XSJUXT:W\'.GV,F-;V] C;Q>N?UH5JL9@/OP_G/X\NST=G1N!\>C8/VPK]N
M6M@_)7"8G*M<"$IPQ#PX9 >"=8)+E5D7/GMI*#=5?F3E) @Z8!YAAAA#;3-^
M >Z0GZZ..N$"09V(>@Q3V;LLUX@+2B.$KU*!^#^HNN.F9,Z6].S*I%*E-[$3
M.@]5MV%&O<V7Q*65<U6J"19H@A2&&/]3G<E$3B7I NN#IDF1.EL'H*C2U.$-
MSA(T8A(H$L_A!DT8Q,0D'2A&P0MTM6#'.6:M+JG;&0LZ5(F2> KR@QS?J8/5
M290?+;\C =6 CFY18=DX4.FK'J=")W<QK42LX#3P'C]<,# ?NIQA?O"GEKLP
M<[,&)@/\EDH_33(L1YUTKBPJ K$/B^-)&)&IY^,EI+F3R>/KMFMVATR596H?
M*@QI"%"+O98FT!ZK&^8-J/T3*H2J6,;19D+4\@#D%&N 84J/5%G77#X@R[ 6
MP@^GH5^>>BCL!2N74_4C+ :RIEW:D$YU&XH[EUJ"%YG,"&%<M5*^60N$FZ5.
M57]_5X!%FP]Z%.+%M6S-J]%KR?6P<CDY0T%"(6VQTTG&AJS5Q7*\1<!=*Y42
MJE)6:P5Z8=RX%3U;Y]90>GF=J3C!+#51+C)1CJAAK#2N0V65\T/@FV3"/L%*
M$DEYXQZP7R2/+*BK:3E]A7ZN@U]IP"N0>20P>? &C;$]$:L=\[,"/E--)57W
MG\!F@U3!'=<$9GMLJ<R_;V>X-4W HB:;#]9D2J./B7KK]FJ=6H''[I$;1.>C
M.$:%3Q':F)47*16T&Z#6\/N;M^UYYC5LA?YI2$NSRBEWAE3JTRY4[#(J%BN8
M%H(Y!'$X3XJLDO[3]@-!KP1".>;9Y8(-01+K#K S&*%)(CXQX%?0,VIOK:6X
M=Z<FK3LEX;Z8K7=ERS:!9!-(WNMI(+E+!ZLU?>?AUI^5("P-P3H,Y;UPTXWF
M8<^8V-L'K77-EJ]%^TH E*9_D_[92J=OKN6W0BD'/5OCX>Z*18;GHN6L+#_0
MNL.%%TE7$5 L0R=BC%2M[A<A%IER85FIA^Q?$8')8:R5;ULD[I:*F9NKE:OV
M2 4"XGTH(IWH:?4R4(7@<H@\W@9LXH8!8]>*2ERN D6Q:D"FK/I!9[M2S=WX
MY/L0=62;C&IVMLP/MM!&Z9>'3H;864NGT]J06N#P==WW&L-[) FL;,K:W,J,
M*%H2RJ"$#CWSR(-><1CBI<>8?-!@267(,US2K?;Y/X?X'_FEAL?%/U_U+(F=
MV,LJ=YWOI4 R&)(F)S5'3.V<8(R#IL)NC"PP(WIU,5Y/,H7/DAQ%#^5G*X^D
M#NKH1"(JF166'_FGJR.72=IVO5MY"BKY:Y'<88\:I>"G#.A0KG5L*&$SGF7,
MSP!EW&P)1@I@A$+"LE5>!+]:[RGB"%-+:-_E$T(.1> C* S0V%4!1Q3&M8 (
MCB/,)C!(Q(N6](3A$"2AL!ZLP.F9?JN5T$4_Z.>@W;O;S5#?L;3RMC\1^C\S
MP^,P6V#^U*4@(PQ^?N:0K!HEUW[(,Y7YR<(^@4:8J0B?H=.Y%U#QIS%O;Q,T
M&.C,F(-KI?Z40XLRCP1IWRZ&5[4D22SH@3HM".]E]J #AGB-"CB67X9/K;[0
M9+%E!..1I,5<._1UUYVI,RDR6+",&C2@JP"?)0-YJIB(1F;'J*1!;US;* ST
M2^0X$,;1W!)F5FT)>@8"BE&F@E*,S+)&W*,#1#0&/ILV"[4,:X-LO!JE[X,(
MH^!Z[*JV$]5D,EQ';C<K4=7QHC#+"F&V/!7<.THI14<S!#<?,]@-C/E\.@5E
M)ZT$?^^Y4F.UVRJ,:V&6ZTWM=(#_2L18\JJGV(EH_]TL,=B<G%W((7=4-',,
M!.<5N!NNQ"8*Y"1'H@!)=?N<OV'HN#KI#*O"4)Z6GE$F7?D0=7HP8%.Z#,[%
M-$RSO$IM<T7 %7R"% $_N!JCDB\(DH-F:C[O]RJ&O-<>0S8=G1KZ..'"H!)?
M2TGNS\*TJ@P/6IAJ;)+J#X@W,HUF+<!L7<6^EOVF.X!];7O;'U$PC0T<>UTO
M30386J]N%0$-#W8.G$_,,2WY3%QWI></;^R)96 G5NM$:E3:,+.,#^J#E%L5
MEMF>RW9==657KVS%O=VPT%411#JC;K^XFO'$R2H][P%*>44V!M+J2+75 ?(?
M'<QA-J]TG%+-O(9]H8Z#]H/440U2[?-([2LSM_%7/RK(5'MFD[&#GIQ8VBS*
MJ(HMZ'E5BF(UTT-+:1IB)^4'G/EG<@B=M#5_$IH.&,F.&FW-PURA:\6K#$%V
M+<HS?D!]I:-,W.%;S<]EB$SCE:(B&N!-7/.!H6Z+0E?HTW^]R/7^)G+]U$Q]
M9>*L!C]QG7D2P,!=3F8BU?'.8[2D,MQEM?F;J]+W-+7_/_;>O;EM),L3_2J,
MGCL3X@U(;?E1=G7M;(3:5O5HUF5[;5?WSOWG!D@D)91)@ V DC6??O.\,D\F
M$B3E1XEDZ=[8Z;)( OD\S]_Y'>[ QV(GO"H'E45]LA9(*^@6NVY7AE(<#14W
M2NELWO+JBJ1<VWSPH!=R'5)V:"'ID%*0#B)^I=4D'<0XJ9HR&=A[?O($UYT(
M=Z97I?WN86' GJQ'AKJUQ.I"C%:!40[4]A4197?""E17,^LY*YIT5L.:PKQW
M).V>',Y*KL..+H3"RJ'4'(.?T1%H7-' AFD[R61RGQZJ5L54E8LS>WX P7&S
M"\4!>/D>1.GY6QC>;T9V>:\.+J<U>*9WTS<YF[/*_"6OK(72W+<KLG5!8<_O
ML"<:JPB/F!;.G@K\H6XFS">T+)!I /X]1J8VG4]R- #T$[#4IYV"&&&'/7H5
M<&K:2>53W[]1#K\3137Z[?S<*52Y$0$& %)+;$J,#0?J^3R?X/Y I;6!+$KI
MZK:DB(J,G,4**AHZG>(C9K:AU@.C(U@L>-1N9UKBL[@+F1;HGJQZ7MNC,L_M
M"+'\(QHN.&HB[.#\$7U!? 2%"8>ZK2#Z$H([0L,!OS"+I5V=I@0ODGO\((\
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M2/X.G:='+^=YN7"D,N2:014$5HLP!S!6BF3RI'S2&L6=\%H(WY&Z808CM \
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MYP/+W6*95\A.T7!74[J%.0\6?NFC+PBYFLU*;$C(VHJ;VD!G*+R&<M>$; X
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MSF"J=M6P+&.A@ZKQFMP7_@E5.;CH^,(]BV1@IYMC\,_A7P78/.EM).8R.V"
M#GR&X!OV&?<]XJ0S=B\+EX4YMB%GD9-UV%_@&@VXZWR^ IL.^VV3Q*04//\#
M.O*MK/U!TN<S1^OH=H8J^@B68:?O#I"Y-7">[MV+4."S6.,.WI?$GL?^*V/7
MVA)SENP6A[..;3\1^YG'G &='9T!:M'6Y8ME!K$U:ZLT##G3Q\9)Z\#B9907
M-'*#VQ:;'NK6MZPN1IBQ@7.H5!%&MEO_#C"@#4 @M"9"Y6":1=H,(W<C7@=K
MN%Y"0$8"?%J!C29U4QF1$':8L!]+1%[ !<(@0LV-ZBK\0'6!(0@I1;D*]#'L
M"+W]:I6AU7$$TZ#D5B+6:>WD9>M:3SFM3XL$DL0/R#Z<A4ML'[8H U:]F;L6
MKIOM>K3KO*-KGYM\(D14R39& 3WP,,?1'D[ S9)WG0VFWLISB.WI,T<JS^[*
M<%SFCY<7?'J@><'="9X]VZ_@V6NPL7>B%"75S50'X0=M%L8*(WI'@O(9*!LH
MSG/A;M*!^73:K!#R!F_":+?#,G4@(/$O"+RJ5@NGI72LF?I<+ZW#BS&S$W,2
M],R4=O00 *,OC4?YI.9$+)C QU/FE5TVD%_!5_YS57-LXJ45*8@ALK(,EO:_
M *3]$N3CD32.(TW7Y(S<:.M50Q$"[7XO5IR>(K_;(XG&CL>6<Y9.WL,*%_#4
MF?>75(<R_ AS49B<XB\\M!G<KC?943X.6@W2>:0<.2PLET)CIBS_7"[LZ9N;
M2T@(47FU.\CP;=\4[F@R#CPDB3!$YQXN")8$B+^"F\Z)94F(\KDBBZKL,/V,
MA@D&',#21PO&-^"#^X,):(Y"Z*OJ@MJ'6Q'ZXSY5A+Y\^^;GBU?G;SY>G+V^
M^/A?AY&K^G'?ROY>ZB*8"Y^1OF?-^\&'3"5J]^/)XVRWW?5=7$MVW*FY(_DE
M)( A4LGNMH<A2-(;O4M.WY 5 -ZF=>F,_>W,R71ZWN['45[1M$"M8#G"#FS(
M6%Q&CA+LR4J^=[[P[BPDIQ2L3V_M"ZI!A+AG&&\)#/3:HRVLKX&HM)>OSGR\
MGVU3:TM I#Z?9Z/KTC[+_J^96VG4U%4Y]1$>N#Y69+T*JXTI31. _.#:@*TU
M.GH^3H,K/R_+)I?TD/W"O(1!8FB&_DQ8'^I"%T>HAL2/<QIR"%E8GZ0UT\8X
ME$]\.3*VL"DOI']@3<5Y74&^ P+)@)ALR1(+OD4K>^9#-:_S&XJUCZ+3(Y(H
MAYA@B=UC!:<W-1I&#L:B0^2%?P: @00..;>9\;X@*,>.CVL](&XFX>@9!<+Z
M2+C;X54<6"Y&GJ6GAIA!AH[GF.%:OU%P4F&.%*RJH1P%<]T&_LM8_[&^-1#D
MID>"@Q8 Z8]TKQ&?*+*K;YT_!)UB='P.N%GXA_T4F'GL4EQ#?? E= 3%T"7%
M<'$$HZ,=%TC!K=\-@31+GG8J)@PSRS=7=5R! 'X9.3FCRE!H$?+6?>BI\YKI
MV ^\UM6 "V@7BX9 7I);A3AQ*J7.V9."3WW.JAU IH&CYZ/$>7%=JB15//<-
M8]O\-G0MIV,,9\OII' "@ 3!+[7_.0%6:+16U//LJRN@(\)KNVI(@-B_(,Y<
M0/!0K-F!_,; 2\O7$%Y$_7,H][?VK@?/<QDV3)/D#0K_*7(BH">[:JGNQ4JD
M#L2WKCVG^^<E1!D*(=R=F\JAI1&XB+).X9[A55F<&2P[+F\+3R'O0C:*[M*H
MJ$/):P?FD*BK*J<X.53&KOSI&Y)M:Y=N(!$$X%D8/%06(^J'YAXC"'C\O>%C
M!A:;M4[K!8O+]/',./,)U<W(HB'M1J+$S/ , ,P^NTTJ"(^'0CP\K":D&VXE
M1M%?R6:D3NNF=3T4OWG/RF$IVPT"YIX]Y4%CPMM(CC6F2A!;I*3UU J3PBSL
MY#H.[KWXB>*%A"$":4B(\8E=G(7!2GO"J0 \DM -<GL[_DOEHL%#"M+JP:'+
MEXVL9#8-2GG0AF@@^W)7MGNX.*BHP:2DD"1H*?L@^LV <N)5P.("R=)=.UZ>
M0.5*9+IO-(.AR5A"%#,EDN%5G;7:[/&I3+VR%NBQV+J08.;2%"Y(8GN^@NPH
MJ")F&H ^;EW;EPL\NRG.SN^']]G9O>PI8D#76>UW'*@82B$@@X.JVL_(NK=S
M[U1N6U(,0NQ"6^9"MA[K@JNG20!<^);'%B_BF"9EYWE4C EHYFK ($G-DI.B
M$X7UI.;U<HU,#W_MF"4<@0S>YB!5'2_6&A>2*H5H!>"GI (!=6"5$MI1Z#M"
M@MN.N*)"I[OZ%OU3M<Z(NLMI.QBUL6<UV^^<X_;*7>7[UB IJP:NJK/[!H]M
MZ%R[J>$Y#:6W0."=7+)+A$DGA/![:P=2IPY4PE+=QTC*BL#'[?I&4GO%IF2/
M\'#. $Q<PGU;([+%\@?<(ER[]^S M>N6'D7JX:S4H)6H,H<0.H-#.I6PVI#
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MZ2,5OH)3>AO#C[G+?!%62!Z(K6#/[)YQ2[Z]J4S37I5+V,J+"@"!]VXL'$8
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M?A=\\XS<,I2B**[W8>TNWNW$VC%MK:@E;)]-'K\!,[L +4':%,E2U6<8&2
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M/E,03T-]B:7!++VA^,,IMC76*\-L?L<E4IXZA):W,"BR 6L"8O'+Y1QU&'+
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M8^SL=COKP7+AI3XRNW#U1D=TX?!40Z$^5H19GQ)ZA>WTBKZT!]*>.@30[)I
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MF.E[#P6)&PL20^[D7ZLYL!UCO"Q::=ALVFCLU[DP1<D'36]\T$8XM/V8*DP
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MU+HW>G^<,T;):0BL@@*9@KK/#:04)8&(B</,MSIG $K_=5008 @A:6^EL2X
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M@;>C\0[F**_CAXX)L[V.% #M)94?>%Y&I(-B)Q(W IZCV,4#4/,"0[)H^=U
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M2F3+W?A6W9X>Z^JIZIY=V^Q+AS$*&'MG*S"$V9EG,Z\\&.[L9\/L"[MYY3Z
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M1-R ! @@@  "2# 0/R4R-!64'!'S Q!   $$D& @2HZAJ:#DB)@?@  """"
M! -1<@Q-!25'Q/P !!!   $D&(B28V@J*#DBY@<@@  """#!0)0<0U-!R1$Q
M/P !!!!   D&HN08F@I*CHCY 0@@@  "2# 0)<?05%!R1,P/0  !!!! E0+B
MWX&@GE'/S$\U0  !!!! @H&X!V5H*B@Y(N8'((   @@@P4"4'$-30<D1,3\
M 0000  )!J+D&)H*2HZ(^0$(((   D@P$"7'T%10<D3,#T   0000(*!*#F&
MIH*2(V)^  ((((  $@Q$R3$T%90<$?,#$$   010I8#X\#OUC'IF?JH! @@@
M@  2#,0]*$-30<D1,3\  0000  )!J+D&)H*2HZ(^0$(((   @@@@(P%HE)2
M*1E&@  """" N&]6U510<D3,#T   0000(*!*#F&IH*2(V)^  ((((  JA00
MG\*CGE'/S$\U0  !!!! @H&X!V5H*B@Y(N8'((   @B@2@%Q#XIZ1CTS/]4
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M#=TV%4U4I:.*)HF_A:WG"Y\D19F2G8C'H_?F56!'IGCYX'ME :-6R5RG#0S
M]M/D%[B/5C4!88%#I_! @GR+C2PZ>D6&1 /S\6=4U<,)B34++S# T5BQ+\%R
MP^O^Y]/3+V,@7+1$Z8,@TP&I\?"_O(&3^"MP/QC+5'#Z@[G TZ8 T06<<&6
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M*DM&>BZ851\_Y9LW^U-_[7,3Z/6&74G#!#!#]/*?>CHM]09$+.C?<?1V/KJ
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M^NE.DMJ1#+&3!$:G5@ZO6KB>]3DKD6"]*2KA8A!VI3,S0S</L,M<6U@5&R+
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M2J?.7.JT\A9OC8R\3?+7B=&[Z0=?#/K!IRK[A$5\97XD,YG1GY=[13P5K].
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M1//]FG'C%/JN+Y?S;#:."V* PG1O/=:=8&GNW"',9.;2%#PRS/^'BHM&&2+
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MZNGI:2"O?1"')X0O,XE=]P[VX>3Y86)U8Y-953>+!/>GT?72)M4LV51MG>A
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MDI5VW;L%W$8=P,%X*!$@TQ[=20@I1[@G- L-O"E#K!J.)N>&8[RY6H+VVNE
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MD0<MPGIUH?VK\6N)H_$7'.LH.<%0<M&Q5\$1W'?N!LOH[L&*>?(H@95I*II
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M_8,F_T\5E"S#=+=&FWG$/Q9BD91"CONW&C7OL)F:DYE@)FQ5*Y5_%^S4L]-
M)@;V4[#>73HQ&\(,OS<E&HE)TK(F%=S2Q; O(ZE:>Q7[[P1'2@&-131OO6\K
M0:/W10W.+VFN1."&M?@O;QU[J)6]GSE-#V%Y)!*^T+Q:0UU[]Z$8"T/J5:_V
M4-%U>ZF:@,E&IK *Q*ZI[(./N?J[=&YLU;G3&X[Z%_U.>]2_&I"K"W(][ \Z
M_>OV);GH#]IP"5=7%S"C-WS2IA]LP_7M\.:V/1B1T149WE[V2+5.2]7&/OU
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MJY@,RY@-3.YM@M(V)_K/UPM/WOC3!1Z6=VPN]/5"V;A!MY8561"8DDO7L;H
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M%<;&B[+%=WEM9RX0C_X%4$L! A0#%     @ 8XMC59M6&@_GQ@( A#X9 !$
M             ( !     &-D='@M,C R,C Y,S N:'1M4$L! A0#%     @
M8XMC54/7H=L0#P  Z9   !$              ( !%L<" &-D='@M,C R,C Y
M,S N>'-D4$L! A0#%     @ 8XMC5<G5^WP*%0  2<(  !4
M ( !5=8" &-D='@M,C R,C Y,S!?8V%L+GAM;%!+ 0(4 Q0    ( &.+8U7<
M7-HQ?T8   EG P 5              "  9+K @!C9'1X+3(P,C(P.3,P7V1E
M9BYX;6Q02P$"% ,4    " !CBV-5T0BT!X*^   >#0@ %0
M@ %$,@, 8V1T>"TR,#(R,#DS,%]L86(N>&UL4$L! A0#%     @ 8XMC5>1\
M> R(<0  L"L% !4              ( !^? # &-D='@M,C R,C Y,S!?<')E
M+GAM;%!+ 0(4 Q0    ( &.+8U7D7(BPV/<  ,$."0 5              "
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64$L%!@     .  X H@,  %[V!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
